FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Teutsch, SM
Fielding, JE
Khoury, MJ
Evans, JP
AF Teutsch, Steven M.
Fielding, Jonathan E.
Khoury, Muin J.
Evans, James P.
TI Utility before business
SO GENETICS IN MEDICINE
LA English
DT Editorial Material
ID MEDICINE; COST
C1 [Teutsch, Steven M.; Fielding, Jonathan E.] Dept Publ Hlth, Los Angeles, CA 90082 USA.
[Fielding, Jonathan E.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA.
[Fielding, Jonathan E.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
[Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA.
[Khoury, Muin J.] NIH, Epidemiol & Genom Res Program, Bethesda, MD 20892 USA.
[Evans, James P.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
RP Teutsch, SM (reprint author), Dept Publ Hlth, Los Angeles, CA 90082 USA.
EM steventeutsch@gmail.com; jfielding@ph.lacounty.gov
FU Intramural CDC HHS [CC999999]; NHGRI NIH HHS [U01 HG006487]
NR 12
TC 2
Z9 2
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
EI 1530-0366
J9 GENET MED
JI Genet. Med.
PD DEC
PY 2014
VL 16
IS 12
BP 869
EP 870
DI 10.1038/gim.2014.71
PG 2
WC Genetics & Heredity
SC Genetics & Heredity
GA AW1HN
UT WOS:000346040900002
PM 25010054
ER
PT J
AU Feero, WG
Manolio, TA
Khoury, MJ
AF Feero, W. Gregory
Manolio, Teri A.
Khoury, Muin J.
TI Translational research is a key to nongeneticist physicians' genomics
education
SO GENETICS IN MEDICINE
LA English
DT Editorial Material
ID GENETICS
C1 [Feero, W. Gregory] Maine Dartmouth Family Med Residency Program, Augusta, ME 04332 USA.
[Manolio, Teri A.] NHGRI, Div Genom Med, NIH, Bethesda, MD 20892 USA.
[Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA.
[Khoury, Muin J.] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, NIH, Rockville, MD USA.
RP Feero, WG (reprint author), Maine Dartmouth Family Med Residency Program, Augusta, ME 04332 USA.
EM wfeero@mainegeneral.org
FU Intramural CDC HHS [CC999999]
NR 8
TC 10
Z9 10
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
EI 1530-0366
J9 GENET MED
JI Genet. Med.
PD DEC
PY 2014
VL 16
IS 12
BP 871
EP 873
DI 10.1038/gim.2014.67
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA AW1HN
UT WOS:000346040900003
PM 24875299
ER
PT J
AU Peng, X
Alfoldi, J
Gori, K
Eisfeld, AJ
Tyler, SR
Tisoncik-Go, J
Brawand, D
Law, GL
Skunca, N
Hatta, M
Gasper, DJ
Kelly, SM
Chang, J
Thomas, MJ
Johnson, J
Berlin, AM
Lara, M
Russell, P
Swofford, R
Turner-Maier, J
Young, S
Hourlier, T
Aken, B
Searle, S
Sun, XS
Yi, YL
Suresh, M
Tumpey, TM
Siepel, A
Wisely, SM
Dessimoz, C
Kawaoka, Y
Birren, BW
Lindblad-Toh, K
Di Palma, F
Engelhardt, JF
Palermo, RE
Katze, MG
AF Peng, Xinxia
Alfoeldi, Jessica
Gori, Kevin
Eisfeld, Amie J.
Tyler, Scott R.
Tisoncik-Go, Jennifer
Brawand, David
Law, G. Lynn
Skunca, Nives
Hatta, Masato
Gasper, David J.
Kelly, Sara M.
Chang, Jean
Thomas, Matthew J.
Johnson, Jeremy
Berlin, Aaron M.
Lara, Marcia
Russell, Pamela
Swofford, Ross
Turner-Maier, Jason
Young, Sarah
Hourlier, Thibaut
Aken, Bronwen
Searle, Steve
Sun, Xingshen
Yi, Yaling
Suresh, M.
Tumpey, Terrence M.
Siepel, Adam
Wisely, Samantha M.
Dessimoz, Christophe
Kawaoka, Yoshihiro
Birren, Bruce W.
Lindblad-Toh, Kerstin
Di Palma, Federica
Engelhardt, John F.
Palermo, Robert E.
Katze, Michael G.
TI The draft genome sequence of the ferret (Mustela putorius furo)
facilitates study of human respiratory disease
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID CYSTIC-FIBROSIS; INFLUENZA-VIRUS; RNA; EXPRESSION; TRACT; ANNOTATION;
PHENOTYPE; INFECTION; IMMUNITY; MODELS
AB The domestic ferret (Mustela putorius furo) is an important animal model for multiple human respiratory diseases. It is considered the 'gold standard' for modeling human influenza virus infection and transmission(1-)4. Here we describe the 2.41 Gb draft genome assembly of the domestic ferret, constituting 2.28 Gb of sequence plus gaps. We annotated 19,910 protein-coding genes on this assembly using RNA-seq data from 21 ferret tissues. We characterized the ferret host response to two influenza virus infections by RNA-seq analysis of 42 ferret samples from influenza time-course data and showed distinct signatures in ferret trachea and lung tissues specific to 1918 or 2009 human pandemic influenza virus infections. Using microarray data from 16 ferret samples reflecting cystic fibrosis disease progression, we showed that transcriptional changes in the CFTR-knockout ferret lung reflect pathways of early disease that cannot be readily studied in human infants with cystic fibrosis disease.
C1 [Peng, Xinxia; Tisoncik-Go, Jennifer; Law, G. Lynn; Kelly, Sara M.; Chang, Jean; Thomas, Matthew J.; Katze, Michael G.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.
[Alfoeldi, Jessica; Brawand, David; Johnson, Jeremy; Berlin, Aaron M.; Lara, Marcia; Russell, Pamela; Swofford, Ross; Turner-Maier, Jason; Young, Sarah; Birren, Bruce W.; Lindblad-Toh, Kerstin; Di Palma, Federica] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Gori, Kevin; Dessimoz, Christophe] European Bioinformat Inst, European Mol Biol Lab, Cambridge, England.
[Eisfeld, Amie J.; Hatta, Masato; Gasper, David J.; Suresh, M.; Kawaoka, Yoshihiro] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA.
[Tyler, Scott R.; Sun, Xingshen; Yi, Yaling; Engelhardt, John F.] Univ Iowa, Dept Anat & Cell Biol, Carver Coll Med, Iowa City, IA USA.
[Tyler, Scott R.] Univ Iowa, Carver Coll Med, Mol & Cellular Biol Program, Iowa City, IA USA.
[Skunca, Nives] ETH, Swiss Fed Inst Technol, Dept Comp Sci, Zurich, Switzerland.
[Skunca, Nives] Swiss Inst Bioinformat, Zurich, Switzerland.
[Hourlier, Thibaut; Aken, Bronwen; Searle, Steve] Wellcome Trust Sanger Inst, Cambridge, England.
[Tumpey, Terrence M.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Siepel, Adam] Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY USA.
[Wisely, Samantha M.] Univ Florida, Dept Wildlife Ecol & Conservat, Gainesville, FL USA.
[Dessimoz, Christophe] UCL, Dept Genet Evolut & Environm, London, England.
[Dessimoz, Christophe] UCL, Dept Comp Sci, London, England.
[Kawaoka, Yoshihiro] Japan Sci & Technol Agcy, ERATO Infect Induced Host Responses Project, Saitama, Japan.
[Kawaoka, Yoshihiro] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Virol, Tokyo, Japan.
[Kawaoka, Yoshihiro] Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Dept Special Pathogens,Minato Ku, Tokyo, Japan.
[Kawaoka, Yoshihiro] Kyoto Univ, Inst Virus Res, Dept Biol Responses, Lab Bioresponses Regulat, Kyoto 606, Japan.
[Lindblad-Toh, Kerstin] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden.
[Engelhardt, John F.] Univ Iowa, Carver Coll Med, Ctr Gene Therapy, Iowa City, IA USA.
[Katze, Michael G.] Washington Natl Primate Res Ctr, Seattle, WA USA.
RP Katze, MG (reprint author), Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.
EM palermor@uw.edu; honey@uw.edu
OI Gori, Kevin/0000-0001-7975-4275; Siepel, Adam/0000-0002-3557-7219; Aken,
Bronwen/0000-0002-3032-4095; Dessimoz, Christophe/0000-0002-2170-853X;
Hourlier, Thibaut/0000-0003-4894-7773
FU National Institute of Allergy and Infectious Diseases, National
Institutes of Health (NIH), Department of Health and Human Services
[HHSN272200800060C, HHSN272201400005C, HHSN272200900018C]; Public Health
Service Grant [P51OD010425]; NIH Office of the Director
[9T32OD010423-06, 5T32RR023916-05]; NIH National Institute of Diabetes
and Digestive and Kidney Diseases [R37 DK047967, R24 DK096518, P30
DK054759]; National Heart, Lung, and Blood Institute [R01 HL108902];
SNSF [136461]; NIH National Institute of General Medical Sciences [R01
GM102192]; EURYI ERC
FX This project was funded in whole or in part with federal funds from the
National Institute of Allergy and Infectious Diseases, National
Institutes of Health (NIH), Department of Health and Human Services,
under Contract Nos. HHSN272200800060C and HHSN272201400005C and Public
Health Service Grant P51OD010425 (M.G.K.). For the Broad Institute of
MIT and Harvard, this project was funded in whole or in part with
federal funds from the National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Department of Health and Human
Services, under Contract No. HHSN272200900018C. D.J.G. also received
training grants 9T32OD010423-06 and 5T32RR023916-05 from the NIH Office
of the Director. J.F.E., S.R.T., X.S. and Y.Y. (University of Iowa) were
supported under the NIH National Institute of Diabetes and Digestive and
Kidney Diseases grants R37 DK047967, R24 DK096518 and P30 DK054759, and
National Heart, Lung, and Blood Institute grant R01 HL108902. C.D.
acknowledges support by SNSF advanced researcher fellowship (#136461).
A.S. receives support under NIH National Institute of General Medical
Sciences R01 GM102192. For S.S., B.A. and T.H., the Wellcome Trust
Sanger Institute is operated by Genome Research Limited, a charity
registered in England with number 1021457 and a company registered in
England with number 2742969. K.L.-T. also receives support under EURYI
ERC. We thank Marshall Farms, New York, for providing three adult sable
female ferrets (M. putorius furo; 421 days old).
NR 42
TC 18
Z9 18
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
EI 1546-1696
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD DEC
PY 2014
VL 32
IS 12
BP 1250
EP U114
DI 10.1038/nbt.3079
PG 10
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA AW3AD
UT WOS:000346156800027
PM 25402615
ER
PT J
AU McCanlies, EC
Mnatsakanova, A
Andrew, ME
Burchfiel, CM
Violanti, JM
AF McCanlies, Erin C.
Mnatsakanova, Anna
Andrew, Michael E.
Burchfiel, Cecil M.
Violanti, John M.
TI Positive Psychological Factors are Associated with Lower PTSD Symptoms
among Police Officers: Post Hurricane Katrina
SO STRESS AND HEALTH
LA English
DT Article
DE police; posttraumatic stress disorder (PTSD); resilience; satisfaction
with life; gratitude; posttraumatic growth
ID POSTTRAUMATIC-STRESS-DISORDER; CONNOR-DAVIDSON RESILIENCE; CHANGE
FOLLOWING TRAUMA; SCALE CD-RISC; MENTAL-HEALTH; LIFE SATISFACTION;
NEW-ORLEANS; GROWTH; PREDICTORS; ADVERSITY
AB Following Hurricane Katrina, police officers in the New Orleans geographic area faced a number of challenges. This cross-sectional study examined the association between resilience, satisfaction with life, gratitude, posttraumatic growth, and symptoms of posttraumatic stress disorder in 84 male and 30 female police officers from Louisiana. Protective factors were measured using the Connor-Davidson Resilience scale, Satisfaction with Life Scale, the Gratitude Questionnaire, and the Posttraumatic Growth inventory. Symptoms of posttraumatic stress disorder were measured using the Posttraumatic Stress Disorder ChecklistCivilian (PCL-C). Potential associations were measured using linear regression and analysis of variance. Models were adjusted for age, sex, race, education, and alcohol. Mean PCL-C symptoms were 29.5 +/- 14.5 for females and 27.8 +/- 12.1 for males. Adjusted mean levels of PCL-C symptoms significantly decreased as quartiles of resilience (p<.001), satisfaction with life (p<.001), and gratitude (p<.001) increased. In contrast, PCL-C symptoms were not associated with posttraumatic growth in this sample. These results indicate that positive factors such as resilience, satisfaction with life, and gratitude may help mitigate symptoms of posttraumatic stress disorder. To further explore these relationships, longitudinal follow-up in a larger population would be of interest. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [McCanlies, Erin C.; Mnatsakanova, Anna; Andrew, Michael E.; Burchfiel, Cecil M.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA.
[Violanti, John M.] SUNY Buffalo, Dept Epidemiol & Environm Hlth, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA.
RP McCanlies, EC (reprint author), NIOSH, CDC, 1095 Willowdale Rd M-S 4050, Morgantown, WV 26505 USA.
EM eim4@cdc.gov
FU National Institute for Occupational Safety and Health (NIOSH), Centers
for Disease Control and Prevention [R03 OH009582-02]
FX The Long-term Psychosocial Impact on Police Officers: Post-Hurricane
Katrina was funded by The National Institute for Occupational Safety and
Health (NIOSH), Centers for Disease Control and Prevention (Grant
Number: R03 OH009582-02).
NR 52
TC 6
Z9 7
U1 1
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1532-3005
EI 1532-2998
J9 STRESS HEALTH
JI Stress Health
PD DEC
PY 2014
VL 30
IS 5
SI SI
BP 405
EP 415
DI 10.1002/smi.2615
PG 11
WC Psychology, Applied; Psychiatry; Psychology
SC Psychology; Psychiatry
GA AW0PU
UT WOS:000345996300007
PM 25476965
ER
PT J
AU Rubio, AV
Avila-Flores, R
Osikowicz, LM
Bai, Y
Suzan, G
Kosoy, MY
AF Rubio, Andre V.
Avila-Flores, Rafael
Osikowicz, Lynn M.
Bai, Ying
Suzan, Gerardo
Kosoy, Michael Y.
TI Prevalence and Genetic Diversity of Bartonella Strains in Rodents from
Northwestern Mexico
SO VECTOR-BORNE AND ZOONOTIC DISEASES
LA English
DT Article
DE Prevalence; Small mammals; Mexico; Genotypes; Bartonella
ID SMALL MAMMALS; HOST-SPECIFICITY; UNITED-STATES; PRAIRIE DOGS; INFECTION;
PATIENT; POPULATIONS; WASHOENSIS; SQUIRRELS; DYNAMICS
AB Bartonella infections were investigated in wild rodents from northwestern Chihuahua, Mexico. A total of 489 rodents belonging to 14 species were surveyed in four areas. Bartonella bacteria were cultured from 50.1% of rodent samples (245/489). Infection rates ranged from 0% to 83.3% per rodent species, with no significant difference between sites except for Cynomys ludovicianus. Phylogenetic analyses of the citrate synthase gene (gltA) of the Bartonella isolates revealed 23 genetic variants (15 novel and 8 previously described), clustering into five phylogroups. Three phylogroups were associated with Bartonella vinsonii subsp. vinsonii, B. vinsonii subsp. arupensis, and B. washoensis, respectively. The other two phylogroups were not genetically related to any known Bartonella species. The genetic variants and phylogenetic groups exhibited a high degree of host specificity, mainly at the genus and family levels. This is the first study that describes the genetic diversity of Bartonella strains in wild rodents from Mexico. Considering that some variants found in this study are associated with Bartonella species that have been reported as zoonotic, more investigations are needed to further understand the ecology of Bartonella species in Mexican wildlife and their implications for human health.
C1 [Rubio, Andre V.; Suzan, Gerardo] Univ Nacl Autonoma Mexico, Fac Med Vet & Zootecnia, Dept Etol Fauna Silvestre & Anim Lab, Mexico City 04510, DF, Mexico.
[Avila-Flores, Rafael] Univ Juarez Autonoma Tabasco, Div Acad Ciencias Biol, Tabasco, Mexico.
[Osikowicz, Lynn M.; Bai, Ying; Kosoy, Michael Y.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA.
RP Suzan, G (reprint author), Univ Nacl Autonoma Mexico, Fac Med Vet & Zootecnia, Dept Etol Fauna Silvestre & Anim Lab, Ave Univ 3000 Ciudad Univ, Mexico City 04510, DF, Mexico.
EM gerardosuz@gmail.com
RI Rubio, Andre/M-5307-2015
OI Rubio, Andre/0000-0001-7297-9535
FU CONACyT [179482]; CDC Global Diseases Detection program; CONICYT
Becas-Chile Scholarship; DGAPA-UNAM; CONACyT; Cleveland Metroparks Zoo;
Cleveland Zoological Society
FX Funding for the study was provided by CONACyT project no. 179482, the
Scott Neotropical Fund Award (Cleveland Metroparks Zoo and the Cleveland
Zoological Society), and the CDC Global Diseases Detection program. The
authors thank A. Fernandez, A. Vigueras, S. Gonzalez, P. Martinez, M.
Verona, A. Lopez, and K. Moreno for assistance during field sampling. We
are grateful to J. Diaz, E. Ponce, and R. Sierra (Janos Grassland
Biological Station, IE-UNAM) for logistical support in the field. A.V
Rubio is supported by a CONICYT Becas-Chile Scholarship. G. Suzan
acknowledges the support provided by DGAPA-UNAM and CONACyT.
NR 37
TC 4
Z9 4
U1 2
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-3667
EI 1557-7759
J9 VECTOR-BORNE ZOONOT
JI Vector-Borne Zoonotic Dis.
PD DEC 1
PY 2014
VL 14
IS 12
BP 838
EP 845
DI 10.1089/vbz.2014.1673
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AW6AJ
UT WOS:000346351600002
PM 25514119
ER
PT J
AU Flegal, KM
Kit, BK
Graubard, BI
AF Flegal, Katherine M.
Kit, Brian K.
Graubard, Barry I.
TI RE: "BODY MASS INDEX CATEGORIES IN OBSERVATIONAL STUDIES OF WEIGHT AND
RISK OF DEATH" AND "EDITORIAL: BODY MASS INDEX AND RISK OF DEATH" REPLY
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Letter
ID OBESITY; OVERWEIGHT; MORTALITY
C1 [Flegal, Katherine M.; Kit, Brian K.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
[Graubard, Barry I.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
RP Flegal, KM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
EM kmf2@cdc.gov
OI Flegal, Katherine/0000-0002-0838-469X
NR 11
TC 0
Z9 0
U1 0
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD DEC 1
PY 2014
VL 180
IS 11
BP 1129
EP 1130
DI 10.1093/aje/kwu300
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU7KZ
UT WOS:000345780800010
PM 25378090
ER
PT J
AU Freedman, DS
Foltz, JL
Berenson, GS
AF Freedman, David S.
Foltz, Jennifer L.
Berenson, Gerald S.
TI Differences Between the Fourth and Fifth Korotkoff Phases Among Children
and Adolescents
SO AMERICAN JOURNAL OF HYPERTENSION
LA English
DT Article
DE blood pressure; children; diastolic blood pressure; hypertension;
Korotkoff phases; longitudinal; systolic blood pressure
ID DIASTOLIC BLOOD-PRESSURE; TASK-FORCE; HYPERTENSION; PREDICTION;
CHILDHOOD; COMMUNITY; PROGRAM; SOUNDS; RISK
AB BACKGROUND
The relative importance of the fourth (K4) and fifth (K5) Korotkoff phases as the indicator of diastolic blood pressure (DBP) levels among children remains uncertain.
METHODS
In a sample of 11,525 youth aged 5-17, we examined interexaminer differences in these 2 phases and the relation of theses 2 phases to adult blood pressure levels and hypertension. The longitudinal analyses were conducted among 2,156 children who were re-examined after age 25 years.
RESULTS
Mean (+/- SD) levels of DBP were 62 (+/- 9) mm Hg (K4) and 49 (+/- 13) mm Hg (K5). K4 showed less interobserver variability than did K5, and 7% of the children had at least 1 (of 6) K5 value of 0 mm Hg. Longitudinal analyses indicated that K4 was more strongly associated with adult blood pressure levels and hypertension. In correlational analyses of hood (n = 1,848), K4 was more strongly associated with the adult DBP level than was K5 (r = 0.22 vs. 0.17; P < 0.01). Analyses of adult hypertension (based on high blood pressure levels or use of antihypertensive medications) indicated that the screening performance of childhood levels of K4 was similar to that of systolic blood pressure and was higher than that of K5, with areas under the receiver operator characteristic curves of 0.63 (systolic blood pressure), 0.63 (K4), and 0.57 (K5).
CONCLUSIONS
As compared with K5 levels among children, K4 shows less interobserver variability and is more strongly associated with adult hypertension.
C1 [Freedman, David S.; Foltz, Jennifer L.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA.
[Berenson, Gerald S.] Tulane Univ, Sch Publ Hlth & Trop Med, Tulane Ctr Cardiovasc Hlth, New Orleans, LA USA.
RP Freedman, DS (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA.
EM dxf1@cdc.gov
FU National Institutes of Aging [AG-16592]
FX This work was supported by grant AG-16592 from the National Institutes
of Aging.
NR 40
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0895-7061
EI 1941-7225
J9 AM J HYPERTENS
JI Am. J. Hypertens.
PD DEC
PY 2014
VL 27
IS 12
BP 1495
EP 1502
DI 10.1093/ajh/hpu064
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AU7LM
UT WOS:000345782100009
PM 24742638
ER
PT J
AU Bridges, DJ
Colborn, J
Chan, AST
Winters, AM
Dengala, D
Fornadel, CM
Kosloff, B
AF Bridges, Daniel J.
Colborn, James
Chan, Adeline S. T.
Winters, Anna M.
Dengala, Dereje
Fornadel, Christen M.
Kosloff, Barry
TI Perspective Piece Modular Laboratories-Cost-Effective and Sustainable
Infrastructure for Resource-Limited Settings
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
AB High-quality laboratory space to support basic science, clinical research projects, or health services is often severely lacking in the developing world. Moreover, the construction of suitable facilities using traditional methods is time-consuming, expensive, and challenging to implement. Three real world examples showing how shipping containers can be converted into modern laboratories are highlighted. These include use as an insectary, a molecular laboratory, and a BSL-3 containment laboratory. These modular conversions have a number of advantages over brick and mortar construction and provide a cost-effective and timely solution to offer high-quality, user-friendly laboratory space applicable within the developing world.
C1 [Bridges, Daniel J.; Winters, Anna M.] Akros, Cresta Golfview Grounds, Lusaka, Zambia.
[Chan, Adeline S. T.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Entomol Branch, Atlanta, GA USA.
[Dengala, Dereje] ABT Associates Inc, Bethesda, MD USA.
[Fornadel, Christen M.] US Agcy Int Dev, Presidents Malaria Initiat, Washington, DC 20523 USA.
[Kosloff, Barry] London Sch Hyg & Trop Med, Fac Trop Infect Dis, Dept Clin Res, London WC1, England.
[Kosloff, Barry] Univ Zambia, Sch Med, ZAMBART Project, Lusaka, Zambia.
RP Bridges, DJ (reprint author), Akros, Cresta Golfview Grounds, Unit 5,Gt East Rd, Lusaka, Zambia.
EM dbridges@akros.com; jcolborn@cdc.gov; asc8@cdc.gov; awinters@akros.com;
Dereje_Dengela@abtassoc.com; cfornadel@usaid.gov;
bkosloff@zambart.org.zm
FU PMI (Insectary Lab in Mali); PATH (Molecular lab in Zambia); Bill and
Melinda Gates Foundation (BSL3 Lab in Zambia)
FX We thank the various funding agencies, i.e., PMI (Insectary Lab in
Mali), PATH (Molecular lab in Zambia) and the Bill and Melinda Gates
Foundation (BSL3 Lab in Zambia) for enabling these designs to become a
reality.
NR 0
TC 0
Z9 0
U1 0
U2 8
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2014
VL 91
IS 6
BP 1074
EP 1078
DI 10.4269/ajtmh.14-0054
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AU8YL
UT WOS:000345879200002
PM 25223943
ER
PT J
AU Raczniak, GA
Kato, C
Chung, IH
Austin, A
McQuiston, JH
Weis, E
Levy, C
Carvalho, MDS
Mitchell, A
Bjork, A
Regan, JJ
AF Raczniak, Gregory A.
Kato, Cecilia
Chung, Ida H.
Austin, Amy
McQuiston, Jennifer H.
Weis, Erica
Levy, Craig
Carvalho, Maria da Gloria S.
Mitchell, Audrey
Bjork, Adam
Regan, Joanna J.
TI Case Report: Co-Infection of Rickettsia rickettsii and Streptococcus
pyogenes: Is Fatal Rocky Mountain Spotted Fever Underdiagnosed?
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID UNITED-STATES; MORTALITY
AB Rocky Mountain spotted fever, a tick-borne disease caused by Rickettsia rickettsii, is challenging to diagnose and rapidly fatal if not treated. We describe a decedent who was co-infected with group A beta-hemolytic streptococcus and R. rickettsii. Fatal cases of Rocky Mountain spotted fever may be underreported because they present as difficult to diagnose co-infections.
C1 [Raczniak, Gregory A.; Kato, Cecilia; Chung, Ida H.; Austin, Amy; McQuiston, Jennifer H.; Carvalho, Maria da Gloria S.; Bjork, Adam; Regan, Joanna J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Weis, Erica] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA.
[Levy, Craig; Mitchell, Audrey] Maricopa Cty Dept Publ Hlth, Phoenix, AZ USA.
RP Raczniak, GA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM vih5@cdc.gov; hex0@cdc.gov; ipi8@cdc.gov; vng4@cdc.gov; fzh7@cdc.gov;
Erica.Weis@azdhs.gov; craiglevy@mail.maricopa.gov; msc8@cdc.gov;
audreymitchell@mail.maricopa.gov; iyk4@cdc.gov; dlo8@cdc.gov
OI Bjork, Adam/0000-0001-7544-2987; Regan, Joanna/0000-0002-9179-6694
FU Centers for Disease Control and Prevention
FX This study was supported by the Centers for Disease Control and
Prevention.
NR 9
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2014
VL 91
IS 6
BP 1154
EP 1155
DI 10.4269/ajtmh.14-0437
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AU8YL
UT WOS:000345879200014
PM 25331804
ER
PT J
AU Romer, Y
Nava, S
Govedic, F
Cicuttin, G
Denison, AM
Singleton, J
Kelly, AJ
Kato, CY
Paddock, CD
AF Romer, Yamila
Nava, Santiago
Govedic, Francisco
Cicuttin, Gabriel
Denison, Amy M.
Singleton, Joseph
Kelly, Aubree J.
Kato, Cecilia Y.
Paddock, Christopher D.
TI Rickettsia parkeri Rickettsiosis in Different Ecological Regions of
Argentina and Its Association with Amblyomma tigrinum as a Potential
Vector
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID MOUNTAIN-SPOTTED-FEVER; MOLECULAR-DETECTION; SOUTH-AMERICA;
UNITED-STATES; 1844 ACARI; TICKS; URUGUAY; IXODIDAE; IDENTIFICATION;
MACULATUM
AB Rickettsia parkeri, a newly recognized tick-borne pathogen of humans in the Americas, is a confirmed cause of spotted fever group rickettsiosis in Argentina. Until recently, almost all cases of R. parkeri rickettsiosis in Argentina have originated from the Parana River Delta, where entomological surveys have identified populations of R. parkeri-infected Amblyomma triste ticks. In this report, we describe confirmed cases of R. parkeri rickettsiosis from Cordoba and La Rioja provinces, which are located several hundred kilometers inland, and in a more arid ecological region, where A. triste ticks do not occur. Additionally, we identified questing A. tigrinum ticks naturally infected with R. parkeri in Cordoba province. These data provide evidence that another human-biting tick species serves as a potential vector of R. parkeri in Argentina and possibly, other countries of South America.
C1 [Romer, Yamila] Hosp FJ Muniz, RA-1282 Buenos Aires, DF, Argentina.
[Nava, Santiago] Inst Nacl Tecnol Agr, Lab Parasitol & Inmunol Rafaela, Santa Fe, Argentina.
[Govedic, Francisco] Sanatorio Allende, Infect Dis, Cordoba, Argentina.
[Cicuttin, Gabriel] Inst Zoonosis Luis Pasteur, Buenos Aires, DF, Argentina.
[Denison, Amy M.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA.
[Singleton, Joseph; Kato, Cecilia Y.; Paddock, Christopher D.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA USA.
[Kelly, Aubree J.] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Atlanta, GA USA.
RP Romer, Y (reprint author), Hosp FJ Muniz, Uspallata 2272, RA-1282 Buenos Aires, DF, Argentina.
EM yromer@hotmail.com; nava.santiago@inta.gob.ar; frangovedic@hotmail.com;
gcicuttin@gmail.com; crk6@cdc.gov; jsingleton@cdc.gov; hrr6@cdc.gov;
hex0@cdc.gov; cdp9@cdc.gov
FU US Department of Health and Human Services
FX This work was funded by the US Department of Health and Human Services.
NR 45
TC 15
Z9 15
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2014
VL 91
IS 6
BP 1156
EP 1160
DI 10.4269/ajtmh.14-0334
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AU8YL
UT WOS:000345879200015
PM 25349376
ER
PT J
AU Poole-Smith, BK
Gilbert, A
Gonzalez, AL
Beltran, M
Tomashek, KM
Ward, BJ
Hunsperger, EA
Ndao, M
AF Poole-Smith, B. Katherine
Gilbert, Alexa
Gonzalez, Andrea L.
Beltran, Manuela
Tomashek, Kay M.
Ward, Brian J.
Hunsperger, Elizabeth A.
Ndao, Momar
TI Discovery and Characterization of Potential Prognostic Biomarkers for
Dengue Hemorrhagic Fever
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID VIRUS-INFECTION; PLASMA-CONCENTRATIONS; DISEASE SEVERITY; SERUM
PROTEOME; VITRONECTIN; BINDING; IDENTIFICATION; TRANSFERRIN; HEMOPEXIN;
MARKERS
AB Half a million patients are hospitalized with severe dengue every year, many of whom would die without timely, appropriate clinical intervention. The majority of dengue cases are uncomplicated; however, 2-5% progress to severe dengue. Severe dengue cases have been reported with increasing frequency over the last 30 years. To discover biomarkers for severe dengue, we used surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to analyze dengue virus positive serum samples from the acute phase of infection. Using this method, 16 proteins were identified as candidate biomarkers for severe dengue. From these 16 biomarkers, three candidates were selected for confirmation by enzyme-linked immunosorbent assay and Western blot: vitronectin (Vtn, 55.1 kDa), hemopexin (Hx, 52.4 kDa), and serotransferrin (Tf, 79.2 kDa). Vitronectin, Hx, and Tf best differentiated between dengue and severe dengue.
C1 [Poole-Smith, B. Katherine; Beltran, Manuela; Tomashek, Kay M.; Hunsperger, Elizabeth A.] Ctr Dis Control & Prevent, Dengue Branch, San Juan, PR 00920 USA.
[Gilbert, Alexa] AssureRx Canada, Toronto, ON, Canada.
[Gonzalez, Andrea L.] Univ Puerto Rico, Grad Sch Publ Hlth, San Juan, PR 00936 USA.
[Ward, Brian J.; Ndao, Momar] McGill Univ, Ctr Hlth, Natl Reference Ctr Parasitol, Res Inst, Montreal, PQ, Canada.
[Ndao, Momar] McGill Univ, FQRNT Ctr Host Parasite Interact, Montreal, PQ, Canada.
RP Poole-Smith, BK (reprint author), Ctr Dis Control & Prevent, Immunodiagnost Dev & Res Lab, NCEZID, DVBD, Dengue Branch 1324 Calle Canada San Juan, San Juan, PR 00920 USA.
EM isd5@cdc.gov; alexa.gilbert@mail.mcgill.ca; andrea.l.gonzalez@upr.edu;
mvb6@cdc.gov; kct9@cdc.gov; brian.ward@mcgill.ca; enh4@cdc.gov;
momar.ndao@mcgill.ca
FU Centers for Disease Control and Prevention; Sandler Foundation;
Foundation of the Montreal General Hospital; Research Institute of the
McGill University Health Centre
FX This work was supported by the Centers for Disease Control and
Prevention, the Sandler Foundation, the Foundation of the Montreal
General Hospital and the Research Institute of the McGill University
Health Centre.
NR 48
TC 3
Z9 3
U1 0
U2 8
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2014
VL 91
IS 6
BP 1218
EP 1226
DI 10.4269/ajtmh.14-0193
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AU8YL
UT WOS:000345879200025
PM 25349378
ER
PT J
AU Woyessa, AB
Omballa, V
Wang, D
Lambert, A
Waiboci, L
Ayele, W
Ahmed, A
Abera, NA
Cao, S
Ochieng, M
Montgomery, JM
Jima, D
Fields, B
AF Woyessa, Abyot Bekele
Omballa, Victor
Wang, David
Lambert, Amy
Waiboci, Lilian
Ayele, Workenesh
Ahmed, Abdi
Abera, Negga Asamene
Cao, Song
Ochieng, Melvin
Montgomery, Joel M.
Jima, Daddi
Fields, Barry
TI An Outbreak of Acute Febrile Illness Caused by Sandfly Fever Sicilian
Virus in the Afar Region of Ethiopia, 2011
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID DEVELOPING-COUNTRIES; PHLEBOVIRUS
AB In malaria-endemic regions, many medical facilities have limited capacity to diagnose non-malarial etiologies of acute febrile illness (AFT). As a result, the etiology of AFT is seldom determined, although AFI remains a major cause of morbidity in developing countries. An outbreak of AFT was reported in the Afar region of Ethiopia in August of 2011. Retrospectively, 12,816 suspected AFT cases were identified by review of medical records. Symptoms were mild and self-limiting within 3 days after the date of onset; no fatalities were identified. All initial test results of AFI patient specimens were negative for selected pathogens using standard microbiological and molecular techniques. High-throughput sequencing of nucleic acid extracts of serum specimens from 29 AFI cases identified 17 (59%) of 29 samples as positive for Sandfly Fever Sicilian Virus (SFSV). These results were further confirmed by specific reverse transcription polymerase chain reaction. This is the first study implicating SFSV as an etiological agent for AFT in Ethiopia.
C1 [Woyessa, Abyot Bekele; Ayele, Workenesh; Ahmed, Abdi; Abera, Negga Asamene; Jima, Daddi] Ethiopian Hlth & Nutr Res Inst, St Louis, MO USA.
[Omballa, Victor; Waiboci, Lilian; Ochieng, Melvin] Ctr Dis Control & Prevent Kenya, Global Dis Detect Program, St Louis, MO USA.
[Wang, David; Cao, Song] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
[Wang, David; Cao, Song] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.
[Wang, David; Cao, Song] Washington Univ, Sch Med, Dept Immunol, St Louis, MO USA.
[Lambert, Amy] Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO USA.
[Montgomery, Joel M.; Fields, Barry] Ctr Dis Control & Prevent Kenya, Global Dis Detect Program, Atlanta, GA USA.
[Montgomery, Joel M.; Fields, Barry] Ctr Dis Control & Prevent Kenya, Ctr Global Hlth, Div Global Hlth Protect, Global Dis Detect Branch, Atlanta, GA USA.
RP Wang, D (reprint author), 660 South Euclid Ave,Campus Box 8230, St Louis, MO 63130 USA.
EM sifanbashu@yahoo.com; VOmballa@kemricdc.org; davewang@borcim.wustl.edu;
ahk7@cdc.gov; waiboci@uonbi.ac.ke; wayele@gmail.com;
abdiseid04@yahoo.com; negaasamene@gmail.com; scao@wustl.edu;
MOchieng@kemricdc.org; ztq9@cdc.gov; daddi_jima@yahoo.com; bsf2@cdc.gov
FU National Institutes of Health Midwest Regional Center of Excellence for
Biodefense and Emerging Infectious Diseases Research Grant [U54
AI057160]
FX This work was supported, in part, by National Institutes of Health
Midwest Regional Center of Excellence for Biodefense and Emerging
Infectious Diseases Research Grant U54 AI057160.
NR 16
TC 3
Z9 3
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2014
VL 91
IS 6
BP 1250
EP 1253
DI 10.4269/ajtmh.14-0299
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AU8YL
UT WOS:000345879200030
PM 25266349
ER
PT J
AU Barrera, R
Amador, M
Acevedo, V
Hemme, RR
Felix, G
AF Barrera, Roberto
Amador, Manuel
Acevedo, Veronica
Hemme, Ryan R.
Felix, Gilberto
TI Sustained, Area-Wide Control of Aedes aegypti Using CDC Autocidal Gravid
Ovitraps
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID CONTAINER-BREEDING MOSQUITOS; VECTOR CONTROL STRATEGIES;
DIPTERA-CULICIDAE; DENGUE VECTORS; URBAN-ENVIRONMENT; STICKY OVITRAPS;
LETHAL OVITRAP; PUERTO-RICO; TRAP; POPULATIONS
AB We have shown that the Centers for Disease Control and Prevention (CDC) autocidal gravid ovitraps (AGO trap) reduced the Aedes aegypti population and prevented mosquito outbreaks in southern Puerto Rico. After showing treatment efficacy for 1 year, we deployed three traps per home in an area that formerly did not have traps and in a site that served as the intervention area. Two new areas were selected as reference sites to compare the density of Ae. aegypti without traps. We monitored mosquitoes and weather every week in all four sites. The hypotheses were the density of Ae. aegypti in the former reference area converges to the low levels observed in the intervention area, and mosquito density in both areas having control traps is lower than in the new reference areas. Mosquito density in the former reference area decreased 79% and mosquito density in the new reference areas was 88% greater than in the intervention areas.
C1 [Barrera, Roberto; Amador, Manuel; Acevedo, Veronica; Hemme, Ryan R.; Felix, Gilberto] Ctr Dis Control & Prevent, Dengue Branch, San Juan, PR 00920 USA.
RP Barrera, R (reprint author), Ctr Dis Control & Prevent, Dengue Branch, 1324 Calle Canada, San Juan, PR 00920 USA.
EM rbarrera@cdc.gov; mamador@cdc.gov; gra3@cdc.gov; wma0@cdc.gov;
ckn5@cdc.gov
FU Division of Vector Borne Infectious Diseases, Centers for Disease
Control and Prevention
FX Funding for this study was provided by the Division of Vector Borne
Infectious Diseases, Centers for Disease Control and Prevention.
NR 55
TC 8
Z9 8
U1 1
U2 13
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2014
VL 91
IS 6
BP 1269
EP 1276
DI 10.4269/ajtmh.14-0426
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AU8YL
UT WOS:000345879200034
PM 25223937
ER
PT J
AU Kapoor, M
Pringle, K
Kumar, A
Dearth, S
Liu, LX
Lovchik, J
Perez, O
Pontones, P
Richards, S
Yeadon-Fagbohun, J
Breakwell, L
Chea, N
Cohen, NJ
Schneider, E
Erdman, D
Haynes, L
Pallansch, M
Tao, Y
Tong, SX
Gerber, S
Swerdlow, D
Feikin, DR
AF Kapoor, Minal
Pringle, Kimberly
Kumar, Alan
Dearth, Stephanie
Liu, Lixia
Lovchik, Judith
Perez, Omar
Pontones, Pam
Richards, Shawn
Yeadon-Fagbohun, Jaime
Breakwell, Lucy
Chea, Nora
Cohen, Nicole J.
Schneider, Eileen
Erdman, Dean
Haynes, Lia
Pallansch, Mark
Tao, Ying
Tong, Suxiang
Gerber, Susan
Swerdlow, David
Feikin, Daniel R.
TI Clinical and Laboratory Findings of the First Imported Case of Middle
East Respiratory Syndrome Coronavirus to the United States
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Middle East respiratory syndrome coronavirus; viral pneumonia
ID SAUDI-ARABIA; INFECTION; COV; RIBAVIRIN; FEATURES
AB Background. The Middle East respiratory syndrome coronavirus (MERS-CoV) was discovered September 2012 in the Kingdom of Saudi Arabia (KSA). The first US case of MERS-CoV was confirmed on 2 May 2014.
Methods. We summarize the clinical symptoms and signs, laboratory and radiologic findings, and MERS-CoV-specific tests.
Results. The patient is a 65-year-old physician who worked in a hospital in KSA where MERS-CoV patients were treated. His illness onset included malaise, myalgias, and low-grade fever. He flew to the United States on day of illness (DOI) 7. His first respiratory symptom, a dry cough, developed on DOI 10. On DOI 11, he presented to an Indiana hospital as dyspneic, hypoxic, and with a right lower lobe infiltrate on chest radiography. On DOI 12, his serum tested positive by real-time reverse transcription polymerase chain reaction (rRT-PCR) for MERS-CoV and showed high MERS-CoV antibody titers, whereas his nasopharyngeal swab was rRT-PCR negative. Expectorated sputum was rRT-PCR positive the following day, with a high viral load (5.31 x 10(6) copies/mL). He was treated with antibiotics, intravenous immunoglobulin, and oxygen by nasal cannula. He was discharged on DOI 22. The genome sequence was similar (>99%) to other known MERS-CoV sequences, clustering with those from KSA from June to July 2013.
Conclusions. This patient had a prolonged nonspecific prodromal illness before developing respiratory symptoms. Both sera and sputum were rRT-PCR positive when nasopharyngeal specimens were negative. US clinicians must be vigilant for MERS-CoV in patients with febrile and/or respiratory illness with recent travel to the Arabian Peninsula, especially among healthcare workers.
C1 [Kapoor, Minal] Community Hosp, Div Infect Dis, Munster, Germany.
[Kumar, Alan] Community Hosp, Dept Emergency Med, Munster, Germany.
[Dearth, Stephanie; Liu, Lixia; Lovchik, Judith; Perez, Omar; Pontones, Pam; Richards, Shawn; Yeadon-Fagbohun, Jaime] Indiana State Dept Hlth, Indianapolis, IN 46202 USA.
[Breakwell, Lucy; Chea, Nora] Natl Ctr Emerging & Zoonot Infect Dis, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA USA.
[Cohen, Nicole J.] Natl Ctr Emerging & Zoonot Infect Dis, Div Global Migrat & Quarantine, Atlanta, GA USA.
[Schneider, Eileen; Erdman, Dean; Haynes, Lia; Pallansch, Mark; Tao, Ying; Tong, Suxiang; Gerber, Susan; Feikin, Daniel R.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30030 USA.
[Swerdlow, David] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30030 USA.
RP Feikin, DR (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd NE,MS-A34, Atlanta, GA 30030 USA.
EM drf0@cdc.gov
FU Community Hospital, Munster, Indiana; IDH; CDC
FX This work was supported by Community Hospital, Munster, Indiana; the
IDH; and the CDC.
NR 26
TC 28
Z9 29
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD DEC 1
PY 2014
VL 59
IS 11
BP 1511
EP 1518
DI 10.1093/cid/ciu635
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AU8JG
UT WOS:000345841900002
PM 25100864
ER
PT J
AU Sanchez, GV
Roberts, RM
Albert, AP
Johnson, DD
Hicks, LA
AF Sanchez, Guillermo V.
Roberts, Rebecca M.
Albert, Alison P.
Johnson, Darcia D.
Hicks, Lauri A.
TI Effects of Knowledge, Attitudes, and Practices of Primary Care Providers
on Antibiotic Selection, United States
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY-TRACT INFECTIONS; CLINICAL-PRACTICE GUIDELINE; ACUTE
OTITIS-MEDIA; DISEASES-SOCIETY; ADULTS; MANAGEMENT; PHYSICIANS;
PRACTITIONERS; OUTPATIENTS; PHARYNGITIS
AB Appropriate selection of antibiotic drugs is critical to optimize treatment of infections and limit the spread of antibiotic resistance. To better inform public health efforts to improve prescribing of antibiotic drugs, we conducted in-depth interviews with 36 primary care providers in the United States (physicians, nurse practitioners, and physician assistants) to explore knowledge, attitudes, and self-reported practices regarding antibiotic drug resistance and antibiotic drug selection for common infections. Participants were generally familiar with guideline recommendations for antibiotic drug selection for common infections but did not always comply with them. Reasons for nonadherence included the belief that nonrecommended agents are more likely to cure an infection, concern for patient or parent satisfaction, and fear of infectious complications. Providers inconsistently defined broad- and narrow-spectrum antibiotic agents. There was widespread concern for antibiotic resistance; however, it was not commonly considered when selecting therapy. Strategies to encourage use of first-line agents are needed in addition to limiting unnecessary prescribing of antibiotic drugs.
C1 [Sanchez, Guillermo V.; Roberts, Rebecca M.; Albert, Alison P.; Johnson, Darcia D.; Hicks, Lauri A.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
RP Sanchez, GV (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C25, Atlanta, GA 30329 USA.
EM gsanchez@cdc.gov
NR 37
TC 11
Z9 11
U1 2
U2 10
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD DEC
PY 2014
VL 20
IS 12
BP 2041
EP 2047
DI 10.3201/eid2012.140331
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AU6RP
UT WOS:000345729900009
PM 25418868
ER
PT J
AU Slater, OM
Terio, KA
Zhang, YG
Erdman, DD
Schneider, E
Kuypers, JM
Wolinsky, SM
Kunstman, KJ
Kunstman, J
Kinsel, MJ
Gamble, KC
AF Slater, Owen M.
Terio, Karen A.
Zhang, Yange
Erdman, Dean D.
Schneider, Eileen
Kuypers, Jane M.
Wolinsky, Steven M.
Kunstman, Kevin J.
Kunstman, Jennifer
Kinsel, Michael J.
Gamble, Kathryn C.
TI Human Metapneumovirus Infection in Chimpanzees, United States
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID WILD CHIMPANZEES; PAN-TROGLODYTES; VIRUSES
AB Zoonotic disease transmission and infections are of particular concern for humans and closely related great apes. In 2009, an outbreak of human metapneumovirus infection was associated with the death of a captive chimpanzee in Chicago, Illinois, USA. Biosecurity and surveillance for this virus in captive great ape populations should be considered.
C1 [Slater, Owen M.; Gamble, Kathryn C.] Lincoln Pk Zoo, Chicago, IL USA.
[Terio, Karen A.; Kinsel, Michael J.] Univ Illinois, Maywood, IL USA.
[Erdman, Dean D.; Schneider, Eileen] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Kuypers, Jane M.] Univ Washington, Seattle, WA 98195 USA.
[Wolinsky, Steven M.; Kunstman, Kevin J.; Kunstman, Jennifer] Northwestern Univ, Chicago, IL 60611 USA.
RP Slater, OM (reprint author), Univ Calgary, Fac Vet Med, 1-202 11th Ave NW, Calgary, AB T2M 0B8, Canada.
EM owenslater@yahoo.com
OI Wolinsky, Steven/0000-0002-9625-6697
NR 12
TC 2
Z9 3
U1 1
U2 7
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD DEC
PY 2014
VL 20
IS 12
BP 2115
EP 2118
DI 10.3201/eid2012.140408
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AU6RP
UT WOS:000345729900025
PM 25417845
ER
PT J
AU Prat, CM
Flusin, O
Panella, A
Tenebray, B
Lanciotti, R
Leparc-Goffart, I
AF Prat, Christine M.
Flusin, Olivier
Panella, Amanda
Tenebray, Bernard
Lanciotti, Robert
Leparc-Goffart, Isabelle
TI Evaluation of Commercially Available Serologic Diagnostic Tests for
Chikungunya Virus
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID FRANCE; INFECTION; DENGUE; OUTBREAK; ASSAYS
AB Chikungunya virus (CHIKV) is present or emerging in dengue virus endemic areas. Infections caused by these viruses share some common signs/symptoms, but prognosis, patient care, and persistent symptoms differ. Thus, accurate diagnostic methods are essential for differentiating the infections. We evaluated 4 CHIKV serologic diagnostic tests, 2 of which showed poor sensitivity and specificity.
C1 [Prat, Christine M.; Flusin, Olivier; Tenebray, Bernard; Leparc-Goffart, Isabelle] French Armed Forces Biomed Res Inst IRBA, Marseille, France.
[Panella, Amanda; Lanciotti, Robert] Ctr Dis Control & Prevent, Ft Collins, CO USA.
RP Prat, CM (reprint author), Natl Reference Ctr, Armed Forces Biomed Res Inst, Trop Med Res Team, Marseille, France.
EM christine.prat.irba@gmail.com
OI FLUSIN, Olivier/0000-0003-0126-9581
FU French National Reference Center for Arboviruses
FX This work was financed by the French National Reference Center for
Arboviruses.
NR 15
TC 18
Z9 18
U1 0
U2 4
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD DEC
PY 2014
VL 20
IS 12
BP 2129
EP 2132
DI 10.3201/eid2012.141269
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AU6RP
UT WOS:000345729900029
PM 25418184
ER
PT J
AU Hall, AJ
Tokars, JI
Badreddine, SA
Bin Saad, Z
Furukawa, E
Al Masri, M
Haynes, LM
Gerber, SI
Kuhar, DT
Miao, CR
Trivedi, SU
Pallansch, MA
Hajjeh, R
Memish, ZA
AF Hall, Aron J.
Tokars, Jerome I.
Badreddine, Samar A.
Bin Saad, Ziad
Furukawa, Elaine
Al Masri, Malak
Haynes, Lia M.
Gerber, Susan I.
Kuhar, David T.
Miao, Congrong
Trivedi, Suvang U.
Pallansch, Mark A.
Hajjeh, Rana
Memish, Ziad A.
TI Health Care Worker Contact with MERS Patient, Saudi Arabia
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; INFECTION
AB To investigate potential transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) to health care workers in a hospital, we serologically tested hospital contacts of the index case-patient in Saudi Arabia, 4 months after his death. None of the 48 contacts showed evidence of MERS-CoV infection.
C1 [Hall, Aron J.; Tokars, Jerome I.; Haynes, Lia M.; Gerber, Susan I.; Kuhar, David T.; Miao, Congrong; Trivedi, Suvang U.; Pallansch, Mark A.; Hajjeh, Rana] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
[Badreddine, Samar A.] Dr Soliman Fakeeh Hosp, Jeddah, Saudi Arabia.
[Bin Saad, Ziad; Furukawa, Elaine; Al Masri, Malak; Memish, Ziad A.] Minist Hlth, Riyadh, Saudi Arabia.
RP Hall, AJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A34, Atlanta, GA 30329 USA.
EM ajhall@cdc.gov; zmemish@yahoo.com
FU US Global Disease Detection Operations Center Outbreak Response
Contingency Fund
FX This work was supported by the US Global Disease Detection Operations
Center Outbreak Response Contingency Fund.
NR 14
TC 13
Z9 13
U1 0
U2 2
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD DEC
PY 2014
VL 20
IS 12
BP 2148
EP 2151
DI 10.3201/eid2012.141211
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AU6RP
UT WOS:000345729900034
PM 25418612
ER
PT J
AU Breedlove, B
AF Breedlove, Byron
TI Variation Is the Exploration of Possibilities
SO EMERGING INFECTIOUS DISEASES
LA English
DT Editorial Material
C1 Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
RP Breedlove, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E41, Atlanta, GA 30329 USA.
EM wbbl@cdc.gov
OI Breedlove, Byron/0000-0002-1026-1963
NR 8
TC 0
Z9 0
U1 0
U2 2
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD DEC
PY 2014
VL 20
IS 12
BP 2187
EP 2188
DI 10.3201/eid2012.AC2012
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AU6RP
UT WOS:000345729900052
ER
PT J
AU Boccia, S
Mc Kee, M
Adany, R
Boffetta, P
Burton, H
Cambon-Thomsen, A
Cornel, MC
Gray, M
Jani, A
Knoppers, BM
Khoury, MJ
Meslin, EM
Van Duijn, CM
Villari, P
Zimmern, R
Cesario, A
Puggina, A
Colotto, M
Ricciardi, W
AF Boccia, Stefania
Mc Kee, Martin
Adany, Roza
Boffetta, Paolo
Burton, Hilary
Cambon-Thomsen, Anne
Cornel, Martina C.
Gray, Muir
Jani, Anant
Knoppers, Bartha Maria
Khoury, Muin J.
Meslin, Eric M.
Van Duijn, Cornelia M.
Villari, Paolo
Zimmern, Ron
Cesario, Alfredo
Puggina, Anna
Colotto, Marco
Ricciardi, Walter
TI Beyond public health genomics: proposals from an international working
group
SO EUROPEAN JOURNAL OF PUBLIC HEALTH
LA English
DT Editorial Material
ID MEDICINE
C1 [Boccia, Stefania; Puggina, Anna; Colotto, Marco; Ricciardi, Walter] Univ Cattolica Sacro Cuore, Sect Hyg, Dept Publ Hlth, Fac Med, I-00168 Rome, Italy.
[Mc Kee, Martin] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, England.
[Adany, Roza] Univ Debrecen, Fac Publ Hlth, Dept Prevent Med, Debrecen, Hungary.
[Boffetta, Paolo] Icahn Sch Med Mt Sinai, Inst Translat Epidemiol, New York, NY 10029 USA.
[Boffetta, Paolo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
[Burton, Hilary] PHG Fdn, Cambridge, England.
[Cambon-Thomsen, Anne] Inst Natl Sante & Rech Med, Toulouse, France.
[Cambon-Thomsen, Anne] Univ Toulouse 3, Joint Unit Epidemiol & Anal Publ Hlth 1027, Fac Med, F-31062 Toulouse, France.
[Cornel, Martina C.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands.
[Cornel, Martina C.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands.
[Knoppers, Bartha Maria] McGill Univ, Fac Med, Dept Human Genet, Ctr Genom & Policy, Montreal, PQ, Canada.
[Khoury, Muin J.] CDC, Off Publ Hlth Genom, Atlanta, GA 30333 USA.
[Meslin, Eric M.] Indiana Univ, Sch Med, Ctr Bioeth, Indianapolis, IN USA.
[Van Duijn, Cornelia M.] Erasmus Univ, Med Ctr, Genet Epidemiol Unit, Dept Epidemiol, Rotterdam, Netherlands.
[Van Duijn, Cornelia M.] Erasmus Univ, Dept Clin Genet, Med Ctr, Genet Epidemiol Unit, NL-3000 DR Rotterdam, Netherlands.
[Villari, Paolo] Univ Roma La Sapienza, Dept Publ Hlth & Infect Dis, I-00185 Rome, Italy.
[Zimmern, Ron] PHG Fdn, Cambridge, England.
[Cesario, Alfredo] IRCCS San Raffaele Pisana, Area Syst Med, Rome, Italy.
RP Ricciardi, W (reprint author), Univ Cattolica Sacro Cuore, Sect Hyg, Dept Publ Hlth, Fac Med, Lgo F Vito 1, I-00168 Rome, Italy.
EM wricciardi@rm.unicatt.it
RI CESARIO, Alfredo/O-4215-2015
OI CESARIO, Alfredo/0000-0003-4687-0709
FU NCRR NIH HHS [UL1RR025761-01]
NR 9
TC 5
Z9 5
U1 1
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1101-1262
EI 1464-360X
J9 EUR J PUBLIC HEALTH
JI Eur. J. Public Health
PD DEC
PY 2014
VL 24
IS 6
BP 877
EP 879
DI 10.1093/eurpub/cku142
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU9EB
UT WOS:000345893200005
PM 25168910
ER
PT J
AU He, L
Zhai, Y
Engelgau, M
Li, WR
Qian, HZ
Si, X
Gao, X
Sereny, M
Liang, J
Zhu, XL
Shi, XM
AF He, Liu
Zhai, Yi
Engelgau, Michael
Li, Weirong
Qian, Hanzhu
Si, Xiang
Gao, Xin
Sereny, Melanie
Liang, Jing
Zhu, Xiaolei
Shi, Xiaoming
TI Association of children's eating behaviors with parental education, and
teachers' health awareness, attitudes and behaviors: a national
school-based survey in China
SO EUROPEAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID PHYSICAL-ACTIVITY; WEIGHT-GAIN; OBESITY; FAMILY; CHILDHOOD;
INTERVENTIONS; OVERWEIGHT; BMI; ADOLESCENTS; ENVIRONMENT
AB Background: In China, childhood obesity is a growing health issue. Eating behaviors among children can be influenced by both the family and school environment. We examine the association between these environments and eating habits among children. Methods: A total of 11 270 fourth to sixth grade school children, 11 270 of their fathers or mothers, and 1348 teachers from 48 schools were sampled using a multistage cluster random sampling method. Questionnaires collected information on eating behaviors among children, non-communicable chronic disease (NCD)-related health knowledge and behaviors among teachers, and education levels among parents. Mixed effect logistic regression models were used to describe the key associations between eating behaviors among children and teacher and parental characteristics. Results: Health awareness, positive health attitudes, never-smoking and regular-exercise among teachers was positively associated with healthy eating behaviors among their students (having breakfast, vegetables and dairy products every day; P<0.05), and negatively associated with the unhealthy behaviors (daily intake of fried foods and desserts and sugary beverages; P<0.05). More than one parent having a high school level or above was positively related to healthy eating behaviors among their children (P<0.05), but its associations with high-calorie eating habits were negative in urban and positive in rural areas (P<0.05). Conclusions: School-based interventions which target health-related awareness, attitude and behaviors among school teachers may help improve school-aged children's eating behaviors. Parental education levels may help guide efforts to target children at higher risk of unhealthy eating habits.
C1 [He, Liu; Zhai, Yi; Si, Xiang; Gao, Xin; Liang, Jing; Zhu, Xiaolei; Shi, Xiaoming] Chinese Ctr Dis Control & Prevent, Div Noncommunicable Dis Control & Community Hlth, Beijing, Peoples R China.
[Engelgau, Michael] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Li, Weirong] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China.
[Qian, Hanzhu] Vanderbilt Univ, Vanderbilt Inst Global Hlth, Nashville, TN 37235 USA.
[Sereny, Melanie] Duke Univ, Dept Sociol, Durham, NC 27706 USA.
RP Shi, XM (reprint author), 155 Changbai Rd, Beijing 102206, Peoples R China.
EM shixm@chinacdc.cn
FU Young Scholar Scientific Research Foundation of China CDC [2010A205,
2013B104]
FX This study sponsored by the Young Scholar Scientific Research Foundation
of China CDC (2010A205, 2013B104).
NR 38
TC 4
Z9 4
U1 3
U2 30
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1101-1262
EI 1464-360X
J9 EUR J PUBLIC HEALTH
JI Eur. J. Public Health
PD DEC
PY 2014
VL 24
IS 6
BP 880
EP 887
DI 10.1093/eurpub/ckt177
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU9EB
UT WOS:000345893200006
PM 24287031
ER
PT J
AU Hagmann, SHF
Han, PV
Stauffer, WM
Miller, AO
Connor, BA
Hale, DC
Coyle, CM
Cahill, JD
Marano, C
Esposito, DH
Kozarsky, PE
AF Hagmann, Stefan H. F.
Han, Pauline V.
Stauffer, William M.
Miller, Andy O.
Connor, Bradley A.
Hale, DeVon C.
Coyle, Christina M.
Cahill, John D.
Marano, Cinzia
Esposito, Douglas H.
Kozarsky, Phyllis E.
CA GeoSentinel Surveillance Network
TI Travel-associated disease among US residents visiting US GeoSentinel
clinics after return from international travel
SO FAMILY PRACTICE
LA English
DT Article
DE Diagnosis; epidemiology; morbidity; prevention; surveillance; travel
ID IRRITABLE-BOWEL-SYNDROME; SURVEILLANCE NETWORK; UNITED-STATES;
HEALTH-CARE; INFECTION; DENGUE; SCHISTOSOMIASIS; RELATIVES; MEDICINE;
FRIENDS
AB Background. US residents make 60 million international trips annually. Family practice providers need to be aware of travel-associated diseases affecting this growing mobile population. Objective. To describe demographics, travel characteristics and clinical diagnoses of US residents who present ill after international travel.
Methods. Descriptive analysis of travel-associated morbidity and mortality among US travellers seeking care at 1 of the 22 US practices and clinics participating in the GeoSentinel Global Surveillance Network from January 2000 to December 2012.
Results. Of the 9624 ill US travellers included in the analysis, 3656 (38%) were tourist travellers, 2379 (25%) missionary/volunteer/research/aid workers (MVRA), 1580 (16%) travellers visiting friends and relatives (VFRs), 1394 (15%) business travellers and 593 (6%) student travellers. Median (interquartile range) travel duration was 20 days (10-60 days). Pre-travel advice was sought by 45%. Hospitalization was required by 7%. Compared with other groups of travellers, ill MVRA travellers returned from longer trips (median duration 61 days), while VFR travellers disproportionately required higher rates of inpatient care (24%) and less frequently had received pre-travel medical advice (20%). Illnesses of the gastrointestinal tract were the most common (58%), followed by systemic febrile illnesses (18%) and dermatologic disorders (17%). Three deaths were reported. Diagnoses varied according to the purpose of travel and region of exposure.
Conclusions. Returning ill US international travellers present with a broad spectrum of travel-associated diseases. Destination and reason for travel may help primary health care providers to generate an accurate differential diagnosis for the most common disorders and for those that may be life-threatening.
C1 [Hagmann, Stefan H. F.] Bronx Municipal Hosp Ctr, Albert Einstein Coll Med, Div Pediat Infect Dis, Bronx, NY 10461 USA.
[Han, Pauline V.; Marano, Cinzia; Esposito, Douglas H.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA.
[Stauffer, William M.] Univ Minnesota, Dept Med & Pediat, Minneapolis, MN USA.
[Miller, Andy O.] Bronx Lebanon Hosp Ctr, Div Infect Dis, Bronx, NY 10456 USA.
[Connor, Bradley A.] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Gastroenterol & Hepatol, New York, NY USA.
[Hale, DeVon C.] Univ Utah, Med Ctr, Dept Internal Med, Salt Lake City, UT USA.
[Coyle, Christina M.] Albert Einstein Coll Med, Jacobi Med Ctr, Div Infect Dis, Bronx, NY 10467 USA.
[Cahill, John D.] Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Salt Lake City, UT USA.
[Kozarsky, Phyllis E.] Emory Univ, Atlanta, GA 30322 USA.
RP Hagmann, SHF (reprint author), Bronx Lebanon Hosp Ctr, Div Pediat Infect Dis, 1650 Selwyn Ave, Bronx, NY 10457 USA.
EM shagmann@bronxleb.org
FU US Centres for Disease Control and Prevention [5U50CK000189];
International Society of Travel Medicine
FX Funding: US Centres for Disease Control and Prevention (5U50CK000189),
International Society of Travel Medicine.
NR 40
TC 4
Z9 4
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0263-2136
EI 1460-2229
J9 FAM PRACT
JI Fam. Pr.
PD DEC
PY 2014
VL 31
IS 6
BP 678
EP 687
DI 10.1093/fampra/cmu063
PG 10
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA AU9EL
UT WOS:000345894200008
PM 25261506
ER
PT J
AU Huebner, DM
Kegeles, SM
Rebchook, GM
Peterson, JL
Neilands, TB
Johnson, WD
Eke, AN
AF Huebner, David M.
Kegeles, Susan M.
Rebchook, Gregory M.
Peterson, John L.
Neilands, Torsten B.
Johnson, Wayne D.
Eke, Agatha N.
TI Social Oppression, Psychological Vulnerability, and Unprotected
Intercourse Among Young Black Men Who Have Sex With Men
SO HEALTH PSYCHOLOGY
LA English
DT Article
DE social oppression; sexual risk behavior; perceived discrimination;
socioeconomic status; HIV prevention
ID SOCIOECONOMIC-STATUS; RISK BEHAVIOR; HIV-INFECTION; GAY MEN;
UNITED-STATES; HELP-SEEKING; FIT INDEXES; LIFE EVENTS; HEALTH; SUPPORT
AB Objective: Young Black men who have sex with men (YBMSM) are at extraordinarily high risk for HIV infection. Given their dual minority identity, they experience multiple forms of social oppression-racism, homophobia, and poverty. This study tested a model for how these forces contribute to their sexual risk behavior. Method: YBMSM (n = 1,289) from 2 Texas cities completed a 1-time assessment of sexual behaviors and psychosocial variables. Structural equation modeling was used to characterize relationships among variables. Results: Experiences of racism, homophobia, and socioeconomic distress were all associated with unprotected anal intercourse (UAI) either directly or indirectly in a manner largely consistent with Diaz's (1997, 1998) model of the effects of social oppression. Racism, homophobia, and socioeconomic distress were each associated with specific psychological vulnerabilities, which were in turn associated with participation in difficult sexual situations (e.g., in a public setting), and then UAI. The effects of racism were largely mediated by depressive symptoms and participation in difficult sexual situations. Homophobia was mediated by depressive symptoms, social support, and internalized homophobia. The effects of socioeconomic distress were partially mediated by decreased social support and greater participation in difficult sexual situations. Socioeconomic distress also had a significant direct effect on UAI not explained by the proposed mediators. Conclusions: Social oppression contributes to YBMSM's psychological vulnerabilities, participation in difficult sexual situations, and their UAI. Interventions to reduce sexual risk in YBMSM should address socioeconomic disadvantage, homophobia, and racism, as well as the psychological challenges that social oppression creates for them.
C1 [Huebner, David M.] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA.
[Kegeles, Susan M.; Rebchook, Gregory M.; Neilands, Torsten B.] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA.
[Peterson, John L.] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA.
[Johnson, Wayne D.; Eke, Agatha N.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Huebner, DM (reprint author), Univ Utah, Dept Psychol, 380 S 1530 E,Room 502, Salt Lake City, UT 84112 USA.
EM david.huebner@psych.utah.edu
FU Centers for Disease Control and Prevention [UR6PS000334]
FX The findings and conclusions in this report are those of the authors and
do not necessarily represent the views of the Centers for Disease
Control and Prevention. This work was supported by cooperative agreement
UR6PS000334 from the Centers for Disease Control and Prevention. The
authors are grateful for the assistance of Anne Freeman, Douglas
Sheehan, and Stephen Brown from the University of Texas Southwestern,
and Jan Risser and Paige Padgett from the University of Texas, Houston.
NR 69
TC 8
Z9 9
U1 1
U2 11
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0278-6133
EI 1930-7810
J9 HEALTH PSYCHOL
JI Health Psychol.
PD DEC
PY 2014
VL 33
IS 12
BP 1568
EP 1578
DI 10.1037/hea0000031
PG 11
WC Psychology, Clinical; Psychology
SC Psychology
GA AU6WK
UT WOS:000345741900013
PM 24274807
ER
PT J
AU Sucaldito, NL
Tayag, EA
Roces, MCR
Malison, MD
Robie, BD
Howze, EH
AF Sucaldito, Nemia L.
Tayag, Enrique A.
Roces, Maria Concepcion R.
Malison, Michael D.
Robie, Brian D.
Howze, Elizabeth H.
TI The Philippines Field Management Training Program (FMTP): strengthening
management capacity in a decentralized public health system
SO INTERNATIONAL JOURNAL OF PUBLIC HEALTH
LA English
DT Article
DE Devolution; Decentralization; Management capacity building;
Sustainability
ID DECISION-MAKING
AB Objectives The decentralization of the Philippines' health sector in 1991 sought to improve the efficiency of local health resource allocation; however, local officials were unprepared for the increased responsibility. In 1999 the Philippines Department of Health, with assistance from the US Centers for Disease Control and Prevention (CDC), implemented the Philippines Field Management Training Program (FMTP) to provide local health officials with the managerial skills needed to perform their new, more responsible jobs. This paper addresses whether the FMTP has provided participants with useful managerial skills needed for their more responsible positions.
Methods The method involved reviewing program outcomes, including results of applied management improvement projects the participants completed to solve managerial problems.
Results Between 2000 and 2010, 294 participants completed the FMTP and many were later promoted to more responsible positions. The participants also completed 204 applied management improvement projects resulting in documented improvements in service delivery, information systems, logistics, health insurance, policy and laboratory outcomes. Examples of their successes are included in this paper.
Conclusions The results provide compelling evidence that managers are using the skills learned to solve significant managerial problems.
C1 [Sucaldito, Nemia L.] NEC Corp Ltd, Appl Publ Hlth Div, Dept Hlth, Manila 1003, Philippines.
[Tayag, Enrique A.] NEC Corp Ltd, Dept Hlth, Support Serv Delivery Tech Cluster 2, Manila 1003, Philippines.
[Roces, Maria Concepcion R.] South Asia Field Epidemiol & Technol Network Inc, Sta Rosa 4026, Laguna, Philippines.
[Robie, Brian D.] CDC, Noncommunicable Dis Unit, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Robie, BD (reprint author), CDC, Noncommunicable Dis Unit, Div Global Hlth Protect, Ctr Global Hlth, 1600 Clifton Rd, Atlanta, GA 30333 USA.
EM manemia_sucaldito@yahoo.com; erictayag4health@yahoo.com;
conchyroces@gmail.com; michael.malison@gmail.com; bir8@cdc.gov;
eggggh6@gmail.com
NR 15
TC 2
Z9 2
U1 1
U2 8
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1661-8556
EI 1661-8564
J9 INT J PUBLIC HEALTH
JI Int. J. Public Health
PD DEC
PY 2014
VL 59
IS 6
BP 897
EP 903
DI 10.1007/s00038-014-0603-5
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU1NL
UT WOS:000345387400003
PM 25238870
ER
PT J
AU Bell, M
AF Bell, Michael
TI Antibiotic Misuse A Global Crisis
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID INFECTION
C1 Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
RP Bell, M (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,A-7, Atlanta, GA 30333 USA.
EM mbell@cdc.gov
NR 9
TC 6
Z9 6
U1 1
U2 13
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD DEC
PY 2014
VL 174
IS 12
BP 1920
EP 1921
DI 10.1001/jamainternmed.2014.3289
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AU9KI
UT WOS:000345911000012
PM 25285726
ER
PT J
AU Rostron, BL
Chang, CM
Pechacek, TF
AF Rostron, Brian L.
Chang, Cindy M.
Pechacek, Terry F.
TI Estimation of Cigarette Smoking-Attributable Morbidity in the United
States
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; AIRWAY-OBSTRUCTION; LUNG-DISEASE; COPD;
DIAGNOSIS; UNDERDIAGNOSIS; POPULATION; PREVALENCE; MANAGEMENT; MORTALITY
AB IMPORTANCE Cigarette smoking has been found to harm nearly every bodily organ and is a leading cause of preventable disease, but current estimates of smoking-attributable morbidity by condition for the United States are generally unavailable.
OBJECTIVE To estimate the burden of major medical conditions attributable to cigarette smoking in the United States.
DESIGN, SETTING, AND PARTICIPANTS The disease burden of smoking was estimated using population-attributable risk calculations, taking into account the uncertainty of estimates. Population estimates came from 2009 US Census Bureau data and smoking prevalence, disease prevalence, and disease relative risk estimates came from National Health Interview Survey data for surveyed adults from 2006 through 2012. National Health and Nutrition Examination Survey spirometry data obtained from medical examination of surveyed adults from 2007 through 2010 was used to adjust for underreporting of chronic obstructive pulmonary disease.
EXPOSURES Smoking status was assessed from self-reported National Health Interview Survey data.
MAIN OUTCOMES AND MEASURES The number of adults 35 years and older who had had a major smoking-attributable disease by sex and condition and the total number of these conditions were estimated for the United States in 2009.
RESULTS Using National Health Interview Survey data, we estimated that 6.9 million (95% CI, 6.5-7.4 million) US adults had had a combined 10.9 million (95% CI, 10.3-11.5 million) self-reported smoking-attributable medical conditions. Using chronic obstructive pulmonary disease prevalence estimates obtained from National Health and Nutrition Examination Survey self-reported and spirometry data, we estimated that US adults had had a combined 14.0 million (95% CI, 12.9-15.1 million) smoking-attributable conditions in 2009.
CONCLUSIONS AND RELEVANCE We estimate that US adults have had approximately 14 million major medical conditions that were attributable to smoking. This figure is generally conservative owing to the existence of other diseases and medical events that were not included in these estimates. Cigarette smoking remains a leading cause of preventable disease in the United States, underscoring the need for continuing and vigorous smoking-prevention efforts.
C1 [Rostron, Brian L.; Chang, Cindy M.] US FDA, Ctr Tobacco Prod, Silver Spring, MD 20993 USA.
[Pechacek, Terry F.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA.
RP Rostron, BL (reprint author), US FDA, Ctr Tobacco Prod, 10903 New Hampshire Ave,Bldg 75,Room 4404, Silver Spring, MD 20993 USA.
EM brian.rostron@fda.hhs.gov
NR 30
TC 23
Z9 23
U1 3
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD DEC
PY 2014
VL 174
IS 12
BP 1922
EP 1928
DI 10.1001/jamainternmed.2014.5219
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA AU9KI
UT WOS:000345911000013
PM 25317719
ER
PT J
AU Peacock, G
Uyeki, TM
Rasmussen, SA
AF Peacock, Georgina
Uyeki, Timothy M.
Rasmussen, Sonja A.
TI Ebola Virus Disease and Children What Pediatric Health Care
Professionals Need to Know
SO JAMA PEDIATRICS
LA English
DT Editorial Material
C1 [Peacock, Georgina; Uyeki, Timothy M.; Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Peacock, G (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-88, Atlanta, GA 30333 USA.
EM gpeacock@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 7
TC 7
Z9 8
U1 2
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6203
EI 2168-6211
J9 JAMA PEDIATR
JI JAMA Pediatr.
PD DEC
PY 2014
VL 168
IS 12
BP 1087
EP 1088
DI 10.1001/jamapediatrics.2014.2835
PG 2
WC Pediatrics
SC Pediatrics
GA AU9GO
UT WOS:000345900000003
PM 25325785
ER
PT J
AU Spanier, AJ
Kahn, RS
Kunselman, AR
Schaefer, EW
Hornung, R
Xu, YY
Calafat, AM
Lanphear, BP
AF Spanier, Adam J.
Kahn, Robert S.
Kunselman, Allen R.
Schaefer, Eric W.
Hornung, Richard
Xu, Yingying
Calafat, Antonia M.
Lanphear, Bruce P.
TI Bisphenol A Exposure and the Development of Wheeze and Lung Function in
Children Through Age 5 Years
SO JAMA PEDIATRICS
LA English
DT Article
ID TANDEM MASS-SPECTROMETRY; INTERIOR SURFACE MATERIALS; URINARY
CONCENTRATIONS; PRESCHOOL-CHILDREN; PULMONARY-FUNCTION; FETAL EXPOSURE;
PREGNANT-WOMEN; YOUNG-CHILDREN; 1ST YEAR; ASTHMA
AB IMPORTANCE Bisphenol A (BPA), a prevalent endocrine-disrupting chemical, has been associated with wheezing in children, but few studies have examined its effect on lung function or wheeze in older children.
OBJECTIVES To test whether BPA exposure is associated with lung function, with wheeze, and with pattern of wheeze in children during their first 5 years.
DESIGN, SETTING, AND PARTICIPANTS A birth cohort study, enrolled during early pregnancy in the greater Cincinnati, Ohio, area among 398 mother-infant dyads. We collected maternal urine samples during pregnancy (at 16 and 26 weeks) and child urine samples annually to assess gestational and child BPA exposure.
MAIN OUTCOMES AND MEASURES We assessed parent-reported wheeze every 6 months for 5 years and measured child forced expiratory volume in the first second of expiration (FEV1) at age 4 and 5 years. We evaluated associations of BPA exposure with respiratory outcomes, including FEV1, child wheeze, and wheeze phenotype.
RESULTS Urinary BPA concentrations and FEV1 data were available for 208 children and urinary BPA concentrations and parent-reported wheeze data were available for 360 children. The mean maternal urinary BPA concentration ranged from 0.53 to 293.55 mu g/g of creatinine. In multivariable analysis, every 10-fold increase in the mean maternal urinary BPA concentration was associated with a 14.2%(95% CI, -24.5% to -3.9%) decrease in the percentage predicted FEV1 at 4 years, but no association was found at 5 years. In multivariable analysis, every 10-fold increase in the mean maternal urinary BPA concentration was marginally associated with a 54.8% increase in the odds of wheezing (adjusted odds ratio, 1.55; 95% CI, 0.91-2.63). While the mean maternal urinary BPA concentration was not associated with wheeze phenotype, a 10-fold increase in the 16-week maternal urinary BPA concentration was associated with a 4.27-fold increase in the odds of persistent wheeze (adjusted odds ratio, 4.27; 95% CI, 1.37-13.30). Child urinary BPA concentrations were not associated with FEV1 or wheeze.
CONCLUSIONS AND RELEVANCE These results provide evidence suggesting that prenatal but not postnatal exposure to BPA is associated with diminished lung function and the development of persistent wheeze in children.
C1 [Spanier, Adam J.] Penn State Univ, Milton S Hershey Med Ctr, Dept Pediat, Hershey, PA 17033 USA.
[Spanier, Adam J.; Kunselman, Allen R.; Schaefer, Eric W.] Penn State Univ, Milton S Hershey Med Ctr, Dept Publ Hlth Sci, Hershey, PA 17033 USA.
[Kahn, Robert S.; Hornung, Richard; Xu, Yingying] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA.
[Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA.
[Lanphear, Bruce P.] British Columbia Childrens Hosp, Child & Family Res Inst, Vancouver, BC V6H 3V4, Canada.
[Lanphear, Bruce P.] Simon Fraser Univ, Fac Hlth Sci, Vancouver, BC, Canada.
RP Spanier, AJ (reprint author), Univ Maryland, Sch Med, Dept Pediat, 300 Armory Pl,Ste 2B2042, Baltimore, MD 21201 USA.
EM aspanier@peds.umaryland.edu
FU National Institute of Environmental Health Sciences [1K23ES016304,
PO1ES11261, 5R01ES014575-02]
FX This study was supported by Young Clinical Scientist Award 1K23ES016304,
PO1ES11261, and 5R01ES014575-02 from the National Institute of
Environmental Health Sciences.
NR 47
TC 16
Z9 17
U1 1
U2 16
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6203
EI 2168-6211
J9 JAMA PEDIATR
JI JAMA Pediatr.
PD DEC
PY 2014
VL 168
IS 12
BP 1131
EP 1137
DI 10.1001/jamapediatrics.2014.1397
PG 7
WC Pediatrics
SC Pediatrics
GA AU9GO
UT WOS:000345900000011
PM 25286153
ER
PT J
AU Ali, SA
Kazi, AM
Cortese, MM
Fleming, JA
Parashar, UD
Jiang, BM
McNeal, MM
Steele, D
Bhutta, Z
Zaidi, A
AF Ali, Syed Asad
Kazi, Abdul Momin
Cortese, Margaret M.
Fleming, Jessica A.
Parashar, Umesh D.
Jiang, Baoming
McNeal, Monica Malone
Steele, Duncan
Bhutta, Zulfiqar
Zaidi, Anita
TI Impact of Different Dosing Schedules on the Immunogenicity of the Human
Rotavirus Vaccine in Infants in Pakistan: A Randomized Trial
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE rotavirus; rotavirus vaccine; vaccination schedule; Rotarix; Pakistan
ID PLACEBO-CONTROLLED TRIAL; AFRICAN INFANTS; DOUBLE-BLIND; EFFICACY;
CHILDREN; SAFETY; GASTROENTERITIS; PROGRAMS; DISEASE; LIVE
AB Background. Current oral rotavirus vaccines perform suboptimally in resource-poor settings. We investigated the effect of an additional dose and later schedule on the immunogenicity of monovalent rotavirus vaccine (RV1) in a developing country.
Methods. Infants received RV1 at 6 and 10, 10 and 14, or 6, 10, and 14 weeks of age. The primary objective was to compare antirotavirus immunoglobulin A (IgA) seroconversion at 18 weeks in the 6/10/14 arm to the cumulative seroconversion (highest result at 14 or 18 weeks) in the 6/10 arm.
Results. Overall, 480 (76.2%) of 630 randomized infants completed the trial per protocol. Seroconversion in the 6/10/14 arm was 36.7% (95% CI, 29.8, 44.2) compared to 36.1% (CI, 29.0, 43.9) in the 6/10 arm, (P = 1.0); the result from the 10/14 arm was 38.5% (CI, 31.2, 46.3). Seroconversion in the 6/10 arm at 14 weeks (post hoc) was lower at 29.7% (CI, 23.1, 37.3).
Conclusions. In Pakistani infants, the immunogenicity of RV1 did not increase significantly with 3 doses at 6, 10, and 14 weeks compared to 2 doses at 6 and 10 weeks. Additional strategies should be evaluated for improving rotavirus vaccine immunogenicity in high burden countries.
C1 [Ali, Syed Asad; Kazi, Abdul Momin; Bhutta, Zulfiqar; Zaidi, Anita] Aga Khan Univ, Dept Pediat & Child Hlth, Karachi, Pakistan.
[Cortese, Margaret M.; Parashar, Umesh D.; Jiang, Baoming] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Fleming, Jessica A.; Steele, Duncan] Program Appropriate Technol Hlth PATH, Seattle, WA USA.
[McNeal, Monica Malone] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Dept Pediat, Cincinnati, OH 45229 USA.
RP Ali, SA (reprint author), Aga Khan Univ, Dept Paediat & Child Hlth, Stadium Rd, Karachi, Pakistan.
EM asad.ali@aku.edu
FU PATH through Global Alliance for Vaccines and Immunization (GAVI)
FX This work was supported by PATH through funding from the Global Alliance
for Vaccines and Immunization (GAVI). The findings and conclusions in
this report are those of the author(s) and do not necessarily represent
the official position of GAVI, PATH, or the Centers for Disease Control
and Prevention.
NR 17
TC 9
Z9 9
U1 1
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 1
PY 2014
VL 210
IS 11
BP 1772
EP 1779
DI 10.1093/infdis/jiu335
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AU7HI
UT WOS:000345771000011
PM 24939906
ER
PT J
AU Monto, AS
Malosh, RE
Petrie, JG
Thompson, MG
Ohmit, SE
AF Monto, Arnold S.
Malosh, Ryan E.
Petrie, Joshua G.
Thompson, Mark G.
Ohmit, Suzanne E.
TI Frequency of Acute Respiratory Illnesses and Circulation of Respiratory
Viruses in Households With Children Over 3 Surveillance Seasons
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE acute respiratory illnesses; influenza; respiratory viruses; households
with children; surveillance
ID INFLUENZA VACCINE EFFECTIVENESS; RHINOVIRUS INFECTIONS; YOUNG-CHILDREN;
INDUSTRIAL POPULATION; HUMAN METAPNEUMOVIRUS; VIRAL-INFECTIONS; TRACT
INFECTIONS; UNITED-STATES; CORONAVIRUS; COMMUNITY
AB Background. The household has traditionally been the site for studying acute respiratory illnesses (ARIs). Most studies were conducted many years ago, and more broadly sensitive laboratory methods to determine ARI etiology are now available.
Methods. We recruited and followed households with children over 3 annual surveillance periods and collected respiratory tract specimens from subjects with reported ARI. Virus etiology was determined by real-time reverse-transcription polymerase chain reaction (RT-PCR) analysis.
Results. Individuals in larger households (defined as households with > 4 members) and those in households with children aged < 5 years had significantly higher ARI frequencies than others. ARI frequency generally declined with increasing age. Virus etiology was most likely to be determined in young children, who were also most likely to have virus coinfection. Overall, 16% of ARIs with 1 virus identified had a parts per thousand yen1 coinfecting virus. Rhinoviruses and coronaviruses were the most frequently identified agents of ARI in all age categories. Influenza virus and adenovirus were less frequently identified but were most likely to cause ARI that required medical attention.
Conclusions. Longitudinal studies in families remain a valuable way to study respiratory infections. RT-PCR has increased the sensitivity of virus detection, including coinfecting viruses, and expanded our ability to detect viruses now known to cause ARI.
C1 [Monto, Arnold S.; Malosh, Ryan E.; Petrie, Joshua G.; Ohmit, Suzanne E.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Thompson, Mark G.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
RP Ohmit, SE (reprint author), Univ Michigan, Sch Publ Hlth, 1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM sohmit@umich.edu
FU National Institute of Allergy and Infectious Diseases [R01 AI097150];
Centers for Disease Control and Prevention [U01 IP000474]
FX This work was supported by the National Institute of Allergy and
Infectious Diseases (grant R01 AI097150) and the Centers for Disease
Control and Prevention (grant U01 IP000474).
NR 41
TC 19
Z9 19
U1 1
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 1
PY 2014
VL 210
IS 11
BP 1792
EP 1799
DI 10.1093/infdis/jiu327
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AU7HI
UT WOS:000345771000013
PM 24907381
ER
PT J
AU Pandey, JP
Kistner-Griffin, E
Radwan, FF
Kaur, N
Namboodiri, AM
Black, L
Butler, MA
Carreon, T
Ruder, AM
AF Pandey, Janardan P.
Kistner-Griffin, Emily
Radwan, Faisal F.
Kaur, Navtej
Namboodiri, Aryan M.
Black, Laurel
Butler, Mary Ann
Carreon, Tania
Ruder, Avima M.
TI Immunoglobulin Genes Influence the Magnitude of Humoral Immunity to
Cytomegalovirus Glycoprotein B
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE GM allotypes; humoral immunity; human cytomegalovirus; glycoprotein B;
candidate genes
ID ASSOCIATION; NEUROBLASTOMA; MARKERS
AB Human cytomegalovirus (HCMV) is a risk factor for many human diseases, but among exposed individuals, not everyone is equally likely to develop HCMV-spurred diseases, implying the presence of host genetic factors that might modulate immunity to this virus. Here, we show that antibody responsiveness to HCMV glycoprotein B (gB) is significantly associated with particular immunoglobulin GM (gamma marker) genotypes. Anti-HCMV gB antibody levels were highest in GM 17/17 homozygotes, intermediate in GM 3/17 heterozygotes, and lowest in GM 3/3 homozygotes (28.2, 19.0, and 8.1 A mu g/mL, respectively; P = .014). These findings provide mechanistic insights in the etiopathogenesis of HCMV-spurred diseases.
C1 [Pandey, Janardan P.; Radwan, Faisal F.; Kaur, Navtej; Namboodiri, Aryan M.; Black, Laurel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
[Kistner-Griffin, Emily] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA.
[Butler, Mary Ann; Carreon, Tania; Ruder, Avima M.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA.
RP Pandey, JP (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
EM pandeyj@musc.edu
FU National Institute of Neurological Disorders and Stroke, National
Institutes of Health (NIH) [NS078545]; Avon Foundation; National
Institute for Occupational Safety and Health, CDC
FX This work was supported by the National Institute of Neurological
Disorders and Stroke, National Institutes of Health (NIH; grant
NS078545); the Avon Foundation; and the National Institute for
Occupational Safety and Health, CDC.
NR 15
TC 4
Z9 4
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 1
PY 2014
VL 210
IS 11
BP 1823
EP 1826
DI 10.1093/infdis/jiu367
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AU7HI
UT WOS:000345771000016
PM 24973460
ER
PT J
AU Lipscomb, JT
Switzer, WM
Li, JF
Masciotra, S
Owen, SM
Johnson, JA
AF Lipscomb, Jonathan T.
Switzer, William M.
Li, Jin-fen
Masciotra, Silvina
Owen, S. Michele
Johnson, Jeffrey A.
TI HIV Reverse-Transcriptase Drug Resistance Mutations During Early
Infection Reveal Greater Transmission Diversity Than in Envelope
Sequences
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE acute HIV-1 infection; HIV-1 diversity; HIV seroconversion; minority
resistance mutations; HIV transmission; multiplicity of infection
ID VARIANTS; DYNAMICS; K65R; SEROCONVERSION; DIAGNOSIS; DONORS; TIME
AB Background. Drug resistance mutations (DRMs) can serve as distinct, nonpolymorphic markers for evaluating diversity of expressed HIV-1. We screened for DRMs during early-acute viremia and examined the diversity in reverse transcriptase (RT) relative to envelope (env) in cases of transmitted drug resistance.
Methods. We evaluated 111 longitudinal plasma samples collected every 2-7 days from 15 individuals who seroconverted for HIV-1 infection in 1994-2000. The samples were screened with sensitive polymerase chain reaction assays for the commonly transmitted M41L and K70R mutations and for K65R, which was undetected by bulk sequencing. Mutation-positive samples were further characterized by clonal sequencing of RT and env V1-V3.
Results. Drug resistance mutations were detected in 4 of 15 seroconverters at 5-50 days of viral nucleic acid expression; most mutations disappeared about the time of seroconversion. Clonal sequencing verified low-level K65R at frequencies of 0.4%-4.9%. In each case, K65R coexisted unlinked with variants carrying 2-5 thymidine analog mutations at frequencies of 1.6%-23.0%. In one seroconverter, variants with M184V and nonnucleoside RT inhibitor mutations were also identified at first RNA expression. Each seroconverter displayed a homogeneous V1-V3 env population.
Conclusions. Reverse-transcriptase DRMs demonstrate that the breadth of variants in transmission may be greater than what is reflected in envelope sequences.
C1 [Lipscomb, Jonathan T.; Switzer, William M.; Li, Jin-fen; Masciotra, Silvina; Owen, S. Michele; Johnson, Jeffrey A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
RP Lipscomb, JT (reprint author), 1600 Clifton Rd NE,MS G45, Atlanta, GA 30333 USA.
EM jjohnson1@cdc.gov
FU Centers for Disease Control and Prevention
FX This work was supported entirely by intramural funds from the Centers
for Disease Control and Prevention.
NR 21
TC 3
Z9 3
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 1
PY 2014
VL 210
IS 11
BP 1827
EP 1837
DI 10.1093/infdis/jiu333
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AU7HI
UT WOS:000345771000017
PM 24924164
ER
PT J
AU Aral, SO
Ward, H
AF Aral, Sevgi O.
Ward, Helen
TI Behavioral Convergence: Implications for Mathematical Models of Sexually
Transmitted Infection Transmission
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE sex work; mathematical models; sexually transmitted infections; sexual
behavior
ID COMMERCIAL SEX WORK; WOMEN; RUSSIA; HEALTH; HIV
AB Recent trends in the behaviors of some groups with high sexual activity and of the general population in some countries suggest that sexual behavior profiles of high and low sexual activity categories may be converging and may call into question the assumptions around sexual mixing that are built into theoretical models of sexually transmitted infections (STIs)/human immunodeficiency virus (HIV) transmission dynamics. One category of high sexual activity, sex work, has been undergoing modification in many societies, becoming more acceptable, more dispersed, and larger in volume in some societies and shrinking in others. Concurrent with changes in the characteristics of sex work, the accumulating data on the sexual behaviors of the general population suggest a shift toward those of sex workers, including large numbers of sex partners and short-duration partnerships. The closing of the gap between behaviors associated with high and low sexual activity may have important implications for theories of sexual structure and models of transmission dynamics for STIs, including HIV infection.
C1 [Aral, Sevgi O.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
[Ward, Helen] Imperial Coll London, Sch Publ Hlth, Dept Infect Dis Epidemiol, London, England.
RP Aral, SO (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,Mailstop E02, Atlanta, GA 30333 USA.
EM saral@cdc.gov
OI Ward, Helen/0000-0001-8238-5036
FU Wellcome Trust [G090285/Z/09]
FX This work was supported by the Wellcome Trust (G090285/Z/09 to H. W.).
NR 35
TC 3
Z9 3
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 1
PY 2014
VL 210
SU 2
BP S600
EP S604
DI 10.1093/infdis/jiu431
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AU7HM
UT WOS:000345771500009
PM 25381381
ER
PT J
AU Paulozzi, LJ
Mack, KA
Hockenberry, JM
AF Paulozzi, Leonard J.
Mack, Karin A.
Hockenberry, Jason M.
TI Variation among states in prescribing of opioid pain relievers and
benzodiazepines - United States, 2012
SO JOURNAL OF SAFETY RESEARCH
LA English
DT Article
DE Opioid; Benzodiazepine; Drug abuse; Inappropriate prescribing
ID GEOGRAPHIC-VARIATION; REGIONAL-VARIATIONS; ANALGESICS; FLORIDA; DEATHS;
ABUSE
AB Introduction: Overprescribing of opioid pain relievers (OPR) can result in multiple adverse health outcomes, including fatal overdoses. Interstate variation in rates of prescribing OPR and other prescription drugs prone to abuse, such as benzodiazepines, might indicate areas where prescribing patterns need further evaluation. Methods: CDC analyzed a commercial database (IMS Health) to assess the potential for improved prescribing of OPR and other drugs. CDC calculated state rates and measures of variation for OPR, long-acting/extended-release (LA/ER) OPR, high-dose OPR, and benzodiazepines. Results: In 2012, prescribers wrote 82.5 OPR and 37.6 benzodiazepine prescriptions per 100 persons in the United States. State rates varied 2.7-fold for OPR and 3.7-fold for benzodiazepines. For both OPR and benzodiazepines, rates were higher in the South census region, and three Southern states were two or more standard deviations above the mean. Rates for LA/ER and high-dose OPR were highest in the Northeast. Rates varied 22-fold for one type of OPR, oxymorphone. Conclusions: Factors accounting for the regional variation are unknown. Such wide variations are unlikely to be attributable to underlying differences in the health status of the population. High rates indicate the need to identify prescribing practices that might not appropriately balance pain relief and patient safety. Implications for Public Health: State policy makers might reduce the harms associated with the abuse of prescription drugs by implementing changes that will make the prescribing of these drugs more cautious and more consistent with clinical recommendations. National Safety Council and Elsevier Ltd.
C1 [Paulozzi, Leonard J.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
[Mack, Karin A.] CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
[Hockenberry, Jason M.] Emory Univ, Dept Hlth Policy & Management, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
RP Hockenberry, JM (reprint author), Emory Univ, Dept Hlth Policy & Management, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
EM lpaulozzi@cdc.gov
NR 18
TC 7
Z9 7
U1 2
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-4375
EI 1879-1247
J9 J SAFETY RES
JI J. Saf. Res.
PD DEC
PY 2014
VL 51
BP 125
EP 129
DI 10.1016/j.jsr.2014.09.001
PG 5
WC Ergonomics; Public, Environmental & Occupational Health; Social
Sciences, Interdisciplinary; Transportation
SC Engineering; Public, Environmental & Occupational Health; Social
Sciences - Other Topics; Transportation
GA AU6PA
UT WOS:000345723400017
PM 25453186
ER
PT J
AU Vargas, CM
Dye, BA
Kolasny, CR
Buckman, DW
McNeel, TS
Tinanoff, N
Marshall, TA
Levy, SM
AF Vargas, Clemencia M.
Dye, Bruce A.
Kolasny, Catherine R.
Buckman, Dennis W.
McNeel, Timothy S.
Tinanoff, Norman
Marshall, Teresa A.
Levy, Steven M.
TI Early childhood caries and intake of 100 percent fruit juice Data from
NHANES, 1999-2004
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Article
DE Caries; eating habits; pediatric dentistry; epidemiology; National
Health and Nutrition Examination Survey
ID EPISODICALLY CONSUMED FOODS; AFRICAN-AMERICAN CHILDREN; PEDIATRIC
DENTAL-CARIES; ORAL-HEALTH COMPONENT; YOUNG-CHILDREN; LOW-INCOME;
QUALITY-ASSURANCE; NATIONAL-HEALTH; SOFT DRINKS; US CHILDREN
AB Background. The results of several studies conducted in the United States show no association between intake of 100 percent fruit juice and early childhood caries (ECC). The authors examined this association according to poverty and race/ethnicity among U.S. preschool children.
Methods. The authors analyzed data from the 19992004 National Health and Nutrition Examination Survey (NHANES) for 2,290 children aged 2 through 5 years. They used logistic models for caries (yes or no) to assess the association between caries and intake of 100 percent fruit juice, defined as consumption (yes or no), ounces (categories) consumed in the previous 24 hours or usual intake (by means of a statistical method from the National Cancer Institute).
Results. The association between caries and consumption of 100 percent fruit juice (yes or no) was not statistically significant in an unadjusted logistic model (odds ratio [OR], 0.76; 95 percent confidence interval [CI], 0.57-1.01), and it remained nonsignificant after covariate adjustment (OR, 0.89; 95 percent CI, 0.63-1.24). Similarly, models in which we evaluated categorical consumption of 100 percent juice (that is, 0 oz; > 0 and <= 6 oz; and > 6 oz), unadjusted and adjusted by covariates, did not indicate an association with ECC.
Conclusions. Our study findings are consistent with those of other studies that show consumption of 100 percent fruit juice is not associated with ECC.
Practical Implications. Dental practitioners should educate their patients and communities about the low risk of developing caries associated with consumption of 100 percent fruit juice. Limiting consumption of 100 percent fruit juice to 4 to 6 oz per day among children 1 through 5 years of age should be taught as part of general health education.
C1 [Vargas, Clemencia M.; Kolasny, Catherine R.] Univ Maryland, Sch Dent, Baltimore, MD 21250 USA.
[Dye, Bruce A.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
[Buckman, Dennis W.; McNeel, Timothy S.] Informat Management Serv Inc, Calverton, MD USA.
[Tinanoff, Norman] Univ Maryland, Sch Dent, Div Pediat Dent, Baltimore, MD USA.
[Marshall, Teresa A.] Univ Iowa, Coll Dent, Dept Prevent & Community Dent, Iowa City, IA 52242 USA.
[Levy, Steven M.] Univ Iowa, Coll Dent, Iowa City, IA 52242 USA.
[Levy, Steven M.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA.
RP Vargas, CM (reprint author), Univ Maryland, Sch Dent, 650 W Baltimore St,Room 2217, Baltimore, MD 21250 USA.
EM cvargas@umaryland.edu
FU National Institute of Dental and Craniofacial Research, National
Institutes of Health, Bethesda, Md. [5R03 DE 018389-02]
FX This research was funded by grant 5R03 DE 018389-02 from the National
Institute of Dental and Craniofacial Research, National Institutes of
Health, Bethesda, Md., to Dr. Vargas.
NR 37
TC 2
Z9 3
U1 1
U2 10
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
EI 1943-4723
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD DEC
PY 2014
VL 145
IS 12
BP 1254
EP 1261
PG 8
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA AU5GF
UT WOS:000345634400016
PM 25429039
ER
PT J
AU Grigorescu, VI
D'Angelo, DV
Harrison, LL
Taraporewalla, AJ
Shulman, H
Smith, RA
AF Grigorescu, Violanda I.
D'Angelo, Denise V.
Harrison, Leslie L.
Taraporewalla, Aspy J.
Shulman, Holly
Smith, Ruben A.
TI Implementation Science and the Pregnancy Risk Assessment Monitoring
System
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
AB This paper describes the restructuring of the Pregnancy Risk Assessment Monitoring System (PRAMS), a surveillance system of the Centers for Disease Control and Prevention (CDC)'s Division of Reproductive Health conducted for 25 years in collaboration with state and city health departments. With the ultimate goal to better inform health care providers, public health programs, and policy, changes were made to various aspects of PRAMS to enhance its capacity on assessing and monitoring public health interventions and clinical practices in addition to risk behaviors, disease prevalence, comorbidities, and service utilization. Specifically, the three key PRAMS changes identified as necessary and described in this paper are questionnaire revision, launching the web-based centralized PRAMS Integrated Data Collection System, and enhancing the access to PRAMS data through the web query system known as Centers for Disease Control and Prevention's PRAMS Online Data for Epidemiologic Research/PRAMStat. The seven action steps of Knowledge To Action cycle, an illustration of the implementation science process, that reflect the milestones necessary in bridging the knowledge-to-action gap were used as framework for each of these key changes.
C1 [Grigorescu, Violanda I.; D'Angelo, Denise V.; Harrison, Leslie L.; Taraporewalla, Aspy J.; Shulman, Holly; Smith, Ruben A.] Ctr Dis Control & Prevent, Appl Sci Branch, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
RP Grigorescu, VI (reprint author), Ctr Dis Control & Prevent, Appl Sci Branch, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway, Atlanta, GA 30341 USA.
EM vdg6@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 16
TC 0
Z9 0
U1 1
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD DEC 1
PY 2014
VL 23
IS 12
BP 989
EP 994
DI 10.1089/jwh.2014.5047
PG 6
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA AW1SM
UT WOS:000346070200001
PM 25405525
ER
PT J
AU Homsy, J
Dorsey, G
Arinaitwe, E
Wanzira, H
Kakuru, A
Bigira, V
Muhindo, M
Kamya, MR
Sandison, TG
Tappero, JW
AF Homsy, Jaco
Dorsey, Grant
Arinaitwe, Emmanuel
Wanzira, Humphrey
Kakuru, Abel
Bigira, Victor
Muhindo, Mary
Kamya, Moses R.
Sandison, Taylor G.
Tappero, Jordan W.
TI Protective efficacy of prolonged co-trimoxazole prophylaxis in
HIV-exposed children up to age 4 years for the prevention of malaria in
Uganda: a randomised controlled open-label trial
SO LANCET GLOBAL HEALTH
LA English
DT Article
ID TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS; HUMAN-IMMUNODEFICIENCY-VIRUS;
INSECTICIDE-TREATED BEDNETS; INFECTED ZAMBIAN CHILDREN; SUB-SAHARAN
AFRICA; ANTIRETROVIRAL THERAPY; RURAL UGANDA; SULFADOXINE-PYRIMETHAMINE;
TRANSMISSION INTENSITY; FALCIPARUM-MALARIA
AB Background WHO recommends daily co-trimoxazole for children born to HIV-infected mothers from 6 weeks of age until breastfeeding cessation and exclusion of HIV infection. We have previously reported on the effectiveness of continuation of co-trimoxazole prophylaxis up to age 2 years in these children. We assessed the protective efficacy and safety of prolonging co-trimoxazole prophylaxis until age 4 years in HIV-exposed children.
Methods We undertook an open-label randomised controlled trial alongside two observational cohorts in eastern Uganda, an area with high HIV prevalence, malaria transmission intensity, and antifolate resistance. We enrolled HIV-exposed infants between 6 weeks and 9 months of age and prescribed them daily co-trimoxazole until breastfeeding cessation and HIV-status confirmation. At the end of breastfeeding, children who remained HIV-uninfected were randomly assigned (1:1) to discontinue co-trimoxazole or to continue taking it up to age 2 years. At age 2 years, children who continued co-trimoxazole prophylaxis were randomly assigned (1:1) to discontinue or continue prophylaxis from age 2 years to age 4 years. The primary outcome was incidence of malaria (defined as the number of treatments for new episodes of malaria diagnosed with positive thick smear) at age 4 years. For additional comparisons, we observed 48 HIV-infected children who took continuous co-trimoxazole prophylaxis and 100 HIV-unexposed uninfected children who never received prophylaxis. We measured grade 3 and 4 serious adverse events and hospital admissions. All children were followed up to age 5 years and all analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00527800.
Findings 203 HIV-exposed infants were enrolled between Aug 10, 2007, and March 28, 2008. After breastfeeding ended, 185 children were not infected with HIV and were randomly assigned to stop (n=87) or continue (n=98) co-trimoxazole up to age 2 years. At age 2 years, 91 HIV-exposed children who had remained on co-trimoxazole prophylaxis were randomly assigned to discontinue (n=46) or continue (n=45) co-trimoxazole from age 2 years to age 4 years. We recorded 243 malaria episodes (2.91 per person-years) in the 45 HIV-exposed children assigned to continue co-trimoxazole until age 4 years compared with 503 episodes (5.60 per person-years) in the 46 children assigned to stop co-trimoxazole at age 2 years (incidence rate ratio 0.53, 95% CI 0.39-0.71; p<0.0001). There was no evidence of malaria incidence rebound in the year after discontinuation of co-trimoxazole in the HIV-exposed children who stopped co-trimoxazole at age 2 years, but incidence increased significantly in HIV-exposed children who stopped co-trimoxazole at age 4 years (odds ratio 1.78, 95% CI 1.19-2.66; p=0.005). Incidence of grade 3 or 4 serious adverse events, hospital admissions, or deaths did not significantly differ between HIV-exposed, HIV-unexposed, and HIV-infected children.
Interpretation Continuation of co-trimoxazole prophylaxis up to 4 years of age seems safe and efficacious to protect HIV-exposed children living in malaria-endemic areas.
C1 [Homsy, Jaco] Univ Calif San Francisco, San Francisco, CA 94158 USA.
[Dorsey, Grant; Muhindo, Mary] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA.
[Homsy, Jaco; Tappero, Jordan W.] Ctr Dis Control & Prevent, Entebbe, Uganda.
[Arinaitwe, Emmanuel; Wanzira, Humphrey; Kakuru, Abel; Bigira, Victor] Infect Dis Res Collaborat, Kampala, Uganda.
[Kamya, Moses R.] Makerere Univ, Sch Med, Dept Med, Kampala, Uganda.
[Sandison, Taylor G.] Univ Washington, Dept Med, Seattle, WA USA.
[Tappero, Jordan W.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA.
RP Homsy, J (reprint author), Univ Calif San Francisco, San Francisco, CA 94158 USA.
EM jaco.homsy@ucsf.edu
FU Centers for Disease Control and Prevention Global AIDS Program, Doris
Duke Charitable Foundation
FX Centers for Disease Control and Prevention Global AIDS Program, Doris
Duke Charitable Foundation
NR 51
TC 6
Z9 6
U1 3
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2214-109X
J9 LANCET GLOB HEALTH
JI Lancet Glob. Health
PD DEC
PY 2014
VL 2
IS 12
BP E727
EP E736
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU5SB
UT WOS:000345665600021
PM 25433628
ER
PT J
AU Jarvis, MJ
Giovino, GA
O'Connor, RJ
Kozlowski, LT
Bernert, JT
AF Jarvis, Martin J.
Giovino, Gary A.
O'Connor, Richard J.
Kozlowski, Lynn T.
Bernert, John T.
TI Variation in Nicotine Intake Among US Cigarette Smokers During the Past
25 Years: Evidence From NHANES Surveys
SO NICOTINE & TOBACCO RESEARCH
LA English
DT Article
ID TANDEM MASS-SPECTROMETRY; COTININE MEASUREMENTS; SERUM COTININE;
NONSMOKERS; VALIDATION; EXPOSURE
AB To estimate changes in nicotine intakes among U.S. cigarette smokers from 1988 to 2012 with the National Health and Nutrition Examination Survey (NHANES).
NHANES provides data on nationally representative samples of cigarette smokers from the civilian noninstitutionalized U.S. population. A total of 4,304 smokers aged 20 years and older were studied in NHANES III 1988-1994 and 7,095 were studied in the continuous NHANES 1999-2012. We examined serum cotinine concentrations, daily cigarette consumption, and estimated nicotine intake per cigarette, with adjustment for sex, age, racial/ethnic background, level of education, and body mass index.
There was little overall change in nicotine intake from smoking cigarettes either in the U.S. population as a whole or in major racial/ethnic subgroups during the 25-year period from 1988. Serum cotinine averaged 223.7ng/mL (95% confidence interval [CI] = 216.1-231.3) in 1988-1994, which was not significantly different from the adjusted mean of 219.2ng/mL (95% CI = 214.1-224.4) in 1999-2012. During the same period, average daily cigarette consumption declined substantially, from 17.3 (95% CI = 16.5-18.0) in 1988-1994 to 12.3 (95% CI = 11.0-13.6) by 2012. Cotinine per cigarette smoked increased by some 42% between 1988-1994 and 2011-2012, from a geometric mean of 12.4 (95% CI = 11.7-13.1) to 17.6 (95% CI = 16.1-19.2).
Reductions in cigarette smoking prevalence since the late 1980s, changes in cigarette product design, and the widespread introduction of smoke-free policies have not had a significant impact on nicotine intakes among U.S. smokers. Reductions in cigarette consumption have been offset by increased nicotine intake per cigarette smoked.
C1 [Jarvis, Martin J.] UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England.
[Giovino, Gary A.; Kozlowski, Lynn T.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Community Hlth & Hlth Behav, New York, NY USA.
[O'Connor, Richard J.] Roswell Pk Canc Inst, Dept Hlth Behav, Buffalo, NY 14263 USA.
[Bernert, John T.] Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA USA.
RP Jarvis, MJ (reprint author), UCL, Dept Epidemiol & Publ Hlth, 1-19 Torrington Pl, London WC1E 6BT, England.
EM martin.jarvis@ucl.ac.uk
RI O'Connor, Richard/A-6961-2009; Jarvis, Martin/B-1034-2008
OI Jarvis, Martin/0000-0001-9238-8038
NR 20
TC 3
Z9 3
U1 1
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-2203
EI 1469-994X
J9 NICOTINE TOB RES
JI Nicotine Tob. Res.
PD DEC
PY 2014
VL 16
IS 12
BP 1620
EP 1628
DI 10.1093/ntr/ntu120
PG 9
WC Substance Abuse; Public, Environmental & Occupational Health
SC Substance Abuse; Public, Environmental & Occupational Health
GA AU7IE
UT WOS:000345773300014
PM 25063772
ER
PT J
AU Fleming-Dutra, KE
Shapiro, DJ
Hicks, LA
Gerber, JS
Hersh, AL
AF Fleming-Dutra, Katherine E.
Shapiro, Daniel J.
Hicks, Lauri A.
Gerber, Jeffrey S.
Hersh, Adam L.
TI Race, Otitis Media, and Antibiotic Selection
SO PEDIATRICS
LA English
DT Article
DE otitis media; antibiotic use; NAMCS; NHAMCS; children; pediatric
ID STREPTOCOCCUS-PNEUMONIAE INFECTIONS; RESPIRATORY-TRACT INFECTIONS; 1ST 2
YEARS; UNITED-STATES; AMBULATORY-CARE; RISK-FACTORS; CHILDREN;
PREVALENCE; MANAGEMENT; SETTINGS
AB BACKGROUND AND OBJECTIVE: Previous research suggests that physicians may be less likely to diagnose otitis media (OM) and to prescribe broad-spectrum antibiotics for black versus nonblack children. Our objective was to determine whether race is associated with differences in OM diagnosis and antibiotic prescribing nationally.
METHODS: We examined OM visit rates during 2008 to 2010 for children <= 14 years old using the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey. We compared OM visits between black and nonblack children, as percentages of all outpatient visits and visit rates per 1000. We compared antibiotic prescribing by race as the percentage of OM visits receiving narrow-spectrum (eg, amoxicillin) versus broader-spectrum antibiotics. We used multivariable logistic regression to examine whether race was independently associated with antibiotic selection for OM.
RESULTS: The percentage of all visits resulting in OM diagnosis was 30% lower in black children compared with others (7% vs 10%, P = .004). However, OM visits per 1000 population were not different between black and nonblack children (253 vs 321, P = .12). When diagnosed with OM during visits in which antibiotics were prescribed, black children were less likely to receive broad-spectrum antibiotics than nonblack children (42% vs 52%, P = .01). In multivariable analysis, black race was negatively associated with broad-spectrum antibiotic prescribing (adjusted odds ratio 0.59; 95% confidence interval, 0.40-0.86).
CONCLUSIONS: Differences in treatment choice for black children with OM may indicate race-based differences in physician practice patterns and parental preferences for children with OM.
C1 [Fleming-Dutra, Katherine E.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA.
[Shapiro, Daniel J.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Hicks, Lauri A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Gerber, Jeffrey S.] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Gerber, Jeffrey S.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Hersh, Adam L.] Univ Utah, Salt Lake City, UT USA.
RP Fleming-Dutra, KE (reprint author), Childrens Healthcare Atlanta, Div Emergency Med, 1645 Tullie Circle, Atlanta, GA 30329 USA.
EM keflemi@emory.edu
FU Centers for Disease Control and Prevention
FX Funding for this study was provided by the Centers for Disease Control
and Prevention.
NR 33
TC 10
Z9 10
U1 1
U2 4
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD DEC
PY 2014
VL 134
IS 6
BP 1059
EP 1066
DI 10.1542/peds.2014-1781
PG 8
WC Pediatrics
SC Pediatrics
GA AU8KB
UT WOS:000345844200044
PM 25404720
ER
PT J
AU Sull, M
Eavey, J
Papadouka, V
Mandell, R
Hansen, MA
Zucker, JR
AF Sull, Monica
Eavey, Joanna
Papadouka, Vikki
Mandell, Rebecca
Hansen, Michael A.
Zucker, Jane R.
TI Adolescent Vaccine Co-administration and Coverage in New York City:
2007-2013
SO PEDIATRICS
LA English
DT Article
DE HPV vaccine; Tdap; MCV4; adolescent immunization; co-administration
ID HUMAN-PAPILLOMAVIRUS VACCINATION; NATIONAL IMMUNIZATION SURVEY; AGED
13-17 YEARS; UNITED-STATES; MISSED OPPORTUNITIES; QUADRIVALENT VACCINE;
ADVISORY-COMMITTEE; SENTINEL SITES; PRACTICES ACIP; ENTRY
AB OBJECTIVES: To investigate adolescent vaccination in New York City, we assessed tetanus, diphtheria, and acellular pertussis (Tdap), meningococcal conjugate (MCV4), and human papillomavirus (HPV) vaccine uptake, vaccine co-administration, and catch-up coverage over time.
METHODS: We analyzed data from the Citywide Immunization Registry, a population-based immunization information system, to measure vaccine uptake and co-administration, defined as a Tdap vaccination visit where MCV4 or HPV vaccine was co-administered, among 11-year-olds. Catch-up vaccinations were evaluated through 2013 for adolescents born 1996 to 2000, by birth cohort. HPV vaccination among boys included data from 2010 to 2013.
RESULTS: Adolescent vaccine administration was greatest during the back-to-school months of August to October and was highest for Tdap. Although MCV4 uptake improved over the study years, HPV vaccine uptake among girls stagnated; boys achieved similar uptake of HPV vaccine by 2012. By 2013, 65.4% had MCV4 co-administered with Tdap vaccine, whereas 28.4% of girls and 25.9% of boys had their first dose of HPV vaccine co-administered. By age 17, Tdap and MCV4 vaccination coverage increased to 97.5% and 92.8%, respectively, whereas $ 1-dose and 3-dose HPV vaccination coverage were, respectively, 77.5% and 53.1% for girls and 49.3% and 21.6% for boys. Age-specific vaccination coverage increased with each successive birth cohort (P,.001).
CONCLUSIONS: From 2007 to 2013, there were greater improvements in Tdap and MCV4 vaccination than HPV vaccination, for which coadministration with Tdap vaccine and coverage through adolescence remained lower. Parent and provider outreach efforts should promote timely HPV vaccination for all adolescents and vaccine co-administration.
C1 [Sull, Monica; Eavey, Joanna; Papadouka, Vikki; Mandell, Rebecca; Hansen, Michael A.; Zucker, Jane R.] New York City Dept Hlth & Mental Hyg, Bur Immunizat, New York, NY USA.
[Eavey, Joanna] Univ Michigan, Ctr Hlth Stat, Washington Dept Hlth, Ann Arbor, MI 48109 USA.
[Mandell, Rebecca] Univ Michigan, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA.
[Hansen, Michael A.] Atlantic Management Ctr Inc, Columbus, OH USA.
[Zucker, Jane R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA USA.
RP Sull, M (reprint author), New York City Dept Hlth & Mental Hyg, Gotham Ctr, Bur Immunizat, 42-09 28th St, Long Isl City, NY 11101 USA.
EM msull@health.nyc.gov
FU Centers for Disease Control and Prevention [CDC-RFA-IP13-1301];
Prevention and Public Health Fund [CDC-RFAIP12-1206PPHF12]
FX This work was supported by Centers for Disease Control and Prevention
grant CDC-RFA-IP13-1301 and Prevention and Public Health Fund grant
CDC-RFAIP12- 1206PPHF12.
NR 38
TC 2
Z9 5
U1 0
U2 3
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD DEC
PY 2014
VL 134
IS 6
BP E1576
EP E1583
DI 10.1542/peds.2014-1452
PG 8
WC Pediatrics
SC Pediatrics
GA AU8KB
UT WOS:000345844200009
PM 25384490
ER
PT J
AU Kolasa, MS
Stevenson, J
Ossa, A
Lutz, J
AF Kolasa, M. S.
Stevenson, J.
Ossa, A.
Lutz, J.
TI Does closure of children's medical home impact their immunization
coverage?
SO PUBLIC HEALTH
LA English
DT Article
DE Immunization; Minority health; Children/adolescents; Health disparities;
Health services
AB Objectives: Little is known about the impact closing a health care facility has on immunization coverage of children utilizing that facility as a medical home. The authors assessed the impact of closing a Medicaid managed care facility in Philadelphia on immunization coverage of children, primarily low income children from racial/ethnic minority groups, utilizing that facility for routine immunizations.
Study design: Observational longitudinal cohort case study.
Methods: Eligible children were born 03/01/05-06/30/07, present in Philadelphia's immunization information system (IIS), and were active clients of the facility before it closed in September 2007. IIS-recorded immunization coverage at ages 5, 7, 13, 16 and 19 months through January 2009 was compared between clinic children age-eligible to receive specific vaccines before clinic closing (preclosure cohorts) and children not age-eligible to receive those vaccines prior to closing (postclosure cohorts).
Results: Of 630 eligible children, 99 (16%) had no additional IIS-recorded immunizations. Third dose DTaP vaccine coverage at age seven months among preclosure cohorts was 54.4% vs. 40.3% among postclosure cohorts [risk ratio 1.31 (1.15,1.49)]. Fourth dose DTaP coverage at 19 months was 65.9% vs. 57.7% [risk ratio 1.24 (1.08,1.42)]. MMR coverage at 16 months was 79.5% vs. 69.9% [risk ratio 1.47 (1.22, 1.76)]. Coverage for the 431331 vaccination series at 19 months was 63.8% vs. 53.8% [risk ratio 1.28 (1.12,1.88)].
Conclusions: Immunization coverage declined at key age milestones for active clients of a Medicaid managed care that closed as compared with preclosure cohorts of clients from the same facility. When a primary health care facility closes, efforts should be made to ensure that children who had received vaccinations at that facility quickly establish a new medical home. Published by Elsevier Ltd on behalf of The Royal Society for Public Health.
C1 [Kolasa, M. S.; Stevenson, J.] Ctr Dis Control & Prevent, Hlth Serv Res & Evaluat Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Ossa, A.] Philadelphia Dept Publ Hlth, Philadelphia, PA 19146 USA.
[Lutz, J.] Ctr Dis Control & Prevent, Program Operat Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Kolasa, MS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop A19, Atlanta, GA 30333 USA.
EM mkolasa@cdc.gov; jxs7@cdc.gov; Alexandra.Ossa@phila.gov;
James.Lutz@phila.gov
NR 16
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0033-3506
EI 1476-5616
J9 PUBLIC HEALTH
JI Public Health
PD DEC
PY 2014
VL 128
IS 12
BP 1106
EP 1111
DI 10.1016/j.puhe.2014.08.002
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU8PC
UT WOS:000345857600009
PM 25443105
ER
PT J
AU Adlard, B
Davis, K
Liang, CL
Curren, MS
Rodriguez-Dozal, S
Riojas-Rodriguez, H
Hernandez-Avila, M
Foster, W
Needham, L
Wong, LY
Weber, JP
Marro, L
Leech, T
Van Oostdam, J
AF Adlard, Bryan
Davis, Karelyn
Liang, Chun Lei
Curren, Meredith S.
Rodriguez-Dozal, Sandra
Riojas-Rodriguez, Horacio
Hernandez-Avila, Mauricio
Foster, Warren
Needham, Larry
Wong, Lee-Yang
Weber, Jean-Philippe
Marro, Leonora
Leech, Tara
Van Oostdam, Jay
TI Persistent organic pollutants (POPs) and metals in primiparous women: a
comparison from Canada and Mexico
SO SCIENCE OF THE TOTAL ENVIRONMENT
LA English
DT Article
DE Primiparous women; Persistent Organic Pollutants (POPS); Metals; Canada;
Mexico
ID BROMINATED FLAME RETARDANTS; BLOOD LEAD LEVELS;
POLYCHLORINATED-BIPHENYLS; UNITED-STATES; PRENATAL EXPOSURE; INUIT
CHILDREN; ENVIRONMENTAL CONTAMINANTS; ORGANOCHLORINE PESTICIDES; SERUM
CONCENTRATIONS; NATIONAL-HEALTH
AB Under the North American Commission for Environmental Cooperation (CEC) and its Sound Management of Chemicals (SMOC) program, a tri-national human contaminant monitoring initiative was completed to provide baseline exposure information for several environmental contaminants in Canada, Mexico and the United States (U.S). Blood samples were collected from primiparous women in Canada and Mexico, and were analysed for a suite of environmental contaminants including polychlorinated biphenyls (PCBs), dichlorodiphenyldichloroethylene(p,p'-DDE),beta-hexachlorocyclohexane (beta-HCH), mercury and lead. A multiple stepwise linear regression analysis was conducted using data from Canadian and Mexican primiparous mothers, adjusting for ethnicity group, age, pre-pregnancy BMI, years at current city and ever-smoking status. Concentrations of p,p'-DDE, beta-HCH, and lead were found to be higher among Mexican participants; however, concentrations of most PCBs among Mexican participants were similar to Canadian primiparous women after adjusting for covariates. Concentrations of total mercury were generally higher among Mexican primiparous women although this difference was smaller as age increased. This initial dataset can be used to determine priorities for future activities and to track progress in the management of the selected chemicals, both domestically and on a broader cooperative basis within North America. Crown Copyright (C) 2014 Published by Elsevier B.V. All rights reserved.
C1 [Adlard, Bryan; Curren, Meredith S.; Leech, Tara] Hlth Canada, Hlth Environm & Consumer Safety Branch, Chem Surveillance Bur, Ottawa, ON K1A 0K9, Canada.
[Davis, Karelyn; Liang, Chun Lei; Marro, Leonora] Hlth Canada, Hlth Environm & Consumer Safety Branch, Environm Hlth Sci & Res Bur, Ottawa, ON K1A 0K9, Canada.
[Rodriguez-Dozal, Sandra; Riojas-Rodriguez, Horacio] Natl Inst Publ Hlth, Ctr Populat Heath Res, Dept Environm Hlth, Cuernavaca 62100, Morelos, Mexico.
[Hernandez-Avila, Mauricio] Natl Inst Publ Hlth, Off Director, Cuernavaca 62100, Morelos, Mexico.
[Foster, Warren] McMaster Univ, Dept Obstet & Gynecol, Hamilton, ON L8N 3Z5, Canada.
[Needham, Larry; Wong, Lee-Yang] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA.
[Weber, Jean-Philippe] Inst Natl Sante Publ, Quebec City, PQ G1V 5B3, Canada.
RP Adlard, B (reprint author), Hlth Canada, Hlth Environm & Consumer Safety Branch, Chem Surveillance Bur, 269 Laurier Ave West, Ottawa, ON K1A 0K9, Canada.
EM bryan.adlard@hc-sc.gc.ca; karelyn.davis@hc-sc.gc.ca;
chun.lei.liang@hc-sc.gc.ca; meredith.curren@hc-sc.gc.ca;
Irodriguez@insp.mx; hriojas@insp.mx; mheman@insp.mx;
fosterw@mcmaster.ca; lyw8@cdc.gov; jeanphilippe.weber@gmail.com;
leonora.marro@hc-sc.gc.ca; tara.leech@hc-sc.gc.ca; jvanoostdam@yahoo.com
FU Intramural CDC HHS [CC999999]
NR 85
TC 2
Z9 2
U1 1
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0048-9697
EI 1879-1026
J9 SCI TOTAL ENVIRON
JI Sci. Total Environ.
PD DEC 1
PY 2014
VL 500
BP 302
EP 313
DI 10.1016/j.scitotenv.2014.08.074
PG 12
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA AU6OX
UT WOS:000345723100030
PM 25233368
ER
PT J
AU Knowles, JW
O'Brien, EC
Greendale, K
Wilemon, K
Genest, J
Sperling, LS
Neal, WA
Rader, DJ
Khoury, MJ
AF Knowles, Joshua W.
O'Brien, Emily C.
Greendale, Karen
Wilemon, Katherine
Genest, Jacques
Sperling, Laurence S.
Neal, William A.
Rader, Daniel J.
Khoury, Muin J.
TI Reducing the burden of disease and death from familial
hypercholesterolemia: A call to action
SO AMERICAN HEART JOURNAL
LA English
DT Editorial Material
ID COST-EFFECTIVENESS ANALYSIS; ASSOCIATION EXPERT PANEL;
CORONARY-ARTERY-DISEASE; HEART-DISEASE; GUIDELINES; DIAGNOSIS;
PREVALENCE; MANAGEMENT; GUIDANCE; IDENTIFICATION
AB Familial hypercholesterolemia (FH) is a genetic disease characterized by substantial elevations of low-density lipoprotein cholesterol, unrelated to diet or lifestyle. Untreated FH patients have 20 times the risk of developing coronary artery disease, compared with the general population. Estimates indicate that as many as 1 in 500 people of all ethnicities and 1 in 250 people of Northern European descent may have FH; nevertheless, the condition remains largely undiagnosed. In the United States alone, perhaps as little as 1% of FH patients have been diagnosed. Consequently, there are potentially millions of children and adults worldwide who are unaware that they have a life-threatening condition. In countries like the Netherlands, the United Kingdom, and Spain, cascade screening programs have led to dramatic improvements in FH case identification. Given that there are currently no systematic approaches in the United States to identify FH patients or affected relatives, the patient-centric nonprofit FH Foundation convened a national FH Summit in 2013, where participants issued a "call to action" to health care providers, professional organizations, public health programs, patient advocacy groups, and FH experts, in order to bring greater attention to this potentially deadly, but (with proper diagnosis) eminently treatable, condition.
C1 [Knowles, Joshua W.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Knowles, Joshua W.] Stanford Univ, Cardiovasc Inst, Stanford, CA 94305 USA.
[Knowles, Joshua W.; Greendale, Karen; Wilemon, Katherine] FH Fdn, South Pasadena, CA USA.
[O'Brien, Emily C.] Duke Clin Res Inst, Durham, NC 27705 USA.
[Genest, Jacques] McGill Univ, Montreal, PQ, Canada.
[Sperling, Laurence S.] Emory Univ, Sch Med, Atlanta, GA USA.
[Neal, William A.] W Virginia Univ, Morgantown, WV 26506 USA.
[Rader, Daniel J.] Univ Penn, Philadelphia, PA 19104 USA.
[Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA.
RP O'Brien, EC (reprint author), Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA.
EM emily.obrien@duke.edu
FU Intramural CDC HHS [CC999999]
NR 40
TC 10
Z9 10
U1 0
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD DEC
PY 2014
VL 168
IS 6
BP 807
EP 811
DI 10.1016/j.ahj.2014.09.001
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AU3IN
UT WOS:000345506100001
PM 25458642
ER
PT J
AU Wurzelbacher, SJ
Bertke, SJ
Lampl, MP
Bushnell, PT
Meyers, AR
Robins, DC
Al-Tarawneh, IS
AF Wurzelbacher, Steven J.
Bertke, Stephen J.
Lampl, Michael P.
Bushnell, P. Timothy
Meyers, Alysha R.
Robins, David C.
Al-Tarawneh, Ibraheem S.
TI The Effectiveness of Insurer-Supported Safety and Health Engineering
Controls in Reducing Workers' Compensation Claims and Costs
SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE
LA English
DT Article
DE workers' compensation; prevention effectiveness; engineering controls;
ergonomics; safety
ID LOW-BACK-PAIN; MUSCULOSKELETAL DISORDERS; ERGONOMIC INTERVENTIONS;
NURSING-HOMES; INJURY; PREVENTION; INDUSTRY; WORKING; IMPACT
AB BackgroundThis study evaluated the effectiveness of a program in which a workers' compensation (WC) insurer provided matching funds to insured employers to implement safety/health engineering controls.
MethodsPre- and post-intervention WC metrics were compiled for the employees designated as affected by the interventions within 468 employers for interventions occurring from 2003 to 2009. Poisson, two-part, and linear regression models with repeated measures were used to evaluate differences in pre- and post-data, controlling for time trends independent of the interventions.
ResultsFor affected employees, total WC claim frequency rates (both medical-only and lost-time claims) decreased 66%, lost-time WC claim frequency rates decreased 78%, WC paid cost per employee decreased 81%, and WC geometric mean paid claim cost decreased 30% post-intervention. Reductions varied by employer size, specific industry, and intervention type.
ConclusionsThe insurer-supported safety/health engineering control program was effective in reducing WC claims and costs for affected employees. Am. J. Ind. Med. 57:1398-1412, 2014. (c) 2014 Wiley Periodicals, Inc.
C1 [Wurzelbacher, Steven J.; Bertke, Stephen J.; Bushnell, P. Timothy; Meyers, Alysha R.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA.
[Lampl, Michael P.; Robins, David C.; Al-Tarawneh, Ibraheem S.] Ohio Bur Workers Compensat, Div Safety & Hyg, Columbus, OH USA.
RP Wurzelbacher, SJ (reprint author), NIOSH, Industrywide Studies Branch, Div Surveillance Hazard Evaluat & Field Studies, 1090 Tusculum Ave,MS R-14, Cincinnati, OH 45226 USA.
EM srw3@cdc.gov
OI Wurzelbacher, Steve/0000-0002-8843-8239; Meyers,
Alysha/0000-0002-6402-0145
FU NIOSH
FX This research was supported by NIOSH intramural funds, awarded as part
of the competitive National Occupational Research Agenda process.
NR 29
TC 0
Z9 0
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0271-3586
EI 1097-0274
J9 AM J IND MED
JI Am. J. Ind. Med.
PD DEC
PY 2014
VL 57
IS 12
BP 1398
EP 1412
DI 10.1002/ajim.22372
PG 15
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU2KO
UT WOS:000345447400010
PM 25223846
ER
PT J
AU Maeda, A
Bateman, BT
Clancy, CR
Creanga, AA
Leffert, LR
AF Maeda, Ayumi
Bateman, Brian T.
Clancy, Caitlin R.
Creanga, Andreea A.
Leffert, Lisa R.
TI Opioid Abuse and Dependence during Pregnancy Temporal Trends and
Obstetrical Outcomes
SO ANESTHESIOLOGY
LA English
DT Article
ID VITAL SIGNS OVERDOSES; UNITED-STATES; MATERNAL MORBIDITY; CESAREAN
DELIVERY; PAIN MANAGEMENT; SMOKING; PREECLAMPSIA; ADDICTION; WOMEN;
HEALTH
AB Background: The authors investigated nationwide trends in opioid abuse or dependence during pregnancy and assessed the impact on maternal and obstetrical outcomes in the United States.
Methods: Hospitalizations for delivery were extracted from the Nationwide Inpatient Sample from 1998 to 2011. Temporal trends were assessed and logistic regression was used to examine the associations between maternal opioid abuse or dependence and obstetrical outcomes adjusting for relevant confounders.
Results: The prevalence of opioid abuse or dependence during pregnancy increased from 0.17% (1998) to 0.39% (2011) for an increase of 127%. Deliveries associated with maternal opioid abuse or dependence compared with those without opioid abuse or dependence were associated with an increased odds of maternal death during hospitalization (adjusted odds ratio [aOR], 4.6; 95% CI, 1.8 to 12.1, crude incidence 0.03 vs. 0.006%), cardiac arrest (aOR, 3.6; 95% CI, 1.4 to 9.1; 0.04 vs. 0.01%), intrauterine growth restriction (aOR, 2.7; 95% CI, 2.4 to 2.9; 6.8 vs. 2.1%), placental abruption (aOR, 2.4; 95% CI, 2.1 to 2.6; 3.8 vs. 1.1%), length of stay more than 7 days (aOR, 2.2; 95% CI, 2.0 to 2.5; 3.0 vs. 1.2%), preterm labor (aOR, 2.1; 95% CI, 2.0 to 2.3; 17.3 vs. 7.4%), oligohydramnios (aOR, 1.7; 95% CI, 1.6 to 1.9; 4.5 vs. 2.8%), transfusion (aOR, 1.7; 95% CI, 1.5 to 1.9; 2.0 vs. 1.0%), stillbirth (aOR, 1.5; 95% CI, 1.3 to 1.8; 1.2 vs. 0.6%), premature rupture of membranes (aOR, 1.4; 95% CI, 1.3 to 1.6; 5.7 vs. 3.8%), and cesarean delivery (aOR, 1.2; 95% CI, 1.1 to 1.3; 36.3 vs. 33.1%).
Conclusions: Opioid abuse or dependence during pregnancy is associated with considerable obstetrical morbidity and mortality, and its prevalence is dramatically increasing in the United States. Identifying preventive strategies and therapeutic interventions in pregnant women who abuse drugs are important priorities for clinicians and scientists.
C1 [Maeda, Ayumi; Bateman, Brian T.; Clancy, Caitlin R.; Leffert, Lisa R.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Bateman, Brian T.] Harvard Univ, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Sch Med,Dept Med, Boston, MA 02115 USA.
[Creanga, Andreea A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Leffert, LR (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Div Obstet Anesthesia, 55 Fruit St, Boston, MA 02114 USA.
EM lleffert@partners.org
NR 44
TC 16
Z9 16
U1 2
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD DEC
PY 2014
VL 121
IS 6
BP 1158
EP 1165
DI 10.1097/ALN.0000000000000472
PG 8
WC Anesthesiology
SC Anesthesiology
GA AU2FB
UT WOS:000345430700007
PM 25405293
ER
PT J
AU Riccardo, F
Shigematsu, M
Chow, C
McKnight, CJ
Linge, J
Doherty, B
Dente, MG
Declich, S
Barker, M
Barboza, P
Vaillant, L
Donachie, A
Mawudeku, A
Blench, M
Arthur, R
AF Riccardo, Flavia
Shigematsu, Mika
Chow, Catherine
McKnight, C. Jason
Linge, Jens
Doherty, Brian
Dente, Maria Grazia
Declich, Silvia
Barker, Mike
Barboza, Philippe
Vaillant, Laetitia
Donachie, Alastair
Mawudeku, Abla
Blench, Michael
Arthur, Ray
TI Interfacing a Biosurveillance Portal and an International Network of
Institutional Analysts to Detect Biological Threats
SO BIOSECURITY AND BIOTERRORISM-BIODEFENSE STRATEGY PRACTICE AND SCIENCE
LA English
DT Article
ID EARLY-WARNING SYSTEM; EMERGING DISEASES; HEALTH SECURITY; PROMED-MAIL;
SURVEILLANCE; INTERNET; RUMORS
AB The Early Alerting and Reporting (EAR) project, launched in 2008, is aimed at improving global early alerting and risk assessment and evaluating the feasibility and opportunity of integrating the analysis of biological, chemical, radionuclear (CBRN), and pandemic influenza threats. At a time when no international collaborations existed in the field of event-based surveillance, EAR's innovative approach involved both epidemic intelligence experts and internet-based biosurveillance system providers in the framework of an international collaboration called the Global Health Security Initiative, which involved the ministries of health of the G7 countries and Mexico, the World Health Organization, and the European Commission. The EAR project pooled data from 7 major internet-based biosurveillance systems onto a common portal that was progressively optimized for biological threat detection under the guidance of epidemic intelligence experts from public health institutions in Canada, the European Centre for Disease Prevention and Control, France, Germany, Italy, Japan, the United Kingdom, and the United States. The group became the first end users of the EAR portal, constituting a network of analysts working with a common standard operating procedure and risk assessment tools on a rotation basis to constantly screen and assess public information on the web for events that could suggest an intentional release of biological agents. Following the first 2-year pilot phase, the EAR project was tested in its capacity to monitor biological threats, proving that its working model was feasible and demonstrating the high commitment of the countries and international institutions involved. During the testing period, analysts using the EAR platform did not miss intentional events of a biological nature and did not issue false alarms. Through the findings of this initial assessment, this article provides insights into how the field of epidemic intelligence can advance through an international network and, more specifically, how it was further developed in the EAR project.
C1 [Riccardo, Flavia; Dente, Maria Grazia; Declich, Silvia] Inst Super Sanita ISS Natl Inst Hlth, Natl Ctr Epidemiol Surveillance & Hlth Promot, I-00161 Rome, Italy.
[Shigematsu, Mika] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan.
[Chow, Catherine; McKnight, C. Jason; Arthur, Ray] US Ctr Dis Control & Prevent, Global Dis Detect Operat Ctr, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA.
[Linge, Jens; Doherty, Brian] Commiss European Communities, Joint Res Ctr, Inst Protect & Secur Citizen, Global Secur & Crisis Management Unit, I-21020 Ispra, VA, Italy.
[Barker, Mike] Publ Hlth England, Emergency Response Dept, Porton Down Salisbury, Wilts, England.
[Barboza, Philippe; Vaillant, Laetitia] French Publ Hlth Inst, Insitut Veille Sanit, Int Dept, St Maurice, France.
[Donachie, Alastair] European Ctr Dis Prevent & Control ECDC, Surveillance & Response Unit, Stockholm, Sweden.
[Mawudeku, Abla; Blench, Michael] Publ Hlth Agcy Canada, Ctr Emergency Preparedness & Response, Ottawa, ON, Canada.
RP Riccardo, F (reprint author), Inst Super Sanita ISS Natl Inst Hlth, Viale Regina Elena 299, I-00161 Rome, Italy.
EM flavia.riccardo@iss.it
OI Riccardo, Flavia/0000-0002-1582-6329
NR 25
TC 3
Z9 4
U1 1
U2 13
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1538-7135
EI 1557-850X
J9 BIOSECUR BIOTERROR
JI Biosecur. Bioterror.
PD DEC 1
PY 2014
VL 12
IS 6
BP 325
EP 336
DI 10.1089/bsp.2014.0031
PG 12
WC Public, Environmental & Occupational Health; International Relations
SC Public, Environmental & Occupational Health; International Relations
GA AU4YK
UT WOS:000345614100006
PM 25470464
ER
PT J
AU Altekruse, SF
Dickie, L
Wu, XC
Hsieh, MC
Wu, MX
Lee, R
Delacroix, S
AF Altekruse, Sean F.
Dickie, Lois
Wu, Xiao-Cheng
Hsieh, Mei-Chin
Wu, Manxia
Lee, Richard
Delacroix, Scott, Jr.
TI Clinical and Prognostic Factors for Renal Parenchymal, Pelvis, and
Ureter Cancers in SEER Registries: Collaborative Stage Data Collection
System, Version 2
SO CANCER
LA English
DT Article
DE kidney; renal pelvis; cancer; AJCC collaborative stage; site-specific
factors
ID INTERNATIONAL MULTICENTER EXPERIENCE; ADRENAL-GLAND INVOLVEMENT; CELL
CARCINOMA; RADICAL NEPHROURETERECTOMY; UROTHELIAL CARCINOMA; CONSENSUS
CLASSIFICATION; LYMPH-NODES; TUMOR SIZE; SURVIVAL; IMPACT
AB BACKGROUNDThe American Joint Committee on Cancer's (AJCC) 7th edition cancer staging manual reflects recent changes in cancer care practices. This report assesses changes from the AJCC 6th to the AJCC 7th edition stage distributions and the quality of site-specific factors (SSFs).
METHODSIncidence data for renal parenchyma and pelvis and ureter cancers from 18 Surveillance, Epidemiology, and End Results (SEER) registries were examined, including staging trends during 2004-2010, stage distribution changes between the AJCC 6th and 7th editions, and SSF completeness for cases diagnosed in 2010.
RESULTSFrom 2004 to 2010, the percentage of stage I renal parenchyma cancers increased from 50% to 58%, whereas stage IV and unknown stage cases decreased (18% to 15%, and 10% to 6%, respectively). During this period, the percentage of stage 0a renal pelvis and ureter cancers increased from 21% to 25%, and stage IV and unknown stage tumors decreased (20% to 18%, and 7% to 5%, respectively). Stage distributions under the AJCC 6th and 7th editions were about the same. For renal parenchymal cancers, 71%-90% of cases had known values for 6 required SSFs. For renal pelvis and ureter cancers, 74% of cases were coded as known for SSF1 (WHO/ISUP grade) and 47% as known for SSF2 (depth of renal parenchymal invasion). SSF values were known for larger proportions of cases with reported resections.
CONCLUSIONSStage distributions between the AJCC 6th and 7th editions were similar. SSFs were known for more than two-thirds of cases, providing more detail in the SEER database relevant to prognosis. Cancer 2014;120(23 suppl):3826-35. (c) 2014 American Cancer Society.
The percentage of early-stage cases increased, whereas late- and known-stage cases decreased over time for renal parenchymal and pelvic and ureter cancers. Stage distributions between the AJCC 6th and 7th editions are about the same, and site-specific factors were known for more than two-thirds of the cases.
C1 [Altekruse, Sean F.; Dickie, Lois] NCI, Div Canc Control & Populat Sci, Rockville, MD 20850 USA.
[Wu, Xiao-Cheng; Hsieh, Mei-Chin] Louisiana State Univ, Sch Publ Hlth, Louisiana Tumor Registry, New Orleans, LA USA.
[Wu, Manxia] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA.
[Lee, Richard] Informat Management Serv Inc, Calverton, MD USA.
[Delacroix, Scott, Jr.] Louisiana State Univ, Sch Med, Stanley S Scott Canc Ctr, New Orleans, LA USA.
RP Altekruse, SF (reprint author), NCI, Div Canc Control & Populat Sci, 9609 Med Ctr Dr,Room 4E536, Rockville, MD 20850 USA.
EM altekrusesf@mail.nih.gov
FU National Cancer Institute; University of Southern California
[HHSN261201300004I]; Cancer Prevention Institute of California
[HHSN261201300005I]; University of Hawaii [HHSN261201300009I];
University of New Mexico [HHSN261201300010I]; Rutgers University
[HHSN261201300021I]; Connecticut Department of Health
[HHSN261201300019I]; University of Iowa [HHSN 261201300020I]; Emory
University [HHSN261201300015I]; Louisiana State University
[HHSN261201300016I]; University of Utah [HHSN 261201300017I]; Wayne
State University [HHSN261201300011I]; Fred Hutchinson Cancer Center
[HHSN261201300012I]; University of Kentucky [HHSN261201300013O]; Public
Health Institute [HHSN26120 1300014I]; Information Management Services,
Inc. [HHSN261201100007I]
FX This supplement edition of Cancer has been sponsored by the National
Cancer Institute. Data used in the production of this supplement was
supported under Contract HHSN261201300004I (University of Southern
California), HHSN261201300005I (Cancer Prevention Institute of
California, HHSN261201300009I (University of Hawaii), HHSN261201300010I
(University of New Mexico), HHSN261201300021I (Rutgers University),
HHSN261201300019I (Connecticut Department of Health), HHSN 261201300020I
(University of Iowa), HHSN261201300015I (Emory University),
HHSN261201300016I (Louisiana State University), HHSN 261201300017I
(University of Utah), HHSN261201300011I (Wayne State University),
HHSN261201300012I (Fred Hutchinson Cancer Center), HHSN261201300013O
(University of Kentucky), and HHSN26120 1300014I (Public Health
Institute). Technical support was provided under contract
HHSN261201100007I (Information Management Services, Inc.).
NR 50
TC 1
Z9 1
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD DEC 1
PY 2014
VL 120
IS 23
SU S
BP 3826
EP 3835
DI 10.1002/cncr.29051
PG 10
WC Oncology
SC Oncology
GA AU0WM
UT WOS:000345342900008
PM 25412394
ER
PT J
AU Lam, T
Williams, PL
Lee, MM
Korrick, SA
Birnbaum, LS
Burns, JS
Sergeyev, O
Revich, B
Altshul, LM
Patterson, DG
Turner, WE
Hauser, R
AF Lam, Thuy
Williams, Paige L.
Lee, Mary M.
Korrick, Susan A.
Birnbaum, Linda S.
Burns, Jane S.
Sergeyev, Oleg
Revich, Boris
Altshul, Larisa M.
Patterson, Donald G., Jr.
Turner, Wayman E.
Hauser, Russ
TI Prepubertal organochlorine pesticide concentrations and age of pubertal
onset among Russian boys
SO ENVIRONMENT INTERNATIONAL
LA English
DT Article
DE beta-HCH; HCB; Organochlorine pesticides; Male puberty; p,p '-DDE
ID SECONDARY SEXUAL CHARACTERISTICS; NUTRITION EXAMINATION SURVEY; BLOOD
LEAD LEVELS; POLYCHLORINATED-BIPHENYLS; HUMAN-SERUM; REPRODUCTIVE
DEVELOPMENT; HEXACHLOROBENZENE HCB; NATIONAL-HEALTH; DIOXIN EXPOSURE;
SECULAR TRENDS
AB Background: In animal studies, organochlorine pesticide (OCP) exposure alters pubertal development; however, epidemiological data are limited and inconsistent.
Objective: To evaluate the associations of serum OCP concentrations [hexachlorobenzene (HCB), beta-hexachlorocyclohexane (beta-HCH), and p,p'-dichlorodiphenyldichloroethylene (p,p'-DDE)] with male pubertal onset
Methods: In Chapaevsk, Russia, a town environmentally contaminated with OCPs, 350 8-9 year old boys with measured OCPs were enrolled during 2003-2005 and were followed annually for eight years. We evaluated three measures of pubertal onset: testicular volume (TV) >3 mL in either testis, or stage 2 or greater for genitalia (G2+), or pubic hair (P2+). We used multivariable interval-censored models to evaluate associations of OCPs (quartiles) with physician-assessed pubertal onset. Results: In adjusted models, boys with higher HCB concentrations had later mean ages of TV > 3 mL and P2+ (but not G2+). Mean age at attaining TV > 3 mL was delayed 3.6 (95% CI: -2.6, 9.7), 7.9 (95% CI: 1.7, 14.0), and 4.7 months (95% CI: -1.4, 10.9) for HCB Q2, Q3, and Q4, respectively, compared to Q1 (trend p: 0.06). Boys with higher HCB concentrations reached P2+ 0.1 months earlier (95% CI: -5.8, 5.6) for Q2, 4.7 months later (95% CI: -1.0, 10.3) for Q3 and 4.6 months later (95% CI: -1.1, 10.3) for Q4 compared to Q1 (trend p: 0.04). There were no associations of serum beta-HCH and p,p'-DDE concentrations with age of pubertal onset.
Conclusion: Higher prepubertal serum HCB concentrations were associated with later age of gonadarche and pubarche. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Lam, Thuy; Korrick, Susan A.; Burns, Jane S.; Hauser, Russ] Harvard Univ, Environm & Occupat Med & Epidemiol Program, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Lam, Thuy] Quintiles, Cambridge, MA USA.
[Williams, Paige L.] Harvard Univ, Dept Biostat, Sch Publ Hlth, Boston, MA 02115 USA.
[Williams, Paige L.] Harvard Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA 02115 USA.
[Lee, Mary M.] Univ Massachusetts, Sch Med, Dept Pediat, Pediat Endocrine Div, Worcester, MA USA.
[Lee, Mary M.] Univ Massachusetts, Sch Med, Dept Cell & Dev Biol, Worcester, MA USA.
[Korrick, Susan A.] Harvard Univ, Brigham & Womens Hosp, Channing Div Network Med, Dept Med,Med Sch, Boston, MA 02115 USA.
[Birnbaum, Linda S.] NCI, NIH, US Dept HHS, Res Triangle Pk, NC USA.
[Sergeyev, Oleg] Samara State Med Univ, Dept Phys Educ & Hlth, Samara, Russia.
[Sergeyev, Oleg] Chapaevsk Med Assoc, Chapaevsk, Samara Region, Russia.
[Revich, Boris] Russian Acad Sci, Inst Forecasting, Moscow, Russia.
[Altshul, Larisa M.] Harvard Univ, Dept Environm Hlth, Sch Publ Hlth, Exposure Epidemiol & Risk Program, Boston, MA 02115 USA.
[Altshul, Larisa M.] Environm Hlth & Engn Inc, Needham, MA USA.
[Patterson, Donald G., Jr.] EnviroSolut Consulting Inc, Auburn, GA USA.
[Patterson, Donald G., Jr.] Axys Analyt Solut, Sidney, BC, Canada.
[Patterson, Donald G., Jr.] Exponent Inc, Maynard, MA USA.
[Turner, Wayman E.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Hauser, R (reprint author), Harvard Univ, Environm & Occupat Med & Epidemiol Program, Sch Publ Hlth, 665 Huntington Ave,Bldg 1,Room 1409, Boston, MA 02115 USA.
EM rhauser@hsph.harvard.edu
OI Sergeyev, Oleg/0000-0002-5745-3348
FU U.S. Environmental Protection Agency [R82943701]; National Institute of
Environmental Health Sciences [R01 ES014370, P30 ES000002, R03
ES017117]; intramural program of the National Cancer Institute, National
Institutes of Health; National Institute for Occupational Safety and
Health training grant [T42-OH008416-09]
FX This work was funded by the U.S. Environmental Protection Agency (grant
R82943701), the National Institute of Environmental Health Sciences
(grant R01 ES014370, P30 ES000002, and R03 ES017117), and the intramural
program of the National Cancer Institute, National Institutes of Health.
TL was supported by the National Institute for Occupational Safety and
Health training grant T42-OH008416-09.
NR 71
TC 5
Z9 5
U1 5
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0160-4120
EI 1873-6750
J9 ENVIRON INT
JI Environ. Int.
PD DEC
PY 2014
VL 73
BP 135
EP 142
DI 10.1016/j.envint.2014.06.020
PG 8
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA AU3WE
UT WOS:000345540700016
PM 25118086
ER
PT J
AU Aminov, Z
Haase, R
Olson, JR
Pavuk, M
Carpenter, DO
AF Aminov, Zafar
Haase, Richard
Olson, James R.
Pavuk, Marian
Carpenter, David O.
CA Anniston Environm Hlth Res
TI Racial differences in levels of serum lipids and effects of exposure to
persistent organic pollutants on lipid levels in residents of Anniston,
Alabama
SO ENVIRONMENT INTERNATIONAL
LA English
DT Article
DE PCBs; Pesticides; Cardiovascular disease; Cholesterol; Triglycerides;
HDL
ID POLYCHLORINATED-BIPHENYLS PCBS; AMERICAN-HEART-ASSOCIATION;
CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; AFRICAN-AMERICANS;
CIGARETTE-SMOKING; BLOOD-PRESSURE; RISK; POLYMORPHISM; CHOLESTEROL
AB Serum lipid levels are major risk factors for cardiovascular disease. In addition to diet, exercise, genetics, age and race, serum concentrations of persistent organic pollutants (POPs) influence concentrations of serum lipids. We investigated associations between fasting concentrations of 35 polychlorinated biphenyl (PCB) congeners and nine organochlorine pesticides in relation to total serum lipids, total cholesterol, low-density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol and triglycerides in 525 Caucasian and African American residents of Anniston, Alabama, who were not on any lipid-lowering medication. In Model 1, data were adjusted for age, age quadratic, gender, BMI, alcohol consumption, smoking and exercise, while in Model 2, additional adjustment was done for other POPs. As compared to Caucasians, African Americans had lower levels of total lipids and triglycerides with higher concentrations of HDL cholesterol, but higher concentrations of PCBs and pesticides. Total pesticides were more strongly associated with elevations in serum lipids than were total PCBs, and the associations were stronger in African Americans. Total DDTs were not associated with serum lipids after adjustment for other POPs in either racial group, while the strongest positive associations were seen for hexachlorobenzene (HCB) in both racial groups. Racial differences in lipid profiles, concentrations of POPs and associations between POP concentrations and serum lipids are relevant to racial differences in rates of cardiovascular disease. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Aminov, Zafar; Haase, Richard; Carpenter, David O.] SUNY Albany, Inst Hlth & Environm, Rensselaer, NY 12144 USA.
[Olson, James R.] SUNY Buffalo, Buffalo, NY 14260 USA.
[Pavuk, Marian] Agcy Tox Subst & Dis Registry, Atlanta, GA USA.
RP Carpenter, DO (reprint author), SUNY Albany, Inst Hlth & Environm, Rensselaer, NY 12144 USA.
EM zafaruz979@gmail.com; rfhremote@aol.com; jolson@buffalo.edu;
fsh8@cdc.gov; dcarpenter@albany.edu
FU Passport Foundation [56052]; Agency for Toxic Substances and Disease
Registry [5U50TS473215]; Environment of the University at Albany [56052]
FX Supported by a grant from the Passport Foundation to the Institute for
Health and the Environment of the University at Albany (reference
#56052) and a grant from the Agency for Toxic Substances and Disease
Registry to Jacksonville State University, #5U50TS473215. The contents
of this publication are solely the responsibility of the authors and do
not necessarily represent ATSDR's official views. GIS analysis was
conducted by HoeHun Ha, Department of Geography, Central Michigan
University. The Anniston Environmental Health Research Consortium
Steering Committee members include Shirley Baker, community
representative; Scott Bartell, UC Irvine; James Olson, University at
Buffalo; Russell Foushee and Alan Percy, University of Alabama at
Birmingham; David O. Carpenter, University at Albany; Jane Cash; Martha
Lavender and Christie Shelton, Jacksonville State University; Howard
Frumkin, University of Washington; Marian Pavuk ATSCR/CDC; Paula
Rosenbaum, Allen Silverstone and Ruth Weinstock, Upstate Medical
University; and Kirsten Moysich, Roswell Park Cancer Institute. The map
showing the geographic distribution of ACHS participants by race was
created by Jessica Kolling of the Geospatial Research, Analysis, and
Services Program (GRASP) at the Agency for Toxic Substances and Disease
Registry.
NR 44
TC 1
Z9 2
U1 2
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0160-4120
EI 1873-6750
J9 ENVIRON INT
JI Environ. Int.
PD DEC
PY 2014
VL 73
BP 216
EP 223
DI 10.1016/j.envint.2014.07.022
PG 8
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA AU3WE
UT WOS:000345540700025
PM 25160080
ER
PT J
AU Gilboa, SM
Ailes, EC
Rai, RP
Anderson, JA
Honein, MA
AF Gilboa, Suzanne M.
Ailes, Elizabeth C.
Rai, Ramona P.
Anderson, Jaynia A.
Honein, Margaret A.
TI Antihistamines and birth defects: a systematic review of the literature
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Review
DE antihistamines; birth defects; pregnancy; prenatal exposure
ID CONGENITAL HEART-DEFECTS; COLLABORATIVE PERINATAL PROJECT; MATERNAL
MEDICATION USE; 1ST-TRIMESTER DRUG-USE; PYLORIC-STENOSIS;
EARLY-PREGNANCY; 1ST TRIMESTER; HYPEREMESIS GRAVIDARUM; GESTATIONAL
EXPOSURE; BENDECTIN DEBENDOX
AB Introduction: Approximately 10 - 15% of women reportedly take an antihistamine during pregnancy for the relief of nausea and vomiting, allergy and asthma symptoms, or indigestion. Antihistamines include histamine H1- receptor and H-2- receptor antagonists.
Areas covered: This is a systematic evaluation of the peer- reviewed epidemiologic literature published through February 2014 on the association between prenatal exposure to antihistamines and birth defects. Papers addressing histamine H1- or H2- receptor antagonists are included. Papers addressing pyridoxine plus doxylamine (Bendectin in the United States, Debendox in the United Kingdom, Diclectin in Canada, Lenotan and Merbental in other countries) prior to the year 2001 were excluded post hoc because of several previously published meta- analyses and commentaries on this medication.
Expert opinion: The literature on the safety of antihistamine use during pregnancy with respect to birth defects is generally reassuring though the positive findings from a few large studies warrant corroboration in other populations. The findings in the literature are considered in light of three critical methodological issues: i) selection of appropriate study population; ii) ascertainment of antihistamine exposures; and iii) ascertainment of birth defect outcomes. Selected antihistamines have been very well studied (e.g., loratadine); others, especially H2- receptor antagonists, require additional study before an assessment of safety with respect to birth defect risk could be made.
C1 [Gilboa, Suzanne M.] Natl Ctr Birth Defects & Dev Disabil, Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
[Ailes, Elizabeth C.] Natl Ctr Birth Defects & Dev Disabil, Ctr Dis Control & Prevent, Atlanta, GA USA.
[Rai, Ramona P.; Anderson, Jaynia A.] Emory Univ, Atlanta, GA 30322 USA.
[Honein, Margaret A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Gilboa, SM (reprint author), Natl Ctr Birth Defects & Dev Disabil, Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Mail Stop E 86,1600 Clifton Rd, Atlanta, GA 30333 USA.
EM sgilboa@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 82
TC 10
Z9 10
U1 0
U2 20
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1474-0338
EI 1744-764X
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD DEC
PY 2014
VL 13
IS 12
BP 1667
EP 1698
DI 10.1517/14740338.2014.970164
PG 32
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AU0XR
UT WOS:000345346100009
PM 25307228
ER
PT J
AU Nahar, N
Mondal, UK
Hossain, MJ
Khan, MSU
Sultana, R
Gurley, ES
Luby, SP
AF Nahar, Nazmun
Mondal, Utpal Kumar
Hossain, M. Jahangir
Khan, M. Salah Uddin
Sultana, Rebeca
Gurley, Emily S.
Luby, Stephen P.
TI Piloting the promotion of bamboo skirt barriers to prevent Nipah virus
transmission through date palm sap in Bangladesh
SO GLOBAL HEALTH PROMOTION
LA English
DT Article
DE communicable disease; community; health behaviour; health promotion
ID ENCEPHALITIS OUTBREAK; BATS; INFECTION; COMMUNITY; MALAYSIA; HUMANS;
PARAMYXOVIRUS
AB Drinking raw date palm sap contaminated with infected fruit bat saliva or urine is an important mode of Nipah virus transmission to humans in Bangladesh. Bamboo skirts are an effective way to interrupt bat access to the sap. We conducted a study from November 2008 to March 2009 to explore the effectiveness of higher- and lower-intensity interventions by promoting bamboo skirt preparation and use among sap harvesters (gachhis). We spent 280 person-hours in two villages for the higher-intensity intervention and half that amount of time in two other villages for the lower-intensity intervention. To evaluate the interventions we followed up all gachhis once a month for three months. A high percentage of gachhis (83% in higher-, 65% in lower-intensity interventions) prepared and used a skirt of bamboo or other materials - jute stalk, dhoincha (Sesbania aculeata), or polythene - at least once after intervention. In general, 15% of gachhis consistently used skirts throughout the sap collection season. The intensive nature of this intervention is very expensive for a large-scale programme. Future efforts should focus on developing a low-cost behaviour change intervention and evaluate if it reduces the human exposure to potentially contaminated fresh date palm sap.
C1 [Nahar, Nazmun; Mondal, Utpal Kumar; Hossain, M. Jahangir; Khan, M. Salah Uddin; Sultana, Rebeca; Gurley, Emily S.; Luby, Stephen P.] Icddr B, Dhaka 1212, Bangladesh.
[Luby, Stephen P.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA.
RP Nahar, N (reprint author), Icddr B, CCD, GPO Box 128, Dhaka 1212, Bangladesh.
EM nahar.nazmun@yahoo.com
RI Gurley, Emily/B-7903-2010;
OI Gurley, Emily/0000-0002-8648-9403; Luby, Stephen/0000-0001-5385-899X
FU Intramural CDC HHS [CC999999]; NCPDCID CDC HHS [5-U01-CI000298-03, U01
CI000298]
NR 31
TC 4
Z9 4
U1 0
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1757-9759
EI 1757-9767
J9 GLOB HEALTH PROMOT
JI Glob. Health Promot.
PD DEC
PY 2014
VL 21
IS 4
BP 7
EP 15
DI 10.1177/1757975914528249
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3SL
UT WOS:000345533700002
PM 24755262
ER
PT J
AU Xu, FJ
Ward, JW
Gordon, SC
Holmberg, SD
AF Xu, Fujie
Ward, John W.
Gordon, Stuart C.
Holmberg, Scott D.
TI Patients Meeting 'Highest' or 'High' Priority for HCV Treatment in the
Chronic Hepatitis Cohort Study (CHeCS)
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 [Xu, Fujie; Ward, John W.; Holmberg, Scott D.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA.
[Gordon, Stuart C.] Henry Ford Hlth Syst, Detroit, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD DEC
PY 2014
VL 60
IS 6
MA LB-29
BP 1284A
EP 1284A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AU3MI
UT WOS:000345517000030
ER
PT J
AU Lin, MY
Woeltje, KF
Khan, YM
Hota, B
Doherty, JA
Borlawsky, TB
Stevenson, KB
Fridkin, SK
Weinstein, RA
Trick, WE
AF Lin, Michael Y.
Woeltje, Keith F.
Khan, Yosef M.
Hota, Bala
Doherty, Joshua A.
Borlawsky, Tara B.
Stevenson, Kurt B.
Fridkin, Scott K.
Weinstein, Robert A.
Trick, William E.
CA Ctr Dis Control Prevention Epictr
TI Multicenter Evaluation of Computer Automated versus Traditional
Surveillance of Hospital-Acquired Bloodstream Infections
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID CARE-ASSOCIATED INFECTIONS; HEALTH; RATES
AB Objective.Central line-associated bloodstream infection (BSI) rates are a key quality metric for comparing hospital quality and safety. Traditional BSI surveillance may be limited by interrater variability. We assessed whether a computer-automated method of central line-associated BSI detection can improve the validity of surveillance.Design.Retrospective cohort study.Setting.Eight medical and surgical intensive care units (ICUs) in 4 academic medical centers.Methods.Traditional surveillance (by hospital staff) and computer algorithm surveillance were each compared against a retrospective audit review using a random sample of blood culture episodes during the period 2004-2007 from which an organism was recovered. Episode-level agreement with audit review was measured with statistics, and differences were assessed using the test of equal coefficients. Linear regression was used to assess the relationship between surveillance performance () and surveillance-reported BSI rates (BSIs per 1,000 central line-days).Results.We evaluated 664 blood culture episodes. Agreement with audit review was significantly lower for traditional surveillance (kappa[95% confidence interval (CI)] = 0.44 [0.37-0.51]) than computer algorithm surveillance (kappa[95% CI] = 0.58 [0.52-0.64]; P = .001). Agreement between traditional surveillance and audit review was heterogeneous across ICUs (P = .01); furthermore, traditional surveillance performed worse among ICUs reporting lower (better) BSI rates (P = .001). In contrast, computer algorithm performance was consistent across ICUs and across the range of computer-reported central line-associated BSI rates.Conclusions.Compared with traditional surveillance of bloodstream infections, computer automated surveillance improves accuracy and reliability, making interfacility performance comparisons more valid.
C1 [Lin, Michael Y.; Hota, Bala; Weinstein, Robert A.; Trick, William E.; Ctr Dis Control Prevention Epictr] Rush Univ Med Ctr, Dept Med, Chicago, IL USA.
[Woeltje, Keith F.; Doherty, Joshua A.] Washington Univ Sch Med, Dept Med, St Louis, MO USA.
[Khan, Yosef M.; Borlawsky, Tara B.; Stevenson, Kurt B.] Ohio State Univ Med Ctr, Dept Med, Columbus, OH USA.
[Hota, Bala; Weinstein, Robert A.; Trick, William E.] Cook Cty Hlth & Hosp Syst, Dept Med, Chicago, IL USA.
[Fridkin, Scott K.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Lin, MY (reprint author), 600 South Paulina St,Suite 143, Chicago, IL 60612 USA.
EM michael_lin@rush.edu
FU Centers for Disease Control and Prevention (CDC) from CDC Prevention
Epicenter Grants [U01-CI000327, U01-CI000328, U01-CI000333]
FX Financial support. This study was funded by Centers for Disease Control
and Prevention (CDC) cooperative agreements U01-CI000327, U01-CI000328,
and U01-CI000333 from the CDC Prevention Epicenter Grants.
NR 24
TC 1
Z9 1
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD DEC
PY 2014
VL 35
IS 12
BP 1483
EP 1490
DI 10.1086/678602
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AU3NN
UT WOS:000345520500007
PM 25419770
ER
PT J
AU Albrecht, VS
Zervos, MJ
Kaye, KS
Tosh, PK
Arshad, S
Hayakawa, K
Kallen, AJ
McDougal, LK
Limbago, BM
Guh, AY
AF Albrecht, Valerie S.
Zervos, Marcus J.
Kaye, Keith S.
Tosh, Pritish K.
Arshad, Samia
Hayakawa, Kayoko
Kallen, Alexander J.
McDougal, Linda K.
Limbago, Brandi M.
Guh, Alice Y.
TI Prevalence of and Risk Factors for Vancomycin-Resistant Staphylococcus
aureus Precursor Organisms in Southeastern Michigan
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID UNITED-STATES; ENTEROCOCCUS; PLASMID
AB We assessed for vancomycin-resistant Staphylococcus aureus (VRSA) precursor organisms in southeastern Michigan, an area known to have VRSA. The prevalence was 2.5% (pSK41-positive methicillin-resistant S. aureus, 2009-2011) and 1.5% (Inc18-positive vancomycin-resistant Enterococcus, 2006-2013); Inc18 prevalence significantly decreased after 2009 (3.7% to 0.82%). Risk factors for pSK41 included intravenous vancomycin exposure.
C1 [Albrecht, Valerie S.; Tosh, Pritish K.; Kallen, Alexander J.; McDougal, Linda K.; Limbago, Brandi M.; Guh, Alice Y.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA.
[Zervos, Marcus J.; Arshad, Samia] Henry Ford Hlth Syst, Div Infect Dis, Detroit, MI USA.
[Kaye, Keith S.; Hayakawa, Kayoko] Detroit Med Ctr, Div Infect Dis, Detroit, MI USA.
[Tosh, Pritish K.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA.
[Tosh, Pritish K.] Mayo Clin, Div Infect Dis, Rochester, MN USA.
RP Guh, AY (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd, Atlanta, GA 30329 USA.
EM ggt4@cdc.gov
FU Centers for Disease Control and Prevention; Pfizer; Cubist; Merck;
Forest Research Institute; Cerexa; AstraZeneca; Cempra; Durata
Therapeutics; Tetraphase Pharmaceuticals
FX Financial support. Funding for this study was provided by the Centers
for Disease Control and Prevention.; Potential conflicts of interest.
M.J.Z. reports having received grant support from Pfizer, Cubist, Merck,
Forest Research Institute, Cerexa, AstraZeneca, Cempra, Durata
Therapeutics, and Tetraphase Pharmaceuticals. All other authors report
no conflicts of interest relevant to this article. All authors submitted
the ICMJE Form for Disclosure of Potential Conflicts of Interest, and
the conflicts that the editors consider relevant to this article are
disclosed here.
NR 9
TC 1
Z9 1
U1 2
U2 17
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD DEC
PY 2014
VL 35
IS 12
BP 1531
EP 1534
DI 10.1086/678605
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AU3NN
UT WOS:000345520500013
PM 25419776
ER
PT J
AU Westheimer, E
Fu, J
Radix, A
Giancotti, FR
Hall, L
Daskalakis, DC
Tsoi, B
Peters, PJ
AF Westheimer, Emily
Fu, Jie
Radix, Anita
Giancotti, Francesca R.
Hall, Laura
Daskalakis, Demetre C.
Tsoi, Benjamin
Peters, Philip J.
TI An HIV-1 RNA test following a reactive fourth-generation
antigen/antibody combination assay confirms a high proportion of HIV
infections
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Letter
ID UNITED-STATES
C1 [Westheimer, Emily; Fu, Jie; Giancotti, Francesca R.; Tsoi, Benjamin] New York City Dept Hlth & Mental Hyg, New York, NY USA.
[Radix, Anita] Callen Lorde Community Hlth Ctr, New York, NY USA.
[Hall, Laura; Peters, Philip J.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Hall, Laura] ICF Int, Atlanta, GA USA.
[Daskalakis, Demetre C.] Mt Sinai Sch Med, New York, NY USA.
RP Westheimer, E (reprint author), Bur STD Control, NYC DOHMH, 42-09 28th St,20-63, Queens, NY 11101 USA.
EM ewestheimer@health.nyc.gov
OI Radix, Asa/0000-0001-9611-4181; Radix, Asa/0000-0001-8594-1077
FU NCHHSTP CDC HHS [5U01PS001561]
NR 6
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD DEC
PY 2014
VL 61
IS 4
BP 623
EP 624
DI 10.1016/j.jcv.2014.10.010
PG 2
WC Virology
SC Virology
GA AU4KO
UT WOS:000345579900030
PM 25453336
ER
PT J
AU Gounder, P
Ralph, N
Maroko, A
Thorpe, L
AF Gounder, Prabhu
Ralph, Nancy
Maroko, Andrew
Thorpe, Lorna
TI Bedbug Complaints among Public Housing Residents-New York City,
2010-2011
SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE
LA English
DT Article
DE Bedbugs; Public housing; Epidemiology; Environmental health
ID LARGE SOCIAL NETWORK; CIMEX-LECTULARIUS; BUG INFESTATIONS; CONSEQUENCES;
CIMICIDAE; BITES
AB Few studies have evaluated population-level risk factors for having a bedbug infestation. We describe characteristics associated with bedbug complaints among New York City Housing Authority (NYCHA) residents. Unique households receiving bedbug extermination services in response to a complaint during January 1, 2010 to December 31, 2011 were identified from NYCHA's central facilities work order database. We examined associations between household characteristics and having a bedbug complaint using a generalized estimating equation Poisson regression model, accounting for clustering by housing development. Of the 176,327 NYCHA households, 11,660 (6.6 %) registered a bedbug complaint during 2010-2011. Bedbug complaints were independently associated with households having five or more children versus no children (prevalence ratio [PR] = 2.0), five or more adults versus one adult (PR = 1.6), a head of household (HOH) with impaired mobility (PR = 1.3), a household member receiving public assistance (PR = 1.2), a household income below poverty level (PR = 1.1), and a female HOH (PR = 1.1). Infestations were less likely to be reported by households with employed members (PR = 0.9), and an HOH aged 30-44 years (PR = 0.9) or 45-61 years (PR = 0.9), compared with an HOH aged 18-29 years. These results indicate that bedbug control efforts in public housing should be targeted toward households with low income and high occupancy.
C1 [Gounder, Prabhu] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK 99508 USA.
[Ralph, Nancy; Thorpe, Lorna] CUNY Hunter Coll, CUNY Sch Publ Hlth, Epidemiol & Biostat Program, New York, NY USA.
[Maroko, Andrew] CUNY Herbert H Lehman Coll, CUNY Sch Publ Hlth, Dept Earth Environm & Geospatial Sci, New York, NY USA.
RP Gounder, P (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA.
EM iym4@cdc.gov
FU New York Public Housing Authority; City University of New York School of
Public Health at Hunter College
FX New York Public Housing Authority and City University of New York School
of Public Health at Hunter College
NR 27
TC 0
Z9 0
U1 2
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1099-3460
EI 1468-2869
J9 J URBAN HEALTH
JI J. Urban Health
PD DEC
PY 2014
VL 91
IS 6
BP 1076
EP 1086
DI 10.1007/s11524-013-9859-y
PG 11
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AU1RA
UT WOS:000345396700004
PM 24549436
ER
PT J
AU Teshale, E
Lu, M
Rupp, LB
Holmberg, SD
Moorman, AC
Spradling, P
Vijayadeva, V
Boscarino, JA
Schmidt, MA
Gordon, SC
AF Teshale, E.
Lu, M.
Rupp, L. B.
Holmberg, S. D.
Moorman, A. C.
Spradling, P.
Vijayadeva, V.
Boscarino, J. A.
Schmidt, M. A.
Gordon, S. C.
CA CHeCS Investigators
TI APRI and FIB-4 are good predictors of the stage of liver fibrosis in
chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS)
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Article
DE APRI; AST; ALT ratio; chronic hepatitis B; FIB-4; liver fibrosis
ID ACCURACY
AB We aim to determine the predictive ability of APRI, FIB-4 and AST/ALT ratio for staging of liver fibrosis and to differentiate significant fibrosis (F2-F4) from none to minimal fibrosis (F0-F1) in chronic hepatitis B (CHB). Liver biopsy results were mapped to an F0-4 equivalent fibrosis stage. Mean APRI and FIB-4 scores were significantly higher for each successive fibrosis level from F1 to F4 (P<0.05). Based on optimized cut-offs, the AUROCs in distinguishing F2-F4 from F0 to F1 were 0.81 (0.76-0.87) for APRI, 0.81 (0.75-0.86) for FIB-4 and 0.56 (0.49-0.64) for AST/ALT ratio. APRI and FIB-4 distinguished F2-F4 from F0 to F1 with good sensitivity and specificity and can be useful for treatment decisions and monitoring progression of fibrosis.
C1 [Teshale, E.; Holmberg, S. D.; Moorman, A. C.; Spradling, P.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA.
[Lu, M.; Rupp, L. B.; Gordon, S. C.] Henry Ford Hlth Syst HFHS Data Coordinating Ctr, Detroit, MI USA.
[Vijayadeva, V.] Kaiser Permanente Ctr Hlth Res, Honolulu, HI USA.
[Boscarino, J. A.] Geisinger Hlth Syst, Danville, PA USA.
[Schmidt, M. A.] Kaiser Permanente Ctr Hlth Res Northwest, Portland, OR USA.
RP Teshale, E (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, CDC Mailstop G-37,1600 Clifton Rd, Atlanta, GA 30333 USA.
EM eht4@cdc.gov
FU CDC Foundation; AbbVie; Janssen Pharmaceuticals, Inc.; Bristol-Myers
Squibb
FX CHeCS was funded by the CDC Foundation, which currently receives grants
from AbbVie, and Janssen Pharmaceuticals, Inc. Past funders include
Genentech, A Member of the Roche Group and Vertex Pharmaceuticals. Past
partial funders include Bristol-Myers Squibb. Granting corporations do
not have access to CHeCS data and do not contribute to data analysis or
writing of manuscripts.
NR 8
TC 18
Z9 21
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD DEC
PY 2014
VL 21
IS 12
BP 917
EP 920
DI 10.1111/jvh.12279
PG 4
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA AU1YP
UT WOS:000345413700014
PM 25131445
ER
PT J
AU Ramachandran, S
Purdy, MA
Xia, GL
Campo, DS
Dimitrova, ZE
Teshale, EH
Teo, CG
Khudyakov, YE
AF Ramachandran, Sumathi
Purdy, Michael A.
Xia, Guo-liang
Campo, David S.
Dimitrova, Zoya E.
Teshale, Eyasu H.
Teo, Chong Gee
Khudyakov, Yury E.
TI Recent Population Expansions of Hepatitis B Virus in the United States
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID VACCINATION COVERAGE; DRUG-RESISTANCE; HBV INFECTION; GENOTYPES;
RECOMMENDATIONS; IDENTIFICATION; EPIDEMIOLOGY; TRANSMISSION;
IMMUNIZATION; COEVOLUTION
AB The recent epidemic history of hepatitis B virus (HBV) infections in the United States is complex, as indicated by current disparity in HBV genotype distribution between acute and chronic hepatitis B cases and the rapid decline in hepatitis B incidence since the 1990s. We report temporal changes in the genetic composition of the HBV population using whole-genome sequences (n = 179) from acute hepatitis B cases (n = 1,206) identified through the Sentinel County Surveillance for Acute Hepatitis (1998 to 2006). HBV belonged mainly to subtypes A2 (75%) and D3 (18%), with times of their most recent common ancestors being 1979 and 1987, respectively. A2 underwent rapid population expansions in ca. 1995 and ca. 2002, coinciding with transient rises in acute hepatitis B notification rates among adults; D3 underwent expansion in ca. 1998. A2 strains from cases identified after 2002, compared to those before 2002, tended to cluster phylogenetically, indicating selective expansion of specific strains, and were significantly reduced in genetic diversity (P = 0.001) and frequency of drug resistance mutations (P = 0.001). The expansion of genetically close HBV A2 strains was associated with risk of infection among male homosexuals (P = 0.03). Incident HBV strains circulating in the United States were recent in origin and restricted in genetic diversity. Disparate transmission dynamics among phylogenetic lineages affected the genetic composition of HBV populations and their capacity to maintain drug resistance mutations. The tendency of selectively expanding HBV strains to be transmitted among male homosexuals highlights the need to improve hepatitis B vaccination coverage among at-risk adults.
IMPORTANCE
Hepatitis B virus (HBV) remains an important cause of acute and chronic liver disease globally and in the United States. Genetic analysis of HBV whole genomes from cases of acute hepatitis B identified from 1998 to 2006 in the United States showed dominance of genotype A2 (75%), followed by D3 (18%). Strains of both subtypes were recent in origin and underwent rapid population expansions from 1995 to 2000, indicating increase in transmission rate for certain HBV strains during a period of decline in the reported incidence of acute hepatitis B in the United States. HBV A2 strains from a particular cluster that experienced the most recent population expansion were more commonly detected among men who have sex with men. Vaccination needs to be stepped up to protect persons who remain at risk of HBV infection.
C1 [Ramachandran, Sumathi; Purdy, Michael A.; Xia, Guo-liang; Campo, David S.; Dimitrova, Zoya E.; Teshale, Eyasu H.; Teo, Chong Gee; Khudyakov, Yury E.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA.
RP Ramachandran, S (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA.
EM dcq6@cdc.gov
NR 36
TC 4
Z9 6
U1 1
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2014
VL 88
IS 24
BP 13971
EP 13980
DI 10.1128/JVI.=1594-14
PG 10
WC Virology
SC Virology
GA AU0CZ
UT WOS:000345292100005
PM 25187549
ER
PT J
AU Kulkarni, RR
Rasheed, MAU
Bhaumik, SK
Ranjan, P
Cao, WP
Davis, C
Marisetti, K
Thomas, S
Gangappa, S
Sambhara, S
Murali-Krishna, K
AF Kulkarni, Raveendra R.
Rasheed, Mohammed Ata Ur
Bhaumik, Siddhartha Kumar
Ranjan, Priya
Cao, Weiping
Davis, Carl
Marisetti, Krishna
Thomas, Sunil
Gangappa, Shivaprakash
Sambhara, Suryaprakash
Murali-Krishna, Kaja
TI Activation of the RIG-I Pathway during Influenza Vaccination Enhances
the Germinal Center Reaction, Promotes T Follicular Helper Cell
Induction, and Provides a Dose-Sparing Effect and Protective Immunity
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID PANDEMIC INFLUENZA; CLONAL EXPANSION; CUTTING EDGE; VIRUS; RESPONSES;
RNA; RECOGNITION; MEMORY; INFECTION; ANTIBODIES
AB Pattern recognition receptors (PRR) sense certain molecular patterns uniquely expressed by pathogens. Retinoic-acid-inducible gene I (RIG-I) is a cytosolic PRR that senses viral nucleic acids and induces innate immune activation and secretion of type I interferons (IFNs). Here, using influenza vaccine antigens, we investigated the consequences of activating the RIG-I pathway for antigen-specific adaptive immune responses. We found that mice immunized with influenza vaccine antigens coadministered with 5' ppp-double-stranded RNA (dsRNA), a RIG-I ligand, developed robust levels of hemagglutination-inhibiting antibodies, enhanced germinal center reaction, and T follicular helper cell responses. In addition, RIG-I activation enhanced antibody affinity maturation and plasma cell responses in the draining lymph nodes, spleen, and bone marrow and conferred protective immunity against virus challenge. Importantly, activation of the RIG-I pathway was able to reduce the antigen requirement by 10- to 100-fold in inducing optimal influenza-specific cellular and humoral responses, including protective immunity. The effects induced by 5' ppp-dsRNA were significantly dependent on type I IFN and IPS-1 (an adapter protein downstream of the RIG-I pathway) signaling but were independent of the MyD88- and TLR3-mediated pathways. Our results show that activation of the RIG-I-like receptor pathway programs the innate immunity to achieve qualitatively and quantitatively enhanced protective cellular adaptive immune responses even at low antigen doses, and this indicates the potential utility of RIG-I ligands as molecular adjuvants for viral vaccines.
IMPORTANCE
The recently discovered RNA helicase family of RIG-I-like receptors (RLRs) is a critical component of host defense mechanisms responsible for detecting viruses and triggering innate antiviral cytokines that help control viral replication and dissemination. In this study, we show that the RLR pathway can be effectively exploited to enhance adaptive immunity and protective immune memory against viral infection. Our results show that activation of the RIG-I pathway along with influenza vaccination programs the innate immunity to induce qualitatively and quantitatively superior protective adaptive immunity against pandemic influenza viruses. More importantly, RIG-I activation at the time of vaccination allows induction of robust adaptive responses even at low vaccine antigen doses. These results highlight the potential utility of exploiting the RIG-I pathway to enhance viral-vaccine-specific immunity and have broader implications for designing better vaccines in general.
C1 [Kulkarni, Raveendra R.; Bhaumik, Siddhartha Kumar; Marisetti, Krishna; Murali-Krishna, Kaja] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.
[Kulkarni, Raveendra R.; Bhaumik, Siddhartha Kumar; Marisetti, Krishna; Murali-Krishna, Kaja] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA.
[Rasheed, Mohammed Ata Ur; Davis, Carl] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.
[Ranjan, Priya; Cao, Weiping; Gangappa, Shivaprakash; Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Thomas, Sunil] Univ Washington, Sch Med, Dept Immunol, Seattle, WA USA.
[Murali-Krishna, Kaja] Int Ctr Genet Engn & Biotechnol, ICGEB Emory Vaccine Ctr, New Delhi, India.
RP Murali-Krishna, K (reprint author), Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.
EM ssambhara@cdc.gov; murali.kaja@emory.edu
FU National Institutes of Health (NIH) [R01AI086133, U19AI083019]
FX This work was supported by National Institutes of Health (NIH) grants
R01AI086133 and U19AI083019 to K.M.-K.
NR 47
TC 15
Z9 15
U1 0
U2 16
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2014
VL 88
IS 24
BP 13990
EP 14001
DI 10.1128/JVI.02273-14
PG 12
WC Virology
SC Virology
GA AU0CZ
UT WOS:000345292100007
PM 25253340
ER
PT J
AU Vega, E
Donaldson, E
Huynh, J
Barclay, L
Lopman, B
Baric, R
Chen, LF
Vinje, J
AF Vega, Everardo
Donaldson, Eric
Huynh, Jeremy
Barclay, Leslie
Lopman, Ben
Baric, Ralph
Chen, Luke F.
Vinje, Jan
TI RNA Populations in Immunocompromised Patients as Reservoirs for Novel
Norovirus Variants
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID UNITED-STATES; MOLECULAR EVOLUTION; BLOCKADE EPITOPE; GII.4 VARIANT;
IN-VIVO; GASTROENTERITIS; INFECTION; EMERGENCE; OUTBREAKS; PREVALENCE
AB Noroviruses are the leading cause of acute gastroenteritis outbreaks worldwide. The majority of norovirus outbreaks are caused by genogroup II. 4 (GII. 4). Novel GII. 4 strains emerge every 2 to 4 years and replace older variants as the dominant norovirus. Novel variants emerge through a combination of recombination, genetic drift, and selection driven by population immunity, but the exact mechanism of how or where is not known. We detected two previously unknown novel GII. 4 variants, termed GII. 4 UNK1 and GII. 4 UNK2, and a diverse norovirus population in fecal specimens from immunocompromised individuals with diarrhea after they had undergone bone marrow transplantation. We hypothesized that immunocompromised individuals can serve as reservoirs for novel norovirus variants. To test our hypothesis, metagenomic analysis of viral RNA populations was combined with a full-genome bioinformatic analysis of publicly available GII. 4 norovirus sequences from 1974 to 2014 to identify converging sites. Variable sites were proportionally more likely to be within two amino acids (P<0.05) of positively selected sites. Further analysis using a hypergeometric distribution indicated that polymorphic site distribution was random and its proximity to positively selected sites was dependent on the size of the norovirus genome and the number of positively selected sites. In conclusion, random mutations may have a positive impact on driving norovirus evolution, and immunocompromised individuals could serve as potential reservoirs for novel GII. 4 strains.
IMPORTANCE
Norovirus is the most common cause of viral gastroenteritis in the United States. Every 2 to 3 years novel norovirus variants emerge and replace dominant strains. The continual emergence of novel noroviruses is believed to be caused by a combination of genetic drift, population immunity, and recombination, but exactly how this emergence occurs remains unknown. In this study, we identified two novel GII. 4 variants in immunocompromised bone marrow transplant patients. Using metagenomic and bioinformatic analysis, we showed that most genetic polymorphisms in the novel variants occur near 0 to 2 amino acids of positively selected sites, but the distribution of mutations was random; clustering of polymorphisms with positively selected sites was a result of genome size and number of mutations and positively selected sites. This study shows that immunocompromised patients can harbor infectious novel norovirus variants, and although mutations in viruses are random, they can have a positive effect on viral evolution.
C1 [Vega, Everardo; Barclay, Leslie; Lopman, Ben; Vinje, Jan] Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
[Donaldson, Eric; Huynh, Jeremy; Baric, Ralph] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[Chen, Luke F.] Duke Univ Hosp, Durham, NC USA.
RP Vega, E (reprint author), Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
EM evega@cdc.gov
FU Intramural Food Safety Program at the Centers for Disease Control and
Prevention; National Institutes of Health [AI 056351]; Gillings
Innovation Laboratory award from the UNC Gillings School of Global
Public Health; University of North Carolina research grant
FX This work was supported by the Intramural Food Safety Program at the
Centers for Disease Control and Prevention and in part by a grant from
the National Institutes of Health to R.B. (AI 056351), a Gillings
Innovation Laboratory award from the UNC Gillings School of Global
Public Health to E. D., and a University of North Carolina research
grant.
NR 50
TC 17
Z9 17
U1 5
U2 18
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2014
VL 88
IS 24
BP 14184
EP 14196
DI 10.1128/JVI.02494-14
PG 13
WC Virology
SC Virology
GA AU0CZ
UT WOS:000345292100024
PM 25275120
ER
PT J
AU Byrareddy, SN
Kallam, B
Arthos, J
Cicala, C
Nawaz, F
Hiatt, J
Kersh, EN
McNicholl, JM
Hanson, D
Reimann, KA
Brameier, M
Walter, L
Rogers, K
Mayne, AE
Dunbar, P
Villinger, T
Little, D
Parslow, TG
Santangelo, PJ
Villinger, F
Fauci, AS
Ansari, AA
AF Byrareddy, Siddappa N.
Kallam, Brianne
Arthos, James
Cicala, Claudia
Nawaz, Fatima
Hiatt, Joseph
Kersh, Ellen N.
McNicholl, Janet M.
Hanson, Debra
Reimann, Keith A.
Brameier, Markus
Walter, Lutz
Rogers, Kenneth
Mayne, Ann E.
Dunbar, Paul
Villinger, Tara
Little, Dawn
Parslow, Tristram G.
Santangelo, Philip J.
Villinger, Francois
Fauci, Anthony S.
Ansari, Aftab A.
TI Targeting alpha(4)beta(7) integrin reduces mucosal transmission of
simian immunodeficiency virus and protects gut-associated lymphoid
tissue from infection
SO NATURE MEDICINE
LA English
DT Article
ID T-CELL SUBSET; SIV INFECTION; GASTROINTESTINAL-TRACT; MAINTENANCE
THERAPY; ULCERATIVE-COLITIS; IMMUNE ACTIVATION; RHESUS MACAQUES;
ALPHA-4-BETA-7; VEDOLIZUMAB; HIV-1
AB alpha(4)beta(7) integrin expressing CD4(+) T cells preferentially traffic to gut-associated lymphoid tissue (GALT) and have a key role in HIV and simian immunodeficiency virus (SIV) pathogenesis. We show here that the administration of an anti-alpha(4)beta(7) monoclonal antibody just prior to and during acute infection protects rhesus macaques from transmission following repeated low-dose intravaginal challenges with SIVmac251. In treated animals that became infected, the GALT was significantly protected from infection and CD4(+) T cell numbers were maintained in both the blood and the GALT. Thus, targeting alpha(4)beta(7) reduces mucosal transmission of Sly in macaques.
C1 [Byrareddy, Siddappa N.; Kallam, Brianne; Mayne, Ann E.; Dunbar, Paul; Villinger, Tara; Little, Dawn; Parslow, Tristram G.; Villinger, Francois; Ansari, Aftab A.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
[Arthos, James; Cicala, Claudia; Nawaz, Fatima; Hiatt, Joseph; Fauci, Anthony S.] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA.
[Kersh, Ellen N.; McNicholl, Janet M.; Hanson, Debra] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
[Reimann, Keith A.] Univ Massachusetts, Sch Med, Mass Biol, Boston, MA 02125 USA.
[Brameier, Markus; Walter, Lutz] German Primate Ctr, Leibniz Inst Primate Res, Primate Genet Lab, Gottingen, Germany.
[Rogers, Kenneth; Villinger, Francois] Emory Univ, Yerkes Natl Primate Res Ctr, Div Microbiol & Immunol, Atlanta, GA 30322 USA.
[Santangelo, Philip J.] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.
[Santangelo, Philip J.] Emory Univ, Atlanta, GA 30322 USA.
RP Ansari, AA (reprint author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
EM pathaaa@emory.edu
OI Hiatt, Joseph/0000-0002-8015-9614
FU NIH-NIAID [AI-098628-01]; NIAID NIH Intramural Research Program;
Nonhuman Primate Reagent Resource (NIAID, NIH) [HHSN272200900037C]; [OD
51POD1113]
FX This work was supported by a grant from the NIH-NIAID AI-098628-01 (to
A.A.A.), the NIAID NIH Intramural Research Program and OD 51POD1113 to
the Yerkes National Primate Research Center. We are grateful to F.
Connor-Stroud for help with the cytobrush studies and to the veterinary
staff and animal caretakers of the Yerkes National Primate Center of
Emory University, specially S. Ehnert and her team. The authors also
acknowledge the assistance of M. Piatak for performing the
ultrasensitive PCR analysis and R. Kaul and L.R. McKinnon for sharing
with us their finding on cervical brush analyses in Africa and advising
us on how to proceed in adapting their human findings to our nonhuman
primates. Recombinant mAbs were produced by the Nonhuman Primate Reagent
Resource (NIAID, NIH contract # HHSN272200900037C). The virus stock of
SIVmac251 was obtained courtesy of N. Miller (NIAID, NIH). We
apologize to all the authors whose publications we failed to cite. The
findings in this report are those of the authors and do not necessarily
reflect the views of the US Centers for Disease Control and Prevention.
NR 20
TC 30
Z9 30
U1 1
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD DEC
PY 2014
VL 20
IS 12
BP 1397
EP 1400
DI 10.1038/nm.3715
PG 4
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA AU7ZZ
UT WOS:000345817900014
PM 25419708
ER
PT J
AU To, TM
Soldatos, A
Sheriff, H
Schmid, DS
Espinosa, N
Cosentino, G
Preas, CP
Glaser, CA
AF To, Tu M.
Soldatos, Ariane
Sheriff, Heather
Schmid, D. Scott
Espinosa, Natasha
Cosentino, Giorgio
Preas, Christopher P.
Glaser, Carol A.
TI INSIGHTS INTO PEDIATRIC HERPES SIMPLEX ENCEPHALITIS FROM A COHORT OF 21
CHILDREN FROM THE CALIFORNIA ENCEPHALITIS PROJECT, 1998-2011
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE herpes simplex encephalitis; California Encephalitis Project; pediatric
encephalitis
ID DIAGNOSIS
AB Twenty-one children with confirmed herpes simplex encephalitis were identified in the California Encephalitis Project. Noteworthy features included 6 (29%) patients with an initial negative herpes simplex virus cerebrospinal fluid polymerase chain reaction test and 13 (59%) patients with extratemporal lobe involvement identified by neuroimaging. Eleven cases were <4 years of age, but all 4 fatal cases occurred in adolescents.
C1 [To, Tu M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA.
[To, Tu M.; Glaser, Carol A.] Calif Dept Publ Hlth, Ctr Infect Dis, Div Communicable Dis Control, Communicable Dis & Emergency Response Branch, Richmond, CA USA.
[To, Tu M.] Calif Dept Publ Hlth, Calif Epidemiol Investigat Serv Cal EIS, Sacramento, CA USA.
[Soldatos, Ariane] NINDS, NIH, Bethesda, MD 20892 USA.
[Sheriff, Heather; Espinosa, Natasha; Cosentino, Giorgio; Preas, Christopher P.] Calif Dept Publ Hlth, Ctr Infect Dis, Div Communicable Dis Control, Viral & Rickettsial Dis Lab, Richmond, CA USA.
[Schmid, D. Scott] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpesvirus Lab Branch, Div Viral Dis, Off Infect Dis,Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
RP To, TM (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 185 Berry St,Lobby 5,Suite 5700, San Francisco, CA 94107 USA.
EM tumy.to@ucsf.edu
FU Centers for Disease Control and Prevention Emerging Infections Program
[U50/CCU915546-09]
FX Financial support was by Centers for Disease Control and Prevention
Emerging Infections Program (U50/CCU915546-09).
NR 10
TC 9
Z9 9
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD DEC
PY 2014
VL 33
IS 12
BP 1287
EP 1288
DI 10.1097/INF.0000000000000422
PG 3
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA AU2ND
UT WOS:000345454300018
PM 24911898
ER
PT J
AU Adedinsewo, DA
Wei, SC
Robertson, M
Rose, C
Johnson, CH
Dombrowski, J
Skarbinski, J
AF Adedinsewo, Demilade A.
Wei, Stanley C.
Robertson, McKaylee
Rose, Charles
Johnson, Christopher H.
Dombrowski, Julie
Skarbinski, Jacek
TI Timing of Antiretroviral Therapy Initiation in a Nationally
Representative Sample of HIV-Infected Adults Receiving Medical Care in
the United States
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID INJECTION-DRUG USERS; MONITORING PROJECT; TRENDS; INDIVIDUALS;
DISPARITIES; PREVALENCE; MEN; RNA; SEX
AB Early antiretroviral therapy (ART) initiation reduces the risk of disease progression and HIV transmission, but data on time from HIV care entry to ART initiation are lacking. Using data from the Medical Monitoring Project (MMP), a population-based probability sample of HIV-infected adults receiving medical care in the United States, we assessed time from care entry to ART initiation among persons diagnosed May 2004-April 2009 and used multivariable Cox proportional-hazards models to identify factors associated with time to ART initiation. Among 1094 MMP participants, 83.9% reported initiating ART, with median time to ART initiation of 10 months. In multivariable models, blacks compared to whites [hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.70-0.98], persons without continuous health insurance (HR 0.82; CI 0.70-0.97), heterosexual women and men who have sex with men compared to heterosexual men (HR 0.66; CI 0.51-0.85 and HR 0.71; CI 0.60-0.84, respectively), and persons without AIDS at care entry (HR 0.37; CI 0.31-0.43) had significantly longer times to ART initiation. Overall, time to ART initiation was suboptimal by current standards and significant disparities were noted among certain subgroups. Efforts to encourage prompt ART initiation should address delays among those without health insurance and among certain sociodemographic subgroups.
C1 [Adedinsewo, Demilade A.; Robertson, McKaylee] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA.
[Adedinsewo, Demilade A.; Wei, Stanley C.; Robertson, McKaylee; Rose, Charles; Johnson, Christopher H.; Skarbinski, Jacek] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA.
[Wei, Stanley C.] US PHS, Atlanta, GA USA.
[Dombrowski, Julie] Univ Washington, Dept Med, Seattle, WA USA.
[Dombrowski, Julie] Publ Hlth Seattle & King Cty HIV STD Program, Seattle, WA USA.
RP Skarbinski, J (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mailstop E-46, Atlanta, GA 30329 USA.
EM jskarbinski@cdc.gov
OI Adedinsewo, Demilade/0000-0002-8629-2029
FU Research Participation Program at the Centers for Disease Control and
Prevention; Centers for Disease Control and Prevention [PS09-937]
FX This research was supported in part by an appointment to the Research
Participation Program at the Centers for Disease Control and Prevention
administered by the Oak Ridge Institute for Science and Education
through an agreement between the US Department of Energy and CDC.
Funding for the Medical Monitoring Project is provided by a cooperative
agreement (PS09-937) from the Centers for Disease Control and
Prevention.
NR 31
TC 6
Z9 6
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD DEC 1
PY 2014
VL 28
IS 12
BP 613
EP 621
DI 10.1089/apc.2014.0194
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AU4FI
UT WOS:000345564900001
PM 25329710
ER
PT J
AU Yehia, BR
Cui, WJ
Thompson, WW
Zack, MM
McKnight-Eily, L
DiNenno, E
Rose, CE
Blank, MB
AF Yehia, Baligh R.
Cui, Wanjun
Thompson, William W.
Zack, Matthew M.
McKnight-Eily, Lela
DiNenno, Elizabeth
Rose, Charles E.
Blank, Michael B.
TI HIV Testing Among Adults with Mental Illness in the United States
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; PSYCHIATRIC-DISORDERS; VIRAL SUPPRESSION;
INFECTED PATIENTS; HEALTH-SERVICES; CARE; PREVENTION; INDIVIDUALS; RISK;
TRANSMISSION
AB Nationally representative data from the 2007 National Health Interview Survey (NHIS) were used to compare HIV testing prevalence among US adults with mental illness (schizophrenia spectrum disorder, bipolar disorder, depression, and/or anxiety) to those without, providing an update of prior work using 1999 and 2002 NHIS data. Logistic regression modeling was used to estimate the probability of ever being tested for HIV by mental illness status, adjusting for age, sex, race/ethnicity, marital status, substance abuse, excessive alcohol or tobacco use, and HIV risk factors. Based on data from 21,785 respondents, 15% of adults had a psychiatric disorder and 37% ever had an HIV test. Persons with schizophrenia (64%), bipolar disorder (63%), and depression and/or anxiety (47%) were more likely to report ever being tested for HIV than those without mental illness (35%). In multivariable models, individuals reporting schizophrenia (adjusted prevalence ratio=1.68, 95% confidence interval=1.33-2.13), bipolar disease (1.58, 1.39-1.81), and depression and/or anxiety (1.31, 1.25-1.38) were more likely to be tested for HIV than persons without these diagnoses. Similar to previous analyses, persons with mental illness were more likely to have been tested than those without mental illness. However, the elevated prevalence of HIV in populations with mental illness suggests that high levels of testing along with other prevention efforts are needed.
C1 [Yehia, Baligh R.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Blank, Michael B.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Cui, Wanjun; Zack, Matthew M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
[Thompson, William W.; McKnight-Eily, Lela] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
[DiNenno, Elizabeth; Rose, Charles E.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA USA.
RP Yehia, BR (reprint author), Univ Penn, Perelman Sch Med, 1021 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM byehia@upenn.edu
FU National Institutes of Health [K23-MH097647]; Centers for Disease
Control and Prevention [U18-PS000704]; Penn Center for AIDS Research
[P30-AI045008]; Penn Mental Health AIDS Research Center [P30-MH097488]
FX This work was supported by the National Institutes of Health
(K23-MH097647), Centers for Disease Control and Prevention
(U18-PS000704), Penn Center for AIDS Research (P30-AI045008), and the
Penn Mental Health AIDS Research Center (P30-MH097488).
NR 45
TC 6
Z9 6
U1 2
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD DEC 1
PY 2014
VL 28
IS 12
BP 628
EP 634
DI 10.1089/apc.2014.0196
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AU4FI
UT WOS:000345564900003
PM 25459230
ER
PT J
AU Kohler, PK
Ondenge, K
Mills, LA
Okanda, J
Kinuthia, J
Olilo, G
Odhiambo, F
Laserson, KF
Zierler, B
Voss, J
John-Stewart, G
AF Kohler, Pamela K.
Ondenge, Kenneth
Mills, Lisa A.
Okanda, John
Kinuthia, John
Olilo, George
Odhiambo, Frank
Laserson, Kayla F.
Zierler, Brenda
Voss, Joachim
John-Stewart, Grace
TI Shame, Guilt, and Stress: Community Perceptions of Barriers to Engaging
in Prevention of Mother to Child Transmission (PMTCT) Programs in
Western Kenya
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID HIV-RELATED STIGMA; ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; HEALTH; CARE;
PREGNANCY; SERVICES; IMPACT; WOMEN; SELF
AB While global scale-up of prevention of mother-to-child transmission of HIV (PMTCT) services has been expansive, only half of HIV-infected pregnant women receive antiretroviral regimens for PMTCT in sub-Saharan Africa. To evaluate social factors influencing uptake of PMTCT in rural Kenya, we conducted a community-based, cross-sectional survey of mothers residing in the KEMRI/CDC Health and Demographic Surveillance System (HDSS) area. Factors included referrals and acceptability, HIV-related stigma, observed discrimination, and knowledge of violence. Chi-squared tests and multivariate regression analyses were used to detect stigma domains associated with uptake of PMTCT services. Most HIV-positive women (89%) reported blame or judgment of people with HIV, and 46% reported they would feel shame if they were associated with someone with HIV. In multivariate analyses, shame was significantly associated with decreased likelihood of maternal HIV testing (Prevalence Ratio 0.91, 95% Confidence Interval 0.84-0.99), a complete course of maternal antiretrovirals (ARVs) (PR 0.73, 95% CI 0.55-0.97), and infant HIV testing (PR 0.86, 95% CI 0.75-0.99). Community perceptions of why women may be unwilling to take ARVs included stigma, guilt, lack of knowledge, denial, stress, and despair or futility. Interventions that seek to decrease maternal depression and internalization of stigma may facilitate uptake of PMTCT.
C1 [Kohler, Pamela K.; John-Stewart, Grace] Univ Washington, Dept Global Hlth, Seattle, WA 98104 USA.
[Kohler, Pamela K.] Univ Washington, Dept Psychosocial & Community Hlth, Seattle, WA 98104 USA.
[Zierler, Brenda; Voss, Joachim] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98104 USA.
[John-Stewart, Grace] Univ Washington, Dept Med, Seattle, WA 98104 USA.
[John-Stewart, Grace] Univ Washington, Dept Pediat, Seattle, WA 98104 USA.
[John-Stewart, Grace] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA.
[Ondenge, Kenneth; Mills, Lisa A.; Okanda, John; Olilo, George; Odhiambo, Frank; Laserson, Kayla F.] Ctr Dis Control & Prevent, Res & Publ Hlth Collaborat, Kenya Med Res Inst KEMRI, Kisumu, Kenya.
[Mills, Lisa A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
[Laserson, Kayla F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA.
[Kinuthia, John] Univ Nairobi, Kenyatta Natl Hosp, Nairobi, Kenya.
RP Kohler, PK (reprint author), Univ Washington, Dept Global Hlth, 325 9th Ave,Box 359932, Seattle, WA 98104 USA.
EM pkohler2@uw.edu
FU National Institutes of Health [R24 HD056799]; UW Center for Integrated
Health of Women, Adolescents, and Children (Global WACh); KEMRI/CDC
Health and Demographic Surveillance System team
FX This study was funded through the A Kenya Free of AIDS grant (R24
HD056799) from the National Institutes of Health and received assistance
from the University of Washington Center for AIDS Research (P30
AI027757) and Pediatric HIV-1 in Africa (K24 HD054314). Authors
gratefully acknowledge the support and advice of Dr. Martina Morris, Dr.
Barbara Richardson, Dr. Nancy Woods, and Dr. Lisa Manhart; the UW Center
for Integrated Health of Women, Adolescents, and Children (Global WACh);
the Director of the Kenya Medical Research Institute; and the KEMRI/CDC
Health and Demographic Surveillance System team.
NR 42
TC 10
Z9 10
U1 2
U2 18
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD DEC 1
PY 2014
VL 28
IS 12
BP 643
EP 651
DI 10.1089/apc.2014.0171
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AU4FI
UT WOS:000345564900005
PM 25361205
ER
PT J
AU Marques, MB
Hickner, J
Thompson, PJ
Taylor, JR
AF Marques, Marisa B.
Hickner, John
Thompson, Pamela J.
Taylor, Julie R.
TI Primary Care Physicians and the Laboratory Now and the Future
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Editorial Material
C1 [Marques, Marisa B.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Hickner, John] Univ Illinois, Coll Med, Dept Family Med, Chicago, IL USA.
[Thompson, Pamela J.; Taylor, Julie R.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Marques, MB (reprint author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
OI Marques, Marisa/0000-0002-6689-7856
NR 7
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL PATHOLOGY
PI CHICAGO
PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA
SN 0002-9173
EI 1943-7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD DEC
PY 2014
VL 142
IS 6
BP 738
EP 740
DI 10.1309/AJCP56OUNZKXZPTD
PG 3
WC Pathology
SC Pathology
GA AT6MZ
UT WOS:000345053900003
PM 25389325
ER
PT J
AU Camperlengo, L
Shapiro-Mendoza, CK
Gibbs, F
AF Camperlengo, Lena
Shapiro-Mendoza, Carrie K.
Gibbs, Falicia
TI Improving Sudden Unexplained Infant Death Investigation Practices An
Evaluation of the Centers for Disease Control and Prevention's SUID
Investigation Training Academies
SO AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY
LA English
DT Article
DE SIDS; SUID; train the trainer; infant death investigation
ID CLASSIFICATION
AB Lack of thorough sudden unexplained infant death investigations (SUIDIs) has hindered accurate cause-of-death determination, infant mortality surveillance, and prevention strategies. To standardize SUIDI practices, the Centers for Disease Control and Prevention created a reporting form, guidelines, training curriculum, and SUIDI Training Academies using a train-the-trainer format. The training goal was to train teams of five in each state, who would reach an additional 1250 participants.
The aim of this study is to evaluate the SUIDI Training Academies by determining professional characteristics of participants, assessing the level of confidence in infant death investigation components, enumerating the number of secondary trainings, and discussing recommendations for future trainings.
To evaluate the training and the success of the train-the-trainer strategy, we used training evaluations, participant lists, and Web-based training logs to assess participant knowledge, skills, perceptions, and characteristics and number of secondary trainings.
We trained 270 trainers at 5 SUIDI Training Academies. Greater than 96% of respondents reported confidence in case investigation skills and reported that hands-on laboratory sessions facilitated the practice of new skills. Academy trainers have trained greater than 23,000 medicolegal professionals, exceeding the training goal. This evaluation allowed us to identify opportunities to improve future SUIDI trainings.
C1 [Camperlengo, Lena; Shapiro-Mendoza, Carrie K.; Gibbs, Falicia] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA.
RP Camperlengo, L (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,NE MS-F74, Atlanta, GA 30341 USA.
EM gtx6@cdc.gov
NR 12
TC 2
Z9 2
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-7910
EI 1533-404X
J9 AM J FOREN MED PATH
JI Am. J. Forensic Med. Pathol.
PD DEC
PY 2014
VL 35
IS 4
BP 278
EP 282
DI 10.1097/PAF.0000000000000123
PG 5
WC Medicine, Legal; Pathology
SC Legal Medicine; Pathology
GA AU0FW
UT WOS:000345299900015
PM 25330248
ER
PT J
AU Morales-Aleman, MM
Hageman, K
Gaul, ZJ
Le, B
Paz-Bailey, G
Sutton, MY
AF Morales-Aleman, Mercedes M.
Hageman, Kathy
Gaul, Zaneta J.
Le, Binh
Paz-Bailey, Gabriela
Sutton, Madeline Y.
TI Intimate Partner Violence and Human Immunodeficiency Virus Risk Among
Black and Hispanic Women
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID SEXUALLY TRANSMISSIBLE INFECTIONS; TRANSMITTED-DISEASE CLINICS;
HIV-RISK; UNITED-STATES; ANAL INTERCOURSE; PREVENTION INTERVENTION;
MINORITY WOMEN; RECEIVING CARE; SUBSTANCE USE; URBAN WOMEN
AB Background: Approximately 80% of new HIV infections among U.S. women are among black/African American and Hispanic women. HIV risk may be associated with intimate partner violence (IPV); data regarding IPV for women in high-HIV prevalence areas are scarce.
Purpose: To examine prevalence and correlates of IPV among women.
Methods: Heterosexual women and their male partners in cities with high HIV prevalence were enrolled. During 2006-2007, participants completed interviews about HIV risk factors and IPV (physical violence or forced sex) experiences. Data were analyzed during 2012-2013 using multivariate logistic regression to identify individual- and partner-level IPV correlates.
Results: Of 1,011 female respondents, 985 (97.4%) provided risk factor and demographic data. Most were non-Hispanic black/African American (82.7%); living at or below poverty (86.7%); and tested HIV-negative (96.8%). IPV-physical violence was reported by 29.1%, and IPV-forced sex by 13.7%. Being married/living with a partner (AOR=1.60, 95% CI=1.06, 2.40); non-injection drug use (AOR=1.74, 95% CI=1.22, 2.48); and ever discussing male partners' number of current sex partners (AOR=1.60, 95% CI=1.15, 2.24) were associated with IPV-physical violence. Women reporting concurrent sex partners (AOR=1.80, 95% CI=1.04, 3.13) and ever discussing number of male partners' past sex partners (AOR=1.85, 95% CI=1.13, 3.05) were associated with IPV-forced sex. Feeling comfortable asking a male partner to use condoms was associated with decreased IPV-physical violence (AOR=0.32, 95% CI=0.16,0.64) and -forced sex (AOR=0.37, 95% CI=0.16, 0.85).
Conclusions: Prevention interventions that enhance women's skills to decrease HIV and IPV risk are important strategies for decreasing racial/ethnic disparities among women. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine
C1 [Morales-Aleman, Mercedes M.; Hageman, Kathy; Gaul, Zaneta J.; Le, Binh; Paz-Bailey, Gabriela; Sutton, Madeline Y.] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
[Gaul, Zaneta J.] ICF Int, Atlanta, GA USA.
RP Sutton, MY (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis Sexually Transm, 1600 Clifton Rd NE MS E-45, Atlanta, GA 30333 USA.
EM zxa3@cdc.gov
FU Minority AIDS Initiative; National HIV Behavioral Surveillance System
Partner Study Group; CDC [04017, U62/CCU523584]
FX The authors thank the Minority AIDS Initiative for funding support and
the National HIV Behavioral Surveillance System Partner Study Group for
study support activities.; This study was funded in part by CDC, Program
Announcement No. 04017/Cooperative Agreement No. U62/CCU523584.
NR 60
TC 1
Z9 1
U1 5
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD DEC
PY 2014
VL 47
IS 6
BP 689
EP 702
DI 10.1016/j.amepre.2014.08.007
PG 14
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AT9RP
UT WOS:000345264200001
PM 25455114
ER
PT J
AU Lu, PJ
Rodriguez-Lainz, A
O'Halloran, A
Greby, S
Williams, WW
AF Lu, Peng-jun
Rodriguez-Lainz, Alfonso
O'Halloran, Alissa
Greby, Stacie
Williams, Walter W.
TI Adult Vaccination Disparities Among Foreign-Born Populations in the US,
2012
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; UNITED-STATES; SELF-REPORT;
NATIONAL-HEALTH; PNEUMOCOCCAL VACCINATION; IMMUNIZATION PRACTICES;
ELDERLY OUTPATIENTS; SEASONAL INFLUENZA; PRIMARY LANGUAGE; COVERAGE
AB Background: Foreign-born persons are considered at higher risk of undervaccination and exposure to many vaccine-preventable diseases. Information on vaccination coverage among foreign-born populations is limited.
Purpose: To assess adult vaccination coverage disparities among foreign-born populations in the U.S.
Methods: Data from the 2012 National Health Interview Survey were analyzed in 2013. For non-influenza vaccines, the weighted proportion vaccinated was calculated. For influenza vaccination, Kaplan-Meier survival analysis was used to assess coverage among individuals interviewed during September 2011-June 2012 and vaccinated in August 2011-May 2012.
Results: Overall, unadjusted vaccination coverage among U.S.-born respondents was significantly higher than that of foreign-born respondents: influenza, age >= 18 years (40.4% vs 33.8%); pneumococcal polysaccharide vaccine (PPV), 18-64 years with high-risk conditions (20.8% vs 13.7%); PPV, >= 65 years (62.6% vs 40.5%); tetanus vaccination, >= 18 years (65.0% vs 50.6%); tetanus, diphtheria, and acellular pertussis (Tdap), >= 18 years (15.5% vs 9.3%); hepatitis B, 18-49 years (37.2% vs 28.4%); shingles, >= 60 years (21.3% vs 12.0%); and human papilloma virus (HPV), women 18-26 years (38.7% vs 14.7%). Among the foreign born, vaccination coverage was generally lower for non-U.S. citizens, recent immigrants, and those interviewed in a language other than English. Foreign-born individuals were less likely than U.S.-born people to be vaccinated for pneumococcal ( >= 65 years), tetanus, Tdap, and HPV (women) after adjusting for confounders.
Conclusions: Vaccination coverage is lower among foreign-born adults than those born in the U.S. It is important to consider foreign birth and immigration status when assessing vaccination disparities and planning interventions. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine
C1 [Lu, Peng-jun; O'Halloran, Alissa; Greby, Stacie; Williams, Walter W.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Rodriguez-Lainz, Alfonso] CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Lu, PJ (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop A-19, Atlanta, GA 30333 USA.
EM lhp8@cdc.gov
NR 62
TC 6
Z9 6
U1 3
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD DEC
PY 2014
VL 47
IS 6
BP 722
EP 733
DI 10.1016/j.amepre.2014.08.009
PG 12
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AT9RP
UT WOS:000345264200004
PM 25300733
ER
PT J
AU Grohskopf, LA
Olsen, SJ
Sokolow, LZ
Bresee, JS
Cox, NJ
Broder, KR
Karron, RA
Walter, EB
AF Grohskopf, Lisa A.
Olsen, Sonja J.
Sokolow, Leslie Z.
Bresee, Joseph S.
Cox, Nancy J.
Broder, Karen R.
Karron, Ruth A.
Walter, Emmanuel B.
TI Prevention and Control of Seasonal Influenza With Vaccines:
Recommendations of the Advisory Committee on Immunization Practices
(ACIP)-United States, 2014-15 Influenza Season
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Editorial Material
ID LIVE ATTENUATED VACCINES; EGG-ALLERGIC PATIENTS; YOUNG-CHILDREN;
TRIVALENT; EFFICACY; IMMUNOGENICITY; REACTOGENICITY; PERSISTENCE;
ANTIBODY; UPDATE
AB The annual influenza prevention recommendations are provided in this report.
C1 [Grohskopf, Lisa A.; Olsen, Sonja J.; Sokolow, Leslie Z.; Bresee, Joseph S.; Cox, Nancy J.] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Broder, Karen R.] CDC, Immunizat Safety Off, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Karron, Ruth A.] Johns Hopkins Univ, Baltimore, MD 21218 USA.
[Walter, Emmanuel B.] Duke Univ, Sch Med, Durham, NC 27706 USA.
RP Grohskopf, LA (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM lkg6@cdc.gov
NR 30
TC 1
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD DEC
PY 2014
VL 14
IS 12
BP 2906
EP 2913
DI 10.1111/ajt.13065
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AU0DR
UT WOS:000345294300033
ER
PT J
AU Mainous, AG
Tanner, RJ
Hulihan, MM
Amaya, M
Coates, TD
AF Mainous, Arch G., III
Tanner, Rebecca J.
Hulihan, Mary M.
Amaya, Mirna
Coates, Thomas D.
TI The impact of chelation therapy on survival in transfusional iron
overload: a meta-analysis of myelodysplastic syndrome
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Letter
DE iron overload; chelation; myelodysplastic syndrome
C1 [Mainous, Arch G., III; Tanner, Rebecca J.; Amaya, Mirna] Univ Florida, Dept Hlth Serv Res Management & Policy, Gainesville, FL 32611 USA.
[Mainous, Arch G., III] Univ Florida, Dept Community Hlth & Family Med, Gainesville, FL USA.
[Hulihan, Mary M.] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA.
[Coates, Thomas D.] Univ So Calif, Keck Sch Med, Dept Pediat & Pathol, Los Angeles, CA 90033 USA.
RP Mainous, AG (reprint author), Univ Florida, Dept Hlth Serv Res Management & Policy, Gainesville, FL 32611 USA.
EM arch.mainous@phhp.ufl.edu
OI Mainous, Arch/0000-0002-2535-7685; Coates, Thomas/0000-0001-9878-6029
FU Intramural CDC HHS [CC999999]; NCBDD CDC HHS [3U01DD000754-03S1, U01
DD000754]
NR 10
TC 7
Z9 7
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD DEC
PY 2014
VL 167
IS 5
BP 720
EP 723
DI 10.1111/bjh.13053
PG 5
WC Hematology
SC Hematology
GA AT9BG
UT WOS:000345222100022
PM 25048454
ER
PT J
AU Sinks, TH
AF Sinks, Thomas H.
TI Challenges in Investigating the Association Between Agent Orange and
Cancer: Site-Specific Cancer Risk and Accuracy of Exposure Assessment
SO CANCER
LA English
DT Editorial Material
ID VETERANS; VIETNAM
AB The findings of the study by Yi and Ohrr in the current issue of Cancer add to our overall understanding of the health risks from exposures to Agent Orange. Large numbers of individuals were potentially exposed to Agent Orange during the Vietnam War, and this report reminds us of the critical importance of accurate exposure assessment and the desire for epidemiologic studies to provide scientific clarity, even in the most difficult of circumstances.
C1 Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30329 USA.
RP Sinks, TH (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 1600 Clifton Rd,MS D75, Atlanta, GA 30329 USA.
EM tsinks@cdc.gov
NR 11
TC 2
Z9 2
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD DEC 1
PY 2014
VL 120
IS 23
BP 3595
EP 3597
DI 10.1002/cncr.28962
PG 3
WC Oncology
SC Oncology
GA AU0QU
UT WOS:000345329600005
PM 25103199
ER
PT J
AU Bayer, DK
Martinez, CA
Sorte, HS
Forbes, LR
Demmler-Harrison, GJ
Hanson, IC
Pearson, NM
Noroski, LM
Zaki, SR
Bellini, WJ
Leduc, MS
Yang, Y
Eng, CM
Patel, A
Rodningen, OK
Muzny, DM
Gibbs, RA
Campbell, IM
Shaw, CA
Baker, MW
Zhang, V
Lupski, JR
Orange, JS
Seeborg, FO
Stray-Pedersen, A
AF Bayer, D. K.
Martinez, C. A.
Sorte, H. S.
Forbes, L. R.
Demmler-Harrison, G. J.
Hanson, I. C.
Pearson, N. M.
Noroski, L. M.
Zaki, S. R.
Bellini, W. J.
Leduc, M. S.
Yang, Y.
Eng, C. M.
Patel, A.
Rodningen, O. K.
Muzny, D. M.
Gibbs, R. A.
Campbell, I. M.
Shaw, C. A.
Baker, M. W.
Zhang, V.
Lupski, J. R.
Orange, J. S.
Seeborg, F. O.
Stray-Pedersen, A.
TI Vaccine-associated varicella and rubella infections in severe combined
immunodeficiency with isolated CD4 lymphocytopenia and mutations in IL7R
detected by tandem whole exome sequencing and chromosomal microarray
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE copy number variation; IL7R; revertant mosaicism; SCID; whole exome
sequencing
ID ADENOSINE-DEAMINASE DEFICIENCY; COPY NUMBER VARIATION; KILLER T-CELLS;
ZOSTER-VIRUS; REVERTANT MOSAICISM; SOMATIC MOSAICISM; THYMIDINE KINASE;
FANCONI-ANEMIA; STRAIN; REVERSION
AB In areas without newborn screening for severe combined immunodeficiency (SCID), disease-defining infections may lead to diagnosis, and in some cases, may not be identified prior to the first year of life. We describe a female infant who presented with disseminated vaccine-acquired varicella (VZV) and vaccine-acquired rubella infections at 13 months of age. Immunological evaluations demonstrated neutropenia, isolated CD4 lymphocytopenia, the presence of CD8(+) T cells, poor lymphocyte proliferation, hypergammaglobulinaemia and poor specific antibody production to VZV infection and routine immunizations. A combination of whole exome sequencing and custom-designed chromosomal microarray with exon coverage of primary immunodeficiency genes detected compound heterozygous mutations (one single nucleotide variant and one intragenic copy number variant involving one exon) within the IL7R gene. Mosaicism for wild-type allele (20-30%) was detected in pretransplant blood and buccal DNA and maternal engraftment (5-10%) demonstrated in pretransplant blood DNA. This may be responsible for the patient's unusual immunological phenotype compared to classical interleukin (IL)-7R deficiency. Disseminated VZV was controlled with anti-viral and immune-based therapy, and umbilical cord blood stem cell transplantation was successful. Retrospectively performed T cell receptor excision circle (TREC) analyses completed on neonatal Guthrie cards identified absent TREC. This case emphasizes the danger of live viral vaccination in severe combined immunodeficiency (SCID) patients and the importance of newborn screening to identify patients prior to high-risk exposures. It also illustrates the value of aggressive pathogen identification and treatment, the influence newborn screening can have on morbidity and mortality and the significant impact of newer genomic diagnostic tools in identifying the underlying genetic aetiology for SCID patients.
C1 [Bayer, D. K.; Forbes, L. R.; Hanson, I. C.; Noroski, L. M.; Orange, J. S.; Seeborg, F. O.; Stray-Pedersen, A.] Baylor Coll Med, Dept Pediat, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA.
[Martinez, C. A.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA.
[Demmler-Harrison, G. J.] Baylor Coll Med, Dept Pediat, Infect Dis Sect, Houston, TX 77030 USA.
[Pearson, N. M.] Baylor Coll Med, Dept Pediat, Sect Pediat Emergency Med, Houston, TX 77030 USA.
Texas Childrens Hosp, Houston, TX 77030 USA.
[Leduc, M. S.; Eng, C. M.; Gibbs, R. A.; Lupski, J. R.] Baylor Coll Med, Whole Genome Lab, Houston, TX 77030 USA.
[Patel, A.; Shaw, C. A.; Lupski, J. R.] Baylor Coll Med, Med Genet Labs, Houston, TX 77030 USA.
[Muzny, D. M.; Gibbs, R. A.; Lupski, J. R.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Muzny, D. M.; Gibbs, R. A.; Campbell, I. M.; Zhang, V.; Lupski, J. R.; Stray-Pedersen, A.] Baylor Coll Med, Dept Mol & Human Genet, Baylor Hopkins Ctr Mendelian Genom, Houston, TX 77030 USA.
[Lupski, J. R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
[Forbes, L. R.; Hanson, I. C.; Orange, J. S.; Stray-Pedersen, A.] Texas Childrens Hosp, Ctr Human Immunobiol, Houston, TX 77030 USA.
[Forbes, L. R.; Hanson, I. C.; Orange, J. S.; Stray-Pedersen, A.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
[Baker, M. W.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA.
[Baker, M. W.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin State Lab Hyg, Madison, WI USA.
[Bellini, W. J.; Yang, Y.] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpes Virus Lab Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Zaki, S. R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
[Sorte, H. S.; Rodningen, O. K.; Stray-Pedersen, A.] Oslo Univ Hosp, Dept Med Genet, Oslo, Norway.
RP Stray-Pedersen, A (reprint author), Baylor Coll Med, 1 Baylor Plaza,Suite 604B, Houston, TX 77030 USA.
EM strayped@bcm.edu
OI orange, jordan/0000-0001-7117-7725
FU National Human Genome Research Institute, National Institutes of Health,
USA [U54HG006542, U54HG003273]
FX The authors are grateful to the family for their participation in this
study. We thank Texas Department of Health Services Newborn Screening
Program for retrieval of newborn screening specimens. We gratefully
acknowledge the following individuals at the CDC for their respective
roles in evaluation of vaccine-acquired viral infections: Dr. C. Paddock
of the NCEZID, Division of High-Consequence Pathogens and Pathology,
Infectious Diseases Pathology Branch, and the following individuals and
their respective teams in the NCIRD, Division of Viral Diseases,
Measles, Mumps, Rubella, and Herpesvirus Laboratory Branch: Dr. D. S.
Schmid and K. W. Radford, Herpesvirus Team, Dr. J. Icenogle and E.
Abernaty, MS, Rubella Team, and Dr. P. Rota and Dr. R. McNall, Measles
Team. Sincere thanks to Dr C. Bollard, Dr A. Leen, Dr A. Papadopoulou
and Dr H. Tashiro for evaluation of immune reconstitution by ELISPOT
assay and editing contributions. Special thanks are due to Lillian
Gundersen for technical assistance and to Dr S. Nicholas for editing
contributions. The Baylor-Hopkins Center for Mendelian Genomics is
funded by the National Human Genome Research Institute (U54HG006542 and
U54HG003273), National Institutes of Health, USA.
NR 59
TC 10
Z9 10
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD DEC
PY 2014
VL 178
IS 3
BP 459
EP 469
DI 10.1111/cei.12421
PG 11
WC Immunology
SC Immunology
GA AU0PA
UT WOS:000345324300006
PM 25046553
ER
PT J
AU Schauer, GL
Wheaton, AG
Malarcher, AM
Croft, JB
AF Schauer, Gillian L.
Wheaton, Anne G.
Malarcher, Ann M.
Croft, Janet B.
TI Smoking Prevalence and Cessation Characteristics among US Adults With
and Without COPD: Findings from the 2011 Behavioral Risk Factor
Surveillance System
SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
LA English
DT Article
DE Asthma; Behavioral Risk Factor Surveillance System; Chronic Disease;
COPD; Epidemiology; Smoking Cessation
ID OBSTRUCTIVE PULMONARY-DISEASE; UNITED-STATES; LUNG-FUNCTION; MORTALITY;
HEALTH; TRIAL
AB Introduction: Cigarette smoking is a major cause of chronic obstructive pulmonary disease, (COPD) but many persons with COPD continue to smoke. Quitting can help prevent the development of and complications from COPD. This study examined whether smoking and cessation behaviors differed among adults with a) COPD, b) asthma, c) other chronic conditions only, or d) no chronic conditions. Methods: Smoking and chronic disease status was obtained from 488,909 adults aged > 18 years using the Behavioral Risk Factor Surveillance System; 9,476 current smokers and recent quitters in 5 states responded to additional questions about cessation. We computed age-adjusted prevalence of smoking and past-year quit attempts, and used bivariate and multivariable logistic regression to identify correlates of past-year quit attempts. Results: Similar to the overall sample, in the 5-state sample, 47.3% of adults with COPD were current smokers versus 23.1% of those with asthma, 28.8% of adults with other chronic conditions, and 20.0% of those with no chronic conditions. Those with COPD did not differ significantly from those with asthma, other chronic diseases, or no chronic disease in having made a past-year quit attempt (59.7% versus 64.0%, 61.5%, and 53.9%, respectively). Smokers with COPD were significantly more likely than those with no chronic disease to have used cessation treatment resources, including a quitline, counseling, or medication (p < 0.001). Conclusions: Adults with COPD were just as likely as those without COPD to make a past-year quit attempt; however, approximately 40% of smokers with COPD did not try to quit.
C1 [Schauer, Gillian L.] Carter Consulting Inc, Atlanta, GA 30345 USA.
[Schauer, Gillian L.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA.
[Schauer, Gillian L.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA.
[Wheaton, Anne G.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
[Malarcher, Ann M.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Schauer, GL (reprint author), Carter Consulting Inc, Atlanta, GA 30345 USA.
EM gschauer@cdc.gov
NR 23
TC 3
Z9 3
U1 0
U2 6
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1541-2555
EI 1541-2563
J9 COPD
JI COPD-J. Chronic Obstr. Pulm. Dis.
PD DEC
PY 2014
VL 11
IS 6
BP 697
EP 704
DI 10.3109/15412555.2014.898049
PG 8
WC Respiratory System
SC Respiratory System
GA AT3XZ
UT WOS:000344870100012
PM 24841392
ER
PT J
AU Staimez, LR
Weber, MB
Gregg, EW
AF Staimez, Lisa R.
Weber, Mary Beth
Gregg, Edward W.
TI The Role of Lifestyle Change for Prevention of Cardiovascular Disease in
Diabetes
SO CURRENT ATHEROSCLEROSIS REPORTS
LA English
DT Article
DE Cardiovascular disease; Diabetes; Lifestyle; Diet; Physical activity;
Weight loss
ID IMPAIRED GLUCOSE-TOLERANCE; LOOK-AHEAD ACTION; FOLLOW-UP;
RANDOMIZED-TRIAL; CLINICAL-TRIAL; RISK-FACTORS; MEDITERRANEAN DIET;
PHYSICAL-ACTIVITY; COHORT ANALYSIS; WEIGHT-LOSS
AB The burden of cardiovascular disease (CVD) is disproportionately greater in those with diabetes than in the general population, including higher rates of hospitalization, stroke, myocardial infarction, and mortality. Health-promoting lifestyle factors reduce both diabetes and CVD in healthy individuals; however, the efficacy of these strategies for CVD reduction in people with preexisting diabetes is unclear. In this review, we describe the most recent evidence (2013-2014) surrounding the effects of lifestyle changes on CVD outcomes in those with diabetes, and we contextualize the evidence against a backdrop of earlier key findings. Two major randomized controlled trials were identified, providing opposing conclusions about the role of lifestyle factors on CVD events in those with diabetes. Other recent prospective observational analyses support associations of physical activity and reduced CVD risk in diabetes. Limitations across studies include the use of self-report for measurement of lifestyle or lifestyle change, the length of follow-up needed to measure CVD outcomes, and the role of participants' medications on associations of lifestyle factors and CVD outcomes. Equivocal findings from the two randomized controlled trials support the need for additional research to identify the specific lifestyle factors that reduce CVD mortality and macrovascular complications in populations with diabetes.
C1 [Staimez, Lisa R.; Weber, Mary Beth] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30329 USA.
[Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Staimez, LR (reprint author), Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, 1518 Clifton Rd NE,CNR Room 7043, Atlanta, GA 30329 USA.
EM lisa.staimez@emory.edu; mbweber@emory.edu; edg7@cdc.gov
NR 48
TC 2
Z9 2
U1 2
U2 17
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1523-3804
EI 1534-6242
J9 CURR ATHEROSCLER REP
JI Curr. Atheroscleros. Rep.
PD DEC
PY 2014
VL 16
IS 12
AR 460
DI 10.1007/s11883-014-0460-y
PG 11
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AT6UU
UT WOS:000345075700004
PM 25363453
ER
PT J
AU Bardenheier, BH
Cogswell, ME
Gregg, EW
Williams, DE
Zhang, ZF
Geiss, LS
AF Bardenheier, Barbara H.
Cogswell, Mary E.
Gregg, Edward W.
Williams, Desmond E.
Zhang, Zefeng
Geiss, Linda S.
TI Does Knowing One's Elevated Glycemic Status Make a Difference in
Macronutrient Intake?
SO DIABETES CARE
LA English
DT Article
ID NUTRITION THERAPY; NUTRIENT INTAKE; UNITED-STATES; ADULTS; ENERGY; CARE
AB OBJECTIVE
To determine whether macronutrient intake differs by awareness of glycemic status among people with diabetes and prediabetes.
RESEARCH DESIGN AND METHODS
We used 24-h dietary recall and other data from 3,725 nonpregnant adults with diabetes or prediabetes aged >= 20 years from the morning fasting sample of the 2005-2010 National Health and Nutrition Examination Survey. Diabetes and prediabetes awareness were self-reported; those unaware of diabetes and prediabetes were defined by fasting plasma glucose (FPG) >= 126 mg/dL or HbA(1c) >= 6.5% and FPG 100-125 mg/dL or HbA(1c) of 5.7%-6.4%, respectively. Components of nutrient intake on a given day assessed were total calories, sugar, carbohydrates, fiber, protein, fat, and total cholesterol, stratified by sex and glycemic status awareness. Estimates of nutrient intake were adjusted for age, race/ethnicity, education level, BMI, smoking status, and family history of diabetes.
RESULTS
Men with diagnosed diabetes consumed less sugar (mean 86.8 vs. 116.8 g) and carbohydrates (mean 235.0 vs. 262.1 g) and more protein (mean 92.3 vs. 89.7 g) than men with undiagnosed diabetes. Similarly, women with diagnosed diabetes consumed less sugar (mean 79.1 vs. 95.7 g) and more protein (mean 67.4 vs. 56.6 g) than women with undiagnosed diabetes. No significant differences in macronutrient intake were found by awareness of prediabetes. All participants, regardless of sex or glycemic status, consumed on average less than the American Diabetes Association recommendations for fiber intake (i.e., 14 g/1,000 kcal) and slightly more saturated fat than recommended (>10% of total kcal).
CONCLUSIONS
Screening and subsequent knowledge of glycemic status may favorably affect some dietary patterns for people with diabetes.
C1 [Bardenheier, Barbara H.; Gregg, Edward W.; Williams, Desmond E.; Geiss, Linda S.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
[Cogswell, Mary E.; Zhang, Zefeng] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Bardenheier, BH (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM bfb7@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 22
TC 3
Z9 3
U1 0
U2 5
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD DEC
PY 2014
VL 37
IS 12
BP 3143
EP 3149
DI 10.2337/dc14-1342
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AU0SQ
UT WOS:000345335200020
PM 25205140
ER
PT J
AU Hamman, RF
Bell, RA
Dabelea, D
D'Agostino, RB
Dolan, L
Imperatore, G
Lawrence, JM
Linder, B
Marcovina, SM
Mayer-Davis, EJ
Pihoker, C
Rodriguez, BL
Saydah, S
AF Hamman, Richard F.
Bell, Ronny A.
Dabelea, Dana
D'Agostino, Ralph B., Jr.
Dolan, Lawrence
Imperatore, Giuseppina
Lawrence, Jean M.
Linder, Barbara
Marcovina, Santica M.
Mayer-Davis, Elizabeth J.
Pihoker, Catherine
Rodriguez, Beatriz L.
Saydah, Sharon
CA SEARCH Diabet Youth Study Grp
TI The SEARCH for Diabetes in Youth Study: Rationale, Findings, and Future
Directions
SO DIABETES CARE
LA English
DT Article
ID CARDIOVASCULAR RISK-FACTORS; HEART-RATE-VARIABILITY; TODAY
CLINICAL-TRIAL; QUALITY-OF-LIFE; INCREASED ARTERIAL STIFFNESS; HISPANIC
WHITE YOUTH; BETA-CELL FUNCTION; CHILDHOOD TYPE-1; US YOUTH; NUTRITION
ANCILLARY
AB The SEARCH for Diabetes in Youth (SEARCH) study was initiated in 2000, with funding from the Centers for Disease Control and Prevention and support fromthe National Institute of Diabetes and Digestive and Kidney Diseases, to address major knowledge gaps in the understanding of childhood diabetes. SEARCH is being conducted at five sites across the U. S. and represents the largest, most diverse study of diabetes among U. S. youth. An active registry of youth diagnosed with diabetes at age < 20 years allows the assessment of prevalence (in 2001 and 2009), annual incidence (since 2002), and trends by age, race/ethnicity, sex, and diabetes type. Prevalence increased significantly from 2001 to 2009 for both type 1 and type 2 diabetes in most age, sex, and race/ethnic groups. SEARCH has also established a longitudinal cohort to assess the natural history and risk factors for acute and chronic diabetes-related complications as well as the quality of care and quality of life of persons with diabetes from diagnosis into young adulthood. Many youth with diabetes, particularly those from low-resourced racial/ethnic minority populations, are notmeeting recommended guidelines for diabetes care. Markers of micro-and macrovascular complications are evident in youth with either diabetes type, highlighting the seriousness of diabetes in this contemporary cohort. This review summarizes the study methods, describes key registry and cohort findings and their clinical and public health implications, and discusses future directions.
C1 [Hamman, Richard F.; Dabelea, Dana] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA.
[Bell, Ronny A.] Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC 27157 USA.
[D'Agostino, Ralph B., Jr.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA.
[Dolan, Lawrence] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
[Imperatore, Giuseppina; Saydah, Sharon] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA.
[Lawrence, Jean M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA.
[Linder, Barbara] NIDDK, Childhood Diabet Res Div Diabet Endocrinol & Meta, Bethesda, MD 20892 USA.
[Marcovina, Santica M.] Univ Washington, Northwest Lipid Res Lab, Seattle, WA 98195 USA.
[Mayer-Davis, Elizabeth J.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA.
[Mayer-Davis, Elizabeth J.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
[Pihoker, Catherine] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
[Rodriguez, Beatriz L.] Univ Hawaii, John A Burns Sch Med, Kuakini Med Ctr, Honolulu, HI 96822 USA.
[Rodriguez, Beatriz L.] Inst Tecnol Monterrey, Monterrey, Mexico.
RP Bell, RA (reprint author), Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC 27157 USA.
EM rbell@wakehealth.edu
RI Dagostino Jr, Ralph/C-4060-2017
OI Dagostino Jr, Ralph/0000-0002-3550-8395
FU Centers for Disease Control and Prevention [00097, DP-05-069,
DP-10-001]; National Institute of Diabetes and Digestive and Kidney
Diseases; General Clinical Research Centers at the South Carolina
Clinical & Translational Research Institute, at the Medical University
of South Carolina (National Institutes of Health [NIH]/National Center
for Research Resources [UL1-RR-029882]; Seattle Children's Hospital (NIH
Clinical and Translational Science Award of the University of
Washington) [UL1-TR-000423]; University of Colorado Pediatric Clinical
and Translational Research Center [UL1-TR-000154]; Barbara Davis Center
at the University of Colorado at Denver (Diabetes Endocrinology Research
Centers NIH) [P30-DK-057516]; National Center for Research Resources;
National Center for Advancing Translational Sciences, NIH
[8-UL1-TR-000077]; Kaiser Permanente Southern California [U48/CCU919219,
U01-DP-000246, U18-DP-002714]; University of Colorado Denver
[U48/CCU819241-3, U01-DP-000247, U18-DP-000247-06A1]; Kuakini Medical
Center [U58CCU919256, U01-DP-000245]; Children's Hospital Medical Center
(Cincinnati) [U48/CCU519239, U01-DP-000248, 1-U18-DP-002709]; University
of North Carolina at Chapel Hill [U48/CCU419249, U01-DP-000254,
U18-DP-002708]; University of Washington School of Medicine
[U58/CCU019235-4, U01-DP-000244, U18-DP-002710-01]; Wake Forest
University School of Medicine [U48/CCU919219, U01-DP-000250,
200-2010-35171]; Children with Medical Handicaps program
FX SEARCH is funded by the Centers for Disease Control and Prevention (PA
numbers 00097, DP-05-069, and DP-10-001) and supported by the National
Institute of Diabetes and Digestive and Kidney Diseases. Support was
also provided by General Clinical Research Centers at the South Carolina
Clinical & Translational Research Institute, at the Medical University
of South Carolina (National Institutes of Health [NIH]/National Center
for Research Resources grant UL1-RR-029882), Seattle Children's Hospital
(NIH Clinical and Translational Science Award grant UL1-TR-000423 of the
University of Washington), University of Colorado Pediatric Clinical and
Translational Research Center (grant UL1-TR-000154), the Barbara Davis
Center at the University of Colorado at Denver (Diabetes Endocrinology
Research Centers NIH P30-DK-057516), the National Center for Research
Resources and the National Center for Advancing Translational Sciences,
NIH, through grant 8-UL1-TR-000077, and the Children with Medical
Handicaps program managed by the Ohio Department of Health. Site
contract numbers are as follows: Kaiser Permanente Southern California
(U48/CCU919219, U01-DP-000246, and U18-DP-002714), University of
Colorado Denver (U48/CCU819241-3, U01-DP-000247, and
U18-DP-000247-06A1), Kuakini Medical Center (U58CCU919256 and
U01-DP-000245), Children's Hospital Medical Center (Cincinnati)
(U48/CCU519239, U01-DP-000248, and 1-U18-DP-002709), University of North
Carolina at Chapel Hill (U48/CCU419249, U01-DP-000254, and
U18-DP-002708), University of Washington School of Medicine
(U58/CCU019235-4, U01-DP-000244, and U18-DP-002710-01), and Wake Forest
University School of Medicine (U48/CCU919219, U01-DP-000250, and
200-2010-35171).
NR 101
TC 40
Z9 41
U1 2
U2 17
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD DEC
PY 2014
VL 37
IS 12
BP 3336
EP 3344
DI 10.2337/dc14-0574
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AU0SQ
UT WOS:000345335200045
PM 25414389
ER
PT J
AU Gregg, EW
Ali, MK
Albright, A
AF Gregg, Edward W.
Ali, Mohammed K.
Albright, Ann
TI The Reality of Type 2 Diabetes Prevention. Diabetes Care 2014;37:943-949
SO DIABETES CARE
LA English
DT Letter
ID LIFE-STYLE INTERVENTION; PEOPLE
C1 [Gregg, Edward W.; Ali, Mohammed K.; Albright, Ann] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
[Ali, Mohammed K.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
RP Gregg, EW (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM edg7@cdc.gov
NR 8
TC 2
Z9 2
U1 0
U2 4
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD DEC
PY 2014
VL 37
IS 12
BP E274
EP E275
DI 10.2337/dc14-1211
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AU0SQ
UT WOS:000345335200013
PM 25414406
ER
PT J
AU Lu, M
Rupp, LB
Moorman, AC
Li, J
Zhang, TL
Lamerato, LE
Holmberg, SD
Spradling, PR
Teshale, EH
Vijayadeva, V
Boscarino, JA
Schmidt, MA
Nerenz, DR
Gordon, SC
AF Lu, Mei
Rupp, Loralee B.
Moorman, Anne C.
Li, Jia
Zhang, Talan
Lamerato, Lois E.
Holmberg, Scott D.
Spradling, Philip R.
Teshale, Eyasu H.
Vijayadeva, Vinutha
Boscarino, Joseph A.
Schmidt, Mark A.
Nerenz, David R.
Gordon, Stuart C.
TI Comparative Effectiveness Research of Chronic Hepatitis B and C Cohort
Study (CHeCS): Improving Data Collection and Cohort Identification
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Chronic hepatitis B; Chronic hepatitis C; Comparative effectiveness
research; Classification and Regression Trees; Cohort identification
ID LONGITUDINAL DATA-ANALYSIS; VIRUS-INFECTION; CARE
AB Background and Aims The Chronic Hepatitis Cohort Study (CHeCS) is a longitudinal observational study of risks and benefits of treatments and care in patients with chronic hepatitis B (HBV) and C (HCV) infection from four US health systems. We hypothesized that comparative effectiveness methods-including a centralized data management system and an adaptive approach for cohort selection-would improve cohort selection while controlling data quality and reducing the cost.
Methods Cohort selection and data collection were performed primarily via the electronic health record (EHR); cases were confirmed via chart abstraction. Two parallel sources fed data to a centralized data management system: direct EHR data collection with common data elements, and chart abstraction via electronic data capture. An adaptive Classification and Regression Tree (CART) identified a set of electronic variables to improve case ascertainment accuracy.
Results Over 16 million patient records were collected on 23 case report forms in 2006-2008. The vast majority of data (99.2 %) were collected electronically from EHR; only 0.8 % was collected via chart abstraction. Initial electronic criteria identified 12,144 chronic hepatitis patients; 10,098 were confirmed via chart abstraction with positive predictive values (PPV) 79 and 83 % for HBV and HCV, respectively. CART-optimized models significantly increased PPV to 88 for HBV and 95 % for HCV.
Conclusions CHeCS is a comparative effectiveness research project that leverages electronic centralized data collection and adaptive cohort identification approaches to enhance study efficiency. The adaptive CART model significantly improved the positive predictive value of cohort identification methods.
C1 [Lu, Mei; Rupp, Loralee B.; Li, Jia; Zhang, Talan; Lamerato, Lois E.; Nerenz, David R.; Gordon, Stuart C.] Henry Ford Hlth Syst, Ctr Hlth Serv Res & Gastroenterol, Dept Publ Hlth Sci, Detroit, MI 48202 USA.
[Moorman, Anne C.; Holmberg, Scott D.; Spradling, Philip R.; Teshale, Eyasu H.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA USA.
[Vijayadeva, Vinutha] Kaiser Permanente Hawaii, Ctr Hlth Res, Honolulu, HI USA.
[Boscarino, Joseph A.] Weis Ctr Res, Geisinger Clin, Ctr Hlth Res, Danville, PA 17822 USA.
[Schmidt, Mark A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA.
RP Lu, M (reprint author), Henry Ford Hlth Syst, Ctr Hlth Serv Res & Gastroenterol, Dept Publ Hlth Sci, One Ford Pl,3E, Detroit, MI 48202 USA.
EM mlu1@hfhs.org
FU CDC Foundation; AbbVie; Janssen Pharmaceuticals, Inc.; Vertex
Pharmaceuticals; Gilead Sciences; Bristol-Myers Squibb
FX CHeCS is funded by the CDC Foundation, which currently receives grants
from AbbVie, Janssen Pharmaceuticals, Inc., and Vertex Pharmaceuticals.
Past funders include Genentech, A Member of the Roche Group. Current and
past partial funders include Gilead Sciences and Bristol-Myers Squibb.
Granting corporations do not have access to CHeCS data and do not
contribute to data analysis or writing of manuscripts.
NR 20
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD DEC
PY 2014
VL 59
IS 12
BP 3053
EP 3061
DI 10.1007/s10620-014-3272-6
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AU0OG
UT WOS:000345322100026
PM 25030940
ER
PT J
AU Ly, KN
Roberts, H
Williams, RE
Masunu-Faleafaga, Y
Drobeniuc, J
Kamili, S
Teshale, EH
AF Ly, K. N.
Roberts, H.
Williams, R. E.
Masunu-Faleafaga, Y.
Drobeniuc, J.
Kamili, S.
Teshale, E. H.
TI Hepatitis B vaccination for healthcare personnel in American Samoa:
pre-implementation survey for policy decision
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE American Samoa; healthcare personnel; hepatitis B awareness; hepatitis B
serostatus; hepatitis B vaccination policy; occupational risk
ID INFECTION; WORKERS; RISK
AB American Samoa does not have a hepatitis B vaccination policy for healthcare personnel (HCP). Consequently, hepatitis B has remained a health threat to HCP. In this study, we performed a cross- sectional study and examined demographic and risk information and hepatitis B vaccination, testing, and serostatus in hospital employees in American Samoa. Of 604 hospital employees, 231 (38.2%) participated, and of these, 158 (68.4%) were HCP. Of HCP participants, 1.9% had chronic hepatitis B infection, 36.1% were susceptible, and 60.8% were immune. Nearly half of HCP participants reported history of needlestick injury. Overall, participants' knowledge of their hepatitis B infection and vaccination status was low. These data support the adoption of a hepatitis B vaccination policy for HCP by American Samoa, as currently recommended by the World Health Organization and the US Centers for Disease Control and Prevention. Adherence to the policy could be monitored as a way to measure protection.
C1 [Ly, K. N.; Roberts, H.; Williams, R. E.; Drobeniuc, J.; Kamili, S.; Teshale, E. H.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA.
[Masunu-Faleafaga, Y.] Amer Samoa Dept Hlth, Amer Samoa Immunizat Program, Pago Pago, AS USA.
RP Ly, KN (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE,Mailstop G-37, Atlanta, GA 30333 USA.
EM KathleenLy@cdc.gov
FU U.S. Centers for Disease Control and Prevention; U.S. Department of
Energy; Centers for Disease Control and Prevention
FX Kathleen Ly was supported in part by an appointment to the Research
Participation Program at the U.S. Centers for Disease Control and
Prevention administered by the Oak Ridge Institute for Science and
Education through an inter-agency agreement between the U.S. Department
of Energy and the Centers for Disease Control and Prevention.
NR 9
TC 1
Z9 1
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD DEC
PY 2014
VL 142
IS 12
BP 2610
EP 2615
DI 10.1017/S0950268813003506
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AT4OY
UT WOS:000344920800017
PM 24476680
ER
PT J
AU Shah, NS
Kim, E
Ayala, FDH
Escobar, MEG
Nieto, AI
Kim, AA
Paz-Bailey, G
AF Shah, Neha S.
Kim, Evelyn
Ayala, Flor de Maria Hernandez
Guardado Escobar, Maria Elena
Isabel Nieto, Ana
Kim, Andrea A.
Paz-Bailey, Gabriela
TI Performance and comparison of self-reported STI symptoms among high-risk
populations - MSM, sex workers, persons living with HIV/AIDS - in El
Salvador
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE Sexually transmitted infections; diagnosis; high-risk behaviour;
screening; sex workers; men who have sex with men; MSM; HIV; AIDS;
syndromic management
ID SEXUALLY-TRANSMITTED INFECTIONS; PERIODIC PRESUMPTIVE TREATMENT;
SYNDROMIC MANAGEMENT; HIDDEN POPULATIONS; PREVENTION; HIV; MEN;
CHALLENGES; GONORRHEA; DISEASES
AB Resource-limited countries have limited laboratory capability and rely on syndromic management to diagnose sexually transmitted infections (STIs). We aimed to estimate the sensitivity, specificity and positive predictive value (PPV) of STI syndromic management when used as a screening method within a study setting. Men who have sex with men (MSM), female sex workers (FSWs) and people living with HIV/AIDS (PLWHA) participated in a behavioural surveillance study. Data were obtained on demographics, sexual behaviours, STI history and service utilisation. Biological specimens were tested for genital inflammatory infections (Neisseria gonorrhoeae [GC], Chlamydia trachomatis [CT], Mycoplasma genitalium [MG], Trichomonas vaginalis [TV]) and genital ulcerative infection (syphilis and Herpes simplex virus-2). There was a high prevalence of Herpes simplex virus-2 (MSM 48.1%, FSW 82.0% and PLWHA 84.4%). Most participants reported no ulcerative symptoms and the majority of men reported no inflammatory symptoms. Sensitivity and PPV were poor for inflammatory infections among PLWHA and MSM. Sensitivity in FSWs for inflammatory infections was 75%. For ulcerative infections, sensitivity was poor, but specificity and PPV were high. Reliance on self-reported symptoms may not be an effective screening strategy for these populations. STI prevention studies should focus on symptom recognition and consider routine screening and referral for high-risk populations.
C1 [Shah, Neha S.; Kim, Evelyn; Kim, Andrea A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Ayala, Flor de Maria Hernandez; Paz-Bailey, Gabriela] Training Programs Epidemiol & Publ Hlth Intervent, Atlanta, GA USA.
[Guardado Escobar, Maria Elena; Isabel Nieto, Ana] Minist Publ Hlth, San Salvador, El Salvador.
[Paz-Bailey, Gabriela] Univ Valle Guatemala, Guatemala City, Guatemala.
RP Shah, NS (reprint author), 850 Marina Bay Pkwy,Bldg P,2nd Floor, Richmond, CA 94804 USA.
EM nshah6@cdc.gov
FU Epidemic Intelligence Service Program in Atlanta, USA; US President's
Emergency Plan for AIDS Relief; US Centers for Disease Control and
Prevention - Central American and Panama Region, Guatemala City,
Guatemala; El Salvador Ministry of Health; World Bank
FX This analysis was supported by the Epidemic Intelligence Service Program
in Atlanta, USA, the US President's Emergency Plan for AIDS Relief and
the US Centers for Disease Control and Prevention - Central American and
Panama Region, Guatemala City, Guatemala, the El Salvador Ministry of
Health and the World Bank. The opinions expressed by authors do not
necessarily reflect the opinions of the Centers for Disease Control and
Prevention or the institutions with which the authors are affiliated.
NR 41
TC 1
Z9 1
U1 2
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD DEC
PY 2014
VL 25
IS 14
BP 984
EP 991
DI 10.1177/0956462414526860
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AT5OL
UT WOS:000344992000002
PM 24616119
ER
PT J
AU Olsen, RJ
Fittipaldi, N
Kachroo, P
Sanson, MA
Long, SW
Como-Sabetti, KJ
Valson, C
Cantu, C
Lynfield, R
Van Beneden, C
Beres, SB
Musser, JM
AF Olsen, Randall J.
Fittipaldi, Nahuel
Kachroo, Priyanka
Sanson, Misu A.
Long, S. Wesley
Como-Sabetti, Kathryn J.
Valson, Chandni
Cantu, Concepcion
Lynfield, Ruth
Van Beneden, Chris
Beres, Stephen B.
Musser, James M.
TI Clinical Laboratory Response to a Mock Outbreak of Invasive Bacterial
Infections: a Preparedness Study
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID GROUP-A STREPTOCOCCUS; MYCOBACTERIUM-TUBERCULOSIS; VIRULENCE; DISEASE;
EPIDEMIC; DISSECTION; SEQUENCES; PATHOLOGY
AB Large hospital-based clinical laboratories must be prepared to rapidly investigate potential infectious disease outbreaks. To challenge the ability of our molecular diagnostics laboratory to use whole-genome sequencing in a potential outbreak scenario and identify impediments to these efforts, we studied 84 invasive serotype emm59 group A streptococcus (GAS) strains collected in the United States. We performed a rapid-response exercise to the mock outbreak scenario using whole-genome sequencing, genome-wide transcript analysis, and mouse virulence studies. The protocol changes installed in response to the lessons learned were tested in a second iteration. The initial investigation was completed in 9 days. Whole-genome sequencing showed that the invasive infections were caused by multiple subclones of epidemic emm59 GAS strains likely spread to the United States from Canada. The phylogenetic tree showed a strong temporal-spatial structure with diversity in mobile genetic element content, features that are useful for identifying closely related strains and possible transmission events. The genome data informed the epidemiology, identifying multiple patients who likely acquired the organisms through direct person-to-person transmission. Transcriptome analysis unexpectedly revealed significantly altered expression of genes encoding a two-component regulator and the hyaluronic acid capsule virulence factor. Mouse infection studies confirmed a high-virulence capacity of these emm59 organisms. Whole-genome sequencing, coupled with transcriptome analysis and animal virulence studies, can be rapidly performed in a clinical environment to effectively contribute to patient care decisions and public health maneuvers.
C1 [Olsen, Randall J.; Kachroo, Priyanka; Sanson, Misu A.; Long, S. Wesley; Valson, Chandni; Cantu, Concepcion; Beres, Stephen B.; Musser, James M.] Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX 77030 USA.
[Olsen, Randall J.; Kachroo, Priyanka; Sanson, Misu A.; Long, S. Wesley; Valson, Chandni; Cantu, Concepcion; Beres, Stephen B.; Musser, James M.] Houston Methodist Res Inst, Ctr Mol & Translat Human Infect Dis Res, Houston, TX USA.
[Fittipaldi, Nahuel] Publ Hlth Ontario, Toronto, ON, Canada.
[Fittipaldi, Nahuel] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
[Sanson, Misu A.] Tecnol Monterrey, Escuela Biotecnol & Alimentos & Escuela Med & Cie, Monterrey, Nuevo Leon, Mexico.
[Como-Sabetti, Kathryn J.; Lynfield, Ruth] Minnesota Dept Hlth, Infect Dis Epidemiol Prevent & Control Sect, St Paul, MN USA.
[Van Beneden, Chris] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Resp Dis Branch, Atlanta, GA USA.
RP Olsen, RJ (reprint author), Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX 77030 USA.
EM rjolsen@houstonmethodist.org
OI Long, S. Wesley/0000-0003-3043-5307; Kachroo,
Priyanka/0000-0002-3563-7832
FU Fondren Foundation; Houston Methodist Hospital, Houston, TX; Minnesota
Emerging Infections Program; CDC's Emerging Infections Program Network
FX This work was supported by the Fondren Foundation and Houston Methodist
Hospital, Houston, TX, and the Minnesota Emerging Infections Program and
the CDC's Emerging Infections Program Network.
NR 26
TC 6
Z9 6
U1 6
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD DEC
PY 2014
VL 52
IS 12
BP 4210
EP 4216
DI 10.1128/JCM.02164-14
PG 7
WC Microbiology
SC Microbiology
GA AT9BM
UT WOS:000345222900014
PM 25253790
ER
PT J
AU Simner, PJ
Hyle, EP
Buckwalter, SP
Branda, JA
Brown-Elliott, BA
Franklin, J
Toney, NC
de Man, TJB
Wallace, RJ
Vasireddy, R
Gandhi, RT
Wengenack, NL
AF Simner, Patricia J.
Hyle, Emily P.
Buckwalter, Seanne P.
Branda, John A.
Brown-Elliott, Barbara A.
Franklin, Jameelah
Toney, Nadege C.
de Man, Tom J. B.
Wallace, Richard J., Jr.
Vasireddy, Ravikiran
Gandhi, Rajesh T.
Wengenack, Nancy L.
TI Tenosynovitis Caused by a Novel Nontuberculous Mycobacterium Species
Initially Misidentified as a Member of the Mycobacterium tuberculosis
Complex
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID DNA PROBES; PNCA GENE; IDENTIFICATION; PYRAZINAMIDE; SYSTEM; STRAIN;
ASSAY
AB We present a case of tenosynovitis caused by a novel, slowly growing, nonchromogenic, nontuberculous mycobacterium (NTM). Originally misidentified as Mycobacterium tuberculosis complex, the NTM cross-reacts with the M. tuberculosis complex nucleic acid hybridization probe, a M. tuberculosis gamma interferon release assay, and is closely related to M. tuberculosis by 16S rRNA gene sequencing.
C1 [Simner, Patricia J.; Buckwalter, Seanne P.; Wengenack, Nancy L.] Mayo Clin, Dept Lab Med & Pathol, Div Clin Microbiol, Rochester, MN 55905 USA.
[Hyle, Emily P.; Gandhi, Rajesh T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Branda, John A.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Brown-Elliott, Barbara A.; Wallace, Richard J., Jr.; Vasireddy, Ravikiran] Univ Texas Hlth Ctr Tyler, Dept Microbiol, Mycobacteria Nocardia Lab, Tyler, TX 75710 USA.
[Toney, Nadege C.; de Man, Tom J. B.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA.
[Franklin, Jameelah] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA.
[Gandhi, Rajesh T.] Ragon Inst MGH & Harvard, Boston, MA USA.
RP Wengenack, NL (reprint author), Mayo Clin, Dept Lab Med & Pathol, Div Clin Microbiol, Rochester, MN 55905 USA.
EM wengenack.nancy@mayo.edu
FU Carter Foundation
FX This study was supported in part by a grant from the Carter Foundation
to the Mycobacteria/Nocardia Laboratory at the University of Texas
Health Science Center.
NR 16
TC 2
Z9 2
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD DEC
PY 2014
VL 52
IS 12
BP 4414
EP 4418
DI 10.1128/JCM.00967-14
PG 5
WC Microbiology
SC Microbiology
GA AT9BM
UT WOS:000345222900056
PM 25253791
ER
PT J
AU Vousden, CL
Johnson, JE
AF Vousden, Claudia L.
Johnson, Jean E.
TI Communicating About Biomonitoring and the Results of a Community-Based
Project: A Case Study on One State's Experience
SO JOURNAL OF ENVIRONMENTAL HEALTH
LA English
DT Article
AB Communicating biomonitoring results is a challenge. This article describes the communication strategies used by the Minnesota Department of Health (MDH) to support a biomonitoring project in communities exposed to perfluorochemicals through contamination of their drinking water. Using archival documents, media reports, and informant interviews, the case study described here elucidates MDH's successes, challenges, and lessons learned with communicating biomonitoring results characterized by uncertainty about health effects and risk levels. MDH's communication approach focused on engaging audiences and repeating key messages. Despite the repeated message that the biomonitoring project was an exposure study and not a health study, lay audiences generally expressed lingering discontent with the results while others expressed satisfaction and understanding. This outcome highlights the importance of implementing carefully developed communication plans with well-defined goals, objectives, and intended audiences, and with evaluation guiding the entire process.
C1 [Vousden, Claudia L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
[Johnson, Jean E.] Minnesota Dept Hlth, Hlth Promot & Chron Dis Div, Minneapolis, MN 55414 USA.
RP Vousden, CL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, 4770 Buford Highway,MS F-10, Atlanta, GA 30341 USA.
EM cbv5@cdc.gov
NR 12
TC 2
Z9 2
U1 1
U2 3
PU NATL ENVIRON HEALTH ASSOC
PI DENVER
PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA
SN 0022-0892
J9 J ENVIRON HEALTH
JI J. Environ. Health
PD DEC
PY 2014
VL 77
IS 5
BP 20
EP 26
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AT9SX
UT WOS:000345267400004
PM 25619023
ER
PT J
AU Kunz, CDRJ
Beach, M
AF Kunz, C. D. R. Jasen
Beach, Michael
TI The First Edition of the Model Aquatic Health Code Is Now Available:
What's Next?
SO JOURNAL OF ENVIRONMENTAL HEALTH
LA English
DT Article
C1 [Kunz, C. D. R. Jasen; Beach, Michael] Natl Ctr Environm Hlth, CDC, Div Emergency & Environm Hlth Serv, Atlanta, GA 30341 USA.
RP Kunz, CDRJ (reprint author), Natl Ctr Environm Hlth, CDC, Div Emergency & Environm Hlth Serv, 4770 Buford Highway NE,MS F-58, Atlanta, GA 30341 USA.
EM izk0@cdc.gov
NR 1
TC 0
Z9 0
U1 0
U2 0
PU NATL ENVIRON HEALTH ASSOC
PI DENVER
PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA
SN 0022-0892
J9 J ENVIRON HEALTH
JI J. Environ. Health
PD DEC
PY 2014
VL 77
IS 5
BP 34
EP 36
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AT9SX
UT WOS:000345267400006
ER
PT J
AU Fechter-Leggett, E
AF Fechter-Leggett, Ethan
TI Disease Detective Applies Skills to Surveillance Evaluation
SO JOURNAL OF ENVIRONMENTAL HEALTH
LA English
DT Article
C1 CDC, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Environm Hlth Tracking Branch, Atlanta, GA 30341 USA.
RP Fechter-Leggett, E (reprint author), CDC, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Environm Hlth Tracking Branch, 4770 Buford Highway NE,MS F-60, Atlanta, GA 30341 USA.
EM iun8@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 3
TC 0
Z9 0
U1 0
U2 0
PU NATL ENVIRON HEALTH ASSOC
PI DENVER
PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA
SN 0022-0892
J9 J ENVIRON HEALTH
JI J. Environ. Health
PD DEC
PY 2014
VL 77
IS 5
BP 38
EP 41
PG 4
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AT9SX
UT WOS:000345267400007
PM 25619026
ER
PT J
AU Miller, TR
Bergen, G
Ballesteros, MF
Bhattacharya, S
Gielen, AC
Sheppard, MS
AF Miller, Ted R.
Bergen, Gwen
Ballesteros, Michael F.
Bhattacharya, Soma
Gielen, Andrea Carlson
Sheppard, Monique S.
TI Increasing smoke alarm operability through theory-based health
education: a randomised trial
SO JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH
LA English
DT Article
ID INSTALLATION; SAFETY; HOUSEHOLDS; COMMUNITY; PREVALENCE; PROGRAM;
DEATHS; FIRES; US
AB Background Although working smoke alarms halve deaths in residential fires, many households do not keep alarms operational. We tested whether theory-based education increases alarm operability.
Methods Randomised multiarm trial, with a single arm randomly selected for use each day, in low-income neighbourhoods in Maryland, USA. Intervention arms: (1) Full Education combining a health belief module with a social-cognitive theory module that provided hands-on practice installing alarm batteries and using the alarm's hush button; (2) Hands-on Practice social-cognitive module supplemented by typical fire department education; (3) Current Norm receiving typical fire department education only. Four hundred and thirty-six homes recruited through churches or by knocking on doors in 2005-2008. Followup visits checked alarm operability in 370 homes (85%) 1-3.5 years after installation. Main outcome measures: number of homes with working alarms defined as alarms with working batteries or hard-wired and number of working alarms per home. Regressions controlled for alarm status preintervention; demographics and beliefs about fire risks and alarm effectiveness.
Results Homes in the Full Education and Practice arms were more likely to have a functioning smoke alarm at follow-up (OR=2.77, 95% CI 1.09 to 7.03) and had an average of 0.32 more working alarms per home (95% CI 0.09 to 0.56). Working alarms per home rose 16%. Full Education and Practice had similar effectiveness (p=0.97 on both outcome measures).
Conclusions Without exceeding typical fire department installation time, installers can achieve greater smoke alarm operability. Hands-on practice is key. Two years after installation, for every three homes that received hands-on practice, one had an additional working alarm.
C1 [Miller, Ted R.; Bhattacharya, Soma] Pacific Inst Res & Evaluat, Calverton, MD USA.
[Miller, Ted R.] Curtin Univ, Fac Hlth Sci, Ctr Populat Hlth Res, Perth, WA 6845, Australia.
[Bergen, Gwen; Ballesteros, Michael F.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA.
[Gielen, Andrea Carlson] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Ctr Injury Res & Policy, Baltimore, MD USA.
[Sheppard, Monique S.] Econometrica Inc, Bethesda, MD USA.
RP Miller, TR (reprint author), Pacific Inst Res & Evaluat, 814 Bromley St, Silver Spring, MD 20902 USA.
EM miller@pire.org
OI Miller, Ted/0000-0002-0958-2639
FU National Center for Injury Prevention and Control, US Department of
Health and Human Services, Centers for Disease Control and Prevention
(CDC) [U17/CCU323334]
FX This research was supported in part by grant U17/CCU323334 from the
National Center for Injury Prevention and Control, US Department of
Health and Human Services, Centers for Disease Control and Prevention
(CDC). The findings and conclusions reported are those of the authors
and do not necessarily represent the official position of the CDC.
NR 21
TC 1
Z9 1
U1 11
U2 17
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0143-005X
EI 1470-2738
J9 J EPIDEMIOL COMMUN H
JI J. Epidemiol. Community Health
PD DEC
PY 2014
VL 68
IS 12
BP 1168
EP 1174
DI 10.1136/jech-2014-204182
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT3RE
UT WOS:000344850600009
PM 25165090
ER
PT J
AU Hayes, D
McFarlane, E
Duggan, A
AF Hayes, Donald
McFarlane, Elizabeth
Duggan, Anne
TI In Memoriam: Loretta "Deliana" Fuddy (1948-2013)
SO MATERNAL AND CHILD HEALTH JOURNAL
LA English
DT Biographical-Item
C1 Family Hlth Serv Div, Hawaii Dept Hlth, Honolulu, HI USA.
[Hayes, Donald] Div Reprod Hlth, Centers Dis Control & Prevent, Atlanta, GA USA.
[McFarlane, Elizabeth; Duggan, Anne] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Hayes, D (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA.
EM don.hayes@doh.hawaii.gov
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1092-7875
EI 1573-6628
J9 MATERN CHILD HLTH J
JI Matern. Child Health J.
PD DEC
PY 2014
VL 18
IS 10
SI SI
BP 2250
EP 2252
DI 10.1007/s10995-014-1578-9
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT2RA
UT WOS:000344780500002
PM 25146594
ER
PT J
AU Chen, L
Bell, EM
Browne, ML
Druschel, CM
Romitti, PA
AF Chen, Lei
Bell, Erin M.
Browne, Marilyn L.
Druschel, Charlotte M.
Romitti, Paul A.
TI Exploring Maternal Patterns of Dietary Caffeine Consumption Before
Conception and During Pregnancy
SO MATERNAL AND CHILD HEALTH JOURNAL
LA English
DT Article
DE Caffeine; Coffee; Tea; Soda; Pregnancy
ID INDUCED LIMB MALFORMATIONS; BIRTH-DEFECTS; RISK; PREVENTION; HEALTH
AB We describe patterns of dietary caffeine consumption before and after pregnancy recognition in a cohort of women who recently gave birth. This study included 8,347 mothers of non-malformed liveborn control infants who participated in the National Birth Defects Prevention Study during 1997-2007. Maternal self-reported consumption of beverages (caffeinated coffee, tea, and soda) and chocolate the year before pregnancy was used to estimate caffeine intake. The proportions of prepregnancy caffeine consumption stratified by maternal characteristics are reported. In addition, patterns of reported change in consumption before and after pregnancy were examined by maternal and pregnancy characteristics. Adjusted prevalence ratios were estimated to assess factors most associated with change in consumption. About 97 % of mothers reported any caffeine consumption (average intake of 129.9 mg/day the year before pregnancy) and soda was the primary source of caffeine. The proportion of mothers reporting dietary caffeine intake of more than 300 mg/day was significantly increased among those who smoked cigarettes or drank alcohol. Most mothers stopped or decreased their caffeinated beverage consumption during pregnancy. Young maternal age and unintended pregnancy were associated with increases in consumption during pregnancy. Dietary caffeine consumption during pregnancy is still common in the US. A high level of caffeine intake was associated with known risk factors for adverse reproductive outcomes. Future studies may improve the maternal caffeine exposure assessment by acquiring additional information regarding the timing and amount of change in caffeine consumption after pregnancy recognition.
C1 [Chen, Lei] Eli Lilly & Co, Global Patient Safety Pharmacoepidemiol, Indianapolis, IN 46285 USA.
[Bell, Erin M.; Browne, Marilyn L.; Druschel, Charlotte M.] SUNY Albany, Sch Publ Hlth, Rensselaer, NY 12144 USA.
[Browne, Marilyn L.; Druschel, Charlotte M.] New York State Dept Hlth, Bur Environm & Occupat Epidemiol, Albany, NY 12237 USA.
[Romitti, Paul A.] Univ Iowa, Coll Publ Hlth, Iowa City, IA 52242 USA.
[Romitti, Paul A.] Ctr Dis Control & Prevent, Natl Birth Defects Prevent Study, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
RP Chen, L (reprint author), Eli Lilly & Co, Global Patient Safety Pharmacoepidemiol, LCC DP 2638, Indianapolis, IN 46285 USA.
EM chen_lei@lilly.com
FU NCBDD CDC HHS [U01 DD000492, U01/DD00048702]
NR 24
TC 3
Z9 3
U1 3
U2 16
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1092-7875
EI 1573-6628
J9 MATERN CHILD HLTH J
JI Matern. Child Health J.
PD DEC
PY 2014
VL 18
IS 10
SI SI
BP 2446
EP 2455
DI 10.1007/s10995-014-1483-2
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT2RA
UT WOS:000344780500022
PM 24791972
ER
PT J
AU Dietz, P
Bombard, J
Mulready-Ward, C
Gauthier, J
Sackoff, J
Brozicevic, P
Gambatese, M
Nyland-Funke, M
England, L
Harrison, L
Taylor, A
AF Dietz, Patricia
Bombard, Jennifer
Mulready-Ward, Candace
Gauthier, John
Sackoff, Judith
Brozicevic, Peggy
Gambatese, Melissa
Nyland-Funke, Michael
England, Lucinda
Harrison, Leslie
Taylor, Allan
TI Validation of Self-reported Maternal and Infant Health Indicators in the
Pregnancy Risk Assessment Monitoring System
SO MATERNAL AND CHILD HEALTH JOURNAL
LA English
DT Article
DE Validation; Pregnancy; Preterm; HIV test
ID PERINATAL EVENTS; GESTATIONAL-AGE; MEDICAL RECORDS; RECALL; ACCURACY;
VALIDITY; HISTORY
AB To assess the validity of self-reported maternal and infant health indicators reported by mothers an average of 4 months after delivery. Three validity measures-sensitivity, specificity and positive predictive value (PPV)-were calculated for pregnancy history, pregnancy complications, health care utilization, and infant health indicators self-reported on the Pregnancy Risk Assessment Monitoring System (PRAMS) questionnaire by a representative sample of mothers delivering live births in New York City (NYC) (n = 603) and Vermont (n = 664) in 2009. Data abstracted from hospital records served as gold standards. All data were weighted to be representative of women delivering live births in NYC or Vermont during the study period. Most PRAMS indicators had > 90 % specificity. Indicators with > 90 % sensitivity and PPV for both sites included prior live birth, any diabetes, and Medicaid insurance at delivery, and for Vermont only, infant admission to the NICU and breastfeeding in the hospital. Indicators with poor sensitivity and PPV (< 70 %) for both sites (i.e., NYC and Vermont) included placenta previa and/or placental abruption, urinary tract infection or kidney infection, and for NYC only, preterm labor, prior low-birth-weight birth, and prior preterm birth. For Vermont only, receipt of an HIV test during pregnancy had poor sensitivity and PPV. Mothers accurately reported information on prior live births and Medicaid insurance at delivery; however, mothers' recall of certain pregnancy complications and pregnancy history was poor. These findings could be used to prioritize data collection of indicators with high validity.
C1 [Dietz, Patricia; Bombard, Jennifer; England, Lucinda; Harrison, Leslie] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA.
[Dietz, Patricia; Taylor, Allan] Ctr Dis Control & Prevent, Program Evaluat Branch, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
[Mulready-Ward, Candace; Sackoff, Judith] New York City Dept Hlth & Mental Hyg, Gotham Ctr, Queens, NY USA.
[Gauthier, John; Brozicevic, Peggy; Gambatese, Melissa; Nyland-Funke, Michael] Vermont Dept Hlth, Agcy Human Serv, Burlington, VT USA.
RP Dietz, P (reprint author), Ctr Dis Control & Prevent, Program Evaluat Branch, Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mailstop E-59, Atlanta, GA 30333 USA.
EM PDietz@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 16
TC 10
Z9 10
U1 0
U2 17
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1092-7875
EI 1573-6628
J9 MATERN CHILD HLTH J
JI Matern. Child Health J.
PD DEC
PY 2014
VL 18
IS 10
SI SI
BP 2489
EP 2498
DI 10.1007/s10995-014-1487-y
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT2RA
UT WOS:000344780500026
PM 24770954
ER
PT J
AU Zhong, VW
Pfaff, ER
Beavers, DP
Thomas, J
Jaacks, LM
Bowlby, DA
Carey, TS
Lawrence, JM
Dabelea, D
Hamman, RF
Pihoker, C
Saydah, SH
Mayer-Davis, EJ
AF Zhong, Victor W.
Pfaff, Emily R.
Beavers, Daniel P.
Thomas, Joan
Jaacks, Lindsay M.
Bowlby, Deborah A.
Carey, Timothy S.
Lawrence, Jean M.
Dabelea, Dana
Hamman, Richard F.
Pihoker, Catherine
Saydah, Sharon H.
Mayer-Davis, Elizabeth J.
CA Search Diabet Youth Study Grp
TI Use of administrative and electronic health record data for development
of automated algorithms for childhood diabetes case ascertainment and
type classification: the SEARCH for Diabetes in Youth Study
SO PEDIATRIC DIABETES
LA English
DT Article
DE administrative data; case ascertainment; childhood diabetes; electronic
health record; type classification
ID NUTRITION EXAMINATION SURVEY; CANADIAN CHILDREN; NATIONAL-HEALTH;
HBA(1C) LEVELS; YOUNG-ADULTS; PREVALENCE; VALIDATION; MELLITUS;
SURVEILLANCE; ADOLESCENTS
AB BackgroundThe performance of automated algorithms for childhood diabetes case ascertainment and type classification may differ by demographic characteristics.
ObjectiveThis study evaluated the potential of administrative and electronic health record (EHR) data from a large academic care delivery system to conduct diabetes case ascertainment in youth according to type, age, and race/ethnicity.
SubjectsOf 57767 children aged <20yr as of 31 December 2011 seen at University of North Carolina Health Care System in 2011 were included.
MethodsUsing an initial algorithm including billing data, patient problem lists, laboratory test results, and diabetes related medications between 1 July 2008 and 31 December 2011, presumptive cases were identified and validated by chart review. More refined algorithms were evaluated by type (type 1 vs. type 2), age (<10 vs. 10yr) and race/ethnicity (non-Hispanic White vs. other'). Sensitivity, specificity, and positive predictive value were calculated and compared.
ResultsThe best algorithm for ascertainment of overall diabetes cases was billing data. The best type 1 algorithm was the ratio of the number of type 1 billing codes to the sum of type 1 and type 2 billing codes 0.5. A useful algorithm to ascertain youth with type 2 diabetes with other' race/ethnicity was identified. Considerable age and racial/ethnic differences were present in type-non-specific and type 2 algorithms.
ConclusionsAdministrative and EHR data may be used to identify cases of childhood diabetes (any type), and to identify type 1 cases. The performance of type 2 case ascertainment algorithms differed substantially by race/ethnicity.
C1 [Zhong, Victor W.; Thomas, Joan; Jaacks, Lindsay M.; Mayer-Davis, Elizabeth J.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA.
[Pfaff, Emily R.] Univ N Carolina, North Carolina TraCS Inst, Chapel Hill, NC 27599 USA.
[Beavers, Daniel P.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA.
[Bowlby, Deborah A.] Med Univ S Carolina, Div Pediat Endocrinol, Charleston, SC 29425 USA.
[Carey, Timothy S.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA.
[Lawrence, Jean M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA.
[Dabelea, Dana; Hamman, Richard F.] Univ Colorado, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO USA.
[Pihoker, Catherine] Univ Washington, Dept Washington, Seattle, WA 98195 USA.
[Saydah, Sharon H.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA.
[Mayer-Davis, Elizabeth J.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA.
RP Mayer-Davis, EJ (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, 135 Dauer Dr,245C Rosenau Hall,Campus Box 7461, Chapel Hill, NC 27599 USA.
EM ejmayer-davis@unc.edu
RI Beavers, Daniel/G-5338-2016
FU HSRD VA [HIR 10-001]; NCATS NIH HHS [UL1 TR000154, UL1 TR00423, UL1
TR000077, UL1 TR001111, UL1 TR000083, UL1TR000083, UL1 TR001082, UL1
TR000423]; NCCDPHP CDC HHS [U18DP002714, U18DP002710-01, U01 DP000248,
U01 DP000250, U18 DP002708, U18 DP002710, 1U18DP002709, U01 DP000254,
DP-10001, U18 DP002709, U01 DP000245, U18 DP002714, DP-05069, U01
DP000247, U01 DP000246, U01 DP000244]; NCRR NIH HHS [UL1 RR026314, M01
RR000069, UL1RR029882, UL1 RR025014, UL1 RR029882]; NIDDK NIH HHS [P30
DK017047, P30 DK57516, P30 DK057516]
NR 34
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1399-543X
EI 1399-5448
J9 PEDIATR DIABETES
JI Pediatr. Diabetes
PD DEC
PY 2014
VL 15
IS 8
BP 573
EP 584
DI 10.1111/pedi.12152
PG 12
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA AT6FU
UT WOS:000345035600005
PM 24913103
ER
PT J
AU Margolis, AD
Joseph, H
Hirshfield, S
Chiasson, MA
Belcher, L
Purcell, DW
AF Margolis, Andrew D.
Joseph, Heather
Hirshfield, Sabina
Chiasson, Mary Ann
Belcher, Lisa
Purcell, David W.
TI Anal Intercourse Without Condoms Among HIV-Positive Men Who Have Sex
With Men Recruited From a Sexual Networking Web site, United States
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID SUBSTANCE USE; SEROPOSITIVE MEN; RISK BEHAVIOR; BISEXUAL MEN;
PREVENTION; TRANSMISSION; ONLINE; GAY; RESPONSIBILITY; INFECTION
AB Background: The changing landscape of HIV prevention in the United States underscores the need to improve our ability to efficiently reach HIV-positive men who have sex with men (MSM) who engage in behaviors that could transmit HIV.
Methods: We examined the prevalence of anal intercourse (AI) without condoms with HIV-negative or unknown serostatus partners ("at-risk partners") among 1319 HIV-positive adult male members of a sexual networking Web site for MSM. Sexual behaviors and substance use were measured over a 60-day recall period. Logistic regression was used to identify correlates of insertive and receptive AI without condoms with at-risk partners.
Results: Approximately 25% of the men had been diagnosed as having HIV 12 months or less before study enrollment. Overall, 32% of men engaged in AI without condomswith at-risk partners. Multiple logistic regression identified behavioral predictors of insertive AI without condoms with at-risk partners, including HIV diagnosis within the last 12 months, sex with multiple male partners, substance use in conjunction with sex, and use of phosphodiesterase type 5 inhibitors. Receptive AI without condoms with at-risk partners was associated with younger age (19-24 years), residing outside metropolitan cities, substance use in conjunction with sex, and having multiple male partners.
Conclusions: High levels of sexual risk were found among these MSM. Increased Internet-based HIV prevention marketing efforts and prevention strategies should be considered to efficiently reach HIV-positive MSM who engage in serodiscordant AI without condoms.
C1 [Margolis, Andrew D.; Joseph, Heather; Belcher, Lisa; Purcell, David W.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA.
[Hirshfield, Sabina; Chiasson, Mary Ann] Publ Hlth Solut, New York, NY USA.
RP Margolis, AD (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Prevent Res Branch, 1600 Clifton Rd,Mail Stop E-37, Atlanta, GA 30333 USA.
EM AMargolis@cdc.gov
OI Purcell, David/0000-0001-8125-5168
FU Centers for Disease Control and Prevention of the Department of Health
and Human Services [UR6/PS000415]; Public Health Solutions
FX Supported by the Centers for Disease Control and Prevention of the
Department of Health and Human Services through a cooperative agreement
(UR6/PS000415) with Public Health Solutions. There are no conflicts of
interest.
NR 30
TC 2
Z9 2
U1 3
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD DEC
PY 2014
VL 41
IS 12
BP 749
EP 755
DI 10.1097/OLQ.0000000000000206
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA AU0CX
UT WOS:000345291900010
PM 25581813
ER
PT J
AU Wallace, RM
Stanek, D
Griese, S
Krulak, D
Vora, NM
Pacha, L
Kan, V
Said, M
Williams, C
Burgess, TH
Clausen, SS
Austin, C
Gabel, J
Lehman, M
Finelli, LN
Selvaggi, G
Joyce, P
Gordin, F
Benator, D
Bettano, A
Cersovsky, S
Blackmore, C
Jones, SV
Buchanan, BD
Fernandez, AI
Dinelli, D
Agnes, K
Clark, A
Gill, J
Irmler, M
Blythe, D
Mitchell, K
Whitman, TJ
Zapor, MJ
Zorich, S
Witkop, C
Jenkins, P
Mora, P
Droller, D
Turner, S
Dunn, L
Williams, P
Richards, C
Ewing, G
Chapman, K
Corbitt, C
Girimont, T
Franka, R
Recuenco, S
Blanton, JD
Feldman, KA
AF Wallace, R. M.
Stanek, D.
Griese, S.
Krulak, D.
Vora, N. M.
Pacha, L.
Kan, V.
Said, M.
Williams, C.
Burgess, T. H.
Clausen, S. S.
Austin, C.
Gabel, J.
Lehman, M.
Finelli, L. N.
Selvaggi, G.
Joyce, P.
Gordin, F.
Benator, D.
Bettano, A.
Cersovsky, S.
Blackmore, C.
Jones, S. V.
Buchanan, B. D.
Fernandez, A. I.
Dinelli, D.
Agnes, K.
Clark, A.
Gill, J.
Irmler, M.
Blythe, D.
Mitchell, K.
Whitman, T. J.
Zapor, M. J.
Zorich, S.
Witkop, C.
Jenkins, P.
Mora, P.
Droller, D.
Turner, S.
Dunn, L.
Williams, P.
Richards, C.
Ewing, G.
Chapman, K.
Corbitt, C.
Girimont, T.
Franka, R.
Recuenco, S.
Blanton, J. D.
Feldman, K. A.
TI A Large-scale, Rapid Public Health Response to Rabies in an Organ
Recipient and the Previously Undiagnosed Organ Donor
SO ZOONOSES AND PUBLIC HEALTH
LA English
DT Article
ID POSTEXPOSURE PROPHYLAXIS; CARE-WORKERS; TRANSPLANT RECIPIENTS;
UNITED-STATES; TRANSMISSION; PREVENTION; VIRUS; RISK
AB This article describes and contrasts the public health response to two human rabies cases: one organ recipient diagnosed within days of symptom onset and the transplant donor who was diagnosed 18months post-symptom onset. In response to an organ-transplant-related rabies case diagnosed in 2013, organ donor and recipient investigations were conducted by multiple public health agencies. Persons with potential exposure to infectious patient materials were assessed for rabies virus exposure. An exposure investigation was conducted to determine the source of the organ donor's infection. Over 100 persons from more than 20 agencies spent over 2700h conducting contact investigations in healthcare, military and community settings. The 564 persons assessed include 417 healthcare workers [5.8% recommended for post-exposure prophylaxis (PEP)], 96 community contacts (15.6% recommended for PEP), 30 autopsy personnel (50% recommended for PEP), and 21 other persons (4.8% recommended for PEP). Donor contacts represented 188 assessed with 20.2% recommended for PEP, compared with 5.6% of 306 recipient contacts recommended for PEP. Human rabies cases result in substantial use of public health and medical resources, especially when diagnosis is delayed. Although rare, clinicians should consider rabies in cases of encephalitis of unexplained aetiology, particularly for cases that may result in organ donation.
C1 [Wallace, R. M.; Vora, N. M.; Franka, R.; Recuenco, S.; Blanton, J. D.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, DHCPP, Atlanta, GA 30333 USA.
[Wallace, R. M.; Griese, S.; Vora, N. M.; Said, M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Stanek, D.; Blackmore, C.] Florida Dept Hlth, Tallahassee, FL USA.
[Griese, S.; Williams, C.] North Carolina Dept Hlth, Raleigh, NC USA.
[Krulak, D.; Jones, S. V.; Buchanan, B. D.; Fernandez, A. I.; Dinelli, D.] Naval Hosp Pensacola, Pensacola, FL USA.
[Pacha, L.; Cersovsky, S.] US Army Publ Hlth Command, Aberdeen Proving Ground, MD USA.
[Kan, V.; Joyce, P.; Gordin, F.; Benator, D.; Agnes, K.; Clark, A.; Gill, J.; Irmler, M.] Washington DC Vet Affairs Med Ctr, Washington, DC USA.
[Kan, V.; Gordin, F.; Benator, D.] George Washington Univ, Washington, DC USA.
[Said, M.; Blythe, D.; Mitchell, K.; Feldman, K. A.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA.
[Burgess, T. H.; Clausen, S. S.; Whitman, T. J.; Zapor, M. J.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA.
[Austin, C.] Illinois Dept Publ Hlth, Springfield, IL 62761 USA.
[Gabel, J.] Georgia Dept Hlth, Atlanta, GA USA.
[Lehman, M.; Bettano, A.; Zorich, S.] US Air Force Sch Aerosp Med, Dayton, OH USA.
[Finelli, L. N.] Off Armed Forces Med Examiner, Dover, DE USA.
[Selvaggi, G.; Mora, P.; Droller, D.] Broward Cty Hosp, Broward, FL USA.
[Witkop, C.] Air Force Med Support Agcy, Dayton, OH USA.
[Jenkins, P.] Florida Dept Hlth Broward Cty, Ft Lauderdale, FL USA.
[Turner, S.; Dunn, L.; Williams, P.; Richards, C.] Florida Dept Hlth Escambia Cty, Pensacola, FL USA.
[Ewing, G.] Sacred Heart Hosp, Pensacola, FL USA.
[Chapman, K.] Okaloosa Cty Hlth Dept, Ft Walton Beach, FL USA.
[Corbitt, C.] LifeQuest, Pensacola, FL USA.
[Girimont, T.] Shands Transplant Ctr, Shands Transplant Lab, Gainesville, FL USA.
RP Wallace, RM (reprint author), Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, DHCPP, 1600 Clifton Rd,Mailstop G-33, Atlanta, GA 30333 USA.
EM EUK5@cdc.gov
OI Recuenco-Cabrera, Sergio/0000-0002-8446-7411
NR 32
TC 3
Z9 3
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1863-1959
EI 1863-2378
J9 ZOONOSES PUBLIC HLTH
JI Zoonoses Public Health
PD DEC
PY 2014
VL 61
IS 8
BP 560
EP 570
DI 10.1111/zph.12105
PG 11
WC Public, Environmental & Occupational Health; Infectious Diseases;
Veterinary Sciences
SC Public, Environmental & Occupational Health; Infectious Diseases;
Veterinary Sciences
GA AU0LI
UT WOS:000345313800005
PM 24673934
ER
PT J
AU Zhang, J
Pals, SL
Medley, A
Nichols, C
Bachanas, P
van Zyl, D
Katuta, F
Juma, J
AF Zhang, Jun
Pals, Sherri L.
Medley, Amy
Nichols, Catherine
Bachanas, Pam
van Zyl, Deon
Katuta, Frieda
Juma, James
TI Parameters for Sample Size Estimation from a Group-Randomized HIV
Prevention Trial in HIV Clinics in Sub-Saharan Africa
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Intraclass correlation coefficient; Group-randomized trials; Sample
size; HIV/AIDS
ID SEXUALLY-TRANSMITTED-DISEASES; INTRACLASS CORRELATION; SOUTH-AFRICA; SEX
WORKERS; GROUP-LEVEL; IMPACT; CLUSTER; UGANDA; INTERVENTIONS; TANZANIA
AB Sample size calculations for a group-randomized trial (GRT) require an estimate of the expected intraclass correlation coefficient (ICC). However, few ICC estimates from GRTs in HIV/AIDS research have been published, leaving investigators with little data on which to base expectations. We used data from a multi-country study to estimate ICCs for variables related to physical and mental health and HIV risk behaviors. ICCs for perceptions of physical and mental health tended to be higher than those for HIV risk behavior variables, which were higher than ICCs for CD4 count. Covariate adjustment for country and socio-demographic variables reduced most ICC estimates. For risk behavior variables, adjustment for country and socio-demographic variables reduced ICC estimates by as much as 84 %. Variability in ICC estimates has important implications for study design, as a larger ICC reduces power. ICC estimates presented in this analysis will allow more precise sample size estimates for future GRTs.
C1 [Zhang, Jun; Pals, Sherri L.; Medley, Amy; Nichols, Catherine; Bachanas, Pam] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Zhang, Jun] ICF MACRO, Atlanta, GA USA.
[van Zyl, Deon] Namibia CDC Off, Windhoek, Namibia.
[Katuta, Frieda] Namibia Minist Hlth & Social Serv, Windhoek, Namibia.
[Juma, James] Tanzania Minist Hlth & Social Welf, Dar Es Salaam, Tanzania.
RP Pals, SL (reprint author), Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Ctr Global Hlth, 1600 Clifton Rd,MS E-30, Atlanta, GA 30333 USA.
EM sfv3@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 27
TC 2
Z9 2
U1 0
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD DEC
PY 2014
VL 18
IS 12
BP 2359
EP 2365
DI 10.1007/s10461-013-0631-9
PG 7
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA AT1ZY
UT WOS:000344731300011
PM 24146070
ER
PT J
AU Raiford, JL
Herbst, JH
Carry, M
Browne, FA
Doherty, I
Wechsberg, WM
AF Raiford, Jerris L.
Herbst, Jeffrey H.
Carry, Monique
Browne, Felicia A.
Doherty, Irene
Wechsberg, Wendee M.
TI Low Prospects and High Risk: Structural Determinants of Health
Associated with Sexual Risk Among Young African American Women Residing
in Resource-Poor Communities in the South
SO AMERICAN JOURNAL OF COMMUNITY PSYCHOLOGY
LA English
DT Article
DE African American; Youth; Women; Structural determinants; Sexual health;
Risk
ID DAR-ES-SALAAM; TRANSACTIONAL SEX; SURVIVAL SEX; TRANSMITTED-DISEASES;
HIV-INFECTION; ADOLESCENTS; HOPELESSNESS; BEHAVIOR; VIOLENCE; YOUTH
AB African American women at increased risk of HIV/sexually transmitted infection (STI) may engage in risky sex as a coping mechanism for depressed economic conditions. This study examines the association between high-risk sexual behavior and structural determinants of sexual health among a sample of young African American women. 237 young African American women (16-19 years old) from economically disadvantaged neighborhoods in North Carolina were enrolled into a randomized trial testing the efficacy of an adapted HIV/STI prevention intervention. Logistic regression analyses predicted the likelihood that young women reporting lack of food at home, homelessness and low future prospects would also report sexual risk behaviors. Young women reporting a lack of food at home (22 %), homelessness (27 %), and low perceived education/employment prospects (19 %) had between 2.2 and 4.7 times the odds as those not reporting these risk factors of reporting multiple sex partners, risky sex partners including older men and partners involved in gangs, substance use prior to sex, and exchange sex. Self-reported structural determinants of sexual health were associated with myriad sexual risk behaviors. Diminished economic conditions among these young women may lead to sexual risk due to hopelessness, the need for survival or other factors.
C1 [Raiford, Jerris L.; Herbst, Jeffrey H.; Carry, Monique] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
[Browne, Felicia A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Doherty, Irene; Wechsberg, Wendee M.] Res Triangle Inst Int, Subst Abuse Treatment Evaluat & Intervent, Res Triangle Pk, NC USA.
RP Raiford, JL (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mailstop E-37, Atlanta, GA 30333 USA.
EM jraiford@cdc.gov
NR 58
TC 8
Z9 8
U1 1
U2 12
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0091-0562
EI 1573-2770
J9 AM J COMMUN PSYCHOL
JI Am. J. Community Psychol.
PD DEC
PY 2014
VL 54
IS 3-4
BP 243
EP 250
DI 10.1007/s10464-014-9668-9
PG 8
WC Public, Environmental & Occupational Health; Psychology,
Multidisciplinary; Social Work
SC Public, Environmental & Occupational Health; Psychology; Social Work
GA AS8ZT
UT WOS:000344534100005
PM 25134798
ER
PT J
AU Trogdon, JG
Ekwueme, DU
Subramanian, S
Crouse, W
AF Trogdon, Justin G.
Ekwueme, Donatus U.
Subramanian, Sujha
Crouse, Wesley
TI Economies of scale in federally-funded state-organized public health
programs: results from the National Breast and Cervical Cancer Early
Detection Programs
SO HEALTH CARE MANAGEMENT SCIENCE
LA English
DT Article
DE Cost; Cost function; Breast cancer; Cervical cancer; Screening
ID UNITED-STATES
AB This study investigates the existence of economies of scale in the provision of breast and cervical cancer screening and diagnostic services by state National Breast and Cervical Cancer Early Detection Program (NBCCEDP) grantees. A translog cost function is estimated as a system with input factor share equations. The estimated cost function is then used to determine output levels for which average costs are decreasing (i.e., economies of scale exist). Data were collected from all state NBCCEDP programs and District of Columbia for program years 2006-2007, 2008-2009 and 2009-2010 (N = 147). Costs included all programmatic and in-kind contributions from federal and non-federal sources, allocated to breast and cervical cancer screening activities. Output was measured by women served, women screened and cancers detected, separately by breast and cervical services for each measure. Inputs included labor, rent and utilities, clinical services, and quasi-fixed factors (e.g., percent of women eligible for screening by the NBCCEDP). 144 out of 147 program-years demonstrated significant economies of scale for women served and women screened; 136 out of 145 program-years displayed significant economies of scale for cancers detected. The cost data were self-reported by the NBCCEDP State programs. Quasi-fixed inputs were allowed to affect costs but not economies of scale or the share equations. The main analysis accounted for clustering of observations within State programs, but it did not make full use of the panel data. The average cost of providing breast and cervical cancer screening services decreases as the number of women screened and served increases.
C1 [Trogdon, Justin G.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC USA.
[Ekwueme, Donatus U.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA.
[Subramanian, Sujha; Crouse, Wesley] RTI Int, Res Triangle Pk, NC USA.
RP Ekwueme, DU (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway,NE,MS F-76, Atlanta, GA 30341 USA.
EM dce3@cdc.gov
NR 18
TC 4
Z9 4
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1386-9620
EI 1572-9389
J9 HEALTH CARE MANAG SC
JI Health Care Manag. Sci.
PD DEC
PY 2014
VL 17
IS 4
BP 321
EP 330
DI 10.1007/s10729-013-9261-z
PG 10
WC Health Policy & Services
SC Health Care Sciences & Services
GA AT2DN
UT WOS:000344741800002
PM 24326873
ER
PT J
AU Taulbee, TD
AF Taulbee, Timothy D.
TI BRYCE RICH at the 59th Annual Meeting of the Health Physics Society
Baltimore, Maryland 13-17 July 2014
SO HEALTH PHYSICS
LA English
DT Biographical-Item
C1 NIOSH, Cincinnati, OH 45226 USA.
RP Taulbee, TD (reprint author), NIOSH, Cincinnati, OH 45226 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0017-9078
EI 1538-5159
J9 HEALTH PHYS
JI Health Phys.
PD DEC
PY 2014
VL 107
IS 6
BP 493
EP 494
PG 2
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA AT2BS
UT WOS:000344736600009
PM 25353227
ER
PT J
AU Radzio, J
Hanley, K
Mitchell, J
Ellis, S
Deyounks, F
Jenkins, L
Heneine, W
Garcia-Lerma, JG
AF Radzio, Jessica
Hanley, Krisztina
Mitchell, James
Ellis, Shanon
Deyounks, Frank
Jenkins, Leecresia
Heneine, Walid
Garcia-Lerma, J. Gerardo
TI Depot-Medroxyprogesterone Acetate Does Not Reduce the Prophylactic
Efficacy of Emtricitabine and Tenofovir Disoproxil Fumarate in Macaques
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE depot-medroxyprogesterone acetate; injections; contraception; macaques;
pre-exposure prophylaxis; simian HIV
ID EPIDEMIOLOGIC EVIDENCE; TRANSMISSION; CELLS
AB Concerns that the injectable contraceptive depot-medroxyprogesterone acetate (DMPA) may increase the risk of HIV acquisition in women led to questions on whether DMPA could reduce efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention. We used a macaque model to investigate the impact of prolonged DMPA exposure on PrEP with emtricitabine/tenofovir disoproxil fumarate. Twelve pigtail macaques treated with DMPA were exposed vaginally to simian HIV once a week for up to 5 months and received either placebo (n = 6) or emtricitabine/tenofovir disoproxil fumarate (n = 6). All control macaques were infected, whereas the PrEP-treated animals remained protected (P = 0.0007). This model suggests that women using DMPA will fully benefit from PrEP.
C1 [Radzio, Jessica; Mitchell, James; Ellis, Shanon; Deyounks, Frank; Jenkins, Leecresia; Heneine, Walid; Garcia-Lerma, J. Gerardo] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
[Hanley, Krisztina] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA.
RP Garcia-Lerma, JG (reprint author), Div HIV AIDS Prevent, Branch Lab, MS G45,1600 Clifton Rd, Atlanta, GA 30329 USA.
EM GGarcia-Lerma@cdc.gov
FU Centers for Disease Control and Prevention (CDC); CDC [Y1-AI-0681-02];
National Institutes of Health [Y1-AI-0681-02]
FX Supported by Centers for Disease Control and Prevention (CDC)
intramural. Partially supported by Interagency Agreement Y1-AI-0681-02
between CDC and National Institutes of Health.
NR 17
TC 8
Z9 8
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 1
PY 2014
VL 67
IS 4
BP 365
EP 369
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AT2NR
UT WOS:000344771900005
PM 25202923
ER
PT J
AU Fox, MH
Witten, MH
Lullo, C
AF Fox, Michael H.
Witten, Mary Helen
Lullo, Carolyn
TI Reducing Obesity Among People With Disabilities
SO JOURNAL OF DISABILITY POLICY STUDIES
LA English
DT Article
DE disability; conceptual model; disparities; obesity; surveillance
ID BODY-MASS INDEX; SPINAL-CORD-INJURY; PHYSICAL-DISABILITIES; WAIST
CIRCUMFERENCE; MOBILITY DISABILITY; HEALTH DISPARITIES; UNITED-STATES;
ADULTS; PREVALENCE; ADOLESCENTS
AB Achieving healthy weight for people with disabilities in the United States is a challenge. Obesity rates for adults and children with disabilities are significantly higher than for those without disabilities, with differences remaining even when controlling for other factors. Reasons for this disparity include lack of healthy food options for many people with disabilities living in restrictive environments, difficulty with chewing or swallowing food, medication use contributing to changes in appetite, physical limitations that can reduce a person's ability to exercise, constant pain, energy imbalance, lack of accessible environments in which to exercise or fully participate in other activities, and resource scarcity among many segments of the disability population. In order for there to be a coordinated national effort to address this issue, a framework needs to be developed from which research, policy, and practice can emerge. This paper reviews existing literature and presents a conceptual model that can be used to inform such a framework, provides examples of promising practices, and discusses challenges and opportunities moving forward.
C1 [Fox, Michael H.; Witten, Mary Helen] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Lullo, Carolyn] Carter Consulting Inc, Atlanta, GA USA.
RP Fox, MH (reprint author), Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E88, Atlanta, GA 30333 USA.
EM mhfox@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 53
TC 7
Z9 7
U1 0
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1044-2073
EI 1538-4802
J9 J DISABIL POLICY STU
JI J. Disabil. Policy Stud.
PD DEC
PY 2014
VL 25
IS 3
BP 175
EP 185
DI 10.1177/1044207313494236
PG 11
WC Rehabilitation
SC Rehabilitation
GA AT3RN
UT WOS:000344851500005
PM 26113785
ER
PT J
AU Taylor, EM
Yanni, EA
Pezzi, C
Guterbock, M
Rothney, E
Harton, E
Montour, J
Elias, C
Burke, H
AF Taylor, Eboni M.
Yanni, Emad A.
Pezzi, Clelia
Guterbock, Michael
Rothney, Erin
Harton, Elizabeth
Montour, Jessica
Elias, Collin
Burke, Heather
TI Physical and Mental Health Status of Iraqi Refugees Resettled in the
United States
SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH
LA English
DT Article
DE Refugee; Mental health; Healthcare access; Healthcare utilization;
Chronic conditions
ID AL-RAMADI MATERNITY; ARAB-AMERICANS; SOUTHEAST MICHIGAN; RISK-FACTORS;
AFRICAN-AMERICANS; WESTERN IRAQ; EPIDEMIOLOGY; HYPERTENSION; PREVALENCE;
DEFECTS
AB We conducted a survey among Iraqi refugees resettled in the United States to assess their physical and mental health status and healthcare access and utilization following the initial 8-month, post-arrival period. We randomly selected Iraqi refugees: a parts per thousand yen18 years of age; living in the United States for 8-36 months; and residents of Michigan, California, Texas and Idaho. Participants completed a household questionnaire and mental health assessment. We distributed 366 surveys. Seventy-five percent of participants had health insurance at the time of the survey; 43 % reported delaying or not seeking care for a medical problem in the past year. Sixty percent of participants reported one chronic condition; 37 % reported a parts per thousand yen2 conditions. The prevalence of emotional distress, anxiety, and depression was approximately 50 % of participants; 31 % were at risk for post-traumatic stress disorder. Iraqi refugees in this evaluation reported a high prevalence of chronic conditions and mental health symptoms despite relatively high access to healthcare. It is important for resettlement partners to be aware of the distinctive health concerns of this population to best address needs within this community.
C1 [Taylor, Eboni M.] US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Immigrant Refugee & Migrant Hlth Branch, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.
[Taylor, Eboni M.] US PHS, Washington, DC 20201 USA.
[Yanni, Emad A.; Guterbock, Michael; Burke, Heather] CDC, Immigrant Refugee & Migrant Hlth Branch, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.
[Pezzi, Clelia] US Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, San Diego, CA USA.
[Rothney, Erin; Harton, Elizabeth] US Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Detroit, MI USA.
[Montour, Jessica] Texas Dept State Hlth Serv, Refugee Hlth Program, Austin, TX USA.
[Elias, Collin] Idaho Dept Hlth & Welf, Refugee Hlth Screening Program, Boise, ID USA.
RP Taylor, EM (reprint author), US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Immigrant Refugee & Migrant Hlth Branch, Div Global Migrat & Quarantine, 1600 Clifton Rd NE,Mail Stop E-03, Atlanta, GA 30333 USA.
EM etaylor1@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 41
TC 5
Z9 5
U1 6
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1912
EI 1557-1920
J9 J IMMIGR MINOR HEALT
JI J. Immigr. Minor. Health
PD DEC
PY 2014
VL 16
IS 6
BP 1130
EP 1137
DI 10.1007/s10903-013-9893-6
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AS9FZ
UT WOS:000344549800013
PM 23959695
ER
PT J
AU Palmer, BA
Dimitrova, Z
Skums, P
Crosbie, O
Kenny-Walsh, E
Fanning, LJ
AF Palmer, Brendan A.
Dimitrova, Zoya
Skums, Pavel
Crosbie, Orla
Kenny-Walsh, Elizabeth
Fanning, Liam J.
TI Analysis of the Evolution and Structure of a Complex Intrahost Viral
Population in Chronic Hepatitis C Virus Mapped by Ultradeep
Pyrosequencing
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMORAL IMMUNE-RESPONSE; HYPERVARIABLE REGION 1; CHRONIC INFECTION;
NEUTRALIZING ANTIBODIES; MAXIMUM-LIKELIHOOD; CELL TRANSMISSION; RNA
VIRUS; RECOMBINATION; GLYCOPROTEIN; GENOMES
AB Hepatitis C virus (HCV) causes chronic infection in up to 50% to 80% of infected individuals. Hypervariable region 1 (HVR1) variability is frequently studied to gain an insight into the mechanisms of HCV adaptation during chronic infection, but the changes to and persistence of HCV subpopulations during intrahost evolution are poorly understood. In this study, we used ultradeep pyrosequencing (UDPS) to map the viral heterogeneity of a single patient over 9.6 years of chronic HCV genotype 4a infection. Informed error correction of the raw UDPS data was performed using a temporally matched clonal data set. The resultant data set reported the detection of low-frequency recombinants throughout the study period, implying that recombination is an active mechanism through which HCV can explore novel sequence space. The data indicate that polyvirus infection of hepatocytes has occurred but that the fitness quotients of recombinant daughter virions are too low for the daughter virions to compete against the parental genomes. The subpopulations of parental genomes contributing to the recombination events highlighted a dynamic virome where subpopulations of variants are in competition. In addition, we provide direct evidence that demonstrates the growth of subdominant populations to dominance in the absence of a detectable humoral response.
IMPORTANCE
Analysis of ultradeep pyrosequencing data sets derived from virus amplicons frequently relies on software tools that are not optimized for amplicon analysis, assume random incorporation of sequencing errors, and are focused on achieving higher specificity at the expense of sensitivity. Such analysis is further complicated by the presence of hypervariable regions. In this study, we made use of a temporally matched reference sequence data set to inform error correction algorithms. Using this methodology, we were able to (i) detect multiple instances of hepatitis C virus intrasubtype recombination at the E1/E2 junction (a phenomenon rarely reported in the literature) and (ii) interrogate the longitudinal quasispecies complexity of the virome. Parallel to the UDPS, isolation of IgG-bound virions was found to coincide with the collapse of specific viral subpopulations.
C1 [Palmer, Brendan A.; Fanning, Liam J.] Natl Univ Ireland Univ Coll Cork, Dept Med, Mol Virol Diagnost & Res Lab, Cork, Ireland.
[Dimitrova, Zoya; Skums, Pavel] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA.
[Crosbie, Orla; Kenny-Walsh, Elizabeth] Cork Univ Hosp, Dept Gastroenterol, Cork, Ireland.
RP Fanning, LJ (reprint author), Natl Univ Ireland Univ Coll Cork, Dept Med, Mol Virol Diagnost & Res Lab, Cork, Ireland.
EM l.fanning@ucc.ie
RI FANNING, LIAM/F-5281-2015
OI FANNING, LIAM/0000-0001-6629-8418
NR 64
TC 11
Z9 12
U1 1
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2014
VL 88
IS 23
BP 13709
EP 13721
PG 13
WC Virology
SC Virology
GA AT3CI
UT WOS:000344812800016
PM 25231312
ER
PT J
AU Rith, S
Davis, CT
Duong, V
Sar, B
Horm, SV
Chin, S
Ly, S
Laurent, D
Richner, B
Oboho, I
Jang, Y
Davis, W
Thor, S
Balish, A
Iuliano, AD
Sorn, S
Holl, D
Sok, T
Seng, H
Tarantola, A
Tsuyuoka, R
Parry, A
Chea, N
Allal, L
Kitsutani, P
Warren, D
Prouty, M
Horwood, P
Widdowson, MA
Lindstrom, S
Villanueva, J
Donis, R
Cox, N
Buchy, P
AF Rith, Sareth
Davis, C. Todd
Duong, Veasna
Sar, Borann
Horm, Srey Viseth
Chin, Savuth
Ly, Sovann
Laurent, Denis
Richner, Beat
Oboho, Ikwo
Jang, Yunho
Davis, William
Thor, Sharmi
Balish, Amanda
Iuliano, A. Danielle
Sorn, San
Holl, Davun
Sok, Touch
Seng, Heng
Tarantola, Arnaud
Tsuyuoka, Reiko
Parry, Amy
Chea, Nora
Allal, Lotfi
Kitsutani, Paul
Warren, Dora
Prouty, Michael
Horwood, Paul
Widdowson, Marc-Alain
Lindstrom, Stephen
Villanueva, Julie
Donis, Ruben
Cox, Nancy
Buchy, Philippe
TI Identification of Molecular Markers Associated with Alteration of
Receptor-Binding Specificity in a Novel Genotype of Highly Pathogenic
Avian Influenza A(H5N1) Viruses Detected in Cambodia in 2013
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID H5N1 VIRUSES; A VIRUSES; HEMAGGLUTININ; VIRULENCE; FERRETS; PROTEIN;
MICE; TRANSMISSION; ADAPTATION; CONTRIBUTE
AB Human infections with influenza A(H5N1) virus in Cambodia increased sharply during 2013. Molecular characterization of viruses detected in clinical specimens from human cases revealed the presence of mutations associated with the alteration of receptor-binding specificity (K189R, Q222L) and respiratory droplet transmission in ferrets (N220K with Q222L). Discovery of quasispecies at position 222 (Q/L), in addition to the absence of the mutations in poultry/environmental samples, suggested that the mutations occurred during human infection and did not transmit further.
C1 [Rith, Sareth; Duong, Veasna; Horm, Srey Viseth; Tarantola, Arnaud; Horwood, Paul; Buchy, Philippe] Inst Pasteur Cambodia, Virol Unit Natl Influenza Ctr, Phnom Penh, Cambodia.
[Davis, C. Todd; Sar, Borann; Oboho, Ikwo; Jang, Yunho; Davis, William; Thor, Sharmi; Balish, Amanda; Iuliano, A. Danielle; Kitsutani, Paul; Warren, Dora; Widdowson, Marc-Alain; Lindstrom, Stephen; Villanueva, Julie; Donis, Ruben; Cox, Nancy] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Sar, Borann; Kitsutani, Paul; Warren, Dora] Ctr Dis Control & Prevent, Phnom Penh, Cambodia.
[Chin, Savuth] Natl Inst Publ Hlth, Phnom Penh, Cambodia.
[Sok, Touch; Seng, Heng] Minist Hlth, Communicable Dis Dept, Phnom Penh, Cambodia.
[Laurent, Denis; Richner, Beat] Kantha Bopha Hosp, Phnom Penh, Cambodia.
[Oboho, Ikwo] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA.
[Sorn, San; Holl, Davun] Minist Agr Forestry & Fisheries, Natl Inst Vet Res, Phnom Penh, Cambodia.
[Tsuyuoka, Reiko; Parry, Amy; Chea, Nora] WHO, Phnom Penh, Cambodia.
[Allal, Lotfi] Food & Agr Org, Phnom Penh, Cambodia.
[Prouty, Michael] US Naval Med Res Unit 2, Phnom Penh, Cambodia.
RP Buchy, P (reprint author), Inst Pasteur Cambodia, Virol Unit Natl Influenza Ctr, Phnom Penh, Cambodia.
EM buchyphilippe@hotmail.com
OI Duong, Veasna/0000-0003-0353-1678; Tarantola, Arnaud/0000-0002-6946-7958
FU World Health Organization (WHO) in Cambodia; Food and Agriculture
Organization (FAO) in Cambodia; Office of the Assistant Secretary for
Preparedness and Response within the U.S. Department of Health and Human
Services
FX This work was funded by the World Health Organization (WHO) in Cambodia,
the Food and Agriculture Organization (FAO) in Cambodia, and the Office
of the Assistant Secretary for Preparedness and Response within the U.S.
Department of Health and Human Services. We thank the Centers for
Disease Control and Prevention's Division of Global Disease Detection
and Emergency Response for their support.
NR 24
TC 11
Z9 11
U1 0
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2014
VL 88
IS 23
BP 13897
EP 13909
DI 10.1128/JVI.01887-14
PG 13
WC Virology
SC Virology
GA AT3CI
UT WOS:000344812800032
PM 25210193
ER
PT J
AU Foshee, VA
Reyes, LM
Agnew-Brune, CB
Simon, TR
Vagi, KJ
Lee, RD
Suchindran, C
AF Foshee, Vangie A.
Reyes, Luz McNaughton
Agnew-Brune, Christine B.
Simon, Thomas R.
Vagi, Kevin J.
Lee, Rosalyn D.
Suchindran, Chiravath
TI The Effects of the Evidence-Based Safe Dates Dating Abuse Prevention
Program on Other Youth Violence Outcomes
SO PREVENTION SCIENCE
LA English
DT Article
DE Youth violence prevention; Dating abuse; Youth violence; Safe Dates
ID AGGRESSIVE-BEHAVIOR; REDUCING VIOLENCE; PHYSICAL VIOLENCE; URBAN
ADOLESCENTS; SEXUAL VIOLENCE; RISK BEHAVIORS; PEER; CHILDHOOD; CHILDREN;
STUDENTS
AB In response to recent calls for programs that can prevent multiple types of youth violence, the current study examined whether Safe Dates, an evidence-based dating violence prevention program, was effective in preventing other forms of youth violence. Using data from the original Safe Dates randomized controlled trial, this study examined (1) the effectiveness of Safe Dates in preventing peer violence victimization and perpetration and school weapon carrying 1 year after the intervention phase was completed and (2) moderation of program effects by the sex or race/ethnicity of the adolescent. Ninety percent (n = 1,690) of the eighth and ninth graders who completed baseline questionnaires completed the 1-year follow-up assessment. The sample was 51 % female and 26 % minority (of whom 69 % was black and 31 % was of another minority race/ethnicity). There were no baseline treatment group differences in violence outcomes. Treatment condition was significantly associated with peer violence victimization and school weapon carrying at follow-up; there was 12 % less victimization and 31 % less weapon carrying among those exposed to Safe Dates than those among controls. Treatment condition was significantly associated with perpetration among the minority but not among white adolescents; there was 23 % less violence perpetration among minority adolescents exposed to Safe Dates than that among controls. The observed effect sizes were comparable with those of other universal school-based youth violence prevention programs. Implementing Safe Dates may be an efficient way of preventing multiple types of youth violence.
C1 [Foshee, Vangie A.; Reyes, Luz McNaughton; Agnew-Brune, Christine B.] Univ N Carolina, Dept Hlth Behav, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA.
[Simon, Thomas R.; Vagi, Kevin J.; Lee, Rosalyn D.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA.
[Suchindran, Chiravath] Univ N Carolina, Dept Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA.
RP Foshee, VA (reprint author), Univ N Carolina, Dept Hlth Behav, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA.
EM foshee@email.unc.edu
FU PHS HHS [13IPA1303570, 13IPA130569, U81/CCU409964]
NR 52
TC 11
Z9 11
U1 4
U2 20
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-4986
EI 1573-6695
J9 PREV SCI
JI Prev. Sci.
PD DEC
PY 2014
VL 15
IS 6
BP 907
EP 916
DI 10.1007/s11121-014-0472-4
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT3AN
UT WOS:000344806700018
PM 24599482
ER
PT J
AU Brown, DR
Carroll, DD
Workman, LM
Carlson, SA
Brown, DW
AF Brown, David R.
Carroll, Dianna D.
Workman, Lauren M.
Carlson, Susan A.
Brown, David W.
TI Physical activity and health-related quality of life: US adults with and
without limitations
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE Exercise; Well-being; Unhealthy days; Disability status
ID FACTOR SURVEILLANCE SYSTEM; PUBLIC-HEALTH; UNITED-STATES; LEISURE-TIME;
OLDER-ADULTS; ASSOCIATIONS; PREVALENCE; BRFSS
AB The purpose of this study was to examine the dose-response relationship between physical activity (PA) and health-related quality of life (HRQOL) among adults with and without limitations.
We dichotomized HRQOL as a parts per thousand yen14 unhealthy (physical or mental) days (past 30 days), or < 14 unhealthy days. By using a moderate-intensity minute equivalent, PA categories were as follows: inactive, 10-60, 61-149, 150-300, and > 300 min/week. Persons with limitations reported having problems that limited their activities or required use of special equipment. Age-adjusted prevalence estimates and logistic regression analyses were performed with 2009 Behavioral Risk Factor Surveillance System data (n = 357,665), controlling for demographics, BMI, smoking, and heavy alcohol use.
For adults without limitations, the odds of a parts per thousand yen14 unhealthy days were lower among adults obtaining any PA (10-60 min/week, AOR = 0.79, 95 % CI 0.70, 0.88), compared with those inactive. A quadratic trend (P < 0.001) indicated enhanced HRQOL with each PA level, but improvements were less marked between lower and upper sufficient PA categories (150-300 and > 300 min/week). Because of a significant age interaction, persons with limitations were stratified by age (18-34, 35-64, and 65+ years). Findings for persons aged 35 years or older with limitations were similar to those without limitations. Lower odds of poor HRQOL for persons aged 18-34 years with limitations were associated with recommended levels of PA (150-300 min/week; AOR = 0.61, 95 % CI 0.43, 0.88 and > 300 min/week; AOR = 0.58, 95 % CI 0.43, 0.80).
PA is positively associated with HRQOL among persons with and without limitations.
C1 [Brown, David R.; Carlson, Susan A.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA.
[Carroll, Dianna D.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Commissioned Corps, US PHS, Atlanta, GA 30341 USA.
[Workman, Lauren M.] Univ S Carolina, Arnold Sch Publ Hlth, Dept Hlth Promot Educ & Behav, Columbia, SC 29208 USA.
[Brown, David W.] Brown Consulting Grp, Charlotte, NC USA.
RP Brown, DR (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, MS K-77,4770 Buford Hwy NE, Atlanta, GA 30341 USA.
EM drb8@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 24
TC 2
Z9 2
U1 2
U2 21
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
EI 1573-2649
J9 QUAL LIFE RES
JI Qual. Life Res.
PD DEC
PY 2014
VL 23
IS 10
BP 2673
EP 2680
DI 10.1007/s11136-014-0739-z
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA AT2RQ
UT WOS:000344783000003
PM 24952110
ER
PT J
AU Koole, O
Tsui, S
Wabwire-Mangen, F
Kwesigabo, G
Menten, J
Mulenga, M
Auld, A
Agolory, S
Mukadi, YD
Colebunders, R
Bangsberg, DR
van Praag, E
Torpey, K
Williams, S
Kaplan, J
Zee, A
Denison, J
AF Koole, Olivier
Tsui, Sharon
Wabwire-Mangen, Fred
Kwesigabo, Gideon
Menten, Joris
Mulenga, Modest
Auld, Andrew
Agolory, Simon
Mukadi, Ya Diul
Colebunders, Robert
Bangsberg, David R.
van Praag, Eric
Torpey, Kwasi
Williams, Seymour
Kaplan, Jonathan
Zee, Aaron
Denison, Julie
TI Retention and risk factors for attrition among adults in antiretroviral
treatment programmes in Tanzania, Uganda and Zambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE ART; HIV; retention; sub-Saharan Africa; VIH; ART; retention; Afrique
subsaharienne; VIH; TAR; retencion; africa sub-Sahariana
ID SUB-SAHARAN AFRICA; FOLLOW-UP; THERAPY PROGRAMS; RURAL DISTRICT;
HIV-INFECTION; SOUTH-AFRICA; 1ST YEAR; OUTCOMES; MORTALITY; SURVIVAL
AB ObjectivesWe assessed retention and predictors of attrition (recorded death or loss to follow-up) in antiretroviral treatment (ART) clinics in Tanzania, Uganda and Zambia.
MethodsWe conducted a retrospective cohort study among adults (18years) starting ART during 2003-2010. We purposefully selected six health facilities per country and randomly selected 250 patients from each facility. Patients who visited clinics at least once during the 90days before data abstraction were defined as retained. Data on individual and programme level risk factors for attrition were obtained through chart review and clinic manager interviews. Kaplan-Meier curves for retention across sites were created. Predictors of attrition were assessed using a multivariable Cox-proportional hazards model, adjusted for site-level clustering.
ResultsFrom 17 facilities, 4147 patients were included. Retention ranged from 52.0% to 96.2% at 1year to 25.8%-90.4% at 4years. Multivariable analysis of ART initiation characteristics found the following independent risk factors for attrition: younger age [adjusted hazard ratio (aHR) and 95% confidence interval (95%CI)=1.30 (1.14-1.47)], WHO stage 4 ([aHR (95% CI): 1.56 (1.29-1.88)], >10% bodyweight loss [aHR (95%CI)=1.17 (1.00-1.38)], poor functional status [ambulatory aHR (95%CI)=1.29 (1.09-1.54); bedridden aHR1.54 (1.15-2.07)], and increasing years of clinic operation prior to ART initiation in government facilities [aHR (95%CI)=1.17 (1.10-1.23)]. Patients with higher CD4 cell count were less likely to experience attrition [aHR (95%CI)=0.88 (0.78-1.00)] for every log (tenfold) increase. Sites offering community ART dispensing [aHR (95%CI)=0.55 (0.30-1.01) for women; 0.40 (0.21-0.75) for men] had significantly less attrition.
ConclusionsPatient retention to an individual programme worsened over time especially among males, younger persons and those with poor clinical indicators. Community ART drug dispensing programmes could improve retention.
ObjectifsNous avons evalue la retention et les predicteurs de l'attrition (deces ou pertes au suivi enregistres) dans le traitement antiretroviral (ART) dans des cliniques en Tanzanie, en Ouganda et en Zambie.
MethodesNous avons mene une etude de cohorte retrospective chez les adultes (18 ans) ayant debute l'ART au cours de 2003-2010. Nous avons deliberement choisi six etablissements de sante par pays et avons choisi au hasard 250 patients dans chaque etablissement. Les patients qui ont visite les cliniques au moins une fois au cours des 90 jours avant l'extraction des donnees ont ete definis comme retenus. Les donnees sur les facteurs de risque individuels et a l'echelle du programme pour l'attrition ont ete obtenues par l'examen des dossiers et des entrevues avec les directeur des cliniques. Les courbes de Kaplan-Meier pour la retention a travers les sites ont ete creees. Les predicteurs de l'attrition ont ete evalues a l'aide d'un modele multivarie des risques proportionnels de Cox, corriges par le regroupement au niveau du site.
ResultatsDe 17 etablissements, 4147 patients ont ete inclus. La retention variait de 52,0% a 96,2% a un an et de 25,8% a 90,4% a 4 ans. L'analyse multivariee des caracteristiques a l'initiation de l'ART a trouve les facteurs independants de risque pour l'attrition suivants: le plus jeune age [Hazard Ratio ajuste (aHR) et intervalle de confiance a 95% (IC 95%)=1,30 (1,14 a 1,47)], le stade 4 de l'OMS ([aHR (IC 95%): 1,56 (1,29 a 1,88)], > 10% de perte de poids corporel [aHR (IC 95%)=1,17 (1,00 a 1,38)], un mauvais etat fonctionnel [aHR ambulatoire=1,29 (1,09-1,54); aHR alite=1,54 (01,15 a 02,07)] et de plus en plus d'annees d'operations en clinique avant le debut de l'ART dans les etablissements publics [aHR(IC 95%)=1,17 (1,10 a 1,23)]. Les patients avec un taux plus eleve de cellules CD4 etaient moins susceptibles a l'attrition [aHR (IC 95%) = 0,88 (0,78 a 1,00)] pour chaque augmentation logarithmique. Les sites offrant la distribution communautaire de l'ART [aHR (IC 95%)=0,55 (0,30 a 1,01) pour les femmes; =0,40 (0,21 a 0,75) pour les hommes] avaient significativement moins d'attrition.
ConclusionsLa retention des patients dans un programme individuel empirait au fil du temps surtout chez les hommes, les personnes plus jeunes et ceux avec de mauvais indicateurs cliniques. Les programmes de distribution communautaire de l'ART pourraient ameliorer la retention.
ObjetivosHemos evaluado la retencion y los vaticinadores de abandono (muerte registrada o perdida durante el seguimiento) en centros de tratamiento antirretroviral (TAR) en Tanzania, Uganda y Zambia.
MetodosHemos realizado un estudio retrospectivo de cohortes con adultos (18 anos) en TAR durante el 2003-2010. Seleccionamos seis centros sanitarios por pais, y de forma aleatoria a 250 pacientes de cada centro. Los pacientes que visitaron los centros al menos una vez durante los 90 dias anteriores a la fecha de obtencion de los datos se definieron como retenidos. Se obtuvieron datos sobre los factores de riesgo de abandono de los individuos y el nivel del programa mediante la revision de graficos y entrevistas con el gestor del centro. Se realizaron curvas de Kaplan-Meier para la retencion en los distintos centros. Los vaticinadores de abandono se evaluaron utilizando un modelo de riesgos proporcionales de Cox, ajustado para agrupacion a nivel de centros.
ResultadosSe incluyeron 4147 pacientes de 17 centros. La retencion estaba entre 52.0%-96.2% al ano y 25.8%-90.4% a los 4 anos. En un analisis multivariante de las caracteristicas presentes en el momento de iniciar TAR, se encontraron los siguientes factores de riesgo de abandono independientes: ser mas joven [razon de riesgo ajustada (RRa) and IC 95=1.30 (1.14-1.47)], estadio 4 de la OMS ([RRa(IC 95%): 1.56 (1.29-1.88)], > 10% perdida de peso corporal [RRa (IC 95%)=1.17 (1.00-1.38)], un estatus funcional pobre [RRa ambulatorio (IC 95%)=1.29 (1.09-1.54); estar en cama RRa 1.54 (1.15-2.07) ], y un mayor numero de anos en clinicas privadas antes de comenzar TAR en un centro gubernamental [RRa (IC 95%)=1.17 (1.10-1.23)]. Los pacientes con un mayor conteo de CD4 tenian una menor probabilidad de experimentar abandono [RRa (IC 95%)=0.88 (0.78-1.00)] para un aumento logaritmico (x10). Los centros que ofrecian dispensarios comunitarios de TAR [aHR (IC95%)=0.55 (0.30-1.01) para mujeres; 0.40 (0.21-0.75) para hombres] tenian significativamente menos abandono.
ConclusionesLa retencion de pacientes en un programa individual empeoro a lo largo del tiempo, especialmente entre los hombres, personas jovenes y aquellos con indicadores clinicos pobres. Los programas comunitarios de dispensacion de TAR podrian mejorar la retencion.
C1 [Koole, Olivier] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England.
[Koole, Olivier; Menten, Joris; Colebunders, Robert] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.
[Tsui, Sharon; Mukadi, Ya Diul; van Praag, Eric; Torpey, Kwasi; Denison, Julie] FHI 360, Durham, NC USA.
[Tsui, Sharon; Denison, Julie] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
[Wabwire-Mangen, Fred] Makerere Univ, Infect Dis Inst, Coll Hlth Sci, Kampala, Uganda.
[Kwesigabo, Gideon] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania.
[Mulenga, Modest] Trop Dis Res Ctr, Ndola, Zambia.
[Auld, Andrew; Agolory, Simon; Williams, Seymour; Kaplan, Jonathan; Zee, Aaron] US Ctr Dis Control & Prevent, Div Global AIDS, Atlanta, GA USA.
[Colebunders, Robert] Univ Antwerp, B-2020 Antwerp, Belgium.
[Bangsberg, David R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Bangsberg, David R.] Harvard Univ, Sch Med, Boston, MA USA.
RP Koole, O (reprint author), London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England.
EM olivier.koole@lshtm.ac.uk
OI Koole, Olivier/0000-0002-1122-5382; Auld, Andrew/0000-0001-5089-9163
FU PEPFAR through CDC; PEPFAR through HRSA
FX We wish to acknowledge the study participants and participating clinics
for their critical role in this study. This research was been supported
by PEPFAR through CDC and HRSA. The views, opinions and content of this
publication are those of the authors and do not necessarily reflect the
views, opinions or policies of the CDC, HRSA or any other federal agency
or office. This paper was presented in part at the XIX International
AIDS Conference 2012, 22-27 July, Washington DC, USA.
NR 33
TC 17
Z9 17
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD DEC
PY 2014
VL 19
IS 12
BP 1397
EP 1410
DI 10.1111/tmi.12386
PG 14
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AT2TO
UT WOS:000344789200002
PM 25227621
ER
PT J
AU Namuwulya, P
Abernathy, E
Bukenya, H
Bwogi, J
Tushabe, P
Birungi, M
Seguya, R
Kabaliisa, T
Alibu, VP
Kayondo, JK
Rivailler, P
Icenogle, J
Bakamutumaho, B
AF Namuwulya, Prossy
Abernathy, Emily
Bukenya, Henry
Bwogi, Josephine
Tushabe, Phionah
Birungi, Molly
Seguya, Ronald
Kabaliisa, Theopista
Alibu, Vincent P.
Kayondo, Jonathan K.
Rivailler, Pierre
Icenogle, Joseph
Bakamutumaho, Barnabas
TI Phylogenetic Analysis of Rubella Viruses Identified in Uganda, 2003-2012
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE genotype; molecular characterization; sequences; rubella epidemiology
ID VIROLOGICAL SURVEILLANCE; AFRICA; ERA
AB Molecular data on rubella viruses are limited in Uganda despite the importance of congenital rubella syndrome (CRS). Routine rubella vaccination, while not administered currently in Uganda, is expected to begin by 2015. The World Health Organization recommends that countries without rubella vaccination programs assess the burden of rubella and CRS before starting a routine vaccination program. Uganda is already involved in integrated case-based surveillance, including laboratory testing to confirm measles and rubella, but molecular epidemiologic aspects of rubella circulation have so far not been documented in Uganda. Twenty throat swab or oral fluid samples collected from 12 districts during routine rash and fever surveillance between 2003 and 2012 were identified as rubella virus RNA positive and PCR products encompassing the region used for genotyping were sequenced. Phylogenetic analysis of the 20 sequences identified 19 genotype 1G viruses and 1 genotype 1E virus. Genotype-specific trees showed that the Uganda viruses belonged to specific clusters for both genotypes 1G and 1E and grouped with similar sequences from neighboring countries. Genotype 1G was predominant in Uganda. More epidemiological and molecular epidemiological data are required to determine if genotype 1E is also endemic in Uganda. The information obtained in this study will assist the immunization program in monitoring changes in circulating genotypes. J. Med. Virol. 86:2107-2113, 2014. (c) 2014 Wiley Periodicals, Inc.
C1 [Namuwulya, Prossy; Bukenya, Henry; Bwogi, Josephine; Tushabe, Phionah; Birungi, Molly; Seguya, Ronald; Kabaliisa, Theopista; Kayondo, Jonathan K.; Bakamutumaho, Barnabas] Uganda Virus Inst, Entebbe, Uganda.
[Abernathy, Emily; Rivailler, Pierre; Icenogle, Joseph] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA.
[Alibu, Vincent P.] Makerere Univ, Kampala, Uganda.
RP Namuwulya, P (reprint author), Uganda Virus Inst, EPI LAB, 51-59 Nakiwogo Rd,POB 49, Entebbe, Uganda.
EM pnamuwulya@uvri.go.ug; jci1@cdc.gov
FU welcome trust [087540]
FX We thank the MoH Uganda Surveillance team, EPI lab staff, rubella cases
and their families, and health officials in the respective districts who
participated in the sample collection. Makerere University lecturers are
very much appreciated for their academic input. Special thanks to the
WHO, MoH Uganda, IANPHI, and THRIVE grant number 087540 funded by
welcome trust for the support they provided towards the study. We thank
the WHO African Regional Office for facilitating the training of two of
the authors in virus isolation, genotyping, and sequencing. We thank
MathWorks Consulting for assistance with maps. The findings and
conclusions in this report are those of authors and do not necessarily
represent the views of the US Department of Health and Human Services.
NR 20
TC 5
Z9 5
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD DEC
PY 2014
VL 86
IS 12
BP 2107
EP 2113
DI 10.1002/jmv.23935
PG 7
WC Virology
SC Virology
GA AS3LN
UT WOS:000344179400016
PM 24700073
ER
PT J
AU Zhu, Z
Chen, MH
Abernathy, E
Zhou, SJ
Wang, CY
Icenogle, J
Xu, WB
AF Zhu, Zhen
Chen, Min-hsin
Abernathy, Emily
Zhou, Shujie
Wang, Changyin
Icenogle, Joseph
Xu, Wenbo
TI Genomic Analysis of the Chinese Genotype 1F Rubella Virus that
Disappeared After 2002 in China
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE Rubella virus; genotype 1F; whole genome sequence; molecular clock
ID NONSTRUCTURAL PROTEASE; E1 GLYCOPROTEIN; CAPSID PROTEIN; DOMAIN; RNA;
REPLICATION; MUTATIONS; STRAINS
AB Genotype 1F was likely localized geographically to China as it has not been reported elsewhere. In this study, whole genome sequences of two rubella 1F virus isolates were completed. Both viruses contained 9,761 nt with a single nucleotide deletion in the intergenic region, compared to the NCBI rubella reference sequence (NC 001545). No evidence of recombination was found between 1F and other rubella viruses. The genetic distance between 1F viruses and 10 other rubella virus genotypes (1a, 1B, 1C, 1D, 1E, 1G, 1J 2A, 2B, and 2C) ranged from 3.9% to 8.6% by pairwise comparison. A region known to be hypervariable in other rubella genotypes was also the most variable region in the 1F genomes. Comparisons to all available rubella virus sequences from GenBank identified 22 nucleotide variations exclusively in 1F viruses. Among these unique variations, C9306U is located within the recommended molecular window for rubella virus genotyping assignment, could be useful to confirm 1F viruses. Using the Bayesian Markov Chain Monte Carlo (MCMC) method, the time of the most recent common ancestor for the genotype 1F was estimated between 1976 and 1995. Recent rubella molecular surveillance suggests that this indigenous strain may have circulated for less than three decades, as it has not been detected since 2002. J. Med. Virol. 86:2114-2121, 2014. (c) 2014 Wiley Periodicals, Inc.
C1 [Zhu, Zhen; Xu, Wenbo] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Rubella Lab, WHO WPRO Reg Reference Measles, Beijing 102206, Peoples R China.
[Zhu, Zhen; Xu, Wenbo] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Minist Hlth, Key Lab Med Virol, Beijing 102206, Peoples R China.
[Chen, Min-hsin; Abernathy, Emily; Icenogle, Joseph] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Zhou, Shujie] Anhui Ctr Dis Control & Prevent, Hefei, Peoples R China.
[Wang, Changyin] Shandong Ctr Dis Control & Prevent, Jinan, Peoples R China.
RP Xu, WB (reprint author), Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Rubella Lab, WHO WPRO Reg Reference Measles, Room 605,155 Changbai Rd, Beijing 102206, Peoples R China.
EM wenbo_xu1@aliyun.com
FU National Natural Science Foundation of China [81101244]; Key
Technologies R&D Program of National Ministry of Science
[2013ZX10004-202, 2012ZX10004201-003, 2012ZX10004215, 2012ZX10004-206,
2011ZX10004-001]; National Science and Technology Major Project for
Creation of Major New Drugs [2013ZX09304101]; WHO Measles Regional
Reference Laboratory Funding [WPCHN1002802]
FX Grant sponsor: National Natural Science Foundation of China; Grant
number: 81101244; Grant sponsor: Key Technologies R&D Program of
National Ministry of Science; Grant numbers: 2013ZX10004-202;
2012ZX10004201-003; 2012ZX10004215; 2012ZX10004-206; 2011ZX10004-001;
Grant sponsor: National Science and Technology Major Project for
Creation of Major New Drugs; Grant number: 2013ZX09304101; Grant
sponsor: WHO Measles Regional Reference Laboratory Funding; Grant
number: WPCHN1002802.
NR 32
TC 3
Z9 3
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD DEC
PY 2014
VL 86
IS 12
BP 2114
EP 2121
DI 10.1002/jmv.23936
PG 8
WC Virology
SC Virology
GA AS3LN
UT WOS:000344179400017
PM 24962600
ER
PT J
AU Luby, SP
Lu, XY
Cromeans, T
Sharker, MAY
Kadir, MA
Erdman, DD
AF Luby, Stephen P.
Lu, Xiaoyan
Cromeans, Theresa
Sharker, M. A. Yushuf
Kadir, Mohammad Abdul
Erdman, Dean D.
TI Hand Contamination With Human Rhinovirus in Bangladesh
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE rhinovirus; handwashing; Bangladesh; hand
ID RANDOMIZED CONTROLLED-TRIAL; REVERSE TRANSCRIPTION-PCR;
RESPIRATORY-INFECTIONS; TRANSMISSION; COLDS; CULTURE
AB As one step in developing a measure of hand contamination with respiratory viruses, this study assessed if human rhinovirus (HRV) was detectable on hands in a low income non-temperate community where respiratory disease is a leading cause of child death. Research assistants observed residents in a low income community in Dhaka, Bangladesh. When they observed a resident sneeze or pick their nose, they collected a hand rinse and anterior nare sample from the resident. Samples were first tested for HRV RNA by real-time RT-PCR (rRT-PCR). A subset of rRT-PCR positive samples were cultured into MRC-5 and HeLa Ohio cells. Among 177 hand samples tested for HRV by real-time RT-PCR, 52 (29%) were positive. Among 15 RT-PCR positive hand samples that were cultured, two grew HRV. HRV was detected in each of the sampling months (January, February, June, July, November, and December). This study demonstrates in the natural setting that, at least after sneezing or nasal cleaning, hands were contaminated commonly with potentially infectious HRV. Future research could explore if HRV RNA is present consistently and is associated sufficiently with the incidence of respiratory illness in communities that it may provide a proxy measure of respiratory viral hand contamination. J. Med. Virol. 86:2177??2180, 2014. (c) Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
C1 [Luby, Stephen P.; Sharker, M. A. Yushuf; Kadir, Mohammad Abdul] Ctr Communicable Dis, Int Ctr Diarrhoeal Dis Res, Dhaka, Bangladesh.
[Luby, Stephen P.; Lu, Xiaoyan; Cromeans, Theresa; Erdman, Dean D.] Centers Dis Control & Prevent, Atlanta, GA USA.
[Luby, Stephen P.; Sharker, M. A. Yushuf; Kadir, Mohammad Abdul] Int Ctr Diarrhoeal Dis Res, Ctr Communicable Dis, Dhaka 1000, Bangladesh.
[Luby, Stephen P.; Lu, Xiaoyan; Cromeans, Theresa] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Luby, SP (reprint author), Stanford Univ, Woods Inst Environm, Yang & Yamazaki Environm & Energy Bldg,MC 4205, Stanford, CA 94305 USA.
EM sluby@stanford.edu
RI Kadir, Mohammad/I-4613-2015;
OI Luby, Stephen/0000-0001-5385-899X
FU Procter Gamble Company; Centers for Disease Control and Prevention
FX Grant sponsor: Procter & Gamble Company; Grant sponsor: Centers for
Disease Control and Prevention
NR 19
TC 1
Z9 1
U1 5
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD DEC
PY 2014
VL 86
IS 12
BP 2177
EP 2180
DI 10.1002/jmv.23959
PG 4
WC Virology
SC Virology
GA AS3LN
UT WOS:000344179400026
PM 24760731
ER
PT J
AU Pelletier, AR
Tongren, JE
Gilchrist, J
AF Pelletier, Andrew R.
Tongren, Jon Eric
Gilchrist, Julie
TI Firearm Use in G- and PG-Rated Movies, 2008-2012
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Letter
C1 [Pelletier, Andrew R.; Tongren, Jon Eric; Gilchrist, Julie] CDC, Atlanta, GA 30333 USA.
RP Pelletier, AR (reprint author), CDC, Atlanta, GA 30333 USA.
EM arpl@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD DEC
PY 2014
VL 47
IS 6
BP 1
EP 2
DI 10.1016/j.amepre.2014.09.010
PG 2
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA V43UM
UT WOS:000209706300001
PM 25455124
ER
PT J
AU Carroll, L
Ali, MK
Cuff, P
Huffman, MD
Kelly, BB
Kishore, SP
Narayan, KMV
Siegel, KR
Vedanthan, R
AF Carroll, Leigh
Ali, Mohammed K.
Cuff, Patricia
Huffman, Mark D.
Kelly, Bridget B.
Kishore, Sandeep P.
Narayan, K. M. Venkat
Siegel, Karen R.
Vedanthan, Rajesh
TI Envisioning a Transdisciplinary University
SO JOURNAL OF LAW MEDICINE & ETHICS
LA English
DT Article
C1 [Carroll, Leigh; Kelly, Bridget B.] Inst Med, Atlanta, GA USA.
[Ali, Mohammed K.] Emory Univ, Dept Global Hlth, Atlanta, GA 30322 USA.
[Ali, Mohammed K.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA.
[Ali, Mohammed K.] Ctr Dis Control, Div Diabet Translat, Atlanta, GA 30333 USA.
[Cuff, Patricia] Inst Med Global Forum Innovat Hlth Profess Educ, Minneapolis, MN USA.
[Huffman, Mark D.] Northwestern Univ, Prevent Med & Med Cardiol, Evanston, IL 60208 USA.
[Kishore, Sandeep P.] YP CDN, Evanston, IL USA.
[Narayan, K. M. Venkat] Emory Global Diabet Res Ctr, Atlanta, GA USA.
[Narayan, K. M. Venkat] Emory Univ, Epidemiol & Med, Atlanta, GA 30322 USA.
[Siegel, Karen R.] Emory Univ, Nutr & Hlth Sci, Laney Grad Sch, Atlanta, GA 30322 USA.
[Siegel, Karen R.] Emory Univ, Nutr & Hlth Sci, Rollins Sch Publ Health, Atlanta, GA 30322 USA.
[Vedanthan, Rajesh] Icahn Sch Med Mt Sinai, Med Cardiol & Hlth Evidence & Policy, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA.
RP Carroll, L (reprint author), Inst Med, Atlanta, GA USA.
OI Huffman, Mark/0000-0001-7412-2519
FU Fogarty International Center of the National Institutes of Health [K01
TW 009218 - 03]
FX The views expressed in this article are solely those of the authors and
not necessarily those of the authors' organizations or grant funders,
nor of the Institute of Medicine. Author Vedanthan is supported by the
Fogarty International Center of the National Institutes of Health under
Award Number K01 TW 009218 - 03.
NR 17
TC 2
Z9 2
U1 1
U2 31
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1073-1105
EI 1748-720X
J9 J LAW MED ETHICS
JI J. Law Med. Ethics
PD WIN
PY 2014
VL 42
SU 2
SI SI
BP 17
EP 25
DI 10.1111/jlme.12183
PG 9
WC Ethics; Law; Medical Ethics; Medicine, Legal
SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal
Medicine
GA V45SI
UT WOS:000209835900003
PM 25564706
ER
PT J
AU Li, ZN
Carney, PJ
Lin, SC
Li, J
Chang, JC
Veguilla, V
Stevens, J
Miller, JD
Levine, M
Katz, JM
Hancock, K
AF Li, Zhu-Nan
Carney, Paul J.
Lin, Seh-Ching
Li, Ji
Chang, Jessie C.
Veguilla, Vic
Stevens, James
Miller, Joseph D.
Levine, Min
Katz, Jacqueline M.
Hancock, Kathy
TI Improved specificity and reduced subtype cross-reactivity for antibody
detection by ELISA using globular head domain recombinant hemagglutinin
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Influenza; Ectodomain hemagglutinin; Globular head domain HA; ELISA
ID INFLUENZA-A-VIRUSES; ANTIGENIC STRUCTURE; SEROLOGIC ASSAYS; RESPONSES;
INFECTION; WAVE
AB The relative performance of ELISA using globular head domain (GH) and ectodomain hemagglutinins (HAs) as antigens to detect influenza A virus IgG antibody responses was assessed. Assay sensitivity and subtype cross-reactivity were evaluated using sera collected from recipients of monovalent H5N1 vaccine and A(H1N1)pdm09 virus-infected persons. Assay specificity was determined using collections of sera from either individuals unexposed to either H5N1 or A(H1N1)pdm09 viruses or exposed to H5N1 or A(H1N1)pdm09 viruses through vaccination or infection, respectively. ELISA using GH HA showed a similar degree of sensitivity, significantly higher specificity, and significantly lower subtype cross-reactivity compared to ELISA using ectodomain HA. Published by Elsevier B.V.
C1 [Li, Zhu-Nan; Carney, Paul J.; Li, Ji; Chang, Jessie C.; Veguilla, Vic; Stevens, James; Miller, Joseph D.; Levine, Min; Katz, Jacqueline M.; Hancock, Kathy] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Lin, Seh-Ching] Ctr Dis Control & Prevent, Sci Resources Div, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Li, ZN (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM hix7@cdc.gov
NR 29
TC 1
Z9 2
U1 0
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD DEC 1
PY 2014
VL 209
BP 121
EP 125
DI 10.1016/j.jviromet.2014.09.006
PG 5
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Virology
GA AR8TQ
UT WOS:000343847600019
PM 25239367
ER
PT J
AU Chen, HT
Yip, F
Lavonas, EJ
Iqbal, S
Turner, N
Cobb, B
Garbe, P
AF Chen, Huey T.
Yip, Fuyuen
Lavonas, Eric J.
Iqbal, Shahed
Turner, Nannette
Cobb, Bobby
Garbe, Paul
TI Using the exhibited generalization approach to evaluate a carbon
monoxide alarm ordinance
SO EVALUATION AND PROGRAM PLANNING
LA English
DT Article
DE Exhibited generalization approach; External validity; Transferability;
Effectuality; Viability; Carbon monoxide alarm ordinance
ID EXTERNAL VALIDITY; PREVENTION RESEARCH; HEALTH-PROMOTION; CHILDHOOD
OBESITY; COMMUNITY SCIENCE; UNITED-STATES; INTERVENTIONS; GAP;
DISSEMINATION; TRANSLATION
AB Current interests in enhancing the focus of external validity or transferability call for developing practical evaluation approaches and illustrating their applications in this area for meeting the need. This study takes the challenge by introducing an innovative evaluation approach, named the exhibited generalization approach, and applying it in evaluating the carbon monoxide (CO) alarm ordinance passed by Mecklenburg County, North Carolina. The stakeholders specifically asked evaluators to determine the answers to the following two questions: (1) Does the alarm ordinance work? (2) What generalizable information can the Mecklenburg experience provide to other jurisdictions trying to decide if the alarm ordinance's planning, implementation, adoption, and outcomes are transferable to their communities? This study illustrates how to apply the exhibited generalization approach to provide the stakeholders with answers to these questions. Our results indicate that the alarm ordinance was effective in increasing CO alarm ownerships and reducing CO poisoning cases. The evaluation provides potential users and other interested parties with the necessary information on contextual factors and the causal mechanism underlying the CO alarm ordinance, so that these parties and users could decide whether the Mecklenburg alarm ordinance would be transferable to their own communities. Discussions include implications of this study for contributing in further advancing evaluation theory in addressing transferability or external validity issues. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Chen, Huey T.; Turner, Nannette] Mercer Univ, Dept Publ Hlth, Macon, GA 31207 USA.
[Chen, Huey T.] Mercer Univ, Coll Hlth Profess, Ctr Appl Res & Evaluat, Macon, GA 31207 USA.
[Turner, Nannette] Mercer Univ, Master Publ Hlth Program, Macon, GA 31207 USA.
[Turner, Nannette] Mercer Univ, Coll Hlth Profess, Macon, GA 31207 USA.
[Yip, Fuyuen] Ctr Dis Control & Prevent, Air Pollut & Asthma Epidemiol Team, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, Atlanta, GA USA.
[Iqbal, Shahed] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Garbe, Paul] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, Atlanta, GA USA.
[Lavonas, Eric J.] Rocky Mt Poison & Drug Ctr, Denver, CO USA.
[Cobb, Bobby] Mecklenburg Cty Hlth Dept, Charlotte, NC USA.
RP Chen, HT (reprint author), Mercer Univ, Dept Publ Hlth, Macon, GA 31207 USA.
EM chen_h@mercer.edu
RI bebarta, vikhyat/K-3476-2015; Siry, Bonnie/D-7189-2017
NR 43
TC 1
Z9 3
U1 2
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7189
EI 1873-7870
J9 EVAL PROGRAM PLANN
JI Eval. Program Plan.
PD DEC
PY 2014
VL 47
BP 35
EP 44
DI 10.1016/j.evalprogplan.2014.06.003
PG 10
WC Social Sciences, Interdisciplinary
SC Social Sciences - Other Topics
GA AR6JC
UT WOS:000343688900005
PM 25105583
ER
PT J
AU Marshall, KM
Nowaczyk, L
Raphael, BH
Skinner, GE
Reddy, NR
AF Marshall, Kristin M.
Nowaczyk, Louis, II
Raphael, Brian H.
Skinner, Guy E.
Reddy, N. Rukma
TI Identification and genetic characterization of Clostridium botulinum
serotype A strains from commercially pasteurized carrot juice
SO FOOD MICROBIOLOGY
LA English
DT Article
DE Clostridium botulinum DNA microarray; PFGE (pulsed-field gel
electrophoresis); Botulinum neurotoxin (BoNT); Plasmids; Bacteriophage
ID FIELD GEL-ELECTROPHORESIS; INFANT BOTULISM; GENOME SEQUENCE; PLASMID;
TOXIN; CLUSTERS; DNA; DIFFERENTIATION; NEUROTOXINS; PREVALENCE
AB Clostridium botulinum is an important foodborne pathogen capable of forming heat resistant endospores and producing deadly botulinum neurotoxins (BoNTs). In 2006, C. botulinum was responsible for an international outbreak of botulism attributed to the consumption of commercially pasteurized carrot juice. The purpose of this study was to isolate and characterize strains of C. botulinum from the adulterated product. Carrot juice bottles retrieved from the manufacturing facility were analyzed for the presence of BoNT and BoNT-producing isolates using DIG-ELISA. Toxigenic isolates from the carrot juice were analyzed using pulsed-field gel electrophoresis (PFGE) and DNA microarray analysis to determine their genetic relatedness to the original outbreak strains CDC51348 and CDC51303. PFGE revealed that isolates CJ4-1 and CJ10-1 shared an identical pulsotype with strain CDC51303, whereas isolate CJ5-1 displayed a unique restriction banding pattern. DNA microarray analysis identified several phage related genes unique to strain CJ5-1, and Southern hybridization analysis of Xhol digested and non-digested DNA showed their chromosomal location, while a homolog to pCLI_A009 of plasmid pCLI of C botulinum serotype Langeland F, was located on a small plasmid. The acquisition or loss of bacterio-phages and other mobile genetic elements among C. botulinum strains has epidemiological and evolutionary implications. Published by Elsevier Ltd.
C1 [Marshall, Kristin M.; Nowaczyk, Louis, II; Skinner, Guy E.; Reddy, N. Rukma] USDA, Ctr Food Safety & Appl Nutr, Bedford Pk, IL 60501 USA.
[Raphael, Brian H.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
RP Marshall, KM (reprint author), USDA, Ctr Food Safety & Appl Nutr, 6502 South Archer Rd, Bedford Pk, IL 60501 USA.
EM Kristin.Marshall@fda.hhs.gov; Nowaczyk@gmail.com; BRaphael@cdc.gov;
Skinner@fda.hhs.gov; Rukma.Reddy@fda.hhs.gov
OI Raphael, Brian/0000-0003-2778-2623
NR 39
TC 0
Z9 0
U1 2
U2 73
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0740-0020
EI 1095-9998
J9 FOOD MICROBIOL
JI Food Microbiol.
PD DEC
PY 2014
VL 44
BP 149
EP 155
DI 10.1016/j.fm.2014.05.009
PG 7
WC Biotechnology & Applied Microbiology; Food Science & Technology;
Microbiology
SC Biotechnology & Applied Microbiology; Food Science & Technology;
Microbiology
GA AN8JS
UT WOS:000340851100020
PM 25084657
ER
PT J
AU Chowdhury, PP
Balluz, LS
Zhao, GX
Town, M
AF Chowdhury, Pranesh P.
Balluz, Lina S.
Zhao, Guixiang
Town, Machell
TI HEALTH BEHAVIORS AND OBESITY AMONG HISPANICS WITH DEPRESSION, UNITED
STATES 2006
SO ETHNICITY & DISEASE
LA English
DT Article
DE Depression; Ethnicity; Hispanics; Physical Activity; BRFSS
ID BODY-MASS INDEX; US ADULTS; PHYSICAL-ACTIVITY; MAJOR DEPRESSION;
PRIMARY-CARE; ANXIETY; PHQ-9; POPULATION; PREVALENCE; VALIDITY
AB Objective: To examine the differences in health behaviors, and obesity between Hispanics and non-Hispanic Whites with depression.
Design: Depression data were gathered from 38 states, the District of Columbia, Puerto Rico, and the US Virgin Islands using the 2006 Behavioral Risk Factor Surveillance System, a state-based random-digit-dialed telephone survey of adults aged >= 18 years (n=156,991). The Patient Health Questionnaire.8 was used to determine current depression. Lifetime diagnosis of depression was assessed by self-report of physician diagnosis. Prevalence ratios were calculated to examine the racial/ethnic differences in leisure-time physical activity, cigarette smoking, binge drinking, heavy drinking and obesity among people with current depression and lifetime diagnosis of depression.
Results: There were significant differences in age, education, and health care coverage between Hispanics and non-Hispanic Whites with current depression and lifetime diagnosis of depression. Hispanics with current depression and with lifetime diagnosis of depression were more likely to be obese than non-Hispanic Whites. After adjusting for demographic factors, health care coverage, and self-rated health status, Hispanics with current depression were 17% more likely not to participate in leisuretime physical activity and 42% less likely to be a current cigarette smoker compared with nonHispanic Whites. Hispanics with lifetime diagnosis of depression were 14% more likely not to participate in leisure-time physical activity and 44% less likely to be a current cigarette smoker than non-Hispanic Whites after adjusting for confounders.
Conclusions: Public health intervention programs are needed to promote healthy behaviors especially physical activity participation with in the Hispanic community, and paying particular attention to people who already are depressed.
C1 [Chowdhury, Pranesh P.; Zhao, Guixiang; Town, Machell] Ctr Dis Control & Prevent, Div Behav Surveillance, Atlanta, GA USA.
[Balluz, Lina S.] Ctr Dis Control & Prevent, Environm Hlth Tracking Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA.
RP Chowdhury, PP (reprint author), 2500 Century Blvd NE,MSE-97, Atlanta, GA 30345 USA.
EM Pranesh.Chowdhury@cdc.hhs.gov
NR 27
TC 3
Z9 3
U1 1
U2 129
PU INT SOC HYPERTENSION BLACKS-ISHIB
PI ATLANTA
PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA
SN 1049-510X
EI 1945-0826
J9 ETHNIC DIS
JI Ethn. Dis.
PD WIN
PY 2014
VL 24
IS 1
BP 92
EP 96
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AB3IA
UT WOS:000331683300014
PM 24620454
ER
PT J
AU Pignone, MP
Crutchfield, TM
Brown, PM
Hawley, ST
Laping, JL
Lewis, CL
Lich, KH
Richardson, LC
Tangka, FKL
Wheeler, SB
AF Pignone, Michael P.
Crutchfield, Trisha M.
Brown, Paul M.
Hawley, Sarah T.
Laping, Jane L.
Lewis, Carmen L.
Lich, Kristen Hassmiller
Richardson, Lisa C.
Tangka, Florence K. L.
Wheeler, Stephanie B.
TI Using a discrete choice experiment to inform the design of programs to
promote colon cancer screening for vulnerable populations in North
Carolina
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
DE Early detection of cancer; Colorectal neoplasms; Vulnerable populations;
Rural population; Choice behavior; Decision making; Economics;
Behavioral; Questionnaires; Health policy
ID SERVICES TASK-FORCE; COLORECTAL-CANCER; FINANCIAL INCENTIVES;
CONJOINT-ANALYSIS; PREFERENCES; BEHAVIOR; US; CLARIFICATION; STRATEGIES;
TRIAL
AB Background: Screening for colorectal cancer (CRC) is suboptimal, particularly for vulnerable populations. Effective intervention programs are needed to increase screening rates. We used a discrete choice experiment (DCE) to learn about how vulnerable individuals in North Carolina value different aspects of CRC screening programs.
Methods: We enrolled English-speaking adults ages 50-75 at average risk of CRC from rural North Carolina communities with low rates of CRC screening, targeting those with public or no insurance and low incomes. Participants received basic information about CRC screening and potential program features, then completed a 16 task DCE and survey questions that examined preferences for four attributes of screening programs: testing options available; travel time required; money paid for screening or rewards for completing screening; and the portion of the cost of follow-up care paid out of pocket. We used Hierarchical Bayesian methods to calculate individual-level utilities for the 4 attributes' levels and individual-level attribute importance scores. For each individual, the attribute with the highest importance score was considered the most important attribute. Individual utilities were then aggregated to produce mean utilities for each attribute. We also compared DCE-based results with those from direct questions in a post-DCE survey.
Results: We enrolled 150 adults. Mean age was 57.8 (range 50-74); 55% were women; 76% White and 19% African-American; 87% annual household income under $ 30,000; and 51% were uninsured. Individuals preferred shorter travel; rewards or small copayments compared with large copayments; programs that included stool testing as an option; and greater coverage of follow-up costs. Follow-up cost coverage was most frequently found to be the most important attribute from the DCE (47%); followed by test reward/copayment (33%). From the survey, proportion of follow-up costs paid was most frequently cited as most important (42% of participants), followed by testing options (32%). There was moderate agreement (45%) in attribute importance between the DCE and the single question in the post-DCE survey.
Conclusions: Screening test copayments and follow-up care coverage costs are important program characteristics in this vulnerable, rural population.
C1 [Pignone, Michael P.] Univ N Carolina, Div Gen Internal Med, Sch Med, Chapel Hill, NC 27599 USA.
[Crutchfield, Trisha M.] Univ N Carolina, Ctr Hlth Promot & Dis Prevent, Chapel Hill, NC 27599 USA.
[Brown, Paul M.] Univ Calif Merced, Hlth Sci Res Inst, Merced, CA 95343 USA.
[Hawley, Sarah T.] Univ Michigan, Div Gen Med, Ann Arbor, MI 48109 USA.
[Laping, Jane L.] Univ N Carolina, Translat & Clin Sci Inst, Chapel Hill, NC 27599 USA.
[Lewis, Carmen L.] Univ Colorado, Sch Med, Dept Med, Div Gen Internal Med, Aurora, CO 80045 USA.
[Lich, Kristen Hassmiller; Wheeler, Stephanie B.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC 27599 USA.
[Richardson, Lisa C.; Tangka, Florence K. L.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30333 USA.
RP Pignone, MP (reprint author), Univ N Carolina, Div Gen Internal Med, Sch Med, 5045 Old Clin Bldg,CB 7110, Chapel Hill, NC 27599 USA.
EM Michael_Pignone@med.unc.edu
OI Crutchfield, Trisha/0000-0002-6266-8976
FU Agency for Healthcare Research and Quality (AHRQ) [1-K-12 HS019468-01];
Centers for Disease Control and Prevention (CDC) Special Interest
Project, "Behavioral economics of colorectal cancer screening in
underserved populations" [CDC-SIP-11-041]
FX This publication is a product of a Prevention Research Center and MP,
TC, PB, SH, JL, CL, KHL and SW were funded by the Centers for Disease
Control and Prevention (CDC) Special Interest Project, "Behavioral
economics of colorectal cancer screening in underserved populations"
(CDC-SIP-11-041, Co-PIs: Pignone and Wheeler) SBW was further supported
by the Agency for Healthcare Research and Quality (AHRQ), 1-K-12
HS019468-01 Mentored Clinical Scientists Comparative Effectiveness
Development Award (PI: Weinberger; Scholar: Wheeler). LCR & FT were
funded through their roles at the Centers for Disease Control and
Prevention and were involved in the study design, data analysis, data
interpretation, and writing of the manuscript. The authors thank Linda
Block, Deborah Briggs, Sandra Diehl, and Marjorie Vestal for their
assistance with data collection and the creators of gutcheck. cancer.
gov for the images used in the survey instrument.
NR 25
TC 7
Z9 7
U1 2
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD NOV 30
PY 2014
VL 14
AR 611
DI 10.1186/s12913-014-0611-4
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA AY1LI
UT WOS:000347354300001
PM 25433801
ER
PT J
AU Price, SM
Bonilla, E
Zador, P
Levis, DM
Kilgo, CL
Cannon, MJ
AF Price, Simani M.
Bonilla, Erika
Zador, Paul
Levis, Denise M.
Kilgo, Christina L.
Cannon, Michael J.
TI Educating women about congenital cytomegalovirus: assessment of health
education materials through a web-based survey
SO BMC WOMENS HEALTH
LA English
DT Article
DE Cytomegalovirus; Congenital; Health education materials; Web-based
survey; Prevention guidelines; Pregnant women
ID VACCINE DEVELOPMENT; CONTROLLED-TRIAL; INFECTION; DISEASE;
COMMUNICATION; TRANSMISSION; PREVENTION; KNOWLEDGE; VIDEO; CMV
AB Background: Congenital cytomegalovirus (CMV) is the most common congenital infection in the U.S. and can result in permanent disabilities, such as hearing and vision loss, intellectual disability, and psychomotor and language impairments. Women can adopt prevention behaviors in an attempt to reduce their exposure to CMV. Currently, few women are familiar with CMV. To increase awareness of CMV, the Centers for Disease Control and Prevention (CDC) developed draft health education materials. The purpose of this study was to pilot test two health education materials to gauge their appeal and to determine if they increase knowledge about CMV and motivate audiences to seek additional information on CMV and adopt CMV prevention behaviors.
Methods: African-American (n = 404) and Caucasian women (n = 405), who had a young child and were either pregnant or planning a pregnancy, were recruited to participate in a 15-minute web survey. Participants were randomly assigned to view one of two CMV health education materials, either a factsheet or video. Pre and post survey measures were used to assess changes in knowledge of CMV and motivation to adopt prevention behaviors. We also examined audience preferences regarding materials and motivation.
Results: CMV knowledge score increased significantly after presentation of either the video or factsheet (from 3.7 out of 10 to 9.1 out of 10, p < 0.001). The average materials appeal score was high, with a mean of 3.6 on a four-point scale, indicating women responded very positively to both materials. Regression analyses indicated that appeal, message involvement (e.g., information seeking, discussing with others), post materials knowledge score, and viewing the video (vs. factsheet) were significantly positively associated with increased support for CMV prevention behaviors.
Conclusions: Overall, we found that the health education materials improved women's knowledge of CMV and encouraged them to adopt prevention behaviors. Given the low awareness levels among women currently, these findings suggest that appropriate education materials have the potential to greatly increase knowledge of CMV. As women become more knowledgeable about CMV and transmission routes, we expect they will be more likely to adopt prevention behaviors, thereby reducing their risk of CMV infection.
C1 [Price, Simani M.; Bonilla, Erika; Zador, Paul] Westat Corp, Rockville, MD 20850 USA.
[Levis, Denise M.; Cannon, Michael J.] Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
[Kilgo, Christina L.] Carter Consulting Inc, Atlanta, GA 30345 USA.
RP Cannon, MJ (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mailstop E-86, Atlanta, GA 30333 USA.
EM mrc7@cdc.gov
NR 30
TC 6
Z9 6
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6874
J9 BMC WOMENS HEALTH
JI BMC Womens Health
PD NOV 30
PY 2014
VL 14
AR 144
DI 10.1186/s12905-014-0144-3
PG 10
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA AW1CA
UT WOS:000346027100001
PM 25433837
ER
PT J
AU Pazol, K
Creanga, AA
Burley, KD
Jamieson, DJ
AF Pazol, Karen
Creanga, Andreea A.
Burley, Kim D.
Jamieson, Denise J.
TI Abortion Surveillance - United States, 2011
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID UNINTENDED PREGNANCIES; CONTRACEPTIVE USE; SURGICAL ABORTION;
RISK-FACTORS; SERVICES; RATES; TRENDS; COMPLICATIONS; DIFFERENCE;
TRIMESTER
AB Problem/Condition: Since 1969, CDC has conducted abortion surveillance to document the number and characteristics of women obtaining legal induced abortions in the United States.
Reporting Period Covered: 2011.
Description of System: Each year, CDC requests abortion data from the central health agencies of 52 reporting areas (the 50 states, the District of Columbia, and New York City). The reporting areas provide this information voluntarily. For 2011, data were received from 49 reporting areas. For trend analysis, abortion data were evaluated from 46 areas that reported data every year during 2002-2011. Census and natality data, respectively, were used to calculate abortion rates (number of abortions per 1,000 women) and ratios (number of abortions per 1,000 live births).
Results: A total of 730,322 abortions were reported to CDC for 2011. Of these abortions, 98.3% were from the 46 reporting areas that provided data every year during 2002-2011. Among these same 46 reporting areas, the abortion rate for 2011 was 13.9 abortions per 1,000 women aged 15-44 years, and the abortion ratio was 219 abortions per 1,000 live births. From 2010 to 2011, the total number and rate of reported abortions decreased 5% and the abortion ratio decreased 4%, and from 2002 to 2011, the total number, rate, and ratio of reported abortions decreased 13%, 14%, and 12%, respectively. In 2011, all three measures reached their lowest level for the entire period of analysis (2002-2011).
In 2011 and throughout the period of analysis, women in their 20s accounted for the majority of abortions and had the highest abortion rates, and women in their 30s and older accounted for a much smaller percentage of abortions and had lower abortion rates. In 2011, women aged 20-24 and 25-29 years accounted for 32.9% and 24.9% of all abortions, respectively, and had abortion rates of 24.9 and 19.4 abortions per 1,000 women aged 20-24 and 25-29 years, respectively. In contrast, women aged 30-34, 35-39, and >= 40 years accounted for 15.8%, 8.9%, and 3.6% of all abortions, respectively, and had abortion rates of 12.7, 7.5, and 2.8 abortions per 1,000 women aged 30-34 years, 35-39 years, and >= 40 years, respectively. Throughout the period of analysis, abortion rates decreased among women aged 20-24 and 25-29 years by 21% and 16%, respectively, whereas they increased among women aged >= 40 years by 8%.
In 2011, adolescents aged <15 and 15-19 years accounted for 0.4% and 13.5% of all abortions, respectively, and had abortion rates of 0.9 and 10.5 abortions per 1,000 adolescents aged <15 and 15-19 years, respectively. From 2002 to 2011, the percentage of abortions accounted for by adolescents aged 15-19 years decreased 21% and their abortion rate decreased 34%. These decreases were greater than the decreases for women in any older age group.
In contrast to the percentage distribution of abortions and abortion rates by age, abortion ratios in 2011 and throughout the entire period of analysis were highest among adolescents and lowest among women aged 30-39 years. Abortion ratios decreased from 2002 to 2011 for women in all age groups except for those aged <15 years, for whom they increased.
In 2011, most (64.5%) abortions were performed by <= 8 weeks' gestation, and nearly all (91.4%) were performed by 13 weeks' gestation. Few abortions (7.3%) were performed between 14-20 weeks' gestation or at weeks' gestation (1.4%). From 2002 to 2011, the percentage of all abortions performed at <= 8 weeks' gestation increased 6%.
In 2011, among reporting areas that included medical (nonsurgical) abortion on their reporting form, a total of 71.0% of abortions were performed by curettage at <= 13 weeks' gestation, 19.1% were performed by early medical abortion (a nonsurgical abortion at weeks' gestation), and 8.6% were performed by curettage at >13 weeks' gestation; all other methods were uncommon. Among abortions performed at <= 8 weeks' gestation that were eligible for early medical abortion on the basis of gestational age, 28.5% were completed by this method. The percentage of abortions reported as early medical abortions increased 3% from 2010 to 2011.
Deaths of women associated with complications from abortions for 2011 are being investigated as part of CDC's Pregnancy Mortality Surveillance System. In 2010, the most recent year for which data were available, 10 women were identified to have died as a result of complications from known legal induced abortions. No reported deaths were associated with known illegal induced abortions.
Interpretation: Among the 46 areas that reported data every year during 2002-2011, large decreases in the total number, rate, and ratio of reported abortions from 2010 to 2011, in combination with decreases that occurred during 2008-2010, resulted in historic lows for all three measures of abortion.
Public Health Actions: Unintended pregnancy is the major contributor to abortion. Because unintended pregnancies are rare among women who use the most effective methods of contraception, increasing access to and use of these methods can help further reduce the number of abortions performed in the United States. The data in this report can help program planners and policy makers identify groups of women at greatest risk for unintended pregnancy and help guide and evaluate prevention efforts.
C1 [Pazol, Karen; Creanga, Andreea A.; Burley, Kim D.; Jamieson, Denise J.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
RP Pazol, K (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 1600 Clifton Rd NE,MS K-21, Atlanta, GA 30333 USA.
EM cdcinfo@cdc.gov
NR 85
TC 11
Z9 11
U1 0
U2 12
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 28
PY 2014
VL 63
IS 11
SU S
BP 1
EP 41
PG 41
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AX3CQ
UT WOS:000346818600001
PM 25426741
ER
PT J
AU Ford, ES
Li, CY
Cunningham, TJ
Croft, JB
AF Ford, Earl S.
Li, Chaoyang
Cunningham, Timothy J.
Croft, Janet B.
TI Associations between antioxidants and all-cause mortality among US
adults with obstructive lung function
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Antioxidants; Chronic obstructive pulmonary disease; Mortality
ID VITAMIN-C INTAKE; CARDIOVASCULAR-DISEASE MORTALITY;
NUTRITION-EXAMINATION-SURVEY; TOTAL PLASMA CAROTENOIDS; FRESH FRUIT
CONSUMPTION; 3 EUROPEAN COUNTRIES; 3RD NATIONAL-HEALTH; MIDDLE-AGED MEN;
BETA-CAROTENE; PULMONARY-FUNCTION
AB Chronic obstructive pulmonary disease is characterised by oxidative stress, but little is known about the associations between antioxidant status and all-cause mortality in adults with this disease. The objective of the present study was to examine the prospective associations between concentrations of alpha- and beta-carotene, beta-cryptoxanthin, lutein/zeaxanthin, lycopene, Se, vitamin C and alpha-tocopherol and all-cause mortality among US adults with obstructive lung function. Data collected from 1492 adults aged 20-79 years with obstructive lung function in the National Health and Nutrition Examination Survey III (1988-94) were used. Through 2006, 629 deaths were identified during a median follow-up period of 14 years. After adjustment for demographic variables, the concentrations of the following antioxidants modelled as continuous variables were found to be inversely associated with all-cause mortality among adults with obstructive lung function: alpha-carotene (P = 0.037); beta-carotene (P = 0.022); cryptoxanthin (P = 0.022); lutein/zeaxanthin (P = 0.004); total carotenoids (P = 0.001); vitamin C (P<0.001). In maximally adjusted models, only the concentrations of lycopene (P = 0.013) and vitamin C (P = 0.046) were found to be significantly and inversely associated with all-cause mortality. No effect modification by sex was detected, but the association between lutein/zeaxanthin concentrations and all-cause mortality varied by smoking status (P-interaction = 0.048). The concentrations of lycopene and vitamin C were inversely associated with all-cause mortality in this cohort of adults with obstructive lung function. British Journal of Nutrition
C1 [Ford, Earl S.; Cunningham, Timothy J.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
[Li, Chaoyang] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
RP Ford, ES (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS F78, Atlanta, GA 30341 USA.
EM eford@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 109
TC 2
Z9 2
U1 0
U2 6
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD NOV 28
PY 2014
VL 112
IS 10
BP 1662
EP 1673
DI 10.1017/S0007114514002669
PG 12
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AX7MW
UT WOS:000347100900010
PM 25315508
ER
PT J
AU Khoury, MJ
Ioannidis, JPA
AF Khoury, Muin J.
Ioannidis, John P. A.
TI Big data meets public health
SO SCIENCE
LA English
DT Editorial Material
C1 [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA.
[Khoury, Muin J.] NCI, Epidemiol & Genom Res Program, Bethesda, MD 20850 USA.
[Ioannidis, John P. A.] Stanford Univ, Stanford Prevent Res Ctr, Palo Alto, CA 94305 USA.
[Ioannidis, John P. A.] Stanford Univ, Meta Res Innovat Ctr Stanford, Palo Alto, CA 94305 USA.
RP Khoury, MJ (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA.
EM muk1@cdc.gov; jioannid@stanford.edu
FU Intramural CDC HHS [CC999999]
NR 12
TC 40
Z9 47
U1 19
U2 97
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD NOV 28
PY 2014
VL 346
IS 6213
BP 1054
EP 1055
DI 10.1126/science.aaa2709
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU7EK
UT WOS:000345763400019
PM 25430753
ER
PT J
AU Agarkhedkar, S
Kulkarni, PS
Winston, S
Sievers, R
Dhere, RM
Gunale, B
Powell, K
Rota, PA
Papania, M
AF Agarkhedkar, Sharad
Kulkarni, Prasad S.
Winston, Scott
Sievers, Robert
Dhere, Rajeev M.
Gunale, Bhagwat
Powell, Ken
Rota, Paul A.
Papania, Mark
CA MVDP Author Grp
TI Safety and immunogenicity of dry powder measles vaccine administered by
inhalation: A randomized controlled Phase I clinical trial
SO VACCINE
LA English
DT Article
DE Dry powder measles vaccine; Respiratory administration; Inhalation;
Subcutaneous measles vaccine; Safety; Immunogenicity
ID 9-MONTH-OLD MEXICAN CHILDREN; AEROSOLIZED MEASLES; IMMUNE-RESPONSE;
VIRUS VACCINE; IMMUNIZATION; ANTIBODY; SCHOOLCHILDREN; MACAQUES
AB Background: Measles is a highly infectious respiratory disease which causes 122,000 deaths annually. Although measles vaccine is extremely safe and effective, vaccine coverage could be improved by a vaccine that is more easily administered and transported. We developed an inhalable dry powder measles vaccine (MVDP) and two delivery devices, and demonstrated safety, immunogenicity, and efficacy of the vaccine in preclinical studies. Here we report the first clinical trial of MVDP delivered by inhalation.
Methodology: Sixty adult males aged 18 to 45 years, seropositive for measles antibody, were enrolled in this controlled Phase I clinical study. Subjects were randomly assigned in 1:1:1 ratio to receive either MVDP by Puffhaler (R) or by Solovent (TM) devices or the licensed subcutaneous measles vaccine. Adverse events (AEs) were recorded with diary cards until day 28 post-vaccination and subjects were followed for 180 days post-vaccination to assess potential serious long term adverse events. Measles antibody was measured 7 days before vaccination and at days 21 and 77 after vaccination by ELISA and a plaque reduction neutralization test.
Results: All subjects completed the study according to protocol. Most subjects had high levels of baseline measles antibody. No adverse events were reported. MVDP produced serologic responses similar to subcutaneous vaccination.
Conclusions: MVDP was well tolerated in all subjects. Most subjects had high baseline measles antibody titer which limited ability to measure the serologic responses, and may have limited the adverse events following vaccination. Additional studies in subjects without pre-existing measles antibody are needed to further elucidate the safety and immunogenicity of MVDP. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Agarkhedkar, Sharad] Padmashri DY Patil Med Coll, Pune, Maharashtra, India.
[Kulkarni, Prasad S.; Dhere, Rajeev M.; Gunale, Bhagwat] Serum Inst India Ltd, Pune, Maharashtra, India.
[Winston, Scott; Sievers, Robert] Aktivny LLC, Boulder, CO USA.
[Powell, Ken] Becton Dickinson & Co, East Rutherford, NJ USA.
[Rota, Paul A.; Papania, Mark] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Kulkarni, PS (reprint author), Serum Inst India Ltd, Pune, Maharashtra, India.
EM drpsk@seruminstitute.com
FU Bill and Melinda Gates Foundation; Grand Challenges in Global Health
Initiative; Foundation for the National Institutes of Health (FNIH), USA
[1077]
FX The Needle Free Delivery of Stable, Respirable Powder Vaccine Project
was funded by the Bill and Melinda Gates Foundation, Grand Challenges in
Global Health Initiative to develop needle-free delivery systems [36].
The Grant No. 1077 was administered by the Foundation for the National
Institutes of Health (FNIH), USA. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 34
TC 6
Z9 6
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 28
PY 2014
VL 32
IS 50
BP 6791
EP 6797
DI 10.1016/j.vaccine.2014.09.071
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AU8BY
UT WOS:000345822800010
ER
PT J
AU Babu, TM
Levine, M
Fitzgerald, T
Luke, C
Sangster, MY
Jin, H
Topham, D
Katz, J
Treanor, J
Subbarao, K
AF Babu, Tara M.
Levine, Min
Fitzgerald, Theresa
Luke, Catherine
Sangster, Mark Y.
Jin, Hong
Topham, David
Katz, Jacqueline
Treanor, John
Subbarao, Kanta
TI Live attenuated H7N7 influenza vaccine primes for a vigorous antibody
response to inactivated H7N7 influenza vaccine
SO VACCINE
LA English
DT Article
DE Influenza; H7N7; Pandemic; Priming; Live attenuated vaccine
ID VIRUS-VACCINE; HEALTHY-ADULTS; ANTIGENIC VARIANT; YOUNG-CHILDREN; A
VIRUS; H5N1; IMMUNOGENICITY; SAFETY; PROTECTION; EFFICACY
AB Background: H7 influenza viruses have emerged as potential pandemic threat. We evaluated the safety and immunogenicity of two candidate H7 pandemic live attenuated influenza vaccines (pLAIV) and their ability to prime for responses to an unadjuvanted H7 pandemic inactivated influenza vaccine (pIIV).
Methods: Healthy seronegative adults received two doses of A/Netherlands/219/03 (H7N7) or one dose of A/chicken/British Columbia/CN-6/04 (H7N3) pLAIV all given as 10(7.5) 50% tissue culture infective doses (TCID50) intranasally. A subset of subjects received one 45 mu g dose of H7N7 pIIV containing the A/Mallard/Netherlands/12/2000 HA intramuscularly 18-24 months after pLAIV. Viral shedding was assessed by culture and real-time polymerase chain reaction (rRT-PCR), B cell responses following pLAIV were evaluated by ELISPOT and flow cytometry. Serum antibody was assessed by hemagglutination-inhibition (HAI), microneutralization (MN) and ELISA assays after each vaccine.
Results: Serum HAI or MN responses were not detected in any subject following one or two doses of either H7 pLAIV, although some subjects had detectable H7 specific B cells after vaccination. However, 10/13 subjects primed with two doses of H7N7 pLAIV responded to a subsequent dose of the homologous H7N7 pIIV with high titer HAI and MN antibody that cross-reacted with both North American and Eurasian lineage H7 viruses, including H7N9. In contrast, nave subjects and recipients of a single dose of the mismatched H7N3 pLAIV did not develop HAI or MN antibody after plIV.
Conclusions: While pLAIVs did not elicit detectable serum MN or HAI antibody, strain-specific pLAIV priming established long term immune memory that was cross-reactive with other H7 influenza strains. Understanding the mechanisms underlying priming by pLAIV may aid in pandemic vaccine development. (C) 2014 Published by Elsevier Ltd.
C1 [Babu, Tara M.; Fitzgerald, Theresa; Treanor, John] Univ Rochester, Med Ctr, Div Infect Dis, Rochester, NY 14642 USA.
[Levine, Min; Katz, Jacqueline] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
[Luke, Catherine; Subbarao, Kanta] NIH, Infect Dis Lab, Bethesda, MD 20892 USA.
[Jin, Hong] MedImmune LLC, Gaithersburg, MD USA.
[Sangster, Mark Y.; Topham, David] Univ Rochester, Med Ctr, David Smith Ctr Immunol & Vaccine Biol, Rochester, NY 14642 USA.
RP Treanor, J (reprint author), Univ Rochester, Med Ctr, Div Infect Dis, 601 Elmwood Ave, Rochester, NY 14642 USA.
EM John_Treanor@urmc.rochester.edu
OI Babu, Tara/0000-0001-7093-4077
FU Division of Intramural Research, NIAID, NIH; Biomedical Advanced
Research and Development Authority, US Department of Health and Human
Services [HHSN272200900026C]
FX This study was supported in part by the Division of Intramural Research,
NIAID, NIH and by the Biomedical Advanced Research and Development
Authority, US Department of Health and Human Services (under contract #
HHSN272200900026C). Preliminary results of this study were presented at
the Options for Control of Influenza meeting in Cape Town, South Africa
September 2013.
NR 33
TC 21
Z9 22
U1 2
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 28
PY 2014
VL 32
IS 50
BP 6798
EP 6804
DI 10.1016/j.vaccine.2014.09.070
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AU8BY
UT WOS:000345822800011
PM 25446831
ER
PT J
AU Auld, AF
Agolory, SG
Shiraishi, RW
Wabwire-Mangen, F
Kwesigabo, G
Mulenga, M
Hachizovu, S
Asadu, E
Tuho, MZ
Ettiegne-Traore, V
Mbofana, F
Okello, V
Azih, C
Denison, JA
Tsui, S
Koole, O
Kamiru, H
Nuwagaba-Biribonwoha, H
Alfredo, C
Jobarteh, K
Odafe, S
Onotu, D
Ekra, KA
Kouakou, JS
Ehrenkranz, P
Bicego, G
Torpey, K
Mukadi, YD
van Praag, E
Menten, J
Mastro, T
Hamilton, CD
Swaminathan, M
Dokubo, EK
Baughman, AL
Spira, T
Colebunders, R
Bangsberg, D
Marlink, R
Zee, A
Kaplan, J
Ellerbrock, TV
AF Auld, Andrew F.
Agolory, Simon G.
Shiraishi, Ray W.
Wabwire-Mangen, Fred
Kwesigabo, Gideon
Mulenga, Modest
Hachizovu, Sebastian
Asadu, Emeka
Tuho, Moise Zanga
Ettiegne-Traore, Virginie
Mbofana, Francisco
Okello, Velephi
Azih, Charles
Denison, Julie A.
Tsui, Sharon
Koole, Olivier
Kamiru, Harrison
Nuwagaba-Biribonwoha, Harriet
Alfredo, Charity
Jobarteh, Kebba
Odafe, Solomon
Onotu, Dennis
Ekra, Kunomboa A.
Kouakou, Joseph S.
Ehrenkranz, Peter
Bicego, George
Torpey, Kwasi
Mukadi, Ya Diul
van Praag, Eric
Menten, Joris
Mastro, Timothy
Hamilton, Carol Dukes
Swaminathan, Mahesh
Dokubo, E. Kainne
Baughman, Andrew L.
Spira, Thomas
Colebunders, Robert
Bangsberg, David
Marlink, Richard
Zee, Aaron
Kaplan, Jonathan
Ellerbrock, Tedd V.
TI Antiretroviral Therapy Enrollment Characteristics and Outcomes Among
HIV-Infected Adolescents and Young Adults Compared with Older Adults -
Seven African Countries, 2004-2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Auld, Andrew F.; Agolory, Simon G.; Shiraishi, Ray W.; Swaminathan, Mahesh; Dokubo, E. Kainne; Baughman, Andrew L.; Spira, Thomas; Zee, Aaron; Kaplan, Jonathan; Ellerbrock, Tedd V.] CDC, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30333 USA.
[Wabwire-Mangen, Fred] Makerere Univ, Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda.
[Kwesigabo, Gideon] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania.
[Mulenga, Modest; Hachizovu, Sebastian] Trop Dis Res Ctr, Ndola, Zambia.
[Asadu, Emeka] Minist Hlth, Abuja, Nigeria.
[Tuho, Moise Zanga; Ettiegne-Traore, Virginie] Minist Hlth, Abidjan, Cote Ivoire.
[Mbofana, Francisco] Natl Inst Hlth, Maputo, Mozambique.
[Okello, Velephi; Azih, Charles] Minist Hlth, Manzini, Swaziland.
[Denison, Julie A.; Tsui, Sharon] FHI 360, Social & Behav Hlth Sci, Washington, DC USA.
[Koole, Olivier; Menten, Joris; Colebunders, Robert] Inst Trop Med, Dept Clin Sci, Antwerp, Belgium.
[Kamiru, Harrison; Nuwagaba-Biribonwoha, Harriet] Columbia Univ, Int Ctr AIDS Care, New York, NY USA.
[Kamiru, Harrison; Nuwagaba-Biribonwoha, Harriet] Columbia Univ, Treatment Programs, New York, NY USA.
[Alfredo, Charity; Jobarteh, Kebba] CDC, Ctr Global Hlth, Div Global HIV AIDS, Maputo, Mozambique.
[Odafe, Solomon; Onotu, Dennis] CDC, Ctr Global Hlth, Div Global HIV AIDS, Lagos, Nigeria.
[Ekra, Kunomboa A.; Kouakou, Joseph S.] CDC, Ctr Global Hlth, Div Global HIV AIDS, Abidjan, Cote Ivoire.
[Ehrenkranz, Peter; Bicego, George] CDC, Ctr Global Hlth, Div Global HIV AIDS, Mbabane, Swaziland.
[Torpey, Kwasi] FHI 360, Lusaka, Zambia.
[Mukadi, Ya Diul] FHI 360, Port Au Princ, Haiti.
[van Praag, Eric] FHI 360, Dar Es Salaam, Tanzania.
[Mastro, Timothy; Hamilton, Carol Dukes] FHI 360, Global Hlth Populat & Nutr, Durham, NC USA.
[Bangsberg, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Marlink, Richard] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP Auld, AF (reprint author), CDC, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30333 USA.
EM aauld@cdc.gov
FU NIMH NIH HHS [F31 MH095665]
NR 10
TC 17
Z9 17
U1 0
U2 3
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 28
PY 2014
VL 63
IS 47
BP 1097
EP 1103
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3LR
UT WOS:000345515200001
PM 25426651
ER
PT J
AU Dokubo, EK
Baddeley, A
Pathmanathan, I
Coggin, W
Firth, J
Getahun, H
Kaplan, J
Date, A
AF Dokubo, E. Kainne
Baddeley, Annabel
Pathmanathan, Ishani
Coggin, William
Firth, Jacqueline
Getahun, Haileyesus
Kaplan, Jonathan
Date, Anand
TI Provision of Antiretroviral Therapy for HIV-Positive TB Patients-19
Countries, Sub-Saharan Africa, 2009-2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID TUBERCULOSIS
C1 [Dokubo, E. Kainne; Pathmanathan, Ishani; Kaplan, Jonathan; Date, Anand] CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Baddeley, Annabel; Getahun, Haileyesus] WHO, Global TB Programme, Geneva, Switzerland.
[Firth, Jacqueline] US Agcy Int Dev, Off HIV AIDS, Washington, DC 20523 USA.
RP Dokubo, EK (reprint author), CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA.
EM kdokubo@cdc.gov
NR 10
TC 0
Z9 0
U1 0
U2 1
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 28
PY 2014
VL 63
IS 47
BP 1104
EP 1107
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3LR
UT WOS:000345515200002
PM 25426652
ER
PT J
AU Jamal, A
Agaku, IT
O'Connor, E
King, BA
Kenemer, JB
Neff, L
AF Jamal, Ahmed
Agaku, Israel T.
O'Connor, Erin
King, Brian A.
Kenemer, John B.
Neff, Linda
TI Current Cigarette Smoking Among Adults - United States, 2005-2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID HEALTH
C1 [Jamal, Ahmed; Agaku, Israel T.; O'Connor, Erin; King, Brian A.; Kenemer, John B.; Neff, Linda] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
RP Jamal, A (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM ajamal@cdc.gov
NR 8
TC 177
Z9 178
U1 0
U2 12
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 28
PY 2014
VL 63
IS 47
BP 1108
EP 1112
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3LR
UT WOS:000345515200003
PM 25426653
ER
PT J
AU Bradley, H
Hall, HI
Wolitski, RJ
Van Handel, MM
Stone, AE
LaFlam, M
Skarbinski, J
Higa, DH
Prejean, J
Frazier, EL
Patel, R
Huang, P
An, Q
Song, RG
Tang, T
Valleroy, LA
AF Bradley, Heather
Hall, H. Irene
Wolitski, Richard J.
Van Handel, Michelle M.
Stone, Amy E.
LaFlam, Michael
Skarbinski, Jacek
Higa, Darrel H.
Prejean, Joseph
Frazier, Emma L.
Patel, Roshni
Huang, Ping
An, Qian
Song, Ruiguang
Tang, Tian
Valleroy, Linda A.
TI Vital Signs: HIV Diagnosis, Care, and Treatment Among Persons Living
with HIV - United States, 2011
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID RETENTION
AB Background: Infection with human immunodeficiency virus (HIV), if untreated, leads to acquired immunodeficiency syndrome (AIDS) and premature death. However, a continuum of services including HIV testing, HIV medical care, and antiretroviral therapy (ART) can lead to viral suppression, improved health and survival of persons infected with HIV, and prevention of HIV transmission.
Methods: CDC used data from the National HIV Surveillance System and the Medical Monitoring Project to estimate the percentages of persons living with HIV infection, diagnosed with HIV infection, linked to HIV medical care, engaged in HIV medical care, prescribed ART, and virally suppressed in the United States during 2011.
Results: In 2011, an estimated 1.2 million persons were living with HIV infection in the United States; an estimated 86% were diagnosed with HIV, 40% were engaged in HIV medical care, 37% were prescribed ART, and 30% achieved viral suppression. The prevalence of viral suppression was significantly lower among persons aged 18-24 years (13%), 25-34 years (23%), and 35-44 years (27%) compared with those aged >= 65 years (37%).
Conclusions: A comprehensive continuum of services is needed to ensure that all persons living with HIV infection receive the HIV care and treatment needed to achieve viral suppression. Improvements are needed across the HIV care continuum to protect the health of persons living with HIV, reduce HIV transmission, and reach prevention and care goals.
Implications for public health practice: State and local health departments, community-based organizations, and health care providers play essential roles in improving outcomes on the HIV care continuum that increase survival among persons living with HIV and prevent new HIV infections. The greatest opportunities for increasing the percentage of persons with a suppressed viral load are reducing undiagnosed HIV infections and increasing the percentage of persons living with HIV who are engaged in care.
C1 [Bradley, Heather; Hall, H. Irene; Wolitski, Richard J.; Van Handel, Michelle M.; Stone, Amy E.; LaFlam, Michael; Skarbinski, Jacek; Higa, Darrel H.; Prejean, Joseph; Frazier, Emma L.; Patel, Roshni; Huang, Ping; An, Qian; Song, Ruiguang; Tang, Tian; Valleroy, Linda A.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
RP Bradley, H (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
EM hmbradley@cdc.gov
NR 13
TC 112
Z9 112
U1 1
U2 6
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 28
PY 2014
VL 63
IS 47
BP 1113
EP 1117
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3LR
UT WOS:000345515200004
PM 25426654
ER
PT J
AU Davis, NL
Miller, WC
Hudgens, MG
Chasela, CS
Sichali, D
Kayira, D
Nelson, JAE
Stringer, JSA
Ellington, SR
Kourtis, AP
Jamieson, DJ
van der Horst, C
AF Davis, Nicole L.
Miller, William C.
Hudgens, Michael G.
Chasela, Charles S.
Sichali, Dorothy
Kayira, Dumbani
Nelson, Julie A. E.
Stringer, Jeffrey S. A.
Ellington, Sascha R.
Kourtis, Athena P.
Jamieson, Denise J.
van der Horst, Charles
CA BAN Study Team
TI Adherence to extended postpartum antiretrovirals is associated with
decreased breast milk HIV-1 transmission
SO AIDS
LA English
DT Article
DE adherence; antiretroviral; breastfeeding; HIV transmission; prevention
of mother-to-child HIV transmission
ID TO-CHILD TRANSMISSION; SINGLE-DOSE NEVIRAPINE; RANDOMIZED
CONTROLLED-TRIAL; PROTEASE INHIBITOR THERAPY; SELF-REPORTED ADHERENCE;
VIROLOGICAL SUPPRESSION; INFECTED WOMEN; SOUTH-AFRICA; PREVENTION;
PREGNANCY
AB Objective: Estimate association between postpartum antiretroviral adherence and breast milk HIV-1 transmission.
Design: Prospective cohort study.
Methods: Mother-infant pairs were randomized after delivery to immediately begin receiving 28 weeks of either triple maternal antiretrovirals (zidovudine, lamivudine, and either nevirapine, nelfinavir, or lopinavir-ritonavir) or daily infant nevirapine as part of the Breastfeeding, Antiretrovirals, and Nutrition (BAN) study. Associations between postpartum antiretroviral adherence and rate of breast milk HIV-1 transmission were estimated using Cox models. We measured adherence over four postpartum time intervals using pill count, suspension bottle weight, and maternal self-report. Adherence was categorized and lagged by one interval. Missing adherence measures were multiply imputed. Infant HIV-1 infection was determined by DNA PCR every 2-6 weeks. The primary endpoint was infant HIV-1 infection by 38 weeks of age among infants alive and uninfected at 5 weeks.
Results: Analyses included 1479 mother-infant pairs and 45 transmission events. Using pill count and bottle weight information, 22-40% of mother-infant pairs at any given interval were less than 90% adherent. Having at least 90% adherence was associated with a 52% [95% confidence interval (CI) 3-76] relative reduction in the rate of breast milk HIV-1 transmission, compared with having less than 90% adherence when controlling for study arm, breastfeeding status, and maternal characteristics. Complete case analysis rendered similar results (n = 501; relative reduction 59%, 95% CI 6-82).
Conclusion: Nonadherence to extended postpartum antiretroviral regimens in 'real world' settings is likely to be higher than that seen in BAN. Identifying mothers with difficulty adhering to antiretrovirals, and developing effective adherence interventions, will help maximize benefits of antiretroviral provision throughout breastfeeding. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Davis, Nicole L.; Miller, William C.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA.
[Davis, Nicole L.; Miller, William C.; van der Horst, Charles] Univ N Carolina, Sch Med, Dept Med, Div Infect Dis, Chapel Hill, NC 27599 USA.
[Hudgens, Michael G.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA.
[Chasela, Charles S.] Univ Witwatersrand, Div Epidemiol & Biostat, Sch Publ Hlth, Parktown, South Africa.
[Sichali, Dorothy; Kayira, Dumbani] Univ N Carolina, UNC Project, Lilongwe, Malawi.
[Nelson, Julie A. E.] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
[Nelson, Julie A. E.] Univ N Carolina, Ctr AIDS Res, Chapel Hill, NC 27599 USA.
[Stringer, Jeffrey S. A.] Univ N Carolina, Dept Obstet & Gynecol, Global Womens Hlth Div, Chapel Hill, NC 27599 USA.
[Stringer, Jeffrey S. A.] Univ N Carolina, Sch Med, Inst Global Hlth & Infect Dis, Chapel Hill, NC 27599 USA.
[Ellington, Sascha R.; Kourtis, Athena P.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.
RP Davis, NL (reprint author), Univ N Carolina, Dept Epidemiol, 135 Dauer Dr,2101 McGavran Greenberg Hall,CB 7435, Chapel Hill, NC 27599 USA.
EM nld@unc.edu
RI Miller, William/H-4800-2014;
OI Miller, William/0000-0002-1934-7827; Flax, Valerie/0000-0003-0200-3355
FU Prevention Research Centers Special Interest Project of the Centers for
Disease Control and Prevention [SIP 13-01 U48-CCU409660-09, SIP 26-04
U48-DP000059-01, SIP 22-09 U48-DP001944-01]; National Institute of
Allergy and Infectious Diseases; University of North Carolina Center for
AIDS Research [P30-AI50410]; NIH Fogarty AIDS International Training and
Research Program [DHHS/NIH/FIC 2-D43 TW01039-06]; NIH Fogarty AIDS
International Training and Research Program (Fogarty International
Clinical Research Scholars Program) [R24 TW007988]; NIH Fogarty AIDS
International Training and Research Program (American Recovery and
Reinvestment Act); Infectious Disease Epidemiology Training Grant
[5T32AI070114]; Elizabeth Glaser Pediatric AIDS Foundation; United
Nations Children's Fund; World Food Program; Malawi Ministry of Health
and Population; Johnson Johnson; U.S. Agency for International
Development
FX Source of funding: The BAN Study was supported by grants from the
Prevention Research Centers Special Interest Project of the Centers for
Disease Control and Prevention (SIP 13-01 U48-CCU409660-09, SIP 26-04
U48-DP000059-01, and SIP 22-09 U48-DP001944-01), the National Institute
of Allergy and Infectious Diseases, the University of North Carolina
Center for AIDS Research (P30-AI50410), the NIH Fogarty AIDS
International Training and Research Program (DHHS/NIH/FIC 2-D43
TW01039-06, the Fogarty International Clinical Research Scholars Program
R24 TW007988; the American Recovery and Reinvestment Act), and the
Infectious Disease Epidemiology Training Grant (5T32AI070114). The
antiretrovirals used in the BAN study were donated by Abbott
Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche
Pharmaceuticals, and Bristol-Myers Squibb. The Call to Action PMTCT
programme was supported by the Elizabeth Glaser Pediatric AIDS
Foundation, the United Nations Children's Fund, the World Food Program,
the Malawi Ministry of Health and Population, Johnson & Johnson, and the
U.S. Agency for International Development.
NR 38
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD NOV 28
PY 2014
VL 28
IS 18
BP 2739
EP 2749
DI 10.1097/QAD.0000000000000492
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AT9XO
UT WOS:000345277300012
PM 25493600
ER
PT J
AU Bulterys, M
Berry, RJ
Watts, DH
AF Bulterys, Marc
Berry, Robert J.
Watts, D. Heather
TI Preconception antiretroviral therapy and birth defects: what is needed?
SO AIDS
LA English
DT Editorial Material
DE antiretroviral therapy; birth defects; drug safety; HIV infection;
mother-to-child transmission; pregnancy; surveillance
ID TO-CHILD TRANSMISSION; NEURAL-TUBE DEFECTS; INFECTED WOMEN;
HIV-INFECTION; FOLIC-ACID; SCALE-UP; MOTHER; PREVENTION; SAFETY;
PREGNANCY
C1 [Bulterys, Marc] NHRC, Dept Def HIV AIDS Prevent Program, San Diego, CA 92106 USA.
[Bulterys, Marc] Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA USA.
[Berry, Robert J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA USA.
[Watts, D. Heather] US Dept State, Off Global AIDS, Washington, DC 20520 USA.
RP Bulterys, M (reprint author), NHRC, Dept Def HIV AIDS Prevent Program DHAPP, 140 Sylvester Rd, San Diego, CA 92106 USA.
EM Marc.Bulterys@med.navy.mil
OI Berry, Robert/0000-0002-7162-5046
NR 31
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD NOV 28
PY 2014
VL 28
IS 18
BP 2777
EP 2780
DI 10.1097/QAD.0000000000000500
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AT9XO
UT WOS:000345277300016
PM 25493603
ER
PT J
AU Phillips-Howard, PA
Laserson, KF
Amek, N
Beynon, CM
Angell, SY
Khagayi, S
Byass, P
Hamel, MJ
van Eijk, AM
Zielinski-Gutierrez, E
Slutsker, L
De Cock, KM
Vulule, J
Odhiambo, FO
AF Phillips-Howard, Penelope A.
Laserson, Kayla F.
Amek, Nyaguara
Beynon, Caryl M.
Angell, Sonia Y.
Khagayi, Sammy
Byass, Peter
Hamel, Mary J.
van Eijk, Anne M.
Zielinski-Gutierrez, Emily
Slutsker, Laurence
De Cock, Kevin M.
Vulule, John
Odhiambo, Frank O.
TI Deaths Ascribed to Non-Communicable Diseases among Rural Kenyan Adults
Are Proportionately Increasing: Evidence from a Health and Demographic
Surveillance System, 2003-2010
SO PLOS ONE
LA English
DT Article
ID SUB-SAHARAN AFRICA; COMPARATIVE RISK-ASSESSMENT; WESTERN KENYA; VERBAL
AUTOPSY; GLOBAL BURDEN; BREAST-CANCER; MORTALITY; CARE; HYPERTENSION;
METAANALYSIS
AB Background: Non-communicable diseases (NCDs) result in more deaths globally than other causes. Monitoring systems require strengthening to attribute the NCD burden and deaths in low and middle-income countries (LMICs). Data from health and demographic surveillance systems (HDSS) can contribute towards this goal.
Methods and Findings: Between 2003 and 2010, 15,228 deaths in adults aged 15 years (y) and older were identified retrospectively using the HDSS census and verbal autopsy in rural western Kenya, attributed into broad categories using InterVA-4 computer algorithms; 37% were ascribed to NCDs, 60% to communicable diseases (CDs), 3% to injuries, and,1% maternal causes. Median age at death for NCDs was 66y and 71y for females and males, respectively, with 43% (39% male, 48% female) of NCD deaths occurring prematurely among adults aged below 65y. NCD deaths were mainly attributed to cancers (35%) and cardiovascular diseases (CVDs; 29%). The proportionate mortality from NCDs rose from 35% in 2003 to 45% in 2010 (chi(2) linear trend 93.4; p<0.001). While overall annual mortality rates (MRs) for NCDs fell, cancer-specific MRs rose from 200 to 262 per 100,000 population, mainly due to increasing deaths in adults aged 65y and older, and to respiratory neoplasms in all age groups. The substantial fall in CD MRs resulted in similar MRs for CDs and NCDs among all adult females by 2010. NCD MRs for adults aged 15y to <65y fell from 409 to 183 per 100,000 among females and from 517 to 283 per 100,000 population among males. NCD MRs were higher among males than females aged both below, and at or above, 65y.
Conclusions: NCDs constitute a significant proportion of deaths in rural western Kenya. Evidence of the increasing contribution of NCDs to overall mortality supports international recommendations to introduce or enhance prevention, screening, diagnosis and treatment programmes in LMICs.
C1 [Phillips-Howard, Penelope A.] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England.
[Phillips-Howard, Penelope A.; Laserson, Kayla F.; Amek, Nyaguara; Khagayi, Sammy; Zielinski-Gutierrez, Emily; Vulule, John; Odhiambo, Frank O.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya.
[Laserson, Kayla F.; De Cock, Kevin M.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA.
[Beynon, Caryl M.] Liverpool John Moores Univ, Ctr Publ Hlth, Liverpool L3 5UX, Merseyside, England.
[Angell, Sonia Y.] Ctr Dis Control & Prevent, Dept Noncommunicable Dis, Div Global Hlth Protect, Atlanta, GA USA.
[Byass, Peter] Umea Univ, Umea Ctr Global Hlth Res, Umea, Sweden.
[Hamel, Mary J.; Slutsker, Laurence] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA.
[Zielinski-Gutierrez, Emily] Ctr Dis Control & Prevent, Div Global HIV & AIDS, Kisumu, Kenya.
[De Cock, Kevin M.] Ctr Dis Control & Prevent Kenya, Ctr Global Hlth, Nairobi, Kenya.
RP Phillips-Howard, PA (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England.
EM Penelope.Phillips-Howard@lstmed.ac.uk
OI Phillips-Howard, Penelope A/0000-0003-1018-116X; Byass,
Peter/0000-0001-5474-4361
FU CDC; KEMRI
FX The HDSS has been funded through the CDC Cooperative Agreement grant
with KEMRI, with supplemental support from project grants. The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 69
TC 0
Z9 0
U1 2
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 26
PY 2014
VL 9
IS 11
AR e114010
DI 10.1371/journal.pone.0114010
PG 29
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA8CZ
UT WOS:000349145400107
PM 25426945
ER
PT J
AU Lucchi, NW
Karell, MA
Journel, I
Rogier, E
Goldman, I
Ljolje, D
Huber, C
Mace, KE
Jean, SE
Akom, EE
Oscar, R
Buteau, J
Boncy, J
Barnwell, JW
Udhayakumar, V
AF Lucchi, Naomi W.
Karell, Mara A.
Journel, Ito
Rogier, Eric
Goldman, Ira
Ljolje, Dragan
Huber, Curtis
Mace, Kimberly E.
Jean, Samuel E.
Akom, Eniko E.
Oscar, Roland
Buteau, Josiane
Boncy, Jacques
Barnwell, John W.
Udhayakumar, Venkatachalam
TI PET-PCR method for the molecular detection of malaria parasites in a
national malaria surveillance study in Haiti, 2011
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Diagnosis; Haiti; PET-PCR
ID PLASMODIUM-FALCIPARUM INFECTION; POLYMERASE-CHAIN-REACTION; ASYMPTOMATIC
MALARIA; ANTIGEN-DETECTION; TRANSMISSION; ELIMINATION; PREVALENCE;
DIAGNOSTICS; MICROSCOPY; TANZANIA
AB Background: Recently, a real-time PCR assay known as photo-induced electron transfer (PET)-PCR which relies on self-quenching primers for the detection of Plasmodium spp. and Plasmodium falciparum was described. PET-PCR assay was found to be robust, and easier to use when compared to currently available real-time PCR methods. The potential of PET-PCR for molecular detection of malaria parasites in a nationwide malaria community survey in Haiti was investigated.
Methods: DNA from the dried blood spots was extracted using QIAGEN methodology. All 2,989 samples were screened using the PET-PCR assay in duplicate. Samples with a cycle threshold (CT) of 40 or less were scored as positive. A subset of the total samples (534) was retested using a nested PCR assay for confirmation. In addition, these same samples were also tested using a TaqMan-based real-time PCR assay.
Results: A total of 12 out of the 2,989 samples screened (0.4%) were found to be positive by PET-PCR (mean CT value of 35.7). These same samples were also found to be positive by the nested and TaqMan-based methods. The nested PCR detected an additional positive sample in a subset of 534 samples that was not detected by either PET-PCR or TaqMan-based PCR method.
Conclusion: While the nested PCR was found to be slightly more sensitive than the PET-PCR, it is not ideal for high throughput screening of samples. Given the ease of use and lower cost than the nested PCR, the PET-PCR provides an alternative assay for the rapid screening of a large number of samples in laboratory settings.
C1 [Lucchi, Naomi W.; Rogier, Eric; Goldman, Ira; Huber, Curtis; Mace, Kimberly E.; Barnwell, John W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA 30333 USA.
[Karell, Mara A.; Ljolje, Dragan] Atlanta Res & Educ Fdn, Decatur, GA USA.
[Journel, Ito; Buteau, Josiane; Boncy, Jacques] Lab Natl Sante Publ, Port Au Prince, Haiti.
[Jean, Samuel E.; Akom, Eniko E.] Populat Serv Int Haiti, Port Au Prince, Haiti.
[Oscar, Roland] Programme Natl Controle Malaria, Port Au Prince, Haiti.
RP Lucchi, NW (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA 30333 USA.
EM NLucchi@cdc.gov
FU Global Fund; Centers for Disease Control and Prevention; Atlanta
Research and Education Foundation
FX We gratefully acknowledge the willingness of participants to contribute
to this study. Michelle Chang provided technical assistance which
improved the study implementation and analysis. This report was made
possible through support provided by the Global Fund to Fight AIDS
Tuberculosis and Malaria, the Centers for Disease Control and Prevention
and the Atlanta Research and Education Foundation. The findings and
conclusions in this report are those of the authors and do not
necessarily represent the official position of the Centers for Disease
Control and Prevention.
NR 22
TC 7
Z9 7
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD NOV 26
PY 2014
VL 13
AR 462
DI 10.1186/1475-2875-13-462
PG 5
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AW5LP
UT WOS:000346317000001
PM 25428550
ER
PT J
AU Ortiz, JR
Neuzil, KM
Cooke, CR
Neradilek, MB
Goss, CH
Shay, DK
AF Ortiz, Justin R.
Neuzil, Kathleen M.
Cooke, Colin R.
Neradilek, Moni B.
Goss, Christopher H.
Shay, David K.
TI Influenza Pneumonia Surveillance among Hospitalized Adults May
Underestimate the Burden of Severe Influenza Disease
SO PLOS ONE
LA English
DT Article
ID IMMUNIZATION PRACTICES ACIP; UNITED-STATES; SENTINEL SURVEILLANCE;
RESPIRATORY VIRUSES; ADVISORY-COMMITTEE; EMERGENCY CARE; SEVERE SEPSIS;
MORTALITY; ILLNESS; RECOMMENDATIONS
AB Background: Studies seeking to estimate the burden of influenza among hospitalized adults often use case definitions that require presence of pneumonia. The goal of this study was to assess the extent to which restricting influenza testing to adults hospitalized with pneumonia could underestimate the total burden of hospitalized influenza disease.
Methods: We conducted a modelling study using the complete State Inpatient Databases from Arizona, California, and Washington and regional influenza surveillance data acquired from CDC from January 2003 through March 2009. The exposures of interest were positive laboratory tests for influenza A (H1N1), influenza A (H3N2), and influenza B from two contiguous US Federal Regions encompassing the study area. We identified the two outcomes of interest by ICD-9-CM code: respiratory and circulatory hospitalizations, as well as critical illness hospitalizations (acute respiratory failure, severe sepsis, and in-hospital death). We linked the hospitalization datasets with the virus surveillance datasets by geographic region and month of hospitalization. We used negative binomial regression models to estimate the number of influenza-associated events for the outcomes of interest. We sub-categorized these events to include all outcomes with or without pneumonia diagnosis codes.
Results: We estimated that there were 80,834 (95% CI 29,214-174,033) influenza-associated respiratory and circulatory hospitalizations and 26,760 (95% CI 14,541-47,464) influenza-associated critical illness hospitalizations. When a pneumonia diagnosis was excluded, the estimated number of influenza-associated respiratory and circulatory hospitalizations was 24,816 (95% CI 6,342-92,624). The estimated number of influenza-associated critical illness hospitalizations was 8,213 (95% CI 3,764-20,799). Around 30% of both influenza-associated respiratory and circulatory hospitalizations, as well as influenza-associated critical illness hospitalizations did not have pneumonia diagnosis codes.
Conclusions: Surveillance studies which only consider hospitalizations that include a diagnosis of pneumonia may underestimate the total burden of influenza hospitalizations.
C1 [Ortiz, Justin R.; Neuzil, Kathleen M.; Goss, Christopher H.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Ortiz, Justin R.; Neuzil, Kathleen M.] Univ Washington, Dept Global Hlth, Seattle, WA USA.
[Ortiz, Justin R.; Neuzil, Kathleen M.] PATH, Vaccine Access & Delivery Global Program, Seattle, WA USA.
[Cooke, Colin R.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA.
[Neradilek, Moni B.] Mt Whisper Light Stat, Seattle, WA USA.
[Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
RP Ortiz, JR (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA.
EM jrortiz@uw.edu
OI Shay, David/0000-0001-9619-4820; Cooke, Colin/0000-0001-9713-5371
FU Robert Wood Johnson Harold Amos Medical Faculty Development Program
[67423]
FX This work was supported by the Robert Wood Johnson Harold Amos Medical
Faculty Development Program, grant 67423 (JRO), http://www.amfdp.org/.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 40
TC 1
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 25
PY 2014
VL 9
IS 11
AR e113903
DI 10.1371/journal.pone.0113903
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU9GL
UT WOS:000345899700076
PM 25423025
ER
PT J
AU Nandakumar, S
Kannanganat, S
Posey, JE
Amara, RR
Sable, SB
AF Nandakumar, Subhadra
Kannanganat, Sunil
Posey, James E.
Amara, Rama Rao
Sable, Suraj B.
TI Attrition of T-Cell Functions and Simultaneous Upregulation of
Inhibitory Markers Correspond with the Waning of BCG-Induced Protection
against Tuberculosis in Mice
SO PLOS ONE
LA English
DT Article
ID MYCOBACTERIUM-BOVIS BCG; BACILLUS-CALMETTE-GUERIN; CHRONIC
VIRAL-INFECTION; INTERFERON-GAMMA; IMMUNE-RESPONSE; CENTRAL MEMORY;
ANTIGEN LOAD; PULMONARY TUBERCULOSIS; PUBLISHED LITERATURE; EFFECTOR
FUNCTIONS
AB Mycobacterium bovis bacille Calmette-Guerin (BCG) is the most widely used live attenuated vaccine. However, the correlates of protection and waning of its immunity against tuberculosis is poorly understood. In this study, we correlated the longitudinal changes in the magnitude and functional quality of CD4(+) and CD8(+) T-cell response over a period of two years after mucosal or parenteral BCG vaccination with the strength of protection against Mycobacterium tuberculosis in mice. The BCG vaccination-induced CD4(+) and CD8(+) T cells exhibited comparable response kinetics but distinct functional attributes in-terms of IFN-gamma, IL-2 and TNF-alpha co-production and CD62L memory marker expression. Despite a near life-long BCG persistence and the induction of enduring CD4(+) T-cell responses characterized by IFN-gamma and/or TNF-alpha production with comparable protection, the protective efficacy waned regardless of the route of vaccination. The progressive decline in the multifactorial functional abilities of CD4(+) and CD8(+) T cells in-terms of type-1 cytokine production, proliferation and cytolytic potential corresponded with the waning of protection against M. tuberculosis infection. In addition, simultaneous increase in the dysfunctional and terminally-differentiated T cells expressing CTLA-4, KLRG-1 and IL-10 during the contraction phase of BCG-induced response coincided with the loss of protection. Our results question the empirical development of BCG-booster vaccines and emphasize the pursuit of strategies that maintain superior T-cell functional capacity. Furthermore, our results underscore the importance of understanding the comprehensive functional dynamics of antigen-specific T-cell responses in addition to cytokine polyfunctionality in BCG-vaccinated hosts while optimizing novel vaccination strategies against tuberculosis.
C1 [Nandakumar, Subhadra; Posey, James E.; Sable, Suraj B.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30329 USA.
[Kannanganat, Sunil; Amara, Rama Rao] Emory Univ, Yerkes Natl Primate Res Ctr, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.
RP Sable, SB (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30329 USA.
EM SSable@cdc.gov
FU Centers for Disease Control and Prevention (CDC); Georgia Research
Alliance
FX The study was supported by Centers for Disease Control and Prevention
(CDC) intramural funds and the Georgia Research Alliance grant to SBS,
RRA, JEP, and TM Shinnick. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 88
TC 5
Z9 5
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 24
PY 2014
VL 9
IS 11
AR e113951
DI 10.1371/journal.pone.0113951
PG 25
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX2IM
UT WOS:000346766900081
PM 25419982
ER
PT J
AU Wong, J
Hamel, MJ
Drakeley, CJ
Kariuki, S
Shi, YP
Lal, AA
Nahlen, BL
Bloland, PB
Lindblade, K
Were, V
Otieno, K
Otieno, P
Odero, C
Slutsker, L
Vulule, JM
Gimnig, JE
AF Wong, Jacklyn
Hamel, Mary J.
Drakeley, Chris J.
Kariuki, Simon
Shi, Ya Ping
Lal, Altaf A.
Nahlen, Bernard L.
Bloland, Peter B.
Lindblade, Kima
Were, Vincent
Otieno, Kephas
Otieno, Peter
Odero, Chris
Slutsker, Laurence
Vulule, John M.
Gimnig, John E.
TI Serological markers for monitoring historical changes in malaria
transmission intensity in a highly endemic region of Western Kenya,
1994-2009
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Plasmodium falciparum; Serology; Epidemiology; Transmission
intensity; Antibodies
ID TREATED BED NETS; PLASMODIUM-FALCIPARUM TRANSMISSION; ENTOMOLOGICAL
INOCULATION RATE; SAMPLING ANOPHELINE MOSQUITOS; ANTIBODY-RESPONSES;
CIRCUMSPOROZOITE PROTEIN; CHILD-MORTALITY; YOUNG-CHILDREN; DEMOGRAPHIC
SURVEILLANCE; LONGITUDINAL COHORT
AB Background: Monitoring local malaria transmission intensity is essential for planning evidence-based control strategies and evaluating their impact over time. Anti-malarial antibodies provide information on cumulative exposure and have proven useful, in areas where transmission has dropped to low sustained levels, for retrospectively reconstructing the timing and magnitude of transmission reduction. It is unclear whether serological markers are also informative in high transmission settings, where interventions may reduce transmission, but to a level where considerable exposure continues.
Methods: This study was conducted through ongoing KEMRI and CDC collaboration. Asembo, in Western Kenya, is an area where intense malaria transmission was drastically reduced during a 1997-1999 community-randomized, controlled insecticide-treated net (ITN) trial. Two approaches were taken to reconstruct malaria transmission history during the period from 1994 to 2009. First, point measurements were calculated for seroprevalence, mean antibody titre, and seroconversion rate (SCR) against three Plasmodium falciparum antigens (AMA-1, MSP-1(19), and CSP) at five time points for comparison against traditional malaria indices (parasite prevalence and entomological inoculation rate). Second, within individual post-ITN years, age-stratified seroprevalence data were analysed retrospectively for an abrupt drop in SCR by fitting alternative reversible catalytic conversion models that allowed for change in SCR.
Results: Generally, point measurements of seroprevalence, antibody titres and SCR produced consistent patterns indicating that a gradual but substantial drop in malaria transmission (46-70%) occurred from 1994 to 2007, followed by a marginal increase beginning in 2008 or 2009. In particular, proportionate changes in seroprevalence and SCR point estimates (relative to 1994 baseline values) for AMA-1 and CSP, but not MSP-1(19), correlated closely with trends in parasite prevalence throughout the entire 15-year study period. However, retrospective analyses using datasets from 2007, 2008 and 2009 failed to detect any abrupt drop in transmission coinciding with the timing of the 1997-1999 ITN trial.
Conclusions: In this highly endemic area, serological markers were useful for generating accurate point estimates of malaria transmission intensity, but not for retrospective analysis of historical changes. Further investigation, including exploration of different malaria antigens and/or alternative models of population seroconversion, may yield serological tools that are more informative in high transmission settings.
C1 [Wong, Jacklyn; Hamel, Mary J.; Shi, Ya Ping; Lal, Altaf A.; Nahlen, Bernard L.; Bloland, Peter B.; Lindblade, Kima; Slutsker, Laurence; Gimnig, John E.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA.
[Drakeley, Chris J.] London Sch Hyg & Trop Med, Dept Immunol & Infect, London WC1, England.
[Kariuki, Simon; Were, Vincent; Otieno, Kephas; Otieno, Peter; Odero, Chris; Vulule, John M.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya.
RP Wong, J (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA.
EM vsm0@cdc.gov
FU CDC through a cooperative agreement with KEMRI.; Malaria Transmission
Consortium [45114]; American Society for Microbiology
FX We thank the residents of Asembo who participated in this study, as well
as the KEMRI and CDC personnel who conducted surveys and collected
serological specimens. Funding for surveys and sample collection came
from CDC through a cooperative agreement with KEMRI. Funding for
reagents and serological analysis was through the Malaria Transmission
Consortium (grant no. 45114). JW was supported by a fellowship from the
American Society for Microbiology. This paper was published with the
permission of the KEMRI director.
NR 61
TC 13
Z9 13
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD NOV 22
PY 2014
VL 13
AR 451
DI 10.1186/1475-2875-13-451
PG 14
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AU6WB
UT WOS:000345741000001
PM 25416454
ER
PT J
AU Sunderam, S
Kissin, DM
Crawford, SB
Folger, SG
Jamieson, DJ
Barfield, WD
AF Sunderam, Saswati
Kissin, Dmitry M.
Crawford, Sara B.
Folger, Suzanne G.
Jamieson, Denise J.
Barfield, Wanda D.
TI Assisted Reproductive Technology Surveillance - United States, 2011
SO MMWR SURVEILLANCE SUMMARIES
LA English
DT Article
ID IN-VITRO FERTILIZATION; INSURANCE MANDATES; MULTIPLE GESTATION;
EMBRYO-TRANSFER; BIRTH-DEFECTS; INFERTILITY TREATMENTS; PRETERM BIRTH;
RISK; PREGNANCIES; OUTCOMES
AB Since the first U.S. infant conceived with Assisted Reproductive Technology (ART) was born in 1981, both the use of advanced technologies to overcome infertility and the number of fertility clinics providing ART services have increased steadily in the United States. ART includes fertility treatments in which both eggs and embryos are handled in the laboratory (i.e., in vitro fertilization [IVF] and related procedures). Women who undergo ART procedures are more likely to deliver multiple-birth infants than those who conceive naturally because more than one embryo might be transferred during a procedure. Multiple births pose substantial risks to both mothers and infants, including pregnancy complications, preterm delivery, and low birthweight infants. This report provides state-specific information on U.S. ART procedures performed in 2011 and compares infant outcomes that occurred in 2011 (resulting from procedures performed in 2010 and 2011) with outcomes for all infants born in the United States in 2011.
C1 [Sunderam, Saswati; Kissin, Dmitry M.; Crawford, Sara B.; Folger, Suzanne G.; Jamieson, Denise J.; Barfield, Wanda D.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA.
RP Sunderam, S (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA.
EM msunderam@cdc.gov
NR 48
TC 20
Z9 22
U1 1
U2 3
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-8636
J9 MMWR SURVEILL SUMM
JI MMWR Surv. Summ.
PD NOV 21
PY 2014
VL 63
IS 10
BP 1
EP 30
PG 30
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AY5RX
UT WOS:000347630400001
ER
PT J
AU Hopkins, DR
Ruiz-Tiben, E
Eberhard, ML
Roy, SL
AF Hopkins, Donald R.
Ruiz-Tiben, Ernesto
Eberhard, Mark L.
Roy, Sharon L.
TI Progress Toward Global Eradication of Dracunculiasis - January 2013-June
2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID CHAD
C1 [Hopkins, Donald R.; Ruiz-Tiben, Ernesto] Emory Univ, Carter Ctr, Atlanta, GA 30322 USA.
[Eberhard, Mark L.] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Roy, Sharon L.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Roy, Sharon L.] CDC, World Hlth Org Collaborating Ctr Res Training & E, Atlanta, GA 30333 USA.
RP Roy, SL (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM slroy@cdc.gov
NR 7
TC 3
Z9 3
U1 1
U2 10
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 21
PY 2014
VL 63
IS 46
BP 1050
EP 1054
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3LO
UT WOS:000345514900002
PM 25412061
ER
PT J
AU Harris, JB
Gacic-Dobo, M
Eggers, R
Brown, DW
Sodha, SV
AF Harris, Jennifer B.
Gacic-Dobo, Marta
Eggers, Rudolf
Brown, David W.
Sodha, Samir V.
TI Global Routine Vaccination Coverage, 2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID CHILDREN
C1 [Harris, Jennifer B.; Sodha, Samir V.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Harris, Jennifer B.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Gacic-Dobo, Marta; Eggers, Rudolf] World Hlth Org, Dept Immunizat Vaccines & Biol, Geneva, Switzerland.
[Brown, David W.] United Nations Childrens Fund, Div Data Res & Policy, New York, NY 10017 USA.
RP Harris, JB (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
EM jbharris@cdc.gov
NR 9
TC 15
Z9 16
U1 0
U2 2
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 21
PY 2014
VL 63
IS 46
BP 1055
EP 1058
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3LO
UT WOS:000345514900003
PM 25412062
ER
PT J
AU Etsano, A
Gunnala, R
Shuaib, F
Damisa, E
Mkanda, P
Banda, R
Korir, C
Enemaku, O
Corkum, M
Usman, S
Davis, LB
Nganda, GW
Burns, CC
Mahoney, F
Vertefeuille, JF
AF Etsano, Andrew
Gunnala, Rajni
Shuaib, Faisal
Damisa, Eunice
Mkanda, Pascal
Banda, Richard
Korir, Charles
Enemaku, Ogu
Corkum, Melissa
Usman, Samuel
Davis, Lora B.
Nganda, Gatei Wa
Burns, Cara C.
Mahoney, Frank
Vertefeuille, John F.
TI Progress Toward Poliomyelitis Eradication - Nigeria, January
2013-September 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Etsano, Andrew; Damisa, Eunice] Natl Primary Hlth Care Dev Agcy, Lagos, Nigeria.
[Gunnala, Rajni; Davis, Lora B.; Nganda, Gatei Wa; Mahoney, Frank; Vertefeuille, John F.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Shuaib, Faisal] Fed Minist Hlth, Lagos, Nigeria.
[Mkanda, Pascal; Banda, Richard; Korir, Charles] World Hlth Org, Nigeria Off, Lagos, Nigeria.
[Enemaku, Ogu; Corkum, Melissa] United Nations Childrens Fund, Nigeria Off, Lagos, Nigeria.
[Usman, Samuel] CORE Grp Partners Project Nigeria, Lagos, Nigeria.
[Burns, Cara C.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Gunnala, R (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
EM rgunnala@cdc.gov
NR 9
TC 9
Z9 9
U1 0
U2 9
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 21
PY 2014
VL 63
IS 46
BP 1059
EP 1063
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3LO
UT WOS:000345514900004
PM 25412063
ER
PT J
AU Sharma, A
Heijenberg, N
Peter, C
Bolongei, J
Reeder, B
Alpha, T
Sterk, E
Robert, H
Kurth, A
Cannas, A
Bocquin, A
Strecker, T
Logue, C
Di Caro, A
Pottage, T
Yue, C
Stoecker, K
Wolfel, R
Gabriel, M
Gunther, S
Damon, I
AF Sharma, Aditya
Heijenberg, Nico
Peter, Clement
Bolongei, Josephus
Reeder, Bruce
Alpha, Tamba
Sterk, Esther
Robert, Hugues
Kurth, Andreas
Cannas, Angela
Bocquin, Anne
Strecker, Thomas
Logue, Christopher
Di Caro, Antonino
Pottage, Thomas
Yue, Constanze
Stoecker, Kilian
Woelfel, Roman
Gabriel, Martin
Guenther, Stephan
Damon, Inger
TI Evidence for a Decrease in Transmission of Ebola Virus - Lofa County,
Liberia, June 8-November 1, 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Sharma, Aditya] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Heijenberg, Nico] Medecins Sans Frontieres, Operat Ctr Geneva, Voinjama, Liberia.
[Peter, Clement] World Hlth Org, Monrovia Country Off, Monrovia, Liberia.
[Bolongei, Josephus; Alpha, Tamba] Minist Hlth & Social Welf, Lofa Cty Hlth Off, Voinjama, Liberia.
[Reeder, Bruce; Sterk, Esther; Robert, Hugues] Medecins Sans Frontieres, Operat Ctr Geneva, Geneva, Switzerland.
[Reeder, Bruce] Univ Saskatchewan, Coll Med, Saskatoon, SK S7N 0W0, Canada.
[Kurth, Andreas; Cannas, Angela; Bocquin, Anne; Strecker, Thomas; Logue, Christopher; Di Caro, Antonino; Pottage, Thomas; Yue, Constanze; Stoecker, Kilian; Woelfel, Roman; Gabriel, Martin; Guenther, Stephan] European Mobile Lab Consortium, Copenhagen, Denmark.
[Kurth, Andreas; Yue, Constanze] Robert Koch Inst, Berlin, Germany.
[Cannas, Angela; Di Caro, Antonino] Ist Nazl Malattie Infett Lazzaro Spallanzani, Rome, Italy.
[Bocquin, Anne] Lab P4 INSERM Jean Merieux, Lyon, France.
[Strecker, Thomas] Univ Marburg, Inst Virol, D-35032 Marburg, Germany.
[Logue, Christopher; Pottage, Thomas] Publ Hlth England, Porton Down, Wilts, England.
[Stoecker, Kilian; Woelfel, Roman] Bundeswehr Inst Microbiol, Munich, Germany.
[Gabriel, Martin; Guenther, Stephan] Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany.
[Damon, Inger] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Sharma, A (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
EM asharma4@cdc.gov
RI Di Caro, Antonino/K-6854-2016
OI Di Caro, Antonino/0000-0001-6027-3009
NR 8
TC 9
Z9 10
U1 0
U2 12
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 21
PY 2014
VL 63
IS 46
BP 1067
EP 1071
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3LO
UT WOS:000345514900006
PM 25412065
ER
PT J
AU Nyenswah, TG
Westercamp, M
Kamali, AA
Qin, J
Zielinski-Gutierrez, E
Amegashie, F
Fallah, M
Gergonne, B
Nugba-Ballah, R
Singh, G
Aberle-Grasse, JM
Havers, F
Montgomery, JM
Bawo, L
Wang, SA
Rosenberg, R
AF Nyenswah, Tolbert G.
Westercamp, Matthew
Kamali, Amanda Ashraf
Qin, Jin
Zielinski-Gutierrez, Emily
Amegashie, Fred
Fallah, Mosaka
Gergonne, Bernadette
Nugba-Ballah, Roselyn
Singh, Gurudev
Aberle-Grasse, John M.
Havers, Fiona
Montgomery, Joel M.
Bawo, Luke
Wang, Susan A.
Rosenberg, Ronald
TI Evidence for Declining Numbers of Ebola Cases - Montserrado County,
Liberia, June-October 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID VIRUS DISEASE
C1 [Nyenswah, Tolbert G.; Amegashie, Fred; Fallah, Mosaka; Bawo, Luke] Liberia Minist Hlth & Social Welf, Monrovia, Liberia.
[Westercamp, Matthew; Havers, Fiona] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Westercamp, Matthew; Kamali, Amanda Ashraf; Qin, Jin] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Kamali, Amanda Ashraf] Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA.
[Qin, Jin] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
[Zielinski-Gutierrez, Emily; Aberle-Grasse, John M.; Montgomery, Joel M.; Wang, Susan A.] CDC, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Amegashie, Fred] Montserrado Cty Community Hlth Dept, Monrovia, Liberia.
[Gergonne, Bernadette] Medecins Sans Frontieres, Geneva, Switzerland.
[Nugba-Ballah, Roselyn] Liberian Red Cross Soc, Monrovia, Liberia.
[Singh, Gurudev] Int Federat Red Cross & Red Crescent Soc, Geneva, Switzerland.
[Rosenberg, Ronald] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Westercamp, M (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM mwestercamp@cdc.gov
NR 6
TC 7
Z9 7
U1 1
U2 3
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 21
PY 2014
VL 63
IS 46
BP 1072
EP 1076
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3LO
UT WOS:000345514900007
PM 25412066
ER
PT J
AU Matanock, A
Arwady, MA
Ayscue, P
Forrester, JD
Gaddis, B
Hunter, JC
Monroe, B
Pillai, SK
Reed, C
Schafer, IJ
Massaquoi, M
Dahn, B
De Cock, KM
AF Matanock, Almea
Arwady, M. Allison
Ayscue, Patrick
Forrester, Joseph D.
Gaddis, Bethany
Hunter, Jennifer C.
Monroe, Benjamin
Pillai, Satish K.
Reed, Christie
Schafer, Ilana J.
Massaquoi, Moses
Dahn, Bernice
De Cock, Kevin M.
TI Ebola Virus Disease Cases Among Health Care Workers Not Working in Ebola
Treatment Units - Liberia, June-August, 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Matanock, Almea; Arwady, M. Allison; Ayscue, Patrick; Forrester, Joseph D.; Hunter, Jennifer C.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Gaddis, Bethany] US Agcy Int Dev, Monrovia, Liberia.
[Monroe, Benjamin] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Pillai, Satish K.] CDC, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Reed, Christie] CDC, Presidents Malaria Initiat, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Schafer, Ilana J.] CDC, Div Epidemiol Anal & Lib Serv, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA.
[Massaquoi, Moses] Clinton Hlth Access Initiat, New York, NY USA.
[Dahn, Bernice] Liberian Minist Hlth & Social Welf, Monrovia, Liberia.
[De Cock, Kevin M.] CDC, CDC Kenya, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Matanock, A (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
EM amatanock@cdc.gov
NR 7
TC 26
Z9 27
U1 0
U2 6
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 21
PY 2014
VL 63
IS 46
BP 1077
EP 1081
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3LO
UT WOS:000345514900008
PM 25412067
ER
PT J
AU Nyenswah, T
Fahnbulleh, M
Massaquoi, M
Nagbe, T
Bawo, L
Falla, JD
Kohar, H
Gasasira, A
Nabeth, P
Yett, S
Gergonne, B
Casey, S
Espinosa, B
McCoy, A
Feldman, H
Hensley, L
Baily, M
Fields, B
Lo, T
Lindblade, K
Mott, J
Boulanger, L
Christie, A
Wang, SS
Montgomery, J
Mahoney, F
AF Nyenswah, Tolbert
Fahnbulleh, Miatta
Massaquoi, Moses
Nagbe, Thomas
Bawo, Luke
Falla, James Dorbor
Kohar, Henry
Gasasira, Alex
Nabeth, Pierre
Yett, Sheldon
Gergonne, Bernadette
Casey, Sean
Espinosa, Benjamin
McCoy, Andrea
Feldman, Heinz
Hensley, Lisa
Baily, Mark
Fields, Barry
Lo, Terrence
Lindblade, Kim
Mott, Josh
Boulanger, Lucy
Christie, Athalia
Wang, Susan
Montgomery, Joel
Mahoney, Frank
TI Ebola Epidemic - Liberia, March-October 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID DISEASE OUTBREAK; VIRUS DISEASE
C1 [Nyenswah, Tolbert; Fahnbulleh, Miatta; Massaquoi, Moses; Nagbe, Thomas; Bawo, Luke; Falla, James Dorbor; Kohar, Henry] Minist Hlth & Social Welf, Monrovia, Liberia.
[Gasasira, Alex; Nabeth, Pierre] World Hlth Org, Geneva, Switzerland.
[Yett, Sheldon] United Nations Childrens Fund, New York, NY USA.
[Gergonne, Bernadette] Medecins Sans Frontieres, Geneva, Switzerland.
[Casey, Sean] Int Med Corps, Los Angeles, CA USA.
[Espinosa, Benjamin; McCoy, Andrea] US Navy, Pentagon, AR USA.
[Feldman, Heinz; Hensley, Lisa] Natl Inst Hlth, Bethesda, MD USA.
[Baily, Mark] US Army Med Res Inst Infect Dis, Ft Detroit, MD USA.
[Fields, Barry; Lo, Terrence; Lindblade, Kim; Mott, Josh; Boulanger, Lucy; Christie, Athalia; Wang, Susan; Montgomery, Joel; Mahoney, Frank] CDC, Atlanta, GA 30333 USA.
RP Mahoney, F (reprint author), CDC, Atlanta, GA 30333 USA.
EM fmahoney@cdc.gov
NR 5
TC 15
Z9 16
U1 0
U2 14
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 21
PY 2014
VL 63
IS 46
BP 1082
EP 1086
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3LO
UT WOS:000345514900009
PM 25412068
ER
PT J
AU Chevalier, MS
Chung, W
Smith, J
Weil, LM
Hughes, SM
Joyner, SN
Hall, E
Srinath, D
Ritch, J
Thathiah, P
Threadgill, H
Cervantes, D
Lakey, DL
AF Chevalier, Michelle S.
Chung, Wendy
Smith, Jessica
Weil, Lauren M.
Hughes, Sonya M.
Joyner, Sibeso N.
Hall, Emily
Srinath, Divya
Ritch, Julia
Thathiah, Prea
Threadgill, Heidi
Cervantes, Diana
Lakey, David L.
TI Ebola Virus Disease Cluster in the United States - Dallas County, Texas,
2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Chevalier, Michelle S.] CDC, Epidem Intelligence Serv, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
[Chevalier, Michelle S.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
[Chung, Wendy; Smith, Jessica; Weil, Lauren M.; Hughes, Sonya M.; Joyner, Sibeso N.; Hall, Emily; Srinath, Divya; Ritch, Julia; Thathiah, Prea] Dallas Cty Hlth & Human Serv, Dallas, TX USA.
[Threadgill, Heidi; Cervantes, Diana; Lakey, David L.] Texas Dept State Hlth Serv, Austin, TX USA.
RP Chevalier, MS (reprint author), CDC, Epidem Intelligence Serv, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM mchevalier@cdc.gov
NR 3
TC 47
Z9 48
U1 0
U2 9
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 21
PY 2014
VL 63
IS 46
BP 1087
EP 1088
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3LO
UT WOS:000345514900010
PM 25412069
ER
PT J
AU McCarty, CL
Basler, C
Karwowski, M
Erme, M
Nixon, G
Kippes, C
Allan, T
Parrilla, T
DiOrio, M
de Fijter, S
Stone, ND
Yost, DA
Lippold, SA
Regan, JJ
Honein, MA
Knust, B
Braden, C
AF McCarty, Carolyn L.
Basler, Colin
Karwowski, Mateusz
Erme, Marguerite
Nixon, Gene
Kippes, Chris
Allan, Terry
Parrilla, Toinette
DiOrio, Mary
de Fijter, Sietske
Stone, Nimalie D.
Yost, David A.
Lippold, Susan A.
Regan, Joanna J.
Honein, Margaret A.
Knust, Barbara
Braden, Christopher
TI Response to Importation of a Case of Ebola Virus Disease - Ohio, October
2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [McCarty, Carolyn L.; Basler, Colin; Karwowski, Mateusz] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[McCarty, Carolyn L.; DiOrio, Mary; de Fijter, Sietske] Ohio Dept Hlth, Columbus, OH 43266 USA.
[McCarty, Carolyn L.; Basler, Colin; Karwowski, Mateusz; Stone, Nimalie D.; Yost, David A.; Honein, Margaret A.; Knust, Barbara; Braden, Christopher] CDC Ebola Response Team, Dayton, OH USA.
[Erme, Marguerite; Nixon, Gene] Summit Cty Publ Hlth, Akron, OH USA.
[Kippes, Chris; Allan, Terry] Cuyahoga Cty Board Hlth, Parma, OH USA.
[Parrilla, Toinette] Cleveland City Hlth Dept, Cleveland, OH USA.
[Lippold, Susan A.; Regan, Joanna J.] CDC Ebola Outbreak Response Global Migrat Task Fo, Atlanta, GA USA.
RP McCarty, CL (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
EM clmccarty@cdc.gov
NR 3
TC 20
Z9 20
U1 0
U2 6
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 21
PY 2014
VL 63
IS 46
BP 1089
EP 1091
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3LO
UT WOS:000345514900011
PM 25412070
ER
PT J
AU Nyenswah, T
Fahnbulleh, M
Ketah, F
Massaquoi, M
Nagbe, T
Bawo, L
Falla, JD
Kohar, H
Gasasira, A
Nabeth, P
Popowitz, H
Yett, S
Hurum, L
Sailly, L
Casey, S
Espinosa, B
Mccoy, A
Feldman, H
Hensley, L
Baily, M
Pendarvis, J
Fields, B
Lo, T
Quin, J
Aberle-Grasse, J
Lindblade, K
Mott, J
Boulanger, L
Christie, A
Wang, SS
Montgomery, J
Mahoney, F
AF Nyenswah, Tolbert
Fahnbulleh, Miatta
Ketah, Francis
Massaquoi, Moses
Nagbe, Thomas
Bawo, Luke
Falla, James Dorbor
Kohar, Henry
Gasasira, Alex
Nabeth, Pierre
Popowitz, Heather
Yett, Sheldon
Hurum, Lindis
Sailly, Laurence
Casey, Sean
Espinosa, Benjamin
McCoy, Andrea
Feldman, Heinz
Hensley, Lisa
Baily, Mark
Pendarvis, Justin
Fields, Barry
Lo, Terrence
Quin, Jin
Aberle-Grasse, John
Lindblade, Kim
Mott, Josh
Boulanger, Lucy
Christie, Athalia
Wang, Susan
Montgomery, Joel
Mahoney, Frank
TI Ebola Epidemic - Liberia, March-October 2014 (vol 63, pg 1082, 2014)
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Correction
C1 [Nyenswah, Tolbert; Fahnbulleh, Miatta; Ketah, Francis; Massaquoi, Moses; Nagbe, Thomas; Bawo, Luke; Falla, James Dorbor; Kohar, Henry] Minist Hlth & Social Welf, Monrovia, Liberia.
[Gasasira, Alex; Nabeth, Pierre] World Hlth Org, Geneva, Switzerland.
[Popowitz, Heather; Yett, Sheldon] United Nations Childrens Fund, New York, NY USA.
[Hurum, Lindis; Sailly, Laurence] Medecins Sans Frontieres, Geneva, Switzerland.
[Casey, Sean] Int Med Corps, Los Angeles, CA USA.
[Espinosa, Benjamin; McCoy, Andrea] US Navy, Pentagon, AR USA.
[Feldman, Heinz; Hensley, Lisa] Natl Inst Hlth, Atlanta, GA USA.
[Baily, Mark] US Army Med Res Inst Infect Dis, Ft Detroit, MD USA.
[Pendarvis, Justin] US Agcy Int Dev, Washington, DC 20523 USA.
[Fields, Barry; Lo, Terrence; Quin, Jin; Aberle-Grasse, John; Lindblade, Kim; Mott, Josh; Boulanger, Lucy; Christie, Athalia; Wang, Susan; Montgomery, Joel; Mahoney, Frank] CDC, Atlanta, GA 30333 USA.
RP Nyenswah, T (reprint author), Minist Hlth & Social Welf, Monrovia, Liberia.
NR 1
TC 2
Z9 2
U1 0
U2 3
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 21
PY 2014
VL 63
IS 46
BP 1094
EP 1094
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU3LO
UT WOS:000345514900012
ER
PT J
AU Ruckart, PZ
Bove, FJ
Maslia, M
AF Ruckart, Perri Zeitz
Bove, Frank J.
Maslia, Morris
TI Evaluation of contaminated drinking water and preterm birth, small for
gestational age, and birth weight at Marine Corps Base Camp Lejeune,
North Carolina: a cross-sectional study
SO ENVIRONMENTAL HEALTH
LA English
DT Article
DE Low birth weight; Preterm birth; Small for gestational age; Volatile
organic compounds; Solvents; Military exposures
ID ADVERSE PREGNANCY OUTCOMES; FETAL-GROWTH; EXPOSURE; SMOKING;
EPIDEMIOLOGY
AB Background: Births during 1968-1985 at Camp Lejeune were exposed to drinking water contaminated with trichloroethylene (TCE), tetrachloroethylene (PCE), and benzene.
Methods: We conducted a cross-sectional study to evaluate associations between residential prenatal exposure to contaminated drinking water at Camp Lejeune during 1968-1985 and preterm birth, small for gestational age (SGA), term low birth weight (TLBW), and mean birth weight (MBW) deficit. Birth certificates identified mothers residing at Camp Lejeune at delivery. We analyzed exposure data for the entire pregnancy and individual trimesters. For each period examined, births were categorized as unexposed if mothers did not reside at Camp Lejeune or if their residence on base received uncontaminated drinking water. Ground water contaminant fate/transport and distribution system models provided monthly estimated contaminant levels at residences. For PCE and TCE, the exposed group was divided into four levels: < median value, >= median value, >= 75th percentile, and >= 90th percentile. For benzene, the exposed group was categorized as < 1 part per billion (ppb) versus >= 1 ppb because of sparse data. Magnitude of effect estimates and exposure response relationships were used to assess associations. Confidence intervals (CIs) indicated precision of estimates.
Results: For the highest TCE exposure category during the entire pregnancy, odds ratios (ORs) were 1.5 (95% CI: 1.2, 1.9) and 1.3 (95% CI: 0.8, 2.2) for SGA and TLBW, respectively, and reduced MBW beta = -78.3 g (95% CI: -115.0, -41.7). The OR = 1.3 (95% CI: 1.0, 1.6) for preterm birth and the highest PCE exposure category during the entire pregnancy. Monotonic exposure-response relationships were observed for benzene exposure during the entire pregnancy and TLBW (highest category OR = 1.5, 85% CI: 0.9, 2.3). Although a monotonic association between benzene and adjusted MBW difference was also observed (highest category beta = -36.2 g, 95% CI: -72.3, -0.1), the association disappeared when TCE was also added to the model. We found no evidence suggesting any other associations between outcomes and exposures.
Conclusion: Findings suggested associations between in utero exposures to TCE and SGA, TLBW and reduced MBW; benzene and TLBW; and PCE and preterm birth.
C1 [Ruckart, Perri Zeitz; Bove, Frank J.] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA 30341 USA.
[Maslia, Morris] Agcy Tox Subst & Dis Registry, Div Community Hlth Invest, Atlanta, MS 30341 USA.
RP Ruckart, PZ (reprint author), Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, 4770 Buford Highway,MS F-58, Atlanta, GA 30341 USA.
EM pruckart@cdc.gov
NR 23
TC 6
Z9 6
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-069X
J9 ENVIRON HEALTH-GLOB
JI Environ. Health
PD NOV 20
PY 2014
VL 13
AR UNSP 99
DI 10.1186/1476-069X-13-99
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AU7RB
UT WOS:000345796500001
PM 25413571
ER
PT J
AU Lafond, KE
Tam, JS
Bresee, JS
Widdowson, MA
AF Lafond, Kathryn E.
Tam, John S.
Bresee, Joseph S.
Widdowson, Marc-Alain
TI International meeting on influenza vaccine effectiveness, 3-4 December
2012, Geneva, Switzerland
SO VACCINE
LA English
DT Article
DE Conference report; Influenza; Vaccines; Vaccine effectiveness
ID SEASONAL INFLUENZA; PREGNANT-WOMEN; IMMUNIZATION; METAANALYSIS;
PERCEPTION; KNOWLEDGE; BURDEN
AB On December 3-4 2012, the World Health Organization convened a meeting of influenza vaccine effectiveness (VE) experts from over 25 countries in Geneva, Switzerland, to review recent developments in the global influenza vaccine landscape and evaluate approaches to determining the effectiveness of influenza vaccine products among target populations. Vaccine manufacturers from Thailand, Vietnam, India, and Brazil shared recent advances illustrating the expansion of influenza vaccine production worldwide. Randomized controlled trials are underway in several low and middle-income countries including India, Thailand, Bangladesh, and South Africa, to fill knowledge gaps in target populations such as children and pregnant women. National and international networks in the United States, Canada, Europe, Latin America and Australia are conducting multi-site observational studies with shared methodologies to generate national influenza VE estimates and pool data for regional estimates. Standardized VE estimation methods are key to generating point estimates that are comparable internationally and across different settings.
C1 [Lafond, Kathryn E.; Bresee, Joseph S.; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA.
[Tam, John S.] WHO, Initiat Vaccine Res, CH-1211 Geneva, Switzerland.
RP Widdowson, MA (reprint author), 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30329 USA.
EM zux5@cdc.gov
FU US Centers for Disease Control and Prevention Project 49 through the
World Health Organization [5U50C1000748]
FX This study was funded by the US Centers for Disease Control and
Prevention Grant 5U50C1000748, Project 49 through the World Health
Organization.
NR 17
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 20
PY 2014
VL 32
IS 49
BP 6591
EP 6595
DI 10.1016/j.vaccine.2014.09.069
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AU8BD
UT WOS:000345820800001
PM 25446822
ER
PT J
AU Otieno, NA
Nyawanda, BO
Audi, A
Emukule, G
Lebo, E
Bigogo, G
Ochola, R
Muthoka, P
Widdowson, MA
Shay, DK
Burton, DC
Breiman, RF
Katz, MA
Mott, JA
AF Otieno, Nancy A.
Nyawanda, Bryan O.
Audi, Allan
Emukule, Gideon
Lebo, Emmaculate
Bigogo, Godfrey
Ochola, Rachel
Muthoka, Phillip
Widdowson, Marc-Alain
Shay, David K.
Burton, Deron C.
Breiman, Robert F.
Katz, Mark A.
Mott, Joshua A.
TI Demographic, socio-economic and geographic determinants of seasonal
influenza vaccine uptake in rural western Kenya, 2011
SO VACCINE
LA English
DT Article
DE Vaccine uptake; Determinants; Seasonal influenza; Children
ID YOUNG-CHILDREN; IMMUNIZATION; HEALTH; COVERAGE; SURVEILLANCE; MORTALITY;
ATTITUDES; DISTRICT; BURDEN; URBAN
AB Influenza-associated acute lower respiratory infections cause a considerable burden of disease in rural and urban sub-Saharan Africa communities with the greatest burden among children. Currently, vaccination is the best way to prevent influenza infection and accompanying morbidities.
We examined geographic, socio-economic and demographic factors that contributed to acceptance of childhood seasonal influenza vaccination among children living in a population-based morbidity surveillance system in rural western Kenya, where influenza vaccine was offered free-of-charge to children 6 months-10 years old from April to June, 2011. We evaluated associations between maternal and household demographic variables, socio-economic status, and distance from home to vaccination clinics with family vaccination status.
7249 children from 3735 households were eligible for vaccination. Of these, 2675 (36.9%) were fully vaccinated, 506 (7.0%) were partially vaccinated and 4068 (56.1%) were not vaccinated. Children living in households located >5 km radius from the vaccination facilities were significantly less likely to be vaccinated (aOR = 0.70; 95% CI 0.54-0.91; p = 0.007). Children with mothers aged 25-34 and 35-44 years were more likely to be vaccinated than children with mothers less than 25 years of age (aOR = 1.36; 95% CI 1.15-1.62; p < 0.001; and aOR = 1.35; 95% CI 1.10-1.64; p = 0.003, respectively). Finally, children aged 2-5 years and >5 years of age (aOR = 138; 95% CI 1.20-1.59; p < 0.001; and aOR = 1.41; 95% CI 1.23-1.63; p < 0.001, respectively) and who had a sibling hospitalized within the past year (aOR = 1.73; 95% CI 1.40-2.14; p < 0.001) were more likely to be vaccinated.
Shorter distance from the vaccination center, older maternal and child age, household administrator's occupation that did not require them to be away from the home, and having a sibling hospitalized during the past year were associated with increased likelihood of vaccination against influenza in western Kenya. These findings should inform the design of future childhood seasonal influenza vaccination campaigns in rural Kenya, and perhaps elsewhere in Africa. (C) 2014 The Authors. Published by Elsevier Ltd. All rights reserved.
C1 [Otieno, Nancy A.; Nyawanda, Bryan O.; Audi, Allan; Emukule, Gideon; Lebo, Emmaculate; Bigogo, Godfrey; Ochola, Rachel] Ctr Dis Control & Prevent Kenya KEMRI CDC, Kenya Med Res Inst, Kisumu, Kenya.
[Muthoka, Phillip] Minist Publ Hlth & Sanitat, MoPHS, Div Dis Surveillance & Response, Nairobi, Kenya.
[Widdowson, Marc-Alain; Shay, David K.; Katz, Mark A.; Mott, Joshua A.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
[Burton, Deron C.; Breiman, Robert F.] Ctr Dis Control & Prevent, Global Dis Detect Div, Atlanta, GA USA.
RP Otieno, NA (reprint author), KEMRI CDC Program, POB 1578, Kisumu 40100, Kenya.
EM Notieno@kemricdc.org
OI Shay, David/0000-0001-9619-4820
NR 41
TC 3
Z9 3
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 20
PY 2014
VL 32
IS 49
BP 6699
EP 6704
DI 10.1016/j.vaccine.2013.10.089
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AU8BD
UT WOS:000345820800018
PM 24462406
ER
PT J
AU Lewis, RC
Cantonwine, DE
Del Toro, LVA
Calafat, AM
Valentin-Blasini, L
Davis, MD
Baker, SE
Alshawabkeh, AN
Cordero, JF
Meeker, JD
AF Lewis, Ryan C.
Cantonwine, David E.
Del Toro, Liza V. Anzalota
Calafat, Antonia M.
Valentin-Blasini, Liza
Davis, Mark D.
Baker, Samuel E.
Alshawabkeh, Akram N.
Cordero, Jose F.
Meeker, John D.
TI Urinary biomarkers of exposure to insecticides, herbicides, and one
insect repellent among pregnant women in Puerto Rico
SO ENVIRONMENTAL HEALTH
LA English
DT Article
DE Biomarker; Pesticides; Pregnancy; Urine; Women
ID PYRETHROID PESTICIDE EXPOSURE; SEMEN QUALITY; CHILDRENS EXPOSURE;
METABOLITE LEVELS; HORMONE-LEVELS; CORD BLOOD; ORGANOPHOSPHORUS;
VARIABILITY; MEN; PREDICTORS
AB Background: There are potential adverse health risks to the mother and fetus from exposure to pesticides. Thus, studies of exposure to pesticides among pregnant women are of interest as they will assist with understanding the potential burden of exposure globally, identifying sources of exposure, and designing epidemiology studies.
Methods: We measured urinary concentrations of the insect repellent N-N-diethyl-meta-toluamide (DEET) and two of its metabolites [3-diethyl-carbamoyl benzoic acid (DCBA) and N,N-diethyl-3-hydroxymethylbenzamide (DHMB)], four pyrethroid insecticide metabolites [4-fluoro-3-phenoxybenzoic acid (4-F-3-PBA); 3-phenoxybenzoic acid (3-PBA); trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid (trans-DCCA); and cis-3-(2,2-dibromovinyl)-2,2- dimethylcyclopropane carboxylic acid (cis-DBCA)], and two chlorophenoxy herbicides [2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T)] in 54 pregnant women from Puerto Rico at three separate time points (20 +/- 2 weeks, 24 +/- 2 weeks, and 28 +/- 2 weeks of gestation). We calculated the distributions of the biomarker concentrations and compared them to those of women of reproductive age from the general U.S. population where available, and estimated the within-subject temporal variability of these repeated measurements. We also collected questionnaire data on demographics, consumption of select fruits, vegetables, and legumes in the past 48-hr, and pest-related issues, and associations between these variables and biomarker concentrations were examined.
Results: We found that 95th percentile urinary concentrations of DEET, 3-PBA, trans-DCCA, and 2,4-D were lower than women of reproductive age on the U. S. mainland, whereas 95th percentile urinary concentrations of 4-F-3-PBA, cis-DBCA, and 2,4,5-T were similar. DCBA, the only urinary biomarker detected in >50% of the samples, showed fair to good reproducibility across pregnancy (intraclass correlation coefficient: 0.60). Women were more likely (p <0.05) to have greater urinary concentrations of pesticide biomarkers if they were less educated (DCBA and trans-DCCA), unemployed (DHMB), or married (2,4-D), had consumed collards or spinach in past 48-hr (2,4-D) or had been using insect repellent since becoming pregnant (DCBA), or were involved with residential applications of pesticides (trans-DCCA).
Conclusions: We identified concentrations and predictors of several pesticides among pregnant women in Puerto Rico. Further research is needed to understand what aspects of the predictors identified lead to greater exposure, and whether exposure during pregnancy is associated with adverse health.
C1 [Lewis, Ryan C.; Meeker, John D.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.
[Cantonwine, David E.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA.
[Del Toro, Liza V. Anzalota; Cordero, Jose F.] Univ Puerto Rico, Grad Sch Publ Hlth, San Juan, PR 00935 USA.
[Calafat, Antonia M.; Valentin-Blasini, Liza; Davis, Mark D.; Baker, Samuel E.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA.
[Alshawabkeh, Akram N.] Northeastern Univ, Coll Engn, Boston, MA 02115 USA.
RP Meeker, JD (reprint author), Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, 1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM meekerj@umich.edu
FU National Institute of Environmental Health Sciences, National Institutes
of Health (NIH) [P42ES017198, P30ES017885]; National Institute on
Minority Health and Health Disparities, NIH [G12MD007600, U54MD007587]
FX Work was supported by grants P42ES017198 and P30ES017885 from the
National Institute of Environmental Health Sciences, National Institutes
of Health (NIH), and by grants G12MD007600 and U54MD007587 from the
National Institute on Minority Health and Health Disparities, NIH. The
content is solely the responsibility of the authors and does not
necessarily represent the official position of NIH or CDC. We thank
Amanda Bishop, Pilar Morales-Agudelo, William Roman, Erin Wade and
Charlie Chambers of CDC for their technical support with the urinalysis.
NR 44
TC 6
Z9 6
U1 2
U2 19
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-069X
J9 ENVIRON HEALTH-GLOB
JI Environ. Health
PD NOV 19
PY 2014
VL 13
AR 97
DI 10.1186/1476-069X-13-97
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AU7QW
UT WOS:000345796000002
PM 25409771
ER
PT J
AU Wall, HK
Hannan, JA
Wright, JS
AF Wall, Hilary K.
Hannan, Judy A.
Wright, Janet S.
TI Patients With Undiagnosed Hypertension Hiding in Plain Sight
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID GUIDELINES; MANAGEMENT; SOCIETY
C1 [Wall, Hilary K.; Hannan, Judy A.; Wright, Janet S.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA.
RP Wall, HK (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,MS F72, Atlanta, GA 30341 USA.
EM hwall@cdc.gov
OI Mihailidis, Alex/0000-0003-2233-0919
FU Intramural CDC HHS [CC999999]
NR 10
TC 6
Z9 7
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD NOV 19
PY 2014
VL 312
IS 19
BP 1973
EP 1974
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AU2LT
UT WOS:000345450500008
PM 25399269
ER
PT J
AU Ritchey, MD
Loustalot, F
Bowman, BA
Hong, YL
AF Ritchey, Matthew D.
Loustalot, Fleetwood
Bowman, Barbara A.
Hong, Yuling
TI Trends in Mortality Rates by Subtypes of Heart Disease in the United
States, 2000-2010
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Ritchey, Matthew D.; Loustalot, Fleetwood; Bowman, Barbara A.; Hong, Yuling] US Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA.
RP Ritchey, MD (reprint author), US Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE, Atlanta, GA 30341 USA.
EM hha7@cdc.gov
NR 6
TC 5
Z9 5
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD NOV 19
PY 2014
VL 312
IS 19
BP 2037
EP 2039
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AU2LT
UT WOS:000345450500020
PM 25399281
ER
PT J
AU Ali, MK
Bullard, KM
Gregg, EW
del Rio, C
AF Ali, Mohammed K.
Bullard, Kai McKeever
Gregg, Edward W.
del Rio, Carlos
TI A Cascade of Care for Diabetes in the United States: Visualizing the
Gaps
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID BLOOD-GLUCOSE CONTROL; MULTIFACTORIAL INTERVENTION;
CARDIOVASCULAR-DISEASE; COST-EFFECTIVENESS; RANDOMIZED-TRIALS;
RISK-FACTORS; HIV CARE; TYPE-2; MANAGEMENT; MELLITUS
AB Background: A "cascade-of-care" concept helped to address implementation gaps in HIV care.
Objective: To develop a similar cascade for U.S. diabetes care to visualize gaps in awareness of diagnosis, engagement, and treatment.
Design: Nationally representative cross-sectional surveys.
Setting: 2007 to 2012 NHANES (National Health and Nutrition Examination Surveys).
Participants: Nonpregnant civilians aged 18 years or older.
Measurements: Standardized data collection and laboratory procedures. Diabetes care was benchmarked against recent diabetes and cardiovascular risk reduction guidelines.
Results: In 2012, an estimated 28.4 million (11.8%) U.S. adults had diabetes, of whom 20.5 million (72.2%) were aware of their diagnosis. Among diagnosed adults, 95.3% had a usual care provider and 91.7% made 2 or more visits in the past year. In contrast, among undiagnosed adults, 84.5% had a usual care provider and 66.5% reported 2 or more visits in the past year. Among diagnosed adults, 63.7%, 65.5%, 56.6%, and 80.6% met individualized hemoglobin A(1c), blood pressure (BP <140/80 mmHg), lipid (low-density lipoprotein [LDL] cholesterol <2.6 mmol/L [<100 mg/dL]), and nonsmoking goals, respectively; 26.7% met combined ABC (hemoglobin A1c, BP, and LDL cholesterol) targets, and 21.3% met combined ABC targets and did not smoke. Among undiagnosed adults, 77.0%, 57.9%, 36.0%, and 77.9% met hemoglobin A1c, BP, lipid, and nonsmoking goals, respectively; 22.1% met combined ABC targets; and 18.8% met combined ABC targets and were nonsmokers.
Limitation: Institutionalized and noncivilian persons are not surveyed in NHANES.
Conclusion: Three of 10 adults with diabetes remain undiagnosed, which may be related to less access to care. Compared with diagnosed adults, undiagnosed adults have less elevated hemoglobin A1c levels, less lipid treatment and worse control, and similarly poor BP and combined ABC control regardless of smoking status. Addressing these care gaps in both groups would prevent long-term complications.
C1 Emory Univ, Natl Ctr Chron Dis Prevent & Hlth Promot, Rollins Sch Publ Hlth, Ctr Dis Control & Prevent, Atlanta, GA 30322 USA.
Emory Univ, Sch Med, Atlanta, GA USA.
RP Ali, MK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, 4770 Buford Highway NE, Atlanta, GA 30341 USA.
EM mkali@emory.edu
RI del Rio, Carlos/B-3763-2012
OI del Rio, Carlos/0000-0002-0153-3517
NR 55
TC 18
Z9 19
U1 0
U2 0
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD NOV 18
PY 2014
VL 161
IS 10
BP 681
EP 689
DI 10.7326/M14-0019
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA AX9TT
UT WOS:000347245600025
PM 25402511
ER
PT J
AU Leonard, L
Diop, S
Doumbia, S
Sadou, A
Mihigo, J
Koenker, H
Berthe, S
Monroe, A
Bertram, K
Weber, R
AF Leonard, Lori
Diop, Samba
Doumbia, Seydou
Sadou, Aboubacar
Mihigo, Jules
Koenker, Hannah
Berthe, Sara
Monroe, April
Bertram, Kathryn
Weber, Rachel
TI Net use, care and repair practices following a universal distribution
campaign in Mali
SO MALARIA JOURNAL
LA English
DT Article
DE Mali; Long-lasting insecticide treated nets; Malaria; Net distribution
campaign; Use; Care; Repair; Perceived value of nets
ID INSECTICIDE-TREATED NETS; MOSQUITO NET; BED-NETS; WESTERN KENYA;
INTRAHOUSEHOLD ALLOCATION; PHYSICAL CONDITION; DECISION-MAKING;
OWNERSHIP; SENEGAL; HOUSEHOLDS
AB Background: The Government of Mali and the President's Malaria Initiative conducted a long-lasting, insecticidal net (LLIN) distribution campaign in April 2011 in the Sikasso region of Mali, with the aim of universal coverage, defined as one insecticide-treated net for every two persons. This study examines how households in post-and pre-campaign regions value and care for nets.
Methods: The study was conducted in October 2012 in Sikasso and Kayes in the southeast and western regions of Mali, respectively. The regions were purposively selected to allow for comparison between areas that had already had a mass distribution campaign (Sikasso) and areas that had not yet had a mass distribution campaign (Kayes). Study sites and households were randomly selected. Sleeping space questionnaires and structured interviews with household heads were conducted to obtain information on net use, perceived value of free nets in relation to other malaria prevention activities, and net care and repair practices.
Results: The study included 40 households, split evenly across the two regions. Forty interviews were conducted with household heads and 151 sleeping spaces were inventoried using the sleeping space questionnaire. Nets obtained through the free distribution were reported to be highly valued in comparison to other malaria prevention strategies. Overall, net ownership and use were higher among households in areas that had already experienced a mass distribution. While participants reported using and valuing these nets, care and repair practices varied.
Conclusion: National net use is high in Mali, and comparatively higher in the region covered by the universal distribution campaign than in the region not yet covered. While the Government of Mali and implementing partners have made strides to ensure high net coverage, some gaps remain related to communication messaging of correct and consistent net use throughout the year, and on improving net care and repair behaviour. By focusing on these areas as well as improved access to nets, coverage and use rates should continue to increase, contributing to improvements in malaria control.
C1 [Leonard, Lori] Cornell Univ, Dept Dev Sociol, Ithaca, NY 14853 USA.
[Diop, Samba; Doumbia, Seydou] Int Ctr Excellence Res, Malaria Res & Training Ctr, Bamako, Mali.
[Sadou, Aboubacar; Mihigo, Jules] United States Agcy Int Dev, Bamako, Mali.
[Mihigo, Jules] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Koenker, Hannah; Berthe, Sara; Monroe, April; Bertram, Kathryn; Weber, Rachel] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Commun Programs, Baltimore, MD 21202 USA.
RP Leonard, L (reprint author), Cornell Univ, Dept Dev Sociol, Ithaca, NY 14853 USA.
EM ll536@cornell.edu
FU USAID/PMI [GHS-A-00-09-00014-00]; National Malaria Control Programme
FX This work was supported by USAID/PMI under Cooperative Agreement
#GHS-A-00-09-00014-00. We are grateful to the research team and to the
participants for their time, and to the National Malaria Control
Programme for its support.
NR 36
TC 2
Z9 2
U1 1
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD NOV 18
PY 2014
VL 13
AR 435
DI 10.1186/1475-2875-13-435
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AU6ND
UT WOS:000345718700001
PM 25408158
ER
PT J
AU LeBlanc, TT
Reid, L
Dean, HD
Green, Y
AF LeBlanc, Tanya Telfair
Reid, Laurie
Dean, Hazel D.
Green, Yvonne
TI Introduction: Health Equity Among Incarcerated Female Adolescents and
Adult Women: Infectious and Other Disease Morbidity
SO WOMEN & HEALTH
LA English
DT Editorial Material
C1 [LeBlanc, Tanya Telfair; Reid, Laurie; Dean, Hazel D.; Green, Yvonne] Ctr Dis Control & Prevent, Off Hlth Equ, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
RP LeBlanc, TT (reprint author), Ctr Dis Control & Prevent, Off Hlth Equ, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
NR 26
TC 0
Z9 0
U1 0
U2 1
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0363-0242
EI 1541-0331
J9 WOMEN HEALTH
JI Women Health
PD NOV 17
PY 2014
VL 54
IS 8
SI SI
BP 687
EP 693
DI 10.1080/03630242.2014.962859
PG 7
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA AS7UL
UT WOS:000344460000001
PM 25375857
ER
PT J
AU Fogel, CI
Gelaude, DJ
Carry, M
Herbst, JH
Parker, S
Scheyette, A
Neevel, A
AF Fogel, Catherine I.
Gelaude, Deborah J.
Carry, Monique
Herbst, Jeffrey H.
Parker, Sharon
Scheyette, Anna
Neevel, A.
TI Context of Risk for HIV and Sexually Transmitted Infections Among
Incarcerated Women in the South: Individual, Interpersonal, and Societal
Factors
SO WOMEN & HEALTH
LA English
DT Article
DE HIV/STI prevention; behavioral intervention; women prisoners; sexual
risk; relationship abuse; substance abuse; reentry
ID SOCIAL DETERMINANTS; HEALTH; PREVENTION; HIV/AIDS; US; INTERVENTION;
PREVALENCE; CHLAMYDIA; INMATES
AB Incarcerated women are disproportionately affected by HIV and sexually transmitted infections (STIs) due to risk factors before, during, and after imprisonment. This study assessed the behavioral, social, and contextual conditions that contribute to continuing sexual risk behaviors among incarcerated women to inform the adaptation of an evidenced-based behavioral intervention for this population. Individual, in-depth interviews were conducted with 25 current and 28 former women prisoners to assess HIV/STI knowledge, perceptions of risk, intimate relationships, and life circumstances. Interviews were independently coded using an iterative process and analyzed using established qualitative analytic methods. Major themes identified in the interviews involved three focal points: individual risk (substance abuse, emotional need, self-worth, perceptions of risk, and safer sex practices); interpersonal risk (partner pressure, betrayal, and violence); and risk environment (economic self-sufficiency and preparation for reentry). These findings highlight the critical components of HIV/STI prevention interventions for incarcerated women.
C1 [Fogel, Catherine I.; Parker, Sharon; Scheyette, Anna; Neevel, A.] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27599 USA.
[Gelaude, Deborah J.; Carry, Monique; Herbst, Jeffrey H.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
RP Fogel, CI (reprint author), Univ N Carolina, Sch Nursing, Carrington Hall,CB 7460, Chapel Hill, NC 27599 USA.
EM cfogel@email.unc.edu
FU NCHHSTP CDC HHS [5UR6PS000670-05]; NIAID NIH HHS [P30 AI050410]; NICHD
NIH HHS [K24 HD069204]
NR 36
TC 4
Z9 4
U1 3
U2 13
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0363-0242
EI 1541-0331
J9 WOMEN HEALTH
JI Women Health
PD NOV 17
PY 2014
VL 54
IS 8
SI SI
BP 694
EP 711
DI 10.1080/03630242.2014.932888
PG 18
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA AS7UL
UT WOS:000344460000002
PM 25204565
ER
PT J
AU Satterwhite, CL
Newman, D
Collins, D
Torrone, E
AF Satterwhite, Catherine Lindsey
Newman, Daniel
Collins, Dayne
Torrone, Elizabeth
TI Chlamydia Screening and Positivity in Juvenile Detention Centers, United
States, 2009-2011
SO WOMEN & HEALTH
LA English
DT Article
DE screening; prevention; chlamydia; positivity; juvenile detention centers
ID SEXUALLY-TRANSMITTED-DISEASES; PROGRAMS; PERFORMANCE; WOMEN
AB An estimated 2.9 million new chlamydia infections occur in the United States each year. Among women, chlamydia can lead to serious adverse outcomes, including pelvic inflammatory disease and infertility. Chlamydia prevalence is highest among females aged 15-19 years. Despite long-standing recommendations directed at young, sexually active females, screening remains sub-optimal. Juvenile detention centers (JDCs) are uniquely situated to screen and treat high-risk adolescents. From 2009-2011, performance measure data on chlamydia screening coverage (proportion of eligible females screened) and positivity (proportion of females tested who were positive) were available from 126 geographically-dispersed JDCs in the United States. These facilities reported screening 55.2% of females entering the facilities (149,923), with a facility-specific median of 66.4% (range: 0-100%). Almost half (44.4%) of facilities had screening coverage levels of 75-100%. This screening resulted in the detection of 12,305 chlamydial infections, for an overall positivity of 14.7% (facility-specific median = 14.9%, range: 0-36.9%). In linear regression analysis, chlamydia positivity was inversely associated with screening coverage: as coverage increased, positivity decreased. The burden of chlamydia in JDCs is substantial; facilities should continue to deliver recommended chlamydia screening and treatment to females and identify mechanisms to increase coverage.
C1 [Satterwhite, Catherine Lindsey; Newman, Daniel; Collins, Dayne; Torrone, Elizabeth] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA.
[Satterwhite, Catherine Lindsey] Univ Kansas, Sch Med, Dept Prevent Med & Publ Hlth, Kansas City, KS 66160 USA.
RP Satterwhite, CL (reprint author), Univ Kansas, Sch Med, Dept Prevent Med & Publ Hlth, 3901 Rainbow Blvd,MS 1008, Kansas City, KS 66160 USA.
EM csatterwhite@kumc.edu
NR 21
TC 1
Z9 1
U1 1
U2 4
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0363-0242
EI 1541-0331
J9 WOMEN HEALTH
JI Women Health
PD NOV 17
PY 2014
VL 54
IS 8
SI SI
BP 712
EP 725
DI 10.1080/03630242.2014.932890
PG 14
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA AS7UL
UT WOS:000344460000003
PM 25189136
ER
PT J
AU DiClemente, RJ
Davis, TL
Swartzendruber, A
Fasula, AM
Boyce, L
Gelaude, D
Gray, SC
Hardin, J
Rose, E
Carry, M
Sales, JM
Brown, JL
Staples-Horne, M
AF DiClemente, Ralph J.
Davis, Teaniese L.
Swartzendruber, Andrea
Fasula, Amy M.
Boyce, Lorin
Gelaude, Deborah
Gray, Simone C.
Hardin, James
Rose, Eve
Carry, Monique
Sales, Jessica M.
Brown, Jennifer L.
Staples-Horne, Michelle
TI Efficacy of an HIV/STI Sexual Risk-Reduction Intervention for African
American Adolescent Girls in Juvenile Detention Centers: A Randomized
Controlled Trial
SO WOMEN & HEALTH
LA English
DT Article
DE HIV; adolescents; intervention; African Americans; juvenile detention
ID HIV PREVENTION INTERVENTION; FEMALES; WOMEN; BEHAVIOR; OFFENDERS;
HIV/AIDS; OUTCOMES; STRESS; ADAPT
AB Few HIV/STI interventions exist for African American adolescent girls in juvenile detention. The objective was to evaluate the efficacy of an intervention to reduce incident STIs, improve HIV-preventive behaviors, and enhance psychosocial outcomes. We conducted a randomized controlled trial among African American adolescent girls (13-17 years, N = 188) in juvenile detention from March 2011 to May 2012. Assessments occurred at baseline and 3- and 6-months post-randomization and included: audio computer-assisted self-interview, condom skills assessment, and self-collected vaginal swab to detect Chlamydia and gonorrhea. The Imara intervention included three individual-level sessions and four phone sessions; expedited partner therapy was offered to STI-positive adolescents. The comparison group received the usual care provided by the detention center: STI testing, treatment, and counseling. At the 6-month assessment (3-months post-intervention), Imara participants reported higher condom use self-efficacy (p < 0.001), HIV/STI knowledge (p < 0.001), and condom use skills (p < 0.001) compared to control participants. No significant differences were observed between trial conditions in incident Chlamydia or gonorrhea infections, condom use, or number of vaginal sex partners. Imara for detained African American adolescent girls can improve condom use skills and psychosocial outcomes; however, a critical need for interventions to reduce sexual risk remains.
C1 [DiClemente, Ralph J.; Davis, Teaniese L.; Swartzendruber, Andrea; Boyce, Lorin; Rose, Eve; Sales, Jessica M.; Brown, Jennifer L.; Staples-Horne, Michelle] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA.
[DiClemente, Ralph J.; Davis, Teaniese L.; Swartzendruber, Andrea; Rose, Eve; Sales, Jessica M.; Brown, Jennifer L.] Ctr AIDS Res, Atlanta, GA USA.
[DiClemente, Ralph J.] Emory Univ, Sch Med, Dept Pediat, Div Infect Dis Epidemiol & Immunol, Atlanta, GA 30322 USA.
[Fasula, Amy M.; Gelaude, Deborah; Gray, Simone C.; Carry, Monique] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
[Hardin, James] Univ S Carolina, Dept Epidemiol & Biostat, Arnold Sch Publ Hlth, Columbia, SC 29208 USA.
[Staples-Horne, Michelle] Georgia Dept Juvenile Justice, Atlanta, GA USA.
RP DiClemente, RJ (reprint author), Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd NE,Room 554, Atlanta, GA 30322 USA.
EM rdiclem@sph.emory.edu
RI Hardin, James/Q-7617-2016
OI Hardin, James/0000-0003-0506-5500
FU NCHHSTP CDC HHS [5 UR6 PS000679, UR6 PS000679]; NIAAA NIH HHS [F32
AA022058]; NIDA NIH HHS [P30 DA027827]; NIGMS NIH HHS [K12 GM000680];
NIMH NIH HHS [K01 MH085506]
NR 51
TC 13
Z9 13
U1 0
U2 14
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0363-0242
EI 1541-0331
J9 WOMEN HEALTH
JI Women Health
PD NOV 17
PY 2014
VL 54
IS 8
SI SI
BP 726
EP 749
DI 10.1080/03630242.2014.932893
PG 24
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA AS7UL
UT WOS:000344460000004
PM 25190056
ER
PT J
AU Dyer, JL
Yager, P
Orciari, L
Greenberg, L
Wallace, R
Hanlon, CA
Blanton, JD
AF Dyer, Jessie L.
Yager, Pamela
Orciari, Lillian
Greenberg, Lauren
Wallace, Ryan
Hanlon, Cathleen A.
Blanton, Jesse D.
TI Rabies surveillance in the United States during 2013
SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION
LA English
DT Article
ID PREVENT HUMAN RABIES; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE;
VACCINATION; RECOMMENDATIONS; CHALLENGES; DOGS
AB During 2013, 53 reporting jurisdictions reported 5,865 rabid animals and 3 human rabies cases to the CDC, representing a 4.8% decrease from the 6,162 rabid animals and 1 human case reported in 2012. Ninety-two percent of reported rabid animals were wildlife. Relative contributions by the major animal groups were as follows: 1,898 raccoons (32.4%), 1,598 bats (27.2%), 1,447 skunks (24.7%), 344 foxes (5.9%), 247 cats (4.2%), 86 cattle (1.5%), and 89 dogs (1.5%). One human case was reported from Maryland. The infection was determined to have been transmitted via organ transplantation. Infection in the organ donor, a North Carolina resident, was retrospectively diagnosed. Both the organ donor and the organ recipient were infected with the raccoon rabies virus variant. The third human case, reported by Texas, involved a Guatemalan resident who was detained while crossing the US border. The infection was determined to be caused by a canine rabies virus variant that circulates in Central America.
C1 [Dyer, Jessie L.; Yager, Pamela; Orciari, Lillian; Greenberg, Lauren; Wallace, Ryan; Hanlon, Cathleen A.; Blanton, Jesse D.] CDC, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Blanton, JD (reprint author), CDC, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM asi5@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 23
TC 20
Z9 21
U1 3
U2 23
PU AMER VETERINARY MEDICAL ASSOC
PI SCHAUMBURG
PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA
SN 0003-1488
EI 1943-569X
J9 JAVMA-J AM VET MED A
JI JAVMA-J. Am. Vet. Med. Assoc.
PD NOV 15
PY 2014
VL 245
IS 10
BP 1111
EP 1123
PG 13
WC Veterinary Sciences
SC Veterinary Sciences
GA CA6DN
UT WOS:000348999000021
PM 25356711
ER
PT J
AU Patel, MD
Kalbaugh, CA
Chang, PP
Matsushita, K
Agarwal, SK
Caughey, MC
Ni, HY
Rosamond, WD
Wruck, LM
Loehr, LR
AF Patel, Mehul D.
Kalbaugh, Corey A.
Chang, Patricia P.
Matsushita, Kunihiro
Agarwal, Sunil K.
Caughey, Melissa C.
Ni, Hanyu
Rosamond, Wayne D.
Wruck, Lisa M.
Loehr, Laura R.
TI Characteristics and Outcomes of Patients With Acute Decompensated Heart
Failure Developing After Hospital Admission
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID ASSOCIATION; MORTALITY; RISK; CLASSIFICATION; PRECIPITANTS; GUIDELINES;
PROGRAM
AB There are limited data on acute decompensated heart failure (ADHF) that develops after hospital admission. This study sought to compare patient characteristics, co-morbidities, mortality, and length of stay by timing of ADHF onset. The surveillance component of the Atherosclerosis Risk in Communities study (2005 to 2011) sampled, abstracted, and adjudicated hospitalizations with select International Classification of Disease, Ninth Revision, Clinical Modification discharge codes from 4 United States communities among those aged 55 years. We included 5,602 validated ADHF hospitalizations further classified as preadmission or postadmission onset. Vital status was assessed up to 1 year since admission. We estimated multivariate-adjusted associations of in-hospital mortality and 28- and 365-day case fatalities with timing of ADHF onset (postadmission vs preadmission). All analyses were weighted to account for the stratified sampling design. Of 25,862 weighted ADHF hospitalizations, 7% had postadmission onset of ADHF. Patients with postadmission ADHF were more likely to be older, white, and women. The most common primary discharge diagnosis codes for those with postadmission ADHF included diseases of the circulatory or digestive systems or infectious diseases. Short-term mortality among postadmission ADHF was almost 3 times that of preadmission ADHF (in-hospital mortality: odds ratio 2.7, 95% confidence interval 1.9 to 3.9; 28-day case fatality: odds ratio 2.6, 95% confidence interval 1.8 to 3.7). The average hospital stay was almost twice as long among postadmission as preadmission ADHF (9.6 vs 5.0 days). In conclusion, postadmission onset of ADHF is characterized by differences in co-morbidities and worse shortterm prognosis, and opportunities for reducing postadmission ADHF occurrence and associated risks need to be studied. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Patel, Mehul D.; Kalbaugh, Corey A.; Caughey, Melissa C.; Rosamond, Wayne D.; Loehr, Laura R.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.
[Chang, Patricia P.; Loehr, Laura R.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
[Wruck, Lisa M.] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA.
[Matsushita, Kunihiro; Agarwal, Sunil K.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA.
[Agarwal, Sunil K.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
[Ni, Hanyu] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
RP Patel, MD (reprint author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.
EM mehul.patel@unc.edu
FU National Heart, Lung, and Blood Institute [HHSN268201100005C,
HHSN268201100006C, HHSN268201100007C, HH5N268201100008C,
HH5N268201100009C, HH5N268201100010C, HHSN268201100011C,
HHSN268201100012C, T32HL7055, R00HL098458]
FX The Atherosclerosis Risk in Communities Study is carried out as a
collaborative study supported by National Heart, Lung, and Blood
Institute contracts (HHSN268201100005C, HHSN268201100006C,
HHSN268201100007C, HH5N268201100008C, HH5N268201100009C,
HH5N268201100010C, HHSN268201100011C, and HHSN268201100012C). At the
time this study was conducted, Dr. Patel and Mr. Kalbaugh were supported
by the National Heart, Lung, and Blood Institute training grant
T32HL7055, and Ms. Caughey was supported by National Heart, Lung, and
Blood Institute grant R00HL098458.
NR 13
TC 2
Z9 3
U1 2
U2 6
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD NOV 15
PY 2014
VL 114
IS 10
BP 1530
EP 1536
DI 10.1016/j.amjcard.2014.08.014
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AT3LY
UT WOS:000344837500011
PM 25248811
ER
PT J
AU Spitz, MR
Lam, TK
Schully, SD
Khoury, MJ
AF Spitz, Margaret R.
Lam, Tram Kim
Schully, Sheri D.
Khoury, Muin J.
TI The Next Generation of Large-Scale Epidemiologic Research: Implications
for Training Cancer Epidemiologists
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Editorial Material
DE cancer epidemiologists; education; large-scale epidemiologic research
ID POPULATION HEALTH; PUBLIC-HEALTH; TEAM SCIENCE; COLLABORATION; FUTURE
AB There is expanding consensus on the need to modernize the training of cancer epidemiologists to accommodate rapidly emerging technological advancements and the digital age, which are transforming the practice of cancer epidemiology. There is also a growing imperative to extend cancer epidemiology research that is etiological to that which is applied and has the potential to affect individual and public health. Medical schools and schools of public health are recognizing the need to develop such integrated programs; however, we lack the data to estimate how many current training programs are effectively equipping epidemiology students with the knowledge and tools to design, conduct, and analyze these increasingly complex studies. There is also a need to develop new mentoring approaches to account for the transdisciplinary team-science environment that now prevails. With increased dialogue among schools of public health, medical schools, and cancer centers, revised competencies and training programs at predoctoral, doctoral, and postdoctoral levels must be developed. Continuous collection of data on the impact and outcomes of such programs is also recommended.
C1 [Spitz, Margaret R.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
[Lam, Tram Kim; Schully, Sheri D.] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA.
RP Spitz, MR (reprint author), Baylor Coll Med, Dan L Duncan Canc Ctr, One Baylor Plaza, Houston, TX 77030 USA.
EM spitz@bcm.edu
NR 19
TC 5
Z9 5
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD NOV 15
PY 2014
VL 180
IS 10
BP 964
EP 967
DI 10.1093/aje/kwu256
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT2OK
UT WOS:000344773900002
PM 25234430
ER
PT J
AU Pelat, C
Ferguson, NM
White, PJ
Reed, C
Finelli, L
Cauchemez, S
Fraser, C
AF Pelat, Camille
Ferguson, Neil M.
White, Peter J.
Reed, Carrie
Finelli, Lyn
Cauchemez, Simon
Fraser, Christophe
TI Optimizing the Precision of Case Fatality Ratio Estimates Under the
Surveillance Pyramid Approach
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE case fatality ratio; emerging infectious diseases; influenza; pandemics;
statistical planning; surveillance protocol
ID SENTINEL SURVEILLANCE; INFECTIOUS-DISEASE; 2009 INFLUENZA; SEVERITY;
ENGLAND; STRATEGIES
AB In the management of emerging infectious disease epidemics, precise and accurate estimation of severity indices, such as the probability of death after developing symptoms-the symptomatic case fatality ratio (sCFR)-is essential. Estimation of the sCFR may require merging data gathered through different surveillance systems and surveys. Since different surveillance strategies provide different levels of precision and accuracy, there is need for a theory to help investigators select the strategy that maximizes these properties. Here, we study the precision of sCFR estimators that combine data from several levels of the severity pyramid. We derive a formula for the standard error, which helps us find the estimator with the best precision given fixed resources. We further propose rules of thumb for guiding the choice of strategy: For example, should surveillance of a particular severity level be started? Which level should be preferred? We derive a formula for the optimal allocation of resources between chosen surveillance levels and provide a simple approximation that can be used in thinking more heuristically about planning surveillance. We illustrate these concepts with numerical examples corresponding to 3 influenza pandemic scenarios. Finally, we review the equally important issue of accuracy.
C1 [Pelat, Camille; Ferguson, Neil M.; White, Peter J.; Cauchemez, Simon; Fraser, Christophe] Univ London Imperial Coll Sci Technol & Med, MRC Ctr Outbreak Anal & Modelling, London, England.
[Pelat, Camille; Ferguson, Neil M.; White, Peter J.; Cauchemez, Simon; Fraser, Christophe] Univ London Imperial Coll Sci Technol & Med, Natl Inst Hlth Res, Hlth Protect Res Unit Modelling Methodol, Dept Infect Dis Epidemiol,Sch Publ Hlth, London, England.
[White, Peter J.] Publ Hlth England, Modelling & Econ Unit, London, England.
[Reed, Carrie; Finelli, Lyn] US Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Cauchemez, Simon] Inst Pasteur, Math Modelling Infect Dis Unit, Paris, France.
RP Pelat, C (reprint author), Inst Veille Sanit, Dept Malad Infect, 12 Rue Val dOsne, F-94415 St Maurice, France.
EM c.pelat@invs.sante.fr
RI Fraser, Christophe/A-8109-2008; Ferguson, Neil/B-8578-2008
OI Fraser, Christophe/0000-0003-2399-9657; Ferguson,
Neil/0000-0002-1154-8093
FU methodology research program of the Medical Research Council [G0800596];
European Commission Seventh Framework Programme project EMPERIE
(European Management Platform for Emerging and Re-emerging Infectious
Disease Entities) [223 498]; European Commission Seventh Framework
Programme project PREDEMICS (Preparedness, Prediction and Prevention of
Emerging Zoonotic Viruses with Pandemic Potential using
Multidisciplinary Approaches) [278433]; Models of Infectious Disease
Agent Study (MIDAS) network of the US National Institute of General
Medical Sciences [5U54GM0884941-05]; United Kingdom National Institute
for Health Research Health Protection Research Unit in Modelling
Methodology at Imperial College London; Public Health England
[HPRU-2012-10080]; Integrative Biology of Emerging Infectious Diseases
Laboratory of Excellence at the Institut Pasteur [ANR-10-LABX-62-IBEID];
Sanofi Pasteur MSD (Lyon, France); Kendle Healthcare (London, United
Kingdom); Elsevier (Reed Elsevier Group plc, Amsterdam, the Netherlands)
FX This work was supported by the methodology research program of the
Medical Research Council (grant G0800596 to C. F. and S. C.); the
European Commission Seventh Framework Programme projects EMPERIE
(European Management Platform for Emerging and Re-emerging Infectious
Disease Entities; grant 223 498 to N.M.F.) and PREDEMICS (Preparedness,
Prediction and Prevention of Emerging Zoonotic Viruses with Pandemic
Potential using Multidisciplinary Approaches; grant 278433 to S. C.);
the Models of Infectious Disease Agent Study (MIDAS) network of the US
National Institute of General Medical Sciences (grant 5U54GM0884941-05
to N.M.F. and S. C.); the United Kingdom National Institute for Health
Research Health Protection Research Unit in Modelling Methodology at
Imperial College London, in partnership with Public Health England
(grant HPRU-2012-10080 to N.M.F., C. F., and P.J.W.); and the
Integrative Biology of Emerging Infectious Diseases Laboratory of
Excellence at the Institut Pasteur (grant ANR-10-LABX-62-IBEID to
S.C.).; S.C. received consulting fees from Sanofi Pasteur MSD (Lyon,
France) for a project on the modeling of varicella zoster virus. P.J.W.
has received funds from Kendle Healthcare (London, United Kingdom) for
providing an expert opinion on influenza and received funding from
Elsevier (Reed Elsevier Group plc, Amsterdam, the Netherlands) in 2010
to attend an influenza-related meeting. All other authors have declared
no competing interests.
NR 32
TC 2
Z9 2
U1 1
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD NOV 15
PY 2014
VL 180
IS 10
BP 1036
EP 1046
DI 10.1093/aje/kwu213
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT2OK
UT WOS:000344773900010
PM 25255809
ER
PT J
AU McLean, HQ
Thompson, MG
Sundaram, ME
Meece, JK
McClure, DL
Friedrich, TC
Belongia, EA
AF McLean, Huong Q.
Thompson, Mark G.
Sundaram, Maria E.
Meece, Jennifer K.
McClure, David L.
Friedrich, Thomas C.
Belongia, Edward A.
TI Impact of Repeated Vaccination on Vaccine Effectiveness Against
Influenza A(H3N2) and B During 8 Seasons
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE influenza; vaccine effectiveness
ID IMMUNIZATION PRACTICES ACIP; TEST-NEGATIVE DESIGN; ADVISORY-COMMITTEE;
ANTIBODY-RESPONSE; VIRUS VACCINE; UNITED-STATES; EFFICACY; PROTECTION;
STRAINS; RECOMMENDATIONS
AB Background. Recent studies suggest that influenza vaccination in the previous season may influence the effectiveness of current-season vaccination, but this has not been assessed in a single population over multiple years.
Methods. Patients presenting with acute respiratory illness were prospectively enrolled during the 2004-2005 through 2012-2013 influenza seasons. Respiratory swabs were tested for influenza and vaccination dates obtained from a validated registry. Vaccination status was determined for the current, previous, and prior 5 seasons. Vaccine effectiveness (VE) was calculated for participants aged >= 9 years using logistic regression models with an interaction term for vaccination history.
Results. There were 7315 enrollments during 8 seasons; 1056 (14%) and 650 (9%) were positive for influenza A (H3N2) and B, respectively. Vaccination during current only, previous only, or both seasons yielded similar protection against H3N2 (adjusted VE range, 31%-36%) and B (52%-66%). In the analysis using 5 years of historical vaccination data, current season VE against H3N2 was significantly higher among vaccinated individuals with no prior vaccination history (65%; 95% confidence interval [CI], 36%-80%) compared with vaccinated individuals with a frequent vaccination history (24%; 95% CI, 3%-41%; P = .01). VE against B was 75% (95% CI, 50%-87%) and 48% (95% CI, 29%-62%), respectively (P = .05). Similar findings were observed when analysis was restricted to adults 18-49 years.
Conclusions. Current-and previous-season vaccination generated similar levels of protection, and vaccine-induced protection was greatest for individuals not vaccinated during the prior 5 years. Additional studies are needed to understand the long-term effects of annual vaccination.
C1 [McLean, Huong Q.; Sundaram, Maria E.; McClure, David L.; Belongia, Edward A.] Marshfield Clin Res Fdn, Ctr Clin Epidemiol & Populat Hlth, Marshfield, WI USA.
[Thompson, Mark G.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
[Meece, Jennifer K.] Marshfield Clin Res Fdn, Integrated Res & Dev Lab, Marshfield, WI USA.
[Friedrich, Thomas C.] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA.
[Friedrich, Thomas C.] Wisconsin Natl Primate Res Ctr, Madison, WI USA.
RP McLean, HQ (reprint author), Marshfield Clin Res Fdn ML2, 1000 N Oak Ave, Marshfield, WI 54449 USA.
EM mclean.huong@marshfieldclinic.org
OI Friedrich, Thomas/0000-0001-9831-6895
FU Centers for Disease Control and Prevention [U01 IP000471]
FX This work was supported by the Centers for Disease Control and
Prevention through a cooperative agreement (U01 IP000471).
NR 38
TC 44
Z9 44
U1 1
U2 18
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 15
PY 2014
VL 59
IS 10
BP 1375
EP 1385
DI 10.1093/cid/ciu680
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0TC
UT WOS:000344646700006
PM 25270645
ER
PT J
AU Esposito, DH
Stich, A
Epelboin, L
Malvy, D
Han, PV
Bottieau, E
da Silva, A
Zanger, P
Slesak, G
van Genderen, PJJ
Rosenthal, BM
Cramer, JP
Visser, LG
Munoz, J
Drew, CP
Goldsmith, CS
Steiner, F
Wagner, N
Grobusch, MP
Plier, DA
Tappe, D
Sotir, MJ
Brown, C
Brunette, GW
Fayer, R
von Sonnenburg, F
Neumayr, A
Kozarsky, PE
AF Esposito, Douglas H.
Stich, August
Epelboin, Loic
Malvy, Denis
Han, Pauline V.
Bottieau, Emmanuel
da Silva, Alexandre
Zanger, Philipp
Slesak, Guenther
van Genderen, Perry J. J.
Rosenthal, Benjamin M.
Cramer, Jakob P.
Visser, Leo G.
Munoz, Jose
Drew, Clifton P.
Goldsmith, Cynthia S.
Steiner, Florian
Wagner, Noemie
Grobusch, Martin P.
Plier, D. Adam
Tappe, Dennis
Sotir, Mark J.
Brown, Clive
Brunette, Gary W.
Fayer, Ronald
von Sonnenburg, Frank
Neumayr, Andreas
Kozarsky, Phyllis E.
CA Tioman Island Sarcocystosis Invest
TI Acute Muscular Sarcocystosis: An International Investigation Among Ill
Travelers Returning From Tioman Island, Malaysia, 2011-2012
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE infectious disease outbreak; sarcocystosis; parasitic disease; Malaysia;
travel
ID SKELETAL-MUSCLE; PENINSULAR MALAYSIA; MACACA-FASCICULARIS; PULAU TIOMAN;
INFECTION; NESBITTI; OUTBREAK; SPP.; SNAKES; MONKEY
AB Background. Through 2 international traveler-focused surveillance networks (GeoSentinel and TropNet), we identified and investigated a large outbreak of acute muscular sarcocystosis (AMS), a rarely reported zoonosis caused by a protozoan parasite of the genus Sarcocystis, associated with travel to Tioman Island, Malaysia, during 2011-2012.
Methods. Clinicians reporting patients with suspected AMS to GeoSentinel submitted demographic, clinical, itinerary, and exposure data. We defined a probable case as travel to Tioman Island after 1 March 2011, eosinophilia (>5%), clinical or laboratory-supported myositis, and negative trichinellosis serology. Case confirmation required histologic observation of sarcocysts or isolation of Sarcocystis species DNA from muscle biopsy.
Results. Sixty-eight patients met the case definition (62 probable and 6 confirmed). All but 2 resided in Europe; all were tourists and traveled mostly during the summer months. The most frequent symptoms reported were myalgia (100%), fatigue (91%), fever (82%), headache (59%), and arthralgia (29%); onset clustered during 2 distinct periods: "early" during the second and "late" during the sixth week after departure from the island. Blood eosinophilia and elevated serum creatinine phosphokinase (CPK) levels were observed beginning during the fifth week after departure. Sarcocystis nesbitti DNA was recovered from 1 muscle biopsy.
Conclusions. Clinicians evaluating travelers returning ill from Malaysia with myalgia, with or without fever, should consider AMS, noting the apparent biphasic aspect of the disease, the later onset of elevated CPK and eosinophilia, and the possibility for relapses. The exact source of infection among travelers to Tioman Island remains unclear but needs to be determined to prevent future illnesses.
C1 [Esposito, Douglas H.; Han, Pauline V.; Sotir, Mark J.; Brown, Clive; Brunette, Gary W.; Kozarsky, Phyllis E.] Ctr Dis Control & Prevent CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
[Stich, August] Med Mission Hosp, Dept Trop Med, Wurzburg, Germany.
[Epelboin, Loic] Grp Hosp Pitie Salpetriere, AP HP, Infect & Trop Dis Dept, Paris, France.
[Epelboin, Loic] Univ Paris 06, Paris, France.
[Malvy, Denis] Univ Hosp Ctr, Div Trop Med & Clin Int Hlth, Bordeaux, France.
[Bottieau, Emmanuel] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.
[da Silva, Alexandre] CDC, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA.
[Zanger, Philipp] Univ Tubingen, Inst Trop Med, Tubingen, Germany.
[Slesak, Guenther] Tropenklin Paul Lechler Krankenhaus, Tubingen, Germany.
[van Genderen, Perry J. J.] Harbor Hosp, Inst Trop Med, Rotterdam, Netherlands.
[Rosenthal, Benjamin M.; Fayer, Ronald] USDA, Beltsville Agr Res Ctr, Annapolis, MD USA.
[Cramer, Jakob P.] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med, Sect Trop Med 1, Hamburg, Germany.
[Cramer, Jakob P.; Tappe, Dennis] Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany.
[Visser, Leo G.] Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RA Leiden, Netherlands.
[Munoz, Jose] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res, E-08007 Barcelona, Spain.
[Drew, Clifton P.; Goldsmith, Cynthia S.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
[Steiner, Florian] Charite Univ Med Berlin, Inst Trop Med & Int Hlth, Berlin, Germany.
[Wagner, Noemie] Univ Hosp Geneva, Childrens Hosp, Dept Pediat, Geneva, Switzerland.
[Grobusch, Martin P.] Univ Amsterdam, Acad Med Ctr, Dept Infect Dis, Ctr Trop Med & Travel Med, NL-1012 WX Amsterdam, Netherlands.
[Plier, D. Adam] Univ Alabama Birmingham, Div Infect Dis, Gorgas Ctr Geog Med, Birmingham, AL USA.
[von Sonnenburg, Frank] Univ Munich, Dept Infect Dis & Trop Med, D-81377 Munich, Germany.
[Neumayr, Andreas] TropNet & Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
[Neumayr, Andreas] Univ Basel, CH-4003 Basel, Switzerland.
[Kozarsky, Phyllis E.] Emory Univ, Div Infect Dis, Dept Med, Atlanta, GA 30322 USA.
RP Esposito, DH (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Travelers Hlth Branch, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE,MS E-03, Atlanta, GA 30333 USA.
EM hgj4@cdc.gov
RI Zanger, Philipp/B-8033-2010;
OI Visser, Leo/0000-0002-3600-9782; Rosenthal, Benjamin/0000-0002-0224-3773
FU CDC
FX This work was supported by the CDC.
NR 31
TC 16
Z9 17
U1 0
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 15
PY 2014
VL 59
IS 10
BP 1401
EP 1410
DI 10.1093/cid/ciu622
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0TC
UT WOS:000344646700009
PM 25091309
ER
PT J
AU Suryaprasad, AG
White, JZ
Xu, FJ
Eichler, BA
Hamilton, J
Patel, A
Hamdounia, SB
Church, DR
Barton, K
Fisher, C
Macomber, K
Stanley, M
Guilfoyle, SM
Sweet, K
Liu, S
Iqbal, K
Tohme, R
Sharapov, U
Kupronis, BA
Ward, JW
Holmberg, SD
AF Suryaprasad, Anil G.
White, Jianglan Z.
Xu, Fujie
Eichler, Beth-Ann
Hamilton, Janet
Patel, Ami
Hamdounia, Shadia Bel
Church, Daniel R.
Barton, Kerri
Fisher, Charde
Macomber, Kathryn
Stanley, Marisa
Guilfoyle, Sheila M.
Sweet, Kristin
Liu, Stephen
Iqbal, Kashif
Tohme, Rania
Sharapov, Umid
Kupronis, Benjamin A.
Ward, John W.
Holmberg, Scott D.
TI Emerging Epidemic of Hepatitis C Virus Infections Among Young Nonurban
Persons Who Inject Drugs in the United States, 2006-2012
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE hepatitis C; analgesics; opioid; incidence; young adult
ID HUMAN-IMMUNODEFICIENCY-VIRUS; VITAL SIGNS OVERDOSES; OPIOID PAIN
RELIEVERS; VIRAL-HEPATITIS; RISK-FACTORS; NEW-YORK; USERS; ADULTS;
PREVENTION; SEROCONVERSION
AB Background. Reports of acute hepatitis C in young persons in the United States have increased. We examined data from national surveillance and supplemental case follow-up at selected jurisdictions to describe the US epidemiology of hepatitis C virus (HCV) infection among young persons (aged <= 30 years).
Methods. We examined trends in incidence of acute hepatitis C among young persons reported to the Centers for Disease Control and Prevention (CDC) during 2006-2012 by state, county, and urbanicity. Sociodemographic and behavioral characteristics of HCV-infected young persons newly reported from 2011 to 2012 were analyzed from case interviews and provider follow-up at 6 jurisdictions.
Results. From 2006 to 2012, reported incidence of acute hepatitis C increased significantly in young persons-13% annually in nonurban counties (P = .003) vs 5% annually in urban counties (P = .028). Thirty (88%) of 34 reporting states observed higher incidence in 2012 than 2006, most noticeably in nonurban counties east of the Mississippi River. Of 1202 newly reported HCV-infected young persons, 52% were female and 85% were white. In 635 interviews, 75% of respondents reported injection drug use. Of respondents reporting drug use, 75% had abused prescription opioids, with first use on average 2.0 years before heroin.
Conclusions. These data indicate an emerging US epidemic of HCV infection among young nonurban persons of predominantly white race. Reported incidence was higher in 2012 than 2006 in at least 30 states, with largest increases in nonurban counties east of the Mississippi River. Prescription opioid abuse at an early age was commonly reported and should be a focus for medical and public health intervention.
C1 [Suryaprasad, Anil G.; White, Jianglan Z.; Xu, Fujie; Liu, Stephen; Iqbal, Kashif; Tohme, Rania; Sharapov, Umid; Kupronis, Benjamin A.; Ward, John W.; Holmberg, Scott D.] Ctr Dis Control & Prevent CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA.
[Eichler, Beth-Ann; Hamilton, Janet] Florida Dept Hlth, Bur Epidemiol, Tallahassee, FL USA.
[Patel, Ami; Hamdounia, Shadia Bel] Philadelphia Dept Hlth, Philadelphia, PA USA.
[Patel, Ami] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.
[Church, Daniel R.; Barton, Kerri] Massachusetts Dept Publ Hlth, Jamaica Plain, MA USA.
[Fisher, Charde; Macomber, Kathryn] Michigan Dept Community Hlth, Lansing, MI USA.
[Stanley, Marisa; Guilfoyle, Sheila M.] Wisconsin Div Publ Hlth, Madison, WI USA.
[Sweet, Kristin] Minnesota Dept Hlth, St Paul, MN USA.
RP Suryaprasad, AG (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,Mailstop G-37, Atlanta, GA 30329 USA.
EM asuryaprasad@cdc.gov
FU Centers for Disease Control and Prevention
FX This work was supported by the Centers for Disease Control and
Prevention.
NR 39
TC 66
Z9 66
U1 3
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 15
PY 2014
VL 59
IS 10
BP 1411
EP 1419
DI 10.1093/cid/ciu643
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0TC
UT WOS:000344646700010
PM 25114031
ER
PT J
AU Wolter, N
Tempia, S
Cohen, C
Madhi, SA
Venter, M
Moyes, J
Walaza, S
Malope-Kgokong, B
Groome, M
du Plessis, M
Magomani, V
Pretorius, M
Hellferscee, O
Dawood, H
Kahn, K
Variava, E
Klugman, KP
von Gottberg, A
AF Wolter, Nicole
Tempia, Stefano
Cohen, Cheryl
Madhi, Shabir A.
Venter, Marietjie
Moyes, Jocelyn
Walaza, Sibongile
Malope-Kgokong, Babatyi
Groome, Michelle
du Plessis, Mignon
Magomani, Victoria
Pretorius, Marthi
Hellferscee, Orienka
Dawood, Halima
Kahn, Kathleen
Variava, Ebrahim
Klugman, Keith P.
von Gottberg, Anne
TI High Nasopharyngeal Pneumococcal Density, Increased by Viral
Coinfection, Is Associated With Invasive Pneumococcal Pneumonia
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE pneumococcus; colonization; bacterial loads; invasive pneumococcal
disease; respiratory virus
ID COMMUNITY-ACQUIRED PNEUMONIA; RESPIRATORY-TRACT INFECTION;
STREPTOCOCCUS-PNEUMONIAE; INFLUENZA-VIRUS; CONJUGATE VACCINE;
SOUTH-AFRICA; CHILDREN; CARRIAGE; DISEASE; HIV
AB Background. We identified factors associated with pneumococcal colonization, high colonization density, and invasive pneumococcal pneumonia among patients hospitalized with acute lower respiratory tract infections (ALRTIs).
Methods. In 2010, 4025 cases were enrolled in surveillance in South Africa. A total of 969 of 4025 systematically selected nasopharyngeal-oropharyngeal specimens (24%) were tested for respiratory viruses and Streptococcus pneumoniae by real-time polymerase chain reaction. Of these, 749 (77%) had blood tested for S. pneumoniae.
Results. Pneumococcal colonization was detected in 55% of cases (534 of 969). On multivariable analysis that controlled for age and tuberculosis treatment, infection with influenza virus (adjusted odds ratio [OR], 2.2; 95% confidence interval [CI], 1.1-4.5), adenovirus (adjusted OR, 1.7; 95% CI, 1.1-2.7), rhinovirus (adjusted OR, 1.6; 95% CI, 1.1-2.3), and human immunodeficiency virus (HIV; adjusted OR, 1.6; 95% CI, 1.1-2.4) were associated with pneumococcal colonization. High colonization density was associated with respiratory virus coinfection (adjusted OR, 1.7; 95% CI, 1.1-2.6) and invasive pneumococcal pneumonia (adjusted OR, 2.3; 95% CI, 1.3-4.0), after adjustment for age and sex. Seven percent (52 of 749) had pneumococci detected in blood. On multivariable analysis among colonized cases, invasive pneumococcal pneumonia was associated with HIV (adjusted OR, 3.2; 95% CI, 1.4-7.5), influenza virus (adjusted OR, 8.2; 95% CI, 2.7-25.0), high colonization density (adjusted OR, 18.7; 95% CI, 2.3-155.1), and >= 5 days of hospitalization (adjusted OR, 3.7; 95% CI, 1.7-8.2).
Conclusions. Respiratory virus infection was associated with elevated colonization density and, in turn, invasive pneumococcal pneumonia.
C1 [Wolter, Nicole; Tempia, Stefano; Cohen, Cheryl; Madhi, Shabir A.; Venter, Marietjie; Moyes, Jocelyn; Walaza, Sibongile; Malope-Kgokong, Babatyi; du Plessis, Mignon; Magomani, Victoria; Pretorius, Marthi; Hellferscee, Orienka; Klugman, Keith P.; von Gottberg, Anne] Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Natl Hlth Lab Serv, ZA-2131 Johannesburg, Gauteng, South Africa.
[Wolter, Nicole; Cohen, Cheryl; du Plessis, Mignon; von Gottberg, Anne] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa.
[Wolter, Nicole; Madhi, Shabir A.; du Plessis, Mignon; Magomani, Victoria; von Gottberg, Anne] Univ Witwatersrand, Resp & Meningeal Pathogens Res Unit, MRC, Johannesburg, South Africa.
[Madhi, Shabir A.; Groome, Michelle] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa.
[Kahn, Kathleen] Univ Witwatersrand, MRC, Wits Rural Publ Hlth & Hlth Transit Res Unit, Fac Hlth Sci,Res Unit Agincourt, Johannesburg, South Africa.
[Venter, Marietjie] Univ Pretoria, Dept Med Virol, Zoonoses Res Unit, ZA-0002 Pretoria, South Africa.
[Dawood, Halima] Pietermaritzburg Metropolitan Hosp, Kwa Zulu, South Africa.
[Dawood, Halima] Univ KwaZulu Natal, Kwa Zulu, South Africa.
[Variava, Ebrahim] Klerksdorp Tshepong Hosp, Klerksdorp, South Africa.
[Tempia, Stefano] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
[Klugman, Keith P.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
[Klugman, Keith P.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA.
[Kahn, Kathleen] Umea Univ, Ctr Global Hlth Res, S-90187 Umea, Sweden.
[Kahn, Kathleen] INDEPTH Network, Accra, Ghana.
RP Wolter, N (reprint author), Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Private Bag X4, ZA-2131 Johannesburg, Gauteng, South Africa.
EM nicolew@nicd.ac.za
RI Venter, Marietjie/P-9604-2016
OI Venter, Marietjie/0000-0003-2696-824X
FU Pfizer South Africa [WS1167521]; Centers for Disease Control and
Prevention [5U51IP000155]; Robert Austrian Research Award in
Pneumococcal Vaccinology
FX This work was supported by Pfizer South Africa (investigator-initiated
research agreement number, WS1167521), the Centers for Disease Control
and Prevention (cooperative agreement, 5U51IP000155), and the 2010
Robert Austrian Research Award in Pneumococcal Vaccinology.
NR 49
TC 23
Z9 24
U1 4
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 15
PY 2014
VL 210
IS 10
BP 1649
EP 1657
DI 10.1093/infdis/jiu326
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0EY
UT WOS:000344611200019
PM 24907383
ER
PT J
AU Rasanen, RM
Dwivedi, P
Fernandez, FM
Kauppila, TJ
AF Rasanen, Riikka-Marjaana
Dwivedi, Prabha
Fernandez, Facundo M.
Kauppila, Tiina J.
TI Desorption atmospheric pressure photoionization and direct analysis in
real time coupled with travelling wave ion mobility mass spectrometry
SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
LA English
DT Article
ID ELECTROSPRAY-IONIZATION; AMBIENT CONDITIONS; SMALL MOLECULES; DAPPI-MS;
OPEN-AIR; DESI-MS; MECHANISMS; DRUGS; FORMULATIONS; EVAPORATION
AB RATIONALE: Ambient mass spectrometry (MS) is a tool for screening analytes directly from sample surfaces. However, background impurities may complicate the spectra and therefore fast separation techniques are needed. Here, we demonstrate the use of travelling wave ion mobility spectrometry in a comparative study of two ambient MS techniques.
METHODSDesorption atmospheric pressure photoionization (DAPPI) and direct analysis in real time (DART) were coupled with travelling wave ion mobility mass spectrometry (TWIM-MS) for highly selective surface analysis. The ionization efficiencies of DAPPI and DART were compared. Test compounds were: bisphenol A, benzo[a]pyrene, ranitidine, cortisol and -tocopherol. DAPPI-MS and DART-TWIM-MS were also applied to the analysis of chloroquine from dried blood spots, and -tocopherol from almond surface, and DAPPI-TWIM-MS was applied to analysis of pharmaceuticals and multivitamin tablets.
RESULTSDAPPI was approximately 100 times more sensitive than DART for bisphenol A and 10-20 times more sensitive for the other compounds. The limits of detection were between 30-290 and 330-8200 fmol for DAPPI and DART, respectively. Also, from the authentic samples, DAPPI ionized chloroquine and -tocopherol more efficiently than DART. The mobility separation enabled the detection of species with low signal intensities, e.g. thiamine and cholecalciferol, in the DAPPI-TWIM-MS analysis of multivitamin tablets.
CONCLUSIONSDAPPI ionized the studied compounds of interest more efficiently than DART. For both DAPPI and DART, the mobility separation prior to MS analysis reduced the amount of chemical noise in the mass spectrum and significantly increased the signal-to-noise ratio for the analytes. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Rasanen, Riikka-Marjaana; Kauppila, Tiina J.] Univ Helsinki, Div Pharmaceut Chem & Technol, Fac Pharm, FIN-00014 Helsinki, Finland.
[Rasanen, Riikka-Marjaana; Dwivedi, Prabha; Fernandez, Facundo M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA.
[Dwivedi, Prabha; Fernandez, Facundo M.] Georgia Inst Technol, Ctr Chem Evolut, Atlanta, GA 30332 USA.
[Dwivedi, Prabha] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA.
RP Fernandez, FM (reprint author), Georgia Inst Technol, Sch Chem & Biochem, 901 Atlantic Dr NW, Atlanta, GA 30332 USA.
EM facundo.fernandez@chemistry.gatech.edu; tiina.kauppila@helsinki.fi
OI Kauppila, Tiina/0000-0002-3796-5573
FU Academy of Finland [125758, 218150, 255559]; CHEMSEM Graduate School;
NSF; NASA Astrobiology Program under the NSF Center for Chemical
Evolution [CHE-1004570]; Photonis USA
FX The Academy of Finland (Projects 125758, 218150 and 255559) and CHEMSEM
Graduate School are acknowledged for financial support. Markus Haapala
is thanked for manufacturing the microchip heated nebulizers and Joel
Keelor (JK) for assistance in the laboratory. Paul Newton and David
Jenkins (University of Oxford, Oxford, UK and FHI 360 USA) are
acknowledged for providing the genuine and fake levonorgestrel tablets.
Michael D. Green (Center for Disease Control and Prevention (CDC),
Atlanta, GA, USA) is acknowledged for providing the dried chloroquine
spiked blood samples. FMF, JK and PD acknowledge support from the NSF
and NASA Astrobiology Program under the NSF Center for Chemical
Evolution (CHE-1004570). PD acknowledges partial financial support from
a research contract with Photonis USA.
NR 38
TC 9
Z9 9
U1 1
U2 43
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-4198
EI 1097-0231
J9 RAPID COMMUN MASS SP
JI Rapid Commun. Mass Spectrom.
PD NOV 15
PY 2014
VL 28
IS 21
BP 2325
EP 2336
DI 10.1002/rcm.7028
PG 12
WC Biochemical Research Methods; Chemistry, Analytical; Spectroscopy
SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy
GA AQ6DM
UT WOS:000342898700011
PM 25279746
ER
PT J
AU Arrazola, RA
Neff, LJ
Kennedy, SM
Holder-Hayes, E
Jones, CD
AF Arrazola, Rene A.
Neff, Linda J.
Kennedy, Sara M.
Holder-Hayes, Enver
Jones, Christopher D.
TI Tobacco Use Among Middle and High School Students - United States, 2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Arrazola, Rene A.; Neff, Linda J.; Jones, Christopher D.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
[Kennedy, Sara M.] RTI Int, Dept Biostat & Epidemiol, Res Triangle Pk, NC USA.
[Holder-Hayes, Enver] US FDA, Ctr Tobacco Prod, Rockville, MD 20857 USA.
RP Arrazola, RA (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM rarrazola@cdc.gov
NR 9
TC 60
Z9 61
U1 0
U2 5
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 14
PY 2014
VL 63
IS 45
BP 1021
EP 1026
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT6DW
UT WOS:000345030400001
PM 25393220
ER
PT J
AU Collier, SA
Gronostaj, MP
MacGurn, AK
Cope, JR
Awsumb, KL
Yoder, JS
Beach, MJ
AF Collier, Sarah A.
Gronostaj, Michael P.
MacGurn, Amanda K.
Cope, Jennifer R.
Awsumb, Kate L.
Yoder, Jonathan S.
Beach, Michael J.
TI Estimated Burden of Keratitis - United States, 2010
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID CONTACT-LENS SOLUTION; MICROBIAL KERATITIS; RISK-FACTORS; OUTBREAK
C1 [Collier, Sarah A.; Gronostaj, Michael P.; MacGurn, Amanda K.; Cope, Jennifer R.; Awsumb, Kate L.; Yoder, Jonathan S.; Beach, Michael J.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Collier, SA (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM scollier@cdc.gov
NR 10
TC 10
Z9 10
U1 1
U2 4
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 14
PY 2014
VL 63
IS 45
BP 1027
EP 1030
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT6DW
UT WOS:000345030400002
PM 25393221
ER
PT J
AU Kew, OM
Cochi, SL
Jafari, HS
Wassilak, SGF
Mast, EE
Diop, OM
Tangermann, RH
Armstrong, GL
AF Kew, Olen M.
Cochi, Stephen L.
Jafari, Hamid S.
Wassilak, Steven G. F.
Mast, Eric E.
Diop, Ousmane M.
Tangermann, Rudolf H.
Armstrong, Gregory L.
TI Possible Eradication of Wild Poliovirus Type 3-Worldwide, 2012
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID WORLDWIDE; PROGRESS
C1 [Kew, Olen M.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp, Atlanta, GA 30333 USA.
[Cochi, Stephen L.; Wassilak, Steven G. F.; Mast, Eric E.; Armstrong, Gregory L.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Jafari, Hamid S.; Diop, Ousmane M.; Tangermann, Rudolf H.] World Hlth Org, Polio Eradicat Dept, Geneva, Switzerland.
RP Cochi, SL (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
EM scochi@cdc.gov
NR 10
TC 24
Z9 24
U1 0
U2 1
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 14
PY 2014
VL 63
IS 45
BP 1031
EP 1033
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT6DW
UT WOS:000345030400003
PM 25393222
ER
PT J
AU Perry, RT
Gacic-Dobo, M
Dabbagh, A
Mulders, MN
Strebel, PM
Okwo-Bele, JM
Rota, PA
Goodson, JL
AF Perry, Robert T.
Gacic-Dobo, Marta
Dabbagh, Alya
Mulders, Mick N.
Strebel, Peter M.
Okwo-Bele, Jean-Marie
Rota, Paul A.
Goodson, James L.
TI Progress Toward Regional Measles Elimination -Worldwide, 2000-2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Perry, Robert T.; Gacic-Dobo, Marta; Dabbagh, Alya; Mulders, Mick N.; Strebel, Peter M.; Okwo-Bele, Jean-Marie] World Hlth Org, Dept Immunizat Vaccines & Biol, Geneva, Switzerland.
[Rota, Paul A.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Goodson, James L.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Goodson, JL (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
EM jgoodson@cdc.gov
NR 9
TC 15
Z9 15
U1 0
U2 6
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 14
PY 2014
VL 63
IS 45
BP 1034
EP 1038
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT6DW
UT WOS:000345030400004
PM 25393223
ER
PT J
AU Lafond, KE
Dalhatu, I
Shinde, V
Ekanem, EE
Ahmed, S
Peebles, P
Kudumu, M
Bynum, M
Salami, K
Okeibunor, J
Schwingl, P
Mounts, A
Nasidi, A
Gross, D
AF Lafond, Kathryn E.
Dalhatu, Ibrahim
Shinde, Vivek
Ekanem, Ekanem E.
Ahmed, Saidu
Peebles, Patrick
Kudumu, Mwenda
Bynum, Milele
Salami, Kabiru
Okeibunor, Joseph
Schwingl, Pamela
Mounts, Anthony
Nasidi, Abdulsalami
Gross, Diane
TI Notifiable disease reporting among public sector physicians in Nigeria:
a cross-sectional survey to evaluate possible barriers and identify best
sources of information
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
DE Nigeria; Health knowledge; Attitudes; Practice; Disease notification;
Influenza A virus; H5N1 subtype
ID SURVEILLANCE; KNOWLEDGE; NOTIFICATION; DOCTORS; AFRICA; STATE
AB Background: Since 2001, Nigeria has collected information on epidemic-prone and other diseases of public health importance through the Integrated Disease Surveillance and Response system (IDSR). Currently 23 diseases are designated as "notifiable" through IDSR, including human infection with avian influenza (AI). Following an outbreak of highly pathogenic avian influenza A(H5N1) in Nigerian poultry populations in 2006 and one laboratory confirmed human infection in 2007, a study was carried out to describe knowledge, perceptions, and practices related to infectious disease reporting through the IDSR system, physicians' preferred sources of heath information, and knowledge of AI infection in humans among public sector physicians in Nigeria.
Methods: During November to December 2008, 245 physicians in six Nigerian cities were surveyed through in-person interviews. Survey components included reporting practices for avian influenza and other notifiable diseases, perceived obstacles to disease reporting, methods for obtaining health-related information, and knowledge of avian influenza among participating physicians.
Results: All 245 respondents reported that they had heard of AI and that humans could become infected with AI. Two-thirds (163/245) had reported a notifiable disease. The most common perceived obstacles to reporting were lack of infrastructure/logistics or reporting system (76/245, 31%), lack of knowledge among doctors about how to report or to whom to report (64/245, 26%), and that doctors should report certain infectious diseases (60/245, 24%). Almost all participating physicians (>99%) reported having a cell phone that they currently use, and 86% reported using the internet at least weekly.
Conclusions: Although the majority of physicians surveyed were knowledgeable of and had reported notifiable diseases, they identified many perceived obstacles to reporting. In order to effectively identify human AI cases and other infectious diseases through IDSR, reporting system requirements need to be clearly communicated to participating physicians, and perceived obstacles, such as lack of infrastructure, need to be addressed. Future improvements to the reporting system should account for increased utilization of the internet, as well as cell phone and email-based communication.
C1 [Lafond, Kathryn E.; Shinde, Vivek; Peebles, Patrick; Mounts, Anthony; Gross, Diane] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA.
[Dalhatu, Ibrahim] Ctr Dis Control & Prevent, Abuja, Nigeria.
[Ekanem, Ekanem E.; Ahmed, Saidu] Fed Minist Hlth, Abuja, Nigeria.
[Kudumu, Mwenda; Bynum, Milele; Salami, Kabiru; Okeibunor, Joseph; Schwingl, Pamela] Social & Sci Syst Inc, Silver Spring, MD USA.
[Mounts, Anthony] WHO, CH-1211 Geneva, Switzerland.
[Nasidi, Abdulsalami] Nigeria Ctr Dis Control, Abuja, Nigeria.
RP Lafond, KE (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA.
EM gmj3@cdc.gov
FU Centers for Disease Control and Prevention (CDC) [200-2004-05313]
FX The authors would like to thank Michael Deming for contributions to the
study design and questionnaire, and Bill Brady, Brenda Esprit, and Bill
Brieger for contributions in the field. This work was supported by
contract #200-2004-05313 from the Centers for Disease Control and
Prevention (CDC).
NR 18
TC 0
Z9 0
U1 1
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD NOV 13
PY 2014
VL 14
AR 568
DI 10.1186/s12913-014-0568-3
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA AZ7UQ
UT WOS:000348423500001
PM 25391377
ER
PT J
AU Cannon, MJ
Stowell, JD
Clark, R
Dollard, PR
Johnson, D
Mask, K
Stover, C
Wu, K
Amin, M
Hendley, W
Guo, J
Schmid, DS
Dollard, SC
AF Cannon, Michael J.
Stowell, Jennifer D.
Clark, Rebekah
Dollard, Philip R.
Johnson, Delaney
Mask, Karen
Stover, Cynthia
Wu, Karen
Amin, Minal
Hendley, Will
Guo, Jing
Schmid, D. Scott
Dollard, Sheila C.
TI Repeated measures study of weekly and daily cytomegalovirus shedding
patterns in saliva and urine of healthy cytomegalovirus-seropositive
children
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Cytomegalovirus; Congenital; Awareness; Behavior; Pregnancy
ID TO-MOTHER TRANSMISSION; RISK-FACTORS; SEXUAL-ACTIVITY; YOUNG-WOMEN;
DAY-CARE; INFECTION; VIRUS; PREVALENCE; PREVENTION; BEHAVIORS
AB Background: To better understand potential transmission risks from contact with the body fluids of children, we monitored the presence and amount of CMV shedding over time in healthy CMV-seropositive children.
Methods: Through screening we identified 36 children from the Atlanta, Georgia area who were CMV-seropositive, including 23 who were shedding CMV at the time of screening. Each child received 12 weekly in-home visits at which field workers collected saliva and urine. During the final two weeks, parents also collected saliva and urine daily.
Results: Prevalence of shedding was highly correlated with initial shedding status: children shedding at the screening visit had CMV DNA in 84% of follow-up saliva specimens (455/543) and 28% of follow-up urine specimens (151/539); those not shedding at the screening visit had CMV DNA in 16% of follow-up saliva specimens (47/303) and 5% of follow-up urine specimens (16/305). Among positive specimens we found median viral loads of 82,900 copies/mL in saliva and 34,730 copies/mL in urine (P = 0.01), while the viral load for the 75th percentile was nearly 1.5 million copies/mL for saliva compared to 86,800 copies/mL for urine. Younger age was significantly associated with higher viral loads, especially for saliva (P < 0.001). Shedding prevalence and viral loads were relatively stable over time. All children who were shedding at the screening visit were still shedding at least some days during weeks 11 and 12, and median and mean viral loads did not change substantially over time.
Conclusions: Healthy CMV-seropositive children can shed CMV for months at high, relatively stable levels. These data suggest that behavioral prevention messages need to address transmission via both saliva and urine, but also need to be informed by the potentially higher risks posed by saliva and by exposures to younger children.
C1 [Cannon, Michael J.; Stowell, Jennifer D.; Stover, Cynthia; Wu, Karen; Guo, Jing] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
[Clark, Rebekah; Dollard, Philip R.; Johnson, Delaney; Mask, Karen] Emory Univ, Atlanta, GA 30322 USA.
[Amin, Minal; Hendley, Will; Schmid, D. Scott; Dollard, Sheila C.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Cannon, MJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mailstop E-86, Atlanta, GA 30333 USA.
EM mrc7@cdc.gov
FU DeKalb Pediatric Center in Decatur, GA, and Children's Medical Group;
Good Samaritan Health Center in Atlanta, GA
FX We would like to thank DeKalb Pediatric Center in Decatur, GA, and
Children's Medical Group and the Good Samaritan Health Center in
Atlanta, GA for support in the recruitment process. We are grateful to
Elizabeth Henderson for assistance with upkeep of the laboratory
database.
NR 32
TC 7
Z9 7
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD NOV 13
PY 2014
VL 14
AR 569
DI 10.1186/s12879-014-0569-1
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA AU6JL
UT WOS:000345709500001
PM 25391640
ER
PT J
AU Kourtis, AP
Ellington, S
Pazol, K
Flowers, L
Haddad, L
Jamieson, DJ
AF Kourtis, Athena P.
Ellington, Sascha
Pazol, Karen
Flowers, Lisa
Haddad, Lisa
Jamieson, Denise J.
TI Complications of cesarean deliveries among HIV-infected women in the
United States
SO AIDS
LA English
DT Article
DE AIDS; cesarean section; HAART; HIV; obstetric labor complications
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; SECTION MORBIDITY;
ANTIRETROVIRAL TREATMENT; PERINATAL TRANSMISSION; VERTICAL TRANSMISSION;
POSTPARTUM MORBIDITY; VAGINAL DELIVERY; POSITIVE WOMEN; PREGNANT-WOMEN
AB Objective: To compare rates of complications associated with cesarean delivery in HIV-infected and HIV-uninfected women in the United States and to investigate trends in such complications across four study cycles spanning the implementation of HAART in the United States (1995-1996, 2000-2001, 2005-2006, 2010-2011).
Design: The Nationwide Inpatient Sample from the Healthcare Cost and Utilization Project is the largest all-payer hospital inpatient care database in the United States; when weighted to account for the complex sampling design, nationally representative estimates are derived. After restricting the study sample to women aged 15-49 years, our study sample consisted of approximately 1 090 000 cesarean delivery hospitalizations annually.
Methods: Complications associated with cesarean deliveries were categorized as infection, hemorrhage, or surgical trauma, based on groups of specific International Classification of Diseases 9th revision codes. Length of hospitalization, hospital charges, and in-hospital deaths were also examined.
Results: The rate of complications significantly decreased during the study periods for HIV-infected and HIV-uninfected women. However, rates of infectious complications and surgical trauma associated with cesarean deliveries remained higher among HIV-infected, compared with HIV-uninfected women in 2010-2011, as did prolonged hospital stay and in-hospital deaths. Length of hospitalization decreased over time for cesarean deliveries of HIV-infected women to a greater extent compared with HIV-uninfected women.
Conclusion: In the United States, rates of cesarean delivery complications decreased from 1995 to 2011. However, rates of infection, surgical trauma, hospital deaths, and prolonged hospitalization are still higher among HIV-infected women. Clinicians should remain alert to this persistently increased risk of cesarean delivery complications among HIV-infected women. (c) 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
C1 [Kourtis, Athena P.; Ellington, Sascha; Pazol, Karen; Flowers, Lisa; Haddad, Lisa; Jamieson, Denise J.] Ctr Dis Control & Prevent, Womens Hlth & Fertil Branch, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
RP Kourtis, AP (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,F74, Atlanta, GA 30341 USA.
EM apk3@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 42
TC 1
Z9 1
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD NOV 13
PY 2014
VL 28
IS 17
BP 2609
EP 2618
DI 10.1097/QAD.0000000000000474
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AT2CQ
UT WOS:000344739300014
PM 25574961
ER
PT J
AU von Gottberg, A
de Gouveia, L
Tempia, S
Quan, V
Meiring, S
von Mollendorf, C
Madhi, SA
Zell, ER
Verani, JR
O'Brien, KL
Whitney, CG
Klugman, KP
Cohen, C
AF von Gottberg, Anne
de Gouveia, Linda
Tempia, Stefano
Quan, Vanessa
Meiring, Susan
von Mollendorf, Claire
Madhi, Shabir A.
Zell, Elizabeth R.
Verani, Jennifer R.
O'Brien, Katherine L.
Whitney, Cynthia G.
Klugman, Keith P.
Cohen, Cheryl
CA GERMS-SA Investigators
TI Effects of Vaccination on Invasive Pneumococcal Disease in South Africa
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID HIV-INFECTED ADULTS; CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE;
CHILDREN; ERA; IMMUNIZATION; EPIDEMIOLOGY; SURVEILLANCE; PREVENTION;
EFFICACY
AB BACKGROUND
In South Africa, a 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2009 with a three-dose schedule for infants at 6, 14, and 36 weeks of age; a 13-valent vaccine (PCV13) replaced PCV7 in 2011. In 2012, it was estimated that 81% of 12-month-old children had received three doses of vaccine. We assessed the effect of vaccination on invasive pneumococcal disease.
METHODS
We conducted national, active, laboratory-based surveillance for invasive pneumococcal disease. We calculated the change in the incidence of the disease from a prevaccine (baseline) period (2005 through 2008) to postvaccine years 2011 and 2012, with a focus on high-risk age groups.
RESULTS
Surveillance identified 35,192 cases of invasive pneumococcal disease. The rates among children younger than 2 years of age declined from 54.8 to 17.0 cases per 100,000 person-years from the baseline period to 2012, including a decline from 32.1 to 3.4 cases per 100,000 person-years in disease caused by PCV7 serotypes (-89%; 95% confidence interval [CI], -92 to -86). Among children not infected with the human immunodeficiency virus (HIV), the estimated incidence of invasive pneumococcal disease caused by PCV7 serotypes decreased by 85% (95% CI, -89 to -79), whereas disease caused by nonvaccine serotypes increased by 33% (95% CI, 15 to 48). Among adults 25 to 44 years of age, the rate of PCV7-serotype disease declined by 57% (95% CI, -63 to -50), from 3.7 to 1.6 cases per 100,000 person-years.
CONCLUSIONS
Rates of invasive pneumococcal disease among children in South Africa fell substantially by 2012. Reductions in the rates of disease caused by PCV7 serotypes among both children and adults most likely reflect the direct and indirect effects of vaccination.
C1 [von Gottberg, Anne; de Gouveia, Linda; Quan, Vanessa; Meiring, Susan; von Mollendorf, Claire; Madhi, Shabir A.; Cohen, Cheryl] Univ Witwatersrand, Ctr Resp Dis & Meningitis, Natl Inst Communicable Dis NICD, Natl Hlth Lab Serv NHLS, Johannesburg, South Africa.
[von Gottberg, Anne; de Gouveia, Linda; Madhi, Shabir A.] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa.
[Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn, Johannesburg, South Africa.
[Tempia, Stefano] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
[Zell, Elizabeth R.; Verani, Jennifer R.; Whitney, Cynthia G.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA.
[Klugman, Keith P.] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
[Klugman, Keith P.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA.
[O'Brien, Katherine L.] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP von Gottberg, A (reprint author), Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Private Bag X4, ZA-2131 Johannesburg, Gauteng, South Africa.
EM annev@nicd.ac.za
FU National Institute for Communicable Diseases of the National Health
Laboratory Service; President's Emergency Plan for AIDS Relief; U.S.
Agency for International Development's Antimicrobial Resistance
Initiative; Centers for Disease Control and Prevention [U62/CCU022901,
5U2GPS001328, U60/CCU022088]; Pfizer; Global Alliance for Vaccines and
Immunization through the Program for Appropriate Technology in Health;
GlaxoSmithKline; Sanofi Pasteur; Novartis
FX Supported by the National Institute for Communicable Diseases of the
National Health Laboratory Service, the President's Emergency Plan for
AIDS Relief, the U.S. Agency for International Development's
Antimicrobial Resistance Initiative, and the Centers for Disease Control
and Prevention (cooperative agreements U62/CCU022901, 5U2GPS001328, and
U60/CCU022088).; Dr. von Gottberg reports receiving grant support
through her institution from Pfizer; Dr. von Mollendorf, receiving
honoraria for presentations from Pfizer and salary support from the
Global Alliance for Vaccines and Immunization through the Program for
Appropriate Technology in Health; Dr. Madhi, receiving fees from
GlaxoSmithKline and Pfizer for serving on advisory boards, lecture fees
from GlaxoSmithKline, Pfizer, and Sanofi Pasteur, and grant support
through his institution from GlaxoSmithKline, Pfizer, and Novartis; Dr.
O'Brien, receiving grant support from GlaxoSmithKline and Pfizer; and
Dr. Klugman, receiving fees from Pfizer and GlaxoSmithKline for serving
on advisory boards and grant support from Pfizer. No other potential
conflict of interest relevant to this article was reported.
NR 41
TC 69
Z9 70
U1 3
U2 11
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD NOV 13
PY 2014
VL 371
IS 20
BP 1889
EP 1899
DI 10.1056/NEJMoa1401914
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA AT1RB
UT WOS:000344709800006
PM 25386897
ER
PT J
AU Meites, E
Markowitz, LE
Paz-Bailey, G
Oster, AM
AF Meites, Elissa
Markowitz, Lauri E.
Paz-Bailey, Gabriela
Oster, Alexandra M.
CA NHBS Study Grp
TI HPV vaccine coverage among men who have sex with men - National HIV
Behavioral Surveillance System, United States, 2011
SO VACCINE
LA English
DT Article
DE Human papillomavirus (HPV); Men who have sex with men (MSM); Vaccine
uptake
ID HUMAN-PAPILLOMAVIRUS VACCINATION; AGED 13-17 YEARS; RISK; PREVENTION;
INFECTION
AB Men who have sex with men (MSM) are at high risk for disease associated with human papillomavirus (HPV). In late 2011, HPV vaccine was recommended for males through age 21 and MSM through age 26. Using data from the 2011 National HIV Behavioral Surveillance System, we assessed self-reported HPV vaccine uptake among MSM, using multivariate analysis to calculate adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs). Among 3221 MSM aged 18-26,157 (4.9%) reported >= 1 vaccine dose. Uptake was higher among men who visited a healthcare provider (aPR 2.3, CI: 1.2-4.2), disclosed same-sex sexual attraction/behavior to a provider (aPR 2.1, CI: 1.3-3.3), reported a positive HIV test (aPR 2.2, CI: 1.5-3.2), or received hepatitis vaccine (aPR 3.9, CI: 2.4-6.4). Of 3064 unvaccinated MSM, 2326(75.9%) had visited a healthcare provider within 1 year. These national data on HPV vaccine uptake among MSM provide a baseline as vaccination recommendations are implemented. Published by Elsevier Ltd.
C1 [Meites, Elissa; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
[Paz-Bailey, Gabriela; Oster, Alexandra M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
RP Meites, E (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E-02, Atlanta, GA 30333 USA.
EM emeites@cdc.gov; lmarkowitz@cdc.gov; gpazbailey@cdc.gov; aoster@cdc.gov
OI Meites, Elissa/0000-0002-0077-2591
FU CDC
FX This study was funded by CDC. The authors thank all of the 2011 NHBS
participants, Nevin Krishna, Brooke Hoots, and Teresa Finlayson
(Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral
Hepatitis, STD and TB Prevention, CDC) for their assistance.
NR 20
TC 11
Z9 11
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 12
PY 2014
VL 32
IS 48
BP 6356
EP 6359
DI 10.1016/j.vaccine.2014.09.033
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AU2SY
UT WOS:000345469000007
PM 25258097
ER
PT J
AU Donahue, JG
Kieke, BA
Szilagy, PG
Blumkin, AK
Hilgemann, D
Flanders, WD
Shay, DK
Meece, J
Gallivan, S
Treanor, J
Belongia, EA
AF Donahue, James G.
Kieke, Burney A.
Szilagy, Peter G.
Blumkin, Aaron K.
Hilgemann, Deborah
Flanders, W. Dana
Shay, David K.
Meece, Jennifer
Gallivan, Sarah
Treanor, John
Belongia, Edward A.
TI Can the rolling cross-sectional survey design be used to estimate the
effectiveness of influenza vaccines?
SO VACCINE
LA English
DT Article
DE Rolling cross section; Influenza vaccine; Vaccine effectiveness
ID TEST-NEGATIVE DESIGN; UNITED-STATES; SEASON; INTERIM
AB Introduction: Observational studies of influenza vaccine effectiveness often study persons seeking medical care for acute respiratory infection (ARI). We conducted a pilot study to determine if vaccine effectiveness could be estimated in the general population with a novel rolling cross-sectional survey sampling design and laboratory confirmation of influenza.
Methods: Cross-sectional samples were selected weekly from defined populations in Marshfield, Wisconsin and Monroe County, New York from January through April, 2011 (12 weeks). Persons were telephoned and asked about the occurrence of ARI in the past week. Nasal and throat swabs were obtained from consenting individuals with ARI and tested by real-time reverse transcription polymerase chain reaction (RT-PCR). Vaccine effectiveness (VE) was defined as (100 x [1 OR]) for vaccination in a logistic regression model that adjusted for age, calendar week, and site. The comparison group included all study participants without RT-PCR confirmed influenza, including those who were not ill.
Results: Study personnel contacted 9537(62%) of 15,303 persons sampled; the primary analysis included 5678 subjects. Of these, 193 (3%) reported an ARI and agreed to be tested for influenza; 13 (7%) were influenza positive. The adjusted effectiveness of the influenza vaccine was 1% (95% confidence limits -239-70%).
Conclusions: The rolling cross-sectional design is methodologically feasible and may be useful as a complement to clinic-based VE studies. This pilot study did not have sufficient power to detect significant vaccine effectiveness during a mild influenza season, but this approach may facilitate rapid estimation of VE in a pandemic setting when normal patterns of health care utilization are disrupted. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Donahue, James G.; Kieke, Burney A.; Hilgemann, Deborah; Meece, Jennifer; Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI 54449 USA.
[Szilagy, Peter G.; Blumkin, Aaron K.; Gallivan, Sarah; Treanor, John] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA.
[Flanders, W. Dana] Emory Univ, Dept Epidemiol Biostat & Bioinformat, Atlanta, GA 30322 USA.
[Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA.
RP Donahue, JG (reprint author), Marshfield Clin Res Fdn, 1000 North Oak Ave, Marshfield, WI 54449 USA.
EM donahue.james@mcrf.mfldclin.edu
OI Shay, David/0000-0001-9619-4820
FU Centers for Disease Control and Prevention [RFA-IP08-001001SUPP10]
FX This work was supported by the Centers for Disease Control and
Prevention (RFA-IP08-001001SUPP10).
NR 26
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 12
PY 2014
VL 32
IS 48
BP 6440
EP 6444
DI 10.1016/j.vaccine.2014.09.051
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AU2SY
UT WOS:000345469000019
PM 25284810
ER
PT J
AU Keck, JW
Wenger, JD
Bruden, DL
Rudolph, KM
Hurlburt, DA
Hennessy, TW
Bruce, MG
AF Keck, James W.
Wenger, Jay D.
Bruden, Dana L.
Rudolph, Karen M.
Hurlburt, Debby A.
Hennessy, Thomas W.
Bruce, Michael G.
TI PCV7-induced changes in pneumococcal carriage and invasive disease
burden in Alaskan children
SO VACCINE
LA English
DT Article
DE Pneumococcal carriage; Pneumococcal disease; Pneumococcal conjugate
vaccine; Invasiveness; Alaska
ID STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; YOUNG-CHILDREN; RURAL
ALASKA; SEROTYPES; IMPACT; COLONIZATION; CAPACITY; NATIVES; CLONES
AB Background: Changes in pneumococcal serotype-specific carriage and invasive pneumococcal disease (IPD) after the introduction of pneumococcal conjugate vaccine (PCV7) could inform serotype epidemiology patterns following the introduction of newer conjugate vaccines.
Methods: We used data from statewide IPD surveillance and annual pneumococcal carriage studies in four regions of Alaska to calculate serotype-specific invasiveness ratios (IR; odds ratio of a carried serotype's likelihood to cause invasive disease compared to other serotypes) in children <5 years of age. We describe changes in carriage, disease burden, and invasiveness between two time periods, the pre-PCV7 period (1996-2000) and the late post-PCV7 period (2006-2009).
Results: Incidence of IPD decreased from the pre- to post-vaccine period (95.7 vs. 57.2 cases per 100,000 children, P < 0.001), with a 99% reduction in PCV7 disease. Carriage prevalence did not change between the two periods (49% vs. 50%), although PCV7 serotype carriage declined by 97%, and non-vaccine serotypes increased in prevalence. Alaska pre-vaccine IRs corresponded to pooled results from eight pre-vaccine comparator studies (Spearman's rho = 0.44, P = 0.002) and to the Alaska post-vaccine period (Spearman's rho = 0.28, P= 0.029). Relatively invasive serotypes (IR > 1) caused 66% of IPD in both periods, although fewer serotypes with IR> 1 remained in the post-vaccine (n = 9) than the pre-vaccine period (n = 13).
Conclusions: After PCV7 introduction, serotype IRs changed little, and four of the most invasive serotypes were nearly eliminated. If PCV13 use leads to a reduction of carriage and IPD for the 13 vaccine serotypes, the overall IPD rate should further decline. Note: The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Published by Elsevier Ltd.
C1 [Keck, James W.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Keck, James W.; Wenger, Jay D.; Bruden, Dana L.; Rudolph, Karen M.; Hurlburt, Debby A.; Hennessy, Thomas W.; Bruce, Michael G.] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK 99508 USA.
RP Keck, JW (reprint author), 30 Symmes St, Boston, MA 02131 USA.
EM jameswkeck@gmail.com
FU Pfizer
FX Arctic Investigations Program received research funding from Pfizer for
a separate, but related study.
NR 24
TC 4
Z9 4
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 12
PY 2014
VL 32
IS 48
BP 6478
EP 6484
DI 10.1016/j.vaccine.2014.09.037
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AU2SY
UT WOS:000345469000025
PM 25269095
ER
PT J
AU Haber, P
Moro, PL
McNeil, MM
Lewis, P
Woo, EJ
Hughes, H
Shimabukuro, TT
AF Haber, Penina
Moro, Pedro L.
McNeil, Michael M.
Lewis, Paige
Woo, Emily Jane
Hughes, Hayley
Shimabukuro, Tom T.
TI Post-licensure surveillance of trivalent live attenuated influenza
vaccine in adults, United States, Vaccine Adverse Event Reporting System
(VAERS), July 2005-June 2013
SO VACCINE
LA English
DT Article
DE Vaccine safety; Post-licensure surveillance; Live attenuated influenza
vaccine
ID GUILLAIN-BARRE-SYNDROME; IMMUNIZATION PRACTICES ACIP;
ADVISORY-COMMITTEE; SMALLPOX VACCINATION; SEASONAL INFLUENZA; SAFETY
DATA; RECOMMENDATIONS; PREVENTION; GUIDELINES; COLLECTION
AB Background: Trivalent live attenuated influenza vaccine (LAIV3) was licensed and recommended for use in 2003 in children and adults 2-49 years of age. Post-licensure safety data have been limited, particularly in adults.
Methods: We searched Vaccine Adverse Event Reporting System (VAERS) for US reports after LAIV3 from July 1,2005-June 30, 2013 (eight influenza seasons) in adults aged >= 18 years old. We conducted descriptive analyses and clinically reviewed serious reports (i.e., death, life-threatening illness, hospitalization, prolonged hospitalization, or permanent disability) and reports of selected conditions of interest. We used empirical Bayesian data mining to identify adverse events (AEs) that were reported more frequently than expected. We calculated crude AE reporting rates to VAERS by influenza season.
Results: During the study period, VAERS received 1207 LAIV3 reports in adults aged 18-49 years old; 107 (8.9%) were serious, including four death reports. The most commonly reported events were expired drug administered (n = 207, 17%), headache (n = 192, 16%), and fever (n = 133, 11%). The most common diagnostic categories for non-fatal serious reports were neurological (n = 40, 39%), cardiovascular (n = 14, 14%), and other non-infectious conditions (n = 20, 19%). We noted a higher proportion of Guillain-Barre syndrome (GBS) and cardiovascular reports in the Department of Defense (DoD) population compared to the civilian population. Data mining detected disproportional reporting of ataxia (n = 15); clinical review revealed that ataxia was a component of diverse clinical entities including GBS.
Conclusions: Review of VAERS reports are reassuring, the only unexpected safety concern for LAIV3 identified was a higher than expected number of GBS reports in the DoD population, which is being investigated. Reports of administration of expired LAIV3 represent administration errors and indicate the need for education, training and screening regarding the approved indications. Published by Elsevier Ltd.
C1 [Haber, Penina; Moro, Pedro L.; McNeil, Michael M.; Lewis, Paige; Shimabukuro, Tom T.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis,CDC, Atlanta, GA 30333 USA.
[Woo, Emily Jane] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA.
[Hughes, Hayley] Mil Vaccine Agcy MILVAX, Safety & Evaluat Div, Falls Church, VA 22042 USA.
RP Haber, P (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis,CDC, 1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM pyh0@cdc.gov
NR 31
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 12
PY 2014
VL 32
IS 48
BP 6499
EP 6504
DI 10.1016/j.vaccine.2014.09.018
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AU2SY
UT WOS:000345469000028
PM 25258101
ER
PT J
AU Donis, RO
Chen, IM
Davis, CT
Foust, A
Hossain, MJ
Johnson, A
Klimov, A
Loughlin, R
Xu, XY
Tsai, T
Blayer, S
Trusheim, H
Colegate, T
Fox, J
Taylor, B
Hussain, A
Barr, I
Baas, C
Louwerens, J
Geuns, E
Lee, MS
Venhuizen, O
Neumeier, E
Ziegler, T
AF Donis, Ruben O.
Chen, i-Mei
Davis, C. Todd
Foust, Angie
Hossain, M. Jaber
Johnson, Adam
Klimov, Alexander
Loughlin, Rosette
Xu, Xiyan
Tsai, Theodore
Blayer, Simone
Trusheim, Heidi
Colegate, Tony
Fox, John
Taylor, Beverly
Hussain, Althaf
Barr, Ian
Baas, Chantal
Louwerens, Jaap
Geuns, Ed
Lee, Min-Shi
Venhuizen, Odewijk
Neumeier, Elisabeth
Ziegler, Thedi
CA Influenza Cell Culture Working Grp
TI Performance characteristics of qualified cell lines for isolation and
propagation of influenza viruses for vaccine manufacturing
SO VACCINE
LA English
DT Article
DE Influenza vaccines; Vaccine-certified cell lines; MDCK; VERO; Virus
isolation; Virus purification; Antigenic stability; Genetic stability
ID A H3N2 VIRUSES; EMBRYONATED CHICKEN EGGS; CANINE KIDNEY-CELLS; CLINICAL
DEVELOPMENT; PANDEMIC INFLUENZA; SEQUENCE IDENTITY; MDCK CELLS; CULTURE;
ADAPTATION; VERO
AB Cell culture is now available as a method for the production of influenza vaccines in addition to eggs. In accordance with currently accepted practice, viruses recommended as candidates for vaccine manufacture are isolated and propagated exclusively in hens' eggs prior to distribution to manufacturers. Candidate vaccine viruses isolated in cell culture are not available to support vaccine manufacturing in mammalian cell bioreactors so egg-derived viruses have to be used. Recently influenza A (H3N2) viruses have been difficult to isolate directly in eggs. As mitigation against this difficulty, and the possibility of no suitable egg-isolated candidate viruses being available, it is proposed to consider using mammalian cell lines for primary isolation of influenza viruses as candidates for vaccine production in egg and cell platforms.
To investigate this possibility, we tested the antigenic stability of viruses isolated and propagated in cell lines qualified for influenza vaccine manufacture and subsequently investigated antigen yields of such viruses in these cell lines at pilot-scale. Twenty influenza A and B-positive, original clinical specimens were inoculated in three MDCK cell lines. The antigenicity of recovered viruses was tested by hemagglutination inhibition using ferret sera against contemporary vaccine viruses and the amino acid sequences of the hemagglutinin and neuraminidase were determined. MDCK cell lines proved to be highly sensitive for virus isolation. Compared to the virus sequenced from the original specimen, viruses passaged three times in the MDCK lines showed up to 2 amino acid changes in the hemagglutinin. Antigenic stability was also established by hemagglutination inhibition titers comparable to those of the corresponding reference virus. Viruses isolated in any of the three MDCK lines grew reasonably well but variably in three MDCK cells and in VERO cells at pilot-scale. These results indicate that influenza viruses isolated in vaccine certified cell lines may well qualify for use in vaccine production. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
C1 [Chen, i-Mei; Davis, C. Todd; Foust, Angie; Hossain, M. Jaber; Johnson, Adam; Klimov, Alexander; Loughlin, Rosette; Xu, Xiyan; Ziegler, Thedi] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA.
[Tsai, Theodore] Novartis Vaccines & Diagnost, Cambridge, MA USA.
[Blayer, Simone; Trusheim, Heidi] Novartis Vaccines & Diagnost GmbH & Co KG, Marburg, Germany.
[Colegate, Tony; Fox, John; Taylor, Beverly] Novartis Vaccines & Diagnost, Liverpool, Merseyside, England.
[Hussain, Althaf] MedImmune Inc, Santa Clara, CA USA.
[Barr, Ian; Baas, Chantal] WHO, Collaborating Ctr Reference & Res Influenza, North Melbourne, Vic, Australia.
[Louwerens, Jaap; Geuns, Ed] Abbott Biol BV, Weesp, Netherlands.
[Lee, Min-Shi] Natl Hlth Res Inst, Zhunan, Taiwan.
[Venhuizen, Odewijk] Crucell, Bern, Switzerland.
[Neumeier, Elisabeth] GSK, Dresden, Germany.
[Ziegler, Thedi] Natl Inst Hlth & Welf THL, Helsinki, Finland.
RP Donis, RO (reprint author), Ctr Dis Control & Prevent, Influenza Div, CDC, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Mailstop A-20, Atlanta, GA 30333 USA.
EM rvd6@cdc.gov
RI Lee, Min-Shi /E-3992-2010;
OI Barr, Ian/0000-0002-7351-418X
FU Australian Government Department of Health
FX The content of this manuscript is solely the responsibility of the
authors and does not necessarily represent the official views of the
Centers for Disease Control and Prevention (CDC) or the Agency for Toxic
Substances and Disease Registry (ATSDR). Part of this work was funded by
the International Federation of Pharmaceutical Manufacturers
Associations (IFPMA). The authors acknowledge Dr. Theodore Tsai and Tony
Piedra for providing clinical samples used in this study. The Melbourne
WHO Collaborating Centre for Reference and Research on Influenza is
supported by the Australian Government Department of Health. We thank
Mr. Wei-Zhou Yeh at National Health Research Institutes, Taiwan for
technical support.
NR 48
TC 13
Z9 13
U1 6
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 12
PY 2014
VL 32
IS 48
BP 6583
EP 6590
DI 10.1016/j.vaccine.2014.06.045
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AU2SY
UT WOS:000345469000040
PM 24975811
ER
PT J
AU Stowell, JD
Mask, K
Amin, M
Clark, R
Levis, D
Hendley, W
Lanzieri, TM
Dollard, SC
Cannon, MJ
AF Stowell, Jennifer D.
Mask, Karen
Amin, Minal
Clark, Rebekah
Levis, Denise
Hendley, Will
Lanzieri, Tatiana M.
Dollard, Sheila C.
Cannon, Michael J.
TI Cross-sectional study of cytomegalovirus shedding and immunological
markers among seropositive children and their mothers
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Congenital; Cytomegalovirus; Transmission; Pregnancy; Children
ID GROUP DAY-CARE; CONGENITAL CYTOMEGALOVIRUS; PREGNANT-WOMEN;
RISK-FACTORS; MOLECULAR EPIDEMIOLOGY; SEXUAL-ACTIVITY; YOUNG-CHILDREN;
INFECTION; TRANSMISSION; INFANTS
AB Background: Congenital cytomegalovirus (CMV) is the leading infectious cause of birth defects in the United States. To better understand factors that may influence CMV transmission risk, we compared viral and immunological factors in healthy children and their mothers.
Methods: We screened for CMV IgG antibodies in a convenience sample of 161 children aged 0-47 months from the Atlanta, Georgia metropolitan area, along with 32 mothers of children who screened CMV-seropositive. We assessed CMV shedding via PCR using saliva collected with oral swabs (children and mothers) and urine collected from diapers using filter paper inserts (children only).
Results: CMV IgG was present in 31% (50/161) of the children. Half (25/50) of seropositive children were shedding in at least one fluid. The proportion of seropositive children who shed in saliva was 100% (8/8) among the 4-12 month-olds, 64% (9/14) among 13-24 month-olds, and 40% (6/15) among 25-47 month-olds (P for trend = 0.003). Seropositive mothers had a lower proportion of saliva shedding (21% [6/29]) than children (P < 0.001). Among children who were shedding CMV, viral loads in saliva were significantly higher in younger children (P < 0.001); on average, the saliva viral load of infants (i.e., < 12 months) was approximately 300 times that of two year-olds (i.e., 24-35 months). Median CMV viral loads were similar in children's saliva and urine but were 10-50 times higher (P < 0.001) than the median viral load of the mothers' saliva. However, very high viral loads (> one million copies/mL) were only found in children's saliva (31% of those shedding); children's urine and mothers' saliva specimens all had fewer than 100,000 copies/mL. Low IgG avidity, a marker of primary infection, was associated with younger age (p = 0.03), higher viral loads in saliva (p = 0.02), and lower antibody titers (p = 0.005).
Conclusions: Young CMV seropositive children, especially those less than one year-old may present high-risk CMV exposures to pregnant women, especially via saliva, though further research is needed to see if this finding can be generalized across racial or other demographic strata.
C1 [Stowell, Jennifer D.; Mask, Karen; Levis, Denise; Cannon, Michael J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
[Amin, Minal; Hendley, Will; Lanzieri, Tatiana M.; Dollard, Sheila C.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Clark, Rebekah] Emory Univ, Atlanta, GA 30322 USA.
RP Cannon, MJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,MS E-86, Atlanta, GA 30333 USA.
EM mcannon@cdc.gov
NR 52
TC 4
Z9 4
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD NOV 12
PY 2014
VL 14
AR 568
DI 10.1186/s12879-014-0568-2
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA AT5CB
UT WOS:000344960100001
PM 25388365
ER
PT J
AU Kharbanda, EO
Vazquez-Benitez, G
Lipkind, HS
Klein, NP
Cheetham, TC
Naleway, A
Omer, SB
Hambidge, SJ
Lee, GM
Jackson, ML
McCarthy, NL
DeStefano, F
Nordin, JD
AF Kharbanda, Elyse O.
Vazquez-Benitez, Gabriela
Lipkind, Heather S.
Klein, Nicola P.
Cheetham, T. Craig
Naleway, Allison
Omer, Saad B.
Hambidge, Simon J.
Lee, Grace M.
Jackson, Michael L.
McCarthy, Natalie L.
DeStefano, Frank
Nordin, James D.
TI Evaluation of the Association of Maternal Pertussis Vaccination With
Obstetric Events and Birth Outcomes
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID INACTIVATED INFLUENZA VACCINE; IMMUNIZATION PRACTICES ACIP; CARE
UTILIZATION INDEX; ADVISORY-COMMITTEE; SAFETY DATALINK; PREGNANT-WOMEN;
CLINICAL CHORIOAMNIONITIS; TDAP IMMUNIZATION; VIRUS VACCINE; DIPHTHERIA
AB IMPORTANCE In 2010, due to a pertussis outbreak and neonatal deaths, the California Department of Health recommended that the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) be administered during pregnancy. Tdap is now recommended by the Advisory Committee on Immunization Practices for all pregnant women, preferably between 27 and 36 weeks' gestation. Limited data exist on Tdap safety during pregnancy.
OBJECTIVE To evaluate whether maternal Tdap vaccination during pregnancy is associated with increased risks of adverse obstetric events or adverse birth outcomes.
DESIGN AND SETTING Retrospective, observational cohort study using administrative health care databases from 2 California Vaccine Safety Datalink sites. PARTICIPANTS AND EXPOSURES Of 123 494 women with singleton pregnancies ending in a live birth between January 1, 2010, and November 15, 2012, 26 229 (21%) received Tdap during pregnancy and 97 265 did not.
MAIN OUTCOMES AND MEASURES Risks of small-for-gestational-age (SGA) births (<10th percentile), chorioamnionitis, preterm birth (<37 weeks' gestation), and hypertensive disorders of pregnancy were evaluated. Relative risk (RR) estimates were adjusted for site, receipt of another vaccine during pregnancy, and propensity to receive Tdap during pregnancy. Cox regression was used for preterm delivery, and Poisson regression for other outcomes.
RESULTS Vaccination was not associated with increased risks of adverse birth outcomes: crude estimates for preterm delivery were 6.3% of vaccinated and 7.8% of unvaccinated women (adjusted RR, 1.03; 95% CI, 0.97-1.09); 8.4% of vaccinated and 8.3% of unvaccinated had an SGA birth (adjusted RR, 1.00; 95% CI, 0.96-1.06). Receipt of Tdap before 20 weeks was not associated with hypertensive disorder of pregnancy (adjusted RR, 1.09; 95% CI, 0.99-1.20); chorioamnionitis was diagnosed in 6.1% of vaccinated and 5.5% of unvaccinated women (adjusted RR, 1.19; 95% CI, 1.13-1.26).
CONCLUSIONS AND RELEVANCE In this cohort of women with singleton pregnancies that ended in live birth, receipt of Tdap during pregnancy was not associated with increased risk of hypertensive disorders of pregnancy or preterm or SGA birth, although a small but statistically significant increased risk of chorioamnionitis diagnosis was observed.
C1 [Kharbanda, Elyse O.; Vazquez-Benitez, Gabriela; Nordin, James D.] HealthPartners Inst Educ & Res, Minneapolis, MN 55440 USA.
[Lipkind, Heather S.] Yale Univ, New Haven, CT USA.
[Klein, Nicola P.] Kaiser Permanente No Calif, Oakland, CA USA.
[Cheetham, T. Craig] Kaiser Permanente So Calif, Pasadena, CA 91101 USA.
[Naleway, Allison] Kaiser Permanente Northwest, Portland, OR USA.
[Omer, Saad B.] Kaiser Permanente Georgia, Atlanta, GA USA.
[Hambidge, Simon J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA.
[Hambidge, Simon J.] Denver Hlth, Dept Ambulatory Care Serv, Denver, CO USA.
[Lee, Grace M.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Lee, Grace M.] Harvard Univ, Sch Med, Boston, MA USA.
[Jackson, Michael L.] Grp Hlth Cooperat Puget Sound, Seattle, WA USA.
[McCarthy, Natalie L.; DeStefano, Frank] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Kharbanda, EO (reprint author), HealthPartners Inst Educ & Res, POB 1524,MS 21111R, Minneapolis, MN 55440 USA.
EM elyse.o.kharbanda@healthpartners.com
FU CDC [200-2012-53526]; CDC Vaccine Safety Datalink infrastructure task
order [200-2012-53581, 200-2012-53580]
FX This study was funded through contract 200-2012-53526 from the CDC.
Additional funding for chart reviews came from contracts 200-2012-53581
and 200-2012-53580 from the CDC Vaccine Safety Datalink infrastructure
task order.
NR 45
TC 39
Z9 40
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD NOV 12
PY 2014
VL 312
IS 18
BP 1897
EP 1904
DI 10.1001/jama.2014.14825
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA AS8ZE
UT WOS:000344532600019
PM 25387187
ER
PT J
AU Duffy, J
Weintraub, E
Vellozzi, C
DeStefano, F
AF Duffy, Jonathan
Weintraub, Eric
Vellozzi, Claudia
DeStefano, Frank
CA Vaccine Safety Datalink
TI Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United
States
SO NEUROLOGY
LA English
DT Article
ID H1N1; POPULATION; DIAGNOSIS; CHILDREN; RISK; EPIDEMIOLOGY; DATALINK;
SAFETY; AS03
AB Objective: To assess the occurrence of narcolepsy after influenza vaccines used in the United States that contained the influenza A(H1N1)pdm09 virus strain.
Methods: A population-based cohort study in the Vaccine Safety Datalink with an annual population of more than 8.5 million people. All persons younger than 30 years who received a 2009 pandemic or a 2010-2011 seasonal influenza vaccine were identified. Their medical visit history was searched for a first-ever occurrence of an ICD-9 narcolepsy diagnosis code through the end of 2011. Chart review was done to confirm the diagnosis and determine the date of symptom onset. Cases were patients who met the International Classification of Sleep Disorders, 2nd edition, narcolepsy diagnostic criteria. We compared the observed number of cases after vaccination to the number expected to occur by chance alone.
Results: The number vaccinated with 2009 pandemic vaccine was 650,995 and with 2010-2011 seasonal vaccine was 870,530. Among these patients, 70 had a first-ever narcolepsy diagnosis code after vaccination, of which 16 had a chart-confirmed incident diagnosis of narcolepsy. None had their symptom onset during the 180 days after receipt of a 2009 pandemic vaccine compared with 6.52 expected, and 2 had onset after a 2010-2011 seasonal vaccine compared with 8.83 expected.
Conclusions: Influenza vaccines containing the A(H1N1) pdm09 virus strain used in the United States were not associated with an increased risk of narcolepsy. Vaccination with the influenza A(H1N1) pdm09 vaccine viral antigens does not appear to be sufficient by itself to increase the incidence of narcolepsy in a population.
C1 [Duffy, Jonathan; Weintraub, Eric; Vellozzi, Claudia; DeStefano, Frank; Vaccine Safety Datalink] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30333 USA.
RP Duffy, J (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30333 USA.
EM jduffy@cdc.gov
NR 24
TC 12
Z9 12
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD NOV 11
PY 2014
VL 83
IS 20
BP 1823
EP 1830
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA AT3SR
UT WOS:000344854400011
PM 25320099
ER
PT J
AU Joo, H
Dunet, DO
Fang, J
Wang, GJ
AF Joo, Heesoo
Dunet, Diane O.
Fang, Jing
Wang, Guijing
TI Cost of informal caregiving associated with stroke among the elderly in
the United States
SO NEUROLOGY
LA English
DT Article
ID OLDER AMERICANS; ECONOMIC VALUATION; CARE; POPULATION; DISABILITY;
SURVIVORS; QUANTITY; FAMILY; ADULTS
AB Objectives: We estimated the informal caregiving hours and costs associated with stroke.
Methods: We selected persons aged 65 years and older in 2006 and who were also included in the 2008 follow-up survey from the Health and Retirement Study. We adapted the case-control study design by using self-reported occurrence of an initial stroke event during 2006 and 2008 to classify persons into the stroke (case) and the nonstroke (control) groups. We compared informal caregiving hours between case and control groups in 2006 (prestroke period for case group) and in 2008 (poststroke period for case group) and estimated incremental informal caregiving hours attributable to stroke by applying a difference-in-differences technique to propensity score-matched populations. We used a replacement approach to estimate the economic value of informal caregiving.
Results: The weekly incremental informal caregiving hours attributable to stroke were 8.5 hours per patient. The economic value of informal caregiving per stroke survivor was $8,211 per year, of which $4,356 (53%) was attributable to stroke. At the national level, the annual economic burden of informal caregiving associated with stroke among elderly was estimated at $14.2 billion in 2008.
Conclusions: Recent changes in public health and social support policies recognize the economic burden of informal caregiving. Our estimates reinforce the high economic burden of stroke in the United States and provide up-to-date information for policy development and decision-making.
C1 [Joo, Heesoo; Dunet, Diane O.; Fang, Jing; Wang, Guijing] US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Joo, H (reprint author), US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
EM hj528176@gmail.com
OI Joo, Heesoo/0000-0002-1342-6428
FU Intramural CDC HHS [CC999999]
NR 32
TC 9
Z9 9
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD NOV 11
PY 2014
VL 83
IS 20
BP 1831
EP 1837
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA AT3SR
UT WOS:000344854400012
PM 25305152
ER
PT J
AU Okoro, CA
Dhingra, SS
AF Okoro, Catherine A.
Dhingra, Satvinder S.
TI Severity of Psychological Distress among Adults with and without
Disabilities
SO SOCIAL WORK IN PUBLIC HEALTH
LA English
DT Article
DE surveillance; Psychological distress; BRFSS; disability; mental health
ID HEALTH BEHAVIOR-CHANGE; MENTAL-HEALTH; UNITED-STATES;
PHYSICAL-DISABILITIES; DEPRESSION; REHABILITATION; DISPARITIES;
POPULATION; MORTALITY; MODEL
AB The aim of this study is to examine psychological distress and its individual symptoms between adults with and without disabilities, and among adults with disabilities, to examine whether an association exists between severity of distress and health-related factors. Cross-sectional data from the 2007 Behavioral Risk Factor Surveillance System were used for this study. Severity of psychological distress was assessed using the Kessler 6 scale of nonspecific psychological distress. Logistic regression analyses were performed to estimate predicted marginals and prevalence ratios. Nine percent of adults had mild to moderate psychological distress and 3.9% had serious psychological distress. The adjusted mean Kessler 6 total scores and individual item scores were higher for adults with disabilities, as was the average number of days that a mental health condition interfered with activities in the past 30 days. Among adults with disabilities, mild to moderate and serious psychological distress were particularly high among those who were unemployed or unable to work. Those who had either mild to moderate or serious psychological distress were significantly more likely than those with no psychological distress to be physically inactive, to smoke, and to report fair or poor health, life dissatisfaction, and inadequate social support. A dose-response relationship exists between categorical severity of psychological distress and examined health-related factors. These findings may inform the design of targeted public health strategies that aim to eliminate health disparities between people with and without disabilities.
C1 [Okoro, Catherine A.; Dhingra, Satvinder S.] Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance & Informat Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA.
RP Okoro, CA (reprint author), Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance & Informat Program Off, Off Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd NE,M-S E-97, Atlanta, GA 30333 USA.
EM COkoro@cdc.gov
NR 56
TC 0
Z9 0
U1 1
U2 9
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1937-1918
EI 1937-190X
J9 SOC WORK PUBLIC HLTH
JI Soc. Work Public Health
PD NOV 10
PY 2014
VL 29
IS 7
BP 671
EP 685
DI 10.1080/19371918.2014.938386
PG 15
WC Public, Environmental & Occupational Health; Social Work
SC Public, Environmental & Occupational Health; Social Work
GA AR6PD
UT WOS:000343704500003
PM 25350897
ER
PT J
AU Kennedy, C
Lordo, R
Sucosky, MS
Boehm, R
Brown, MJ
AF Kennedy, Chinaro
Lordo, Robert
Sucosky, Marissa Scalia
Boehm, Rona
Brown, Mary Jean
TI Primary prevention of lead poisoning in children: a cross-sectional
study to evaluate state specific lead-based paint risk reduction laws in
preventing lead poisoning in children
SO ENVIRONMENTAL HEALTH
LA English
DT Article
DE Children; Prevention; Law; Lead Poisoning
ID LESS-THAN-10 MU-G/DL; EXPOSURE; CHILDHOOD
AB Background: Children younger than 72 months are most at risk of environmental exposure to lead from ingestion through normal mouthing behavior. Young children are more vulnerable to lead poisoning than adults because lead is absorbed more readily in a child's gastrointestinal tract. Our focus in this study was to determine the extent to which state mandated lead laws have helped decrease the number of new cases of elevated blood-lead levels (EBLL) in homes where an index case had been identified.
Methods: A cross-sectional study was conducted to compare 682 residential addresses, identified between 2000 and 2009, in two states with and one state without laws to prevent childhood lead poisoning among children younger than 72 months, to determine whether the laws were effective in preventing subsequent cases of lead poisoning detected in residential addresses after the identification of an index case. In this study, childhood lead poisoning was defined as the blood lead level (BLL) that would have triggered an environmental investigation in the residence. The two states with lead laws, Massachusetts (MA) and Ohio (OH), had trigger levels of >= 25 mu g/dL and >= 15 mu g/dL respectively. In Mississippi (MS), the state without legislation, the trigger level was >= 15 mu g/dL.
Results: The two states with lead laws, MA and OH, were 79% less likely than the one without legislation, MS, to have residential addresses with subsequent lead poisoning cases among children younger than 72 months, adjusted OR = 0.21, 95% CI (0.08-0.54).
Conclusions: For the three states studied, the evidence suggests that lead laws such as those studied herein effectively reduced primary exposure to lead among young children living in residential addresses that may have had lead contaminants.
C1 [Kennedy, Chinaro; Sucosky, Marissa Scalia; Brown, Mary Jean] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Agcy Tox Subst & Dis Registry, Atlanta, GA 30341 USA.
[Lordo, Robert; Boehm, Rona] Battelle Mem Inst, Columbus, OH 43201 USA.
RP Kennedy, C (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Agcy Tox Subst & Dis Registry, 4770 Buford Highway, Atlanta, GA 30341 USA.
EM gjn5@cdc.gov
FU National Center for Environmental Health; Department of Housing and
Urban Development
FX This study was supported by funding from the National Center for
Environmental Health in agreement with the Department of Housing and
Urban Development.
NR 19
TC 4
Z9 4
U1 2
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-069X
J9 ENVIRON HEALTH-GLOB
JI Environ. Health
PD NOV 7
PY 2014
VL 13
AR 93
DI 10.1186/1476-069X-13-93
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AU7QN
UT WOS:000345795200001
PM 25380793
ER
PT J
AU Griffin, MR
Mitchel, E
Moore, MR
Whitney, CG
Grijalva, CG
AF Griffin, Marie R.
Mitchel, Edward
Moore, Matthew R.
Whitney, Cynthia G.
Grijalva, Carlos G.
TI Declines in Pneumonia Hospitalizations of Children Aged < 2 Years
Associated with the Use of Pneumococcal Conjugate Vaccines - Tennessee,
1998-2012
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; TIME-SERIES ANALYSIS; VACCINATION;
ADMISSIONS; IMMUNIZATION; IMPACT
C1 [Griffin, Marie R.; Mitchel, Edward; Grijalva, Carlos G.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37235 USA.
[Moore, Matthew R.; Whitney, Cynthia G.] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Griffin, MR (reprint author), Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37235 USA.
EM marie.griffin@vanderbilt.edu
FU AHRQ HHS [R03 HS022342]; NIA NIH HHS [R03 AG042981]
NR 10
TC 14
Z9 14
U1 0
U2 1
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 7
PY 2014
VL 63
IS 44
BP 995
EP 998
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT1ZM
UT WOS:000344729700003
PM 25375070
ER
PT J
AU Murphy, LB
Helmick, CG
Allen, KD
Theis, KA
Baker, NA
Murray, GR
Qin, J
Hootman, JM
Brady, TJ
Barbour, KE
AF Murphy, Louise B.
Helmick, Charles G.
Allen, Kelli D.
Theis, Kristina A.
Baker, Nancy A.
Murray, Glen R.
Qin, Jin
Hootman, Jennifer M.
Brady, Teresa J.
Barbour, Kamil E.
TI Arthritis Among Veterans - United States, 2011-2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID MILITARY; HEALTH; PREVALENCE; CARE; VHA
C1 [Murphy, Louise B.; Helmick, Charles G.; Theis, Kristina A.; Baker, Nancy A.; Qin, Jin; Hootman, Jennifer M.; Brady, Teresa J.; Barbour, Kamil E.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
[Allen, Kelli D.] US Dept Vet Affairs Med Ctr, Hlth Serv Res & Dev Serv, Durham, NC USA.
[Allen, Kelli D.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC USA.
[Murray, Glen R.] Univ West Georgia, Geog Informat Syst Lab, Carrollton, GA 30118 USA.
RP Murphy, LB (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM lmurphy1@cdc.gov
NR 10
TC 7
Z9 7
U1 0
U2 5
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 7
PY 2014
VL 63
IS 44
BP 999
EP 1003
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT1ZM
UT WOS:000344729700004
PM 25375071
ER
PT J
AU Benard, VB
Thomas, CC
King, J
Massetti, GM
Doria-Rose, VP
Saraiya, M
AF Benard, Vicki B.
Thomas, Cheryll C.
King, Jessica
Massetti, Greta M.
Doria-Rose, V. Paul
Saraiya, Mona
TI Vital Signs: Cervical Cancer Incidence, Mortality, and Screening -
United States, 2007-2012
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID VACCINATION; PREVENTION; PREVALENCE; RATES; AGE
AB Background: Cervical cancer screening is one of the greatest cancer prevention achievements, yet some women still develop or die from this disease.
Objective: To assess recent trends in cervical cancer incidence and mortality, current screening percentages, and factors associated with higher incidence and death rates and inadequate screening.
Methods: Percentages of women who had not been screened for cervical cancer in the past 5 years were estimated using data from the 2012 Behavioral Risk Factor Surveillance System survey. State-specific cervical cancer incidence data from the United States Cancer Statistics and mortality data from the National Vital Statistics System were used to calculate incidence and death rates for 2011 by state. Incidence and death rates and annual percentage changes from 2007 to 2011 were calculated by state and U. S. Census region.
Results: In 2012, the percentage of women who had not been screened for cervical cancer in the past 5 years was estimated to be 11.4%; the percentage was larger for women without health insurance (23.1%) and for those without a regular health care provider (25.5%). From 2007 to 2011, the cervical cancer incidence rate decreased by 1.9% per year while the death rate remained stable. The South had the highest incidence rate (8.5 per 100,000), death rate (2.7 per 100,000), and percentage of women who had not been screened in the past 5 years (12.3%).
Conclusions: Trends in cervical cancer incidence rates have decreased slightly while death rates have been stable over the last 5 years. The proportion of inadequately screened women is higher among older women, Asians/ Pacific Islanders, and American Indians/ Alaska Natives.
Implications for Public Health Practice: There continue to be women who are not screened as recommended, and women who die from this preventable cancer. Evidence-based public health approaches are available to increase women's access to screening and timely follow-up of abnormal results.
C1 [Benard, Vicki B.; Thomas, Cheryll C.; King, Jessica; Massetti, Greta M.; Saraiya, Mona] CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA.
[Doria-Rose, V. Paul] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
RP Benard, VB (reprint author), CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA.
EM vbenard@cdc.gov
NR 16
TC 26
Z9 26
U1 1
U2 8
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 7
PY 2014
VL 63
IS 44
BP 1004
EP 1009
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT1ZM
UT WOS:000344729700005
PM 25375072
ER
PT J
AU Logan, G
Vora, NM
Nyensuah, TG
Gasasira, A
Mott, J
Walke, H
Mahoney, F
Luce, R
Flannery, B
AF Logan, Gorbee
Vora, Neil M.
Nyensuah, Tolbert G.
Gasasira, Alex
Mott, Joshua
Walke, Henry
Mahoney, Frank
Luce, Richard
Flannery, Brendan
TI Establishment of a Community Care Center for Isolation and Management of
Ebola Patients - Bomi County, Liberia, October 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Logan, Gorbee] Bomi Cty Community Hlth Dept, Tubmanburg, Liberia.
[Vora, Neil M.] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Nyensuah, Tolbert G.] Minist Hlth & Social Welf, Monrovia, Liberia.
[Gasasira, Alex; Luce, Richard] WHO, Immunizat Vaccines & Emergencies Program, Reg Off Africa, Brazzaville, Congo.
[Mott, Joshua; Flannery, Brendan] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Walke, Henry] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Mahoney, Frank] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Vora, NM (reprint author), CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA.
EM nvora@cdc.gov
NR 4
TC 4
Z9 4
U1 0
U2 9
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 7
PY 2014
VL 63
IS 44
BP 1010
EP 1012
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT1ZM
UT WOS:000344729700006
PM 25375073
ER
PT J
AU Selassie, AW
Wilson, DA
Malek, AM
Wagner, JL
Smith, G
Martz, G
Edwards, J
Wannamaker, B
Zack, MM
Kobau, R
AF Selassie, Anbesaw W.
Wilson, Dulaney A.
Malek, Angela M.
Wagner, Janelle L.
Smith, Gigi
Martz, Gabriel
Edwards, Jonathan
Wannamaker, Braxton
Zack, Matthew M.
Kobau, Rosemarie
TI Premature Deaths Among Children with Epilepsy - South Carolina,
2000-2011
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID CHILDHOOD EPILEPSY
C1 [Selassie, Anbesaw W.; Wilson, Dulaney A.; Malek, Angela M.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC USA.
[Wagner, Janelle L.; Smith, Gigi] Med Univ S Carolina, Coll Nursing, Charleston, SC USA.
[Martz, Gabriel; Edwards, Jonathan; Wannamaker, Braxton] Med Univ S Carolina, Coll Med, Dept Neurol, Charleston, SC USA.
[Zack, Matthew M.; Kobau, Rosemarie] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
RP Kobau, R (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM rkobau@cdc.gov
NR 9
TC 0
Z9 0
U1 0
U2 0
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD NOV 7
PY 2014
VL 63
IS 44
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT1ZM
UT WOS:000344729700002
ER
PT J
AU Jones, MK
Watanabe, M
Zhu, S
Graves, CL
Keyes, LR
Grau, KR
Gonzalez-Hernandez, MB
Iovine, NM
Wobus, CE
Vinje, J
Tibbetts, SA
Wallet, SM
Karst, SM
AF Jones, Melissa K.
Watanabe, Makiko
Zhu, Shu
Graves, Christina L.
Keyes, Lisa R.
Grau, Katrina R.
Gonzalez-Hernandez, Mariam B.
Iovine, Nicole M.
Wobus, Christiane E.
Vinje, Jan
Tibbetts, Scott A.
Wallet, Shannon M.
Karst, Stephanie M.
TI Enteric bacteria promote human and mouse norovirus infection of B cells
SO SCIENCE
LA English
DT Article
ID BLOOD-GROUP ANTIGEN; INTESTINAL EPITHELIAL-CELLS; MURINE NOROVIRUSES;
NORWALK VIRUS; GASTROENTERITIS; MICROBIOTA; REPLICATION; LEWIS
AB The cell tropism of human noroviruses and the development of an in vitro infection model remain elusive. Although susceptibility to individual human norovirus strains correlates with an individual's histo-blood group antigen (HBGA) profile, the biological basis of this restriction is unknown. We demonstrate that human and mouse noroviruses infected B cells in vitro and likely in vivo. Human norovirus infection of B cells required the presence of HBGA-expressing enteric bacteria. Furthermore, mouse norovirus replication was reduced in vivo when the intestinal microbiota was depleted by means of oral antibiotic administration. Thus, we have identified B cells as a cellular target of noroviruses and enteric bacteria as a stimulatory factor for norovirus infection, leading to the development of an in vitro infection model for human noroviruses.
C1 [Jones, Melissa K.; Watanabe, Makiko; Zhu, Shu; Keyes, Lisa R.; Grau, Katrina R.; Tibbetts, Scott A.; Karst, Stephanie M.] Univ Florida, Coll Med, Emerging Pathogens Inst, Dept Mol Genet & Microbiol, Gainesville, FL 32611 USA.
[Graves, Christina L.; Wallet, Shannon M.] Univ Florida, Coll Dent, Dept Oral Biol, Gainesville, FL 32610 USA.
[Graves, Christina L.; Wallet, Shannon M.] Univ Florida, Coll Dent, Dept Periodontol, Gainesville, FL USA.
[Gonzalez-Hernandez, Mariam B.; Wobus, Christiane E.] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.
[Iovine, Nicole M.] Univ Florida, Dept Med, Div Infect Dis, Gainesville, FL USA.
[Vinje, Jan] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
RP Karst, SM (reprint author), Univ Florida, Coll Med, Emerging Pathogens Inst, Dept Mol Genet & Microbiol, Gainesville, FL 32611 USA.
EM skarst@ufl.edu
FU NIH [R01 AI080611, R21 AI103961]; National Institute of Food and
Agriculture [2011-68003-30395]; NIH/National Institute of Dental and
Craniofacial Research [T90 DE021990-02]
FX We thank R. Condit, G. McFadden, and H. Virgin for critical discussions
and reading of the manuscript. We thank R. Renne and F. Zhu for
providing cell lines and J. Pfeiffer for mouse antibiotic depletion
protocols. The data presented in this manuscript are tabulated in the
main paper and in the supplementary materials. The findings and
conclusions in this article are those of the authors and do not
necessarily represent the official position of the Centers for Disease
Control and Prevention. This work was funded by NIH R01 AI080611 and R21
AI103961 for C. E. W; and National Institute of Food and Agriculture
2011-68003-30395 for J.V. C. L. G. was supported in part by NIH/National
Institute of Dental and Craniofacial Research T90 DE021990-02 (Burne). A
patent application pertinent to this work has been filed (U.S. patent
application no. 61/992,040: Methods and Compositions for Caliciviridae,
M.J. and S. K. as inventors).
NR 32
TC 170
Z9 174
U1 17
U2 59
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD NOV 7
PY 2014
VL 346
IS 6210
BP 755
EP 759
DI 10.1126/science.1257147
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AT1JT
UT WOS:000344690100043
PM 25378626
ER
PT J
AU Okanda, JO
Borkowf, CB
Girde, S
Thomas, TK
Lecher, SL
AF Okanda, John O.
Borkowf, Craig B.
Girde, Sonali
Thomas, Timothy K.
Lecher, Shirley Lee
TI Exclusive breastfeeding among women taking HAART for PMTCT of HIV-1 in
the Kisumu Breastfeeding Study
SO BMC PEDIATRICS
LA English
DT Article
AB Background: One of the most effective ways to promote the prevention of mother-to-child transmission (PMTCT) of HIV-1 in resource-limited settings is to encourage HIV-positive mothers to practice exclusive breastfeeding (EBF) for the first 6 months post-partum while they receive antiretroviral therapy (ARV). Although EBF reduces mortality in this context, its practice has been low. We studied the rate of adherence to EBF and assessed associated maternal and infant characteristics using data from a phase II PMTCT clinical trial conducted in Western Kenya which included a counseling intervention to encourage EBF by all participants.
Methods: We analyzed data from the Kisumu Breastfeeding Study (KiBS), conducted between July 2003 and February 2009. This study enrolled a total of 522 HIV-1 infected pregnant women. Data on breastfeeding were available for 480 mother-infant pairs. Infant feeding and general nutrition counseling began at 35 weeks gestation and continued throughout the 6 month post-partum intervention period, following World Health Organization (WHO) infant feeding guidelines. Data on infant feeding were collected during routine clinic visits and home visits using food frequency questionnaires and dietary recall methods. Participants were instructed to exclusively breastfeed until initiation of weaning at 5.5 months post-partum. We used Kaplan-Meier methods to estimate the rates of EBF at 5.25 months post-partum, stratified by maternal and infant characteristics measured at enrollment, delivery, and 2 weeks post-partum.
Results: The estimated EBF rate at 5.25 months post-partum was 80.4%. Only 3% of women introduced other foods (most commonly water with or without glucose, cow's milk, formula, and fruit) by 2 months; this percentage increased to 5% of women by 4 months. Women who had >= 3 previous births (p < 0.01) and who were not living with the infant's father (p = 0.04) were more likely to exclusively breastfeed. Mixed feeding was more common for male infants than for female infants (p = 0.04).
Conclusion: Exclusive breastfeeding was common in this clinical trial, which emphasized EBF as a best practice until infants reached 5.5 months of age. Counseling initiated prior to delivery and continued during the post-partum period provided a consistent message reinforcing the benefits of EBF. The findings from this study suggest high adherence to EBF in resource limited settings can be achieved by a comprehensive counseling intervention that encourages EBF.
C1 [Okanda, John O.] Kenya Govt Med Res Ctr, US Ctr Dis Control & Prevent KEMRI CDC, Res & Publ Hlth Collaborat, POB 1578, Kisumu 40100, Kenya.
[Borkowf, Craig B.; Girde, Sonali; Lecher, Shirley Lee] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
[Girde, Sonali] ICF Int, Atlanta, GA USA.
[Thomas, Timothy K.] US Ctr Dis Control & Prevent, Kisumu, Kenya.
RP Okanda, JO (reprint author), Kenya Govt Med Res Ctr, US Ctr Dis Control & Prevent KEMRI CDC, Res & Publ Hlth Collaborat, POB 1578, Kisumu 40100, Kenya.
EM JOkanda@kemricdc.org
FU Division of HIV/AIDS Prevention, Centers for Disease Control and
Prevention, Atlanta, Georgia, USA
FX We are grateful to the study participants, the Kisumu Breastfeeding
Study (KiBS) team, Kenya Medical Research Institute (KEMRI) and Kenya
Ministry of Health whose participation made this study possible. We also
thank Glaxo Smith Kline and Boehringer Ingelheim for providing the study
medications, the Division of HIV/AIDS Prevention, Centers for Disease
Control and Prevention, Atlanta, Georgia, USA for funding. KEMRI staff
participated in the design, data collection, analysis and the decision
to submit the manuscript for publication. This paper is published with
the approval of the Director, Kenya Medical Research Institute.
NR 37
TC 4
Z9 4
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2431
J9 BMC PEDIATR
JI BMC Pediatr.
PD NOV 7
PY 2014
VL 14
AR 280
DI 10.1186/1471-2431-14-280
PG 8
WC Pediatrics
SC Pediatrics
GA V42DJ
UT WOS:000209594200001
PM 25380718
ER
PT J
AU Gleim, ER
Conner, LM
Berghaus, RD
Levin, ML
Zemtsova, GE
Yabsley, MJ
AF Gleim, Elizabeth R.
Conner, L. Mike
Berghaus, Roy D.
Levin, Michael L.
Zemtsova, Galina E.
Yabsley, Michael J.
TI The Phenology of Ticks and the Effects of Long-Term Prescribed Burning
on Tick Population Dynamics in Southwestern Georgia and Northwestern
Florida
SO PLOS ONE
LA English
DT Article
ID AMBLYOMMA-AMERICANUM ACARI; IXODES-SCAPULARIS ACARI; GULF-COAST TICK;
LYME-DISEASE; UNITED-STATES; TALLGRASS PRAIRIE; MACULATUM ACARI;
CLIMATE-CHANGE; SPOTTED-FEVER; HABITAT TYPE
AB Some tick populations have increased dramatically in the past several decades leading to an increase in the incidence and emergence of tick-borne diseases. Management strategies that can effectively reduce tick populations while better understanding regional tick phenology is needed. One promising management strategy is prescribed burning. However, the efficacy of prescribed burning as a mechanism for tick control is unclear because past studies have provided conflicting data, likely due to a failure of some studies to simulate operational management scenarios and/or account for other predictors of tick abundance. Therefore, our study was conducted to increase knowledge of tick population dynamics relative to long-term prescribed fire management. Furthermore, we targeted a region, southwestern Georgia and northwestern Florida (USA), in which little is known regarding tick dynamics so that basic phenology could be determined. Twenty-one plots with varying burn regimes (burned surrounded by burned [BB], burned surrounded by unburned [BUB], unburned surrounded by burned [UBB], and unburned surrounded by unburned [UBUB]) were sampled monthly for two years while simultaneously collecting data on variables that can affect tick abundance (e.g., host abundance, vegetation structure, and micro- and macro-climatic conditions). In total, 47,185 ticks were collected, of which, 99% were Amblyomma americanum, 0.7% were Ixodes scapularis, and fewer numbers of Amblyomma maculatum, Ixodes brunneus, and Dermacentor variabilis. Monthly seasonality trends were similar between 2010 and 2011. Long-term prescribed burning consistently and significantly reduced tick counts (overall and specifically for A. americanum and I. scapularis) regardless of the burn regimes and variables evaluated. Tick species composition varied according to burn regime with A. americanum dominating at UBUB, A. maculatum at BB, I. scapularis at UBB, and a more even composition at BUB. These data indicate that regular prescribed burning is an effective tool for reducing tick populations and ultimately may reduce risk of tick-borne disease.
C1 [Gleim, Elizabeth R.; Yabsley, Michael J.] Univ Georgia, Warnell Sch Forestry & Nat Resources, Athens, GA 30602 USA.
[Gleim, Elizabeth R.; Yabsley, Michael J.] Univ Georgia, Coll Vet Med, Southeastern Cooperat Wildlife Dis Study, Athens, GA 30602 USA.
[Gleim, Elizabeth R.; Conner, L. Mike] Joseph W Jones Ecol Res Ctr Ichauway, Wildlife Lab, Newton, GA USA.
[Berghaus, Roy D.] Univ Georgia, Coll Vet Med, Dept Populat Hlth, Athens, GA 30602 USA.
[Levin, Michael L.; Zemtsova, Galina E.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA USA.
RP Gleim, ER (reprint author), Univ Georgia, Warnell Sch Forestry & Nat Resources, Athens, GA 30602 USA.
EM egleim@gmail.com
FU Centers for Disease Control and Prevention/University of Georgia (UGA)
[8212]; Joseph W. Jones Ecological Research Center at Ichauway; Warnell
School of Forestry and Natural Resources (UGA); Southeastern Cooperative
Wildlife Disease Study (SCWDS) (UGA)
FX This work was funded by the Centers for Disease Control and
Prevention/University of Georgia (UGA) collaborative grant,
(http://www.cdc.gov/od/science/technology/innovation/seeds.htm) (8212,
Ecosystem Health and Human Health: Understanding the Ecological Effects
of Prescribed Fire Regimes on the Distribution and Population Dynamics
of Tick-borne Zoonoses, MJY, ERG, LMC, and MLL). Additional funding was
provided by the Joseph W. Jones Ecological Research Center at Ichauway,
Warnell School of Forestry and Natural Resources (UGA), and the
Southeastern Cooperative Wildlife Disease Study (SCWDS) (UGA) through
the Federal Aid to Wildlife Restoration Act (50 Stat. 917) and through
SCWDS sponsorship from fish and wildlife agencies of member states. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 58
TC 3
Z9 3
U1 4
U2 39
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 6
PY 2014
VL 9
IS 11
AR e112174
DI 10.1371/journal.pone.0112174
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS6XM
UT WOS:000344402600112
PM 25375797
ER
PT J
AU Rebeiro, PF
Horberg, MA
Gange, SJ
Gebo, KA
Yehia, BR
Brooks, JT
Buchacz, K
Silverberg, MJ
Gill, J
Moore, RD
Althoff, KN
AF Rebeiro, Peter F.
Horberg, Michael A.
Gange, Stephen J.
Gebo, Kelly A.
Yehia, Baligh R.
Brooks, John T.
Buchacz, Kate
Silverberg, Michael J.
Gill, John
Moore, Richard D.
Althoff, Keri N.
CA North American AIDS Cohort Collabo
TI Strong Agreement of Nationally Recommended Retention Measures from the
Institute of Medicine and Department of Health and Human Services
SO PLOS ONE
LA English
DT Article
ID HIV CARE; PREVENTION; COHORT
AB Objective: We sought to quantify agreement between Institute of Medicine (IOM) and Department of Health and Human Services (DHHS) retention indicators, which have not been compared in the same population, and assess clinical retention within the largest HIV cohort collaboration in the U.S.
Design: Observational study from 2008-2010, using clinical cohort data in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).
Methods: Retention definitions used HIV primary care visits. The IOM retention indicator was: >= 2 visits, >= 90 days apart, each calendar year. This was extended to a 2-year period; retention required meeting the definition in both years. The DHHS retention indicator was: >= 1 visit each semester over 2 years, each >= 60 days apart. Kappa statistics detected agreement between indicators and C statistics (areas under Receiver-Operating Characteristic curves) from logistic regression analyses summarized discrimination of the IOM indicator by the DHHS indicator.
Results: Among 36,769 patients in 2008-2009 and 34,017 in 2009-2010, there were higher percentages of participants retained in care under the IOM indicator than the DHHS indicator (80% vs. 75% in 2008-2009; 78% vs. 72% in 2009-2010, respectively) (p<0.01), persisting across all demographic and clinical characteristics (p<0.01). There was high agreement between indicators overall (kappa = 0.83 in 2008-2009; kappa = 0.79 in 2009-2010, p<0.001), and C statistics revealed a very strong ability to predict retention according to the IOM indicator based on DHHS indicator status, even within characteristic strata.
Conclusions: Although the IOM indicator consistently reported higher retention in care compared with the DHHS indicator, there was strong agreement between IOM and DHHS retention indicators in a cohort demographically similar to persons living with HIV/AIDS in the U.S. Persons with poorer retention represent subgroups of interest for retention improvement programs nationally, particularly in light of the White House Executive Order on the HIV Care Continuum.
C1 [Rebeiro, Peter F.; Gange, Stephen J.; Gebo, Kelly A.; Moore, Richard D.; Althoff, Keri N.] Johns Hopkins Univ, Baltimore, MD 21218 USA.
[Horberg, Michael A.] Kaiser Permanente Mid Atlant States, Rockville, MD USA.
[Yehia, Baligh R.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Brooks, John T.; Buchacz, Kate] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Silverberg, Michael J.] Kaiser Permanente No Calif, Oakland, CA USA.
[Gill, John] Univ Calgary, Calgary, AB, Canada.
RP Rebeiro, PF (reprint author), Johns Hopkins Univ, Baltimore, MD 21218 USA.
EM prebeiro@jhu.edu; kalthoff@jhu.edu
RI Gill, John/G-7083-2016;
OI Gill, John/0000-0002-8546-8790; Rebeiro, Peter/0000-0003-1951-9104;
Justice, Amy/0000-0003-0139-5502
FU National Institutes of Health, USA [U01-AI069918, U01-AA013566,
U24-AA020794, U01-AA020790, U01-AI31834]; Center's for Disease Control
and Prevention, USA [CDC200-2006-18797]; Agency for Healthcare Research
and Quality, USA [90047713]; Health Resources and Services
Administration, USA [90051652]; Canadian Institutes of Health Research,
Canada [TGF-96118, HCP-97105, CBR-86906, CBR-94036]; Ontario Ministry of
Health and Long Term Care; Government of Alberta, Canada;
[UL1-RR024131]; [UL1-TR000083]; [U54-MD007587]; [G12-MD007583];
[K01-AI071754]; [K01-AI093197]; [K23 EY013707]; [K24-AI065298];
[K24-00432]; [MO1-RR-00052]; [N02-CP55504]; [P30-AI027763];
[P30-AI094189]; [U01-AI35041]; [U01-AI35042]; [U01-AI35043];
[U01-AI37613]; [U01-AI37984]; [R01-DA11602]; [R01-DA04334];
[R01-DA12568]; [U01-AI38855]; [U01-AI38858]; [U01-AI42590];
[U01-AI68634]; [U01-AI68636]; [U01-AI69432]; [U01-AI69434];
[U01-HD32632]; [U10-EY08057]; [U10-EY08052]; [U10-EY08067];
[P30-AI27757]; [P30-AI27767]; [P30-AI50410]; [P30-AI54999];
[P30-AI036219]; [P30-MH62246]; [R01-CA165937]; [R01-AA16893];
[R24-AI067039]; [R56-AI102622]; [Z01-CP010214]; [Z01-CP010176];
[U01-AI34989]; [U01-AI34993]; [U01-AI34994]; [U01-AI35004];
[U01-AI35039]; [U01-AI35040]
FX This work was supported by grants U01-AI069918, U01-AA013566,
U24-AA020794, U01-AA020790, U01-AI31834, U01-AI34989, U01-AI34993,
U01-AI34994, U01-AI35004, U01-AI35039, U01-AI35040, U01-AI35041,
U01-AI35042, U01-AI35043, U01-AI37613, U01-AI37984, U01-AI38855,
U01-AI38858, U01-AI42590, U01-AI68634, U01-AI68636, U01-AI69432,
U01-AI69434, U01-HD32632, U10-EY08057, U10-EY08052, U10-EY08067,
UL1-RR024131, UL1-TR000083, U54-MD007587, G12-MD007583, K01-AI071754,
K01-AI093197, K23 EY013707, K24-AI065298, K24-00432, MO1-RR-00052,
N02-CP55504, P30-AI027763, P30-AI094189, P30-AI27757, P30-AI27767,
P30-AI50410, P30-AI54999, P30-AI036219, P30-MH62246, R01-CA165937,
R01-AA16893, R01-DA11602, R01-DA04334, R01-DA12568, R24-AI067039,
R56-AI102622, Z01-CP010214, and Z01-CP010176 from the National
Institutes of Health, USA; contract CDC200-2006-18797 from the Center's
for Disease Control and Prevention, USA; contract 90047713 from the
Agency for Healthcare Research and Quality, USA; contract 90051652 from
the Health Resources and Services Administration, USA; grants TGF-96118,
HCP-97105, CBR-86906, CBR-94036 from the Canadian Institutes of Health
Research, Canada; Ontario Ministry of Health and Long Term Care; and the
Government of Alberta, Canada. PFR: F31-DA035713. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 13
TC 8
Z9 8
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 6
PY 2014
VL 9
IS 11
AR e111772
DI 10.1371/journal.pone.0111772
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS6XM
UT WOS:000344402600061
PM 25375099
ER
PT J
AU Plucinski, MM
Chicuecue, S
Macete, E
Colborn, J
Yoon, SS
Kachur, SP
Aide, P
Alonso, P
Guinovart, C
Morgan, J
AF Plucinski, Mateusz M.
Chicuecue, Silvia
Macete, Eusebio
Colborn, James
Yoon, Steven S.
Kachur, S. Patrick
Aide, Pedro
Alonso, Pedro
Guinovart, Caterina
Morgan, Juliette
TI Evaluation of a universal coverage bed net distribution campaign in four
districts in Sofala Province, Mozambique
SO MALARIA JOURNAL
LA English
DT Article
DE Long-lasting insecticidal net; Malaria; Plasmodium falciparum
ID LASTING INSECTICIDAL NETS; CHILD-MORTALITY; SPATIAL-DISTRIBUTION;
WESTERN KENYA; MALARIA; BEDNETS
AB Background: Malaria is the leading cause of death in Mozambique in children under five years old. In 2009, Mozambique developed a novel bed net distribution model to increase coverage, based on assumptions about sleeping patterns. The coverage and impact of a bed net distribution campaign using this model in four districts in Sofala Province, Mozambique was evaluated.
Methods: Paired household, cross-sectional surveys were conducted one month after the 2010 distribution of 140,000 bed nets and again 14 months after the campaign in 2011. During household visits, malaria blood smears were performed and haemoglobin levels were assessed on children under five and data on bed net ownership, access and use were collected; these indicators were analysed at individual, household and community levels. Logistic regression was used to evaluate predictors of malaria infection and anaemia.
Results: The campaign reached 98% (95% CI: 97-99%) of households registered during the precampaign listing, with 81% (95% CI: 77-85%) of sleeping spaces covered by campaign bed nets and 85% (95% CI: 81-88%) of the population sleeping in a sleeping space with a campaign bed net designated for the sleeping space. One year after the campaign, 65% (95% CI: 57-72%) of sleeping spaces were observed to have hanging bed nets. The proportion of sleeping spaces for which bed nets were reported used four or more times per week was 65% (95% CI: 56-74%) in the wet season and 60% (95% CI: 52-68%) in the dry season. Malaria parasitaemia prevalence in children under five years old was 47% (95% CI: 40-54%) in 2010 and 36% (95% CI: 27-45%) in 2011. Individual-level malaria infection and anaemia were significantly associated with community-level use of bed nets.
Conclusions: The campaign using the novel distribution model achieved high coverage, although usage was not uniformly high. A significant decrease in malaria parasitaemia prevalence a year after the campaign was not observed, but community-level use of bed nets was significantly associated with a reduced risk for malaria infection and anaemia in children under five.
C1 [Plucinski, Mateusz M.; Colborn, James; Yoon, Steven S.; Kachur, S. Patrick; Morgan, Juliette] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Plucinski, Mateusz M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Chicuecue, Silvia; Macete, Eusebio; Aide, Pedro; Alonso, Pedro; Guinovart, Caterina] Manhica Hlth Res Ctr, Manhica, Mozambique.
[Macete, Eusebio] Minist Saude, Direccao Nacl Saude, Maputo, Mozambique.
[Aide, Pedro] Minist Saude, Inst Nacl Saude, Maputo, Mozambique.
[Alonso, Pedro; Guinovart, Caterina] Univ Barcelona, Hosp Clin Barcelona, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain.
RP Plucinski, MM (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
EM mplucinski@cdc.gov
FU Centers for Disease Control and Prevention; President's Malaria
Initiative
FX The findings and conclusions in this report are those of the authors and
do not necessarily represent the official position of the Centers for
Disease Control and Prevention. This work was supported by the Centers
for Disease Control and Prevention and the President's Malaria
Initiative. The authors declare they do not have any commercial or other
associations that might pose a conflict of interest.
NR 20
TC 2
Z9 2
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD NOV 5
PY 2014
VL 13
AR 427
DI 10.1186/1475-2875-13-427
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AW2AQ
UT WOS:000346091000001
PM 25373784
ER
PT J
AU Wang, DX
Baudys, J
Krilich, J
Smith, TJ
Barr, JR
Kalb, SR
AF Wang, Dongxia
Baudys, Jakub
Krilich, Joan
Smith, Theresa J.
Barr, John R.
Kalb, Suzanne R.
TI A Two-Stage Multiplex Method for Quantitative Analysis of Botulinum
Neurotoxins Type A, B, E, and F by MALDI-TOF Mass Spectrometry
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID NEUROTRANSMITTER RELEASE; SEROTYPE-A; TOXIN; CLEAVAGE; SNAP-25;
DIFFERENTIATION; IDENTIFICATION; TECHNOLOGIES; TETANUS; ASSAYS
AB In this publication, we report on the development of a quantitative enzymatic method for the detection of four botulinum neurotoxin (BoNT) serotypes responsible for human botulism by MALDI-TOF mass spectrometry. Factors that might affect the linearity and dynamic range for detection of BoNT cleavage products were initially examined, including the amount of peptide substrate and internal standard, the timing of cleavage reaction, and the components in the reaction solution. It was found that a long incubation time produced sensitive results, but was not capable of determining higher toxin concentrations, whereas a short incubation time was less sensitive so that lower toxin concentrations were not detected. In order to overcome these limitations, a two-stage analysis strategy was applied. The first stage analysis involved a short incubation period (e.g., 30 min). If no toxin was detected at this stage, the cleavage reaction was allowed to continue and the samples were analyzed at a second time point (4 h), so that toxin levels lower than 1 mouse LD50 or 55 attomoles per milliliter (55 amol/mL) could be quantified. By combining the results from two-stage quantification, 4 or 5 orders of magnitude in dynamic range were achieved for the detection of the serotypes of BoNT/A, BoNT/B, BoNT/E, or BoNT/F. The effect of multiplexing the assay by mixing substrates for different BoNT serotypes into a single reaction was also investigated in order to reduce the numbers of the cleavage reactions and save valuable clinical samples.
C1 [Wang, Dongxia; Baudys, Jakub; Barr, John R.; Kalb, Suzanne R.] Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
[Krilich, Joan] Battelle Mem Inst, Atlanta, GA 30341 USA.
[Smith, Theresa J.] USAMRIID, Ft Detrick, MD 21702 USA.
RP Kalb, SR (reprint author), Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
EM skalb@cdc.gov
OI Kalb, Suzanne/0000-0002-8067-136X
FU Centers for Disease Control and Prevention
FX Work performed by Battelle Memorial Institute was conducted while under
contract with the Centers for Disease Control and Prevention. The
opinions, interpretations, conclusions, and recommendations are those of
the authors and are not necessarily endorsed by the Centers for Disease
Control and Prevention or the U.S. Army.
NR 29
TC 7
Z9 8
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD NOV 4
PY 2014
VL 86
IS 21
BP 10847
EP 10854
DI 10.1021/ac502948v
PG 8
WC Chemistry, Analytical
SC Chemistry
GA AS8PK
UT WOS:000344510200049
PM 25285509
ER
PT J
AU Akhvlediani, T
Bautista, CT
Shakarishvili, R
Tsertsvadze, T
Imnadze, P
Tatishvili, N
Davitashvili, T
Samkharadze, T
Chlikadze, R
Dvali, N
Dzigua, L
Karchava, M
Gatserelia, L
Macharashvili, N
Kvirkvelia, N
Habashy, EE
Farrell, M
Rowlinson, E
Sejvar, J
Hepburn, M
Pimentel, G
Dueger, E
House, B
Rivard, R
AF Akhvlediani, Tamar
Bautista, Christian T.
Shakarishvili, Roman
Tsertsvadze, Tengiz
Imnadze, Paata
Tatishvili, Nana
Davitashvili, Tamar
Samkharadze, Tamar
Chlikadze, Rusudan
Dvali, Natia
Dzigua, Lela
Karchava, Mariam
Gatserelia, Lana
Macharashvili, Nino
Kvirkvelia, Nana
Habashy, Engy Emil
Farrell, Margaret
Rowlinson, Emily
Sejvar, James
Hepburn, Matthew
Pimentel, Guillermo
Dueger, Erica
House, Brent
Rivard, Robert
TI Etiologic Agents of Central Nervous System Infections among Febrile
Hospitalized Patients in the Country of Georgia
SO PLOS ONE
LA English
DT Article
ID BACTERIAL-MENINGITIS; VIRAL-INFECTIONS; ENCEPHALITIS; EPIDEMIOLOGY;
DIAGNOSIS
AB Objectives: There is a large spectrum of viral, bacterial, fungal, and prion pathogens that cause central nervous system (CNS) infections. As such, identification of the etiological agent requires multiple laboratory tests and accurate diagnosis requires clinical and epidemiological information. This hospital-based study aimed to determine the main causes of acute meningitis and encephalitis and enhance laboratory capacity for CNS infection diagnosis.
Methods: Children and adults patients clinically diagnosed with meningitis or encephalitis were enrolled at four reference health centers. Cerebrospinal fluid (CSF) was collected for bacterial culture, and in-house and multiplex RT-PCR testing was conducted for herpes simplex virus (HSV) types 1 and 2, mumps virus, enterovirus, varicella zoster virus (VZV), Streptococcus pneumoniae, HiB and Neisseria meningitidis.
Results: Out of 140 enrolled patients, the mean age was 23.9 years, and 58% were children. Bacterial or viral etiologies were determined in 51% of patients. Five Streptococcus pneumoniae cultures were isolated from CSF. Based on in-house PCR analysis, 25 patients were positive for S. pneumoniae, 6 for N. meningitidis, and 1 for H. influenzae. Viral multiplex PCR identified infections with enterovirus (n = 26), VZV (n = 4), and HSV-1 (n = 2). No patient was positive for mumps or HSV-2.
Conclusions: Study findings indicate that S. pneumoniae and enteroviruses are the main etiologies in this patient cohort. The utility of molecular diagnostics for pathogen identification combined with the knowledge provided by the investigation may improve health outcomes of CNS infection cases in Georgia.
C1 [Akhvlediani, Tamar] Javakhishvili Tbilisi State Univ, Dept Neurol & Neurosurg, Tbilisi, Rep of Georgia.
[Akhvlediani, Tamar] US Army, Med Res Unit Georgia, Tbilisi, Rep of Georgia.
[Bautista, Christian T.] Walter Reed Army Inst Res, Silver Spring, MD USA.
[Shakarishvili, Roman] Sarajishvili Inst Clin Neurol & Neurosurg, Tbilisi, Rep of Georgia.
[Tsertsvadze, Tengiz; Davitashvili, Tamar; Dvali, Natia; Dzigua, Lela; Karchava, Mariam; Gatserelia, Lana; Macharashvili, Nino] Sci Res Ctr Infect Pathol AIDS & Clin Immunol, Tbilisi, Rep of Georgia.
[Imnadze, Paata; Chlikadze, Rusudan] Natl Ctr Dis Control & Publ Hlth, Tbilisi, Rep of Georgia.
[Tatishvili, Nana; Samkharadze, Tamar] Iashvili Childrens Hosp, Dept Neurol, Tbilisi, Rep of Georgia.
[Habashy, Engy Emil; Farrell, Margaret; Rowlinson, Emily; Pimentel, Guillermo; Dueger, Erica; House, Brent] US Naval, Global Dis Detect & Response Program, Med Res Unit 3, Cairo, Egypt.
[Sejvar, James] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
[Dueger, Erica] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Hepburn, Matthew; Rivard, Robert] US Army, Med Res Inst Infect Dis, Frederick, MD USA.
RP Akhvlediani, T (reprint author), Javakhishvili Tbilisi State Univ, Dept Neurol & Neurosurg, Tbilisi, Rep of Georgia.
EM t_akhvlediani@yahoo.com
FU U.S. Department of Defense Global Emerging Infections Surveillance
(GEIS) Program; U.S. Centers for Disease Control and Prevention
FX This work was funded by the U.S. Department of Defense Global Emerging
Infections Surveillance (GEIS) Program and supported by the U.S. Centers
for Disease Control and Prevention. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 21
TC 4
Z9 4
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 4
PY 2014
VL 9
IS 11
AR e111393
DI 10.1371/journal.pone.0111393
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS6XG
UT WOS:000344402000051
PM 25369023
ER
PT J
AU Alymova, IV
York, IA
McCullers, JA
AF Alymova, Irina V.
York, Ian A.
McCullers, Jonathan A.
TI Non-Avian Animal Reservoirs Present a Source of Influenza A PB1-F2
Proteins with Novel Virulence-Enhancing Markers
SO PLOS ONE
LA English
DT Article
ID SECONDARY BACTERIAL-INFECTIONS; EQUINE INFLUENZA; VIRUS; SWINE; GENE;
H3N2; DOGS; TRANSMISSION; EXPRESSION; ORIGIN
AB PB1-F2 protein, expressed from an alternative reading frame of most influenza A virus (IAV) PB1 segments, may possess specific residues associated with enhanced inflammation (L62, R75, R79, and L82) and cytotoxicity (I68, L69, and V70). These residues were shown to increase the pathogenicity of primary viral and secondary bacterial infections in a mouse model. In contrast to human seasonal influenza strains, virulence-associated residues are present in PB1-F2 proteins from pandemic H1N1 1918, H2N2 1957, and H3N2 1968, and highly pathogenic H5N1 strains, suggesting their contribution to viruses' pathogenic phenotypes. Non-human influenza strains may act as donors of virulent PB1-F2 proteins. Previously, avian influenza strains were identified as a potential source of inflammatory, but not cytotoxic, PB1-F2 residues. Here, we analyze the frequency of virulence-associated residues in PB1-F2 sequences from IAVs circulating in mammalian species in close contact with humans: pigs, horses, and dogs. All four inflammatory residues were found in PB1-F2 proteins from these viruses. Among cytotoxic residues, I68 was the most common and was especially prevalent in equine and canine IAVs. Historically, PB1-F2 from equine (about 75%) and canine (about 20%) IAVs were most likely to have combinations of the highest numbers of residues associated with inflammation and cytotoxicity, compared to about 7% of swine IAVs. Our analyses show that, in addition to birds, pigs, horses, and dogs are potentially important sources of pathogenic PB1-F2 variants. There is a need for surveillance of IAVs with genetic markers of virulence that may be emerging from these reservoirs in order to improve pandemic preparedness and response.
C1 [Alymova, Irina V.; York, Ian A.] Centers Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30329 USA.
[Alymova, Irina V.; McCullers, Jonathan A.] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA.
[McCullers, Jonathan A.] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA.
RP McCullers, JA (reprint author), Centers Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30329 USA.
EM jon.mccullers@stjude.org
OI York, Ian/0000-0002-3478-3344
FU American Lebanese Syrian Associated Charities (ALSAC)
FX This work was supported by the American Lebanese Syrian Associated
Charities (ALSAC). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 40
TC 1
Z9 1
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 4
PY 2014
VL 9
IS 11
AR e111603
DI 10.1371/journal.pone.0111603
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS6XG
UT WOS:000344402000074
PM 25368997
ER
PT J
AU Parsons, MB
Gillespie, TR
Lonsdorf, EV
Travis, D
Lipende, I
Gilagiza, B
Kamenya, S
Pintea, L
Vazquez-Prokopec, GM
AF Parsons, Michele B.
Gillespie, Thomas R.
Lonsdorf, Elizabeth V.
Travis, Dominic
Lipende, Iddi
Gilagiza, Baraka
Kamenya, Shadrack
Pintea, Lilian
Vazquez-Prokopec, Gonzalo M.
TI Global Positioning System Data-Loggers: A Tool to Quantify Fine-Scale
Movement of Domestic Animals to Evaluate Potential for Zoonotic
Transmission to an Endangered Wildlife Population
SO PLOS ONE
LA English
DT Article
ID EMERGING INFECTIOUS-DISEASES; IMPENETRABLE NATIONAL-PARK;
CRYPTOSPORIDIUM-PARVUM; COLLAR PERFORMANCE; GIARDIA; ECOLOGY; VIRUS;
RISK; BIODIVERSITY; PARASITES
AB Domesticated animals are an important source of pathogens to endangered wildlife populations, especially when anthropogenic activities increase their overlap with humans and wildlife. Recent work in Tanzania reports the introduction of Cryptosporidium into wild chimpanzee populations and the increased risk of ape mortality associated with SIVcpz-Cryptosporidium co-infection. Here we describe the application of novel GPS technology to track the mobility of domesticated animals (27 goats, 2 sheep and 8 dogs) with the goal of identifying potential routes for Cryptosporidium introduction into Gombe National Park. Only goats (5/27) and sheep (2/2) were positive for Cryptosporidium. Analysis of GPS tracks indicated that a crop field frequented by both chimpanzees and domesticated animals was a potential hotspot for Cryptosporidium transmission. This study demonstrates the applicability of GPS data-loggers in studies of fine-scale mobility of animals and suggests that domesticated animal-wildlife overlap should be considered beyond protected boundaries for long-term conservation strategies.
C1 [Parsons, Michele B.; Gillespie, Thomas R.; Vazquez-Prokopec, Gonzalo M.] Emory Univ, Program Populat Biol Ecol & Evolut, Atlanta, GA 30322 USA.
[Parsons, Michele B.; Gillespie, Thomas R.; Vazquez-Prokopec, Gonzalo M.] Emory Univ, Dept Environm Sci, Atlanta, GA 30322 USA.
[Parsons, Michele B.; Gillespie, Thomas R.; Vazquez-Prokopec, Gonzalo M.] Emory Univ, Dept Environm Hlth, Atlanta, GA 30322 USA.
[Parsons, Michele B.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA.
[Lonsdorf, Elizabeth V.] Franklin & Marshall Coll, Dept Psychol, Lancaster, PA 17604 USA.
[Travis, Dominic] Univ Minnesota, Coll Vet Med, Minneapolis, MN 55455 USA.
[Lipende, Iddi; Gilagiza, Baraka; Kamenya, Shadrack; Pintea, Lilian] Jane Goodall Inst, Kigoma, Tanzania.
RP Gillespie, TR (reprint author), Emory Univ, Program Populat Biol Ecol & Evolut, Atlanta, GA 30322 USA.
EM thomas.gillespie@emory.edu; gmvazqu@emory.edu
FU Morris Animal Foundation [MAF D09ZO-041, MAF D09ZO-634]; Emory
University Global Health Institute; Arcus Foundation; Leo S. Guthman
Foundation; National Institutes of Health [R01 AI58715]
FX Funding for this study comes from the Morris Animal Foundation (MAF
D09ZO-041 and MAF D09ZO-634), the Emory University Global Health
Institute, the Arcus Foundation, the Leo S. Guthman Foundation and the
National Institutes of Health (R01 AI58715). QuickBird satellite imagery
was kindly contributed to the Jane Goodall Institute at no cost by
DigitalGlobe. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
NR 46
TC 6
Z9 7
U1 5
U2 32
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 3
PY 2014
VL 9
IS 11
AR e110984
DI 10.1371/journal.pone.0110984
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU4DB
UT WOS:000345558100040
PM 25365070
ER
PT J
AU Tanner, EJ
Liu, HM
Oberste, MS
Pallansch, M
Collett, MS
Kirkegaard, K
AF Tanner, Elizabeth J.
Liu, Hong-mei
Oberste, M. Steven
Pallansch, Mark
Collett, Marc S.
Kirkegaard, Karla
TI Dominant Drug Targets Suppress the Emergence of Antiviral Resistance
SO ELIFE
LA English
DT Article
ID RHINOVIRUS 3C PROTEASE; POLIOVIRUS; RNA; VIRUS; REPLICATION; COMPOUND;
RECEPTOR; POTENT; AGENTS; INHIBITION
AB The emergence of drug resistance can defeat the successful treatment of pathogens that display high mutation rates, as exemplified by RNA viruses. Here we detail a new paradigm in which a single compound directed against a 'dominant drug target' suppresses the emergence of naturally occurring drug-resistant variants in mice and cultured cells. All new drug-resistant viruses arise during intracellular replication and initially express their phenotypes in the presence of drug-susceptible genomes. For the targets of most anti-viral compounds, the presence of these drug-susceptible viral genomes does not prevent the selection of drug resistance. Here we show that, for an inhibitor of the oligomeric capsid proteins of poliovirus, the expression of drug-susceptible genomes causes chimeric oligomers to form, thus rendering the drug-susceptible genomes dominant. The use of dominant drug targets should suppress drug resistance whenever multiple genomes arise in the same cell and express products in a common milieu.
C1 [Tanner, Elizabeth J.; Kirkegaard, Karla] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.
[Liu, Hong-mei; Oberste, M. Steven; Pallansch, Mark] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
[Collett, Marc S.] ViroDefense Inc, Rockville, MD USA.
RP Kirkegaard, K (reprint author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.
EM karlak@stanford.edu
OI Tanner, Elizabeth/0000-0001-9445-6620
FU World Health Organization, an NIH training grant; NIH Director's Pioneer
Award
FX This work was supported by the World Health Organization, an NIH
training grant (EJT) and the NIH Director's Pioneer Award (to KK).
NR 32
TC 7
Z9 8
U1 0
U2 0
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD NOV 3
PY 2014
VL 3
AR e03830
DI 10.7554/eLife.03830
PG 32
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA AS3FX
UT WOS:000344163800001
ER
PT J
AU Ruiz, P
Aylward, LL
Mumtaz, M
AF Ruiz, P.
Aylward, L. L.
Mumtaz, M.
TI Application of pharmacokinetic modelling for
2,3,7,8-tetrachlorodibenzo-p-dioxin exposure assessment
SO SAR AND QSAR IN ENVIRONMENTAL RESEARCH
LA English
DT Article
DE 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCDD; PBPK; dioxins; NHANES
ID DIBENZO-P-DIOXINS; TOXIC EQUIVALENCY FACTORS; RISK-ASSESSMENT;
POLYCHLORINATED-BIPHENYLS; ENVIRONMENTAL-POLLUTANTS; TOXICOKINETIC
MODEL; UNITED-STATES; HUMAN TISSUES; NIOSH COHORT; BODY BURDEN
AB Polychlorinated dibenzo-p-dioxins, polychlorinated dibenzofurans, and mono- and non-ortho polychlorinated biphenyls (dioxin-like PCBs) are identified as a family or group of organic compounds known as 'dioxins' or dioxin-like chemicals (DLCs). The most toxic member of this group is 2,3,7,8-tetrachlorodibenzo-(p)-dioxin (TCDD). Historically, DLCs have caused a variety of negative human health effects, but a disfiguring skin condition known as chloracne is the only health effect reported consistently. As part of translational research to make computerized models accessible to health risk assessors, the Concentration- and Age-Dependent Model (CADM) for TCDD was recoded in the Berkeley Madonna simulation language. The US Agency for Toxic Substances and Disease Registry's computational toxicology laboratory used the recoded model to predict TCDD tissue concentrations at different exposure levels. The model simulations successfully reproduced the National Health and Nutrition Examination Survey (NHANES) 2001-2002 TCDD data in age groups from 6 to 60 years and older, as well as in other human datasets. The model also enabled the estimation of lipid-normalized serum TCDD concentrations in breastfed infants. The model performed best for low background exposures over time compared with a high acute poisoning case that could due to the large dose and associated liver toxicity. Hence, this model may be useful for interpreting human biomonitoring data as a part of an overall DLC risk assessment.
C1 [Ruiz, P.; Mumtaz, M.] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Computat Toxicol & Methods Dev Lab, Atlanta, GA 30333 USA.
[Aylward, L. L.] Summit Toxicol, Falls Church, VA USA.
RP Ruiz, P (reprint author), Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Computat Toxicol & Methods Dev Lab, Atlanta, GA 30333 USA.
EM pruiz@cdc.gov
RI Aylward, Lesa/F-7418-2012
OI Aylward, Lesa/0000-0003-3191-8175
NR 57
TC 2
Z9 2
U1 4
U2 15
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1062-936X
EI 1029-046X
J9 SAR QSAR ENVIRON RES
JI SAR QSAR Environ. Res.
PD NOV 2
PY 2014
VL 25
IS 11
BP 873
EP 890
DI 10.1080/1062936X.2014.962083
PG 18
WC Chemistry, Multidisciplinary; Computer Science, Interdisciplinary
Applications; Environmental Sciences; Mathematical & Computational
Biology; Toxicology
SC Chemistry; Computer Science; Environmental Sciences & Ecology;
Mathematical & Computational Biology; Toxicology
GA AT5TU
UT WOS:000345005800002
PM 25397879
ER
PT J
AU Gao, HJ
Aban, IB
Katholi, CR
AF Gao, Hongjiang
Aban, Inmaculada B.
Katholi, Charles R.
TI Properties of a One-Sided Likelihood Ratio Test as Applied to Pool
Screening
SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS
LA English
DT Article
DE Exact test; Statistical power; One-sided likelihood ratio test; Number
of positive pools
ID POLYMERASE-CHAIN-REACTION; ONCHOCERCA-VOLVULUS; WUCHERERIA-BANCROFTI;
INFECTION; TRANSMISSION; PREVALENCE
AB In the control of tropical disease, data are typically collected using pool screening design. When eradication programs have been in place for a period of time, researchers are interested in testing whether the disease prevalence is below a certain target level using one-sided likelihood ratio test (LRT). We will investigate the finite and large-sample properties of this test statistic. Based on simulations, if the number of pools is not large enough, the LRT has inflated type I error rate. Consequently, researchers will make the critical mistake of stopping the treatment when the target level has not been reached.
C1 [Gao, Hongjiang] Natl Ctr Emerging & Zoonot Infect Dis, Div Global Migrat & Quarantine, Atlanta, GA USA.
[Aban, Inmaculada B.; Katholi, Charles R.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
RP Gao, HJ (reprint author), CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,MS E03, Atlanta, GA 30333 USA.
EM hgao@cdc.gov
NR 18
TC 0
Z9 0
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0361-0926
EI 1532-415X
J9 COMMUN STAT-THEOR M
JI Commun. Stat.-Theory Methods
PD NOV 2
PY 2014
VL 43
IS 21
BP 4546
EP 4565
DI 10.1080/03610926.2012.714037
PG 20
WC Statistics & Probability
SC Mathematics
GA AS6GQ
UT WOS:000344362800008
ER
PT J
AU Fairley, TL
Buchanan, N
Johnson-Turbes, A
Schover, LR
Moore, AR
Yancy, B
Schleuter, D
Hall, MAK
Hodges, KP
Shoretz, R
AF Fairley, Temeika L.
Buchanan, Natasha
Johnson-Turbes, Ashani
Schover, Leslie R.
Moore, Angela R.
Yancy, Brandie
Schleuter, Dara
Hall, Mary-Ann K.
Hodges, Kelly P.
Shoretz, Rochelle
TI Developing culturally appropriate interventions providing psychosocial
and reproductive health support to young breast cancer survivors:
Evaluation findings
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Meeting Abstract
C1 [Fairley, Temeika L.; Buchanan, Natasha; Moore, Angela R.; Yancy, Brandie] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Johnson-Turbes, Ashani; Schleuter, Dara; Hall, Mary-Ann K.] ICF Int, Atlanta, GA USA.
[Schover, Leslie R.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Hodges, Kelly P.] Sisters Network Inc, Houston, TX USA.
[Shoretz, Rochelle] Sharsheret, Teaneck, NJ USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD NOV
PY 2014
VL 23
IS 11
SU S
MA C32
DI 10.1158/1538-7755.DISP13-C32
PG 1
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA CP4JA
UT WOS:000359846600159
ER
PT J
AU Graham, S
Lewis, B
Flanagan, B
Watson, M
Peipins, L
AF Graham, Shannon
Lewis, Brian
Flanagan, Barry
Watson, Meg
Peipins, Lucy
TI Racial and ethnic differences in travel time to mammography facilities
in 5 US cities
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Meeting Abstract
C1 [Graham, Shannon; Lewis, Brian; Flanagan, Barry] Agcy Tox Subst & Dis Registry, Atlanta, GA USA.
[Watson, Meg; Peipins, Lucy] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD NOV
PY 2014
VL 23
IS 11
SU S
MA A75
DI 10.1158/1538-7755.DISP13-A75
PG 2
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA CP4JA
UT WOS:000359846600057
ER
PT J
AU Richards, TB
Negoita, S
McNeei, TS
Li, J
Li, C
AF Richards, Thomas B.
Negoita, Serban
McNeei, Timothy S.
Li, Jun
Li, Chunyu
TI Racial disparities in receipt of initial prostate cancer treatment, SEER
Medicare, 2004-2009
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Meeting Abstract
C1 [Richards, Thomas B.; Li, Jun; Li, Chunyu] CDC, Atlanta, GA 30333 USA.
[Negoita, Serban] WESTAT Corp, Rockville, MD 20850 USA.
[McNeei, Timothy S.] Informat Management Serv Inc, Calverton, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD NOV
PY 2014
VL 23
IS 11
SU S
MA C55
DI 10.1158/1538-7755.DISP13-055
PG 1
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA CP4JA
UT WOS:000359846600181
ER
PT J
AU Roland, K
Benard, V
Greek, A
Hawkins, N
Manninen, D
Saraiya, M
AF Roland, Katherine
Benard, Vicki
Greek, April
Hawkins, Nikki
Manninen, Diane
Saraiya, Mona
TI Human papillomavirus vaccine recommendations and beliefs among primary
care providers in federally qualified health centers
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Meeting Abstract
C1 [Roland, Katherine; Benard, Vicki; Hawkins, Nikki; Saraiya, Mona] CDC, Chamblee, GA USA.
[Greek, April; Manninen, Diane] Baltelle, Hlth & Analyt, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD NOV
PY 2014
VL 23
IS 11
SU S
MA A93
DI 10.1158/1538-7755.DISP13-A93
PG 1
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA CP4JA
UT WOS:000359846600072
ER
PT J
AU Watson, M
Benard, V
Thomas, C
Brayboy, A
Paisano, R
Becker, T
AF Watson, Meg
Benard, Vicki
Thomas, Cheryl
Brayboy, Annie
Paisano, Roberta
Becker, Thomas
TI Cervical cancer incidence and mortality disparities among American
Indians and Alaska Natives, 1999-2009
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Meeting Abstract
C1 [Watson, Meg; Benard, Vicki; Thomas, Cheryl; Brayboy, Annie] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Paisano, Roberta] Indian Hlth Serv, Rockville, MD USA.
[Becker, Thomas] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD NOV
PY 2014
VL 23
IS 11
SU S
MA B55
DI 10.1158/1538-7755.DISP13-B55
PG 2
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA CP4JA
UT WOS:000359846600118
ER
PT J
AU Kissoon, N
Uyeki, T
AF Kissoon, Niranjan
Uyeki, Tim
TI Caught napping in the time of tropical diseases
SO CANADIAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Editorial Material
DE education; emergency medicine; imported diseases; tropical diseases
ID INFLUENZA
C1 [Kissoon, Niranjan] Univ British Columbia, Dept Pediat & Emergency Med, Fac Med, Vancouver, BC V6H 3V4, Canada.
[Uyeki, Tim] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA.
RP Kissoon, N (reprint author), Univ British Columbia, Dept Pediat & Emergency Med, Fac Med, 4480 Oak St,Room B 245, Vancouver, BC V6H 3V4, Canada.
NR 15
TC 1
Z9 1
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1481-8035
EI 1481-8043
J9 CAN J EMERG MED
JI Can. J. Emerg. Med.
PD NOV
PY 2014
VL 16
IS 6
BP 429
EP 431
DI 10.2310/8000.2013.131342
PG 3
WC Emergency Medicine
SC Emergency Medicine
GA CD1ZC
UT WOS:000350872200001
PM 25358271
ER
PT J
AU Buckner-Brown, J
Sharify, DT
Blake, B
Phillips, T
Whitten, K
AF Buckner-Brown, Joyce
Sharify, Denise Tung
Blake, Bonita
Phillips, Tom
Whitten, Kathleen
TI Using the Community Readiness Model to Examine the Built and Social
Environment: A Case Study of the High Point Neighborhood, Seattle,
Washington, 2000-2010
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID HEALTH; SEGREGATION; DISPARITIES
AB Background
Residents of many cities lack affordable, quality housing. Economically disadvantaged neighborhoods often have high rates of poverty and crime, few institutions that enhance the quality of its residents' lives, and unsafe environments for walking and other physical activity. Deteriorating housing contributes to asthma-related illness. We describe the redevelopment of High Point, a West Seattle neighborhood, to improve its built environment, increase neighborhood physical activity, and reduce indoor asthma triggers.
Community Context
High Point is one of Seattle's most demographically diverse neighborhoods. Prior to redevelopment, it had a distressed infrastructure, rising crime rates, and indoor environments that increased asthma-related illness in children and adolescents. High Point residents and partners developed and implemented a comprehensive redevelopment plan to create a sustainable built environment to increase outdoor physical activity and improve indoor environments.
Methods
We conducted a retrospective analysis of the High Point redevelopment, organized by the different stages of change in the Community Readiness Model. We also examined the multisector partnerships among government and community groups that contributed to the success of the High Point project.
Outcome
Overall quality of life for residents improved as a result of neighborhood redevelopment. Physical activity increased, residents reported fewer days of poor physical or mental health, and social connectedness between neighbors grew. Asthma-friendly homes significantly decreased asthma-related illness among children and adolescents.
Interpretation
Providing affordable, quality housing to low-income families improved individual and neighborhood quality of life. Efforts to create social change and improve the health outcomes for entire populations are more effective when multiple organizations work together to improve neighborhood health.
C1 [Sharify, Denise Tung] Neighborhood House Community Hlth Program, Seattle, WA USA.
[Blake, Bonita] High Point Community Council, Seattle, WA USA.
[Phillips, Tom] High Point Community, Seattle, WA USA.
[Whitten, Kathleen] ICF Int, Atlanta, GA USA.
RP Buckner-Brown, J (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,NE,Mailstop K81, Atlanta, GA 30333 USA.
EM jbucknerbrown@cdc.gov
NR 21
TC 0
Z9 0
U1 3
U2 8
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD NOV
PY 2014
VL 11
AR E194
DI 10.5888/pcd11.140235
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CB8BB
UT WOS:000349852100006
PM 25376016
ER
PT J
AU Esser, MB
Hedden, SL
Kanny, D
Brewer, RD
Gfroerer, JC
Naimi, TS
AF Esser, Marissa B.
Hedden, Sarra L.
Kanny, Dafna
Brewer, Robert D.
Gfroerer, Joseph C.
Naimi, Timothy S.
TI Prevalence of Alcohol Dependence Among US Adult Drinkers, 2009-2011
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID USE DISORDERS; DSM-IV; BINGE DRINKING; DRUG-USE; CONSUMPTION; PATTERNS;
STATES
AB Introduction
Excessive alcohol consumption is responsible for 88,000 deaths annually and cost the United States $223.5 billion in 2006. It is often assumed that most excessive drinkers are alcohol dependent. However, few studies have examined the prevalence of alcohol dependence among excessive drinkers. The objective of this study was to update prior estimates of the prevalence of alcohol dependence among US adult drinkers.
Methods
Data were analyzed from the 138,100 adults who responded to the National Survey on Drug Use and Health in 2009, 2010, or 2011. Drinking patterns (ie, past-year drinking, excessive drinking, and binge drinking) were assessed by sociodemographic characteristics and alcohol dependence (assessed through self-reported survey responses and defined as meeting >= 3 of 7 criteria for dependence in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition).
Results
Excessive drinking, binge drinking, and alcohol dependence were most common among men and those aged 18 to 24. Binge drinking was most common among those with annual family incomes of $75,000 or more, whereas alcohol dependence was most common among those with annual family incomes of less than $25,000. The prevalence of alcohol dependence was 10.2% among excessive drinkers, 10.5% among binge drinkers, and 1.3% among non-binge drinkers. A positive relationship was found between alcohol dependence and binge drinking frequency.
Conclusion
Most excessive drinkers (90%) did not meet the criteria for alcohol dependence. A comprehensive approach to reducing excessive drinking that emphasizes evidence-based policy strategies and clinical preventive services could have an impact on reducing excessive drinking in addition to focusing on the implementation of addiction treatment services.
C1 [Esser, Marissa B.; Brewer, Robert D.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA.
[Hedden, Sarra L.; Gfroerer, Joseph C.] Subst Abuse & Mental Hlth Serv Adm, Ctr Behav Hlth Stat & Qual, Rockville, MD USA.
[Naimi, Timothy S.] Boston Univ, Med Ctr, Boston, MA 02215 USA.
RP Kanny, D (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Alcohol Program, 4770 Buford Hwy NE,MS-F78, Atlanta, GA 30341 USA.
EM dkk3@cdc.gov
NR 30
TC 21
Z9 21
U1 1
U2 12
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD NOV
PY 2014
VL 11
AR E206
DI 10.5888/pcd11.140329
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CB8BB
UT WOS:000349852100015
PM 25412029
ER
PT J
AU Homer, J
Wile, K
Yarnoff, B
Trogdon, JG
Hirsch, G
Cooper, L
Soler, R
Orenstein, D
AF Homer, Jack
Wile, Kristina
Yarnoff, Benjamin
Trogdon, Justin G.
Hirsch, Gary
Cooper, Lawton
Soler, Robin
Orenstein, Diane
TI Using Simulation to Compare Established and Emerging Interventions to
Reduce Cardiovascular Disease Risk in the United States
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID DYNAMICS; PREVENTION
AB Introduction
Computer simulation offers the ability to compare diverse interventions for reducing cardiovascular disease risks in a controlled and systematic way that cannot be done in the real world.
Methods
We used the Prevention Impacts Simulation Model (PRISM) to analyze the effect of 50 intervention levers, grouped into 6 (2 x 3) clusters on the basis of whether they were established or emerging and whether they acted in the policy domains of care (clinical, mental health, and behavioral services), air (smoking, secondhand smoke, and air pollution), or lifestyle (nutrition and physical activity). Uncertainty ranges were established through probabilistic sensitivity analysis.
Results
Results indicate that by 2040, all 6 intervention clusters combined could result in cumulative reductions of 49% to 54% in the cardiovascular risk-related death rate and of 13% to 21% in risk factor-attributable costs. A majority of the death reduction would come from Established interventions, but Emerging interventions would also contribute strongly. A slim majority of the cost reduction would come from Emerging interventions.
Conclusion
PRISM allows public health officials to examine the potential influence of different types of interventions - both established and emerging - for reducing cardiovascular risks. Our modeling suggests that established interventions could still contribute much to reducing deaths and costs, especially through greater use of well-known approaches to preventive and acute clinical care, whereas emerging interventions have the potential to contribute significantly, especially through certain types of preventive care and improved nutrition.
C1 [Homer, Jack] Homer Consulting, Barrytown, NY USA.
[Wile, Kristina] Sustainabil Inst, Charleston, SC USA.
[Trogdon, Justin G.] Univ N Carolina, Chapel Hill, NC USA.
[Hirsch, Gary] Creator Learning Environm, Wayland, MA USA.
[Cooper, Lawton] NIH, Bethesda, MD 20892 USA.
[Soler, Robin; Orenstein, Diane] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Yarnoff, B (reprint author), RTI Int, 3040 Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA.
EM byarnoff@rti.org
FU Centers for Disease Control and Prevention [200-2008-27958]; National
Heart, Lung, and Blood Institute
FX This research was supported by contract no. 200-2008-27958 Task Order 12
from the Centers for Disease Control and Prevention and National Heart,
Lung, and Blood Institute.
NR 16
TC 5
Z9 5
U1 0
U2 4
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD NOV
PY 2014
VL 11
AR E195
DI 10.5888/pcd11.140130
PG 14
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CB8BB
UT WOS:000349852100002
PM 25376017
ER
PT J
AU Li, J
Thompson, TD
Tai, E
Zhao, GX
Oster, AM
AF Li, Jun
Thompson, Trevor D.
Tai, Eric
Zhao, Guixiang
Oster, Alexandra M.
TI Testing for Human Immunodeficiency Virus Among Cancer Survivors Under
Age 65 in the United States
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID HIV-INFECTION; AIDS; ADULTS; CARE; OPT; PATHOGENESIS; ADOLESCENTS;
POPULATION; PROGRESS
AB Introduction Knowing the human immunodeficiency virus (HIV) serostatus of patients at the time of cancer diagnosis or cancer recurrence is prerequisite to coordinating HIV and cancer treatments and improving treatment outcomes. However, there are no published data about HIV testing among cancer survivors in the United States. We sought to provide estimates of the proportion of cancer survivors tested for HIV and to characterize factors associated with having had HIV testing. Methods We used data from the 2009 Behavioral Risk Factor Surveillance System to calculate the proportion of cancer survivors under age 65 who had undergone HIV testing, by demographic and health-related factors and by state. Adjusted proportion estimates were calculated by multivariable logistic regression. Results Only 41% of cancer survivors in the United States under the age of 65 reported ever having had an HIV test. The highest proportion of survivors tested was among patients aged 25 to 34 years (72.2%), non-Hispanic blacks (59.5%), and cervical cancer survivors (51.2%). The proportion tested was highest in the District of Columbia (68.3%) and lowest in Nebraska (24.1%). Multivariable analysis showed that factors associated with HIV testing included being non-Hispanic black or Hispanic, being younger, having higher education, not being married or living with a partner, not being disabled, and having medical cost concerns. Having an AIDS-related cancer was associated with HIV testing only among females. Conclusion The proportions of HIV testing varied substantially by demographic and health-related factors and by state. Our study points to the need for public health interventions to promote HIV testing among cancer survivors.
C1 [Thompson, Trevor D.; Tai, Eric; Zhao, Guixiang; Oster, Alexandra M.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA.
RP Li, J (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy,MS F76, Atlanta, GA 30341 USA.
EM ffa2@cdc.gov
NR 30
TC 2
Z9 2
U1 0
U2 2
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD NOV
PY 2014
VL 11
AR E200
DI 10.5888/pcd11.140274
PG 14
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CB8BB
UT WOS:000349852100009
PM 25393748
ER
PT J
AU Phelan, EA
Debnam, K
Anderson, L
Owens, S
AF Phelan, E. A.
Debnam, K.
Anderson, L.
Owens, S.
TI PREVENTING HOSPITALIZATIONS IN COMMUNITY-DWELLING OLDER ADULTS LIVING
WITH DEMENTIA: REVIEW OF STUDIES 1990-2013
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Debnam, K.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Anderson, L.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Phelan, E. A.] Univ Washington, Seattle, WA 98195 USA.
[Owens, S.] Directors Hlth Promot & Educ, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
EI 1758-5341
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2014
VL 54
SU 2
BP 12
EP 12
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA AW5TU
UT WOS:000346337500061
ER
PT J
AU Stevens, JA
Ehrenreich, H
Mahoney, JE
AF Stevens, J. A.
Ehrenreich, H.
Mahoney, J. E.
TI CIRCUMSTANCES AND OUTCOMES OF FALLS AMONG HIGH RISK COMMUNITY-DWELLING
OLDER ADULTS
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Stevens, J. A.; Mahoney, J. E.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Ehrenreich, H.] Univ Wisconsin, Sch Med, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
EI 1758-5341
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2014
VL 54
SU 2
BP 151
EP 151
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA AW5TU
UT WOS:000346337501427
ER
PT J
AU Wallender, EK
Ailes, EC
Yoder, JS
Roberts, VA
Brunkard, JM
AF Wallender, Erika K.
Ailes, Elizabeth C.
Yoder, Jonathan S.
Roberts, Virginia A.
Brunkard, Joan M.
TI Contributing Factors to Disease Outbreaks Associated with Untreated
Groundwater
SO GROUNDWATER
LA English
DT Article
ID DRINKING-WATER; UNITED-STATES; GASTROENTERITIS; SYSTEMS; WELL
AB Disease outbreaks associated with drinking water drawn from untreated groundwater sources represent a substantial proportion (30.3%) of the 818 drinking water outbreaks reported to CDC's Waterborne Disease and Outbreak Surveillance System (WBDOSS) during 1971 to 2008. The objectives of this study were to identify underlying contributing factors, suggest improvements for data collection during outbreaks, and inform outbreak prevention efforts. Two researchers independently reviewed all qualifying outbreak reports (1971 to 2008), assigned contributing factors and abstracted additional information (e.g., cases, etiology, and water system attributes). The 248 outbreaks resulted in at least 23,478 cases of illness, 390 hospitalizations, and 13 deaths. The majority of outbreaks had an unidentified etiology (n=135, 54.4%). When identified, the primary etiologies were hepatitis A virus (n=21, 8.5%), Shigella spp. (n=20, 8.1%), and Giardia intestinalis (n=14, 5.7%). Among the 172 (69.4%) outbreaks with contributing factor data available, the leading contamination sources included human sewage (n=57, 33.1%), animal contamination (n=16, 9.3%), and contamination entering via the distribution system (n=12, 7.0%). Groundwater contamination was most often facilitated by improper design, maintenance or location of the water source or nearby waste water disposal system (i.e., septic tank; n=116, 67.4%). Other contributing factors included rapid pathogen transport through hydrogeologic formations (e.g., karst limestone; n=45, 26.2%) and preceding heavy rainfall or flooding (n=36, 20.9%). This analysis underscores the importance of identifying untreated groundwater system vulnerabilities through frequent inspection and routine maintenance, as recommended by protective regulations such as Environmental Protection Agency's (EPA's) Groundwater Rule, and the need for special consideration of the local hydrogeology.
C1 [Wallender, Erika K.] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA.
[Wallender, Erika K.; Ailes, Elizabeth C.; Yoder, Jonathan S.; Roberts, Virginia A.; Brunkard, Joan M.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA.
[Ailes, Elizabeth C.] IHRC, Atlanta, GA 30333 USA.
[Brunkard, Joan M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Brunkard, JM (reprint author), Ctr Dis Control & Prevent, Mailstop C-09,1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM jbrunkard@cdc.gov
NR 34
TC 9
Z9 9
U1 5
U2 33
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-467X
EI 1745-6584
J9 GROUNDWATER
JI Groundwater
PD NOV-DEC
PY 2014
VL 52
IS 6
BP 886
EP 897
DI 10.1111/gwat.12121
PG 12
WC Geosciences, Multidisciplinary; Water Resources
SC Geology; Water Resources
GA AZ1DM
UT WOS:000347980500013
PM 24116713
ER
PT J
AU Nowalk, MP
Nolan, BAD
Nutini, J
Ahmed, F
Albert, SM
Susick, M
Zimmerman, RK
AF Nowalk, Mary Patricia
Nolan, Beth A. D.
Nutini, Jean
Ahmed, Faruque
Albert, Steven M.
Susick, Michael
Zimmerman, Richard K.
TI Success of the 4 Pillars Toolkit for Influenza and Pneumococcal
Vaccination in Adults
SO JOURNAL FOR HEALTHCARE QUALITY
LA English
DT Article
DE adult immunizations; influenza vaccine; pneumococcal polysaccharide
vaccine; standing order programs
ID PRIMARY-CARE PHYSICIANS; STANDING ORDERS; NATIONAL-SURVEY
AB BackgroundStanding order programs (SOPs) allowing nonphysician personnel to assess patients' immunization status and administer vaccines without an individual physician order are a proven method of increasing adult vaccinations, yet they are underutilized by primary care physicians.
MethodsIn a before-and-after trial, a pilot-tested and revised SOP toolkit (4 Pillars Toolkit) was implemented in four diverse primary care practices. Changes in influenza and pneumococcal polysaccharide vaccine (PPSV) vaccination rates were measured. The toolkit was evaluated using direct observation, group interviews, and surveys of each practice's staff.
ResultsUse of the 4 Pillars Toolkit varied across sites. PPSV rates increased significantly overall for high-risk adults (18-64 years; 25% in 2010-2011 vs. 40% in 2011-2012, p = .02) but not for older adults (65 years; 44% vs. 52%, p = .26) and in two of four practices among both high-risk and older adults (p < .05). Influenza vaccination rates increased significantly in three of four sites and overall (22% in 2010-2011 vs. 33% in 2011-2012, overall; p < .001). Practices more fully implementing the toolkit demonstrated larger increases in vaccination rates.
ConclusionsThe 4 Pillars Toolkit is a promising means of improving primary care practice across diverse settings, with better results observed when strategies were maximally utilized.
C1 [Ahmed, Faruque] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Nutini, Jean; Albert, Steven M.; Zimmerman, Richard K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA.
[Nolan, Beth A. D.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Inst Evaluat Sci, Pittsburgh, PA USA.
[Nowalk, Mary Patricia; Susick, Michael; Zimmerman, Richard K.] Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA 15260 USA.
RP Nowalk, MP (reprint author), Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA 15260 USA.
EM tnowalk@pitt.edu
OI Zimmerman, Richard/0000-0001-5941-6092; Albert,
Steven/0000-0001-6786-9956
FU Association for Prevention Teaching and Research (APTR) [TS-1432]
FX This publication was made possible through the Centers for Disease
Control and Prevention (CDC) and the Association for Prevention Teaching
and Research (APTR) Cooperative Agreement No. 5U50CD300860, Project
TS-1432. The findings and conclusions in this publication are those of
the authors and do not necessarily represent the views of the CDC or the
APTR.
NR 15
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1062-2551
EI 1945-1474
J9 J HEALTHC QUAL
JI J. Healthc. Qual.
PD NOV-DEC
PY 2014
VL 36
IS 6
BP 5
EP 15
DI 10.1111/jhq.12020
PG 11
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA AZ8DB
UT WOS:000348443900001
PM 23777396
ER
PT J
AU Gregg, EW
Zhuo, XH
Cheng, YLJ
Albright, AL
Narayan, KMV
Thompson, TJ
AF Gregg, Edward W.
Zhuo, Xiaohui
Cheng, Yiling J.
Albright, Ann L.
Narayan, K. M. Venkat
Thompson, Theodore J.
TI Trends in lifetime risk and years of life lost due to diabetes in the
USA, 1985-2011: a modelling study
SO LANCET DIABETES & ENDOCRINOLOGY
LA English
DT Article
ID MORTALITY TRENDS; UNITED-STATES; POPULATION; PREVALENCE; COMPLICATIONS;
ASSOCIATION; CRITERIA; ONTARIO; CANADA; BURDEN
AB Background Diabetes incidence has increased and mortality has decreased greatly in the USA, potentially leading to substantial changes in the lifetime risk of diabetes. We aimed to provide updated estimates for the lifetime risk of development of diabetes and to assess the effect of changes in incidence and mortality on lifetime risk and life-years lost to diabetes in the USA.
Methods We incorporated data about diabetes incidence from the National Health Interview Survey, and linked data about mortality from 1985 to 2011 for 598 216 adults, into a Markov chain model to estimate remaining lifetime diabetes risk, years spent with and without diagnosed diabetes, and life-years lost due to diabetes in three cohorts: 1985-89, 1990-99, and 2000-11. Diabetes was determined by self-report and was classified as any diabetes, excluding gestational diabetes. We used logistic regression to estimate the incidence of diabetes and Poisson regression to estimate mortality.
Findings On the basis of 2000-11 data, lifetime risk of diagnosed diabetes from age 20 years was 40.2% (95% CI 39.2-41.3) for men and 39.6% (38.6-40.5) for women, representing increases of 20 percentage points and 13 percentage points, respectively, since 1985-89. The highest lifetime risks were in Hispanic men and women, and non-Hispanic black women, for whom lifetime risk now exceeds 50%. The number of life-years lost to diabetes when diagnosed at age 40 years decreased from 7.7 years (95% CI 6.5-9.0) in 1990-99 to 5.8 years (4.6-7.1) in 2000-11 in men, and from 8.7 years (8.4-8.9) to 6.8 years (6.7-7.0) in women over the same period. Because of the increasing diabetes prevalence, the average number of years lost due to diabetes for the population as a whole increased by 46% in men and 44% in women. Years spent with diabetes increased by 156% in men and 70% in women.
Interpretation Continued increases in the incidence of diagnosed diabetes combined with declining mortality have led to an acceleration of lifetime risk and more years spent with diabetes, but fewer years lost to the disease for the average individual with diabetes. These findings mean that there will be a continued need for health services and extensive costs to manage the disease, and emphasise the need for effective interventions to reduce incidence.
C1 [Gregg, Edward W.; Zhuo, Xiaohui; Cheng, Yiling J.; Albright, Ann L.; Thompson, Theodore J.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA.
[Narayan, K. M. Venkat] Emory Univ, Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
RP Gregg, EW (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
EM edg7@cdc.gov
FU Department of Health and Human Services, Centers for Disease Control and
Prevention
FX This work was funded by the Department of Health and Human Services,
Centers for Disease Control and Prevention. The findings and conclusions
in this report are those of the authors and do not necessarily represent
the official position of the sponsors.
NR 30
TC 60
Z9 60
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2213-8587
J9 LANCET DIABETES ENDO
JI Lancet Diabetes Endocrinol.
PD NOV
PY 2014
VL 2
IS 11
BP 867
EP 874
DI 10.1016/S2213-8587(14)70161-5
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AY8BP
UT WOS:000347779800013
PM 25128274
ER
PT J
AU Ramanathan, T
AF Ramanathan, Tara
TI Legal Mechanisms Supporting Accountable Care Principles
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Editorial Material
ID ALTERNATIVE QUALITY; ORGANIZATIONS; CONTRACT
C1 [Ramanathan, Tara] US Ctr Dis Control & Prevent, Publ Hlth Law Program, Off State Tribal Local & Terr Support, Atlanta, GA USA.
RP Ramanathan, T (reprint author), Ctr Dis Control & Prevent, Publ Hlth Law Program, 4770 Buford Hwy NE,MS E-70, Atlanta, GA 30341 USA.
EM tramanathan@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 16
TC 1
Z9 1
U1 0
U2 3
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD NOV
PY 2014
VL 104
IS 11
BP 2048
EP 2051
DI 10.2105/AJPH.2014.302161
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AX8UR
UT WOS:000347184400034
PM 25211740
ER
PT J
AU Malilay, J
Heumann, M
Perrotta, D
Wolkin, AF
Schnall, AH
Podgornik, MN
Cruz, MA
Horney, JA
Zane, D
Roisman, R
Greenspan, JR
Thoroughman, D
Anderson, HA
Wells, EV
Simms, EF
AF Malilay, Josephine
Heumann, Michael
Perrotta, Dennis
Wolkin, Amy F.
Schnall, Amy H.
Podgornik, Michelle N.
Cruz, Miguel A.
Horney, Jennifer A.
Zane, David
Roisman, Rachel
Greenspan, Joel R.
Thoroughman, Doug
Anderson, Henry A.
Wells, Eden V.
Simms, Erin F.
TI The Role of Applied Epidemiology Methods in the Disaster Management
Cycle
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID RAPID NEEDS-ASSESSMENT; CENTER HEALTH REGISTRY; INFLUENZA-A H1N1; 1994
NORTHRIDGE; SAMPLING METHOD; EXPOSURE; SURVEILLANCE; INJURIES; OKLAHOMA;
EARTHQUAKE
AB Disaster epidemiology (i.e., applied epidemiology in disaster settings) presents a source of reliable and actionable information for decision-makers and stakeholders in the disaster management cycle. However, epidemiological methods have yet to be routinely integrated into disaster response and fully communicated to response leaders. We present a framework consisting of rapid needs assessments, health surveillance, tracking and registries, and epidemiological investigations, including risk factor and health outcome studies and evaluation of interventions, which can be practiced throughout the cycle. Applying each method can result in actionable information for planners and decision-makers responsible for preparedness, response, and recovery. Disaster epidemiology, once integrated into the disaster management cycle, can provide the evidence base to inform and enhance response capability within the public health infrastructure.
C1 [Malilay, Josephine; Wolkin, Amy F.; Schnall, Amy H.; Podgornik, Michelle N.; Cruz, Miguel A.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
[Heumann, Michael] HeumannHlth Consulting, Portland, OR USA.
[Perrotta, Dennis; Simms, Erin F.] Council State & Terr Epidemiologists, Atlanta, GA USA.
[Horney, Jennifer A.] Univ N Carolina, Ctr Publ Hlth Preparedness, Chapel Hill, NC USA.
[Roisman, Rachel] Calif Dept Publ Hlth, Richmond, CA USA.
[Greenspan, Joel R.] Martin Blanck & Associates, Alexandria, VA USA.
[Thoroughman, Doug] Kentucky Dept Publ Hlth, Frankfort, KY USA.
[Anderson, Henry A.] Off State Hlth Officer Chief Med Officer, Madison, WI USA.
[Wells, Eden V.] Univ Michigan, Sch Publ Hlth, Clin Epidemiol & Prevent Med Residency, Ann Arbor, MI 48109 USA.
RP Malilay, J (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,Mailstop F-60, Atlanta, GA 30341 USA.
EM jmalilay@cdc.gov
FU Centers for Disease Control and Prevention [5U38HM000414]
FX This work was supported by Cooperative Agreement 5U38HM000414-05 awarded
to Council of State and Territorial Epidemiologists from Centers for
Disease Control and Prevention.
NR 97
TC 10
Z9 10
U1 0
U2 11
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD NOV
PY 2014
VL 104
IS 11
BP 2092
EP 2102
DI 10.2105/AJPH.2014.302010
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AX8UR
UT WOS:000347184400045
PM 25211748
ER
PT J
AU Zibbell, JE
Hart-Malloy, R
Barry, J
Fan, L
Flanigan, C
AF Zibbell, Jon E.
Hart-Malloy, Rachel
Barry, John
Fan, Lillian
Flanigan, Colleen
TI Risk Factors for HCV Infection Among Young Adults in Rural New York Who
Inject Prescription Opioid Analgesics
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID HEPATITIS-C VIRUS; DRUG PREPARATION EQUIPMENT; UNITED-STATES; USERS;
PREVALENCE; HIV; TRANSMISSION; SEROCONVERSION; SYRINGES; SURVIVAL
AB Objectives. We investigated a cluster of new hepatitis C cases in rural New York among a cohort of young people who inject drugs (PWID) and misuse prescription opioid analgesics (POA).
Methods. We recruited a purposive sample of PWID from Cortland County for an in-person survey and HCV rapid antibody test (March-July 2012). We examined sociodemographics, drugs currently injected, and lifetime and recent injection behaviors to ascertain associations with HCV antibody (anti-HCV) positivity.
Results. Of 123 PWID, 76 (61.8%) were younger than 30 years, and 100 (81.3%) received HCV rapid testing. Of those tested, 34 (34.0%) were positive. Participants who reported injecting POA in the past 12 months were 5 times more likely to be anti-HCV positive than those who injected drugs other than POA, and participants who reported sharing injection equipment in the past 12 months were roughly 4 times more likely to be anti-HCV positive than those who did not.
Conclusions. Our analysis suggests people injecting POA may be at higher risk for HCV infection than people who inject heroin or other drugs but not POA.
C1 [Zibbell, Jon E.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA.
[Hart-Malloy, Rachel; Flanigan, Colleen] New York State Dept Hlth, AIDS Inst, Albany, NY USA.
[Hart-Malloy, Rachel] SUNY Albany, Dept Epidemiol & Biostat, Albany, NY 12222 USA.
[Barry, John; Fan, Lillian] Southern Tier AIDS Program, Broome Cty, NY USA.
RP Zibbell, JE (reprint author), Ctr Dis Control & Prevent, Prevent Branch, Div Viral Hepatitis, 1600 Clifton Rd NE,MS G-37, Atlanta, GA 30333 USA.
EM jzibbell@cdc.gov
NR 46
TC 16
Z9 16
U1 4
U2 8
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD NOV
PY 2014
VL 104
IS 11
BP 2226
EP 2232
DI 10.2105/AJPH.2014.302142
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AX8UR
UT WOS:000347184400062
PM 25211717
ER
PT J
AU Abara, WE
Smith, L
Zhang, S
Fairchild, AJ
Heiman, HJ
Rust, G
AF Abara, Winston E.
Smith, Lerissa
Zhang, Shun
Fairchild, Amanda J.
Heiman, Harry J.
Rust, George
TI The Influence of Race and Comorbidity on the Timely Initiation of
Antiretroviral Therapy Among Older Persons Living With HIV/AIDS
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID HIV-INFECTED PATIENTS; IMMUNODEFICIENCY-VIRUS-INFECTION; UNITED-STATES;
RACIAL/ETHNIC DISPARITIES; ADMINISTRATIVE DATA; RACIAL DISPARITIES;
HAART ERA; HEALTH; ADULTS; CARE
AB Objectives. We examined whether the timely initiation of antiretroviral therapy (ART) differed by race and comorbidity among older (>= 50 years) people living with HIV/AIDS (PLWHA).
Methods. We conducted frequency and descriptive statistics analysis to characterize our sample, which we drew from 2005-2007 Medicaid claims data from 14 states. We employed univariate and multivariable Cox regression analyses to evaluate the relationship between race, comorbidity, and timely ART initiation (<= 90 days post-HIV/AIDS diagnosis).
Results. Approximately half of the participants did not commence ART promptly. After we adjusted for covariates, we found that older PLWHA who reported a comorbidity were 40% (95% confidence interval = 0.26, 0.61) as likely to commence ART promptly. We found no racial differences in the timely initiation of ART among older PLWHA.
Conclusions. Comorbidities affect timely ART initiation in older PLWHA. Older PLWHA may benefit from integrating and coordinating HIV care with care for other comorbidities and the development of ART treatment guidelines specific to older PLWHA. Consistent Medicaid coverage helps ensure consistent access to HIV treatment and care and may eliminate racial disparities in timely ART initiation among older PLWHA.
C1 [Abara, Winston E.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
[Smith, Lerissa; Heiman, Harry J.] Morehouse Sch Med, Satcher Hlth Leadership Inst, Atlanta, GA 30310 USA.
[Zhang, Shun; Rust, George] Morehouse Sch Med, Natl Ctr Primary Care, Atlanta, GA 30310 USA.
[Fairchild, Amanda J.] Univ S Carolina, Dept Psychol, Columbia, SC 29208 USA.
RP Abara, WE (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
EM winston_abara@yahoo.com
FU Agency for Healthcare Research and Quality (AHRQ) as part of the
Multiple Chronic Conditions Research Collaborative [1R24HS019470-01]
FX This research was supported in part by funding from the Agency for
Healthcare Research and Quality (AHRQ grant 1R24HS019470-01) as part of
the Multiple Chronic Conditions Research Collaborative.
NR 65
TC 6
Z9 6
U1 1
U2 4
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD NOV
PY 2014
VL 104
IS 11
BP E135
EP E141
DI 10.2105/AJPH.2014.302227
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AX8UR
UT WOS:000347184400022
PM 25211735
ER
PT J
AU Kucik, JE
Nembhard, WN
Donohue, P
Devine, O
Wang, Y
Minkovitz, CS
Burke, T
AF Kucik, James E.
Nembhard, Wendy N.
Donohue, Pamela
Devine, Owen
Wang, Ying
Minkovitz, Cynthia S.
Burke, Thomas
TI Community Socioeconomic Disadvantage and the Survival of Infants With
Congenital Heart Defects
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID IN-HOSPITAL MORTALITY; UNITED-STATES; BIRTH-DEFECTS; RACIAL/ETHNIC
DISPARITIES; NEIGHBORHOOD INCOME; RACIAL DISPARITIES; ETHNIC
DISPARITIES; OROFACIAL CLEFTS; FETAL DIAGNOSIS; DOWN-SYNDROME
AB Objectives. We examined the association between survival of infants with severe congenital heart defects (CHDs) and community-level indicators of socioeconomic status.
Methods. We identified infants born to residents of Arizona, New Jersey, New York, and Texas between 1999 and 2007 with selected CHDs from 4 population-based, statewide birth defect surveillance programs. We linked data to the 2000 US Census to obtain 11 census tract-level socioeconomic indicators. We estimated survival probabilities and hazard ratios adjusted for individual characteristics.
Results. We observed differences in infant survival for 8 community socioeconomic indicators (P < .05). The greatest mortality risk was associated with residing in communities in the most disadvantaged deciles for poverty (adjusted hazard ratio [AHR] = 1.49; 95% confidence interval [CI] = 1.11, 1.99), education (AHR = 1.51; 95% CI = 1.16, 1.96), and operator or laborer occupations (AHR = 1.54; 95% CI = 1.16, 1.96). Survival decreased with increasing numbers of indicators that were in the most disadvantaged decile. Community-level mortality risk persisted when we adjusted for individual-level characteristics.
Conclusions. The increased mortality risk among infants with CHDs living in socioeconomically deprived communities might indicate barriers to quality and timely care at which public health interventions might be targeted.
C1 [Kucik, James E.; Devine, Owen] Ctr Dis Control & Prevent, Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
[Nembhard, Wendy N.] Univ S Florida, Coll Publ Hlth, Dept Epidemiol & Biostat, Tampa, FL USA.
[Donohue, Pamela] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA.
[Wang, Ying] New York State Dept Hlth, Bur Environm & Occupat Epidemiol, Albany, NY USA.
[Minkovitz, Cynthia S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA.
[Burke, Thomas] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
RP Kucik, JE (reprint author), 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA.
EM jkucik@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 62
TC 6
Z9 6
U1 4
U2 6
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD NOV
PY 2014
VL 104
IS 11
BP E150
EP E157
DI 10.2105/AJPH.2014.302099
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AX8UR
UT WOS:000347184400024
PM 25211743
ER
PT J
AU Wikswo, M
AF Wikswo, Mary
TI Outbreaks of Acute Gastroenteritis Transmitted by Person-to-Person
Contact - United States, 2009-2010
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Editorial Material
C1 CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Wikswo, M (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM ezq1@cdc.gov
NR 0
TC 1
Z9 2
U1 2
U2 2
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD NOV
PY 2014
VL 104
IS 11
BP E13
EP E14
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AX8UR
UT WOS:000347184400008
ER
PT J
AU Park, GW
Cho, M
Cates, EL
Lee, D
Oh, BT
Vinje, J
Kim, JH
AF Park, Geun Woo
Cho, Min
Cates, Ezra L.
Lee, David
Oh, Byung-Taek
Vinje, Jan
Kim, Jae-Hong
TI Fluorinated TiO2 as an ambient light-activated virucidal surface coating
material for the control of human norovirus
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE F-TiO2; Human norovirus; Norovirus surrogates; Surface disinfection
ID NORWALK-LIKE VIRUSES; PHOTOCATALYTIC DISINFECTION; TITANIUM-DIOXIDE;
ESCHERICHIA-COLI; COPPER SURFACES; INACTIVATION; GASTROENTERITIS;
OXIDATION; EFFICACY; INFECTIONS
AB We evaluated the virucidal efficacy of light-activated fluorinated TiO2 surface coatings on human norovirus and several surrogates (bacteriophage MS2, feline calcivirus (FCV), and murine norovirus (MNV)). Inactivation of viruses on surfaces exposed to a common fluorescent lamp was monitored and the effects of UVA intensity, temperature, and fluoride content were assessed. Destruction of RNA and capsid oxidation were evaluated for human norovirus inocula on the F-TiO2 surfaces, while contact with the F-TiO2 surface and exposure to residual UVA radiation of 10 mu W cm(-2) for 60 min resulted in infectivity reductions for the norovirus surrogates of 2-3 log(10). Infectivity reductions on pristine TiO2 surfaces in identical conditions were over 2 orders of magnitude lower. Under realistic room lighting conditions, MS2 infectivity declined below the lower detection limit after 12 h. Reductions in RNA were generally low, with the exception of GII.4, while capsid protein oxidation likely played a larger role in infectivity loss. Inactivation of norovirus surrogates occurred significantly faster on F-TiO2 compared to pristine TiO2 surfaces. The material demonstrated antiviral action against human norovirus surrogates and was shown to effectively inhibit MS2 when exposed to residual UVA present in fluorescent room lighting conditions in a laboratory setting. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Park, Geun Woo; Lee, David; Vinje, Jan] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA.
[Cho, Min; Oh, Byung-Taek] Chonbuk Natl Univ, Coll Environm & Bioresource Sci, Adv Inst Environm Biosci, Div Biotechnol, Iksan 570752, Jeonbuk, South Korea.
[Cates, Ezra L.; Kim, Jae-Hong] Yale Univ, Dept Chem & Environm Engn, New Haven, CT 06520 USA.
[Lee, David] Atlanta Res & Educ Fdn, Atlanta, GA 30033 USA.
RP Cho, M (reprint author), Chonbuk Natl Univ, Coll Environm & Bioresource Sci, Adv Inst Environm Biosci, Div Biotechnol, Iksan 570752, Jeonbuk, South Korea.
EM cho317@jbnu.ac.kr
RI Kim, Jae-Hong/G-7901-2012
FU Korean National Research Foundation (Korean Ministry of Education,
Science and Technology) [NRF-2011-35B-D00020]; Ministry of Food and Drug
Safety, Korea [14162MFDS973]; Hwaseung TC Co. in Korea
FX We thank Dr. Christine Moe for providing the Norwalk virus (GI.1) stool
sample. This work was partly supported by the Korean National Research
Foundation (Korean Ministry of Education, Science and Technology, Award
NRF-2011-35B-D00020), the grant (14162MFDS973) from Ministry of Food and
Drug Safety, Korea and Hwaseung T&C Co. in Korea. All authors report
having no conflicts of interest.
NR 39
TC 5
Z9 5
U1 2
U2 14
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD NOV
PY 2014
VL 140
BP 315
EP 320
DI 10.1016/j.jphotobiol.2014.08.009
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA AX6FM
UT WOS:000347018600038
PM 25222145
ER
PT J
AU Azarian, T
Ali, A
Johnson, JA
Mohr, D
Prosperi, M
Veras, NM
Jubair, M
Strickland, SL
Rashid, MH
Alam, MT
Weppelmann, TA
Katz, LS
Tarr, CL
Colwell, RR
Morris, G
Salemi, M
AF Azarian, Taj
Ali, Afsar
Johnson, Judith A.
Mohr, David
Prosperi, Mattia
Veras, Nazle M.
Jubair, Mohammed
Strickland, Samantha L.
Rashid, Mohammad H.
Alam, Meer T.
Weppelmann, Thomas A.
Katz, Lee S.
Tarr, Cheryl L.
Colwell, Rita R.
Morris, Glenn, Jr.
Salemi, Marco
TI Phylodynamic Analysis of Clinical and Environmental Vibrio cholerae
Isolates from Haiti Reveals Diversification Driven by Positive Selection
SO MBIO
LA English
DT Article
ID MAXIMUM-LIKELIHOOD; PHYLOGENETIC ANALYSIS; POPULATION-DYNAMICS; EL-TOR;
EVOLUTIONARY; INFERENCE; MODEL; OUTBREAK; STRAIN; TRANSMISSION
AB Phylodynamic analysis of genome-wide single-nucleotide polymorphism (SNP) data is a powerful tool to investigate underlying evolutionary processes of bacterial epidemics. The method was applied to investigate a collection of 65 clinical and environmental isolates of Vibrio cholerae from Haiti collected between 2010 and 2012. Characterization of isolates recovered from environmental samples identified a total of four toxigenic V. cholerae O1 isolates, four non-O1/O139 isolates, and a novel nontoxigenic V. cholerae O1 isolate with the classical tcpA gene. Phylogenies of strains were inferred from genome-wide SNPs using coalescent-based demographic models within a Bayesian framework. A close phylogenetic relationship between clinical and environmental toxigenic V. cholerae O1 strains was observed. As cholera spread throughout Haiti between October 2010 and August 2012, the population size initially increased and then fluctuated over time. Selection analysis along internal branches of the phylogeny showed a steady accumulation of synonymous substitutions and a progressive increase of nonsynonymous substitutions over time, suggesting diversification likely was driven by positive selection. Short-term accumulation of nonsynonymous substitutions driven by selection may have significant implications for virulence, transmission dynamics, and even vaccine efficacy.
IMPORTANCE Cholera, a dehydrating diarrheal disease caused by toxigenic strains of the bacterium Vibrio cholerae, emerged in 2010 in Haiti, a country where there were no available records on cholera over the past 100 years. While devastating in terms of morbidity and mortality, the outbreak provided a unique opportunity to study the evolutionary dynamics of V. cholerae and its environmental presence. The present study expands on previous work and provides an in-depth phylodynamic analysis inferred from genome-wide single nucleotide polymorphisms of clinical and environmental strains from dispersed geographic settings in Haiti over a 2-year period. Our results indicate that even during such a short time scale, V. cholerae in Haiti has undergone evolution and diversification driven by positive selection, which may have implications for understanding the global clinical and epidemiological patterns of the disease. Furthermore, the continued presence of the epidemic strain in Haitian aquatic environments has implications for transmission.
C1 [Azarian, Taj] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Epidemiol, Gainesville, FL USA.
[Azarian, Taj] Univ Florida, Coll Med, Gainesville, FL USA.
[Azarian, Taj; Ali, Afsar; Johnson, Judith A.; Prosperi, Mattia; Veras, Nazle M.; Jubair, Mohammed; Strickland, Samantha L.; Rashid, Mohammad H.; Alam, Meer T.; Weppelmann, Thomas A.; Morris, Glenn, Jr.; Salemi, Marco] Univ Florida, Coll Publ Hlth & Hlth Profess, Emerging Pathogens Inst, Gainesville, FL 32611 USA.
[Ali, Afsar; Johnson, Judith A.; Salemi, Marco] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Pathol Immunol & Lab Med, Gainesville, FL USA.
[Jubair, Mohammed; Weppelmann, Thomas A.] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Environm & Global Hlth, Gainesville, FL USA.
[Mohr, David] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA.
[Prosperi, Mattia] Univ Manchester, Inst Populat Hlth, Ctr Hlth Informat, Manchester, Lancs, England.
[Katz, Lee S.; Tarr, Cheryl L.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA USA.
[Colwell, Rita R.] Univ Maryland, Maryland Pathogen Res Inst, College Pk, MD 20742 USA.
[Colwell, Rita R.] Univ Maryland, Inst Adv Comp Studies, College Pk, MD 20742 USA.
[Colwell, Rita R.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Salemi, M (reprint author), Univ Florida, Coll Publ Hlth & Hlth Profess, Emerging Pathogens Inst, Gainesville, FL 32611 USA.
EM jgmorris@epi.ufl.edu; salemi@pathology.ufl.edu
FU NIH R01 grant [AI097405]
FX This work was supported by NIH R01 grant AI097405.
NR 71
TC 9
Z9 9
U1 1
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD NOV-DEC
PY 2014
VL 5
IS 6
AR e01824
DI 10.1128/mBio.01824-14
PG 11
WC Microbiology
SC Microbiology
GA AX7CE
UT WOS:000347073600008
ER
PT J
AU Johnson, TL
Hinnebusch, BJ
Boegler, KA
Graham, CB
MacMillan, K
Montenieri, JA
Bearden, SW
Gage, KL
Eisen, RJ
AF Johnson, Tammi L.
Hinnebusch, B. Joseph
Boegler, Karen A.
Graham, Christine B.
MacMillan, Katherine
Montenieri, John A.
Bearden, Scott W.
Gage, Kenneth L.
Eisen, Rebecca J.
TI Yersinia murine toxin is not required for early-phase transmission of
Yersinia pestis by Oropsylla montana (Siphonaptera: Ceratophyllidae) or
Xenopsylla cheopis (Siphonaptera: Pulicidae)
SO MICROBIOLOGY-SGM
LA English
DT Article
ID PLAGUE EPIZOOTICS; PRAIRIE DOGS; PIGMENTATION PHENOTYPE; VECTOR
COMPETENCE; BIOFILM FORMATION; FLEAS; EXPRESSION; EFFICIENCY; DYNAMICS;
LOCUS
AB Plague, caused by Yersinia pestis, is characterized by quiescent periods punctuated by rapidly spreading epizootics. The classical 'blocked flea' paradigm, by which a blockage forms in the flea's proventriculus on average 1-2 weeks post-infection (p.i.), forces starving fleas to take multiple blood meals, thus increasing opportunities for transmission. Recently, the importance of early-phase transmission (EPT), which occurs prior to blockage formation, has been emphasized during epizootics. Whilst the physiological and molecular mechanisms of blocked flea transmission are well characterized, the pathogen vector interactions have not been elucidated for EPT. Within the blocked flea model, Yersinia murine toxin (Ymt) has been shown to be important for facilitating colonization of the midgut within the flea. One proposed mechanism of EPT is the regurgitation of infectious material from the flea midgut during feeding. Such a mechanism would require bacteria to colonize and survive for at least brief periods in the midgut, a process that is mediated by Ymt. Two key bridging vectors of Y. pestis to humans, Oropsylla montana (Siphonaptera: Ceratophyllidae) or Xenopsylla cheopis (Siphonaptera: Pulicidae), were used in our study to test this hypothesis. Fleas were infected with a mutant strain of Y. pestis containing a non-functional ymt that was shown previously to be incapable of colonizing the midgut and were then allowed to feed on SKH-1 mice 3 days p.i. Our results show that Ymt was not required for EPT by either flea species.
C1 [Johnson, Tammi L.; Boegler, Karen A.; Graham, Christine B.; MacMillan, Katherine; Montenieri, John A.; Bearden, Scott W.; Gage, Kenneth L.; Eisen, Rebecca J.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA.
[Hinnebusch, B. Joseph] NIAID, Lab Zoonot Pathogens, Rocky Mt Labs, NIH, Hamilton, MT USA.
RP Johnson, TL (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA.
EM uzj6@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 37
TC 6
Z9 7
U1 2
U2 9
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
BERKS, ENGLAND
SN 1350-0872
J9 MICROBIOL-SGM
JI Microbiology-(UK)
PD NOV
PY 2014
VL 160
BP 2517
EP 2525
DI 10.1099/mic.0.082123-0
PN 11
PG 9
WC Microbiology
SC Microbiology
GA AX6GN
UT WOS:000347021200017
PM 25187626
ER
PT J
AU Davis, CT
Chen, LM
Pappas, C
Stevens, J
Tumpey, TM
Gubareva, LV
Katz, JM
Villanueva, JM
Donis, RO
Cox, NJ
AF Davis, C. Todd
Chen, Li-Mei
Pappas, Claudia
Stevens, James
Tumpey, Terrence M.
Gubareva, Larisa V.
Katz, Jacqueline M.
Villanueva, Julie M.
Donis, Ruben O.
Cox, Nancy J.
TI Use of Highly Pathogenic Avian Influenza A(H5N1) Gain-Of-Function
Studies for Molecular-Based Surveillance and Pandemic Preparedness
SO MBIO
LA English
DT Article
ID RECEPTOR-BINDING SPECIFICITY; A H5N1 VIRUSES; H7N9 VIRUS; TRANSMISSION;
FERRETS; OSELTAMIVIR; SUSCEPTIBILITY; SUBSTITUTION; REPLICATION;
MUTATIONS
C1 [Davis, C. Todd; Chen, Li-Mei; Pappas, Claudia; Stevens, James; Tumpey, Terrence M.; Gubareva, Larisa V.; Katz, Jacqueline M.; Villanueva, Julie M.; Donis, Ruben O.; Cox, Nancy J.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Cox, NJ (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM njc1@cdc.gov
NR 57
TC 8
Z9 8
U1 1
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD NOV-DEC
PY 2014
VL 5
IS 6
AR e02431-14
DI 10.1128/mBio.02431-14
PG 6
WC Microbiology
SC Microbiology
GA AX7CE
UT WOS:000347073600069
ER
PT J
AU Hughes, K
Bellis, MA
Hardcastle, KA
Butchart, A
Dahlberg, LL
Mercy, JA
Mikton, C
AF Hughes, Karen
Bellis, Mark A.
Hardcastle, Katherine A.
Butchart, Alexander
Dahlberg, Linda L.
Mercy, James A.
Mikton, Christopher
TI Global development and diffusion of outcome evaluation research for
interpersonal and self-directed violence prevention from 2007 to 2013: A
systematic review
SO AGGRESSION AND VIOLENT BEHAVIOR
LA English
DT Review
DE Violence prevention; Evaluation; Evidence; Global health
ID ADVERSE CHILDHOOD EXPERIENCES; RANDOMIZED CONTROLLED-TRIAL;
SOUTH-AFRICA; ABUSE; COUNTRIES; DISEASE; SKILLS
AB Through a global review, we identified gaps in the geographical distribution of violence prevention evidence outcome evaluation studies and the types of violence addressed. Systematic literature searches identified 355 articles published between 2007 and 2013 that evaluated programs to prevent interpersonal or self-directed violence; focused on universal or selected populations; and reported outcomes measuring violence or closely related risk factors. The number of studies identified increased annually from 2008 (n = 37), reaching 64 in 2013. Over half (n = 203) of all studies focused on youth violence yet only one on elder maltreatment. Study characteristics varied by year and violence type. Only 93% of all studies had been conducted in LMICs. These studies were less likely than those in high income countries (HICs) to have tested established interventions yet more likely to involve international collaboration. Evaluation studies successfully established in LMIC had often capitalized on other major regional priorities (e.g. HIV). Relationships between violence and social determinants, communicable and non-communicable diseases, and even economic prosperity should be explored as mechanisms to increase the global reach of violence prevention research. Results should inform future research strategies and provide a baseline for measuring progress in developing the violence prevention evidence-base, especially in LMICs. (C) 2014 The Authors. Published by Elsevier Ltd.
C1 [Hughes, Karen; Bellis, Mark A.; Hardcastle, Katherine A.] Liverpool John Moores Univ, Ctr Publ Hlth, Liverpool L3 2ET, Merseyside, England.
[Butchart, Alexander; Mikton, Christopher] World Hlth Org, Dept Violence & Injury Prevent & Disabil, CH-1211 Geneva 27, Switzerland.
[Dahlberg, Linda L.; Mercy, James A.] US Ctr Dis Control & Prevent, Atlanta, GA 30332 USA.
RP Bellis, MA (reprint author), Liverpool John Moores Univ, Ctr Publ Hlth, 15-21 Webster St, Liverpool L3 2ET, Merseyside, England.
EM k.e.hughes@ljmu.ac.uk; m.a.bellis@ljmu.ac.uk; k.a.hardcastle@ljmu.ac.uk;
butcharta@who.int; lld0@cdc.gov; jam2@cdc.gov; miktonc@who.int
NR 32
TC 7
Z9 7
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-1789
EI 1873-6335
J9 AGGRESS VIOLENT BEH
JI Aggress. Violent Behav.
PD NOV-DEC
PY 2014
VL 19
IS 6
SI SI
BP 655
EP 662
DI 10.1016/j.avb.2014.09.006
PG 8
WC Criminology & Penology; Psychology, Multidisciplinary
SC Criminology & Penology; Psychology
GA AW8XC
UT WOS:000346541700008
ER
PT J
AU Alagramam, KN
Stepanyan, R
Jamesdaniel, S
Chen, DHC
Davis, RR
AF Alagramam, Kumar N.
Stepanyan, Ruben
Jamesdaniel, Samson
Chen, Daniel H. -C.
Davis, Rickie R.
TI Noise exposure immediately activates cochlear mitogen-activated protein
kinase signaling
SO NOISE & HEALTH
LA English
DT Article
DE Acoustic trauma; mitogen-activated protein kinase signaling; noise
induced gene expression; noise induced hearing loss; permanent threshold
shift
ID INDUCED HEARING-LOSS; DIFFERENTIAL GENE-EXPRESSION; IMPULSE NOISE;
OXIDATIVE STRESS; RAT COCHLEA; HAIR-CELLS; INNER-EAR; PROTECTION; MICE
AB Noise-induced hearing loss (NIHL) is a major public health issue worldwide. Uncovering the early molecular events associated with NIHL would reveal mechanisms leading to the hearing loss. Our aim is to investigate the immediate molecular responses after different levels of noise exposure and identify the common and distinct pathways that mediate NIHL. Previous work showed mice exposed to 116 decibels sound pressure level (dB SPL) broadband noise for 1 h had greater threshold shifts than the mice exposed to 110 dB SPL broadband noise, hence we used these two noise levels in this study. Groups of 4-8-week-old CBA/CaJ mice were exposed to no noise (control) or to broadband noise for 1 h, followed by transcriptome analysis of total cochlear RNA isolated immediately after noise exposure. Previously identified and novel genes were found in all data sets. Following exposure to noise at 116 dB SPL, the earliest responses included up-regulation of 243 genes and down-regulation of 61 genes, while a similar exposure at 110 dB SPL up-regulated 155 genes and down-regulated 221 genes. Bioinformatics analysis indicated that mitogen-activated protein kinase (MAPK) signaling was the major pathway in both levels of noise exposure. Nevertheless, both qualitative and quantitative differences were noticed in some MAPK signaling genes, after exposure to different noise levels. Cacna1b, Cacna1g, and Pla2g6, related to calcium signaling were down-regulated after 110 dB SPL exposure, while the fold increase in the expression of Fos was relatively lower than what was observed after 116 dB SPL exposure. These subtle variations provide insight on the factors that may contribute to the differences in NIHL despite the activation of a common pathway.
C1 [Alagramam, Kumar N.; Stepanyan, Ruben; Chen, Daniel H. -C.] Case Western Reserve Univ, Dept Otolaryngol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA.
[Davis, Rickie R.] Univ Cincinnati, Dept Biol Sci, Cincinnati, OH 45221 USA.
[Davis, Rickie R.] NIOSH, Div Appl Res & Technol, Dept Hlth & Human Serv, Cincinnati, OH 45226 USA.
[Jamesdaniel, Samson] Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI USA.
RP Alagramam, KN (reprint author), Case Western Reserve Univ, Dept Otolaryngol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA.
EM kna3@case.edu
OI Jamesdaniel, Samson/0000-0002-5269-9007
FU NIH [R21-DC07866]
FX This work was supported by a grant (R21-DC07866) from the NIH to K.N.A.
NR 30
TC 3
Z9 3
U1 0
U2 3
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 1463-1741
EI 1998-4030
J9 NOISE HEALTH
JI Noise Health
PD NOV-DEC
PY 2014
VL 16
IS 73
BP 400
EP 409
DI 10.4103/1463-1741.144418
PG 10
WC Audiology & Speech-Language Pathology; Public, Environmental &
Occupational Health
SC Audiology & Speech-Language Pathology; Public, Environmental &
Occupational Health
GA AW0NM
UT WOS:000345989400008
PM 25387536
ER
PT J
AU Cassell, CH
Grosse, SD
Kirby, RS
AF Cassell, Cynthia H.
Grosse, Scott D.
Kirby, Russell S.
TI Leveraging Birth Defects Surveillance Data for Health Services Research
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Editorial Material
ID CONGENITAL HEART-DISEASE; PRIVATELY INSURED POPULATION;
SPECIAL-EDUCATION SERVICES; QUALITY-OF-LIFE; CARE EXPENDITURES;
OROFACIAL CLEFTS; SPINA-BIFIDA; PUBLIC-HEALTH; NORTH-CAROLINA;
UNITED-STATES
C1 [Cassell, Cynthia H.; Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
[Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Birth Defects Surveillance Program, Tampa, FL USA.
RP Cassell, CH (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
NR 64
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD NOV
PY 2014
VL 100
IS 11
SI SI
BP 815
EP 821
DI 10.1002/bdra.23330
PG 7
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA AU6CQ
UT WOS:000345690600002
PM 25369783
ER
PT J
AU Honein, MA
Devine, O
Grosse, SD
Reefhuis, J
AF Honein, Margaret A.
Devine, Owen
Grosse, Scott D.
Reefhuis, Jennita
TI Prevention of Orofacial Clefts Caused by Smoking: Implications of the
Surgeon General's Report
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Article
DE smoking; orofacial clefts; prevention; healthcare costs
ID ASSESSMENT MONITORING-SYSTEM; BIRTH-DEFECTS; UNITED-STATES; PREGNANCY;
HEALTH; PRECONCEPTION; POPULATION; INFANT; IMPACT
AB BACKGROUND: According to the 2014 Surgeon General's Report, smoking in early pregnancy can cause orofacial clefts. We sought to examine the implications of this causal link for the potential prevention of orofacial clefts in the United States. METHODS: Using published data on the strength of the association between orofacial clefts and smoking in early pregnancy and the prevalence of smoking at the start of pregnancy, we estimated the attributable fraction for smoking as a cause of orofacial clefts. We then used the prevalence of orofacial clefts in the United States to estimate the number of orofacial clefts that could be prevented in the United States each year by eliminating exposure to smoking during early pregnancy. We also estimated the financial impact of preventing orofacial clefts caused by maternal smoking based on a published estimate of attributable healthcare costs through age 10 for orofacial clefts. RESULTS: The estimated attributable fraction of orofacial clefts caused by smoking in early pregnancy was 6.1% (95% uncertainty interval 4.4%, 7.7%). Complete elimination of smoking in early pregnancy could prevent orofacial clefts in approximately 430 infants per year in the United States, and could save an estimated $40.4 million in discounted healthcare costs through age 10 for each birth cohort. CONCLUSION: Understanding the magnitude of the preventable burden of orofacial clefts related to maternal smoking could help focus smoking cessation efforts on women who might become pregnant. Birth Defects Research (Part A) 100:822-825, 2014. (c) 2014 Wiley Periodicals, Inc.
C1 [Honein, Margaret A.; Devine, Owen; Grosse, Scott D.; Reefhuis, Jennita] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
RP Honein, MA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Mailstop E-86,1600 Clifton Rd, Atlanta, GA 30333 USA.
EM mhonein@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 15
TC 2
Z9 2
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD NOV
PY 2014
VL 100
IS 11
SI SI
BP 822
EP 825
DI 10.1002/bdra.23274
PG 4
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA AU6CQ
UT WOS:000345690600003
PM 25045059
ER
PT J
AU Dawson, AL
Cassell, CH
Oster, ME
Olney, RS
Tanner, JP
Kirby, RS
Correia, J
Grosse, SD
AF Dawson, April L.
Cassell, Cynthia H.
Oster, Matthew E.
Olney, Richard S.
Tanner, Jean Paul
Kirby, Russell S.
Correia, Jane
Grosse, Scott D.
TI Hospitalizations and Associated Costs in a Population-Based Study of
Children with Down Syndrome Born in Florida
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Article
DE Down syndrome; congenital heart defect; cost; hospital; birth defects
surveillance
ID CONGENITAL HEART-DISEASE; BIRTH-DEFECTS; UNITED-STATES; CARE; INFANTS;
PREVALENCE
AB BackgroundOur objective was to examine differences in hospital resource usage for children with Down syndrome by age and the presence of other birth defects, particularly severe and nonsevere congenital heart defects (CHDs).
MethodsThis was a retrospective, population-based, statewide study of children with Down syndrome born 1998 to 2007, identified by the Florida Birth Defects Registry (FBDR) and linked to hospital discharge records for 1 to 10 years after birth. To evaluate hospital resource usage, descriptive statistics on number of hospitalized days and hospital costs were calculated. Results were stratified by isolated Down syndrome (no other coded major birth defect); presence of severe and nonsevere CHDs; and presence of major FBDR-eligible birth defects without CHDs.
ResultsFor 2552 children with Down syndrome, there were 6856 inpatient admissions, of which 68.9% occurred during the first year of life (infancy). Of the 2552 children, 31.7% (n=808) had isolated Down syndrome, 24.0% (n=612) had severe CHDs, 36.3% (n=927) had nonsevere CHDs, and 8.0% (n=205) had a major FBDR-eligible birth defect in the absence of CHD. Infants in all three nonisolated DS groups had significantly higher hospital costs compared with those with isolated Down syndrome. From infancy through age 4, children with severe CHDs had the highest inpatient costs compared with children in the other sub-groups.
ConclusionResults support findings that for children with Down syndrome the presence of other anomalies influences hospital use and costs, and children with severe CHDs have greater hospital resource usage than children with other CHDs or major birth defects without CHDs. Birth Defects Research (Part A) 100:826-836, 2014. (c) 2014 Wiley Periodicals, Inc.
C1 [Dawson, April L.; Cassell, Cynthia H.; Oster, Matthew E.; Olney, Richard S.; Grosse, Scott D.] CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
[Tanner, Jean Paul; Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Birth Defects Surveillance Program, Tampa, FL USA.
[Correia, Jane] Bur Epidemiol, Florida Birth Defects Registry, Div Dis Control & Hlth Protect, Florida Dept Hlth, Tallahassee, FL USA.
RP Dawson, AL (reprint author), 1600 Clifton Rd MS-E86, Atlanta, GA 30333 USA.
EM isp3@cdc.gov
FU March of Dimes Foundation
FX The authors thank the staff of the Florida Department of Health's FBDR,
Children's Medical Services Program, and Florida AHCA for data
accessibility and acquisition. We also thank Adrienne Henderson and
Gloria Barker with the Florida AHCA, Florida Center for Health
Information and Policy Analysis and Karen Freeman with the Florida
Department of Health for consultations on hospital discharge data and
Florida hospitals. We thank Jason L. Salemi at the University of South
Florida and Marie Bailey at the Florida Department of Health for
consultations on data linkages and variables. Lastly, we acknowledge the
March of Dimes Foundation for providing funding for this project. The
authors have no financial relationships relevant to this article to
disclose. The authors have no conflicts of interest to disclose. Parts
of this manuscript were presented at the following meetings: Connecting
What Counts: Surveillance, Services, and Supports for Children with Down
Syndrome Conference, October 11 to 12, 2012, Tampa, Florida; Maternal
Child Health/Epidemiology Conference, San Antonio, Texas, December 12 to
14, 2012; National Birth Defects Prevention Network Annual Meeting,
Atlanta, Georgia, February 25 to 27, 2013; and Pediatric Research
Retreat: Common Complex Childhood Diseases, Atlanta, Georgia, June 28,
2013. The findings and conclusions in this report are those of the
authors and do not necessarily represent the official position of the
Centers for Disease Control and Prevention.
NR 28
TC 3
Z9 3
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD NOV
PY 2014
VL 100
IS 11
SI SI
BP 826
EP 836
DI 10.1002/bdra.23295
PG 11
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA AU6CQ
UT WOS:000345690600004
PM 25124730
ER
PT J
AU Cassell, CH
Strassle, P
Mendez, DD
Lee, KA
Krohmer, A
Meyer, RE
Strauss, RP
AF Cassell, Cynthia H.
Strassle, Paula
Mendez, Dara D.
Lee, Kyung A.
Krohmer, Anne
Meyer, Robert E.
Strauss, Ronald P.
TI Barriers to Care for Children with Orofacial Clefts in North Carolina
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Article
DE health services accessibility; access to health care; orofacial clefts;
cleft lip; cleft palate; birth defects
ID HEALTH-CARE; MEDICAL HOME; CRANIOFACIAL CARE; NATIONAL-SURVEY; NEEDS;
ACCESS; PARENTS; QUESTIONNAIRE; EXPENDITURES; LANGUAGE
AB BackgroundLittle is known about the barriers faced by families of children with birth defects in obtaining healthcare. We examined reported perceived barriers to care and satisfaction with care among mothers of children with orofacial clefts.
MethodsIn 2006, a validated barriers to care mail/phone survey was administered in North Carolina to all resident mothers of children with orofacial clefts born between 2001 and 2004. Potential participants were identified using the North Carolina Birth Defects Monitoring Program, an active, state-wide, population-based birth defects registry. Five barriers to care subscales were examined: pragmatics, skills, marginalization, expectations, and knowledge/beliefs. Descriptive and bivariate analyses were conducted using chi-square and Fisher's exact tests. Results were stratified by cleft type and presence of other birth defects.
ResultsOf 475 eligible participants, 51.6% (n=245) responded. The six most commonly reported perceived barriers to care were all part of the pragmatics subscale: having to take time off work (45.3%); long waits in the waiting rooms (37.6%); taking care of household responsibilities (29.7%); meeting other family members' needs (29.5%); waiting too many days for appointments (27.0%); and cost (25.0%). Most respondents (72.3%, 175/242) felt very satisfied with their child's cleft care.
ConclusionAlthough most participants reported being satisfied with their child's care, many perceived barriers to care were identified. Due to the limited understanding and paucity of research on barriers to care for children with birth defects, including orofacial clefts, additional research on barriers to care and factors associated with them are needed. Birth Defects Research (Part A) 100:837-847, 2014. (c) 2014 Wiley Periodicals, Inc.
C1 [Cassell, Cynthia H.; Strassle, Paula; Lee, Kyung A.; Krohmer, Anne] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
[Strassle, Paula] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
[Mendez, Dara D.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
[Lee, Kyung A.] Northrop Grumman Informat Syst, Atlanta, GA USA.
[Krohmer, Anne] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA.
[Meyer, Robert E.] State Ctr Hlth Stat, North Carolina Div Publ Hlth, North Carolina Birth Defects Monitoring Program, Raleigh, NC USA.
[Strauss, Ronald P.] Univ N Carolina, Off Execut Vice Chancellor & Provost, Chapel Hill, NC USA.
[Strauss, Ronald P.] Univ N Carolina, Dept Dent Ecol, Chapel Hill, NC USA.
[Strauss, Ronald P.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[Strauss, Ronald P.] Univ N Carolina, Dept Social Med, Chapel Hill, NC USA.
RP Cassell, CH (reprint author), CDC, Div Birth Defects & Dev Disabil, NCBDDD, 1600 Clifton Rd,Mail Stop E-86, Atlanta, GA 30329 USA.
EM chcassell@cdc.gov
OI Mendez, Dara/0000-0003-3999-1991
FU National Center on Birth Defects and Developmental Disabilities, Centers
for Disease Control and Prevention [U50/CCU422096]
FX Supported in part by grant number U50/CCU422096 by the National Center
on Birth Defects and Developmental Disabilities, Centers for Disease
Control and Prevention.
NR 31
TC 5
Z9 5
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD NOV
PY 2014
VL 100
IS 11
SI SI
BP 837
EP 847
DI 10.1002/bdra.23303
PG 11
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA AU6CQ
UT WOS:000345690600005
PM 25200965
ER
PT J
AU Hoyt, AT
Canfield, MA
Shaw, GM
Waller, DK
Polen, KND
Ramadhani, T
Anderka, MT
Scheuerle, AE
AF Hoyt, Adrienne T.
Canfield, Mark A.
Shaw, Gary M.
Waller, Dorothy K.
Polen, Kara N. D.
Ramadhani, Tunu
Anderka, Marlene T.
Scheuerle, Angela E.
CA Natl Birth Defects Prevention
TI Sociodemographic and Hispanic Acculturation Factors and Isolated
Anotia/Microtia
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Article
DE anotia; microtia; acculturation; nativity; Hispanic
ID BIRTH-DEFECTS PREVENTION; CONGENITAL-MALFORMATIONS; EPIDEMIOLOGIC
FEATURES; MICROTIA; POPULATION; CHILDREN; ANOTIA; SURVEILLANCE;
CALIFORNIA; ETHNICITY
AB BackgroundIt has been observed in several studies that infants with anotia/microtia are more common among Hispanics compared with other racial/ethnic groups. We examined the association between selected Hispanic ethnicity and acculturation factors and anotia/microtia in the National Birth Defects Prevention Study.
MethodsWe examined data from mothers of 351 infants with isolated anotia/microtia and 8435 unaffected infants from the National Birth Defects Prevention Study with an expected delivery date from 1997 to 2007. Sociodemographic, maternal, and acculturation factors (e.g., age, maternal education, household income, body mass index, gestational diabetes, folic acid, smoking, alcohol intake, study center, parental birthplace, and years lived in the United States, maternal language) were assessed as overall risk factors and also as risk factors among subgroups of Hispanics (United States- and foreign-born) versus non-Hispanic whites.
ResultsCompared with non-Hispanic whites, both United States- and foreign-born Hispanic mothers demonstrated substantially higher odds of delivering infants with anotia/microtia across nearly all strata of sociodemographic and other maternal factors (adjusted odds ratios range: 2.1-11.9). The odds of anotia/microtia was particularly elevated among Hispanic mothers who emigrated from Mexico after age five (adjusted odds ratios=4.88; 95% confidence interval=2.93-8.11) or who conducted the interview in Spanish (adjusted odds ratios=4.97; 95% confidence interval=3.00-8.24).
ConclusionWe observed that certain sociodemographic and acculturation factors are associated with higher risks of anotia/microtia among offspring of Hispanic mothers. Birth Defects Research (Part A) 100:852-862, 2014. (c) 2014 Wiley Periodicals, Inc.
C1 [Hoyt, Adrienne T.; Canfield, Mark A.] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX 78714 USA.
[Shaw, Gary M.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
[Waller, Dorothy K.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX 77030 USA.
[Polen, Kara N. D.] CDC, NCBDDD, Atlanta, GA 30333 USA.
[Ramadhani, Tunu] Texas Dept State Hlth Serv, Ctr Hlth Stat, Austin, TX 78714 USA.
[Anderka, Marlene T.] Massachusetts Ctr Birth Defects Res & Prevent, Massachusetts State Dept Publ Hlth, Boston, MA USA.
[Scheuerle, Angela E.] Tesserae Genet, Dallas, TX USA.
RP Hoyt, AT (reprint author), Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, 1100 W 49th St,MAILCODE 1964,POB 149347, Austin, TX 78714 USA.
EM adrienne.hoyt@dshs.state.tx.us
FU Centers for Disease Control and Prevention [U01DD000494]; Texas
Department of State Health Services (DSHS) [U01DD000494]
FX This publication was supported in part through a cooperative agreement
(U01DD000494) between the Centers for Disease Control and Prevention and
the Texas Department of State Health Services (DSHS).
NR 47
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD NOV
PY 2014
VL 100
IS 11
SI SI
BP 852
EP 862
DI 10.1002/bdra.23282
PG 11
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA AU6CQ
UT WOS:000345690600007
PM 25074828
ER
PT J
AU Conway, KMC
Romitti, PA
Holmes, L
Olney, RS
Richardson, SD
AF Conway, Kristin M. Caspers
Romitti, Paul A.
Holmes, Lewis
Olney, Richard S.
Richardson, Sandra D.
CA Natl Birth Defects Prevention
TI Maternal Periconceptional Alcohol Consumption and Congenital Limb
Deficiencies
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Article
DE limb deficiencies; congenital; maternal exposure; pregnancy; alcohol
drinking; folic acid
ID BIRTH-DEFECTS PREVENTION; URINARY FOLATE EXCRETION; FOR-GESTATIONAL-AGE;
REDUCTION DEFECTS; ACUTE ETHANOL; CHOLESTEROL DEFICIENCY; PRETERM BIRTH;
UNITED-STATES; PREGNANCY; EXPOSURE
AB Background: Women of childbearing age report high rates of alcohol consumption, which may result in alcohol exposure during early pregnancy. Epidemiological research on congenital limb deficiencies (LDs) and periconceptional exposure to alcohol is inconclusive. Methods: Data from the National Birth Defects Prevention Study (NBDPS) were examined for associations between LDs and patterns of maternal periconceptional (1 month before conception through the first trimester) alcohol consumption among LD case (n=906) and unaffected control (n=8352) pregnancies with expected delivery dates from 10/1997 through 12/2007. Adjusted odds ratios (aORs) and 95% confidence intervals were estimated from unconditional logistic regression analysis for all LDs combined, specific LD subtypes (preaxial/terminal transverse), and LD anatomic groups (upper/lower limbs); interactions with folic acid (FA) supplementation were tested. Results: When compared with nondrinkers, inverse associations were found between all LDs combined, preaxial, and upper LDs and any reported periconceptional alcohol consumption (aORs ranged from 0.56-0.83), drinking without binging (aORs: 0.53-0.75), and binge drinking (4 drinks/occasion) (aORs: 0.64-0.94); however, none of the binge drinking aORs were statistically significant. Stratification by alcohol type showed inverse associations between all LDs combined, preaxial, transverse, and upper and lower LDs for drinking without binging of wine only (aORs: 0.39-0.67) and between all LDs combined and upper LDs for drinking without binging of combinations of alcohol (aORs: 0.63-0.87). FA did not modify observed associations. Conclusion: Maternal periconceptional alcohol consumption did not emerge as a teratogen for selected LDs in the NBDPS. Future studies should evaluate additional rare LDs among more highly exposed populations. Birth Defects Research (Part A) 100:863-876, 2014. (c) 2014 Wiley Periodicals, Inc.
C1 [Conway, Kristin M. Caspers; Romitti, Paul A.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA 52242 USA.
[Holmes, Lewis] Massachusetts Gen Hosp, Genet & Teratol Unit, Boston, MA 02114 USA.
[Olney, Richard S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
[Richardson, Sandra D.] Bur Environm & Occupat Epidemiol, Congenital Malformat Registry, New York State Dept Hlth, Albany, NY USA.
RP Romitti, PA (reprint author), Univ Iowa, Dept Epidemiol, Coll Publ Hlth, S416 CPHB,145 N Riverside Dr, Iowa City, IA 52242 USA.
EM paul-romitti@uiowa.edu
FU Centers for Disease Control and Prevention [U01/DD000492]; Birth Defects
Study To Evaluate Pregnancy exposureS [U01/DD001035]
FX This work was supported by cooperative agreements from the Centers for
Disease Control and Prevention to the Iowa Center for Birth Defects
Research and Prevention participating in the National Birth Defects
Prevention Study (U01/DD000492) and the Birth Defects Study To Evaluate
Pregnancy exposureS (U01/DD001035).
NR 55
TC 1
Z9 1
U1 1
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD NOV
PY 2014
VL 100
IS 11
SI SI
BP 863
EP 876
DI 10.1002/bdra.23292
PG 14
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA AU6CQ
UT WOS:000345690600008
ER
PT J
AU Makelarski, JA
Romitti, PA
Rocheleau, CM
Burns, TL
Stewart, PA
Waters, MA
Lawson, CC
Bell, EM
Lin, S
Shaw, GM
Olney, RS
AF Makelarski, Jennifer A.
Romitti, Paul A.
Rocheleau, Carissa M.
Burns, Trudy L.
Stewart, Patricia A.
Waters, Martha A.
Lawson, Christina C.
Bell, Erin M.
Lin, Shao
Shaw, Gary M.
Olney, Richard S.
CA Natl Birth Defects Prevention
TI Maternal Periconceptional Occupational Pesticide Exposure and Neural
Tube Defects
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Article
DE birth defects; neural tube defects; occupational exposure; pesticides;
pregnancy
ID FOOD FREQUENCY QUESTIONNAIRE; FOLIC-ACID ANTAGONISTS; ADULT
BRAIN-TUMORS; BIRTH-DEFECTS; AGRICULTURAL WORK; RISK; PREGNANCY;
PREVENTION; MALFORMATIONS; POPULATION
AB Background: Adverse associations between maternal pesticide exposure and neural tube defects (NTDs) have been suggested but not consistently observed. This study used data from the multisite National Birth Defects Prevention Study to examine associations between maternal periconceptional (1 month preconception through 2 months postconception) occupational pesticide exposure and NTDs. Methods: Mothers of 502 NTD cases and 2950 unaffected live-born control infants with estimated delivery dates from 1997 through 2002 were included. Duration, categorical intensity scores, and categorical frequency scores for pesticide classes (e.g., insecticides) were assigned using a modified, literature-based job-exposure matrix and maternal-reported occupational histories. Adjusted odds ratios (aORs) and 95% confidence intervals were estimated based on fitted multivariable logistic regression models that described associations between maternal periconceptional occupational pesticide exposure and NTDs. The aORs were estimated for pesticide exposure (any [yes/no] and cumulative exposure [intensity x frequency x duration] to any pesticide class, each pesticide class, or combination of pesticide classes) and all NTD cases combined and NTD subtypes. Results: Positive, but marginally significant or nonsignificant, aORs were observed for exposure to insecticides+herbicides for all NTD cases combined and for spina bifida alone. Similarly, positive aORs were observed for any exposure and cumulative exposure to insecticides + herbicides + fungicides and anencephaly alone and encephalocele alone. All other aORs were near unity. Conclusion: Pesticide exposure associations varied by NTD subtype and pesticide class. Several aORs were increased, but not significantly. Future work should continue to examine associations between pesticide classes and NTD subtypes using a detailed occupational pesticide exposure assessment and examine pesticide exposures outside the workplace. Birth Defects Research (Part A) 100:877-886, 2014. (c) 2014 Wiley Periodicals, Inc.
C1 [Makelarski, Jennifer A.; Romitti, Paul A.; Burns, Trudy L.] Univ Iowa, Dept Epidemiol, Iowa City, IA 52242 USA.
[Rocheleau, Carissa M.; Waters, Martha A.; Lawson, Christina C.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA.
[Stewart, Patricia A.] Stewart Exposure Assessments LLC, Arlington, VA USA.
[Bell, Erin M.] SUNY Albany, Dept Environm Hlth Sci, Albany, NY 12222 USA.
[Bell, Erin M.] SUNY Albany, Dept Epidemiol, Albany, NY 12222 USA.
[Lin, Shao] New York State Dept Hlth, Ctr Environm Hlth, Albany, NY USA.
[Shaw, Gary M.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA.
[Olney, Richard S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
RP Romitti, PA (reprint author), Univ Iowa, S416 CPHB,145 N Riverside Dr, Iowa City, IA 52242 USA.
EM paul-romitti@uiowa.edu
OI Lin, Shao/0000-0002-5535-7504
FU Centers for Disease Control and Prevention [5U01DD000492, 1U01DD001035];
Nutrition Epidemiology Core of the University of North Carolina Clinical
Nutrition Research Center [DK56350]; National Institute for Occupational
Safety and Health [200-2000-08018]
FX This work was funded by grants (5U01DD000492 and 1U01DD001035) from the
Centers for Disease Control and Prevention, which participated in study
design and data collection. Coding of drug information in the National
Birth Defects Prevention Study used the Slone Drug Dictionary under
license from the Slone Epidemiology Center of Boston University.
Nutritional analysis was supported by grant no. DK56350 from the
Nutrition Epidemiology Core of the University of North Carolina Clinical
Nutrition Research Center. Exposure assessment was supported by contract
200-2000-08018 from the National Institute for Occupational Safety and
Health.
NR 38
TC 3
Z9 4
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD NOV
PY 2014
VL 100
IS 11
SI SI
BP 877
EP 886
DI 10.1002/bdra.23293
PG 10
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA AU6CQ
UT WOS:000345690600009
PM 25124525
ER
PT J
AU Mai, CT
Cassell, CH
Meyer, RE
Isenburg, J
Canfield, MA
Rickard, R
Olney, RS
Stallings, EB
Beck, M
Hashmi, SS
Cho, SJ
Kirby, RS
AF Mai, Cara T.
Cassell, Cynthia H.
Meyer, Robert E.
Isenburg, Jennifer
Canfield, Mark A.
Rickard, Russel
Olney, Richard S.
Stallings, Erin B.
Beck, Meredith
Hashmi, S. Shahrukh
Cho, Sook Ja
Kirby, Russell S.
CA Natl Birth Defects Prevention
TI Birth Defects Data from Population-based Birth Defects Surveillance
Programs in the United States, 2007 to 2011: Highlighting Orofacial
Clefts
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Article
DE orofacial clefts; birth defects; population-based surveillance
ID ORAL CLEFTS; INFANT CHARACTERISTICS; RISK; PREVALENCE; PREGNANCY;
MALFORMATIONS; EPIDEMIOLOGY; CHILDREN; TOBACCO; PALATE
AB (c) 2014 The Authors Birth Defects Research Part A: Clinical and Molecular Teratology Published by Wiley Periodicals, Inc.
C1 [Mai, Cara T.; Cassell, Cynthia H.; Olney, Richard S.; Beck, Meredith] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
[Meyer, Robert E.] State Ctr Hlth Stat, North Carolina Div Publ Hlth, North Carolina Birth Defects Monitoring Program, Raleigh, NC USA.
[Isenburg, Jennifer; Stallings, Erin B.] Carter Consulting, Atlanta, GA USA.
[Canfield, Mark A.] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX USA.
[Rickard, Russel] Natl Birth Defects Prevent Network, Houston, TX USA.
[Hashmi, S. Shahrukh] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, Houston, TX 77030 USA.
[Cho, Sook Ja] Minnesota Dept Hlth, Div Community & Family Hlth, St Paul, MN USA.
[Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Tampa, FL USA.
RP Mai, CT (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
EM cwm7@cdc.gov
OI Hashmi, S. Shahrukh/0000-0001-8758-8254
FU Intramural CDC HHS [CC999999]
NR 39
TC 12
Z9 12
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD NOV
PY 2014
VL 100
IS 11
SI SI
BP 895
EP 904
DI 10.1002/bdra.23329
PG 10
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA AU6CQ
UT WOS:000345690600011
PM 25399767
ER
PT J
AU Alfano, CM
Smith, T
de Moor, JS
Glasgow, RE
Khoury, MJ
Hawkins, NA
Stein, KD
Rechis, R
Parry, C
Leach, CR
Padgett, L
Rowland, JH
AF Alfano, Catherine M.
Smith, Tenbroeck
de Moor, Janet S.
Glasgow, Russell E.
Khoury, Muin J.
Hawkins, Nikki A.
Stein, Kevin D.
Rechis, Ruth
Parry, Carla
Leach, Corinne R.
Padgett, Lynne
Rowland, Julia H.
TI An Action Plan for Translating Cancer Survivorship Research Into Care
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Editorial Material
ID UNITED-STATES; HEALTH; INTEGRATION; SCIENCE; COLLABORATION;
EPIDEMIOLOGY; POPULATION; ISSUES; POLICY
AB To meet the complex needs of a growing number of cancer survivors, it is essential to accelerate the translation of survivorship research into evidence-based interventions and, as appropriate, recommendations for care that may be implemented in a wide variety of settings. Current progress in translating research into care is stymied, with results of many studies un- or underutilized. To better understand this problem and identify strategies to encourage the translation of survivorship research findings into practice, four agencies (American Cancer Society, Centers for Disease Control and Prevention, LIVE STRONG Foundation, National Cancer Institute) hosted a meeting in June, 2012, titled: "Biennial Cancer Survivorship Research Conference: Translating Science to Care." Meeting participants concluded that accelerating science into care will require a coordinated, collaborative effort by individuals from diverse settings, including researchers and clinicians, survivors and families, public health professionals, and policy makers. This commentary describes an approach stemming from that meeting to facilitate translating research into care by changing the process of conducting research-improving communication, collaboration, evaluation, and feedback through true and ongoing partnerships. We apply the T0-T4 translational process model to survivorship research and provide illustrations of its use. The resultant framework is intended to orient stakeholders to the role of their work in the translational process and facilitate the transdisciplinary collaboration needed to translate basic discoveries into best practices regarding clinical care, self-care/management, and community programs for cancer survivors. Finally, we discuss barriers to implementing translational survivorship science identified at the meeting, along with future directions to accelerate this process.
C1 [Alfano, Catherine M.; Parry, Carla; Padgett, Lynne] NCI, Behav Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[de Moor, Janet S.] NCI, Appl Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Glasgow, Russell E.] NCI, Implementat Sci Team, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Khoury, Muin J.] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Rowland, Julia H.] NCI, Off Canc Survivorship, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Smith, Tenbroeck; Stein, Kevin D.; Leach, Corinne R.] Amer Canc Soc, Behav Res Ctr, Atlanta, GA 30329 USA.
[Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA.
[Hawkins, Nikki A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA.
[Rechis, Ruth] LIVESTRONG Fdn, Austin, TX USA.
RP Alfano, CM (reprint author), NCI, Div Canc Control & Populat Sci, NIH, 9609 Med Ctr Dr MSC 9764, Bethesda, MD 20892 USA.
EM catherine.alfano@nih.gov
NR 31
TC 8
Z9 8
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD NOV
PY 2014
VL 106
IS 11
AR dju287
DI 10.1093/jnci/dju287
PG 9
WC Oncology
SC Oncology
GA AU7IG
UT WOS:000345773500008
ER
PT J
AU Valentino, MD
McGuire, AM
Rosch, JW
Bispo, PJM
Burnham, C
Sanfilippo, CM
Carter, RA
Zegans, ME
Beall, B
Earl, AM
Tuomanen, EI
Morris, TW
Haas, W
Gilmore, MS
AF Valentino, Michael D.
McGuire, Abigail Manson
Rosch, Jason W.
Bispo, Paulo J. M.
Burnham, Corinna
Sanfilippo, Christine M.
Carter, Robert A.
Zegans, Michael E.
Beall, Bernard
Earl, Ashlee M.
Tuomanen, Elaine I.
Morris, Timothy W.
Haas, Wolfgang
Gilmore, Michael S.
TI Unencapsulated Streptococcus pneumoniae from conjunctivitis encode
variant traits and belong to a distinct phylogenetic cluster
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GROUP-B STREPTOCOCCI; OPHTHALMIC SUSPENSION 0.6-PERCENT; C-PROTEIN
COMPLEX; BACTERIAL CONJUNCTIVITIS; ANTIMICROBIAL RESISTANCE;
STAPHYLOCOCCUS-AUREUS; PNEUMOCOCCAL VACCINE; SPECIES DEFINITION;
EPITHELIAL-CELLS; FAMILY ADHESINS
AB Streptococcus pneumoniae, an inhabitant of the upper respiratory mucosa, causes respiratory and invasive infections as well as conjunctivitis. Strains that lack the capsule, a main virulence factor and the target of current vaccines, are often isolated from conjunctivitis cases. Here we perform a comparative genomic analysis of 271 strains of conjunctivitis-causing S. pneumoniae from 72 postal codes in the United States. We find that the vast majority of conjunctivitis strains are members of a distinct cluster of closely related unencapsulated strains. These strains possess divergent forms of pneumococcal virulence factors (such as CbpA and neuraminidases) that are not shared with other unencapsulated nasopharyngeal S. pneumoniae. They also possess putative adhesins that have not been described in encapsulated pneumococci. These findings suggest that the unencapsulated strains capable of causing conjunctivitis utilize a pathogenesis strategy substantially different from that described for S. pneumoniae at other infection sites.
C1 [Valentino, Michael D.; Bispo, Paulo J. M.; Haas, Wolfgang; Gilmore, Michael S.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
[Valentino, Michael D.; Bispo, Paulo J. M.; Haas, Wolfgang; Gilmore, Michael S.] Harvard Univ, Dept Microbiol & Immunobiol, Sch Med, Boston, MA 02115 USA.
[Valentino, Michael D.; McGuire, Abigail Manson; Earl, Ashlee M.; Gilmore, Michael S.] Broad Inst MIT & Harvard, Cambridge, MA 02141 USA.
[Rosch, Jason W.; Burnham, Corinna; Carter, Robert A.; Tuomanen, Elaine I.] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA.
[Sanfilippo, Christine M.; Tuomanen, Elaine I.] Bausch & Lomb Inc, Rochester, NY 14609 USA.
[Zegans, Michael E.] Geisel Sch Med Dartmouth, Dept Microbiol & Immunol, Hanover, NH 03755 USA.
[Beall, Bernard] Ctr Dis Control & Prevent, Streptococcus Lab, Atlanta, GA 30333 USA.
RP Gilmore, MS (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St C703, Boston, MA 02114 USA.
EM michael_gilmore@meei.harvard.edu
RI Manson, Abigail/B-7132-2016;
OI Manson, Abigail/0000-0002-3800-0714; Earl, Ashlee/0000-0001-7857-9145;
Tuomanen, Elaine/0000-0003-0349-8716
FU NIH, Molecular Basis for Ocular Surface Tropism in Conjunctivitis
[EY024285]; Harvard wide Program on Antibiotic Resistance [AI083214,
HHSN272200900018C]; NIH fellowship [EY007145]; Coordenacao de
Aperfeicoamento de Pessoal de Nivel Superior, Brazil (CAPES) [9775-13-7]
FX Portions of this project were supported by NIH grants EY024285,
Molecular Basis for Ocular Surface Tropism in Conjunctivitis and by the
Harvard wide Program on Antibiotic Resistance, AI083214.
HHSN272200900018C supported the involvement of A.M.M. Additional support
for this project was obtained from the ALSAC organization of St Jude
Children's Research Hospital (J.W.R., C.B., R.A.C. and E.I.T.). In
addition, portions of this project were supported by Bausch and Lomb
Inc. (C.M.S., W.H., T.W.M. and M.S.G.). M.D.V. was supported in part by
NIH fellowship through EY007145. P.J.M.B. was supported by a grant from
the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil
(CAPES #9775-13-7). We gratefully thank Drs F. Lebreton, D. Van Tyne and
M. Martin for their helpful comments throughout the course of this work
and during manuscript preparation. Funding agencies had no role in study
design, data analysis, decision to publish or preparation of the
manuscript.
NR 69
TC 9
Z9 9
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD NOV
PY 2014
VL 5
AR 5411
DI 10.1038/ncomms6411
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU5CN
UT WOS:000345624800032
PM 25388376
ER
PT J
AU Kuhn, JH
Andersen, KG
Baize, S
Bao, YM
Bavari, S
Berthet, N
Blinkova, O
Brister, JR
Clawson, AN
Fair, J
Gabriel, M
Garry, RF
Gire, SK
Goba, A
Gonzalez, JP
Gunther, S
Happi, CT
Jahrling, PB
Kapetshi, J
Kobinger, G
Kugelman, JR
Leroy, EM
Maganga, GD
Mbala, PK
Moses, LM
Muyembe-Tamfum, JJ
N'Faly, M
Nichol, ST
Omilabu, SA
Palacios, G
Park, DJ
Paweska, JT
Radoshitzky, SR
Rossi, CA
Sabeti, PC
Schieffelin, JS
Schoepp, RJ
Sealfon, R
Swanepoel, R
Towner, JS
Wada, J
Wauquier, N
Yozwiak, NL
Formenty, P
AF Kuhn, Jens H.
Andersen, Kristian G.
Baize, Sylvain
Bao, Yiming
Bavari, Sina
Berthet, Nicolas
Blinkova, Olga
Brister, J. Rodney
Clawson, Anna N.
Fair, Joseph
Gabriel, Martin
Garry, Robert F.
Gire, Stephen K.
Goba, Augustine
Gonzalez, Jean-Paul
Guenther, Stephan
Happi, Christian T.
Jahrling, Peter B.
Kapetshi, Jimmy
Kobinger, Gary
Kugelman, Jeffrey R.
Leroy, Eric M.
Maganga, Gael Darren
Mbala, Placide K.
Moses, Lina M.
Muyembe-Tamfum, Jean-Jacques
N'Faly, Magassouba
Nichol, Stuart T.
Omilabu, Sunday A.
Palacios, Gustavo
Park, Daniel J.
Paweska, Janusz T.
Radoshitzky, Sheli R.
Rossi, Cynthia A.
Sabeti, Pardis C.
Schieffelin, John S.
Schoepp, Randal J.
Sealfon, Rachel
Swanepoel, Robert
Towner, Jonathan S.
Wada, Jiro
Wauquier, Nadia
Yozwiak, Nathan L.
Formenty, Pierre
TI Nomenclature- and Database-Compatible Names for the Two Ebola Virus
Variants that Emerged in Guinea and the Democratic Republic of the Congo
in 2014
SO VIRUSES-BASEL
LA English
DT Article
DE Ebola; Ebola virus; ebolavirus; filovirid; Filoviridae; filovirus;
genome annotation; Lomela; Lokolia; Makona; mononegavirad;
Mononegavirales; mononegavirus; virus classification; virus isolate;
virus nomenclature; virus strain; virus taxonomy; virus variant
ID INTERNATIONAL COMMITTEE; TAXONOMIC PROPOSALS; FAMILY FILOVIRIDAE;
RATIFICATION VOTE
AB In 2014, Ebola virus (EBOV) was identified as the etiological agent of a large and still expanding outbreak of Ebola virus disease (EVD) in West Africa and a much more confined EVD outbreak in Middle Africa. Epidemiological and evolutionary analyses confirmed that all cases of both outbreaks are connected to a single introduction each of EBOV into human populations and that both outbreaks are not directly connected. Coding-complete genomic sequence analyses of isolates revealed that the two outbreaks were caused by two novel EBOV variants, and initial clinical observations suggest that neither of them should be considered strains. Here we present consensus decisions on naming for both variants (West Africa: "Makona", Middle Africa: "Lomela") and provide database-compatible full, shortened, and abbreviated names that are in line with recently established filovirus sub-species nomenclatures.
C1 [Kuhn, Jens H.; Clawson, Anna N.; Jahrling, Peter B.; Wada, Jiro] NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD 21702 USA.
[Andersen, Kristian G.; Gire, Stephen K.; Sabeti, Pardis C.; Yozwiak, Nathan L.] Harvard Univ, FAS Ctr Syst Biol, Cambridge, MA 02138 USA.
[Baize, Sylvain] Inst Pasteur, Unite Biol Infect Virales Emergentes, Lyon, France.
[Baize, Sylvain] Univ Lyon 1, CNRS, Ecole Normale Super Lyon, CIRI,INSERM,U1111,UMR5308, F-69365 Lyon, France.
[Bao, Yiming; Blinkova, Olga; Brister, J. Rodney] NIH, Informat Engn Branch, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA.
[Bavari, Sina; Kugelman, Jeffrey R.; Palacios, Gustavo; Radoshitzky, Sheli R.; Rossi, Cynthia A.; Schoepp, Randal J.] US Army, Med Res Inst Infect Dis, Frederick, MD 21702 USA.
[Berthet, Nicolas; Leroy, Eric M.; Maganga, Gael Darren] Ctr Int Rech Med Franceville, Franceville, Gabon.
[Fair, Joseph] Fdn Merieux, Washington, DC 20036 USA.
[Gabriel, Martin; Guenther, Stephan] WHO, Bernhard Nocht Inst Trop Med, Collaborating Ctr Arbovirus & Hemorrhag Fever Ref, D-20259 Hamburg, Germany.
[Gabriel, Martin; Guenther, Stephan] German Ctr Infect Res DZIF, D-20259 Hamburg, Germany.
[Garry, Robert F.; Moses, Lina M.; Schieffelin, John S.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA.
[Goba, Augustine] Kenema Govt Hosp, Kenema, Sierra Leone.
[Gonzalez, Jean-Paul; Wauquier, Nadia] Metabiota Inc, San Francisco, CA 94104 USA.
[Happi, Christian T.] Redeemers Univ, Coll Nat Sci, Dept Biol Sci, Mowe, Ogun State, Nigeria.
[Happi, Christian T.] Redeemers Univ, African Ctr Excellence Genom Infect Dis, Mowe, Ogun State, Nigeria.
[Kobinger, Gary] Publ Hlth Agcy Canada, Natl Microbiol Lab, Special Pathogens Program, Winnipeg, MB R3E 3R2, Canada.
[N'Faly, Magassouba] Univ Gamal Abdel Nasser de Conakry, Lab Fievres Hemorrag Guinee, Hop Natl Donka, Serv Malad Infect & Trop, Conakry, Guinea.
[Nichol, Stuart T.; Towner, Jonathan S.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Viral Special Pathogens Branch, Atlanta, GA 30333 USA.
[Omilabu, Sunday A.] Univ Lagos, Coll Med, Dept Med Microbiol & Parasitol, Lagos, Nigeria.
[Park, Daniel J.] Broad Inst, Cambridge, MA 02142 USA.
[Paweska, Janusz T.] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr Emerging & Zoonot Dis, ZA-2192 Sandringham Johannesburg, Gauteng, South Africa.
[Sealfon, Rachel] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
[Swanepoel, Robert] Univ Pretoria, Zoonoses Res Unit, ZA-0028 Pretoria, South Africa.
[Formenty, Pierre] WHO, CH-1211 Geneva, Switzerland.
RP Kuhn, JH (reprint author), NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD 21702 USA.
EM kuhnjens@mail.nih.gov; kandersen@oeb.harvard.edu;
sylvain.baize@inserm.fr; bao@ncbi.nlm.nih.gov; sina.bavari.civ@mail.mil;
nicolas.berthet@pasteur.fr; olga.blinkova@nih.gov;
jamesbr@ncbi.nlm.nih.gov; anna@logosconsulting.us;
joseph.fair@fondation-merieux.org; gabriel@bni-hamburg.de;
rfgarry@tulane.edu; sgire@oeb.harvard.edu; augstgoba@yahoo.com;
jpgonzalez@metabiota.com; guenther@bni.uni-hamburg.de;
happic@run.edu.ng; jahrlingp@niaid.nih.gov; jimmy_kap@hotmail.com;
gary.kobinger@phac-aspc.gc.ca; jeffrey.r.kugelman.mil@mail.mil;
eric.leroy@ird.fr; gael_maganga@yahoo.fr; mbalaplacide@gmail.com;
lmoses2@tulane.edu; muyembejj@gmail.com; cmagassouba01@gmail.com;
stn1@cdc.gov; omilabusa@yahoo.com; gustavo.f.palacios.ctr@us.army.mil;
dpark@broadinstitute.org; januszp@nicd.ac.za;
sheli.r.radoshitzky.ctr@mail.mil; cynthia.a.rossi.civ@mail.mil;
pardis@broadinstitute.org; jschieff@tulane.edu;
randal.j.schoepp.civ@mail.mil; sealfon@gmail.com;
bobswanepoel@gmail.com; jit8@cdc.gov; wadaj@niaid.nih.gov;
nadia.wauquier@gmail.com; nyozwiak@broadinstitute.org; formentyp@who.int
RI Berthet, Nicolas/J-9373-2012; Kuhn, Jens H./B-7615-2011; Palacios,
Gustavo/I-7773-2015; LEROY, Eric/I-4347-2016
OI Kuhn, Jens H./0000-0002-7800-6045; Palacios,
Gustavo/0000-0001-5062-1938; LEROY, Eric/0000-0003-0022-0890
FU Battelle Memorial Institute; US National Institute of Allergy and
Infectious Diseases (NIAID) [HHSN272200700016I]; Intramural Research
Program of the NIH, National Library of Medicine
FX We thank Laura Bollinger (IRF-Frederick) for carefully editing the
manuscript. The content of this publication does not necessarily reflect
the views or policies of the US Department of Health and Human Services
(DHHS) or of the institutions and companies affiliated with the authors.
This work was funded in part through Battelle Memorial Institute's prime
contract with the US National Institute of Allergy and Infectious
Diseases (NIAID) under Contract No. HHSN272200700016I. J.W. performed
this work as an employee of Battelle Memorial Institute. Subcontractors
to Battelle Memorial Institute who performed this work are: J.H.K., an
employee of Tunnell Government Services, Inc. This research was further
supported in part by the Intramural Research Program of the NIH,
National Library of Medicine (Y.B., O.B., and J.R.B.).
NR 22
TC 39
Z9 41
U1 3
U2 29
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD NOV
PY 2014
VL 6
IS 11
BP 4760
EP 4799
DI 10.3390/v6114760
PG 40
WC Virology
SC Virology
GA AU4FL
UT WOS:000345565200035
PM 25421896
ER
PT J
AU Blanchfield, K
Kamal, RP
Tzeng, WP
Music, N
Wilson, JR
Stevens, J
Lipatov, AS
Katz, JM
York, IA
AF Blanchfield, Kristy
Kamal, Ram P.
Tzeng, Wen-Pin
Music, Nedzad
Wilson, Jason R.
Stevens, James
Lipatov, Aleksander S.
Katz, Jacqueline M.
York, Ian A.
TI Recombinant influenza H7 hemagglutinins induce lower neutralizing
antibody titers in mice than do seasonal hemagglutinins
SO INFLUENZA AND OTHER RESPIRATORY VIRUSES
LA English
DT Article
DE H7 influenza viruses; hemagglutinin; immunogenicity; influenza;
influenza pandemics; influenza vaccines
ID IGG AVIDITY ELISA; VIRUS-VACCINE; A VIRUS; A(H7N9) INFECTION;
BRITISH-COLUMBIA; HUMAN-BEINGS; HUMANS; CONJUNCTIVITIS; POULTRY;
PROTECTION
AB BackgroundVaccines against avian influenza viruses often require high hemagglutinin (HA) doses or adjuvants to achieve serological titers associated with protection against disease. In particular, viruses of the H7 subtype frequently do not induce strong antibody responses following immunization.
ObjectivesTo evaluate whether poor immunogenicity of H7 viruses is an intrinsic property of the H7 hemagglutinin.
MethodsWe compared the immunogenicity, in naive mice, of purified recombinant HA from two H7 viruses [A/Netherlands/219/2003(H7N7) and A/New York/107/2003(H7N2)] to that of HA from human pandemic [A/California/07/2009(H1N1pdm09)] and seasonal [A/Perth16/2009(H3N2)] viruses.
ResultsAfter two intramuscular injections with purified hemagglutinin, mice produced antibodies to all HAs, but the response to the human virus HAs was greater than to H7 HAs. The difference was relatively minor when measured by ELISA, greater when measured by hemagglutination inhibition assays, and more marked still by microneutralization assays. H7 HAs induced little or no neutralizing antibody response in mice at either dose tested. Antibodies induced by H7 were of significantly lower avidity than for H3 or H1N1pdm09.
ConclusionsWe conclude that H7 HAs may be intrinsically less immunogenic than HA from seasonal human influenza viruses.
C1 [Blanchfield, Kristy; Kamal, Ram P.; Tzeng, Wen-Pin; Music, Nedzad; Wilson, Jason R.; Stevens, James; Lipatov, Aleksander S.; Katz, Jacqueline M.; York, Ian A.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Blanchfield, Kristy] Carter Consulting Inc, Atlanta, GA USA.
[Kamal, Ram P.; Music, Nedzad] Battelle Mem Inst, Atlanta, GA USA.
RP York, IA (reprint author), Ctr Dis Control & Prevent, Influenza Div, NCIRD, OID, 1600 Clifton Rd Mail Stop G-16, Atlanta, GA 30333 USA.
EM IYork@cdc.gov
OI York, Ian/0000-0002-3478-3344
FU Influenza Division, CDC; Oak Ridge Institute for Science and Education,
Oak Ridge, TN, USA
FX We thank Paul Carney, Angela Yang, and Jessie Chang for purified
recombinant hemagglutinin; Amanda Balish and Jessica Belser for ferret
sera; Li-Mei Chen and Jaber Hossain for PR8 reassortant viruses; Dr.
Ruben Donis for support and helpful suggestions; and the staff of the
CDC animal facilities for excellent animal care. This study was
supported by intramural funding from Influenza Division, CDC. RPK was a
PhD student at Michigan State University. KB, RPK, JW, and NM received
fellowships from Oak Ridge Institute for Science and Education, Oak
Ridge, TN, USA, during this study.
NR 40
TC 9
Z9 9
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1750-2640
EI 1750-2659
J9 INFLUENZA OTHER RESP
JI Influenza Other Respir. Viruses
PD NOV
PY 2014
VL 8
IS 6
BP 628
EP 635
DI 10.1111/irv.12285
PG 8
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA AU6HE
UT WOS:000345703600005
PM 25213778
ER
PT J
AU Ding, YS
Ward, J
Hammond, D
Watson, CH
AF Ding, Yan S.
Ward, Jennye
Hammond, David
Watson, Clifford H.
TI Mouth-Level Intake of Benzo[a]pyrene from Reduced Nicotine Cigarettes
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE cigarette smoke; benzo[a]pyrene; mouth-level intake; cigarette filter;
filter analysis; reduced nicotine cigarette; cotinine; smoking
topography
ID POLYCYCLIC AROMATIC-HYDROCARBONS; TOBACCO-SPECIFIC NITROSAMINES;
SMOKING-BEHAVIOR; MAINSTREAM SMOKE; TOXICANT EXPOSURE; FILTER ANALYSIS;
BIOMARKERS; CONSTITUENTS; METABOLITES; CANCER
AB Cigarette smoke is a known source of exposure to carcinogenic polycyclic aromatic hydrocarbons (PAHs), especially benzo[a]pyrene (BaP). Exposure to BaP in cigarette smoke is influenced by how a person smokes and factors, such as tobacco blend. To determine whether sustained use of reduced-nicotine cigarettes is associated with changes in exposure to nicotine and BaP, levels of BaP in spent cigarette filter butts were correlated with levels of BaP in cigarette smoke to estimate mouth-level intake (MLI) of BaP for 72 daily smokers given three progressively reduced nicotine content cigarettes. Urinary cotinine, a marker of nicotine exposure, and urinary 1-hydroxypyrene (1-HOP), a marker of PAH exposure, were measured throughout the study. Median daily BaP MLI and urine cotinine decreased in a similar manner as smokers switched to progressively lower nicotine cigarettes, despite relatively constant daily cigarette consumption. 1-HOP levels were less responsive to the use of reduced nicotine content cigarettes. We demonstrate that spent cigarette filter butt analysis is a promising tool to estimate MLI of harmful chemicals on a per cigarette or per-day basis, which partially addresses the concerns of the temporal influence of smoking behavior or differences in cigarette design on exposure.
C1 [Ding, Yan S.; Ward, Jennye; Watson, Clifford H.] Ctr Dis Control & Prevent, Tobacco Anal Lab, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
[Hammond, David] Univ Waterloo, Sch Publ Hlth & Hlth Syst, Waterloo, ON N2L 3G1, Canada.
RP Ding, YS (reprint author), Ctr Dis Control & Prevent, Tobacco Anal Lab, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway NE,Mailstop F-19, Atlanta, GA 30341 USA.
EM yding@cdc.gov; vmc3@cdc.gov; dhammond@uwaterloo.ca; cow1@cdc.gov
FU U.S. Food and Drug Administration Center for Tobacco Products; Health
Canada Tobacco Control Program
FX This study was funded through an interagency agreement by the U.S. Food
and Drug Administration Center for Tobacco Products. The original
clinical study was funded by the Health Canada Tobacco Control Program.
NR 22
TC 3
Z9 3
U1 1
U2 5
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD NOV
PY 2014
VL 11
IS 11
BP 11898
EP 11914
DI 10.3390/ijerph111111898
PG 17
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AU3RT
UT WOS:000345532000053
PM 25411724
ER
PT J
AU Vaughan, CP
Fowler, R
Goodman, RA
Graves, TR
Flacker, JM
Johnson, TM
AF Vaughan, Camille P.
Fowler, Rachel
Goodman, Richard A.
Graves, Taylor R.
Flacker, Jonathan M.
Johnson, Theodore M., II
TI Identifying Landmark Articles for Advancing the Practice of Geriatrics
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE education; geriatrics; landmark
ID ELDERLY PEOPLE; INTERVENTION; FRAILTY
AB Landmark articles from the peer-reviewed literature can be used to teach the fundamental principles of geriatric medicine. Three approaches were used in sequential combination to identify landmark articles as a resource for geriatricians and other healthcare practitioners. Candidate articles were identified first through a literature review and expert opinion survey of geriatric medicine faculty. Candidate articles in a winnowed list (n=30) were then included in a bibliometric analysis that incorporated the journal impact factor and average monthly citation index. Finally, a consensus panel reviewed articles to assess each manuscript's clinical relevance. For each article, a final score was determined by averaging, with equal weight, the opinion survey, bibliometric analysis, and consensus panel review. This process ultimately resulted in the identification of 27 landmark articles. Overall, there was weak correlation between articles that the expert opinion survey and bibliometric analysis both rated highly. This process demonstrates a feasible method combining subjective and objective measures that can be used to identify landmark papers in geriatric medicine for the enhancement of geriatrics education and practice.
C1 [Vaughan, Camille P.; Johnson, Theodore M., II] Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, Decatur, GA USA.
[Vaughan, Camille P.; Goodman, Richard A.; Graves, Taylor R.; Flacker, Jonathan M.; Johnson, Theodore M., II] Emory Univ, Dept Med, Div Gen Med & Geriatr, Atlanta, GA 30322 USA.
[Fowler, Rachel] Florida Atlantic Univ, Coll Med, Boca Raton, FL 33431 USA.
[Goodman, Richard A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Vaughan, CP (reprint author), Wesley Woods Hlth Ctr, 1841 Clifton Rd,NE,Room 532, Atlanta, GA 30329 USA.
EM camille.vaughan@emory.edu
FU Rehabilitation R& D CDA-2 Award 1 from the Department of Veterans
Affairs [1 IK2 RX000747-01]; HRSA GEC
FX Donald W. Reynolds and HRSA GEC grants to Emory University. Dr. Vaughan
is supported by Rehabilitation R& D CDA-2 Award 1 IK2 RX000747-01 from
the Department of Veterans Affairs.
NR 15
TC 2
Z9 2
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD NOV
PY 2014
VL 62
IS 11
BP 2159
EP 2162
DI 10.1111/jgs.13087
PG 4
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AU3GO
UT WOS:000345500700019
PM 25366821
ER
PT J
AU Irish, SR
AF Irish, Seth R.
TI The behaviour of mosquitoes in relation to humans under holed bednets:
the evidence from experimental huts
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE mosquito net; holes; malaria; experimental hut; Anopheles; Culex
ID INSECTICIDE-TREATED NETS; CULEX-QUINQUEFASCIATUS MOSQUITOS;
PYRETHROID-RESISTANT MOSQUITOS; ANOPHELES-GAMBIAE; BED NETS; IMPREGNATED
BEDNETS; OLYSET(R) NETS; MALARIA; BENIN; PROTECTION
AB The physical integrity of bednets is a concern of national malaria control programs, as it is a key factor in determining the rate of replacement of bednets. It is largely assumed that increased numbers of holes will result in a loss of protection of sleepers from potentially infective bites. Experimental hut studies are valuable in understanding mosquito behaviour indoors, particularly as it relates to blood feeding and mortality. This review summarises findings from experimental hut studies, focusing on two issues: (i) the effect of different numbers or sizes of holes in bednets and (ii) feeding behaviour and mortality with holed nets as compared with unholed nets. As might be expected, increasing numbers and area of holes resulted in increased blood feeding by mosquitoes on sleepers. However, the presence of holes did not generally have a large effect on the mortality of mosquitoes. Successfully entering a holed mosquito net does not necessarily mean that mosquitoes spend less time in contact with the net, which could explain the lack in differences in mortality. Further behavioural studies are necessary to understand mosquito behaviour around nets and the importance of holed nets on malaria transmission.
C1 Ctr Dis Control & Prevent, Entomol Branch, Dept Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Irish, SR (reprint author), Ctr Dis Control & Prevent, Entomol Branch, Dept Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
EM sirish@cdc.gov
FU CDC as part of the President's Malaria Initiative
FX CDC as part of the President's Malaria Initiative
NR 47
TC 1
Z9 1
U1 3
U2 7
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD NOV
PY 2014
VL 109
IS 7
BP 905
EP 911
DI 10.1590/0074-0276140159
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AU2FD
UT WOS:000345430900009
PM 25410994
ER
PT J
AU Lau, CL
Won, KY
Becker, L
Magalhaes, RJS
Fuimaono, S
Melrose, W
Lammie, PJ
Graves, PM
AF Lau, Colleen L.
Won, Kimberly Y.
Becker, Luke
Magalhaes, Ricardo J. Soares
Fuimaono, Saipale
Melrose, Wayne
Lammie, Patrick J.
Graves, Patricia M.
TI Seroprevalence and Spatial Epidemiology of Lymphatic Filariasis in
American Samoa after Successful Mass Drug Administration
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID WUCHERERIA-BANCROFTI INFECTION; DEFINE END-POINTS; MULTICENTER
EVALUATION; TRANSMISSION; LEPTOSPIROSIS; PROGRAMS; WB123; TOOLS
AB Background: As part of the Global Programme to Eliminate Lymphatic Filariasis (LF), American Samoa conducted mass drug administration (MDA) from 2000-2006, and passed transmission assessment surveys in 2011-2012. We examined the seroprevalence and spatial epidemiology of LF post-MDA to inform strategies for ongoing surveillance and to reduce resurgence risk.
Methods: ELISA for LF antigen (Og4C3) and antibodies (Wb123, Bm14) were performed on a geo-referenced serum bank of 807 adults collected in 2010. Risk factors assessed for association with sero-positivity included age, sex, years lived in American Samoa, and occupation. Geographic clustering of serological indicators was investigated to identify spatial dependence and household-level clustering.
Results: Og4C3 antigen of >128 units (positive) were found in 0.75% (95% CI 0.3-1.6%) of participants, and >32 units (equivocal plus positive) in 3.2% (95% CI 0.6-4.7%). Seroprevalence of Wb123 and Bm14 antibodies were 8.1% (95% CI 6.3-10.2%) and 17.9% (95% CI 15.3-20.7%) respectively. Antigen-positive individuals were identified in all ages, and antibody prevalence higher in older ages. Prevalence was higher in males, and inversely associated with years lived in American Samoa. Spatial distribution of individuals varied significantly with positive and equivocal levels of Og4C3 antigen, but not with antibodies. Using Og4C3 cutoff points of >128 units and >32 units, average cluster sizes were 1,242 m and 1,498 m, and geographical proximity of households explained 85% and 62% of the spatial variation respectively.
Conclusions: High-risk populations for LF in American Samoa include adult males and recent migrants. We identified locations and estimated the size of possible residual foci of antigen-positive adults, demonstrating the value of spatial analysis in post-MDA surveillance. Strategies to monitor cluster residents and high-risk groups are needed to reduce resurgence risk. Further research is required to quantify factors contributing to LF transmission at the last stages of elimination to ensure that programme achievements are sustained.
C1 [Lau, Colleen L.; Magalhaes, Ricardo J. Soares] Univ Queensland, Queensland Childrens Med Res Inst, WHO Collaborating Ctr Childrens Hlth & Environm, Brisbane, Qld, Australia.
[Lau, Colleen L.] Australian Natl Univ, Res Sch Populat Hlth, Canberra, ACT, Australia.
[Won, Kimberly Y.; Lammie, Patrick J.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA.
[Becker, Luke; Melrose, Wayne; Graves, Patricia M.] James Cook Univ, Div Trop Hlth & Med, WHO Collaborating Ctr Lymphat Filariasis Soil Tra, Cairns, Australia.
[Magalhaes, Ricardo J. Soares] Univ Queensland, Sch Vet Sci, Gatton, Australia.
[Fuimaono, Saipale] Amer Samoa Dept Hlth, Pago Pago, AS USA.
RP Lau, CL (reprint author), Univ Queensland, Queensland Childrens Med Res Inst, WHO Collaborating Ctr Childrens Hlth & Environm, Brisbane, Qld, Australia.
EM colleen.lau@uq.edu.au
RI Soares Magalhaes, Ricardo/A-5316-2010;
OI Soares Magalhaes, Ricardo/0000-0001-9157-8470; Graves,
Patricia/0000-0002-5215-3901
FU James Cook University; GLaxoSmithKline
FX We would like to acknowledge James Cook University and GLaxoSmithKline
for providing financial support for the WHO Collaborating Centre for
Lymphatic Filariasis, Soil-Transmitted Helminths, and Other Neglected
Tropical Diseases at James Cook University, Cairns, Australia (LB, WM,
PMG). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 30
TC 4
Z9 4
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD NOV
PY 2014
VL 8
IS 11
AR e3297
DI 10.1371/journal.pntd.0003297
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AU3LF
UT WOS:000345514000028
PM 25393716
ER
PT J
AU Sewlall, NH
Richards, G
Duse, A
Swanepoel, R
Paweska, J
Blumberg, L
Dinh, TH
Bausch, D
AF Sewlall, Nivesh H.
Richards, Guy
Duse, Adriano
Swanepoel, Robert
Paweska, Janusz
Blumberg, Lucille
Thu Ha Dinh
Bausch, Daniel
TI Clinical Features and Patient Management of Lujo Hemorrhagic Fever
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID RECOMBINANT FACTOR VIIA; LASSA FEVER; N-ACETYLCYSTEINE; VIRUS DISEASE;
SEPTIC SHOCK; SEPSIS; RIBAVIRIN; OUTBREAK; ACTIVATION; GUIDELINES
AB Background: In 2008 a nosocomial outbreak of five cases of viral hemorrhagic fever due to a novel arenavirus, Lujo virus, occurred in Johannesburg, South Africa. Lujo virus is only the second pathogenic arenavirus, after Lassa virus, to be recognized in Africa and the first in over 40 years. Because of the remote, resource-poor, and often politically unstable regions where Lassa fever and other viral hemorrhagic fevers typically occur, there have been few opportunities to undertake in-depth study of their clinical manifestations, transmission dynamics, pathogenesis, or response to treatment options typically available in industrialized countries.
Methods and Findings: We describe the clinical features of five cases of Lujo hemorrhagic fever and summarize their clinical management, as well as providing additional epidemiologic detail regarding the 2008 outbreak. Illness typically began with the abrupt onset of fever, malaise, headache, and myalgias followed successively by sore throat, chest pain, gastrointestinal symptoms, rash, minor hemorrhage, subconjunctival injection, and neck and facial swelling over the first week of illness. No major hemorrhage was noted. Neurological signs were sometimes seen in the late stages. Shock and multi-organ system failure, often with evidence of disseminated intravascular coagulopathy, ensued in the second week, with death in four of the five cases. Distinctive treatment components of the one surviving patient included rapid commencement of the antiviral drug ribavirin and administration of HMG-CoA reductase inhibitors (statins), N-acetylcysteine, and recombinant factor VIIa.
Conclusions: Lujo virus causes a clinical syndrome remarkably similar to Lassa fever. Considering the high case-fatality and significant logistical impediments to controlled treatment efficacy trials for viral hemorrhagic fever, it is both logical and ethical to explore the use of the various compounds used in the treatment of the surviving case reported here in future outbreaks. Clinical observations should be systematically recorded to facilitate objective evaluation of treatment efficacy. Due to the risk of secondary transmission, viral hemorrhagic fever precautions should be implemented for all cases of Lujo virus infection, with specialized precautions to protect against aerosols when performing enhanced-risk procedures such as endotracheal intubation.
C1 [Sewlall, Nivesh H.] Morningside MediClin, Johannesburg, South Africa.
[Sewlall, Nivesh H.; Richards, Guy; Duse, Adriano] Univ Witwatersrand, Dept Med, ZA-2001 Johannesburg, South Africa.
[Swanepoel, Robert] Univ Pretoria, Dept Med, ZA-0002 Pretoria, South Africa.
[Paweska, Janusz; Blumberg, Lucille] Natl Inst Communicable Dis, Johannesburg, South Africa.
[Thu Ha Dinh] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Bausch, Daniel] Tulane Sch Publ Hlth & Trop Med, New Orleans, LA USA.
RP Sewlall, NH (reprint author), Morningside MediClin, Johannesburg, South Africa.
EM nivesh.sewlall@wits.ac.za
NR 36
TC 6
Z9 7
U1 3
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD NOV
PY 2014
VL 8
IS 11
AR e3233
DI 10.1371/journal.pntd.0003233
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AU3LF
UT WOS:000345514000009
PM 25393244
ER
PT J
AU Melian, EB
Hall-Mendelin, S
Du, FY
Owens, N
Bosco-Lauth, AM
Nagasaki, T
Rudd, S
Brault, AC
Bowen, RA
Hall, RA
van den Hurk, AF
Khromykh, AA
AF Melian, Ezequiel Balmori
Hall-Mendelin, Sonja
Du, Fangyao
Owens, Nick
Bosco-Lauth, Angela M.
Nagasaki, Tomoko
Rudd, Stephen
Brault, Aaron C.
Bowen, Richard A.
Hall, Roy A.
van den Hurk, Andrew F.
Khromykh, Alexander A.
TI Programmed Ribosomal Frameshift Alters Expression of West Nile Virus
Genes and Facilitates Virus Replication in Birds and Mosquitoes
SO PLOS PATHOGENS
LA English
DT Article
ID JAPANESE ENCEPHALITIS-VIRUS; NONSTRUCTURAL PROTEIN NS2A; GLYCOPROTEIN
NS1; RNA REPLICATION; HOUSE SPARROWS; FEVER VIRUS; IN-VITRO; FLAVIVIRUS;
VIRULENCE; MUTATIONS
AB West Nile virus (WNV) is a human pathogen of significant medical importance with close to 40,000 cases of encephalitis and more than 1,600 deaths reported in the US alone since its first emergence in New York in 1999. Previous studies identified a motif in the beginning of non-structural gene NS2A of encephalitic flaviviruses including WNV which induces programmed -1 ribosomal frameshift (PRF) resulting in production of an additional NS protein NS1'. We have previously demonstrated that mutant WNV with abolished PRF was attenuated in mice. Here we have extended our previous observations by showing that PRF does not appear to have a significant role in virus replication, virion formation, and viral spread in several cell lines in vitro. However, we have also shown that PRF induces an over production of structural proteins over nonstructural proteins in virus-infected cells and that mutation abolishing PRF is present in similar to 11% of the wild type virus population. In vivo experiments in house sparrows using wild type and PRF mutant of New York 99 strain of WNV viruses showed some attenuation for the PRF mutant virus. Moreover, PRF mutant of Kunjin strain of WNV showed significant decrease compared to wild type virus infection in dissemination of the virus from the midgut through the haemocoel, and ultimately the capacity of infected mosquitoes to transmit virus. Thus our results demonstrate an important role for PRF in regulating expression of viral genes and consequently virus replication in avian and mosquito hosts.
C1 [Melian, Ezequiel Balmori; Du, Fangyao; Owens, Nick; Nagasaki, Tomoko; Hall, Roy A.; Khromykh, Alexander A.] Univ Queensland, Australian Infect Dis Res Ctr, Sch Chem & Mol Biosci, St Lucia, Qld, Australia.
[Hall-Mendelin, Sonja; van den Hurk, Andrew F.] Queensland Govt, Dept Hlth, Virol Sect, Coopers Plains, Qld, Australia.
[Hall-Mendelin, Sonja; van den Hurk, Andrew F.] Queensland Govt, Dept Hlth, Publ & Environm Hlth Serv, Coopers Plains, Qld, Australia.
[Hall-Mendelin, Sonja; van den Hurk, Andrew F.] Queensland Govt, Dept Hlth, Forens Serv, Coopers Plains, Qld, Australia.
[Hall-Mendelin, Sonja; van den Hurk, Andrew F.] Queensland Govt, Dept Hlth, Sci Serv, Coopers Plains, Qld, Australia.
[Bosco-Lauth, Angela M.; Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA.
[Bosco-Lauth, Angela M.; Bowen, Richard A.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA.
[Rudd, Stephen] Univ Queensland, QFAB, Brisbane, Qld, Australia.
RP Khromykh, AA (reprint author), Univ Queensland, Australian Infect Dis Res Ctr, Sch Chem & Mol Biosci, St Lucia, Qld, Australia.
EM a.khromykh@uq.edu.au
RI Rudd, Stephen/A-6434-2013;
OI Rudd, Stephen/0000-0002-0344-7487; Khromykh,
Alexander/0000-0001-6206-6935
FU National Health and Medical Research Council of Australia [APP1009874]
FX The work was funded by the grant APP1009874 from the National Health and
Medical Research Council of Australia. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 62
TC 9
Z9 9
U1 1
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD NOV
PY 2014
VL 10
IS 11
AR e1004447
DI 10.1371/journal.ppat.1004447
PG 18
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA AU3LX
UT WOS:000345515800008
PM 25375107
ER
PT J
AU Kuempel, ED
Attfield, MD
Stayner, LT
Castranova, V
AF Kuempel, Eileen D.
Attfield, Michael D.
Stayner, Leslie T.
Castranova, Vincent
TI Human and Animal Evidence Supports Lower Occupational Exposure Limits
for Poorly-Soluble Respirable Particles
SO ANNALS OF OCCUPATIONAL HYGIENE
LA English
DT Letter
ID ALVEOLAR-INTERSTITIAL REGION; TITANIUM-DIOXIDE PARTICLES; COAL-MINERS;
RAT LUNG; BIOMATHEMATICAL MODEL; SUBCHRONIC INHALATION; PULMONARY
RESPONSES; FOLLOW-UP; CLEARANCE; RETENTION
C1 [Kuempel, Eileen D.] NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA.
[Attfield, Michael D.] NIOSH, Div Resp Dis Studies, Morgantown, WV 26505 USA.
[Stayner, Leslie T.] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL USA.
[Castranova, Vincent] NIOSH, Hlth Effects Lab Div, Morgantown, WV USA.
[Castranova, Vincent] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA.
RP Kuempel, ED (reprint author), NIOSH, Educ & Informat Div, 1090 Tusculum Ave, Cincinnati, OH 45226 USA.
EM ekuempel@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 39
TC 4
Z9 4
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0003-4878
EI 1475-3162
J9 ANN OCCUP HYG
JI Ann. Occup. Hyg.
PD NOV
PY 2014
VL 58
IS 9
BP 1205
EP 1208
DI 10.1093/annhyg/meu058
PG 4
WC Public, Environmental & Occupational Health; Toxicology
SC Public, Environmental & Occupational Health; Toxicology
GA AU0DN
UT WOS:000345293800011
PM 25193937
ER
PT J
AU Schully, SD
Rogers, SD
Lam, TK
Chang, CQ
Clyne, M
Cyr, J
Watson, D
Khoury, MJ
AF Schully, Sheri D.
Rogers, Scott D.
Lam, Tram Kim
Chang, Christine Q.
Clyne, Mindy
Cyr, Jean
Watson, Daniel
Khoury, Muin J.
TI The Cancer Genomics and Epidemiology Navigator: An NCI Online Tool to
Enhance Cancer Epidemiology Research
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Letter
C1 [Schully, Sheri D.; Rogers, Scott D.; Lam, Tram Kim; Khoury, Muin J.] Epidemiol & Genom Res Program, Bethesda, MD USA.
[Chang, Christine Q.] NHGRI, Bethesda, MD 20892 USA.
[Clyne, Mindy] Kelly Serv, Troy, MI USA.
[Cyr, Jean; Watson, Daniel] Informat Management Serv Inc, Rockville, MD USA.
[Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA.
RP Schully, SD (reprint author), NCI, NIH, 9609 Med Ctr Dr 4E106, Bethesda, MD 20850 USA.
EM schullys@mail.nih.gov
FU Intramural NIH HHS [Z99 CA999999]
NR 3
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD NOV
PY 2014
VL 23
IS 11
BP 2610
EP 2611
DI 10.1158/1055-9965.EPI-14-0902
PG 2
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA AT9YL
UT WOS:000345279600049
PM 25368405
ER
PT J
AU Luna-Gierke, RE
Griffin, PM
Gould, LH
Herman, K
Bopp, CA
Strockbine, N
Mody, RK
AF Luna-Gierke, R. E.
Griffin, P. M.
Gould, L. H.
Herman, K.
Bopp, C. A.
Strockbine, N.
Mody, R. K.
TI Outbreaks of non-O157 Shiga toxin-producing Escherichia coli infection:
USA
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Diarrhoea; outbreaks; Shiga-like toxin-producing E. coli
ID HEMOLYTIC-UREMIC SYNDROME; UNITED-STATES; SURVEILLANCE; PATHOGENS; O111;
EPIDEMIOLOGY; SAUSAGE; SCHOOL; CAMP
AB Non-O157 Shiga toxin-producing Escherichia coli (STEC) infections are increasingly detected, but sources are not well established. We summarize outbreaks to 2010 in the USA. Single-aetiology outbreaks were defined as >= 2 epidemiologically linked culture-confirmed non-O157 STEC infections; multiple-aetiology outbreaks also had laboratory evidence of >= 2 infections caused by another enteric pathogen. Twenty-six states reported 46 outbreaks with 1727 illnesses and 144 hospitalizations. Of 38 single-aetiology outbreaks, 66% were caused by STEC O111 (n = 14) or O26 (n = 11), and 84% were transmitted through food (n = 17) or person-to-person spread (n = 15); food vehicles included dairy products, produce, and meats; childcare centres were the most common setting for person-to-person spread. Of single-aetiology outbreaks, a greater percentage of persons infected by Shiga toxin 2-positive strains had haemolytic uraemic syndrome compared with persons infected by Shiga toxin 1-only positive strains (7% vs. 0.8%). Compared with single-aetiology outbreaks, multiple-aetiology outbreaks were more frequently transmitted through water or animal contact.
C1 [Luna-Gierke, R. E.; Griffin, P. M.; Gould, L. H.; Herman, K.; Bopp, C. A.; Strockbine, N.; Mody, R. K.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA 30333 USA.
RP Luna-Gierke, RE (reprint author), Ctr Dis Control & Prevent, Mailstop C-09,1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM RGierke@cdc.gov
NR 37
TC 33
Z9 33
U1 3
U2 24
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD NOV
PY 2014
VL 142
IS 11
BP 2270
EP 2280
DI 10.1017/S0950268813003233
PG 11
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AT4OZ
UT WOS:000344921000005
PM 24398154
ER
PT J
AU Viray, MA
Wamala, J
Fagan, R
Luquez, C
Maslanka, S
Downing, R
Biggerstaff, M
Malimbo, M
Kirenga, JB
Nakibuuka, J
Ddumba, E
Mbabazi, W
Swerdlow, DL
AF Viray, M. A.
Wamala, J.
Fagan, R.
Luquez, C.
Maslanka, S.
Downing, R.
Biggerstaff, M.
Malimbo, M.
Kirenga, J. B.
Nakibuuka, J.
Ddumba, E.
Mbabazi, W.
Swerdlow, D. L.
TI Outbreak of type A foodborne botulism at a boarding school, Uganda, 2008
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Botulism; food poisoning; outbreaks
ID PRODUCT
AB Botulism has rarely been reported in Africa. In October 2008, botulism was reported in three Ugandan boarding-school students. All were hospitalized and one died. A cohort study was performed to assess food exposures among students, and clinical specimens and available food samples were tested for botulinum toxin. Three case-patients were identified; a homemade, oil-based condiment was eaten by all three. In the cohort study, no foods were significantly associated with illness. Botulinum toxin type A was confirmed in clinical samples. This is the first confirmed outbreak of foodborne botulism in Uganda. A homemade, oil-based condiment was the probable source. Consumption of homemade oil-based condiments is widespread in Ugandan schools, putting children at risk. Clinicians and public health authorities in Uganda should consider botulism when clusters of acute flaccid paralysis are seen. Additionally, schools should be warned of the hazard of homemade oil-based condiments, and take steps to prevent their use.
C1 [Viray, M. A.; Fagan, R.; Luquez, C.; Maslanka, S.; Biggerstaff, M.; Swerdlow, D. L.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Wamala, J.; Malimbo, M.] Uganda Minist Hlth, Kampala, Uganda.
[Downing, R.] Ctr Dis Control & Prevent, Entebbe, Uganda.
[Kirenga, J. B.; Nakibuuka, J.; Ddumba, E.] Mulago Hosp, Kampala, Uganda.
[Mbabazi, W.] WHO, Kampala, Uganda.
RP Viray, MA (reprint author), Hawaii Dept Hlth, Dis Outbreak Control Div, 1250 Punchbowl St, Honolulu, HI 96813 USA.
EM melissa_viray@hotmail.com
OI Kirenga, Bruce/0000-0002-2023-2840
FU Centers for Disease Control and Prevention, Atlanta, GA; National Cancer
Institute (NCI) at the National Institutes of Health (NIH)
[KM1CA156708]; Clinical and Translational Science Award (CTSA) programme
of the National Center for Advancing Translational Sciences (NCATS) at
the National Institutes of Health (NIH) [UL1TR00448]
FX This work was undertaken with the assistance of Julius Lutwama and the
Uganda Virus Research Institute, Entebbe, Uganda. Financial support for
this investigation was primarily provided by the Centers for Disease
Control and Prevention, Atlanta, GA. Support was also provided through
KM1CA156708 through the National Cancer Institute (NCI) at the National
Institutes of Health (NIH) and grant no. UL1TR00448 through the Clinical
and Translational Science Award (CTSA) programme of the National Center
for Advancing Translational Sciences (NCATS) at the National Institutes
of Health (NIH). The findings and conclusions in this report are those
of the author(s) and do not necessarily represent the views of the
Centers for Disease Control and Prevention.
NR 13
TC 0
Z9 0
U1 0
U2 6
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD NOV
PY 2014
VL 142
IS 11
BP 2297
EP 2301
DI 10.1017/S0950268814000387
PG 5
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AT4OZ
UT WOS:000344921000007
PM 24576562
ER
PT J
AU Ambrose, J
Hampton, LM
Fleming-Dutra, KE
Marten, C
McClusky, C
Perry, C
Clemmons, NA
Mccormic, Z
Peik, S
Mancuso, J
Brown, E
Kozak, N
Travis, T
Lucas, C
Fields, B
Hicks, L
Cersovsky, SB
AF Ambrose, J.
Hampton, L. M.
Fleming-Dutra, K. E.
Marten, C.
McClusky, C.
Perry, C.
Clemmons, N. A.
Mccormic, Z.
Peik, S.
Mancuso, J.
Brown, E.
Kozak, N.
Travis, T.
Lucas, C.
Fields, B.
Hicks, L.
Cersovsky, S. B.
TI Large outbreak of Legionnaires' disease and Pontiac fever at a military
base
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Community outbreaks; Legionella; Legionnaire's disease; legionellosis
(Pontiac fever)
ID SEQUENCE-BASED SCHEME; LEGIONELLA-PNEUMOPHILA; COMMUNITY OUTBREAK;
SOURCE EXPOSURE; UNITED-STATES; SURVEILLANCE; TRANSMISSION; PNEUMONIA;
EPIDEMIC; ASSAY
AB We investigated a mixed outbreak of Legionnaires' disease (LD) and Pontiac fever (PF) at a military base to identify the outbreak's environmental source as well as known legionellosis risk factors. Base workers with possible legionellosis were interviewed and, if consenting, underwent testing for legionellosis. A retrospective cohort study collected information on occupants of the buildings closest to the outbreak source. We identified 29 confirmed and probable LD and 38 PF cases. All cases were exposed to airborne pathogens from a cooling tower. Occupants of the building closest to the cooling tower were 6.9 [95% confidence interval (CI) 2.2-22.0] and 5.5 (95% CI 2.1-14.5) times more likely to develop LD and PF, respectively, than occupants of the next closest building. Thorough preventive measures and aggressive responses to outbreaks, including searching for PF cases in mixed legionellosis outbreaks, are essential for legionellosis control.
C1 [Ambrose, J.; Perry, C.; Clemmons, N. A.; Mccormic, Z.; Peik, S.; Mancuso, J.; Cersovsky, S. B.] US Army Publ Hlth Command, Aberdeen Proving Ground, MD USA.
[Hampton, L. M.; Fleming-Dutra, K. E.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA.
[Hampton, L. M.; Fleming-Dutra, K. E.; Brown, E.; Kozak, N.; Travis, T.; Lucas, C.; Fields, B.; Hicks, L.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30329 USA.
[Marten, C.] Michigan Dept Community Hlth, Lansing, MI USA.
[McClusky, C.] Michigan Air Natl Guard, Harrison Township, MI USA.
RP Hampton, LM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-24, Atlanta, GA 30329 USA.
EM lhampton@cdc.gov
FU U.S. Army Public Health Command; U.S. Centers for Disease Control and
Prevention
FX Financial support was received from U.S. Army Public Health Command and
the U.S. Centers for Disease Control and Prevention.
NR 41
TC 4
Z9 4
U1 1
U2 13
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD NOV
PY 2014
VL 142
IS 11
BP 2336
EP 2346
DI 10.1017/S0950268813003440
PG 11
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AT4OZ
UT WOS:000344921000011
PM 25267405
ER
PT J
AU Benoit, SR
Ellingson, KD
Waterman, SH
Pearson, ML
AF Benoit, S. R.
Ellingson, K. D.
Waterman, S. H.
Pearson, M. L.
TI Antimicrobial resistance in eight US hospitals along the US-Mexico
border, 2000-2006
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Antimicrobial resistance; US-Mexico border
ID BLOOD-STREAM INFECTIONS; SOFT-TISSUE INFECTIONS; INTENSIVE-CARE UNITS;
STAPHYLOCOCCUS-AUREUS; TRACT-INFECTIONS; EL-PASO; DISEASE; SURVEILLANCE;
EMERGENCE; STATES
AB Antimicrobial resistance (AR) is a growing problem worldwide and international travel, cross-border migration, and antimicrobial use may contribute to the introduction or emergence of AR. We examined AR rates and trends along the US-Mexico border by analysing microbiology data from eight US hospitals in three states bordering Mexico. Microbiology data were ascertained for the years 2000-2006 and for select healthcare and community pathogens including, three Gram-negative (Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae) and three Gram-positive (Staphylococcus aureus, Enterococcus, Streptococcus pneumoniae) pathogens and 10 antimicrobial-pathogen combinations. Resistance was highest in S. aureus (oxacillin resistance 45.7%), P. aeruginosa (quinolone resistance 22.3%), and E. coli (quinolone resistance 15.6%); six (60%) of the 10 antimicrobial-pathogen combinations studied had a significantly increasing trend in resistance over the study period. Potential contributing factors in the hospital and community such as infection control practices and antimicrobial use (prescription and non-prescription) should be explored further in the US-Mexico border region.
C1 [Benoit, S. R.; Ellingson, K. D.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Waterman, S. H.] CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Pearson, M. L.] CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
RP Benoit, SR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-03, Atlanta, GA 30333 USA.
EM bvy8@cdc.gov
NR 31
TC 1
Z9 1
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD NOV
PY 2014
VL 142
IS 11
BP 2378
EP 2387
DI 10.1017/S095026881300318X
PG 10
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AT4OZ
UT WOS:000344921000016
PM 24480063
ER
PT J
AU Whyatt, RM
Rundle, AG
Perzanowski, MS
Just, AC
Donohue, KM
Calafat, AM
Hoepner, L
Perera, FP
Miller, RL
AF Whyatt, Robin M.
Rundle, Andrew G.
Perzanowski, Matthew S.
Just, Allan C.
Donohue, Kathleen M.
Calafat, Antonia M.
Hoepner, Lori
Perera, Frederica P.
Miller, Rachel L.
TI Prenatal phthalate and early childhood bisphenol A exposures increase
asthma risk in inner-city children
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID URINE
C1 [Whyatt, Robin M.; Rundle, Andrew G.; Perzanowski, Matthew S.; Donohue, Kathleen M.; Hoepner, Lori; Perera, Frederica P.; Miller, Rachel L.] Columbia Univ, Columbia Ctr Childrens Environm Hlth, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10027 USA.
[Rundle, Andrew G.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
[Just, Allan C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Donohue, Kathleen M.; Miller, Rachel L.] Columbia Univ, Coll Phys & Surg, Dept Med, Div Pulm Allergy & Crit Care, New York, NY USA.
[Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA.
[Miller, Rachel L.] Columbia Univ, Coll Phys & Surg, Dept Pediat, Div Rheumatol Allergy & Immunol, New York, NY USA.
RP Whyatt, RM (reprint author), Columbia Univ, Columbia Ctr Childrens Environm Hlth, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10027 USA.
EM rmw5@columbia.edu
RI Rundle, Andrew/A-5282-2009;
OI Rundle, Andrew/0000-0003-0211-7707; Just, Allan/0000-0003-4312-5957
FU NIEHS NIH HHS [R01 ES014393, P01 ES009600, P01 ES09600, P30 ES009089,
P30ES009089, R01 ES008977, R01 ES013163, R01ES014393, R01ES08977,
R01ES13163, RC2 ES018784, RC2ES018784]
NR 7
TC 5
Z9 5
U1 1
U2 13
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD NOV
PY 2014
VL 134
IS 5
BP 1195
EP 1197
DI 10.1016/j.jaci.2014.07.027
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA AT4UN
UT WOS:000344938900028
PM 25174861
ER
PT J
AU Morgan, RL
AF Morgan, Rebecca L.
TI How much management is necessary? Sustaining the benefit of achieving a
sustained virologic response to hepatitis C
SO JOURNAL OF GASTROENTEROLOGY
LA English
DT Editorial Material
C1 Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA.
RP Morgan, RL (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA.
EM evf5@cdc.gov
NR 7
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
JAPAN
SN 0944-1174
EI 1435-5922
J9 J GASTROENTEROL
JI J. Gastroenterol.
PD NOV
PY 2014
VL 49
IS 11
BP 1514
EP 1515
DI 10.1007/s00535-014-0990-7
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AT4NP
UT WOS:000344916500008
PM 25239674
ER
PT J
AU Corrigan, JD
Cuthbert, JP
Harrison-Felix, C
Whiteneck, GG
Bell, JM
Miller, AC
Coronado, VG
Pretz, CR
AF Corrigan, John D.
Cuthbert, Jeffrey P.
Harrison-Felix, Cynthia
Whiteneck, Gale G.
Bell, Jeneita M.
Miller, A. Cate
Coronado, Victor G.
Pretz, Christopher R.
TI US Population Estimates of Health and Social Outcomes 5 Years After
Rehabilitation for Traumatic Brain Injury
SO JOURNAL OF HEAD TRAUMA REHABILITATION
LA English
DT Article
DE craniocerebral trauma; epidemiology; outcomes; prevalence;
rehabilitation; traumatic brain injury
ID SYSTEMS NATIONAL DATABASE; MODEL SYSTEMS; REPRESENTATIVENESS; MORTALITY;
SCALE; AGE
AB Objective: To estimate the number of adults in the United States from 2006 to 2012 who manifest selected health and social outcomes 5 years following a traumatic brain injury (TBI) that required acute inpatient rehabilitation. Design: Secondary data analysis. Setting: Acute inpatient rehabilitation facilities. Participants: Patients 16 years and older receiving acute inpatient rehabilitation for a primary diagnosis of TBI. Main Outcome Measures: Mortality, functional independence, societal participation, subjective well-being, and global outcome. Results: Annually from 2001 to 2007, an average of 13 700 patients aged 16 years or older received acute inpatient rehabilitation in the United States with a primary diagnosis of TBI. Approximately 1 in 5 patients had died by the 5-year postinjury assessment. Among survivors, 12% were institutionalized and 50% had been rehospitalized at least once. Approximately one-third of patients were not independent in everyday activities. Twenty-nine percent were dissatisfied with life, with 8% reporting markedly depressed mood. Fifty-seven percent were moderately or severely disabled overall, with 39% having deteriorated from a global outcome attained 1 or 2 years postinjury. Of those employed preinjury, 55% were unemployed. Poorer medical, functional, and participation outcomes were associated with, but not limited to, older age. Younger age groups had poorer mental and emotional outcomes. Deterioration in global outcome was common and not age-related. Conclusions: Significant mortality and morbidity were evident at 5 years postinjury. The deterioration in global outcomes observed regardless of age suggests that multiple influences contribute to poorer outcomes. Public health interventions intended to reduce post-acute inpatient rehabilitation mortality and morbidity rates will need to be multifaceted and age-specific.
C1 [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA.
[Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia; Whiteneck, Gale G.; Pretz, Christopher R.] Craig Hosp, Res Dept, Englewood, CO USA.
[Bell, Jeneita M.; Coronado, Victor G.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA.
[Miller, A. Cate] Natl Inst Disabil & Rehabil Res, Dept Educ, Washington, DC USA.
RP Corrigan, JD (reprint author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.
EM corrigan.1@osu.edu
FU US Department of Health and Human Services (HHS); Centers for Disease
Control and Prevention (CDC); US Department of Education, Office of
Special Education and Rehabilitative Services; National Institute on
Disability and Rehabilitation Research (NIDRR); NIDRR; Traumatic Brain
Injury (TBI) Model Systems National Data and Statistical Center
[H133A110006]; TBI Model Systems Centers grant from the NIDRR to Ohio
State University [H133A120086]
FX This research was supported by an interagency agreement between the US
Department of Health and Human Services (HHS), Centers for Disease
Control and Prevention (CDC), and the US Department of Education, Office
of Special Education and Rehabilitative Services, National Institute on
Disability and Rehabilitation Research (NIDRR), with supplemental
funding to the NIDRR-funded Traumatic Brain Injury (TBI) Model Systems
National Data and Statistical Center (grant no. H133A110006). The study
was also supported by a TBI Model Systems Centers grant from the NIDRR
to Ohio State University (grant no. H133A120086). This article does not
reflect the official policy or opinions of the CDC or HHS and does not
constitute an endorsement of the individuals or their programs-by the
CDC, HHS, or other components of the federal government-and none should
be inferred. No commercial party having a direct financial interest in
the results of the research supporting this article has or will confer a
benefit upon the authors or upon any organization with which the authors
are associated. The TBI Model Systems National Database is supported by
the NIDRR and created and maintained by the TBI Model Systems Centers
program. This article is intended to promote the exchange of ideas among
researchers and policy makers. The views expressed in it are part of
ongoing research and analysis and do not necessarily reflect the
position of the US Department of Education.
NR 25
TC 19
Z9 19
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-9701
EI 1550-509X
J9 J HEAD TRAUMA REHAB
JI J. Head Trauma Rehabil.
PD NOV-DEC
PY 2014
VL 29
IS 6
BP E1
EP E9
DI 10.1097/HTR.0000000000000020
PG 9
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AT7LI
UT WOS:000345117800001
PM 24495919
ER
PT J
AU Boegler, KA
Atiku, LA
Mpanga, JT
Clark, RJ
Delorey, MJ
Gage, KL
Eisen, RJ
AF Boegler, Karen A.
Atiku, Linda A.
Mpanga, Joseph Tendo
Clark, Rebecca J.
Delorey, Mark J.
Gage, Kenneth L.
Eisen, Rebecca J.
TI Use of Insecticide Delivery Tubes for Controlling Rodent-Associated
Fleas in a Plague Endemic Region of West Nile, Uganda
SO JOURNAL OF MEDICAL ENTOMOLOGY
LA English
DT Article
DE plague; flea control; Yersinia pestis; Uganda; topical insecticide
ID CTENOCEPHALIDES-FELIS; SIPHONAPTERA; EFFICACY; VECTOR; IDENTIFICATION;
FIPRONIL; RESISTANCE; PULICIDAE; DIELDRIN; MUTATION
AB Plague is a primarily flea-borne rodent-associated zoonosis that is often fatal in humans. Our study focused on the plague-endemic West Nile region of Uganda where affordable means for the prevention of human plague are currently lacking. Traditional hut construction and food storage practices hinder rodent exclusion efforts, and emphasize the need for an inexpensive but effective host-targeted approach for controlling fleas within the domestic environment. Here we demonstrate the ability of an insecticide delivery tube that is made from inexpensive locally available materials to reduce fleas on domestic rodents. Unbaited tubes were treated with either an insecticide alone (fipronil) or in conjunction with an insect growth regulator [(S)-methoprene], and placed along natural rodent runways within participant huts. Performance was similar for both treatments throughout the course of the study, and showed significant reductions in the proportion of infested rodents relative to controls for at least 100 d posttreatment.
C1 [Boegler, Karen A.; Clark, Rebecca J.; Delorey, Mark J.; Gage, Kenneth L.; Eisen, Rebecca J.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
[Atiku, Linda A.; Mpanga, Joseph Tendo] Uganda Virus Res Inst, Entebbe, Uganda.
RP Boegler, KA (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA.
EM kje5@cdc.gov
FU Oak Ridge Institute for Science and Education (ORISE); Centers for
Disease Control and Prevention (CDC)
FX We thank Cyrus Mungujakisa, Emmanuel Tibo, Ezekiel Kajik, Fred Wuuna,
Victor Olowo, Mukobi Yafesi, Robert Kibenga Banjo, Tom Stanley Asaku
(Uganda Virus Research Institute, Arua, Uganda), Jeff N. Borchert (CDC,
Entebbe, Uganda), and Marc Dolan (CDC, Fort Collins, CO) for their
valuable input and assistance with this study, as well as Sarah Bruhn
and Alvin Bronstein (Rocky Mountain Poison and Drug Center, Denver, CO)
for their helpful advice. We also thank the study participants of Okorro
County for kindly allowing us into their villages and homes. This
research was supported through fellowship with Oak Ridge Institute for
Science and Education (ORISE) administered by Oak Ridge Associated
Universities (ORAU) and funded by the Centers for Disease Control and
Prevention (CDC).
NR 40
TC 1
Z9 1
U1 1
U2 11
PU ENTOMOLOGICAL SOC AMER
PI ANNAPOLIS
PA 3 PARK PLACE, STE 307, ANNAPOLIS, MD 21401-3722 USA
SN 0022-2585
EI 1938-2928
J9 J MED ENTOMOL
JI J. Med. Entomol.
PD NOV
PY 2014
VL 51
IS 6
BP 1254
EP 1263
DI 10.1603/ME14083
PG 10
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA AT7NF
UT WOS:000345123800022
PM 26309315
ER
PT J
AU Hoel, DF
Marika, JA
Dunford, JC
Irish, SR
Geier, M
Obermayr, U
Wirtz, RA
AF Hoel, David F.
Marika, Jake A.
Dunford, James C.
Irish, Seth R.
Geier, Martin
Obermayr, Ulla
Wirtz, Robert A.
TI Optimizing Collection of Anopheles gambiae s.s. (Diptera: Culicidae) in
Biogents Sentinel Traps
SO JOURNAL OF MEDICAL ENTOMOLOGY
LA English
DT Article
DE Anopheles gambiae; BG-Sentinel trap; BG-Lure; Limburger cheese
ID AEDES-AEGYPTI DIPTERA; CARBON-DIOXIDE; MOSQUITO TRAPS; BG-SENTINEL;
CULEX-QUINQUEFASCIATUS; SEMIFIELD CONDITIONS; MALARIA MOSQUITOS;
LIMBURGER CHEESE; FIELD-EVALUATION; WESTERN KENYA
AB Surveillance of malaria vectors in Africa is most often accomplished using CDC-type light traps or human landing catches (HLCs). Over the past 30 yr, a variety of commercial and experimental mosquito traps have been developed for residential mosquito control or for improved surveillance of disease vector species, including the BG Sentinel (BGS) trap. To optimize collection of Anopheles gambiae Giles using this trap, BGS traps were modified with an opening (vent) added to the trap base to decrease exhaust airflow. Four traps configurations were tested with colony-reared host-seeking female An. gambiae in free-flying laboratory enclosures. Six attractant treatments (three attractants: BG-Lure, Limburger cheese, and a blank, with and without CO 2) were tested concurrently. Across all trap-attractant combinations, significantly more mosquitoes (P < 0.05) were collected in standard, unmodified traps set upright (mean: 10.0) or upside down (9.8) than vented traps, whether upright (5.9) or upside down (7.0). The BG-Lure + CO2 and Limburger Cheese + CO2 bait combinations were more attractive than the other attractants tested alone. All attractant combinations collected significantly more mosquitoes than unbaited traps. Field studies are needed to determine if BG-Lure + CO2- or Limburger cheese + CO2-baited BGS traps are comparable with HLCs in collecting host-seeking An. gambiae.
C1 [Hoel, David F.] Ctr Dis Control & Prevent, Navy & Marine Corps Publ Hlth Ctr Det, Atlanta, GA 30329 USA.
[Marika, Jake A.] Touro Coll Osteopath Med, New York, NY 10027 USA.
[Dunford, James C.] US Navy, Environm & Prevent Med Unit 2, Norfolk, VA 23511 USA.
[Irish, Seth R.; Wirtz, Robert A.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
[Geier, Martin; Obermayr, Ulla] Biogents AG, D-93055 Regensburg, Germany.
RP Hoel, DF (reprint author), Ctr Dis Control & Prevent, Navy & Marine Corps Publ Hlth Ctr Det, 1600 Clifton Rd, Atlanta, GA 30329 USA.
EM VQP1@cdc.gov
NR 55
TC 0
Z9 0
U1 1
U2 5
PU ENTOMOLOGICAL SOC AMER
PI ANNAPOLIS
PA 3 PARK PLACE, STE 307, ANNAPOLIS, MD 21401-3722 USA
SN 0022-2585
EI 1938-2928
J9 J MED ENTOMOL
JI J. Med. Entomol.
PD NOV
PY 2014
VL 51
IS 6
BP 1268
EP 1275
DI 10.1603/ME14065
PG 8
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA AT7NF
UT WOS:000345123800024
PM 26309317
ER
PT J
AU Ferrari, FAG
Goddard, J
Paddock, CD
Varela-Stokes, AS
AF Ferrari, F. A. G.
Goddard, J.
Paddock, C. D.
Varela-Stokes, A. S.
TI Ultrastructure of Presumed "Candidatus Rickettsia Andeanae" in Amblyomma
maculatum (Acari: Ixodidae)
SO JOURNAL OF MEDICAL ENTOMOLOGY
LA English
DT Article
DE spotted fever group rickettsiae; "Candidatus Rickettsia andeanae";
Amblyomma maculatum; transmission electron microscopy
ID GULF-COAST TICKS; FEVER GROUP RICKETTSIAE; INFECTING WOOD TICKS;
DERMACENTOR-ANDERSONI; UNITED-STATES; PARKERI; USA; IDENTIFICATION;
FRANCISELLA; AMERICANUM
AB Amblyomma maculatum Koch, 1844 (also known as the Gulf Coast tick) is found in parts of the Americas, including the central and southern United States. Its primary importance is as the vector of Rickettsia parkeri, a spotted fever group rickettsia that causes an illness similar to, but milder than, Rocky Mountain spotted fever. A second spotted fever group rickettsia, "Candidatus Rickettsia andeanae," was detected in Gulf Coast ticks approximately 10 yr ago. However, the significance of this organism, including pathogenicity, has not yet been well-characterized. Here, we use transmission electron microscopy to describe bacteria within the tissues of A. maculatum ticks that were positive by polymerase chain reaction assay for "Ca. R. andeanae." In ultrathin sections of unfed A. maculatum adult females, we found evidence of bacteria with morphological features consistent with spotted fever group rickettsiae, including small size (approximate to 0.3 by 0.9 mu m), a halo zone (electron-lucent layer around the bacterium), and a trilaminar cell wall. In female ticks, bacteria were present in granular salivary glands and ducts, foregut, Malpighian tubules, nerve trunks, and reproductive tissue. These findings demonstrate evidence of "Ca. R. andeanae" in situ and contribute to our understanding of this novel rickettsia in A. maculatum.
C1 [Ferrari, F. A. G.; Varela-Stokes, A. S.] Mississippi State Univ, Coll Vet Med, Dept Basic Sci, Mississippi State, MS 39762 USA.
[Goddard, J.] Mississippi State Univ, Dept Biochem Mol Biol Entomol & Plant Pathol, Mississippi State, MS 39762 USA.
[Paddock, C. D.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Rickettsial Zoonoses Branch, Atlanta, GA 30333 USA.
RP Varela-Stokes, AS (reprint author), Mississippi State Univ, Coll Vet Med, Dept Basic Sci, 240 Wise Ctr Dr, Mississippi State, MS 39762 USA.
EM stokes@cvm.msstate.edu
FU Mississippi State University, College of Veterinary Medicine
FX This work was supported by intramural funding through Mississippi State
University, College of Veterinary Medicine.
NR 29
TC 0
Z9 0
U1 0
U2 2
PU ENTOMOLOGICAL SOC AMER
PI ANNAPOLIS
PA 3 PARK PLACE, STE 307, ANNAPOLIS, MD 21401-3722 USA
SN 0022-2585
EI 1938-2928
J9 J MED ENTOMOL
JI J. Med. Entomol.
PD NOV
PY 2014
VL 51
IS 6
BP 1317
EP 1321
DI 10.1603/ME14132
PG 5
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA AT7NF
UT WOS:000345123800031
PM 26309324
ER
PT J
AU Charles, LE
Fekedulegn, D
Landsbergis, P
Burchfiel, CM
Baron, S
Kaufman, JD
Stukovsky, KH
Fujishiro, K
Foy, CG
Andrew, ME
Roux, AVD
AF Charles, Luenda E.
Fekedulegn, Desta
Landsbergis, Paul
Burchfiel, Cecil M.
Baron, Sherry
Kaufman, Joel D.
Stukovsky, Karen Hinckley
Fujishiro, Kaori
Foy, Capri G.
Andrew, Michael E.
Roux, Ana V. Diez
TI Associations of Work Hours, Job Strain, and Occupation With Endothelial
Function The Multi-Ethnic Study of Atherosclerosis (MESA)
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID CORONARY-HEART-DISEASE; FLOW-MEDIATED DILATION; II PROSPECTIVE COHORT;
CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; WHITEHALL-II;
BRACHIAL-ARTERY; RISK; METAANALYSIS; MORTALITY
AB Objective: To investigate associations of work hours, job control, job demands, job strain, and occupational category with brachial artery flow-mediated dilation (FMD) in 1499 Multi-Ethnic Study of Atherosclerosis participants. Methods: Flow-mediated dilation was obtained using high-resolution ultrasound. Mean values of FMD were examined across categories of occupation, work hours, and the other exposures using regression analyses. Results: Occupational category was significantly associated with FMD overall, with blue-collar workers showing the lowest mean values-management/professional = 4.97 +/- 0.22%; sales/office = 5.19 +/- 0.28%; services = 4.73 +/- 0.29%; and blue-collar workers = 4.01 +/- 0.26% (adjusted P < 0.001). There was evidence of effect modification by sex (interaction P = 0.031)-significant associations were observed among women (adjusted P = 0.002) and nearly significant results among men (adjusted P = 0.087). Other exposures were not significantly associated with FMD. Conclusions: Differences in endothelial function may account for some of the variation in cardiovascular disease across occupational groups.
C1 [Charles, Luenda E.; Fekedulegn, Desta; Burchfiel, Cecil M.; Andrew, Michael E.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA.
[Landsbergis, Paul] Suny Downstate Med Ctr, Dept Environm & Occupat Hlth Sci, Brooklyn, NY USA.
SUNY Downstate Sch Publ Hlth, Brooklyn, NY USA.
[Baron, Sherry; Fujishiro, Kaori] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA.
[Kaufman, Joel D.] Univ Washington, Sch Publ Hlth, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA.
[Stukovsky, Karen Hinckley] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA.
[Foy, Capri G.] Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Div Publ Hlth Sci, Winston Salem, NC USA.
[Roux, Ana V. Diez] Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA.
Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
RP Charles, LE (reprint author), NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, HELD BEB, MS L-4050,1095 Willowdale Rd, Morgantown, WV 26505 USA.
EM lcharles@cdc.gov
RI Kaufman, Joel/B-5761-2008
OI Kaufman, Joel/0000-0003-4174-9037
FU National Heart, Lung, and Blood Institute (NHLBI)
FX The Multi-Ethnic Study of Atherosclerosis (MESA) is conducted and
supported by the National Heart, Lung, and Blood Institute (NHLBI) in
collaboration with MESA investigators. This
NR 43
TC 2
Z9 2
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1076-2752
EI 1536-5948
J9 J OCCUP ENVIRON MED
JI J. Occup. Environ. Med.
PD NOV
PY 2014
VL 56
IS 11
BP 1153
EP 1160
DI 10.1097/JOM.0000000000000311
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT7DE
UT WOS:000345096100014
PM 25376409
ER
PT J
AU Matthias, J
Zielinski-Gutierrez, EC
Tisch, DJ
Stanek, D
Blanton, RE
Doyle, MS
Eadie, RB
Gazdick, EJ
Leal, AL
Pattison, KJ
Perez-Guerra, CL
Tittel, CJ
Vyas, J
Wagner, T
Blackmore, CGM
AF Matthias, James
Zielinski-Gutierrez, Emily C.
Tisch, Daniel J.
Stanek, Danielle
Blanton, Ronald E.
Doyle, Michael S.
Eadie, Robert B.
Gazdick, Elizabeth J.
Leal, Andrea L.
Pattison, Kimberly J.
Perez-Guerra, Carmen L.
Tittel, Christopher J.
Vyas, Jooi
Wagner, Todd
Blackmore, Carina G. M.
TI Evaluating Public Housing Residents for Knowledge, Attitudes, and
Practices Following Dengue Prevention Outreach in Key West, Florida
SO VECTOR-BORNE AND ZOONOTIC DISEASES
LA English
DT Article
DE Health education; Public housing; Outreach; Key West; Dengue
ID HEMORRHAGIC-FEVER
AB Background: In 2009-2010, 93 cases of dengue were identified in Key West, Florida. This was the first outbreak of autochthonous transmission of dengue in Florida since 1934. In response to this outbreak, a multifaceted public education outreach campaign was launched. The aim of this study is to compare dengue prevention knowledge, attitudes, perceptions, and prevention practices among residents of subsidized public housing to the general population in Key West and to assess whether there were barriers preventing effective outreach from reaching specific vulnerable populations.
Methods: A randomized population-based evaluation of knowledge, attitudes, and behaviors toward dengue prevention consisting of 521 separate household interviews was undertaken in July of 2011. A subset analysis was performed on interviews collected from 28 public housing units within four subsidized public housing complexes. Analysis was performed to determine whether knowledge, attitudes, and behaviors exhibited by public housing residents differed from the non-public housing study population.
Results: Public housing residents recalled fewer outreach materials (p=0.01) and were 3.4 times (95% confidence interval [CI] 1.4-8.3) more likely not to recall any outreach materials. Public housing residents were less likely to correctly identify how dengue transmission occurs (61% vs. 89%), where mosquitoes lay their eggs (54% vs. 85%), or to identify any signs or symptoms related to dengue (36% vs. 64%). Public housing residents were less likely to perform dengue prevention practices such as removing standing water or always using air conditioning.
Conclusions: Examination of public housing residents identified an at-risk population that recalled less exposure to outreach materials and had less knowledge about dengue infection and prevention than the randomized study population. This provides public health systems the opportunity to target or modify future health messages and interventions to this group. Differences identified in the demographics of this population suggest that alternative methods or non-English materials may be required to reach desired outcomes.
C1 [Matthias, James; Stanek, Danielle; Blackmore, Carina G. M.] Florida Dept Hlth, Tallahassee, FL USA.
[Zielinski-Gutierrez, Emily C.; Pattison, Kimberly J.; Perez-Guerra, Carmen L.] Ctr Dis Control & Prevent, Ft Collins, CO USA.
[Zielinski-Gutierrez, Emily C.; Pattison, Kimberly J.] Ctr Dis Control & Prevent, San Juan, PR USA.
[Tisch, Daniel J.; Blanton, Ronald E.; Gazdick, Elizabeth J.; Vyas, Jooi; Wagner, Todd] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Doyle, Michael S.; Leal, Andrea L.] Florida Keys Mosquito Control Dist, Key West, FL USA.
[Eadie, Robert B.; Tittel, Christopher J.] Florida Dept Hlth Monroe Cty, Key West, FL USA.
RP Matthias, J (reprint author), 4042 Bald Cypress Way,Bin A-08, Tallahassee, FL 32399 USA.
EM james_matthias@doh.state.fl.us
FU Applied Epidemiology Fellowship Program; Centers for Disease Control and
Prevention (CDC) [5U38HM000414]
FX This study/report was supported in part by an appointment to the Applied
Epidemiology Fellowship Program administered by the Council of State and
Territorial Epidemiologists (CSTE) and funded by the Centers for Disease
Control and Prevention (CDC) Cooperative Agreement Number 5U38HM000414.
NR 17
TC 3
Z9 3
U1 1
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-3667
EI 1557-7759
J9 VECTOR-BORNE ZOONOT
JI Vector-Borne Zoonotic Dis.
PD NOV 1
PY 2014
VL 14
IS 11
BP 788
EP 793
DI 10.1089/vbz.2014.1664
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AT5RF
UT WOS:000344998900003
PM 25409269
ER
PT J
AU Fabbri, CM
Garcia, JB
Morales, MA
Enria, DA
Levis, S
Lanciotti, RS
AF Fabbri, Cintia M.
Garcia, Jorge B.
Alejandra Morales, Maria
Enria, Delia A.
Levis, Silvana
Lanciotti, Robert S.
TI Complete Genome Sequences and Phylogenetic Analysis of Two West Nile
Virus Strains Isolated from Equines in Argentina in 2006 Could Indicate
an Early Introduction of the Virus in the Southern Cone
SO VECTOR-BORNE AND ZOONOTIC DISEASES
LA English
DT Article
DE West Nile virus; Equine strain sequences; Argentina; Flavivirus
ID UNITED-STATES; MIDDLE-EAST; HORSES; INFECTION; LINEAGE; ANTIBODIES;
GENOTYPE; DISEASE; AFRICA; HUMANS
AB The complete nucleotide sequences of two West Nile virus (WNV) strains isolated in Argentina were determined. Phylogenetic trees were constructed from the aligned nucleic acid sequences of these two strains along with other previously published complete WNV genome sequences. Phylogenetic data showed that both strains belonged to clade 1a of lineage 1 and clustered in a subclade with American strains isolated during 1999-2002. These results suggest two independent routes of introduction of WNV in Argentina and that the virus could have been circulating in Argentina for some time before being isolated.
C1 [Fabbri, Cintia M.; Garcia, Jorge B.; Alejandra Morales, Maria; Enria, Delia A.; Levis, Silvana] Inst Nacl Enfermedades Virales Humanas Dr Julio I, RA-2700 Pergarmino, Argentina.
[Lanciotti, Robert S.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO USA.
RP Fabbri, CM (reprint author), Inst Nacl Enfermedades Virales Humanas Dr Julio I, RA-2700 Pergarmino, Argentina.
EM cintiafabbri@yahoo.com.ar
FU Argentinean Ministry of Health
FX This study was supported with federal funds from Argentinean Ministry of
Health. Dr. Fabbri is in charge of Molecular Virology of the Arbovirus
Laboratory at INEVH, Pan American Health Organization Collaborating
Centre for Reference and Research on Arbovirus and Hemorrhagic Fever.
Her research interest focuses on diagnosis, research, and epidemiology
of arbovirus diseases.
NR 30
TC 2
Z9 2
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-3667
EI 1557-7759
J9 VECTOR-BORNE ZOONOT
JI Vector-Borne Zoonotic Dis.
PD NOV 1
PY 2014
VL 14
IS 11
BP 794
EP 800
DI 10.1089/vbz.2014.1588
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AT5RF
UT WOS:000344998900004
PM 25409270
ER
PT J
AU Lansky, A
Hall, I
Mermin, J
AF Lansky, Amy
Hall, Irene
Mermin, Jonathan
TI Declining HIV Incidence Among Women in the United States
SO WOMENS HEALTH ISSUES
LA English
DT Editorial Material
ID SEXUAL RISK BEHAVIOR; PREVENTION; CARE; VIRUS
C1 [Lansky, Amy; Hall, Irene] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
[Mermin, Jonathan] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
RP Lansky, A (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
EM alansky@cdc.gov
NR 13
TC 4
Z9 4
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD NOV-DEC
PY 2014
VL 24
IS 6
BP 581
EP 583
DI 10.1016/j.whi.2014.07.002
PG 3
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA AT8BD
UT WOS:000345157900001
PM 25442702
ER
PT J
AU Henley, SJ
Kanny, D
Roland, KB
Grossman, M
Peaker, B
Liu, Y
Gapstur, SM
White, MC
Plescia, M
AF Henley, S. Jane
Kanny, Dafna
Roland, Katherine B.
Grossman, Melissa
Peaker, Brandy
Liu, Yong
Gapstur, Susan M.
White, Mary C.
Plescia, Marcus
TI Alcohol Control Efforts in Comprehensive Cancer Control Plans and
Alcohol Use Among Adults in the USA
SO ALCOHOL AND ALCOHOLISM
LA English
DT Article
ID BREAST-CANCER; CONSUMPTION; RISK; PREVENTION
AB Aims: To understand how US cancer control plans address alcohol use, an important but frequently overlooked cancer risk factor, and how many US adults are at risk. Methods: We reviewed alcohol control efforts in 69 comprehensive cancer control plans in US states, tribes and jurisdictions. Using the 2011 Behavioral Risk Factor Surveillance System, we assessed the prevalence of current alcohol use among US adults and the proportion of these drinkers who exceeded guidelines for moderate drinking. Results: Most comprehensive cancer control plans acknowledged alcohol use as a cancer risk factor but fewer than half included a goal, objective or strategy to address alcohol use. More than half of US adults reported current alcohol use in 2011, and two of three drinkers exceeded moderate drinking guidelines at least once in the past month. Many states that did not address alcohol use in comprehensive cancer control plans also had a high proportion of adults at risk. Conclusion: Alcohol use is a common cancer risk factor in the USA, but alcohol control strategies are not commonly included in comprehensive cancer control plans. Supporting the implementation of evidence-based strategies to prevent the excessive use of alcohol is one tool the cancer control community can use to reduce the risk of cancer.
C1 [Henley, S. Jane; Roland, Katherine B.; Grossman, Melissa; Peaker, Brandy; White, Mary C.; Plescia, Marcus] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
[Kanny, Dafna; Liu, Yong] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
[Gapstur, Susan M.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
RP Henley, SJ (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Bldg 107,Mail Stop F-76, Atlanta, GA 30341 USA.
EM skh3@cdc.gov
FU Division of Cancer Prevention and Control at the National Center for
Chronic Disease Prevention and Health Promotion, Centers for Disease
Control and Prevention
FX This work was supported by the Division of Cancer Prevention and Control
at the National Center for Chronic Disease Prevention and Health
Promotion, Centers for Disease Control and Prevention.
NR 29
TC 2
Z9 2
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0735-0414
EI 1464-3502
J9 ALCOHOL ALCOHOLISM
JI Alcohol Alcohol.
PD NOV-DEC
PY 2014
VL 49
IS 6
BP 661
EP 667
DI 10.1093/alcalc/agu064
PG 7
WC Substance Abuse
SC Substance Abuse
GA AT0BJ
UT WOS:000344601500009
PM 25313255
ER
PT J
AU Richardson, DB
Laurier, D
Schubauer-Berigan, MK
Tchetgen, ET
Cole, SR
AF Richardson, David B.
Laurier, Dominique
Schubauer-Berigan, Mary K.
Tchetgen, Eric
Cole, Stephen R.
TI Assessment and Indirect Adjustment for Confounding by Smoking in Cohort
Studies Using Relative Hazards Models
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE cohort studies; lung cancer; smoking
ID LUNG-CANCER; URANIUM MINERS; MORTALITY; RADON; BIAS; REGRESSION;
COLLIDER; EXPOSURE; TOBACCO; SILICA
AB Workers' smoking histories are not measured in many occupational cohort studies. Here we discuss the use of negative control outcomes to detect and adjust for confounding in analyses that lack information on smoking. We clarify the assumptions necessary to detect confounding by smoking and the additional assumptions necessary to indirectly adjust for such bias. We illustrate these methods using data from 2 studies of radiation and lung cancer: the Colorado Plateau cohort study (1950-2005) of underground uranium miners (in which smoking was measured) and a French cohort study (1950-2004) of nuclear industry workers (in which smoking was unmeasured). A cause-specific relative hazards model is proposed for estimation of indirectly adjusted associations. Among the miners, the proposed method suggests no confounding by smoking of the association between radon and lung cancer-a conclusion supported by adjustment for measured smoking. Among the nuclear workers, the proposed method suggests substantial confounding by smoking of the association between radiation and lung cancer. Indirect adjustment for confounding by smoking resulted in an 18% decrease in the adjusted estimated hazard ratio, yet this cannot be verified because smoking was unmeasured. Assumptions underlying this method are described, and a cause-specific proportional hazards model that allows easy implementation using standard software is presented.
C1 [Richardson, David B.; Cole, Stephen R.] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA.
[Richardson, David B.; Laurier, Dominique] Inst Radiat Protect & Nucl Safety, Lab Epidemiol, Fontenay Aux Roses, France.
[Schubauer-Berigan, Mary K.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA.
[Tchetgen, Eric] Harvard Univ, Dept Biostat, Boston, MA 02115 USA.
RP Richardson, DB (reprint author), Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA.
EM david.richardson@unc.edu
FU AREVA Nuclear Cycle; Electricite de France within the European
Commission
FX The French study of nuclear workers has been completed, with partial
support from AREVA Nuclear Cycle and Electricite de France, within the
European Commission Fifth Framework Programme.
NR 26
TC 5
Z9 5
U1 1
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD NOV 1
PY 2014
VL 180
IS 9
BP 933
EP 940
DI 10.1093/aje/kwu211
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT0BD
UT WOS:000344600900009
PM 25245043
ER
PT J
AU Fang, J
Yang, QH
Ayala, C
Loustalot, F
AF Fang, Jing
Yang, Quanhe
Ayala, Carma
Loustalot, Fleetwood
TI Disparities in Access to Care Among US Adults With Self-Reported
Hypertension
SO AMERICAN JOURNAL OF HYPERTENSION
LA English
DT Article
DE access to care; blood pressure; disparity; hypertension
ID HEALTH-INSURANCE COVERAGE; UNITED-STATES; UNCONTROLLED HYPERTENSION;
POPULATION; AWARENESS; MORTALITY; RISK
AB Hypertension is a major risk factor for cardiovascular disease. Access to care has been identified as a significant factor affecting hypertension treatment and control. We examined disparities in access to care among US adults with self-reported hypertension.
Using Behavioral Risk Factor Surveillance System 2011 data, we identified US adults with self-reported hypertension. Access to care was assessed based on responses to questions about health insurance, having an identified personal doctor, and cost barriers to visiting a doctor. We assessed access to care by geographic location (ie, US state) and selected sociodemographic characteristics.
Overall, 159,947 eligible participants reported having hypertension. Among them, 19.1% had no health insurance, 18.1% had no personal doctor, and 23.6% could not visit a doctor because of cost. Among those with hypertension by state, age-standardized prevalence of no health insurance ranged from 6.3% in Hawaii to 28.1% in Texas. The prevalence of those without a personal doctor ranged from 9.2% in Massachusetts to 32.7% in Nevada, and the prevalence of cost barrier to visiting a doctor ranged from 10.8% in North Dakota to 35.1% in Tennessee. By sociodemographic characteristics, the prevalence with no health insurance was highest among those aged 18-44 years (25.9%), Hispanics (28.1%), those with less than a high school education (32.8%), and those with a household income of less than $25,000 (31.6%). Similar disparity patterns were noted for estimates of the other access-to-care variables.
Among US hypertensive adults, approximately 20% reported access-to-care challenges, with significant geographic and sociodemographic variations.
C1 [Fang, Jing; Yang, Quanhe; Ayala, Carma; Loustalot, Fleetwood] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
RP Fang, J (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM jfang@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 21
TC 9
Z9 9
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0895-7061
EI 1941-7225
J9 AM J HYPERTENS
JI Am. J. Hypertens.
PD NOV
PY 2014
VL 27
IS 11
BP 1377
EP 1386
DI 10.1093/ajh/hpu061
PG 10
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AT0BF
UT WOS:000344601100008
PM 24847953
ER
PT J
AU Chen, LG
Schiffer, JM
Dalton, S
Sabourin, CL
Niemuth, NA
Plikaytis, BD
Quinn, CP
AF Chen, Ligong
Schiffer, Jarad M.
Dalton, Shannon
Sabourin, Carol L.
Niemuth, Nancy A.
Plikaytis, Brian D.
Quinn, Conrad P.
TI Comprehensive Analysis and Selection of Anthrax Vaccine Adsorbed Immune
Correlates of Protection in Rhesus Macaques
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID INTRAMUSCULAR INJECTION; VARIABLE SELECTION; RANDOMIZED-TRIAL; DNA
VACCINE; GUINEA-PIGS; ANTIGEN; EFFICACY; HUMANS; SAFETY; TOXIN
AB Humoral and cell-mediated immune correlates of protection (COP) for inhalation anthrax in a rhesus macaque (Macaca mulatta) model were determined. The immunological and survival data were from 114 vaccinated and 23 control animals exposed to Bacillus anthracis spores at 12, 30, or 52 months after the first vaccination. The vaccinated animals received a 3-dose intramuscular priming series (3-i.m.) of anthrax vaccine adsorbed (AVA) (BioThrax) at 0, 1, and 6 months. The immune responses were modulated by administering a range of vaccine dilutions. Together with the vaccine dilution dose and interval between the first vaccination and challenge, each of 80 immune response variables to anthrax toxin protective antigen (PA) at every available study time point was analyzed as a potential COP by logistic regression penalized by least absolute shrinkage and selection operator (LASSO) or elastic net. The anti-PA IgG level at the last available time point before challenge (last) and lymphocyte stimulation index (SI) at months 2 and 6 were identified consistently as a COP. Anti-PA IgG levels and lethal toxin neutralization activity (TNA) at months 6 and 7 (peak) and the frequency of gamma interferon (IFN-gamma)-secreting cells at month 6 also had statistically significant positive correlations with survival. The ratio of interleukin 4 (IL-4) mRNA to IFN-gamma mRNA at month 6 also had a statistically significant negative correlation with survival. TNA had lower accuracy as a COP than did anti-PA IgG response. Following the 3-i.m. priming with AVA, the anti-PA IgG responses at the time of exposure or at month 7 were practicable and accurate metrics for correlating vaccine-induced immunity with protection against inhalation anthrax.
C1 [Chen, Ligong; Schiffer, Jarad M.; Dalton, Shannon; Plikaytis, Brian D.; Quinn, Conrad P.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Sabourin, Carol L.; Niemuth, Nancy A.] Battelle Mem Inst, Columbus, OH USA.
[Chen, Ligong; Dalton, Shannon] Atlanta Res & Educ Fdn Inc, Decatur, GA USA.
RP Quinn, CP (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
EM cquinn@cdc.gov
FU Centers for Disease Control and Prevention (Atlanta, GA); Biomedical
Advanced Research and Development Authority (BARDA) (Washington, DC);
DHHS CDC [200-2000-10065]; Atlanta Research and Education Foundation
(AREF) through the Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development (Atlanta, GA)
FX This study was funded through the Centers for Disease Control and
Prevention (Atlanta, GA) with additional support from the Biomedical
Advanced Research and Development Authority (BARDA) (Washington, DC).
Battelle was funded under DHHS CDC contract 200-2000-10065. L.C. and
S.D. were funded by the Atlanta Research and Education Foundation (AREF)
through the Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development (Atlanta, GA).
NR 37
TC 11
Z9 11
U1 2
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD NOV
PY 2014
VL 21
IS 11
BP 1512
EP 1520
DI 10.1128/CVI.00469-14
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0UX
UT WOS:000344651200007
PM 25185577
ER
PT J
AU Al-Abdallat, MM
Payne, DC
Alqasrawi, S
Rha, B
Tohme, RA
Abedi, GR
Al Nsour, M
Iblan, I
Jarour, N
Farag, NH
Haddadin, A
Al-Sanouri, T
Tamin, A
Harcourt, JL
Kuhar, DT
Swerdlow, DL
Erdman, DD
Pallansch, MA
Haynes, LM
Gerber, SI
AF Al-Abdallat, Mohammad Mousa
Payne, Daniel C.
Alqasrawi, Sultan
Rha, Brian
Tohme, Rania A.
Abedi, Glen R.
Al Nsour, Mohannad
Iblan, Ibrahim
Jarour, Najwa
Farag, Noha H.
Haddadin, Aktham
Al-Sanouri, Tarek
Tamin, Azaibi
Harcourt, Jennifer L.
Kuhar, David T.
Swerdlow, David L.
Erdman, Dean D.
Pallansch, Mark A.
Haynes, Lia M.
Gerber, Susan I.
CA Jordan MERS-Cov Investigation Team
TI Hospital-Associated Outbreak of Middle East Respiratory Syndrome
Coronavirus: A Serologic, Epidemiologic, and Clinical Description
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE MERS-CoV; Middle East respiratory syndrome; novel coronavirus; Jordan;
seroepidemiology
ID SARS-CORONAVIRUS; SAUDI-ARABIA; ANTIBODIES; INFECTION; FEATURES; PROTEIN
AB Background. In April 2012, the Jordan Ministry of Health investigated an outbreak of lower respiratory illnesses at a hospital in Jordan; 2 fatal cases were retrospectively confirmed by real-time reverse transcription polymerase chain reaction (rRT-PCR) to be the first detected cases of Middle East respiratory syndrome (MERS-CoV).
Methods. Epidemiologic and clinical characteristics of selected potential cases were assessed through serum blood specimens, medical record reviews, and interviews with surviving outbreak members, household contacts, and healthcare personnel. Cases of MERS-CoV infection were identified using 3 US Centers for Disease Control and Prevention serologic tests for detection of anti-MERS-CoV antibodies.
Results. Specimens and interviews were obtained from 124 subjects. Seven previously unconfirmed individuals tested positive for anti-MERS-CoV antibodies by at least 2 of 3 serologic tests, in addition to 2 fatal cases identified by rRT-PCR. The case-fatality rate among the 9 total cases was 22%. Six subjects were healthcare workers at the outbreak hospital, yielding an attack rate of 10% among potentially exposed outbreak hospital personnel. There was no evidence of MERS-CoV transmission at 2 transfer hospitals having acceptable infection control practices.
Conclusions. Novel serologic tests allowed for the detection of otherwise unrecognized cases of MERS-CoV infection among contacts in a Jordanian hospital-associated respiratory illness outbreak in April 2012, resulting in a total of 9 test-positive cases. Serologic results suggest that further spread of this outbreak to transfer hospitals did not occur. Most subjects had no major, underlying medical conditions; none were on hemodialysis. Our observed case-fatality rate was lower than has been reported from outbreaks elsewhere.
C1 [Al-Abdallat, Mohammad Mousa; Alqasrawi, Sultan; Jarour, Najwa] Jordan Minist Hlth, Communicable Dis Directorate, Amman, Jordan.
[Payne, Daniel C.; Rha, Brian; Abedi, Glen R.; Tamin, Azaibi; Harcourt, Jennifer L.; Swerdlow, David L.; Erdman, Dean D.; Pallansch, Mark A.; Haynes, Lia M.; Gerber, Susan I.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Rha, Brian] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Tohme, Rania A.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Al Nsour, Mohannad] Jordan Minist Hlth, Eastern Mediterranean Publ Hlth Network, Amman, Jordan.
[Iblan, Ibrahim] Jordan Minist Hlth, Field Epidemiol Training Program, Amman, Jordan.
[Farag, Noha H.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Haddadin, Aktham; Al-Sanouri, Tarek] Jordan Minist Hlth, Directorate Labs, Amman, Jordan.
[Kuhar, David T.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Payne, DC (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A34, Atlanta, GA 30333 USA.
EM dvp6@cdc.gov
FU US Global Disease Detection Operations Center Outbreak Response
Contingency Fund
FX This work was supported by the US Global Disease Detection Operations
Center Outbreak Response Contingency Fund.
NR 25
TC 85
Z9 89
U1 1
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 1
PY 2014
VL 59
IS 9
BP 1225
EP 1233
DI 10.1093/cid/ciu359
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0TG
UT WOS:000344647100007
PM 24829216
ER
PT J
AU Tate, JE
Parashar, UD
AF Tate, Jacqueline E.
Parashar, Umesh D.
TI Rotavirus Vaccines in Routine Use
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE rotavirus; rotavirus vaccine
ID 1ST 2 YEARS; DIARRHEA-ASSOCIATED HOSPITALIZATIONS; NATIONAL IMMUNIZATION
PROGRAM; CHILDREN LESS-THAN-5 YEARS; ALL-CAUSE GASTROENTERITIS;
PLACEBO-CONTROLLED TRIAL; UNITED-STATES; REASSORTANT ROTAVIRUS;
DOUBLE-BLIND; CHILDHOOD DIARRHEA
AB Vaccines are now available to combat rotavirus, the most common cause of severe diarrhea among children worldwide. We review clinical trial data for available rotavirus vaccines and summarize postlicensure data on effectiveness, impact, and safety from countries routinely using these vaccines in national programs. In these countries, rotavirus vaccines have reduced all-cause diarrhea and rotavirus hospitalizations by 17%-55% and 49%-92%, respectively, and all-cause diarrhea deaths by 22%-50% in some settings. Indirect protection of children who are age-ineligible for rotavirus vaccine has also been observed in some high and upper middle income countries. Experience with routine use of rotavirus vaccines in lower middle income countries has been limited to date, but vaccine introductions in such countries have been increasing in recent years. The risk-benefit analysis of rotavirus vaccines is extremely favorable but other strategies to improve the effectiveness of the vaccine, particularly in lower middle income settings, should be considered.
C1 [Tate, Jacqueline E.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA.
RP Tate, JE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30333 USA.
EM jqt8@cdc.gov
NR 122
TC 23
Z9 24
U1 1
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 1
PY 2014
VL 59
IS 9
BP 1291
EP 1301
DI 10.1093/cid/ciu564
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0TG
UT WOS:000344647100016
PM 25048849
ER
PT J
AU O'Donnell, AT
Vieira, AR
Huang, JY
Whichard, J
Cole, D
Karp, BE
AF O'Donnell, Allison T.
Vieira, Antonio R.
Huang, Jennifer Y.
Whichard, Jean
Cole, Dana
Karp, Beth E.
TI Quinolone-Resistant Salmonella enterica Serotype Enteritidis Infections
Associated With International Travel
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
DE drug resistance; foodborne diseases; quinolones; Salmonella; travel
ID ACTIVE SURVEILLANCE NETWORK; UNITED-STATES; PATHOGENS
AB We found a strong association between nalidixic acid-resistant Salmonella enterica serotype Enteritidis infections in the United States and recent international travel by linking Salmonella Enteritidis data from the National Antimicrobial Resistance Monitoring System and the Foodborne Diseases Active Surveillance Network.
C1 [O'Donnell, Allison T.] Atlanta Res & Educ Fdn, Decatur, GA USA.
[O'Donnell, Allison T.; Vieira, Antonio R.; Huang, Jennifer Y.; Whichard, Jean; Cole, Dana; Karp, Beth E.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA.
RP Karp, BE (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA.
EM bkarp@cdc.gov
NR 12
TC 6
Z9 6
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 1
PY 2014
VL 59
IS 9
BP E139
EP E141
DI 10.1093/cid/ciu505
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0TG
UT WOS:000344647100002
PM 24973311
ER
PT J
AU Hess, JJ
Eidson, M
Tlumak, JE
Raab, KK
Luber, G
AF Hess, Jeremy J.
Eidson, Millicent
Tlumak, Jennifer E.
Raab, Kristin K.
Luber, George
TI An Evidence-Based Public Health Approach to Climate Change Adaptation
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Review
ID HEAT-RELATED MORTALITY; COMPARATIVE RISK-ASSESSMENT; NEW-YORK-STATE;
HOSPITAL ADMISSIONS; UNITED-STATES; IMPACTS; INTERVENTIONS; POLICY;
TEMPERATURES; MODEL
AB Background: Public health is committed to evidence-based practice, yet there has been minimal discussion of how to apply an evidence-based practice framework to climate change adaptation.
Objectives: Our goal was to review the literature on evidence-based public health (EBPH), to determine whether it can be applied to climate change adaptation, and to consider how emphasizing evidence-based practice may influence research and practice decisions related to public health adaptation to climate change.
Methods: We conducted a substantive review of EBPH, identified a consensus EBPH framework, and modified it to support an EBPH approach to climate change adaptation. We applied the framework to an example and considered implications for stakeholders.
Discussion: A modified EBPH framework can accommodate the wide range of exposures, outcomes, and modes of inquiry associated with climate change adaptation and the variety of settings in which adaptation activities will be pursued. Several factors currently limit application of the framework, including a lack of higher-level evidence of intervention efficacy and a lack of guidelines for reporting climate change health impact projections. To enhance the evidence base, there must be increased attention to designing, evaluating, and reporting adaptation interventions; standardized health impact projection reporting; and increased attention to knowledge translation. This approach has implications for funders, researchers, journal editors, practitioners, and policy makers.
Conclusions: The current approach to EBPH can, with modifications, support climate change adaptation activities, but there is little evidence regarding interventions and knowledge translation, and guidelines for projecting health impacts are lacking. Realizing the goal of an evidence-based approach will require systematic, coordinated efforts among various stakeholders.
C1 [Hess, Jeremy J.; Luber, George] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Climate & Hlth Program, Atlanta, GA USA.
[Hess, Jeremy J.; Tlumak, Jennifer E.] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA.
[Hess, Jeremy J.] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA.
[Eidson, Millicent] New York State Dept Hlth, Off Publ Hlth Practice, Albany, NY USA.
[Eidson, Millicent] SUNY Albany, Dept Epidemiol & Biostat, Albany, NY 12222 USA.
[Raab, Kristin K.] Minnesota Dept Hlth, Div Environm Hlth, St Paul, MN USA.
RP Hess, JJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Climate & Hlth Program, 4770 Buford Highway,MS F-59, Chamblee, GA 30341 USA.
EM jhess@emory.edu
NR 97
TC 11
Z9 11
U1 3
U2 36
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD NOV
PY 2014
VL 122
IS 11
BP 1177
EP 1186
DI 10.1289/ehp.1307396
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA AT2IZ
UT WOS:000344759500018
PM 25003495
ER
PT J
AU Hess, JJ
Saha, S
Luber, G
AF Hess, Jeremy J.
Saha, Shubhayu
Luber, George
TI Summertime Acute Heat Illness in U.S. Emergency Departments from 2006
through 2010: Analysis of a Nationally Representative Sample
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID CLIMATE-CHANGE; WAVE; TEMPERATURE; HEATSTROKE; MORBIDITY; MORTALITY;
IMPACTS; FRANCE
AB BACKGROUND: Patients with acute heat illness present primarily to emergency departments (EDs), yet little is known regarding these visits.
OBJECTIVE: We aimed to describe acute heat illness visits to U.S. EDs from 2006 through 2010 and identify factors associated with hospital admission or with death in the ED.
METHODS: We extracted ED case-level data from the Nationwide Emergency Department Sample (NEDS) for 2006-2010, defining cases as ED visits from May through September with any heat illness diagnosis (ICD-9-CM 992.0-992.9). We correlated visit rates and temperature anomalies, analyzed demographics and ED disposition, identified risk factors for adverse outcomes, and examined ED case fatality rates (CFR).
RESULTS: There were 326,497 (95% CI: 308,372, 344,658) cases, with 287,875 (88.2%) treated and released, 38,392 (11.8%) admitted, and 230 (0.07%) died in the ED. Heat illness diagnoses were first-listed in 68%. 74.7% had heat exhaustion, 5.4% heat stroke. Visit rates were highly correlated with annual temperature anomalies (Pearson correlation coefficient 0.882, p = 0.005). Treat-and-release rates were highest for younger adults (26.2/100,000/year), whereas hospitalization and death-in-the-ED rates were highest for older adults (6.7 and 0.03/100,000/year, respectively); all rates were highest in rural areas. Heat stroke had an ED CFR of 99.4/10,000 (95% CI: 78.7, 120.1) visits and was diagnosed in 77.0% of deaths. Adjusted odds of hospital admission or death in the ED were higher among elders, males, urban and low-income residents, and those with chronic conditions.
CONCLUSIONS: Heat illness presented to the ED frequently, with highest rates in rural areas. Case definitions should include all diagnoses. Visit rates were correlated with temperature anomalies. Heat stroke had a high ED CFR. Males, elders, and the chronically ill were at greatest risk of admission or death in the ED. Chronic disease burden exponentially increased this risk.
C1 [Hess, Jeremy J.; Saha, Shubhayu; Luber, George] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Climate & Hlth Program, Atlanta, GA USA.
[Hess, Jeremy J.] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30303 USA.
[Hess, Jeremy J.] Emory Univ, Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30303 USA.
RP Hess, JJ (reprint author), Emory Univ, Dept Emergency Med, 49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA.
EM jhess@emory.edu
NR 35
TC 13
Z9 14
U1 3
U2 11
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD NOV
PY 2014
VL 122
IS 11
BP 1209
EP 1215
DI 10.1289/ehp.1306796
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA AT2IZ
UT WOS:000344759500022
PM 24937159
ER
PT J
AU Braun, JM
Lanphear, BP
Calafat, AM
Deria, S
Khoury, J
Howe, CJ
Venners, SA
AF Braun, Joseph M.
Lanphear, Bruce P.
Calafat, Antonia M.
Deria, Sirad
Khoury, Jane
Howe, Chanelle J.
Venners, Scott A.
TI Early-Life Bisphenol A Exposure and Child Body Mass Index: A Prospective
Cohort Study
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID PHTHALATE METABOLITES; ENVIRONMENTAL-HEALTH; UNITED-STATES; OBESITY;
VARIABILITY; BIRTH; ASSOCIATION; ADOLESCENTS; OVERWEIGHT; PREGNANCY
AB BACKGROUND: Early-life exposure to bisphenol A (BPA) may increase childhood obesity risk, but few prospective epidemiological studies have investigated this relationship.
OBJECTIVE: We sought to determine whether early-life exposure to BPA was associated with increased body mass index (BMI) at 2-5 years of age in 297 mother-child pairs from Cincinnati, Ohio (HOME Study).
METHODS: Urinary BPA concentrations were measured in samples collected from pregnant women during the second and third trimesters and their children at 1 and 2 years of age. BMI z-scores were calculated from weight/height measures conducted annually from 2 through 5 years of age. We used linear mixed models to estimate BMI differences or trajectories with increasing creatinine-normalized BPA concentrations.
RESULTS: After confounder adjustment, each 10-fold increase in prenatal (beta = -0.1; 95% CI: -0.5, 0.3) or early-childhood (beta = -0.2; 95% CI: -0.6, 0.1) BPA concentrations was associated with a modest and nonsignificant reduction in child BMI. These inverse associations were suggestively stronger in girls than in boys [prenatal effect measure modification (EMM) p-value = 0.30, early-childhood EMM p-value = 0.05], but sex-specific associations were imprecise. Children in the highest early-childhood BPA tercile had lower BMI at 2 years (difference = -0.3; 95% CI: -0.6, 0.0) and larger increases in their BMI slope from 2 through 5 years (BMI increase per year = 0.12; 95% CI: 0.07, 0.18) than children in the lowest tercile (BMI increase per year = 0.07; 95% CI: 0.01, 0.13). All associations were attenuated without creatinine normalization.
CONCLUSIONS: Prenatal and early-childhood BPA exposures were not associated with increased BMI at 2-5 years of age, but higher early-childhood BPA exposures were associated with accelerated growth during this period.
C1 [Braun, Joseph M.; Howe, Chanelle J.] Brown Univ, Dept Epidemiol, Sch Publ Hlth, Providence, RI 02912 USA.
[Lanphear, Bruce P.] BC Childrens & Womens Hosp, Child & Family Res Inst, Vancouver, BC, Canada.
[Lanphear, Bruce P.; Deria, Sirad; Venners, Scott A.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada.
[Calafat, Antonia M.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Khoury, Jane] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA.
RP Braun, JM (reprint author), Brown Univ, Dept Epidemiol, Box G-S121-2, Providence, RI 02912 USA.
EM joseph_braun_1@brown.edu
RI Braun, Joseph/H-8649-2014; Khoury, Jane/O-2068-2015
FU National Institute of Environmental Health Sciences [R00 ES020346, PO1
ES11261, R01 ES014575, R01 ES020349]; Canadian Institutes of Health
Research (CIHR) [12301]; Michael Smith Foundation for Health Research
(MSFHR) [5176]
FX This work was supported by National Institute of Environmental Health
Sciences grants R00 ES020346, PO1 ES11261, R01 ES014575, and R01
ES020349. S.A.V. was supported by Canadian Institutes of Health Research
(CIHR) grant 12301 and Michael Smith Foundation for Health Research
(MSFHR) grant 5176.
NR 40
TC 21
Z9 21
U1 7
U2 41
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD NOV
PY 2014
VL 122
IS 11
BP 1239
EP 1245
DI 10.1289/ehp.1408258
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA AT2IZ
UT WOS:000344759500026
PM 25073184
ER
PT J
AU Brown, LG
Le, B
Wong, MR
Reimann, D
Nicholas, D
Faw, B
Davis, E
Selman, CA
AF Brown, Laura G.
Le, Brenda
Wong, Melissa R.
Reimann, David
Nicholas, David
Faw, Brenda
Davis, Ernestine
Selman, Carol A.
TI Restaurant Manager and Worker Food Safety Certification and Knowledge
SO FOODBORNE PATHOGENS AND DISEASE
LA English
DT Article
ID EHS-NET; WORKING
AB Over half of foodborne illness outbreaks occur in restaurants. To combat these outbreaks, many public health agencies require food safety certification for restaurant managers, and sometimes workers. Certification entails passing a food safety knowledge examination, which is typically preceded by food safety training. Current certification efforts are based on the assumption that certification leads to greater food safety knowledge. The Centers for Disease Control and Prevention conducted this study to examine the relationship between food safety knowledge and certification. We also examined the relationships between food safety knowledge and restaurant, manager, and worker characteristics. We interviewed managers (N=387) and workers (N=365) about their characteristics and assessed their food safety knowledge. Analyses showed that certified managers and workers had greater food safety knowledge than noncertified managers and workers. Additionally, managers and workers whose primary language was English had greater food safety knowledge than those whose primary language was not English. Other factors associated with greater food safety knowledge included working in a chain restaurant, working in a larger restaurant, having more experience, and having more duties. These findings indicate that certification improves food safety knowledge, and that complex relationships exist among restaurant, manager, and worker characteristics and food safety knowledge.
C1 [Brown, Laura G.; Le, Brenda; Selman, Carol A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Wong, Melissa R.] New York City Dept Hlth & Mental Hyg, New York, NY USA.
[Reimann, David] Minnesota Dept Hlth, Mankato, MN USA.
[Nicholas, David] New York State Dept Hlth, Albany, NY USA.
[Faw, Brenda] Calif Dept Publ Hlth, Sacramento, CA USA.
[Davis, Ernestine] Tennessee Dept Hlth, Nashville, TN USA.
RP Brown, LG (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, MS F58,4770 Buford Highway, Chamblee, GA 30341 USA.
EM lrgreen@cdc.gov
NR 9
TC 3
Z9 3
U1 5
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1535-3141
EI 1556-7125
J9 FOODBORNE PATHOG DIS
JI Foodborne Pathog. Dis.
PD NOV 1
PY 2014
VL 11
IS 11
BP 835
EP 843
DI 10.1089/fpd.2014.1787
PG 9
WC Food Science & Technology
SC Food Science & Technology
GA AT1BQ
UT WOS:000344668600001
PM 25361386
ER
PT J
AU Kobrynski, L
Powell, RW
Bowen, S
AF Kobrynski, Lisa
Powell, Rachel Waltenburg
Bowen, Scott
TI Prevalence and Morbidity of Primary Immunodeficiency Diseases, United
States 2001-2007
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Article
DE Primary immunodeficiency; prevalence; epidemiology; genetic diseases;
immunology
ID COMMON VARIABLE IMMUNODEFICIENCY; PRIMARY IMMUNE-DEFICIENCY;
INTERNET-BASED PATIENT; NEW-YORK-STATE; 1ST 2 YEARS; NATIONAL REGISTRY;
IMMUNOLOGICAL FEATURES; RESEARCH DATABASE; DIAGNOSIS CODES;
TRANSPLANTATION
AB Few studies have estimated population prevalence and morbidity of primary immunodeficiency diseases (PIDD). We used administrative healthcare databases to estimate the prevalence of PIDD diagnoses in the United States from 2001 to 2007.
MarketScan databases compile claims from commercial health insurance plans and Medicaid, recording individual diagnoses for outpatient encounters and hospital stays. We used a cross sectional survey to estimate prevalence of PIDD using related ICD-9 codes (279.0, 279.1, 279.2, 279.8, 279.9, 288.1 and 288.2). Persons with secondary immunodeficiency diagnoses were excluded from analysis.
Between 2001 and 2007, prevalence of any PIDD diagnosis increased from 38.9 to 50.5 per 100,000 among privately insured and from 29.1 to 41.1 per 100,000 among publicly insured persons. B cell defects predominated. Prevalence was more than twice as high among Whites as among Blacks or Hispanics.
In this large database, we found a higher prevalence of diagnosed PIDD than has been reported previously from registries. Increased awareness may have contributed to the increasing prevalence.
C1 [Kobrynski, Lisa] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.
[Powell, Rachel Waltenburg; Bowen, Scott] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA.
RP Kobrynski, L (reprint author), Emory Univ, Sch Med, Dept Pediat, 2015 Uppergate Dr, Atlanta, GA 30322 USA.
EM lkobryn@emory.edu
FU U.S. Department of Energy; CDC
FX This research was supported in part by an appointment (RWP) to the
Research Participation Program at the CDC administered by the Oak Ridge
Institute for Science and Education through an interagency agreement
between the U.S. Department of Energy and CDC. Thanks to the Jeffrey
Modell Foundation for promoting awareness of Primary Immune
Deficiencies.
NR 41
TC 8
Z9 8
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD NOV
PY 2014
VL 34
IS 8
BP 954
EP 961
DI 10.1007/s10875-014-0102-8
PG 8
WC Immunology
SC Immunology
GA AT2QU
UT WOS:000344780000010
PM 25257253
ER
PT J
AU Donlan, RM
AF Donlan, Rodney M.
TI A New Approach to Mitigate Biofilm Formation on Totally Implantable
Venous Access Ports
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Editorial Material
DE central venous access port; biofilm; methylcellulose; polyethylene
glycol
ID CATHETERS; SURFACES; POLYMER; MODEL
C1 [Donlan, Rodney M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
RP Donlan, RM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop C16, Atlanta, GA 30333 USA.
EM rld8@cdc.gov
NR 16
TC 0
Z9 0
U1 1
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
IS 9
BP 1345
EP 1346
DI 10.1093/infdis/jiu251
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0ER
UT WOS:000344610600001
PM 24795474
ER
PT J
AU Wilson, EMP
Singh, A
Hullsiek, KH
Gibson, D
Henry, WK
Lichtenstein, K
Onen, NF
Kojic, E
Patel, P
Brooks, JT
Sereti, I
Baker, JV
AF Wilson, Eleanor M. P.
Singh, Amrit
Hullsiek, Katherine Huppler
Gibson, Dave
Henry, W. Keith
Lichtenstein, Ken
Oenen, Nur F.
Kojic, Erna
Patel, Pragna
Brooks, John T.
Sereti, Irini
Baker, Jason V.
CA Understand Nat Hist HIV AIDS Era
TI Monocyte-Activation Phenotypes Are Associated With Biomarkers of
Inflammation and Coagulation in Chronic HIV Infection
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE monocytes; HIV; immune activation; IL-6; D-dimer; C-reactive protein
ID ACUTE MYOCARDIAL-INFARCTION; T-CELL-ACTIVATION; ANTIRETROVIRAL THERAPY;
SOLUBLE CD163; CARDIOVASCULAR-DISEASE; GENERAL-POPULATION; PREDICT
MORTALITY; IMMUNE ACTIVATION; RISK-FACTORS; AIDS
AB Background. Soluble biomarkers of inflammation predict non-AIDS related morbidity and mortality among human immunodeficiency virus (HIV)-infected persons. Exploring associations between plasma biomarkers and cellular phenotypes may identify sources of excess inflammation.
Methods. Plasma biomarkers (interleukin 6 [IL-6] level, D-dimer level, high-sensitivity C-reactive protein [hsCRP] level, soluble CD14 [sCD14] level, and soluble CD163 [sCD163] level) were measured from cryopreserved samples from the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study). We performed immunophenotyping of peripheral blood mononuclear cells for markers of T-cell and monocyte activation, maturation, and migration. We evaluated associations between cellular phenotypes and soluble biomarkers by Spearman rank correlation and multivariate linear regression.
Results. Participants' (n = 670) median age was 41 years, 88% were prescribed antiretroviral therapy, 72% had a plasma HIV RNA load of <400 copies/mL, and the median CD4(+) T-lymphocyte count was 471 cells/mu L. After adjustment, CD14(++)CD16(+) monocytes were associated with higher levels of IL-6, hsCRP, and sCD163; associations with IL-6 and hsCRP persisted in persons with suppressed HIV replication. While CCR5(+) monocytes positively associated with D-dimer levels, CCR2(+) monocytes were inversely associated with hsCRP levels.
Conclusions. Plasma inflammatory biomarkers that predict morbidity and mortality were strongly associated with monocyte activation and migration, modestly associated with T-cell maturation, and not associated with CD8(+) T-cell activation phenotypes. These findings suggest that strategies to control monocyte activation warrant further investigation.
C1 [Wilson, Eleanor M. P.; Singh, Amrit; Sereti, Irini] NIAID, NIH, Bethesda, MD 20892 USA.
[Hullsiek, Katherine Huppler] Univ Minnesota, Div Biostat, Minneapolis, MN USA.
[Henry, W. Keith; Baker, Jason V.] Univ Minnesota, Dept Med, Minneapolis, MN USA.
[Baker, Jason V.] Hennepin Cty Med Ctr, Div Infect Dis, Minneapolis, MN 55415 USA.
[Gibson, Dave; Henry, W. Keith; Oenen, Nur F.] Washington Univ Sch Med, St Louis, MO USA.
[Lichtenstein, Ken] Natl Jewish Hlth, Denver, CO USA.
[Kojic, Erna] Miriam Hosp, Providence, RI 02906 USA.
[Patel, Pragna; Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
RP Baker, JV (reprint author), 701 Pk Ave MC G5, Minneapolis, MN 55415 USA.
EM baker459@umn.edu
OI Wilson, Eleanor/0000-0002-4855-514X
FU Centers for Disease Control and Prevention [200 2002 00610, 200 2002
00611, 200 2002-00612, 200-2002-00613, 200-2007-23633, 200-2007-23634,
200-2007-23635, 200-2007-23636]; National Institutes of Health
[1KL2RR033182-01]; National Institute of Allergy and Infectious Diseases
FX This work was supported by the Centers for Disease Control and
Prevention (contracts 200 2002 00610, 200 2002 00611, 200 2002-00612,
200-2002-00613, 200-2007-23633, 200-2007-23634, 200-2007-23635, and
200-2007-23636), the National Institutes of Health (grant
1KL2RR033182-01), and the National Institute of Allergy and Infectious
Diseases (intramural program funds to E. M. P. W., A. S., and I. S.).
NR 41
TC 28
Z9 28
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
IS 9
BP 1396
EP 1406
DI 10.1093/infdis/jiu275
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0ER
UT WOS:000344610600007
PM 24813472
ER
PT J
AU Abdelwahab, J
Dietz, V
Eggers, R
Maher, C
Olaniran, M
Sandhu, H
Vandelaer, J
AF Abdelwahab, Jalaa
Dietz, Vance
Eggers, Rudolf
Maher, Christopher
Olaniran, Marianne
Sandhu, Hardeep
Vandelaer, Jos
TI Strengthening the Partnership Between Routine Immunization and the
Global Polio Eradication Initiative to Achieve Eradication and Assure
Sustainability
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio eradication; strengthening routine immunization
ID MEASLES SURVEILLANCE NETWORKS; EXPANDING POLIOMYELITIS; ESTABLISH
SURVEILLANCE; ENCEPHALITIS SYNDROMES; JAPANESE ENCEPHALITIS; ACUTE
MENINGITIS; BANGLADESH; INDIA; CHINA
AB Since the launch of the Global Polio Eradication Initiative (GPEI) in 1988, the number of polio endemic countries has declined from 125 to 3 in 2013. Despite this remarkable achievement, ongoing circulation of wild poliovirus in polio-endemic countries and the increase in the number of circulating vaccine-derived poliovirus cases, especially those caused by type 2, is a cause for concern. The Polio Eradication and Endgame Strategic Plan 2013-2018 (PEESP) was developed and includes 4 objectives: detection and interruption of poliovirus transmission, containment and certification, legacy planning, and a renewed emphasis on strengthening routine immunization (RI) programs. This is critical for the phased withdrawal of oral poliovirus vaccine, beginning with the type 2 component, and the introduction of a single dose of inactivated polio vaccine into RI programs. This objective has inspired renewed consideration of how the GPEI and RI programs can mutually benefit one another, how the infrastructure from the GPEI can be used to strengthen RI, and how a strengthened RI can facilitate polio eradication. The PEESP is the first GPEI strategic plan that places strong and clear emphasis on the necessity of improving RI to achieve and sustain global polio eradication.
C1 [Abdelwahab, Jalaa; Olaniran, Marianne; Vandelaer, Jos] UNICEF, New York, NY USA.
[Dietz, Vance; Sandhu, Hardeep] CDC, Global Immunizat Div, Atlanta, GA 30329 USA.
[Eggers, Rudolf; Maher, Christopher] WHO, CH-1211 Geneva, Switzerland.
RP Dietz, V (reprint author), CDC, Global Immunizat Div, 1600 Clifton Rd NE,MS A04, Atlanta, GA 30329 USA.
EM vdietz@cdc.gov
FU Centers for Disease Control and Prevention
FX This article is part of a supplement entitled "The Final Phase of Polio
Eradication and Endgame Strategies for the Post-Eradication Era," which
was sponsored by the Centers for Disease Control and Prevention.
NR 22
TC 1
Z9 1
U1 1
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S498
EP S503
DI 10.1093/infdis/jiu041
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400059
PM 25316872
ER
PT J
AU Adams, A
Boualam, L
Diorditsa, S
Gregory, C
Jee, Y
Mendoza-Aldana, J
Roesel, S
AF Adams, Anthony
Boualam, Liliane
Diorditsa, Sergey
Gregory, Christopher
Jee, Youngmee
Mendoza-Aldana, Jorge
Roesel, Sigrun
TI Maintaining Polio-Free Certification in the World Health Organization
Western Pacific Region for Over a Decade
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio; WHO Western Pacific Region; vaccination
AB On 29 October 2000, the World Health Organization (WHO) Regional Commission for the Certification of Poliomyelitis Eradication in the Western Pacific certified the WHO Western Pacific Region as free of indigenous wild poliovirus. This status has been maintained to date: wild poliovirus importations into Singapore (in 2006) and Australia (in 2007) did not lead to secondary cases, and an outbreak in China (in 2011) was rapidly controlled. Circulation of vaccine derived polioviruses in Cambodia, China and the Philippines was quickly interrupted. A robust acute flaccid paralysis surveillance system, including a multitiered polio laboratory network, has been maintained, forming the platform for integrating measles, neonatal tetanus, and other vaccine-preventable disease surveillance and their respective control goals. While polio elimination remains one of the most important achievements in public health in the Western Pacific Region, extended delays in global eradication have, however, led to shifting and competing public health priorities among member states and partners and have made the region increasingly vulnerable.
C1 [Adams, Anthony] Global Commiss Certificat Poliomyelitis Eradicat, Reg Commiss Certificat Poliomyelitis Eradicat Wes, Avoca Beach, Australia.
[Boualam, Liliane; Diorditsa, Sergey; Jee, Youngmee; Mendoza-Aldana, Jorge; Roesel, Sigrun] World Hlth Org, Expanded Programme Immunizat, Western Pacific Reg Off, Manila, Philippines.
[Gregory, Christopher] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA.
RP Roesel, S (reprint author), World Hlth Org Philippines, Expanded Programme Immunizat, United Nations Ave, Manila, Philippines.
EM roesels@wpro.who.int
FU Centers for Disease Control and Prevention
FX This article is part of a supplement entitled "The Final Phase of Polio
Eradication and Endgame Strategies for the Post-Eradication Era," which
was sponsored by the Centers for Disease Control and Prevention.
NR 17
TC 0
Z9 0
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S259
EP S267
DI 10.1093/infdis/jiu164
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400031
PM 25316844
ER
PT J
AU Ado, JM
Etsano, A
Shuaib, F
Damisa, E
Mkanda, P
Gasasira, A
Banda, R
Korir, C
Johnson, T
Dieng, B
Corkum, M
Enemaku, O
Mataruse, N
Ohuabunwo, C
Baig, S
Galway, M
Seaman, V
Wiesen, E
Vertefeuille, J
Ogbuanu, IU
Armstrong, G
Mahoney, FJ
AF Ado, J. Mohammed
Etsano, Andrew
Shuaib, Faisal
Damisa, Eunice
Mkanda, Pascal
Gasasira, Alex
Banda, Richard
Korir, Charles
Johnson, Ticha
Dieng, Boubacar
Corkum, Melissa
Enemaku, Ogu
Mataruse, Noah
Ohuabunwo, Chima
Baig, Shahzad
Galway, Michael
Seaman, Vincent
Wiesen, Eric
Vertefeuille, John
Ogbuanu, Ikechukwu U.
Armstrong, Gregory
Mahoney, Frank J.
TI Progress Toward Poliomyelitis Eradication in Nigeria
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE OPV; oral polio vaccine; poliovirus; Nigeria
ID GLOBAL POLIO ERADICATION; NORTHERN NIGERIA; VACCINATION; COVERAGE
AB Background. Transmission of wild poliovirus (WPV) has never been interrupted in Afghanistan, Pakistan, and Nigeria. Since 2003, infections with WPV of Nigerian origin have been detected in 25 polio-free countries. In 2012, the Nigerian government created an emergency operations center and implemented a national emergency action plan to eradicate polio. The 2013 revision of this plan prioritized (1) improving the quality of supplemental immunization activities (SIAs), (2) implementing strategies to reach underserved populations, (3) adopting special approaches in security-compromised areas, (4) improving outbreak response, (5) enhancing routine immunization and activities implemented between SIAs, and (6) strengthening surveillance. This report summarizes implementation of these activities during a period of unprecedented insecurity and violence, including the killing of health workers and the onset of a state of emergency in the northeast zone.
Methods.aEuro integral This report reviews management strategies, innovations, trends in case counts, vaccination and social mobilization activities, and surveillance and monitoring data to assess progress in polio eradication in Nigeria.
Results.aEuro integral Nigeria has made significant improvements in the management of polio eradication initiative (pei) activities with marked improvement in the quality of SIAs, as measured by lot quality assurance sampling (LQAS). Comparing results from February 2012 with results from December 2013, the proportion of local government areas (LGAs) conducting LQAS in the 11 high-risk states at the a parts per thousand yen90% pass/fail threshold increased from 7% to 42%, and the proportion at the 80%-89% threshold increased from 9% to 30%. During January-December 2013, 53 polio cases were reported from 26 LGAs in 9 states in Nigeria, compared with 122 cases reported from 13 states in 2012. No cases of WPV type 3 infection have been reported since November 2012. In 2013, no polio cases due to any poliovirus type were detected in the northwest sanctuaries of Nigeria. In the second half of 2013, WPV transmission was restricted to Kano, Borno, Bauchi, and Taraba states. Despite considerable progress, 24 LGAs in 2012 and 7 LGAs in 2013 reported a parts per thousand yen2 cases, and WPV continued to circulate in 8 LGAs that had cases in 2012. Campaign activities were negatively impacted by insecurity and violence in Borno and Kano states.
Conclusions.aEuro integral Efforts to interrupt transmission remain impeded by poor SIA implementation in localized areas, anti-polio vaccine sentiment, and limited access to vaccinate children because of insecurity. Sustained improvement in SIA quality, surveillance, and outbreak response and special strategies in security-compromised areas are needed to interrupt WPV transmission in 2014.
C1 [Ado, J. Mohammed; Etsano, Andrew; Damisa, Eunice] Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria.
[Shuaib, Faisal] Fed Minist Hlth, Abuja, Nigeria.
[Mkanda, Pascal; Banda, Richard; Korir, Charles; Johnson, Ticha] WHO, Abuja, Nigeria.
[Dieng, Boubacar; Corkum, Melissa; Enemaku, Ogu; Mataruse, Noah] United Nations Childrens Fund, Abuja, Nigeria.
[Ohuabunwo, Chima] African Field Epidemiol Network, Abuja, Nigeria.
[Baig, Shahzad; Galway, Michael; Seaman, Vincent] Bill & Melinda Gates Fdn, Abuja, Nigeria.
[Gasasira, Alex] WHO Reg Off Africa, Brazzaville, Rep Congo.
[Wiesen, Eric; Vertefeuille, John; Ogbuanu, Ikechukwu U.; Armstrong, Gregory; Mahoney, Frank J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Mahoney, FJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A04, Atlanta, GA 30333 USA.
EM fjm2@cdc.gov
FU Centers for Disease Control and Prevention
FX This article is part of a supplement entitled "The Final Phase of Polio
Eradication and Endgame Strategies for the Post-Eradication Era," which
was sponsored by the Centers for Disease Control and Prevention.
NR 17
TC 4
Z9 4
U1 2
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S40
EP S49
DI 10.1093/infdis/jiu318
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400005
PM 25316862
ER
PT J
AU Alexander, JP
Zubair, M
Khan, M
Abid, N
Durry, E
AF Alexander, James P., Jr.
Zubair, Mufti
Khan, Muzaffar
Abid, Nima
Durry, Elias
TI Progress and Peril: Poliomyelitis Eradication Efforts in Pakistan,
1994-2013
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio; disease eradication; epidemiology; surveillance; Pakistan
ID WORLDWIDE; POLIO
AB Pakistan is one of 3 countries where transmission of indigenous wild poliovirus (WPV) has never been interrupted. Numbers of confirmed polio cases have declined by > 90% from preeradication levels, although outbreaks occurred during 2008-2013. During 2012 and 2013, 58 and 93 WPV cases, respectively, were reported, almost all of which were due to WPV type 1. Of the 151 WPV cases reported during 2012-2013, 123 (81%) occurred in the conflict-affected Federally Administered Tribal Areas (FATA) and in security-compromised Khyber Pakhtunkhwa province. WPV type 3 was isolated from only 3 persons with polio in a single district in 2012. During August 2012-December 2013, 62 circulating vaccine-derived poliovirus type 2 cases were detected, including 40 cases (65%) identified in the FATA during 2013. Approximately 350 000 children in certain districts of the FATA have not received polio vaccine during supplementary immunization activities (SIAs) conducted since mid-2012, because local authorities have banned polio vaccination. In other areas of Pakistan, SIAs have been compromised by attacks targeting polio workers, which started in mid-2012. Further efforts to reach children in conflict-affected and security-compromised areas will be necessary to prevent reintroduction of WPV into other areas of Pakistan and other parts of the world.
C1 [Alexander, James P., Jr.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA.
[Zubair, Mufti; Khan, Muzaffar; Durry, Elias] WHO, Polio Eradicat Initiat, Islamabad, Pakistan.
[Abid, Nima] WHO, Off WHO Representat Pakistan, Islamabad, Pakistan.
RP Alexander, JP (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A-04, Atlanta, GA 30333 USA.
EM axj1@cdc.gov
FU World Health Organization; Centers for Disease Control and Prevention
FX This work was supported by the World Health Organization (to M. Z., M.
K., N. A., and E. D.) and the Centers for Disease Control and Prevention
(J. P. A.).
NR 25
TC 9
Z9 9
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S152
EP S161
DI 10.1093/infdis/jiu450
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400019
PM 25316830
ER
PT J
AU Alleman, MM
Meyer, SA
Mulumba, A
Nyembwe, M
Riziki, Y
Mbule, A
Mayenga, M
Coulibaly, T
AF Alleman, Mary M.
Meyer, Sarah A.
Mulumba, Audry
Nyembwe, Michel
Riziki, Yogolelo
Mbule, Albert
Mayenga, May
Coulibaly, Tiekoura
TI Improved Acute Flaccid Paralysis Surveillance Performance in the
Democratic Republic of the Congo, 2010-2012
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio eradication; acute flaccid paralysis; surveillance; Democratic
Republic of the Congo; Africa; wild poliovirus; vaccine-derived
poliovirus
ID GLOBAL POLIO ERADICATION; VACCINE-DERIVED POLIOVIRUSES; TRACKING
PROGRESS; WORLDWIDE; TRANSMISSION; INTERRUPTION; UPDATE
AB Background. The Democratic Republic of the Congo (DRC) began polio eradication activities in 1996. By 2001, DRC was no longer polio endemic. However, wild poliovirus (WPV) transmission was reestablished in 2006 continuing through 2011 (last WPV case onset 20 December 2011), and vaccine-derived poliovirus type 2 (VDPV2) outbreaks occurred during 2004-2012 (last VDPV2 case onset 4 April 2012). Gaps in acute flaccid paralysis (AFP) surveillance have been consistently documented.
Methods.aEuro integral AFP surveillance indicators were assessed at the national, provincial, and zone de sant, (ZS) levels for 2010-2012. A spatiotemporal analysis of compatible, WPV type 1 (WPV1), and VDPV2 cases was performed.
Results.aEuro integral During 2010-2012, AFP cases were reported from all provinces but not every ZS, particularly in Equateur province and Province Orientale. A spatiotemporal relationship between compatible, WPV1, and VDPV2 cases was noted. Nonpolio AFP rates met objectives at national and provincial levels but were sub-optimal in certain ZS. National and provincial trends in timely stool collection, stool condition, adequate stool, and 60-day follow-up exams improved.
Conclusions.aEuro integral DRC's AFP surveillance system is functional and improved during 2010-2012. Maintaining improvements and strengthening AFP case detection at the ZS level will provide further support for the apparent interruption of WPV and VDPV2 transmission.
C1 [Alleman, Mary M.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA.
[Meyer, Sarah A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Meyer, Sarah A.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA 30333 USA.
[Mulumba, Audry; Nyembwe, Michel] Minist Publ Hlth, Expanded Programme Immunizat, Kinshasa, DEM REP CONGO.
[Riziki, Yogolelo] Minist Publ Hlth, Inst Natl Rech Biomed, Kinshasa, DEM REP CONGO.
[Mbule, Albert; Mayenga, May; Coulibaly, Tiekoura] WHO, Immunizat Vaccines & Emergencies Cluster, Kinshasa, DEM REP CONGO.
RP Alleman, MM (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS A-04, Atlanta, GA 30333 USA.
EM mea4@cdc.gov
FU Ministry of Public Health, DRC; World Health Organization, DRC; Centers
for Disease Control and Prevention
FX This work was supported by the Ministry of Public Health, DRC (A. Mu.,
M. N., and Y. R.); the World Health Organization, DRC (A. Mb., M. M.,
and T. C.); and the Centers for Disease Control and Prevention (M. A.
and S. M.).
NR 51
TC 4
Z9 4
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S50
EP S61
DI 10.1093/infdis/jit670
PG 12
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400006
PM 25316874
ER
PT J
AU Alleman, MM
Wannemuehler, KA
Weldon, WC
Kabuayi, JP
Ekofo, F
Edidi, S
Mulumba, A
Mbule, A
Ntumbannji, RN
Coulibaly, T
Abiola, N
Mpingulu, M
Sidibe, K
Oberste, MS
AF Alleman, Mary M.
Wannemuehler, Kathleen A.
Weldon, William C.
Kabuayi, Jean Pierre
Ekofo, Felly
Edidi, Samuel
Mulumba, Audry
Mbule, Albert
Ntumbannji, Renee N.
Coulibaly, Tiekoura
Abiola, Nadine
Mpingulu, Minlangu
Sidibe, Kassim
Oberste, M. Steven
TI Factors Contributing to Outbreaks of Wild Poliovirus Type 1 Infection
Involving Persons Aged >= 15 Years in the Democratic Republic of the
Congo, 2010-2011, Informed by a Pre-Outbreak Poliovirus Immunity
Assessment
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio eradication; polio seroprevalence; neutralizing antibodies;
Democratic Republic of the Congo; Africa; wild poliovirus outbreaks;
polio in adults
ID POLIOMYELITIS OUTBREAK; PARALYTIC POLIOMYELITIS; TRACKING PROGRESS;
ERADICATION; WORLDWIDE; TRANSMISSION; INTERRUPTION; AFRICA
AB Background. The Democratic Republic of the Congo (DRC) experienced atypical outbreaks of wild poliovirus type 1 (WPV1) infection during 2010-2011 in that they affected persons aged >= 15 years in 4 (Bandundu, Bas Congo, Kasai Occidental, and Kinshasa provinces) of the 6 provinces with outbreaks.
Methods.aEuro integral Analyses of cases of WPV1 infection with onset during 2010-2011 by province, age, polio vaccination status, and sex were conducted. The prevalence of antibodies to poliovirus (PV) types 1, 2, and 3 was assessed in sera collected before the outbreaks from women attending antenatal clinics in 3 of the 4 above-mentioned provinces.
Results.aEuro integral Of 193 cases of WPV1 infection during 2010-2011, 32 (17%) occurred in individuals aged a parts per thousand yen15 years. Of these 32 cases, 31 (97%) occurred in individuals aged 16-29 years; 9 (28%) were notified in Bandundu, 17 (53%) were notified in Kinshasa, and 22 (69%) had an unknown polio vaccination status. In the seroprevalence assessment, PV type 1 and 3 seroprevalence was lower among women aged 15-29 years in Bandundu and Kinshasa, compared with those in Kasa < Occidental. Seropositivity to PVs was associated with increasing age, more pregnancies, and a younger age at first pregnancy.
Conclusions.aEuro integral This spatiotemporal analysis strongly suggests that the 2010-2011 outbreaks of WPV1 infection affecting young adults were caused by a PV type 1 immunity gap in Kinshasa and Bandundu due to insufficient exposure to PV type 1 through natural infection or vaccination. Poliovirus immunity gaps in this age group likely persist in DRC.
C1 [Alleman, Mary M.; Wannemuehler, Kathleen A.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA.
[Weldon, William C.; Oberste, M. Steven] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA.
[Kabuayi, Jean Pierre; Ekofo, Felly; Edidi, Samuel] Minist Publ Hlth, Programme Natl Lutte IST SIDA, Kinshasa, DEM REP CONGO.
[Mulumba, Audry] Minist Publ Hlth, Expanded Programme Immunizat, Kinshasa, DEM REP CONGO.
[Mbule, Albert; Ntumbannji, Renee N.; Coulibaly, Tiekoura] WHO, Immunizat Vaccines & Emergencies Cluster, Kinshasa, DEM REP CONGO.
[Abiola, Nadine; Mpingulu, Minlangu; Sidibe, Kassim] Ctr Dis Control & Prevent, Div Global HIV AIDS, Kinshasa, DEM REP CONGO.
RP Alleman, MM (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS A-04, Atlanta, GA 30333 USA.
EM mea4@cdc.gov
FU Ministry of Public Health, Democratic Republic of the Congo; World
Health Organization, Democratic Republic of the Congo; Centers for
Disease Control and Prevention
FX This work was supported by the Ministry of Public Health, Democratic
Republic of the Congo (to J. P. K., F. E., S. E., and A. M.); the World
Health Organization, Democratic Republic of the Congo (to A. M., R. N.
N., and T. C.); and the Centers for Disease Control and Prevention (to
M. M. A., K. A. W., W. C. W., N. A., M. M., K. S., and M. S. O.).
NR 65
TC 5
Z9 5
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S62
EP S73
DI 10.1093/infdis/jiu282
PG 12
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400007
PM 25316879
ER
PT J
AU Anand, A
Pallansch, MA
Estivariz, CF
Gary, H
Wassilak, SGF
AF Anand, Abhijeet
Pallansch, Mark A.
Estivariz, Concepcion F.
Gary, Howard
Wassilak, Steven G. F.
TI Estimating the Likely Coverage of Inactivated Poliovirus Vaccine in
Routine Immunization: Evidence From Demographic and Health Surveys
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE inactivated poliovirus vaccine; polio eradication; polio; routine
immunization
AB Background. The Strategic Advisory Group of Experts on Immunization (SAGE) has recommended introduction of at least 1 dose of inactivated poliovirus vaccine (IPV) at >= 14 weeks of age through the routine immunization program in countries currently not using IPV.
Methods.aEuro integral We analyzed all available unrestricted data obtained from the Demographic and Health Surveys since 2005 in sub-Saharan Africa (31 countries) and in South and Southeast Asia (9 countries) to determine coverage of the following injectable vaccines delivered through the routine immunization schedule: diphtheria-tetanus-pertussis vaccine dose 1 (DTP1), DTP2, DTP3, and measles vaccine. Coverage with these vaccines was used as a proxy measure of likely 1- and 2-dose IPV coverage.
Results.aEuro integral Coverage with 1 dose of IPV is expected to be lowest when offered with DTP3 (median coverage, 73%) and highest when offered with DTP1 (median coverage, 90%). The median DTP1-DTP3 drop-out rate was 14%, which equates to an additional 12 million children not receiving IPV if IPV is offered with DTP3, rather than with DTP1. An increased geographical clustering of children who have not received IPV is expected in sub-Saharan Africa and Asia if IPV is offered with DTP3, rather than with DTP1. Coverage with 2 doses of IPV is expected to be lowest if IPV is administered with DTP3 and measles vaccine (69%) and highest if administered with DTP1 and DTP2 (84%).
Conclusions.aEuro integral Coverage with 1 dose of IPV is expected to be lowest if it is administered at the DTP3 visit. At present, there is insufficient evidence to determine whether the SAGE-recommended IPV schedule for the polio endgame would maximize population immunity to type 2 poliovirus.
C1 [Anand, Abhijeet; Estivariz, Concepcion F.; Gary, Howard; Wassilak, Steven G. F.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Anand, A (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,MS A04, Atlanta, GA 30333 USA.
EM aanand@cdc.gov
FU Centers for Disease Control and Prevention
FX This work was supported by the Centers for Disease Control and
Prevention.
NR 12
TC 5
Z9 5
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S465
EP S474
DI 10.1093/infdis/jiu343
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400056
PM 25316869
ER
PT J
AU Asghar, H
Diop, OM
Weldegebriel, G
Malik, F
Shetty, S
El Bassioni, L
Akande, AO
Al Maamoun, E
Zaidi, S
Adeniji, AJ
Burns, CC
Deshpande, J
Oberste, MS
Lowther, SA
AF Asghar, Humayun
Diop, Ousmane M.
Weldegebriel, Goitom
Malik, Farzana
Shetty, Sushmitha
El Bassioni, Laila
Akande, Adefunke O.
Al Maamoun, Eman
Zaidi, Sohail
Adeniji, Adekunle J.
Burns, Cara C.
Deshpande, Jagadish
Oberste, M. Steve
Lowther, Sara A.
TI Environmental Surveillance for Polioviruses in the Global Polio
Eradication Initiative
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polioviruses; surveillance; environmental sewage; environmental
monitoring; disease eradication
AB This article summarizes the status of environmental surveillance (ES) used by the Global Polio Eradication Initiative, provides the rationale for ES, gives examples of ES methods and findings, and summarizes how these data are used to achieve poliovirus eradication. ES complements clinical acute flaccid paralysis (AFP) surveillance for possible polio cases. ES detects poliovirus circulation in environmental sewage and is used to monitor transmission in communities. If detected, the genetic sequences of polioviruses isolated from ES are compared with those of isolates from clinical cases to evaluate the relationships among viruses. To evaluate poliovirus transmission, ES programs must be developed in a manner that is sensitive, with sufficiently frequent sampling, appropriate isolation methods, and specifically targeted sampling sites in locations at highest risk for poliovirus transmission. After poliovirus ceased to be detected in human cases, ES documented the absence of endemic WPV transmission and detected imported WPV. ES provides valuable information, particularly in high-density populations where AFP surveillance is of poor quality, persistent virus circulation is suspected, or frequent virus reintroduction is perceived. Given the benefits of ES, GPEI plans to continue and expand ES as part of its strategic plan and as a supplement to AFP surveillance.
C1 [Asghar, Humayun] WHO, Eastern Mediterranean Reg Off, Cairo, Egypt.
[El Bassioni, Laila; Al Maamoun, Eman] VACSERA, Cairo, Egypt.
[Diop, Ousmane M.] WHO, CH-1211 Geneva, Switzerland.
[Weldegebriel, Goitom] WHO, Ibadan, Nigeria.
[Akande, Adefunke O.; Adeniji, Adekunle J.] Natl Polio Lab, Ibadan, Nigeria.
[Malik, Farzana] WHO, Islamabad, Pakistan.
[Zaidi, Sohail] Natl Inst Hlth, Islamabad, Pakistan.
[Shetty, Sushmitha; Deshpande, Jagadish] Enterovirus Res Ctr, Mumbai, Maharashtra, India.
[Burns, Cara C.; Oberste, M. Steve; Lowther, Sara A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Lowther, SA (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,MS A04, Atlanta, GA 30333 USA.
EM Slowther@cdc.gov
RI Zaidi, Syed Sohail Zahoor/F-7432-2015;
OI Deshpande, Jagadish/0000-0001-5194-0375
FU Global Polio Eradication Initiative
FX This work was supported by the Global Polio Eradication Initiative.
NR 12
TC 9
Z9 9
U1 2
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S294
EP S303
DI 10.1093/infdis/jiu384
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400035
PM 25316848
ER
PT J
AU Bahl, S
Estivariz, CF
Sutter, RW
Sarkar, BK
Verma, H
Jain, V
Agrawal, A
Rathee, M
Shukla, H
Pathyarch, SK
Sethi, R
Wannemuehler, KA
Jafari, H
Deshpande, JM
AF Bahl, Sunil
Estivariz, Concepcion F.
Sutter, Roland W.
Sarkar, Bidyut K.
Verma, Harish
Jain, Vibhor
Agrawal, Ashutosh
Rathee, Mandeep
Shukla, Hemant
Pathyarch, Surendra K.
Sethi, Raman
Wannemuehler, Kathleen A.
Jafari, Hamid
Deshpande, Jagadish M.
TI Cross-sectional Serologic Assessment of Immunity to Poliovirus Infection
in High-Risk Areas of Northern India
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE poliovirus; oral poliovirus vaccine; monovalent oral poliovirus vaccine;
bivalent oral poliovirus vaccine; immunization campaigns
ID POLIOMYELITIS ERADICATION; VACCINE; IMMUNOGENICITY; ELIMINATION;
STRATEGIES; EFFICACY; DIARRHEA; PROGRESS; BRAZIL
AB Introduction. The objectives of this survey were to assess the seroprevalence of antibodies to poliovirus types 1 and 3 and the impact of bivalent (types 1 and 3) oral poliovirus vaccine (bOPV) use in immunization campaigns in northern India.
Methods.aEuro integral In August 2010, a 2-stage stratified cluster sampling method identified infants aged 6-7 months in high-risk blocks for wild poliovirus infection. Vaccination history, weight and length, and serum were collected to test for neutralizing antibodies to poliovirus types 1, 2, and 3.
Results.aEuro integral Seroprevalences of antibodies to poliovirus types 1, 2, and 3 were 98% (95% confidence interval [CI], 97%-99%), 66% (95% CI, 62%-69%), and 77% (95% CI, 75%-79%), respectively, among 664 infants from Bihar and 616 infants from Uttar Pradesh. Infants had received a median of 3 bOPV doses and 2 monovalent type 1 OPV (mOPV1) doses through campaigns and 3 trivalent OPV (tOPV) doses through routine immunization. Among subjects with 0 tOPV doses, the seroprevalences of antibodies to type 3 were 50%, 77%, and 82% after 2, 3, and 4 bOPV doses, respectively. In multivariable analysis, malnutrition was associated with a lower seroprevalence of type 3 antibodies.
Conclusions.aEuro integral This study confirmed that replacing mOPV1 with bOPV in campaigns was successful in maintaining very high population immunity to type 1 poliovirus and substantially decreasing the immunity gap to type 3 poliovirus.
C1 [Bahl, Sunil; Sarkar, Bidyut K.; Jain, Vibhor; Agrawal, Ashutosh; Rathee, Mandeep; Shukla, Hemant; Pathyarch, Surendra K.; Sethi, Raman; Jafari, Hamid] World Hlth Org India, Natl Polio Surveillance Project, New Delhi, India.
[Deshpande, Jagadish M.] Haffkine Inst, Enterovirus Res Ctr, Mumbai, Maharashtra, India.
[Estivariz, Concepcion F.; Wannemuehler, Kathleen A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Sutter, Roland W.; Verma, Harish] WHO, CH-1211 Geneva, Switzerland.
RP Sutter, RW (reprint author), WHO, Polio Eradicat Initiat, 20 Ave Appia, CH-1211 Geneva, Switzerland.
EM sutterr@who.int
OI Deshpande, Jagadish/0000-0001-5194-0375
FU World Health Organization
FX This work was supported by the World Health Organization.
NR 31
TC 3
Z9 3
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S243
EP S251
DI 10.1093/infdis/jit492
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400029
PM 25316842
ER
PT J
AU Bahl, S
Gary, HE
Jafari, H
Sarkar, BK
Pathyarch, SK
Sethi, R
Deshpande, J
AF Bahl, Sunil
Gary, Howard E., Jr.
Jafari, Hamid
Sarkar, Bidyut K.
Pathyarch, Surendra K.
Sethi, Raman
Deshpande, Jagadish
TI An Acute Flaccid Paralysis Surveillance-Based Serosurvey of Poliovirus
Antibodies in Western Uttar Pradesh, India
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE seroprevalence; wild poliovirus; vaccination strategy; oral polio
vaccine; immunization campaigns
AB Background. Despite intensified use of monovalent oral poliovirus type 1 vaccine and improved coverage of immunization campaigns, wild poliovirus type 1 persisted in Indian states of Uttar Pradesh and Bihar during 2006 to 2009.
Methods.aEuro integral A serosurvey was conducted among cases of acute flaccid paralysis in the 25 high-polio-incidence districts of western Uttar Pradesh. Children were recruited by age group (6-11 months, 12-24 months, and 25-69 months) from among cases reported through the acute flaccid paralysis surveillance system between November 2008 and August 2009.
Results.aEuro integral Seroprevalence for type 1 wild poliovirus was > 96.4% for each age group. The seroprevalence of wild poliovirus types 2 and 3 increased with age, from 36.7% to 73.4% for type 2 and from 39.0% to 74.1% for type 3. In addition to the number of type-specific vaccine doses, father's level of education, being from a Muslim family, height for age, and female sex were the socioeconomic risk factors associated with seronegativity to poliovirus.
Conclusions.aEuro integral The seroprevalence and risk factors identified in this study were consistent with the epidemiology of polio, and the findings were instrumental in optimizing vaccination strategy in western Uttar Pradesh with respect to the choice of OPV types, the frequency of supplementary immunization campaigns, and the urgency to improve routine immunization services.
C1 [Bahl, Sunil; Pathyarch, Surendra K.; Sethi, Raman] WHO Country Off India, Natl Polio Surveillance Project, New Delhi 110029, India.
[Deshpande, Jagadish] Enterovirus Res Ctr, Mumbai, Maharashtra, India.
[Gary, Howard E., Jr.] Ctr Dis Control & Prevent, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA USA.
[Jafari, Hamid] WHO, CH-1211 Geneva, Switzerland.
[Sarkar, Bidyut K.] UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England.
RP Bahl, S (reprint author), WHO Country Off India, Natl Polio Surveillance Project, Africa Ave, New Delhi 110029, India.
EM bahls@who.int
OI Deshpande, Jagadish/0000-0001-5194-0375
FU Ministry of Health and Family Welfare, Government of India; World Health
Organization
FX This work was supported by the Ministry of Health and Family Welfare,
Government of India, and by the World Health Organization.
NR 10
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S234
EP S242
DI 10.1093/infdis/jiu379
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400028
PM 25316841
ER
PT J
AU Burns, CC
Diop, OM
Sutter, RW
Kew, OM
AF Burns, Cara C.
Diop, Ousmane M.
Sutter, Roland W.
Kew, Olen M.
TI Vaccine-Derived Polioviruses
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE poliovirus; vaccine-derived poliovirus; VDPV; oral poliovirus vaccine;
OPV; poliomyelitis
ID ENTEROVIRUS SPECIES-C; IMMUNODEFICIENT PATIENT; PARALYTIC POLIOMYELITIS;
POLIO ERADICATION; CODING REGION; WIDESPREAD CIRCULATION; UNITED-STATES;
TYPE-2; RECOMBINANT; OUTBREAK
AB The attenuated oral poliovirus vaccine (OPV) has many properties favoring its use in polio eradication: ease of administration, efficient induction of intestinal immunity, induction of durable humoral immunity, and low cost. Despite these advantages, OPV has the disadvantage of genetic instability, resulting in rare and sporadic cases of vaccine-associated paralytic poliomyelitis (VAPP) and the emergence of genetically divergent vaccine-derived polioviruses (VDPVs). Whereas VAPP is an adverse event following exposure to OPV, VDPVs are polioviruses whose genetic properties indicate prolonged replication or transmission. Three categories of VDPVs are recognized: (1) circulating VDPVs (cVDPVs) from outbreaks in settings of low OPV coverage, (2) immunodeficiency-associated VDPVs (iVDPVs) from individuals with primary immunodeficiencies, and (3) ambiguous VDPVs (aVDPVs), which cannot be definitively assigned to either of the first 2 categories. Because most VDPVs are type 2, the World Health Organization's plans call for coordinated worldwide replacement of trivalent OPV with bivalent OPV containing poliovirus types 1 and 3.
C1 [Burns, Cara C.; Kew, Olen M.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
[Diop, Ousmane M.; Sutter, Roland W.] WHO, CH-1211 Geneva, Switzerland.
RP Burns, CC (reprint author), 1600 Clifton Rd NE,Mail Stop G-10, Atlanta, GA 30333 USA.
EM cburns@cdc.gov
FU Centers for Disease Control and Prevention
FX This article is part of a supplement entitled "The Final Phase of Polio
Eradication and Endgame Strategies for the Post-Eradication Era," which
was sponsored by the Centers for Disease Control and Prevention.
NR 86
TC 49
Z9 49
U1 0
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S283
EP S293
DI 10.1093/infdis/jiu295
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400034
PM 25316847
ER
PT J
AU Cardemil, CV
Jonas, A
Gerber, S
Weldon, WC
Oberste, MS
Beukes, A
Sawadogo, S
Patel, SV
Zeko, S
Muroua, C
Gaeb, E
Wannemuehler, K
Goodson, JL
AF Cardemil, Cristina V.
Jonas, Anna
Gerber, Sue
Weldon, William C., III
Oberste, M. Steven
Beukes, Anita
Sawadogo, Souleymane
Patel, Sadhna V.
Zeko, Sikota
Muroua, Clementine
Gaeb, Esegiel
Wannemuehler, Kathleen
Goodson, James L.
TI Poliovirus Immunity Among Pregnant Females Aged 15-44 Years, Namibia,
2010
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE poliovirus; polio; seroprevalence; OPV; Namibia; adults; pregnant women;
population immunity; HIV; neutralizing antibody
ID WILD POLIOVIRUS; POLIOMYELITIS; SEROPREVALENCE; VACCINE; HIV;
POPULATION; ANTIBODIES; OUTBREAK; STUDENTS; CHILDREN
AB Background. Poliovirus (PV) antibody seroprevalence studies assess population immunity, verify an immunization program's performance and vaccine efficacy, and guide polio eradication strategy. Namibia experienced a polio outbreak among adults in 2006, yet population seroimmunity was unknown.
Methods.aEuro integral We tested 2061 specimens from Namibian pregnant females aged 15-44 years for neutralizing antibody to PV types 1-3 (PV1-3); all females were sampled during the 2010 National HIV Sentinel Survey. We determined the proportion of females seropositive for PV antibody by 5-year age strata, and analyzed factors associated with seropositivity, including age, gravidity, human immunodeficiency virus (HIV) infection status, residence, and antiretroviral treatment, by log-binomial regression.
Results.aEuro integral The seroprevalence was 94.6% for PV1, 97.0% for PV2, and 85.1% for PV3. HIV-positive females had significantly lower seroprevalence than HIV-negative females for PV1 (91.8% vs 95.3%; P < .01) and PV3 (80.0% vs 86.1%; P < .01) but not for PV2 (96.4% vs 97.1%; P = .3). The prevalence ratio of seropositivity for HIV-positive females versus HIV-negative females was 0.95 (95% confidence interval [CI], .92-.98) for PV1, 0.99 (95% CI, .97-1.01) for PV2, and 0.92 (95% CI, .87-.96) for PV3.
Conclusions.aEuro integral Despite relatively high PV seroprevalence, Namibia might remain at risk for a PV outbreak, particularly in lower-seroprevalence populations, such as HIV-positive females. Namibia should continue to maintain high routine polio vaccination coverage.
C1 [Cardemil, Cristina V.; Wannemuehler, Kathleen; Goodson, James L.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA.
[Jonas, Anna; Zeko, Sikota; Muroua, Clementine] Minist Hlth & Social Serv, Karas, Namibia.
[Gerber, Sue; Beukes, Anita; Sawadogo, Souleymane; Patel, Sadhna V.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Windhoek, Namibia.
[Weldon, William C., III; Oberste, M. Steven] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA.
[Gaeb, Esegiel] Namibia Inst Pathol, Windhoek, Namibia.
RP Cardemil, CV (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-19, Atlanta, GA 30333 USA.
EM iyk8@cdc.gov
FU Centers for Disease Control and Prevention
FX This work was supported by the Centers for Disease Control and
Prevention.
NR 33
TC 3
Z9 3
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S136
EP S142
DI 10.1093/infdis/jiu086
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400017
PM 25316828
ER
PT J
AU Chandir, S
Ahamed, KU
Baqui, AH
Sutter, RW
Okayasu, H
Pallansch, MA
Oberste, MS
Moulton, LH
Halsey, NA
AF Chandir, Subhash
Ahamed, Kabir U.
Baqui, Abdullah H.
Sutter, Roland W.
Okayasu, Hiromasa
Pallansch, Mark A.
Oberste, Mark S.
Moulton, Lawrence H.
Halsey, Neal A.
TI Effect of Buffer on the Immune Response to Trivalent Oral Poliovirus
Vaccine in Bangladesh: A Community Based Randomized Controlled Trial
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE oral poliovirus vaccine; immunogenicity; serologic response; buffer
ID DEVELOPING-COUNTRIES; CHOLERA VACCINE; HUMAN ROTAVIRUS; IMMUNOGENICITY;
INFANTS; HEALTHY; MILK; PH
AB Background. Polio eradication efforts have been hampered by low responses to trivalent oral poliovirus vaccine (tOPV) in some developing countries. Since stomach acidity may neutralize vaccine viruses, we assessed whether administration of a buffer solution could improve the immunogenicity of tOPV.
Methods.aEuro integral Healthy infants 4-6 weeks old in Sylhet, Bangladesh, were randomized to receive tOPV with or without a sodium bicarbonate and sodium citrate buffer at age 6, 10, and 14 weeks. Levels of serum neutralizing antibodies for poliovirus types 1, 2, and 3 were measured before and after vaccination, at 6 and 18 weeks of age, respectively.
Findings.aEuro integral Serologic response rates following 3 doses of tOPV for buffer recipients and control infants were 95% and 88% (P = .065), respectively, for type 1 poliovirus; 95% and 97% (P = .543), respectively, for type 2 poliovirus; and 90% and 89% (P = .79), respectively, for type 3 poliovirus.
Conclusions.aEuro integral Administration of a buffer solution prior to vaccination was not associated with statistically significant increases in the immune response to tOPV; however, a marginal 7% increase (P = .065) in serologic response to poliovirus type 1 was observed.
Clinical Trials Registration.aEuro integral NCT01579825.
C1 [Chandir, Subhash; Baqui, Abdullah H.; Moulton, Lawrence H.; Halsey, Neal A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
[Pallansch, Mark A.; Oberste, Mark S.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Ahamed, Kabir U.] Shimantik, Dhaka, Bangladesh.
[Sutter, Roland W.; Okayasu, Hiromasa] WHO, Polio Operat & Res Dept, CH-1211 Geneva, Switzerland.
RP Halsey, NA (reprint author), Johns Hopkins Univ, Inst Vaccine Safety, Bloomberg Sch Publ Hlth, 615 N Wolfe St,Rm W5041, Baltimore, MD 21205 USA.
EM nhalsey1@jhu.edu
OI Moulton, Lawrence/0000-0001-7041-7387
FU World Health Organization; Department of International Health, Johns
Hopkins Bloomberg School of Public Health
FX This work was supported by the World Health Organization and the
Department of International Health, Johns Hopkins Bloomberg School of
Public Health.
NR 29
TC 2
Z9 2
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S390
EP S397
DI 10.1093/infdis/jiu378
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400047
PM 25316860
ER
PT J
AU Cochi, SL
Freeman, A
Guirguis, S
Jafari, H
Aylward, B
AF Cochi, Stephen L.
Freeman, Andrew
Guirguis, Sherine
Jafari, Hamid
Aylward, Bruce
TI Global Polio Eradication Initiative: Lessons Learned and Legacy
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio eradication; lessons learned; legacy
ID LABORATORY NETWORK; SURVEILLANCE; IMMUNIZATION; SMALLPOX; VACCINE;
HEALTH
AB The world is on the verge of achieving global polio eradication. During > 25 years of operations, the Global Polio Eradication Initiative (GPEI) has mobilized and trained millions of volunteers, social mobilizers, and health workers; accessed households untouched by other health initiatives; mapped and brought health interventions to chronically neglected and underserved communities; and established a standardized, real-time global surveillance and response capacity. It is important to document the lessons learned from polio eradication, especially because it is one of the largest ever global health initiatives. The health community has an obligation to ensure that these lessons and the knowledge generated are shared and contribute to real, sustained changes in our approach to global health. We have summarized what we believe are 10 leading lessons learned from the polio eradication initiative. We have the opportunity and obligation to build a better future by applying the lessons learned from GPEI and its infrastructure and unique functions to other global health priorities and initiatives. In so doing, we can extend the global public good gained by ending for all time one of the world's most devastating diseases by also ensuring that these investments provide public health dividends and benefits for years to come.
C1 [Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA.
[Guirguis, Sherine] United Nations Childrens Fund, Polio Team, New York, NY USA.
[Freeman, Andrew; Jafari, Hamid] World Hlth Org, Polio Operat & Res Dept, Geneva, Switzerland.
[Aylward, Bruce] World Hlth Org, Polio & Emergencies & Country Collaborat, Geneva, Switzerland.
RP Cochi, SL (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,Mailstop A-04, Atlanta, GA 30333 USA.
EM scochi@cdc.gov
FU Centers for Disease Control and Prevention; United Nations Children's
Fund; World Health Organization
FX This work was supported by the Centers for Disease Control and
Prevention, United Nations Children's Fund, and World Health
Organization.
NR 32
TC 17
Z9 17
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S540
EP S546
DI 10.1093/infdis/jiu345
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400064
PM 25316878
ER
PT J
AU Cochi, SL
Jafari, HS
Armstrong, GL
Sutter, RW
Linkins, RW
Pallansch, MA
Kew, O
Aylward, RB
AF Cochi, Stephen L.
Jafari, Hamid S.
Armstrong, Gregory L.
Sutter, Roland W.
Linkins, Robert W.
Pallansch, Mark A.
Kew, Olen
Aylward, R. Bruce
TI A World Without Polio
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Editorial Material
DE polio eradication; polio-free countries
ID PUBLIC-HEALTH; ERADICATION
C1 [Cochi, Stephen L.; Armstrong, Gregory L.; Linkins, Robert W.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA.
[Pallansch, Mark A.; Kew, Olen] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA.
[Jafari, Hamid S.; Sutter, Roland W.] WHO, Polio Operat & Res Dept, CH-1211 Geneva, Switzerland.
[Aylward, R. Bruce] WHO, Off Assistant Director Gen, Polio & Emergencies, CH-1211 Geneva, Switzerland.
RP Cochi, SL (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,Mailstop A-04, Atlanta, GA 30333 USA.
EM scochi@cdc.gov
FU World Health Organization [001]
NR 6
TC 5
Z9 5
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S1
EP S4
DI 10.1093/infdis/jiu383
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400001
PM 25316822
ER
PT J
AU Deshpande, JM
Bahl, S
Sarkar, BK
Estivariz, CF
Sharma, S
Wolff, C
Sethi, R
Pathyarch, SK
Jain, V
Gary, HE
Pallansch, MA
Jafari, H
AF Deshpande, Jagadish M.
Bahl, Sunil
Sarkar, Bidyut K.
Estivariz, Concepcion F.
Sharma, Shamila
Wolff, Chris
Sethi, Raman
Pathyarch, Surendra K.
Jain, Vibhor
Gary, Howard E., Jr.
Pallansch, Mark A.
Jafari, Hamid
TI Assessing Population Immunity in a Persistently High-Risk Area for Wild
Poliovirus Transmission in India: A Serological Study in Moradabad,
Western Uttar Pradesh
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE seroprevalence; wild poliovirus; neutralizing antibodies; OPV
formulations; immunogenecity; immunization policies; Moradabad
ID POLIOMYELITIS ERADICATION; VACCINE; SEROPREVALENCE; IMMUNOGENICITY;
ANTIBODIES; CHILDREN
AB Background. Moradabad district in Uttar Pradesh reported the highest number of paralytic polio cases in India during 2001-2007. We conducted a study in Moradabad in 2007 to assess seroprevalence against poliovirus types 1, 2, and 3 in children 6-12 and 36-59 months of age to guide future strategies to interrupt wild poliovirus transmission in high-risk areas.
Methods.aEuro integral Children attending 10 health facilities for minor illnesses who met criteria for study inclusion were eligible for enrollment. We recorded vaccination history, weight, and length and tested sera for neutralizing antibodies to poliovirus types 1, 2, and 3.
Results.aEuro integral Poliovirus type 1, 2, and 3 seroprevalences were 88% (95% confidence interval [CI], 84%-91%), 70% (95% CI, 66%-75%), and 75% (95% CI, 71%-79%), respectively, among 467 in the younger age group (n = 467), compared with 100% (95% CI, 99%-100%), 97% (95% CI, 95%-98%), and 93% (91%-95%), respectively, among 447 children in the older age group (P < .001 for all serotypes).
Conclusions.aEuro integral This seroprevalence study provided extremely useful information that was used by the program in India to guide immunization policies, such as optimizing the use of different OPV formulations in vaccination campaigns and strengthening routine immunization services. Similar surveys in populations at risk should be performed at regular intervals in countries where the risk of persistence or spread of indigenous or imported wild poliovirus is high.
C1 [Deshpande, Jagadish M.] Haffkine Inst, Enterovirus Res Ctr, Mumbai, Maharashtra, India.
[Bahl, Sunil; Sethi, Raman; Pathyarch, Surendra K.; Jain, Vibhor] World Hlth Org WHO Country Off India, Natl Polio Surveillance Project, New Delhi, India.
[Sarkar, Bidyut K.] Publ Hlth Fdn India, New Delhi, India.
[Sharma, Shamila] UNICEF India, New Delhi, India.
[Estivariz, Concepcion F.; Gary, Howard E., Jr.; Pallansch, Mark A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Wolff, Chris; Jafari, Hamid] WHO, CH-1211 Geneva, Switzerland.
RP Bahl, S (reprint author), WHO Country Off India, Natl Polio Surveillance Project, Africa Ave, New Delhi 110029, India.
EM bahls@npsuindia.org
OI Deshpande, Jagadish/0000-0001-5194-0375
FU Ministry of Health and Family Welfare, Government of India; World Health
Organization
FX This work was supported by the Ministry of Health and Family Welfare,
Government of India, and by the World Health Organization.
NR 29
TC 4
Z9 4
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S225
EP S233
DI 10.1093/infdis/jiu204
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400027
PM 25316839
ER
PT J
AU Domingues, CMAS
Pereira, SD
Marreiros, ACC
Menezes, N
Flannery, B
AF Domingues, Carla Magda Allan S.
Pereira, Sirlene de Fatima
Cunha Marreiros, Ana Carolina
Menezes, Nair
Flannery, Brendan
TI Introduction of Sequential Inactivated Polio Vaccine-Oral Polio Vaccine
Schedule for Routine Infant Immunization in Brazil's National
Immunization Program
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE acute flaccid paralysis; Brazil; inactivated polio vaccine;
poliomyelitis; vaccination schedule
ID PARALYTIC POLIOMYELITIS; LATIN-AMERICA; IMMUNOGENICITY; ERADICATION;
EXPERIENCE; COVERAGE; ENDGAME; IPV
AB In August 2012, the Brazilian Ministry of Health introduced inactivated polio vaccine (IPV) as part of sequential polio vaccination schedule for all infants beginning their primary vaccination series. The revised childhood immunization schedule included 2 doses of IPV at 2 and 4 months of age followed by 2 doses of oral polio vaccine (OPV) at 6 and 15 months of age. One annual national polio immunization day was maintained to provide OPV to all children aged 6 to 59 months. The decision to introduce IPV was based on preventing rare cases of vaccine-associated paralytic polio, financially sustaining IPV introduction, ensuring equitable access to IPV, and preparing for future OPV cessation following global eradication. Introducing IPV during a national multivaccination campaign led to rapid uptake, despite challenges with local vaccine supply due to high wastage rates. Continuous monitoring is required to achieve high coverage with the sequential polio vaccine schedule.
C1 [Domingues, Carla Magda Allan S.; Pereira, Sirlene de Fatima; Cunha Marreiros, Ana Carolina; Menezes, Nair] Brazilian Minist Hlth, Secretariat Hlth Surveillance, Brasilia, DF, Brazil.
[Domingues, Carla Magda Allan S.] Univ Brasilia, Ctr Trop Med, BR-70910900 Brasilia, DF, Brazil.
[Flannery, Brendan] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA.
RP Domingues, CMAS (reprint author), SCS, Minist Saude, Secretaria Vigilancia Saude, Coordenacao Geral Programa Nacl Imunizacoes, Quadra 04,Bloco A,Ed Principal,4 Andar, BR-70304000 Brasilia, DF, Brazil.
EM carla.domingues@saude.gov.br
FU Centers for Disease Control and Prevention
FX This article is part of a supplement entitled "The Final Phase of Polio
Eradication and Endgame Strategies for the Post-Eradication Era," which
was sponsored by the Centers for Disease Control and Prevention.
NR 36
TC 4
Z9 4
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S143
EP S151
DI 10.1093/infdis/jit588
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400018
PM 25316829
ER
PT J
AU Dunkle, SE
Wallace, AS
MacNeil, A
Mustafa, M
Gasasira, A
Ali, D
Elmousaad, H
Mahoney, F
Sandhu, HS
AF Dunkle, Stacie E.
Wallace, Aaron S.
MacNeil, Adam
Mustafa, Mahmud
Gasasira, Alex
Ali, Daniel
Elmousaad, Hashim
Mahoney, Frank
Sandhu, Hardeep S.
TI Limitations of Using Administratively Reported Immunization Data for
Monitoring Routine Immunization System Performance in Nigeria
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE routine immunization; Nigeria; poliomyelitis; immunization coverage;
DTP3; immunization programs; system monitoring; program improvement
ID COVERAGE; COUNTRIES; PROGRESS
AB Background. Efforts are underway to strengthen Nigeria's routine immunization system, yet measuring impact poses a challenge. We document limitations in using administrative data from 12 states in Nigeria and explore alternative approaches.
Methods.aEuro integral We compared state-reported coverage with the third dose of diphtheria-tetanus-pertussis vaccine (DTP3) to district-reported coverage and data from coverage surveys conducted during 2006-2013. We used district-reported data during 2010-2013 to calculate the annual change in immunization coverage, the percentage of the target population that was unimmunized, and the number of vaccine doses administered. Data quality indicators were also assessed.
Results.aEuro integral State-reported DTP3 coverage was 66%-102% in 2010, 49%-98% in 2011, 38%-84% in 2012, and 75%-123% in 2013 and was a median 46%-114% greater than survey coverage during 2006-2013. The mean local government area (LGA)-reported coverage varied substantially (standard deviation range, 10%-33% across years). For 2010-2013, the mean annual percentage change in LGA-reported DTP3 coverage was -15% from 2010 to 2011, -9% from 2011 to 2012, and 74% from 2012 to 2013; the mean annual percentage change in the percentage of the target population unimmunized was -62%, 426%, and -62%, respectively; and the mean annual percentage change in the number of doses administered was -13%, -7%, and 90%, respectively. Annually, a mean 14% of LGAs reported DTP3 coverage of > 100%.
Discussion.aEuro integral Assessing immunization system performance by using administrative data has notable limitations. In addition to long-term improvements in administrative data management, alternatives for measuring routine immunization performance should be considered.
C1 [Dunkle, Stacie E.; Wallace, Aaron S.; MacNeil, Adam; Elmousaad, Hashim; Mahoney, Frank; Sandhu, Hardeep S.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Mustafa, Mahmud] Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria.
[Gasasira, Alex; Ali, Daniel] World Hlth Org, Abuja, Nigeria.
RP Dunkle, SE (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS-E05, Atlanta, GA 30333 USA.
EM sdunkle@cdc.gov
FU Centers for Disease Control and Prevention
FX This work was supported by the Centers for Disease Control and
Prevention.
NR 18
TC 3
Z9 3
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S523
EP S530
DI 10.1093/infdis/jiu373
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400062
PM 25316876
ER
PT J
AU Esteves-Jaramillo, A
Estivariz, CF
Penaranda, S
Richardson, VL
Reyna, J
Coronel, DL
Carrion, V
Landaverde, JM
Wassilak, SGF
Perez-Sanchez, EE
Lopez-Martinez, I
Burns, CC
Pallansch, MA
AF Esteves-Jaramillo, Alejandra
Estivariz, Concepcion F.
Penaranda, Silvia
Richardson, Vesta L.
Reyna, Jesus
Coronel, Diana L.
Carrion, Veronica
Landaverde, Jose M.
Wassilak, Steven G. F.
Perez-Sanchez, Elda E.
Lopez-Martinez, Irma
Burns, Cara C.
Pallansch, Mark A.
TI Detection of Vaccine-Derived Polioviruses in Mexico Using Environmental
Surveillance
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE environmental surveillance; inactivated poliovirus vaccine; polio;
vaccine-derived poliovirus
ID GLOBAL POLIO ERADICATION; POLIOMYELITIS OUTBREAK; WILD POLIOVIRUS;
UNITED-STATES; SEWAGE; ENDGAME; IDENTIFICATION; EPIDEMIOLOGY;
TRANSMISSION; CIRCULATION
AB Background. Early detection and control of vaccine-derived poliovirus (VDPV) emergences are essential to secure the gains of polio eradication.
Methods.aEuro integral Serial sewage samples were collected in 4 towns of Mexico before, throughout, and after the May 2010 oral poliovirus vaccine (OPV) mass immunization campaign. Isolation and molecular analysis of polioviruses from sewage specimens monitored the duration of vaccine-related strains in the environment and emergence of vaccine-derived polioviruses in a population partially immunized with inactivated poliovirus vaccine (IPV).
Results.aEuro integral Sabin strains were identified up to 5-8 weeks after the campaign in all towns; in Aguascalientes, 1 Sabin 3 was isolated 16 weeks after the campaign, following 7 weeks with no Sabin strains detected. In Tuxtla Guti,rrez, type 2 VDPV was isolated from 4 samples collected before and during the campaign, and type 1 VDPV from 1 sample collected 19 weeks afterward. During 2009-2010, coverage in 4 OPV campaigns conducted averaged only 57% and surveillance for acute flaccid paralysis (AFP) was suboptimal (AFP rate < 1 per 100 000 population < 15 years of age) in Tuxtla Gutierrez.
Conclusions.aEuro integral VDPVs may emerge and spread in settings with inadequate coverage with IPV/OPV vaccination. Environmental surveillance can facilitate early detection in these settings.
C1 [Esteves-Jaramillo, Alejandra; Richardson, Vesta L.; Reyna, Jesus; Coronel, Diana L.] Ctr Nacl Salud Infancia & Adolescencia, Mexico City, DF, Mexico.
[Estivariz, Concepcion F.; Wassilak, Steven G. F.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30033 USA.
[Penaranda, Silvia; Burns, Cara C.; Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30033 USA.
[Carrion, Veronica; Landaverde, Jose M.] Pan Amer Hlth Org, Washington, DC USA.
[Perez-Sanchez, Elda E.; Lopez-Martinez, Irma] Inst Diagnost & Referencia Epidemiol, Mexico City, DF, Mexico.
RP Estivariz, CF (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30033 USA.
EM cge3@cdc.gov
FU Centers for Disease Control and Prevention
FX This article is part of a supplement entitled "The Final Phase of Polio
Eradication and Endgame Strategies for the Post-Eradication Era," which
was sponsored by the Centers for Disease Control and Prevention.
NR 42
TC 4
Z9 5
U1 3
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S315
EP S323
DI 10.1093/infdis/jiu183
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400037
PM 25316850
ER
PT J
AU Gammino, VM
Nuhu, A
Gerber, S
Gasasira, A
Sugerman, DE
Manneh, F
Chenoweth, P
Kurnit, MR
Abanida, EA
AF Gammino, Victoria M.
Nuhu, Adamu
Gerber, Sue
Gasasira, Alex
Sugerman, David E.
Manneh, Fadinding
Chenoweth, Paul
Kurnit, Molly R.
Abanida, Emmanuel A.
TI An Evaluation of Polio Supplemental Immunization Activities in Kano,
Katsina, and Zamfara States, Nigeria: Lessons in Progress
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE eradication; evaluation; immunization; microplanning; Nigeria; outbreak;
polio; social mobilization; structured observation; survey
ID VACCINATION
AB Background. As 1 of 3 remaining poliovirus-endemic countries, Nigeria has become key to the global polio eradication effort. We evaluated supplemental immunization activities, including team performance, communications/mobilization activities, and vaccine acceptance, in 3 high-risk states.
Methods.aEuro integral We used structured survey and observation instruments, document review, and stakeholder interviews.
Results.aEuro integral Observations or surveys were conducted at 1697 households. Vaccine acceptance ranged from 87%-94%; among households rejecting polio vaccine, 38% of mothers sought measles vaccine for their children. Teams performed between 4%-42% of assigned tasks.
Conclusions.aEuro integral Acceptance is high but teams have a critical role in surmounting residual vaccine resistance.
C1 [Gammino, Victoria M.; Gerber, Sue; Sugerman, David E.; Chenoweth, Paul; Kurnit, Molly R.] US Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30329 USA.
[Nuhu, Adamu; Abanida, Emmanuel A.] Natl Primary Hlth Care Dev Agcy Nigeria, Area 11, Abuja, Nigeria.
[Manneh, Fadinding] WHO, Expanded Programme Immunizat, Abuja, Nigeria.
[Gasasira, Alex] WHO, Reg Off Africa, Expanded Programme Immunizat, Brazzaville, Rep Congo.
RP Gammino, VM (reprint author), US Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,MS A-04, Atlanta, GA 30329 USA.
EM vmg0@cdc.gov
FU Centers for Disease Control and Prevention (CDC)
FX This work was supported by the Centers for Disease Control and
Prevention (CDC).
NR 13
TC 0
Z9 0
U1 1
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S91
EP S97
DI 10.1093/infdis/jiu228
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400010
PM 25316881
ER
PT J
AU Gammino, VM
Nuhu, A
Chenoweth, P
Manneh, F
Young, RR
Sugerman, DE
Gerber, S
Abanida, E
Gasasira, A
AF Gammino, Victoria M.
Nuhu, Adamu
Chenoweth, Paul
Manneh, Fadinding
Young, Randall R.
Sugerman, David E.
Gerber, Sue
Abanida, Emmanuel
Gasasira, Alex
TI Using Geographic Information Systems to Track Polio Vaccination Team
Performance: Pilot Project Report
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio; supplemental immunization activity; program evaluation;
operations research; immunization campaign; geospatial analysis; GIS
AB The application of geospatial data to public health problems has expanded significantly with increased access to low-cost handheld global positioning system (GPS) receivers and free programs for geographic information systems analysis. In January 2010, we piloted the application of geospatial analysis to polio supplementary immunization activities (SIAs) in northern Nigeria. SIA teams carried GPS receivers to compare hand-drawn catchment area route maps with GPS tracks of actual vaccination teams. Team tracks overlaid on satellite imagery revealed that teams commonly missed swaths of contiguous households and indicated that geospatial data can improve microplanning and provide nearly real-time monitoring of team performance.
C1 [Gammino, Victoria M.; Chenoweth, Paul; Sugerman, David E.; Gerber, Sue] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA.
[Young, Randall R.] Agcy Tox Subst & Dis Registry, Geospatial Res Anal & Serv Program, Atlanta, GA USA.
[Nuhu, Adamu; Abanida, Emmanuel] Natl Primary Hlth Care Dev Agcy Nigeria, Abuja, Nigeria.
[Manneh, Fadinding; Gasasira, Alex] WHO, Expanded Programme Immunizat, Abuja, Nigeria.
RP Gammino, VM (reprint author), US Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS E05, Atlanta, GA 30333 USA.
EM vgammino@cdc.gov
FU Centers for Disease Control and Prevention
FX This work was supported by the Centers for Disease Control and
Prevention.
NR 3
TC 3
Z9 3
U1 1
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S98
EP S101
DI 10.1093/infdis/jit285
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400011
PM 25316882
ER
PT J
AU Gidado, SO
Ohuabunwo, C
Nguku, PM
Ogbuanu, IU
Waziri, NE
Biya, O
Wiesen, ES
Mba-Jonas, A
Vertefeuille, J
Oyemakinde, A
Nwanyanwu, O
Lawal, N
Mahmud, M
Nasidi, A
Mahoney, FJ
AF Gidado, Saheed O.
Ohuabunwo, Chima
Nguku, Patrick M.
Ogbuanu, Ikechukwu U.
Waziri, Ndadilnasiya E.
Biya, Oladayo
Wiesen, Eric S.
Mba-Jonas, Adamma
Vertefeuille, John
Oyemakinde, Akin
Nwanyanwu, Okey
Lawal, Namadi
Mahmud, Mustapha
Nasidi, Abdulsalami
Mahoney, Frank J.
CA N-STOP Outreach Team
TI Outreach to Underserved Communities in Northern Nigeria, 2012-2013
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio; wild poliovirus; eradication; underserved populations; nomad;
settlement
ID POLIOMYELITIS ERADICATION; PROGRESS; POLIO
AB Background. Persistent wild poliovirus transmission in Nigeria constitutes a major obstacle to global polio eradication. In August 2012, the Nigerian national polio program implemented a strategy to conduct outreach to under-served communities within the context of the country's polio emergency action plans.
Methods.aEuro integral A standard operating procedure (SOP) for outreach to underserved communities was developed and included in the national guidelines for management of supplemental immunization activities (SIAs). The SOP included the following key elements: (1) community engagement meetings, (2) training of field teams, (3) field work, and (4) acute flaccid paralysis surveillance.
Results.aEuro integral Of the 46 437 settlements visited and enumerated during the outreach activities, 8607 (19%) reported that vaccination teams did not visit their settlements during prior SIAs, and 5112 (11.0%) reported never having been visited by polio vaccination teams. Fifty-two percent of enumerated settlements (23 944) were not found in the existing microplan used for the immediate past SIAs.
Conclusions.aEuro integral During a year of outreach to > 45 000 scattered, nomadic, and border settlements, approximately 1 in 5 identified were missed in the immediately preceding SIAs. These missed settlements housed a large number of previously unvaccinated children and potentially served as reservoirs for persistent wild poliovirus transmission in Nigeria.
C1 [Gidado, Saheed O.; Ohuabunwo, Chima; Nguku, Patrick M.; Waziri, Ndadilnasiya E.; Biya, Oladayo] Ctr Dis Control & Prevent CDC, Nigeria Field Epidemiol & Lab Training Programme, Atlanta, GA USA.
[Ogbuanu, Ikechukwu U.; Wiesen, Eric S.; Mba-Jonas, Adamma; Vertefeuille, John; Mahoney, Frank J.] Ctr Dis Control & Prevent CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA.
[Oyemakinde, Akin] Fed Minist Hlth Nigeria, Abuja, Nigeria.
[Nwanyanwu, Okey] CDC Nigeria, Abuja, Nigeria.
[Lawal, Namadi; Mahmud, Mustapha] Nigeria Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria.
[Nasidi, Abdulsalami] Nigeria Ctr Dis Control, Abuja, Nigeria.
RP Ogbuanu, IU (reprint author), Ctr Dis Control & Prevent, CDC Polio Response, Global Immunizat Div, 1600 Clifton Rd NE,MS A04, Atlanta, GA 30333 USA.
EM ige2@cdc.gov
FU Centers for Disease Control and Prevention
FX This work was supported by the Centers for Disease Control and
Prevention.
NR 9
TC 1
Z9 1
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S118
EP S124
DI 10.1093/infdis/jiu197
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400014
PM 25316825
ER
PT J
AU Gumede, N
Jorba, J
Deshpande, J
Pallansch, M
Yogolelo, R
Muyembe-Tamfum, JJ
Kew, O
Venter, M
Burns, CC
AF Gumede, Nicksy
Jorba, Jaume
Deshpande, Jagadish
Pallansch, Mark
Yogolelo, Riziki
Muyembe-Tamfum, Jean Jacques
Kew, Olen
Venter, Marietjie
Burns, Cara C.
TI Phylogeny of Imported and Reestablished Wild Polioviruses in the
Democratic Republic of the Congo From 2006 to 2011
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio eradication; Democratic Republic of Congo; wild poliovirus;
importation; molecular epidemiology
ID VACCINE-DERIVED POLIOVIRUSES; POLIOMYELITIS OUTBREAK; MOLECULAR
EPIDEMIOLOGY; DEOXYINOSINE RESIDUES; CODON DEGENERACY; MIXED-BASE;
IDENTIFICATION; ERADICATION; NETHERLANDS; POSITIONS
AB Background. The last case of polio associated with wild poliovirus (WPV) indigenous to the Democratic Republic of the Congo (DRC) was reported in 2001, marking a major milestone toward polio eradication in Africa. However, during 2006-2011, outbreaks associated with WPV type 1 (WPV1) were widespread in the DRC, with > 250 reported cases.
Methods.aEuro integral WPV1 isolates obtained from patients with acute flaccid paralysis (AFP) were compared by nucleotide sequencing of the VP1 capsid region (906 nucleotides). VP1 sequence relationships among isolates from the DRC and other countries were visualized in phylogenetic trees, and isolates representing distinct lineage groups were mapped.
Results.aEuro integral Phylogenetic analysis indicated that WPV1 was imported twice in 2004-2005 and once in approximately 2006 from Uttar Pradesh, India (a major reservoir of endemicity for WPV1 and WPV3 until 2010-2011), into Angola. WPV1 from the first importation spread to the DRC in 2006, sparking a series of outbreaks that continued into 2011. WPV1 from the second importation was widely disseminated in the DRC and spread to the Congo in 2010-2011. VP1 sequence relationships revealed frequent transmission of WPV1 across the borders of Angola, the DRC, and the Congo. Long branches on the phylogenetic tree signaled prolonged gaps in AFP surveillance and a likely underreporting of polio cases.
Conclusions.aEuro integral The reestablishment of widespread and protracted WPV1 transmission in the DRC and Angola following long-range importations highlights the continuing risks of WPV spread until global eradication is achieved, and it further underscores the need for all countries to maintain high levels of poliovirus vaccine coverage and sensitive surveillance to protect their polio-free status.
C1 [Gumede, Nicksy; Venter, Marietjie] NICD, ZA-2132 Johannesburg, South Africa.
[Jorba, Jaume; Pallansch, Mark; Kew, Olen; Burns, Cara C.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Infect Dis, Atlanta, GA USA.
[Deshpande, Jagadish] Indian Council Med Res, Mumbai, Maharashtra, India.
[Yogolelo, Riziki; Muyembe-Tamfum, Jean Jacques] Natl Inst Biomed Res, Kinshasa Gombe, DEM REP CONGO.
RP Gumede, N (reprint author), NICD, 1 Modderfontein Rd, ZA-2132 Johannesburg, South Africa.
EM nicksymoeletsi@gmail.com
RI Venter, Marietjie/P-9604-2016;
OI Venter, Marietjie/0000-0003-2696-824X; Deshpande,
Jagadish/0000-0001-5194-0375
FU Poliomyelitis Research Foundation, South Africa; National Institutes for
Communicable Diseases; Ministry of Public Health-Democratic Republic of
the Congo; Indian Council of Medical Research; Centers for Disease
Control and Prevention
FX This work was supported by the Poliomyelitis Research Foundation, South
Africa (to N. G.); the National Institutes for Communicable Diseases (to
M. V.); the Ministry of Public Health-Democratic Republic of the Congo
(to J. J. M.-T. and Y. R.); the Indian Council of Medical Research (to
J. D.); and the Centers for Disease Control and Prevention (to J. J., M.
P., O. K., and C. B.).
NR 50
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S361
EP S367
DI 10.1093/infdis/jiu375
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400043
PM 25316856
ER
PT J
AU Kamadjeu, R
Mahamud, A
Webeck, J
Baranyikwa, MT
Chatterjee, A
Bile, YN
Birungi, J
Mbaeyi, C
Mulugeta, A
AF Kamadjeu, Raoul
Mahamud, Abdirahman
Webeck, Jenna
Baranyikwa, Marie Therese
Chatterjee, Anirban
Bile, Yassin Nur
Birungi, Julianne
Mbaeyi, Chukwuma
Mulugeta, Abraham
TI Polio Outbreak Investigation and Response in Somalia, 2013
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Somalia; poliomyelitis eradication; outbreak; wild poliovirus; horn of
Africa
AB Background. For >2 decades, conflicts and recurrent natural disasters have maintained Somalia in a chronic humanitarian crisis. For nearly 5 years, 1 million children <10 years have not had access to lifesaving health services, including vaccination, resulting in the accumulation by 2012 of the largest geographically concentrated cohort of unvaccinated children in the world. This article reviews the epidemiology, risk, and program response to what is now known as the 2013 wild poliovirus (WPV) outbreak in Somalia and highlights the challenges that the program will face in making Somalia free of polio once again.
Methods.aEuro integral A case of acute flaccid paralysis (AFP) was defined as a child < 15 years of age with sudden onset of fever and paralysis. Polio cases were defined as AFP cases with stool specimens positive for WPV.
Results.aEuro integral From 9 May to 31 December 2013, 189 cases of WPV type 1 (WPV1) were reported from 46 districts of Somalia; 42% were from Banadir region (Mogadishu), 60% were males, and 93% were < 5 years of age. All Somalian polio cases belonged to cluster N5A, which is known to have been circulating in northern Nigeria since 2011. In response to the outbreak, 8 supplementary immunization activities were conducted with oral polio vaccine (OPV; trivalent OPV was used initially, followed subsequently by bivalent OPV) targeting various age groups, including children aged < 5 years, children aged < 10 years, and individuals of any age.
Conclusions.aEuro integral The current polio outbreak erupted after a polio-free period of > 6 years (the last case was reported in March 2007). Somalia interrupted indigenous WPV transmission in 2002, was removed from the list of polio-endemic countries a year later, and has since demonstrated its ability to control polio outbreaks resulting from importation. This outbreak reiterates that the threat of large polio outbreaks resulting from WPV importation will remain constant unless polio transmission is interrupted in the remaining polio-endemic countries.
C1 [Kamadjeu, Raoul; Mulugeta, Abraham] WHO, Nairobi, Kenya.
[Baranyikwa, Marie Therese; Chatterjee, Anirban] United Nations Childrens Fund Somalia, Nairobi, Kenya.
[Mahamud, Abdirahman; Webeck, Jenna; Birungi, Julianne; Mbaeyi, Chukwuma] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA.
[Bile, Yassin Nur] Somalia Minist Human Dev & Publ Serv, Hlth Directorate, Mogadishu, Somalia.
RP Kamadjeu, R (reprint author), WHO, POB 63565-00619, Nairobi, Kenya.
EM kamadjeur@who.int
FU Polio Eradication Initiative; US Centers for Disease Control and
Prevention; United Nation Children's Fund; Rotary International; Bill
and Melinda Gate Foundation
FX This work was supported by the Polio Eradication Initiative, which is
spearheaded by the World Health Organization; the US Centers for Disease
Control and Prevention, the United Nation Children's Fund, Rotary
International, and the Bill and Melinda Gate Foundation.
NR 10
TC 5
Z9 5
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S181
EP S186
DI 10.1093/infdis/jiu453
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400022
PM 25316834
ER
PT J
AU Khetsuriani, N
Pfeifer, D
Deshevoi, S
Gavrilin, E
Shefer, A
Butler, R
Jankovic, D
Spataru, R
Emiroglu, N
Martin, R
AF Khetsuriani, Nino
Pfeifer, Dina
Deshevoi, Sergei
Gavrilin, Eugene
Shefer, Abigail
Butler, Robb
Jankovic, Dragan
Spataru, Roman
Emiroglu, Nedret
Martin, Rebecca
TI Challenges of Maintaining Polio-free Status of the European Region
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE poliomyelitis; polio eradication; European region; polio-free status
AB Background. The European region, certified as polio free in 2002, had recent wild poliovirus (WPV) introductions, resulting in a major outbreak in Central Asian countries and Russia in 2010 and in current widespread WPV type 1 circulation in Israel, which endangered the polio-free status of the region.
Methods.aEuro integral We assessed the data on the major determinants of poliovirus transmission risk (population immunity, surveillance, and outbreak preparedness) and reviewed current threats and measures implemented in response to recent WPV introductions.
Results.aEuro integral Despite high regional vaccination coverage and functioning surveillance, several countries in the region are at high or intermediate risk of poliovirus transmission. Coverage remains suboptimal in some countries, subnational geographic areas, and population groups, and surveillance (acute flaccid paralysis, enterovirus, and environmental) needs further strengthening. Supplementary immunization activities, which were instrumental in the rapid interruption of WPV1 circulation in 2010, should be implemented in high-risk countries to close population immunity gaps. National polio outbreak preparedness plans need strengthening. Immunization efforts to interrupt WPV transmission in Israel should continue.
Conclusions.aEuro integral The European region has successfully maintained its polio-free status since 2002, but numerous challenges remain. Staying polio free will require continued coordinated efforts, political commitment and financial support from all countries.
C1 [Khetsuriani, Nino; Martin, Rebecca] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Pfeifer, Dina; Deshevoi, Sergei; Gavrilin, Eugene; Shefer, Abigail; Butler, Robb; Jankovic, Dragan; Spataru, Roman; Emiroglu, Nedret; Martin, Rebecca] WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark.
RP Khetsuriani, N (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, 1600 Clifton Rd, Atlanta, GA 30333 USA.
EM nck7@cdc.gov
FU Centers for Disease Control and Prevention
FX This article is part of a supplement entitled "The Final Phase of Polio
Eradication and Endgame Strategies for the Post-Eradication Era," which
was sponsored by the Centers for Disease Control and Prevention.
NR 35
TC 2
Z9 2
U1 1
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S194
EP S207
DI 10.1093/infdis/jiu096
PG 14
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400024
PM 25316836
ER
PT J
AU Kisjes, KH
Tebbens, RJD
Wallace, GS
Pallansch, MA
Cochi, SL
Wassilak, SGF
Thompson, KM
AF Kisjes, Kasper H.
Tebbens, Radboud J. Duintjer
Wallace, Gregory S.
Pallansch, Mark A.
Cochi, Stephen L.
Wassilak, Steven G. F.
Thompson, Kimberly M.
TI Individual-Based Modeling of Potential Poliovirus Transmission in
Connected Religious Communities in North America With Low Uptake of
Vaccination
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio; immunization; individual-based model; disease outbreaks;
heterogeneity
ID UNITED-STATES; PANDEMIC INFLUENZA; POLICY OPTIONS; DISEASE; OUTBREAKS;
ERADICATION; IMMUNITY; STOCKPILE; EPIDEMIC; NETWORKS
AB Background. Pockets of undervaccinated individuals continue to raise concerns about their potential to sustain epidemic transmission of vaccine-preventable diseases. Prior importations of live polioviruses (LPVs) into Amish communities in North America led to their recognition as a potential and identifiable linked network of undervaccinated individuals.
Methods.aEuro integral We developed an individual-based model to explore the potential transmission of a LPV throughout the North American Amish population.
Results.aEuro integral Our model demonstrates the expected limited impact associated with the historical importations, which occurred in isolated communities during the low season for poliovirus transmission. We show that some conditions could potentially lead to wider circulation of LPVs and cases of paralytic polio in Amish communities if an importation occurred during or after 2013. The impact will depend on the uncertain historical immunity to poliovirus infection among members of the community.
Conclusions.aEuro integral Heterogeneity in immunization coverage represents a risk factor for potential outbreaks of polio if introduction of a LPV occurs, although overall high population immunity in North America suggests that transmission would remain relatively limited. Efforts to prevent spread between Amish church districts with any feasible measures may offer the best opportunity to contain an outbreak and limit its size.
C1 [Kisjes, Kasper H.; Tebbens, Radboud J. Duintjer; Thompson, Kimberly M.] Kid Risk Inc, Orlando, FL 32832 USA.
[Kisjes, Kasper H.] Delft Univ Technol, Delft, Netherlands.
[Wallace, Gregory S.; Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Cochi, Stephen L.; Wassilak, Steven G. F.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA.
[Thompson, Kimberly M.] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA.
RP Thompson, KM (reprint author), Kid Risk Inc, 10524 Moss Pk Rd,Ste 204-364, Orlando, FL 32832 USA.
EM kimt@kidrisk.org
FU Centers for Disease Control and Prevention [U66IP000519-01]
FX Three authors (K. H. K., R.J.D.T., and K. M. T.) acknowledge support for
this work from the Centers for Disease Control and Prevention under
Cooperative Agreement U66IP000519-01. The contents of this article are
solely the responsibility of the authors and do not represent the
official views of the Centers for Disease Control and Prevention.
NR 37
TC 2
Z9 2
U1 1
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S424
EP S433
DI 10.1093/infdis/jit843
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400050
PM 25316864
ER
PT J
AU Kretsinger, K
Gasasira, A
Poy, A
Porter, KA
Everts, J
Salla, M
Brown, KH
Wassilak, SGF
Nshimirimana, D
AF Kretsinger, Katrina
Gasasira, Alex
Poy, Alain
Porter, Kimberly A.
Everts, Johannes
Salla, Mbaye
Brown, Kristin H.
Wassilak, Steven G. F.
Nshimirimana, Deogratias
TI Polio Eradication in the World Health Organization African Region,
2008-2012
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio eradication; wild poliovirus; WHO Africa Region; Africa;
vaccine-derived poliovirus; acute flaccid paralysis; surveillance
ID VACCINE-DERIVED POLIOVIRUSES; WILD POLIOVIRUS; POLIOMYELITIS
ERADICATION; TRACKING PROGRESS; NIGERIA; UPDATE; TRANSMISSION;
INTERRUPTION; OUTBREAK
AB A renewed commitment at the regional and the global levels led to substantial progress in the fight for polio eradication in the African Region (AFR) of the World Health Organization (WHO) during 2008-2012. In 2008, there were 912 reported cases of wild poliovirus (WPV) infection in 12 countries in the region. This number had been reduced to 128 cases in 3 countries in 2012, of which 122 were in Nigeria, the only remaining country with endemic circulation of WPV in AFR. During 2008-2012, circulation apparently ceased in the 3 AFR countries with reestablished WPV transmission-Angola, the Democratic Republic of the Congo, and Chad. Outbreaks in West Africa continued to occur in 2008-2010 but were more rapidly contained, with fewer cases than during earlier years. This progress has been attributed to better implementation of core strategies, increased accountability, and implementation of innovative approaches. During this period, routine coverage with 3 doses of oral polio vaccine in AFR, as measured by WHO-United Nations Children's Fund estimates, increased slightly, from 72% to 74%. Despite this progress, challenges persist in AFR, and 2013 was marked by new setbacks and importations. High population immunity and strong surveillance are essential to sustain progress and assure that AFR reaches its goal of eradicating WPV.
C1 [Kretsinger, Katrina; Porter, Kimberly A.; Brown, Kristin H.; Wassilak, Steven G. F.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA.
[Gasasira, Alex; Poy, Alain; Salla, Mbaye; Nshimirimana, Deogratias] WHO, Immunizat Vaccines & Emergencies, Reg Off Africa, Brazzaville, Rep Congo.
[Everts, Johannes] WHO, Strategy Support & Coordinat Unit, Polio Operat & Res, CH-1211 Geneva, Switzerland.
RP Kretsinger, K (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS A-04, Atlanta, GA 30333 USA.
EM kok4@cdc.gov
FU Centers for Disease Control and Prevention
FX This article is part of a supplement entitled "The Final Phase of Polio
Eradication and Endgame Strategies for the Post-Eradication Era," which
was sponsored by the Centers for Disease Control and Prevention.
NR 37
TC 4
Z9 4
U1 2
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S23
EP S39
DI 10.1093/infdis/jiu408
PG 17
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400004
PM 25316840
ER
PT J
AU Mach, O
Verma, H
Khandait, DW
Sutter, RW
O'Connor, PM
Pallansch, MA
Cochi, SL
Linkins, RW
Chu, SY
Wolff, C
Jafari, HS
AF Mach, Ondrej
Verma, Harish
Khandait, Devendra W.
Sutter, Roland W.
O'Connor, Patrick M.
Pallansch, Mark A.
Cochi, Stephen L.
Linkins, Robert W.
Chu, Susan Y.
Wolff, Chris
Jafari, Hamid S.
TI Prevalence of Asymptomatic Poliovirus Infection in Older Children and
Adults in Northern India: Analysis of Contact and Enhanced Community
Surveillance, 2009
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE poliomyelitis; community transmission; India; enhanced surveillance
ID UNITED STATES CITIES; NATURAL IMMUNITY; MUCOSAL IMMUNITY;
HEALTHY-CHILDREN; POLIOMYELITIS ERADICATION; CONTINUING SURVEILLANCE;
ENTEROVIRUS INFECTIONS; VACCINE IMMUNIZATION; LOUISIANA; TRANSMISSION
AB Background. In 2009, enhanced poliovirus surveillance was established in polio-endemic areas of Uttar Pradesh and Bihar, India, to assess poliovirus infection in older individuals.
Methods.aEuro integral In Uttar Pradesh, stool specimens from asymptomatic household and neighborhood contacts of patients with laboratory-confirmed polio were tested for polioviruses. In Bihar, in community-based surveillance, children and adults from 250 randomly selected households in the Kosi River area provided stool and pharyngeal swab samples that were tested for polioviruses. A descriptive analysis of surveillance data was performed.
Results.aEuro integral In Uttar Pradesh, 89 of 1842 healthy contacts of case patients with polio (4.8%) were shedding wild poliovirus (WPV); 54 of 85 (63.5%) were a parts per thousand yen5 years of age. Shedding was significantly higher in index households than in neighborhood households (P < .05). In Bihar, 11 of 451 healthy persons (2.4%) were shedding WPV in their stool; 6 of 11 (54.5%) were a parts per thousand yen5 years of age. Mean viral titer was similar in older and younger children.
Conclusions.aEuro integral A high proportion of persons a parts per thousand yen5 years of age were asymptomatically shedding polioviruses. These findings provide indirect evidence that older individuals could have contributed to community transmission of WPV in India. Polio vaccination campaigns generally target children < 5 years of age. Expanding this target age group in polio-endemic areas could accelerate polio eradication.
C1 [Mach, Ondrej; Pallansch, Mark A.; Cochi, Stephen L.; Linkins, Robert W.; Chu, Susan Y.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Verma, Harish; Khandait, Devendra W.; Jafari, Hamid S.] Natl Polio Surveillance Unit, New Delhi, India.
[O'Connor, Patrick M.] WHO, Reg Off South East Asia, New Delhi, India.
[Mach, Ondrej; Sutter, Roland W.; Wolff, Chris] WHO, CH-1211 Geneva 27, Switzerland.
RP Mach, O (reprint author), WHO, Ave Appia 20, CH-1211 Geneva 27, Switzerland.
EM macho@who.int
FU Centers for Disease Control and Prevention
FX This article is part of a supplement entitled "The Final Phase of Polio
Eradication and Endgame Strategies for the Post-Eradication Era," which
was sponsored by the Centers for Disease Control and Prevention.
NR 44
TC 2
Z9 2
U1 3
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S252
EP S258
DI 10.1093/infdis/jit234
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400030
PM 25316843
ER
PT J
AU Mach, O
Tangermann, RH
Wassilak, SG
Singh, S
Sutter, RW
AF Mach, Ondrej
Tangermann, Rudolf H.
Wassilak, Steve G.
Singh, Simarjit
Sutter, Roland W.
TI Outbreaks of Paralytic Poliomyelitis During 1996-2012: The Changing
Epidemiology of a Disease in the Final Stages of Eradication
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE poliomyelitis; outbreak; poliovirus eradication
ID GLOBAL POLIO ERADICATION; PROGRESS; CHALLENGES; WORLDWIDE; ANGOLA
AB Background. Despite substantial progress toward eradication of poliomyelitis, the risk of poliomyelitis outbreaks resulting from virus importations into polio-free areas persists. We reviewed the changing epidemiology of outbreaks in the final stages of the eradication initiative.
Methods.aEuro integral Available literature on outbreaks of poliomyelitis caused by wild polioviruses between 1996 and 2012 was reviewed.
Results.aEuro integral During this period, there were 22 outbreaks involving 39 countries. Outbreaks ranged in size from 1 to 1335 cases. These outbreaks caused 4571 cases, representing 21% of all cases reported during this period. Five outbreaks involved multiple countries. In 76% of outbreaks (16/21) with a known age distribution, cases concentrated among children aged < 5 years; in 19% (4/21), most cases were among adolescents and adults. The outbreaks among adolescents and adults were associated with higher case-fatality ratios, ranging from 12% in Albania in 1994 to 41% in the Republic of Congo in 2010. The majority of outbreaks were controlled within 6 months with oral poliovirus vaccine.
Conclusions.aEuro integral Importations resulting in epidemic transmission of wild poliovirus caused thousands of cases of paralysis often in countries where poliomyelitis had not occurred for many years. The changing epidemiology, with cases and higher case-fatality ratios among adults, increased the severity of these outbreaks.
C1 [Mach, Ondrej; Tangermann, Rudolf H.; Singh, Simarjit; Sutter, Roland W.] WHO, CH-1211 Geneva 27, Switzerland.
[Wassilak, Steve G.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Mach, O (reprint author), WHO, Ave Appia 20, CH-1211 Geneva 27, Switzerland.
EM macho@who.int
FU Centers for Disease Control and Prevention
FX This article is part of a supplement entitled "The Final Phase of Polio
Eradication and Endgame Strategies for the Post-Eradication Era," which
was sponsored by the Centers for Disease Control and Prevention.
NR 67
TC 4
Z9 4
U1 2
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S275
EP S282
DI 10.1093/infdis/jit454
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400033
PM 25316846
ER
PT J
AU Mahamud, A
Kamadjeu, R
Webeck, J
Mbaeyi, C
Baranyikwa, MT
Birungi, J
Nurbile, Y
Ehrhardt, D
Shukla, H
Chatterjee, A
Mulugeta, A
AF Mahamud, Abdirahman
Kamadjeu, Raoul
Webeck, Jenna
Mbaeyi, Chukwuma
Baranyikwa, Marie Therese
Birungi, Julianne
Nurbile, Yassin
Ehrhardt, Derek
Shukla, Hemant
Chatterjee, Anirban
Mulugeta, Abraham
TI Effectiveness of Oral Polio Vaccination Against Paralytic Poliomyelitis:
A Matched Case-Control Study in Somalia
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE vaccine effectiveness; oral polio vaccine; Somalia
ID IMMUNIZATION; EFFICACY; OUTBREAK; PAKISTAN
AB Background. After the last case of type 1 wild poliovirus (WPV1) was reported in 2007, Somalia experienced another outbreak of WPV1 (189 cases) in 2013.
Methods.aEuro integral We conducted a retrospective, matched case-control study to evaluate the vaccine effectiveness (VE) of oral polio vaccine (OPV). We retrieved information from the Somalia Surveillance Database. A case was defined as any case of acute flaccid paralysis (AFP) with virological confirmation of WPV1. We selected two groups of controls for each case: non-polio AFP cases ("NPAFP controls") matched to WPV1 cases by age, date of onset of paralysis and region; and asymptomatic "neighborhood controls," matched by age. Using conditional logistic regression, we estimated the VE of OPV as (1- odds ratio) x100.
Result.aEuro integral We matched 99 WPV cases with 99 NPAFP controls and 134 WPV1 cases with 268 neighborhood controls. Using NPAFP controls, the overall VE was 70% (95% confidence interval [CI], 37-86), 59% (2-83) among 1-3 dose recipients, 77% (95% CI, 46-91) among a parts per thousand yen4 dose recipients. In neighborhood controls, the overall VE was 95% (95% CI, 84-98), 92% (72-98) among 1-3 dose recipients, and 97% (89-99) among a parts per thousand yen4 dose recipients. When the analysis was limited to cases and controls a parts per thousand currency sign24 months old, the overall VE in NPAFP and neighborhood controls was 95% (95% CI, 65-99) and 97% (95% CI, 76-100), respectively.
Conclusions.aEuro integral Among individuals who were fully vaccinated with OPV, vaccination was effective at preventing WPV1 in Somalia.
C1 [Mahamud, Abdirahman; Webeck, Jenna; Mbaeyi, Chukwuma; Ehrhardt, Derek] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA.
[Kamadjeu, Raoul; Mulugeta, Abraham] WHO, Somalia Country Off, Nairobi, Kenya.
[Baranyikwa, Marie Therese; Birungi, Julianne; Chatterjee, Anirban] United Nations Childrens Fund UNICEF, Somalia Support Ctr, Nairobi, Kenya.
[Nurbile, Yassin] Somalia Minist Human Dev & Publ Serv, Hlth Directorate, Mogadishu, Somalia.
[Shukla, Hemant] WHO, Global Polio Eradicat Initiat, CH-1211 Geneva, Switzerland.
RP Mahamud, A (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE Mailstop A-04, Atlanta, GA 30333 USA.
EM amahamud@cdc.gov
FU Centers for Disease Control and Prevention; World Health Organization
FX This work was supported by the Centers for Disease Control and
Prevention and the World Health Organization.
NR 17
TC 1
Z9 1
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S187
EP S193
DI 10.1093/infdis/jiu261
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400023
PM 25316835
ER
PT J
AU Mbaeyi, C
Kamadjeu, R
Mahamud, A
Webeck, J
Ehrhardt, D
Mulugeta, A
AF Mbaeyi, Chukwuma
Kamadjeu, Raoul
Mahamud, Abdirahman
Webeck, Jenna
Ehrhardt, Derek
Mulugeta, Abraham
TI Progress Toward Polio Eradication-Somalia, 1998-2013
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio; Somalia; disease eradication; wild poliovirus (WPV); acute
flaccid paralysis (AFP); oral polio vaccine (OPV); immunization;
surveillance
ID VACCINE-DERIVED POLIOVIRUSES; POLIOMYELITIS; MOGADISHU
AB Since the 1988 resolution of the World Health Assembly to eradicate polio, significant progress has been made toward achieving this goal, with the result that only Afghanistan, Nigeria, and Pakistan have never successfully interrupted endemic transmission of wild poliovirus. However, one of the greatest challenges of the Global Polio Eradication Initiative has been that of maintaining the polio-free status of countries in unstable regions with weak healthcare infrastructure, a challenge exemplified by Somalia, a country in the Horn of Africa region. Somalia interrupted indigenous transmission of wild poliovirus in 2002, 4 years after the country established its national polio eradication program. But political instability and protracted armed conflict, with significant disruption of the healthcare system, have left Somalia vulnerable to 2 imported outbreaks of wild poliovirus. The first occurred during 2005-2007, resulting in > 200 cases of paralytic polio, whereas the second, which began in 2013, is currently ongoing. Despite immense challenges, the country has a sensitive surveillance system that has facilitated prompt detection of outbreaks, but its weak routine immunization system means that supplementary immunization activities constitute the primary strategy for reaching children with polio vaccines. Conducting vaccination campaigns in a setting of conflict has been at times hazardous, but the country's polio program has demonstrated resilience in overcoming many obstacles to ensure that children receive lifesaving polio vaccines. Regaining and maintaining Somalia's polio-free status will depend on finding innovative and lasting solutions to the challenge of administering vaccines in a setting of ongoing conflict and instability.
C1 [Mbaeyi, Chukwuma; Kamadjeu, Raoul; Mahamud, Abdirahman; Webeck, Jenna; Ehrhardt, Derek] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Kamadjeu, Raoul; Mulugeta, Abraham] WHO, Somalia Liaison Off, Nairobi, Kenya.
RP Mbaeyi, C (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS A-04, Atlanta, GA 30333 USA.
EM cmbaeyi@cdc.gov
FU Centers for Disease Control and Prevention
FX This article is part of a supplement entitled "The Final Phase of Polio
Eradication and Endgame Strategies for the Post-Eradication Era," which
was sponsored by the Centers for Disease Control and Prevention.
NR 23
TC 0
Z9 0
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S173
EP S180
DI 10.1093/infdis/jit808
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400021
PM 25316833
ER
PT J
AU McKinlay, MA
Collett, MS
Hincks, JR
Oberste, MS
Pallansch, MA
Okayasu, H
Sutter, RW
Modlin, JF
Dowdle, WR
AF McKinlay, Mark A.
Collett, Marc S.
Hincks, Jeffrey R.
Oberste, M. Steven
Pallansch, Mark A.
Okayasu, Hiromasa
Sutter, Roland W.
Modlin, John F.
Dowdle, Walter R.
TI Progress in the Development of Poliovirus Antiviral Agents and Their
Essential Role in Reducing Risks That Threaten Eradication
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE poliovirus; antiviral
ID VACCINE-DERIVED POLIOVIRUS; RHINOVIRUS 3C PROTEASE; IN-VITRO;
IMMUNODEFICIENT PATIENT; BROAD-SPECTRUM; PLECONARIL; INHIBITOR; V-073;
DRUG; RESISTANCE
AB Chronic prolonged excretion of vaccine-derived polioviruses by immunodeficient persons (iVDPV) presents a personal risk of poliomyelitis to the patient as well as a programmatic risk of delayed global eradication. Poliovirus antiviral drugs offer the only mitigation of these risks. Antiviral agents may also have a potential role in the management of accidental exposures and in certain outbreak scenarios. Efforts to discover and develop poliovirus antiviral agents have been ongoing in earnest since the formation in 2007 of the Poliovirus Antivirals Initiative. The most advanced antiviral, pocapavir (V-073), is a capsid inhibitor that has recently demonstrated activity in an oral poliovirus vaccine human challenge model. Additional antiviral candidates with differing mechanisms of action continue to be profiled and evaluated preclinically with the goal of having 2 antivirals available for use in combination to treat iVDPV excreters.
C1 [McKinlay, Mark A.; Dowdle, Walter R.] Task Force Global Hlth, Ctr Vaccine Equ, Decatur, GA 30030 USA.
[Collett, Marc S.; Hincks, Jeffrey R.] ViroDefense Inc, Rockville, MD USA.
[Oberste, M. Steven; Pallansch, Mark A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Okayasu, Hiromasa; Sutter, Roland W.] World Hlth Org, Geneva, Switzerland.
[Modlin, John F.] Geisel Sch Med Dartmouth, Lebanon, NH USA.
RP McKinlay, MA (reprint author), Task Force Global Hlth, Ctr Vaccine Equ, 325 Swanton Way, Decatur, GA 30030 USA.
EM mmckinlay@taskforce.org
FU Bill & Melinda Gates Foundation; Centers for Disease Control and
Prevention; World Health Organization; Rotary International
FX This work was supported by funding from the Bill & Melinda Gates
Foundation, the Centers for Disease Control and Prevention, the World
Health Organization and Rotary International.
NR 34
TC 14
Z9 14
U1 2
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S447
EP S453
DI 10.1093/infdis/jiu043
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400053
PM 25316866
ER
PT J
AU Michael, CA
Ashenafi, S
Ogbuanu, IU
Ohuabunwo, C
Sule, A
Corkum, M
Mackay, S
Storms, AD
Achari, P
Biya, O
Nguku, P
Newberry, D
Bwaka, A
Mahoney, F
AF Michael, Charles A.
Ashenafi, Samra
Ogbuanu, Ikechukwu U.
Ohuabunwo, Chima
Sule, Adamu
Corkum, Melissa
Mackay, Susan
Storms, Aaron D.
Achari, Panchanan
Biya, Oladayo
Nguku, Patrick
Newberry, David
Bwaka, Ado
Mahoney, Frank
CA OPV Campaign Missed Children Study
TI An Evaluation of Community Perspectives and Contributing Factors to
Missed Children During an Oral Polio Vaccination Campaign - Katsina
State, Nigeria
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE OPV; oral polio vaccine; missed children; vaccine coverage;
non-compliance
AB Background. Unvaccinated children contribute to accumulation of susceptible persons and the continued transmission of wild poliovirus in Nigeria. In September 2012, the Expert Review Committee (ERC) on Polio Eradication and Routine Immunization in Nigeria recommended that social research be conducted to better understand why children are missed during supplementary immunization activities (SIAs), also known as "immunization plus days (IPDs)" in Nigeria.
Methods.aEuro integral Immediately following the SIA in October 2012, polio eradication partners and the government of Nigeria conducted a study to assess why children are missed. We used semistructured questionnaires and focus group discussions in 1 rural and 1 urban local government area (LGA) of Katsina State.
Results.aEuro integral Participants reported that 61% of the children were not vaccinated because of poor vaccination team performance: either the teams did not visit the homes (25%) or the children were reported absent and not revisited (36%). This lack of access to vaccine was more frequently reported by respondents from scattered/nomadic communities (85%). In 1 out of 4 respondents (25%), refusal was the main reason their child was not vaccinated. The majority of respondents reported they would have consented to their children being vaccinated if the vaccine had been offered.
Conclusions.aEuro integral Poor vaccination team performance is a major contributor to missed children during IPD campaigns. Addressing such operational deficiencies will help close the polio immunity gap and eradicate polio from Nigeria.
C1 [Michael, Charles A.; Ohuabunwo, Chima; Sule, Adamu; Biya, Oladayo; Nguku, Patrick] African Field Epidemiol Network AFENET, Atlanta, GA USA.
[Ashenafi, Samra; Ogbuanu, Ikechukwu U.; Storms, Aaron D.; Newberry, David; Mahoney, Frank] US Ctr Dis Control & Prevent, Atlanta, GA USA.
[Corkum, Melissa; Mackay, Susan; Achari, Panchanan] United Nations Children Fund UNICEF, Nigeria Country Off, Abuja, Nigeria.
WHO, Katsina State Off, Katsina, Nigeria.
RP Michael, CA (reprint author), 50 Haille Selassia St, Asokoro, Abuja, Nigeria.
EM drcedon@yahoo.com
FU US CDC
FX This work was wholly funded by the US CDC.
NR 5
TC 1
Z9 1
U1 2
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S131
EP S135
DI 10.1093/infdis/jiu288
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400016
PM 25316827
ER
PT J
AU Michael, CA
Ogbuanu, IU
Storms, AD
Ohuabunwo, CJ
Corkum, M
Ashenafi, S
Achari, P
Biya, O
Nguku, P
Mahoney, F
AF Michael, Charles A.
Ogbuanu, Ikechukwu U.
Storms, Aaron D.
Ohuabunwo, Chima J.
Corkum, Melissa
Ashenafi, Samra
Achari, Panchanan
Biya, Oladayo
Nguku, Patrick
Mahoney, Frank
CA NSTOP OPV Refusal Study Team
TI An Assessment of the Reasons for Oral Poliovirus Vaccine Refusals in
Northern Nigeria
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE assessment; OPV; oral polio vaccine; refusals; noncompliance
AB Background. Accumulation of susceptible children whose caregivers refuse to accept oral poliovirus vaccine (OPV) contributes to the spread of poliovirus in Nigeria.
Methods.aEuro integral During and immediately following the OPV campaign in October 2012, polio eradication partners conducted a study among households in which the vaccine was refused, using semistructured questionnaires. The selected study districts had a history of persistent OPV refusals in previous campaigns.
Results.aEuro integral Polio risk perception was low among study participants. The majority (59%) of participants believed that vaccination was either not necessary or would not be helpful, and 30% thought it might be harmful. Religious beliefs were an important driver in the way people understood disease. Fifty-two percent of 48 respondents reported that illnesses were due to God's will and/or destiny and that only God could protect them against illnesses. Only a minority (14%) of respondents indicated that polio was a significant problem in their community.
Conclusions.aEuro integral Caregivers refuse OPV largely because of poor polio risk perception and religious beliefs. Communication strategies should, therefore, aim to increase awareness of polio as a real health threat and educate communities about the safety of the vaccine. In addition, polio eradication partners should collaborate with other agencies and ministries to improve total primary healthcare packages to address identified unmet health and social needs.
C1 [Michael, Charles A.; Ohuabunwo, Chima J.; Biya, Oladayo; Nguku, Patrick] African Field Epidemiol Network, Kampala, Uganda.
[Ogbuanu, Ikechukwu U.; Storms, Aaron D.; Ashenafi, Samra; Mahoney, Frank] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA.
[Corkum, Melissa; Achari, Panchanan] United Nations Childrens Fund, Nigeria Country Off, Abuja, Nigeria.
RP Michael, CA (reprint author), Nigeria Field Epidemiol & Lab Training Program, 50 Haile Selassie St, Abuja, Nigeria.
EM drcedon@yahoo.com
FU Centers for Disease Control and Prevention
FX This work was supported by the Centers for Disease Control and
Prevention.
NR 14
TC 8
Z9 8
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S125
EP S130
DI 10.1093/infdis/jiu436
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400015
PM 25316826
ER
PT J
AU Moulsdale, HJ
Khetsuriani, N
Deshevoi, S
Butler, R
Simpson, J
Salisbury, D
AF Moulsdale, Hilary J.
Khetsuriani, Nino
Deshevoi, Sergei
Butler, Robb
Simpson, John
Salisbury, David
TI Simulation Exercises to Strengthen Polio Outbreak Preparedness:
Experience of the World Health Organization European Region
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE poliovirus; polio outbreak simulation exercise (POSE); preparedness
exercise; polio eradication
AB Background. Poliovirus importations and related outbreaks continue to occur in polio-free countries, including those in the World Health Organization (WHO) European Region. National preparedness plans for responding to poliovirus introduction are insufficient in many countries of the European Region. We describe a series of polio outbreak simulation exercises that were implemented to formally test polio outbreak preparedness plans in the European Region.
Methods.aEuro integral We designed and implemented the exercises, reviewed the results, made recommendations, and assessed the role of outbreak simulation exercises in maintaining regional polio-free status. In addition, we performed a comprehensive review of the national plans of all WHO Member States in the European Region.
Results.aEuro integral Three exercises, delivered during 2011-2013 (for the Balkans, United Kingdom, and the Caucasus and Ukraine), revealed that participating countries were generally prepared for poliovirus introduction, but the level of preparedness needed improvement. The areas in particular need of strengthening were national preparedness plans, initial response, plans for securing vaccine supply, and communications.
Conclusions.aEuro integral Polio outbreak simulation exercises can be valuable tools to help maintain polio-free status and should be extended to other high-risk countries and subnational areas in the European Region and elsewhere.
C1 [Moulsdale, Hilary J.; Simpson, John] Publ Hlth England, London, England.
[Simpson, John] Kings Coll London, Inst Psychiat, London WC2R 2LS, England.
[Salisbury, David] Dept Hlth, London SE1 6TE, England.
[Khetsuriani, Nino] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Deshevoi, Sergei; Butler, Robb] WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark.
RP Moulsdale, HJ (reprint author), Publ Hlth England, Emergency Response Dept, Salisbury SP4 0JG, Wilts, England.
EM hilary.moulsdale@phe.gov.uk
RI yan, liu/A-1822-2015
OI yan, liu/0000-0001-8517-1084
FU WHO Regional Office for Europe; Public Health England
FX This work was supported by the WHO Regional Office for Europe (funding
to POSE 1 and POSE II) and Public Health England (funding to POSE UK).
NR 20
TC 2
Z9 2
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S208
EP S215
DI 10.1093/infdis/jiu120
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400025
PM 25316837
ER
PT J
AU Ndiaye, SM
Ahmed, MA
Denson, M
Craig, AS
Kretsinger, K
Cherif, B
Kandolo, P
Moto, DD
Richelot, A
Tuma, J
AF Ndiaye, Serigne M.
Ahmed, Mahamat Abdoulaye
Denson, Melinda
Craig, Allen S.
Kretsinger, Katrina
Cherif, Baharadine
Kandolo, Pierre
Moto, Daugla Doumagoum
Richelot, Ayangma
Tuma, Jude
TI Polio Outbreak Among Nomads in Chad: Outbreak Response and Lessons
Learned
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE nomad health; vaccinations of mobile populations; vaccination outreach
strategies; polio vaccination
ID DISEASE SURVEILLANCE; HEALTH; RESOURCES; COMMUNITY; PROGRAMS; DELIVERY
AB Background. In response to the 2011 and 2012 polio epidemic in Chad, Chad's Ministry of Public Health, with support from Global Polio Eradication Initiative partners, took steps to increase vaccination coverage of nomadic children with targeted polio campaigns. This article describes the strategies we used to vaccinate nomads in 3 districts of Chad.
Methods.aEuro integral Our targeted interventions involved using mobile vaccination teams, recruiting local nomads to identify settlements, using social mobilization, and offering vaccinations to children, women, and animals.
Results.aEuro integral Vaccination coverage of nomadic children 0-59 months of age increased, particularly among those never before vaccinated against polio. These increases occurred mostly in the intervention districts of Dourbali, from 2956 to 8164 vaccinated children, and Kyabe, from 7319 to 15 868. The number of first-time vaccinated nomadic children also increased the most in these districts, from 60 to 131 in Dourbali and from 1302 to 2973 in Kyabe. Coverage in the Massaguet district was only 37.7%.
Conclusions.aEuro integral Our success was probably due to (1) appointment of staff to oversee implementation, (2) engagement of the national government and its partners, (3) participation of nomadic community leaders, (4) intersectoral collaboration between human and animal health services, and (5) flexibility and capacity of vaccinators to vaccinate when and where nomads were available.
C1 [Ndiaye, Serigne M.; Denson, Melinda; Craig, Allen S.; Kretsinger, Katrina; Tuma, Jude] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA.
[Ahmed, Mahamat Abdoulaye; Moto, Daugla Doumagoum] Minist Sante Publ, Ctr Support Sante Int, Ndjamena, Chad.
[Cherif, Baharadine] Minist Sante Publ, Programme Elargie Ide Vaccinat, Ndjamena, Chad.
[Kandolo, Pierre; Richelot, Ayangma] WHO, Ndjamena, Chad.
RP Ndiaye, SM (reprint author), Ctr Dis Control & Prevent, Dis Eradicat & Eliminat Branch, Global Immunizat Div, MS A-04, Atlanta, GA 30333 USA.
EM scn3@cdc.gov
FU Centers for Disease Control and Prevention
FX This article is part of a supplement entitled "The Final Phase of Polio
Eradication and Endgame Strategies for the Post-Eradication Era," which
was sponsored by the Centers for Disease Control and Prevention.
NR 26
TC 1
Z9 1
U1 6
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S74
EP S84
DI 10.1093/infdis/jit564
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400008
PM 24154734
ER
PT J
AU Okayasu, H
Brown, AE
Nzioki, MM
Gasasira, AN
Takane, M
Mkanda, P
Wassilak, SGF
Sutter, RW
AF Okayasu, Hiromasa
Brown, Alexandra E.
Nzioki, Michael M.
Gasasira, Alex N.
Takane, Marina
Mkanda, Pascal
Wassilak, Steven G. F.
Sutter, Roland W.
TI Cluster Lot Quality Assurance Sampling: Effect of Increasing the Number
of Clusters on Classification Precision and Operational Feasibility
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE cluster lot quality assurance sampling; Nigeria; polio eradication;
supplementary immunization activities; survey methods
ID ASSESS IMMUNIZATION COVERAGE
AB Background. To assess the quality of supplementary immunization activities (SIAs), the Global Polio Eradication Initiative (GPEI) has used cluster lot quality assurance sampling (C-LQAS) methods since 2009. However, since the inception of C-LQAS, questions have been raised about the optimal balance between operational feasibility and precision of classification of lots to identify areas with low SIA quality that require corrective programmatic action.
Methods.aEuro integral To determine if an increased precision in classification would result in differential programmatic decision making, we conducted a pilot evaluation in 4 local government areas (LGAs) in Nigeria with an expanded LQAS sample size of 16 clusters (instead of the standard 6 clusters) of 10 subjects each.
Results.aEuro integral The results showed greater heterogeneity between clusters than the assumed standard deviation of 10%, ranging from 12% to 23%. Comparing the distribution of 4-outcome classifications obtained from all possible combinations of 6-cluster subsamples to the observed classification of the 16-cluster sample, we obtained an exact match in classification in 56% to 85% of instances.
Conclusions.aEuro integral We concluded that the 6-cluster C-LQAS provides acceptable classification precision for programmatic action. Considering the greater resources required to implement an expanded C-LQAS, the improvement in precision was deemed insufficient to warrant the effort.
C1 [Okayasu, Hiromasa; Brown, Alexandra E.; Takane, Marina; Sutter, Roland W.] WHO, Global Polio Eradicat Dept, CH-1211 Geneva 27, Switzerland.
[Nzioki, Michael M.; Gasasira, Alex N.; Mkanda, Pascal] WHO, Country Off, Abuja, Nigeria.
[Wassilak, Steven G. F.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA.
RP Okayasu, H (reprint author), WHO, Polio Eradicat Initiat, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
EM okayasuhi@who.int
FU World Health Organization; Centers for Disease Control and Prevention
FX This work was supported by the World Health Organization, and Centers
for Disease Control and Prevention.
NR 9
TC 1
Z9 1
U1 1
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S341
EP S346
DI 10.1093/infdis/jiu162
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400040
PM 25316853
ER
PT J
AU Platt, LR
Estivariz, CF
Sutter, RW
AF Platt, Lauren R.
Estivariz, Concepcion F.
Sutter, Roland W.
TI Vaccine-Associated Paralytic Poliomyelitis: A Review of the Epidemiology
and Estimation of the Global Burden
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE inactivated poliovirus vaccine (IPV); oral poliovirus vaccine (OPV); OPV
cessation; OPV withdrawal; polio endgame; polio eradication;
poliomyelitis; vaccine-associated paralytic poliomyelitis (VAPP)
ID ORAL POLIOVIRUS VACCINE; UNITED-STATES; RISK; SURVEILLANCE; ERADICATION;
IMPACT; DISEASE; ENGLAND; BRAZIL; WALES
AB Background. Vaccine-associated paralytic poliomyelitis (VAPP) is a rare adverse event associated with oral poliovirus vaccine (OPV). This review summarizes the epidemiology and provides a global burden estimate.
Methods.aEuro integral A literature review was conducted to abstract the epidemiology and calculate the risk of VAPP. A bootstrap method was applied to calculate global VAPP burden estimates.
Results.aEuro integral Trends in VAPP epidemiology varied by country income level. In the low-income country, the majority of cases occurred in individuals who had received > 3 doses of OPV (63%), whereas in middle and high-income countries, most cases occurred in recipients after their first OPV dose or unvaccinated contacts (81%). Using all risk estimates, VAPP risk was 4.7 cases per million births (range, 2.4-9.7), leading to a global annual burden estimate of 498 cases (range, 255-1018). If the analysis is limited to estimates from countries that currently use OPV, the VAPP risk is 3.8 cases per million births (range, 2.9-4.7) and a burden of 399 cases (range, 306-490).
Conclusions.aEuro integral Because many high-income countries have replaced OPV with inactivated poliovirus vaccine, the VAPP burden is concentrated in lower-income countries. The planned universal introduction of inactivated poliovirus vaccine is likely to substantially decrease the global VAPP burden by 80%-90%.
C1 [Platt, Lauren R.; Sutter, Roland W.] WHO, CH-1211 Geneva, Switzerland.
[Estivariz, Concepcion F.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA.
RP Platt, LR (reprint author), WHO, Ave Appia 20, CH-1211 Geneva, Switzerland.
EM laurenreedplatt@gmail.com
FU World Health Organization
FX This work was supported by the World Health Organization.
NR 45
TC 37
Z9 40
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S380
EP S389
DI 10.1093/infdis/jiu184
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400046
PM 25316859
ER
PT J
AU Sazzad, HMS
Rainey, JJ
Kahn, AL
Mach, O
Liyanage, JBL
Alam, AN
Kawser, CA
Hossain, A
Sutter, R
Luby, SP
AF Sazzad, Hossain M. S.
Rainey, Jeanette J.
Kahn, Anna-Lea
Mach, Ondrej
Liyanage, Jayantha B. L.
Alam, Ahmed Nawsher
Kawser, Choudhury A.
Hossain, Asgar
Sutter, Roland
Luby, Stephen P.
TI Screening for Long-term Poliovirus Excretion Among Children With Primary
Immunodeficiency Disorders: Preparation for the Polio Posteradication
Era in Bangladesh
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio; primary immunodeficiency disorders; oral poliovirus vaccine;
vaccine associated paralytic polio; immunodeficiency-associated
vaccine-derived poliovirus (iVDPV); screening
ID VACCINE-DERIVED POLIOVIRUSES; PATIENT; POLIOMYELITIS; ERADICATION;
REPLICATION; EVOLUTION
AB Background. Persons with primary immune deficiency disorders (PIDD) who receive oral poliovirus vaccine (OPV) may transmit immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) and cause paralytic polio. The objective of this study was to identify children with PIDD in Bangladesh, and estimate the proportion with chronic poliovirus excretion.
Methods.aEuro integral Patients admitted at 5 teaching hospitals were screened for PIDD according to standardized clinical case definitions. PIDD was confirmed by age-specific quantitative immunoglobulin levels. Stool specimens were collected from patients with confirmed PIDD.
Results.aEuro integral From February 2011 through January 2013, approximately 96 000 children were screened, and 53 patients were identified who met the clinical case definition for PIDD. Thirteen patients (24%) had age-specific quantitative immunoglobulins results that confirmed PIDD. Of these, 9 (69%) received OPV 3-106 months before stool specimen collection. Among 11 patients, stool specimens from 1 patient tested positive for polioviruses 34 months after OPV ingestion. However, the poliovirus isolate was not available for genetic sequencing, and a subsequent stool specimen 45 days later was negative.
Conclusions.aEuro integral The risk of chronic poliovirus excretion among children with PIDD in Bangladesh seems to be low. The national polio eradication program should incorporate strategies for screening for poliovirus excretion among patients with PIDD.
C1 [Sazzad, Hossain M. S.; Luby, Stephen P.] Icddr B, Dhaka 1212, Bangladesh.
[Liyanage, Jayantha B. L.] WHO, Dhaka, Bangladesh.
[Alam, Ahmed Nawsher] Inst Publ Hlth, Natl Polio & Measles Lab, Dhaka, Bangladesh.
[Kawser, Choudhury A.] Bangabandhu Sheikh Mujib Med Univ, Dhaka, Bangladesh.
[Hossain, Asgar] Rajshahi Med Coll Hosp, Rajshahi, Bangladesh.
[Rainey, Jeanette J.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Luby, Stephen P.] Stanford Univ, Stanford, CA 94305 USA.
[Kahn, Anna-Lea; Mach, Ondrej; Sutter, Roland] WHO, CH-1211 Geneva, Switzerland.
RP Sazzad, HMS (reprint author), Icddr B, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.
EM sazzad@icddrb.org
OI Luby, Stephen/0000-0001-5385-899X
FU US Centers for Disease Control and Prevention, Atlanta; World Health
Organization, Geneva, Switzerland
FX This work was supported by the US Centers for Disease Control and
Prevention, Atlanta, and the World Health Organization, Geneva,
Switzerland. The governments of Australia, Bangladesh, Canada, Sweden,
and the United Kingdom provided core/unrestricted support.
NR 29
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S373
EP S379
DI 10.1093/infdis/jiu221
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400045
PM 25316858
ER
PT J
AU Simpson, DM
Sadr-Azodi, N
Mashal, T
Sabawoon, W
Pardis, A
Quddus, A
Garrigos, C
Guirguis, S
Zaidi, SSZ
Shaukat, S
Sharif, S
Asghar, H
Hadler, SC
AF Simpson, Diane M.
Sadr-Azodi, Nahad
Mashal, Taufiq
Sabawoon, Wrishmeen
Pardis, Ajmal
Quddus, Arshad
Garrigos, Carmen
Guirguis, Sherine
Zaidi, Syed Sohail Zahoor
Shaukat, Shahzad
Sharif, Salmaan
Asghar, Humayan
Hadler, Stephen C.
TI Polio Eradication Initiative in Afghanistan, 1997-2013
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio; disease eradication; Afghanistan; epidemiology; strategies
ID PROGRESS
AB Background. This article reviews the epidemiology of polio, acute flaccid paralysis (AFP) surveillance, and the implementation of supplemental immunization activities (SIAs) in Afghanistan from 1997 thru 2013.
Methods.aEuro integral Published reports and unpublished national data on polio cases, AFP surveillance, and SIAs were analyzed. Recommendations from independent advisory groups and Afghan government informed the conclusions.
Results.aEuro integral From 1997 thru 2013, the annual number of confirmed polio cases fluctuated from a low of 4 in 2004 to a high of 80 in 2011. Wild poliovirus types 2 and 3 were last reported in 1997 and 2010, respectively. Circulating vaccine-derived poliovirus type 2 emerged in 2009. AFP surveillance quality in children aged < 15 years improved over time, achieving rates > 8 per 100 000 population. Since 2001, at least 6 SIAs have been conducted annually.
Conclusions.aEuro integral Afghanistan has made progress moving closer to eliminating polio. The program struggles to reach all children because of management and accountability problems in the field, inaccessible populations, and inadequate social mobilization. Consequently, too many children are missed during SIAs. Afghanistan adopted a national emergency action plan in 2012 to address these issues, but national elimination will require consistent and complete implementation of proven strategies.
C1 [Simpson, Diane M.; Sadr-Azodi, Nahad] Ctr Dis Control & Prevent, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA.
[Mashal, Taufiq] Afghanistan Minist Publ Hlth, Directorate Gen Prevent Med, Kabul, Afghanistan.
[Sabawoon, Wrishmeen] Off Minist Advising President Hlth & Educ Affairs, Kabul, Afghanistan.
[Sabawoon, Wrishmeen] Natl Focal Point Polio Eradicat, Kabul, Afghanistan.
[Pardis, Ajmal] Ctr Dis Control & Prevent, Kabul, Afghanistan.
[Quddus, Arshad] WHO, Polio Eradicat Unit, Kabul, Afghanistan.
[Garrigos, Carmen] United Nations Childrens Fund, Polio Eradicat Unit, Kabul, Afghanistan.
[Guirguis, Sherine] United Nations Childrens Fund, Commun Program, New York, NY USA.
[Zaidi, Syed Sohail Zahoor; Shaukat, Shahzad; Sharif, Salmaan] Pakistan Polio Reg Reference Lab, Islamabad, Pakistan.
[Asghar, Humayan] WHO, Reg Off Eastern Mediterranean, Cairo, Egypt.
[Hadler, Stephen C.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Simpson, DM (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Global Immunizat Div, 1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM dms3@cdc.gov
FU Rotary International; Bill & Melinda Gates Foundation; Australian
Government Overseas Aid Program; Canadian International Development
Agency; Japan International Cooperation Agency; US Agency for
International Development; US Department of Health and Human Services;
CDC; World Bank
FX Donor organizations that have funded PEI activities in Afghanistan
include Rotary International, the Bill & Melinda Gates Foundation,
Australian Government Overseas Aid Program, Canadian International
Development Agency, Japan International Cooperation Agency, US Agency
for International Development, US Department of Health and Human
Services, CDC, and World Bank.
NR 24
TC 3
Z9 3
U1 1
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S162
EP S172
DI 10.1093/infdis/jiu022
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400020
PM 25316832
ER
PT J
AU Wahjuhono, G
Revolusiana
Widhiastuti, D
Sundoro, J
Mardani, T
Ratih, WU
Sutomo, R
Safitri, I
Sampurno, OD
Rana, B
Roivainen, M
Kahn, AL
Mach, O
Pallansch, MA
Sutter, RW
AF Wahjuhono, Gendro
Revolusiana
Widhiastuti, Dyah
Sundoro, Julitasari
Mardani, Tri
Ratih, Woro Umi
Sutomo, Retno
Safitri, Ida
Sampurno, Ondri Dwi
Rana, Bardan
Roivainen, Merja
Kahn, Anna-Lea
Mach, Ondrej
Pallansch, Mark A.
Sutter, Roland W.
TI Switch From Oral to Inactivated Poliovirus Vaccine in Yogyakarta
Province, Indonesia: Summary of Coverage, Immunity, and Environmental
Surveillance
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio; immunization; poliovirus circulation
ID IMMUNIZATION SCHEDULE; ERADICATION
AB Background. Inactivated poliovirus vaccine (IPV) is rarely used in tropical developing countries. To generate additional scientific information, especially on the possible emergence of vaccine-derived polioviruses (VDPVs) in an IPV-only environment, we initiated an IPV introduction project in Yogyakarta, an Indonesian province. In this report, we present the coverage, immunity, and VDPV surveillance results.
Methods.aEuro integral In Yogyakarta, we established environmental surveillance starting in 2004; and conducted routine immunization coverage and seroprevalence surveys before and after a September 2007 switch from oral poliovirus vaccine (OPV) to IPV, using standard coverage and serosurvey methods. Rates and types of polioviruses found in sewage samples were analyzed, and all poliovirus isolates after the switch were sequenced.
Results.aEuro integral Vaccination coverage (> 95%) and immunity (approximately 100%) did not change substantially before and after the IPV switch. No VDPVs were detected. Before the switch, 58% of environmental samples contained Sabin poliovirus; starting 6 weeks after the switch, Sabin polioviruses were rarely isolated, and if they were, genetic sequencing suggested recent introductions.
Conclusions.aEuro integral This project demonstrated that under almost ideal conditions (good hygiene, maintenance of universally high IPV coverage, and corresponding high immunity against polioviruses), no emergence and circulation of VDPV could be detected in a tropical developing country setting.
C1 [Wahjuhono, Gendro] Natl Inst Hlth & Res Dev, Jakarta, Indonesia.
[Sundoro, Julitasari; Sampurno, Ondri Dwi] Minist Hlth, Jakarta, Indonesia.
[Rana, Bardan] WHO, Country Off, Jakarta, Indonesia.
[Revolusiana; Mardani, Tri] Gadjah Mada Univ, Fac Med, Yogyakarta Prov Hlth Off, Yogyakarta, Indonesia.
[Ratih, Woro Umi] Gadjah Mada Univ, Fac Med, Prov Hlth Lab, Yogyakarta, Indonesia.
[Sutomo, Retno; Safitri, Ida] Gadjah Mada Univ, Fac Med, Dept Child Hlth, Yogyakarta, Indonesia.
[Widhiastuti, Dyah] Natl Polio Lab Biofarma, Bandung, Indonesia.
[Roivainen, Merja] Natl Inst Hlth & Welf, Helsinki, Finland.
[Kahn, Anna-Lea; Mach, Ondrej; Sutter, Roland W.] WHO, CH-1211 Geneva 27, Switzerland.
[Pallansch, Mark A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Mach, O (reprint author), WHO, Ave Appia 20, CH-1211 Geneva 27, Switzerland.
EM macho@who.int
FU Centers for Disease Control and Prevention; World Health Organization
FX Funding for the demonstration project was provided by the Centers for
Disease Control and Prevention and the World Health Organization.
NR 18
TC 6
Z9 6
U1 2
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S347
EP S352
DI 10.1093/infdis/jiu060
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400041
PM 25316854
ER
PT J
AU Walker, AT
Sodha, S
Warren, WC
Sergon, K
Kiptoon, S
Ogange, J
Ahmeda, AH
Eshetu, M
Corkum, M
Pillai, S
Scobie, H
Mdodo, R
Tack, DM
Halldin, C
Appelgren, K
Kretsinger, K
Bensyl, DM
Njeru, I
Kolongei, T
Muigai, J
Ismail, A
Okiror, SO
AF Walker, Allison Taylor
Sodha, Samir
Warren, Wick C.
Sergon, Kibet
Kiptoon, Shem
Ogange, John
Ahmeda, Abdi Hassan
Eshetu, Messeret
Corkum, Melissa
Pillai, Satish
Scobie, Heather
Mdodo, Rennatus
Tack, Danielle M.
Halldin, Cara
Appelgren, Kristie
Kretsinger, Katrina
Bensyl, Diana M.
Njeru, Ian
Kolongei, Titus
Muigai, Juliet
Ismail, Amina
Okiror, Samuel O.
TI Forewarning of Poliovirus Outbreaks in the Horn of Africa: An Assessment
of Acute Flaccid Paralysis Surveillance and Routine Immunization Systems
in Kenya
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE decentralization; polio; program review; routine immunization;
surveillance
AB Background. Although the Horn of Africa region has successfully eliminated endemic poliovirus circulation, it remains at risk for reintroduction. International partners assisted Kenya in identifying gaps in the polio surveillance and routine immunization programs, and provided recommendations for improved surveillance and routine immunization during the health system decentralization process.
Methods.aEuro integral Structured questionnaires collected information about acute flaccid paralysis (AFP) surveillance resources, training, data monitoring, and supervision at provincial, district, and health facility levels. The routine immunization program information collected included questions about vaccine and resource availability, cold chain, logistics, health-care services and access, outreach coverage data, microplanning, and management and monitoring of AFP surveillance.
Results.aEuro integral Although AFP surveillance met national performance standards, widespread deficiencies and limited resources were observed and reported at all levels. Deficiencies were related to provider knowledge, funding, training, and supervision, and were particularly evident at the health facility level.
Conclusions.aEuro integral Gap analysis assists in maximizing resources and capacity building in countries where surveillance and routine immunization lag behind other health priorities. Limited resources for surveillance and routine immunization systems in the region indicate a risk for additional outbreaks of wild poliovirus and other vaccine-preventable illnesses. Monitoring and evaluation of program strengthening activities are needed.
C1 [Walker, Allison Taylor; Sodha, Samir; Warren, Wick C.; Pillai, Satish; Scobie, Heather; Mdodo, Rennatus; Tack, Danielle M.; Halldin, Cara; Appelgren, Kristie; Kretsinger, Katrina; Bensyl, Diana M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Sergon, Kibet; Kiptoon, Shem; Ogange, John; Ahmeda, Abdi Hassan] WHO, Kenya Country Off, Nairobi, Kenya.
[Corkum, Melissa] UNICEF Reg Off, Nairobi, Kenya.
[Njeru, Ian; Kolongei, Titus; Muigai, Juliet; Ismail, Amina] Minist Publ Hlth & Sanitat, Nairobi, Kenya.
[Eshetu, Messeret; Okiror, Samuel O.] WHO, Intercountry Support Team, East & Cent Africa, Nairobi, Kenya.
RP Walker, AT (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A38, Atlanta, GA 30333 USA.
EM ATWalker@cdc.gov
FU Centers for Disease Control and Prevention
FX This article is part of a supplement entitled "The Final Phase of Polio
Eradication and Endgame Strategies for the Post-Eradication Era," which
was sponsored by the Centers for Disease Control and Prevention.
NR 6
TC 2
Z9 2
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S85
EP S90
DI 10.1093/infdis/jiu149
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400009
PM 25316880
ER
PT J
AU Wallace, AS
Ryman, TK
Dietz, V
AF Wallace, Aaron S.
Ryman, Tove K.
Dietz, Vance
TI Overview of Global, Regional, and National Routine Vaccination Coverage
Trends and Growth Patterns From 1980 to 2009: Implications for
Vaccine-Preventable Disease Eradication and Elimination Initiatives
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE vaccination; coverage; Polio; DTP3; routine
ID IMMUNIZATION PROGRAMS; PROGRESS; COUNTRIES; SERVICES; AFRICA
AB Background. Review of the historical growth in annual vaccination coverage across countries and regions can better inform decision makers' development of future goals and strategies to improve routine vaccination services.
Methods.aEuro integral Using the World Health Organization (WHO) and the United Nations Children's Fund estimates of annual national third dose of diphtheria-tetanus-pertussis-containing vaccine (DTP3) and third dose of polio vaccine (POL3) coverage for 1980-2009, we calculated the mean absolute annual rate of change in national DTP3 coverage among all countries (globally) and among countries within each WHO region, as well as the number of years taken by each region to reach specific regional coverage levels. Last, we assessed differences in mean absolute annual rate of change in DTP3 coverage, stratified by baseline level of DTP3 coverage.
Results.aEuro integral During the 1980s, global DTP3 coverage increased a mean of 5.3 percentage points/year. Annual rate of change decreased to 0.5 percentage points/year in the 1990s and then increased to 0.9 percentage points/year during the 2000s. Mean annual rate of change in coverage across all countries was highest (9.2 percentage points) when national coverage levels were 26%-30% and lowest (-0.9 percentage points) when national coverage levels were 96%-100%. Regional differences existed as both WHO South-East Asia Region and WHO African Region countries experienced mean negative DTP3 coverage growth at lower coverage levels (81%-85%) than other regions. The regions that have achieved 95% DTP3 coverage (Americas, Western Pacific, and European) took 25-29 years to reach that level from a level of 50% DTP3 coverage. POL3 coverage change trends were similar to described DTP3 coverage change trends.
Conclusions.aEuro integral Mean national coverage growth patterns across all regions are nonlinear as coverage levels increase. Saturation points of mean 0 percentage-point growth in annual coverage varies by region and require further investigation. The achievement of > 90% routine coverage is observed to take decades, which has implications for disease eradication and elimination initiatives.
C1 [Wallace, Aaron S.; Ryman, Tove K.; Dietz, Vance] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Wallace, AS (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS-E05, Atlanta, GA 30333 USA.
EM awallace@cdc.gov
FU Centers for Disease Control and Prevention
FX This work was supported by the Centers for Disease Control and
Prevention.
NR 23
TC 2
Z9 2
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S514
EP S522
DI 10.1093/infdis/jiu108
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400061
PM 25316875
ER
PT J
AU Wassilak, SGF
Oberste, MS
Tangermann, RH
Diop, OM
Jafari, HS
Armstrong, GL
AF Wassilak, Steven G. F.
Oberste, M. Steven
Tangermann, Rudolph H.
Diop, Ousmane M.
Jafari, Hamid S.
Armstrong, Gregory L.
TI Progress Toward Global Interruption of Wild Poliovirus Transmission,
2010-2013, and Tackling the Challenges to Complete Eradication
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio; surveillance; outbreak control; eradication; international health
regulations
ID POLIOMYELITIS SURVEILLANCE; VACCINE; TYPE-1; WORLDWIDE; NEWBORNS;
OUTBREAK; NIGERIA; TRIAL; INDIA
AB Despite substantial progress, global polio eradication has remained elusive. Indigenous wild poliovirus (WPV) transmission in 4 endemic countries (Afghanistan, India, Nigeria, and Pakistan) persisted into 2010 and outbreaks from imported WPV continued. By 2013, most outbreaks in the interim were promptly controlled. The number of polio-affected districts globally has declined by 74% (from 481 in 2009 to 126 in 2013), including a 79% decrease in the number of affected districts in endemic countries (from 304 to 63). India is now polio-free. The challenges to success in the remaining polio-endemic countries include (1) threats to the security of vaccinators in each country and a ban on polio vaccination in areas of Afghanistan and Pakistan; (2) a risk of decreased government commitment; and (3) remaining surveillance gaps. Coordinated efforts under the International Health Regulations and efforts to mitigate the challenges provide a clear opportunity to soon secure global eradication.
C1 [Wassilak, Steven G. F.; Oberste, M. Steven; Armstrong, Gregory L.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Tangermann, Rudolph H.; Diop, Ousmane M.; Jafari, Hamid S.] WHO, CH-1211 Geneva, Switzerland.
RP Wassilak, SGF (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS A04, Atlanta, GA 30333 USA.
EM swassilak@cdc.gov
FU CDC; WHO
FX This work was supported by the CDC and WHO.
NR 44
TC 15
Z9 15
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S5
EP S15
DI 10.1093/infdis/jiu456
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400002
PM 25316873
ER
PT J
AU Waziri, NE
Ohuabunwo, CJ
Nguku, PM
Ogbuanu, IU
Gidado, S
Biya, O
Wiesen, ES
Vertefeuille, J
Townes, D
Oyemakinde, A
Nwanyanwu, O
Gassasira, A
Mkanda, P
Muhammad, AJG
Elmousaad, HA
Nasidi, A
Mahoney, FJ
AF Waziri, Ndadilnasiya E.
Ohuabunwo, Chima J.
Nguku, Patrick M.
Ogbuanu, Ikechukwu U.
Gidado, Saheed
Biya, Oladayo
Wiesen, Eric S.
Vertefeuille, John
Townes, Debra
Oyemakinde, Akin
Nwanyanwu, Okey
Gassasira, Alex
Mkanda, Pascal
Muhammad, Ado J. G.
Elmousaad, Hashim A.
Nasidi, Abdulsalami
Mahoney, Frank J.
TI Polio Eradication in Nigeria and the Role of the National Stop
Transmission of Polio Program, 2012-2013
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE national stop transmission of polio; global polio eradication
initiative; routine immunization; supplemental immunization activity;
Nigeria
ID VACCINATION
AB To strengthen the Nigeria polio eradication program at the operational level, the National Stop Transmission of Polio (N-STOP) program was established in July 2012 as a collaborative effort of the National Primary Health Care Development Agency, the Nigerian Field Epidemiology and Laboratory Training Program, and the US Centers for Disease Control and Prevention. Since its inception, N-STOP has recruited and trained 125 full-time staff, 50 residents in training, and 50 ad hoc officers. N-STOP officers, working at national, state, and district levels, have conducted enumeration outreaches in 46 437 nomadic and hard-to-reach settlements in 253 districts of 19 states, supported supplementary immunization activities in 236 districts, and strengthened routine immunization in 100 districts. Officers have also conducted surveillance assessments, outbreak response, and applied research as needs evolved. The N-STOP program has successfully enhanced Global Polio Eradication Initiative partnerships and outreach in Nigeria, providing an accessible, flexible, and culturally competent technical workforce at the front lines of public health. N-STOP will continue to respond to polio eradication program needs and remain a model for other healthcare initiatives in Nigeria and elsewhere.
C1 [Waziri, Ndadilnasiya E.; Ohuabunwo, Chima J.; Nguku, Patrick M.; Gidado, Saheed; Biya, Oladayo; Elmousaad, Hashim A.] African Field Epidemiol Network, Kampala, Uganda.
[Ogbuanu, Ikechukwu U.; Wiesen, Eric S.; Vertefeuille, John; Townes, Debra; Mahoney, Frank J.] Ctr Dis Control & Prevent CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA.
[Oyemakinde, Akin] Fed Minist Hlth, Abuja, Nigeria.
[Nwanyanwu, Okey] CDC Nigeria, Abuja, Nigeria.
[Mkanda, Pascal] World Hlth Org Country Off, Abuja, Nigeria.
[Muhammad, Ado J. G.] Nigeria Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria.
[Nasidi, Abdulsalami] Nigeria Ctr Dis Control, Abuja, Nigeria.
RP Ogbuanu, IU (reprint author), Ctr Dis Control & Prevent, CDC Polio Response, Global Immunizat Div, 1600 Clifton Rd NE,MS A04, Atlanta, GA 30333 USA.
EM ige2@cdc.gov
FU Centers for Disease Control and Prevention
FX This work was supported by the Centers for Disease Control and
Prevention.
NR 12
TC 2
Z9 2
U1 0
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S111
EP S117
DI 10.1093/infdis/jiu199
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400013
PM 25316824
ER
PT J
AU Yusuf, N
de Wee, R
Foster, N
Watkins, MA
Tiruneh, D
Chauvin, C
Bossarte, R
Mandlhate, C
Jack, A
Gumede, N
Mawela, A
Burns, CC
Pallansch, MA
Allies, T
Rainey, J
Mataruse, N
Nshimirimana, D
AF Yusuf, Nasir
de Wee, Rosalina
Foster, Norbert
Watkins, Margaret A.
Tiruneh, Desta
Chauvin, Claire
Bossarte, Robert
Mandlhate, Custodia
Jack, Abdoulie
Gumede, Nicksy
Mawela, Alfred
Burns, Cara C.
Pallansch, Mark A.
Allies, Tina
Rainey, Jeannette
Mataruse, Noah
Nshimirimana, Deo
TI Outbreak of Type 1 Wild Poliovirus Infection in Adults, Namibia, 2006
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Namibia; poliomyelitis; type 1 wild poliovirus; disease outbreak;
paralysis
ID VACCINE-DERIVED POLIOVIRUS; ALCOHOL SERVING ESTABLISHMENTS; PARALYTIC
POLIOMYELITIS; CAPE-TOWN; RISKS; ERADICATION
AB A paralytic poliomyelitis outbreak occurred in Namibia in 2006, almost exclusively among adults. Nineteen cases were virologically confirmed as due to wild poliovirus type 1 (WPV1), and 26 were classified as polio compatible. Eleven deaths occurred among confirmed and compatible cases (24%). Of the confirmed cases, 97% were aged 15-45 years, 89% were male, and 71% lived in settlement areas in Windhoek. The virus was genetically related to a virus detected in 2005 in Angola, which had been imported earlier from India. The outbreak is likely due to immunity gaps among adults who were inadequately vaccinated during childhood. This outbreak underscores the ongoing risks posed by poliovirus importations, the importance of maintaining strong acute flaccid paralysis surveillance even in adults, and the need to maintain high population immunity to avoid polio outbreaks in the preeradication period and outbreaks due to vaccine-derived polioviruses in the posteradication era.
C1 [Yusuf, Nasir; Jack, Abdoulie; Mataruse, Noah] World Hlth Org WHO Intercountry Program Off, Harare, Zimbabwe.
[de Wee, Rosalina; Foster, Norbert; Allies, Tina] Minist Hlth & Social Serv, Windhoek, Namibia.
[Tiruneh, Desta; Mandlhate, Custodia] WHO Country Off, Windhoek, Namibia.
[Watkins, Margaret A.; Bossarte, Robert; Rainey, Jeannette] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA.
[Burns, Cara C.; Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Chauvin, Claire] WHO Headquarters, Geneva, Switzerland.
[Gumede, Nicksy; Mawela, Alfred] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Johannesburg, South Africa.
[Nshimirimana, Deo] WHO Reg Off Africa, Brazzaville, Congo.
RP Yusuf, N (reprint author), UNICEF Reg Off East and Southern Africa, POB 44145-00100, Nairobi, Kenya.
EM nayusuf@unicef.org
FU Centers for Disease Control and Prevention
FX This article is part of a supplement entitled "The Final Phase of Polio
Eradication and Endgame Strategies for the Post-Eradication Era," which
was sponsored by the Centers for Disease Control and Prevention.
NR 25
TC 3
Z9 3
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2014
VL 210
SU 1
BP S353
EP S360
DI 10.1093/infdis/jiu069
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0FK
UT WOS:000344612400042
PM 25316855
ER
PT J
AU McAfee, T
Burnette, D
AF McAfee, Tim
Burnette, Deborah
TI The Impact of Smoking on Women's Health
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID LUNG-CANCER INCIDENCE; UNITED-STATES; TRENDS
AB Despite half a century of public health efforts, smoking remains the single largest cause of preventable disease and death in the United States, killing 480,000 people a year and inflicting chronic disease on 16 million. Since the early part of the 20th century, tobacco companies' success in aggressively marketing their products to women has resulted in steady increases in smoking-related disease risk for women. Today, women smokers have caught up with their male counterparts and are just as likely to die from lung cancer, heart disease, and chronic obstructive pulmonary disease (COPD) as are men who smoke. Women's risk for developing smoking-related heart disease or dying from COPD now exceeds men's risk.
C1 [McAfee, Tim; Burnette, Deborah] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30341 USA.
[Burnette, Deborah] ICF Int, Atlanta, GA USA.
RP Burnette, D (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, 4770 Buford Highway NE,MS F-79, Atlanta, GA 30341 USA.
EM iqj8@cdc.gov
NR 11
TC 3
Z9 3
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD NOV 1
PY 2014
VL 23
IS 11
BP 881
EP 885
DI 10.1089/jwh.2014.4983
PG 5
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA AT3XO
UT WOS:000344868200001
PM 25260011
ER
PT J
AU Divi, RL
Lindeman, TLE
Shockley, ME
Keshava, C
Weston, A
Poirier, MC
AF Divi, Rao L.
Lindeman, Tracey L. Einem
Shockley, Marie E.
Keshava, Channa
Weston, Ainsley
Poirier, Miriam C.
TI Correlation between CYP1A1 transcript, protein level, enzyme activity
and DNA adduct formation in normal human mammary epithelial cell strains
exposed to benzo[a]pyrene
SO MUTAGENESIS
LA English
DT Article
ID FED COAL-TAR; BREAST-CANCER; DIOL-EPOXIDE; P450 REDUCTASE;
DT-DIAPHORASE; EROD ACTIVITY; RISK; MICE; CYTOCHROME-P450; BIOMARKERS
AB The polycyclic aromatic hydrocarbon (PAH) benzo(a)pyrene (BP) is thought to bind covalently to DNA, through metabolism by cytochrome P450 1A1 (CYP1A1) and CYP1B1, and other enzymes, to form r7, t8, t9-trihydroxy-c-10-(N (2) -deoxyguanosyl)-7,8,9,10-tetrahydro-benzo[a]-pyrene (BPdG). Evaluation of RNA expression data, to understand the contribution of different metabolic enzymes to BPdG formation, is typically presented as fold-change observed upon BP exposure, leaving the actual number of RNA transcripts unknown. Here, we have quantified RNA copies/ng cDNA (RNA cpn) for CYP1A1 and CYP1B1, as well as NAD(P)H:quinone oxidoreductase 1 (NQO1), which may reduce formation of BPdG adducts, using primary normal human mammary epithelial cell (NHMEC) strains, and the MCF-7 breast cancer cell line. In unexposed NHMECs, basal RNA cpn values were 58-836 for CYP1A1, 336-5587 for CYP1B1 and 5943-40112 for NQO1. In cells exposed to 4.0 A mu M BP for 12h, RNA cpn values were 251-13234 for CYP1A1, 4133-57078 for CYP1B1 and 4456-55887 for NQO1. There were 3.5 (mean, range 0.2-15.8) BPdG adducts/10(8) nucleotides in the NHMECs (n = 16), and 790 in the MCF-7s. In the NHMECs, BP-induced CYP1A1 RNA cpn was highly associated with BPdG (P = 0.002), but CYP1B1 and NQO1 were not. Western blots of four NHMEC strains, chosen for different levels of BPdG adducts, showed a linear correlation between BPdG and CYP1A1, but not CYP1B1 or NQO1. Ethoxyresorufin-O-deethylase (EROD) activity, which measures CYP1A1 and CYP1B1 together, correlated with BPdG, but NQO1 activity did not. Despite more numerous levels of CYP1B1 and NQO1 RNA cpn in unexposed and BP-exposed NHMECs and MCF-7cells, BPdG formation was only correlated with induction of CYP1A1 RNA cpn. The higher level of BPdG in MCF-7 cells, compared to NHMECs, may have been due to a much increased induction of CYP1A1 and EROD. Overall, BPdG correlation was observed with CYP1A1 protein and CYP1A1/1B1 enzyme activity, but not with CYP1B1 or NQO1 protein, or NQO1 enzyme activity.
C1 [Divi, Rao L.; Lindeman, Tracey L. Einem; Shockley, Marie E.; Poirier, Miriam C.] NCI, Carcinogen DNA Interact Sect, Ctr Canc Res, NIH, Bethesda, MD 20817 USA.
[Keshava, Channa] US EPA, Natl Ctr Environm Assessment, Off Res & Dev, Res Triangle Pk, NC 27711 USA.
[Weston, Ainsley] Ctr Dis Control & Prevent, Div Resp Dis Studies, NIOSH, Morgantown, WV 26505 USA.
RP Poirier, MC (reprint author), NCI, Carcinogen DNA Interact Sect, Ctr Canc Res, NIH, Bethesda, MD 20817 USA.
EM poirierm@exchange.nih.gov
FU Intramural NIH HHS
NR 39
TC 4
Z9 4
U1 3
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0267-8357
EI 1464-3804
J9 MUTAGENESIS
JI Mutagenesis
PD NOV
PY 2014
VL 29
IS 6
BP 409
EP 417
DI 10.1093/mutage/geu049
PG 9
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA AT0KI
UT WOS:000344624700003
PM 25245543
ER
PT J
AU Zhang, L
Vickerman, K
Malarcher, A
Mowery, P
AF Zhang, Lei
Vickerman, Katrina
Malarcher, Ann
Mowery, Paul
TI Intermediate Cessation Outcomes Among Quitline Callers During a National
Tobacco Education Campaign
SO NICOTINE & TOBACCO RESEARCH
LA English
DT Article
ID SMOKING-CESSATION; MEDIA CAMPAIGN; UNITED-STATES; IMPACT; TELEVISION;
CIGARETTE; SMOKERS; ADVERTISEMENTS; INTERVENTIONS; ADULTS
AB From March 19 through June 10, 2012, the Centers for Disease Control and Prevention launched the first federally funded National Tobacco Education Campaign: Tips From Former Smokers (Tips). This study examined the campaign's impact on quitline callers' intermediate cessation outcomes.
We used quitline data from 23 states to examine changes in enrollment, service utilization, quit attempts, and self-reported quitting for 7 days or longer during Tips versus a similar time period in 2011. We used multivariate models to examine the relationship between Tips exposure (measured as gross rating points [GRPs]) and cessation outcomes during the campaign in 2012. We also assessed whether the Tips campaign's impact differed by state tobacco control funding.
Compared with similar weeks in 2011, the number of quitline callers and callers who received counseling and/or nicotine replacement therapies increased by 88.6% (48,738 in 2011 vs. 91,911 during Tips) and 70.8% (40,546 in 2011 vs. 69,254 during Tips), respectively. Greater numbers of callers reported having made 24-hr quit attempts or quitting for 7 days or longer during the campaign. Higher Tips campaign GRPs were positively associated with quit attempts and with quitting for 7 days or longer among persons from states with higher tobacco control funding. In states with lower funding, the highest GRP group (2,000+ GRPs) had lower levels of cessation compared with the middle GRP group (1,200-1,999 GRPs).
An evidence-based national tobacco education campaign with adequate reach and frequency can lead to substantial increases in quitline use and, to a lesser degree, intermediate cessation outcomes.
C1 [Zhang, Lei; Malarcher, Ann] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA.
[Vickerman, Katrina] Alere Wellbeing Inc, Res Training & Evaluat Serv, Seattle, WA USA.
[Mowery, Paul] Biostatistics Inc, Atlanta, GA USA.
RP Zhang, L (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, 4770 Buford Highway NE,Mailstop F-79, Atlanta, GA 30341 USA.
EM lzhang2@cdc.gov
FU Centers for Disease Control and Prevention [200-2012-M-51442]
FX This research was funded by the Centers for Disease Control and
Prevention (200-2012-M-51442).
NR 34
TC 7
Z9 7
U1 2
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-2203
EI 1469-994X
J9 NICOTINE TOB RES
JI Nicotine Tob. Res.
PD NOV
PY 2014
VL 16
IS 11
BP 1478
EP 1486
DI 10.1093/ntr/ntu105
PG 9
WC Substance Abuse; Public, Environmental & Occupational Health
SC Substance Abuse; Public, Environmental & Occupational Health
GA AT0LO
UT WOS:000344627800009
PM 25006045
ER
PT J
AU Brown-Johnson, CG
England, LJ
Glantz, SA
Ling, PM
AF Brown-Johnson, Cati G.
England, Lucinda J.
Glantz, Stanton A.
Ling, Pamela M.
TI Tobacco industry marketing to low socioeconomic status women in the USA
SO TOBACCO CONTROL
LA English
DT Article
ID YOUNG-ADULTS; SOCIAL-CLASS; SMOKING; GENDER; HEALTH; ASSOCIATION;
DISPARITIES; CIGARETTES; ATTAINMENT; DOCUMENTS
AB Objectives Describe tobacco companies' marketing strategies targeting low socioeconomic status (SES) females in the USA.
Methods Analysis of previously secret tobacco industry documents.
Results Tobacco companies focused marketing on low SES women starting in the late 1970s, including military wives, low-income inner-city minority women, 'discount-susceptible' older female smokers and less-educated young white women. Strategies included distributing discount coupons with food stamps to reach the very poor, discount offers at point-of-sale and via direct mail to keep cigarette prices low, developing new brands for low SES females and promoting luxury images to low SES African-American women. More recently, companies integrated promotional strategies targeting low-income women into marketing plans for established brands.
Conclusions Tobacco companies used numerous marketing strategies to reach low SES females in the USA for at least four decades. Strategies to counteract marketing to low SES women could include (1) counteracting price discounts and direct mail coupons that reduce the price of tobacco products, (2) instituting restrictions on point-of-sale advertising and retail display and (3) creating counteradvertising that builds resistance to psychosocial targeting of low SES women. To achieve health equity, tobacco control efforts are needed to counteract the influence of tobacco industry marketing to low-income women.
C1 [Brown-Johnson, Cati G.; Glantz, Stanton A.; Ling, Pamela M.] Ctr Tobacco Control Res & Educ, San Francisco, CA USA.
[England, Lucinda J.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
[Glantz, Stanton A.] Philip R Lee Inst Hlth Policy Studies, Dept Med, Div Cardiol, San Francisco, CA USA.
[Ling, Pamela M.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA.
RP Ling, PM (reprint author), Univ Calif San Francisco, Ctr Tobacco Control Res & Educ, 350 Parnassus Ave,Suite 366, San Francisco, CA 94143 USA.
EM pling@medicine.ucsf.edu
FU National Cancer Institute [CA-113710, CA-87472]
FX This research was supported in part by National Cancer Institute Grant
CA-113710 and CA-87472.
NR 72
TC 12
Z9 12
U1 1
U2 13
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-4563
EI 1468-3318
J9 TOB CONTROL
JI Tob. Control
PD NOV
PY 2014
VL 23
IS E2
AR e139
DI 10.1136/tobaccocontrol-2013-051224
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT2DX
UT WOS:000344742900010
PM 24449249
ER
PT J
AU Wendt, JM
Kaul, D
Limbago, BM
Ramesh, M
Cohle, S
Denison, AM
Driebe, EM
Rasheed, JK
Zaki, SR
Blau, DM
Paddock, CD
McDougal, LK
Engelthaler, DM
Keim, PS
Roe, CC
Akselrod, H
Kuehnert, MJ
Basavaraju, SV
AF Wendt, J. M.
Kaul, D.
Limbago, B. M.
Ramesh, M.
Cohle, S.
Denison, A. M.
Driebe, E. M.
Rasheed, J. K.
Zaki, S. R.
Blau, D. M.
Paddock, C. D.
McDougal, L. K.
Engelthaler, D. M.
Keim, P. S.
Roe, C. C.
Akselrod, H.
Kuehnert, M. J.
Basavaraju, S. V.
TI Transmission of Methicillin-Resistant Staphylococcus aureus Infection
Through Solid Organ Transplantation: Confirmation Via Whole Genome
Sequencing
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
ID DONOR-DERIVED INFECTIONS; ENDOCARDITIS; CHILDREN; BACTERIA; DISEASE;
KIDNEY; ADULTS; PCR
AB We describe two cases of donor-derived methicillin-resistant Staphylococcus aureus (MRSA) bacteremia that developed after transplantation of organs from a common donor who died from acute MRSA endocarditis. Both recipients developed recurrent MRSA infection despite appropriate antibiotic therapy, and required prolonged hospitalization and hospital readmission. Comparison of S. aureus whole genome sequence of DNA extracted from fixed donor tissue and recipients' isolates confirmed donor-derived transmission. Current guidelines emphasize the risk posed by donors with bacteremia from multidrug-resistant organisms. This investigation suggests that, particularly in the setting of donor endocarditis, even a standard course of prophylactic antibiotics may not be sufficient to prevent donor-derived infection.
This manuscript describes two cases of donor-derived methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, confirmed through comparison of S. aureus whole genome sequence of DNA extracted from fixed donor tissue and recipients' isolates, that developed after transplantation of organs from a common donor who died from acute MRSA endocarditis. Also see case report by Altman et al on page .
C1 [Wendt, J. M.; Limbago, B. M.; Denison, A. M.; Rasheed, J. K.; Zaki, S. R.; Blau, D. M.; Paddock, C. D.; McDougal, L. K.; Kuehnert, M. J.; Basavaraju, S. V.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Wendt, J. M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA.
[Kaul, D.] Univ Michigan, Sch Med, Div Infect Dis, Ann Arbor, MI USA.
[Ramesh, M.] Henry Ford Hlth Syst, Detroit, MI USA.
[Cohle, S.] Kent Cty Off Med Examiner, Grand Rapids, MI USA.
[Driebe, E. M.; Engelthaler, D. M.; Keim, P. S.; Roe, C. C.] TGen North, Translat Genom Res Inst, Flagstaff, AZ USA.
[Akselrod, H.] Mt Sinai Sch Med, New York, NY USA.
RP Basavaraju, SV (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM SBasavaraju@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 25
TC 7
Z9 7
U1 2
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD NOV
PY 2014
VL 14
IS 11
BP 2633
EP 2639
DI 10.1111/ajt.12898
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AS3LH
UT WOS:000344178800024
PM 25250717
ER
PT J
AU Midgley, CM
Jackson, MA
Selvarangan, R
Turabelidze, G
Obringer, E
Johnson, D
Giles, BL
Patel, A
Echols, F
Oberste, MS
Nix, WA
Watson, JT
Gerber, SI
AF Midgley, Claire M.
Jackson, Mary Anne
Selvarangan, Rangaraj
Turabelidze, George
Obringer, Emily
Johnson, Daniel
Giles, B. Louise
Patel, Ajanta
Echols, Fredrick
Oberste, M. Steven
Nix, W. Allan
Watson, John T.
Gerber, Susan I.
TI Severe Respiratory Illness Associated With Enterovirus D68-Missouri and
Illinois, 2014 (Reprinted from MMWR, vol 14, pg 798-799, 2014)
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Reprint
AB This report details an increase in cases of enterovirus D68, a cause of severe respiratory illness most commonly found in children, and one that should be considered as potentially problematic in donors or recipients.
C1 [Midgley, Claire M.] CDC, Epidem Intelligence Serv, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Midgley, Claire M.; Oberste, M. Steven; Nix, W. Allan; Watson, John T.; Gerber, Susan I.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Jackson, Mary Anne] Childrens Mercy Hosp, Dept Infect Dis, Kansas City, MO 64108 USA.
[Selvarangan, Rangaraj] Childrens Mercy Hosp, Dept Pathol & Lab Med, Kansas City, MO 64108 USA.
[Turabelidze, George] Missouri Dept Hlth & Senior Serv, Jefferson City, MO USA.
[Obringer, Emily; Johnson, Daniel; Giles, B. Louise; Patel, Ajanta] Univ Chicago Med, Chicago, IL USA.
[Echols, Fredrick] Illinois Dept Publ Hlth, Springfield, IL 62761 USA.
RP Midgley, CM (reprint author), CDC, Epidem Intelligence Serv, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM cmidgley@cdc.gov
NR 4
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD NOV
PY 2014
VL 14
IS 11
BP 2662
EP 2663
DI 10.1111/ajt.13035
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AS3LH
UT WOS:000344178800029
ER
PT J
AU Ranieri, N
Tabernero, P
Green, MD
Verbois, L
Herrington, J
Sampson, E
Satzger, RD
Phonlavong, C
Thao, K
Newton, PN
Witkowski, MR
AF Ranieri, Nicola
Tabernero, Patricia
Green, Michael D.
Verbois, Leigh
Herrington, James
Sampson, Eric
Satzger, R. Duane
Phonlavong, Chindaphone
Thao, Khamxay
Newton, Paul N.
Witkowski, Mark R.
TI Evaluation of a New Handheld Instrument for the Detection of Counterfeit
Artesunate by Visual Fluorescence Comparison
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID OFFSET RAMAN-SPECTROSCOPY; ANTIMALARIAL TABLETS; FAKE ARTESUNATE;
SOUTHEAST-ASIA; DRUGS; QUALITY; AUTHENTICATION; MEDICINES; CAMBODIA;
AFRICA
AB There is an urgent need for accurate and inexpensive handheld instruments for the evaluation of medicine quality in the field. A blinded evaluation of the diagnostic accuracy of the Counterfeit Detection Device 3 (CD-3), developed by the US Food and Drug Administration Forensic Chemistry Center, was conducted in the Lao People's Democratic Republic. Two hundred three samples of the oral antimalarial artesunate were compared with authentic products using the CD-3 by a trainer and two trainees. The specificity (95% confidence interval [95% CI]), sensitivity (95% CI), positive predictive value (95% CI), and negative predictive value (95% CI) of the CD-3 for detecting counterfeit (falsified) artesunate were 100% (93.8-100%), 98.4% (93.8-99.7%), 100% (96.2-100%), and 97.4% (90.2-99.6%), respectively. Interobserver agreement for 203 samples of artesunate was 100%. The CD-3 holds promise as a relatively inexpensive and easy to use instrument for field evaluation of medicines, potentially empowering drug inspectors, customs agents, and pharmacists.
C1 [Ranieri, Nicola; Satzger, R. Duane; Witkowski, Mark R.] US FDA, Forens Chem Ctr, Cincinnati, OH 45237 USA.
[Tabernero, Patricia; Newton, Paul N.] Mahosot Hosp, Microbiol Lab, Lao Oxford Mahosot Hosp Wellcome Trust Res Unit L, Viangchan, Laos.
[Tabernero, Patricia; Newton, Paul N.] Univ Oxford, Nuffield Dept Clin Med, Worldwide Antimalarial Resistance Network WWARN, Oxford, England.
[Tabernero, Patricia; Newton, Paul N.] Univ Oxford, Churchill Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England.
[Green, Michael D.; Sampson, Eric] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA.
[Verbois, Leigh; Sampson, Eric] US FDA, Off Int Programs, Off Global Regulatory Operat & Policy, Silver Spring, MD USA.
[Herrington, James] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
[Phonlavong, Chindaphone] Govt Lao Peoples Democrat Republ, BIDI, Minist Hlth, Viangchan, Laos.
[Thao, Khamxay] Govern Lao PDR, FDQCC, Minist Hlth, Viangchan, Laos.
RP Ranieri, N (reprint author), US FDA, Forens Chem Ctr, 6751 Steger Dr, Cincinnati, OH 45237 USA.
EM Nicola.Ranieri@fda.hhs.gov; Patricia.Tabernero@wwarn.org; mdg4@CDC.GOV;
Leigh.Verbois@fda.hhs.gov; James.Herrington@nih.gov; ejs1@verizon.net;
RD.Satzger@fda.hhs.gov; bfdi_chindaphone@yahoo.com;
kham_xay@hotmail.com; paul@tropmedres.ac; Mark.Witkowski@fda.hhs.gov
FU US Food and Drug Administration; Wellcome Trust of Great Britain;
Institut de Recherche sur l'Asie du Sud-Est Contemporaine through French
Ministry of Foreign and European Affairs (FSP [Fonds de Solidarite
Prioritaire] Mekong Project); Bill and Melinda Gates Foundation
FX This work was supported by the US Food and Drug Administration and the
Wellcome Trust of Great Britain. The Antimalarial Quality Scientific
Group of the Worldwide Antimalarial Resistance Network is supported by
the Institut de Recherche sur l'Asie du Sud-Est Contemporaine through
funding from the French Ministry of Foreign and European Affairs (FSP
[Fonds de Solidarite Prioritaire] Mekong Project) and the Bill and
Melinda Gates Foundation.
NR 29
TC 9
Z9 9
U1 3
U2 20
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2014
VL 91
IS 5
BP 920
EP 924
DI 10.4269/ajtmh.13-0644
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AS7PO
UT WOS:000344447800013
PM 25266348
ER
PT J
AU Omedo, M
Ogutu, M
Awiti, A
Musuva, R
Muchiri, G
Montgomery, SP
Secor, WE
Mwinzi, P
AF Omedo, Martin
Ogutu, Michael
Awiti, Alphonce
Musuva, Rosemary
Muchiri, Geoffrey
Montgomery, Susan P.
Secor, W. Evan
Mwinzi, Pauline
TI The Effect of a Health Communication Campaign on Compliance with Mass
Drug Administration for Schistosomiasis Control in Western Kenya - The
SCORE Project
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID NEGLECTED TROPICAL DISEASES; SOIL-TRANSMITTED HELMINTHS; LYMPHATIC
FILARIASIS; QUALITATIVE RESEARCH; PHYSICAL-ACTIVITY; MEDIA CAMPAIGNS;
BOTTOM BILLION; IMPACT; CHILDREN; UGANDA
AB Compliance with mass drug administration (MDA) can be affected by rumors and mistrust about the drug. Communication campaigns are an effective way to influence attitudes and health behaviors in diverse public health contexts, but there is very little documentation about experiences using health communications in schistosomiasis control programs. A qualitative study was conducted with community health workers (CHWs) as informants to explore the effect of a health communication campaign on their experiences during subsequent praziquantel MDA for schistosomiasis. Discussions were audio-recorded, transcribed verbatim, translated into English where applicable, and analyzed thematically using ATLAS.ti software. According to the CHWs, exposure to mass media messages improved awareness of the MDA, which in turn, led to better treatment compliance. Our findings suggest that communication campaigns influence health behaviors and create awareness of schistosomiasis control interventions, which may ultimately improve praziquantel MDA.
C1 [Omedo, Martin; Ogutu, Michael; Awiti, Alphonce; Musuva, Rosemary; Muchiri, Geoffrey; Mwinzi, Pauline] Kenya Med Res Inst KEMRI, Ctr Global Hlth Res, Neglected Trop Dis Unit, Kisumu, Kenya.
[Montgomery, Susan P.; Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30341 USA.
RP Secor, WE (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd, Atlanta, GA 30341 USA.
EM Momedo@kemricdc.org; michaelogutu06@yahoo.com; aawiti@kemricdc.org;
RMusuva@kemricdc.org; geoffmosh@yahoo.com; zqu6@cdc.gov; was4@cdc.gov;
PMwinzi@kemricdc.org
FU University of Georgia Research Foundation, Inc. - Bill and Melinda Gates
Foundation
FX This study was made possible by generous support from the University of
Georgia Research Foundation, Inc., which is funded by the Bill and
Melinda Gates Foundation for this Schistosomiasis Consortium for
Operational Research and Evaluation (SCORE) project.
NR 48
TC 4
Z9 4
U1 1
U2 9
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2014
VL 91
IS 5
BP 982
EP 988
DI 10.4269/ajtmh.14-0136
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AS7PO
UT WOS:000344447800021
PM 25246690
ER
PT J
AU Russell, ES
Gray, EB
Marshall, RE
Davis, S
Beaudoin, A
Handali, S
McAuliffe, I
Davis, C
Woodhall, D
AF Russell, Elizabeth S.
Gray, Elizabeth B.
Marshall, Rebekah E.
Davis, Stephanie
Beaudoin, Amanda
Handali, Sukwan
McAuliffe, Isabel
Davis, Cheryl
Woodhall, Dana
TI Short Report: Prevalence of Strongyloides stercoralis Antibodies among a
Rural Appalachian Population - Kentucky, 2013
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID UNITED-STATES; EPIDEMIOLOGIC FEATURES; HELMINTH INFECTIONS; HOOKWORM;
CHILDREN
AB We investigated whether Strongyloides infection remains endemic in rural Kentucky's Appalachian regions; 7 of 378 (1.9%) participants tested positive for Strongyloides antibodies. We identified no statistically significant association between a positive test and travel to a known endemic country (P = 0.58), indicating that transmission in rural Kentucky might be ongoing.
C1 [Russell, Elizabeth S.] Kentucky Dept Publ Hlth, Frankfort, KY USA.
[Russell, Elizabeth S.; Gray, Elizabeth B.; Beaudoin, Amanda] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Gray, Elizabeth B.; Marshall, Rebekah E.; Davis, Stephanie; Handali, Sukwan; McAuliffe, Isabel; Woodhall, Dana] Ctr Dis Control & Prevent, Parasit Dis Branch, Atlanta, GA 30333 USA.
[Davis, Cheryl] Western Kentucky Univ, Dept Biol, Bowling Green, KY 42101 USA.
RP Gray, EB (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE MS A06, Atlanta, GA 30333 USA.
EM wjv4@cdc.gov; EBGray@cdc.gov; RMarshall@cdc.gov; vic6@cdc.gov;
ABeaudoin@cdc.gov; Shandali@cdc.gov; IMcAuliffe@cdc.gov;
cheryl.davis@wku.edu; DWoodhall@cdc.gov
FU National Institute of General Medical Sciences, National Institutes of
Health [5P20GM103436-13]
FX C.D. acknowledges travel support from an Institutional Development Award
(IDeA) from National Institute of General Medical Sciences, National
Institutes of Health Grant 5P20GM103436-13.
NR 11
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2014
VL 91
IS 5
BP 1000
EP 1001
DI 10.4269/ajtmh.14-0310
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AS7PO
UT WOS:000344447800024
PM 25157122
ER
PT J
AU Davis, SM
Worrell, CM
Wiegand, RE
Odero, KO
Suchdev, PS
Ruth, LJ
Lopez, G
Cosmas, L
Neatherlin, J
Njenga, SM
Montgomery, JM
Fox, LM
AF Davis, Stephanie M.
Worrell, Caitlin M.
Wiegand, Ryan E.
Odero, Kennedy O.
Suchdev, Parminder S.
Ruth, Laird J.
Lopez, Gerard
Cosmas, Leonard
Neatherlin, John
Njenga, Sammy M.
Montgomery, Joel M.
Fox, LeAnne M.
TI Soil-Transmitted Helminths in Pre-School-Aged and School-Aged Children
in an Urban Slum: A Cross-Sectional Study of Prevalence, Distribution,
and Associated Exposures
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID INTESTINAL PARASITIC INFECTION; WESTERN KENYA; PREVENTIVE CHEMOTHERAPY;
PRESCHOOL-CHILDREN; RISK-FACTORS; GROWTH; COINFECTION; GUIDELINES;
KARACHI; ANEMIA
AB Soil-transmitted helminths (STHs) are controlled by regular mass drug administration. Current practice targets school-age children (SAC) preferentially over pre-school age children (PSAC) and treats large areas as having uniform prevalence. We assessed infection prevalence in SAC and PSAC and spatial infection heterogeneity, using a cross-sectional study in two slum villages in Kibera, Nairobi. Nairobi has low reported STH prevalence. The SAC and PSAC were randomly selected from the International Emerging Infections Program's surveillance platform. Data included residence location and three stools tested by Kato-Katz for STHs. Prevalences among 692 analyzable children were any STH: PSAC 40.5%, SAC 40.7%; Ascaris: PSAC 24.1%, SAC 22.7%; Trichuris: PSAC 24.0%, SAC 28.8%; hookworm < 0.1%. The STH infection prevalence ranged from 22% to 71% between sub-village sectors. The PSAC have similar STH prevalences to SAC and should receive deworming. Small areas can contain heterogeneous prevalences; determinants of STH infection should be characterized and slums should be assessed separately in STH mapping.
C1 [Davis, Stephanie M.; Worrell, Caitlin M.; Fox, LeAnne M.] Ctr Dis Control & Prevent, Parasit Dis Branch, Atlanta, GA USA.
[Wiegand, Ryan E.; Lopez, Gerard] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA.
[Odero, Kennedy O.; Cosmas, Leonard; Neatherlin, John; Montgomery, Joel M.] CDC, Nairobi, Kenya.
[Njenga, Sammy M.] Kenya Govt Med Res Ctr, Eastern & Southern Africa Ctr Int Parasite Contro, Nairobi, Kenya.
[Suchdev, Parminder S.; Ruth, Laird J.] US Ctr Dis Control & Prevent, Nutr Branch, Atlanta, GA 30333 USA.
RP Davis, SM (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-04, Atlanta, GA 30333 USA.
EM Vic6@cdc.gov; cworrell@cdc.gov; fwk2@cdc.gov; koderos80@gmail.com;
dvo8@cdc.gov; cqe3@cdc.gov; gerardlopex2001@gmail.com;
lcosmas@ke.cdc.gov; jneatherlin@ke.cdc.gov; SNjenga@kemri.org;
JMontgomery@ke.cdc.gov; lff4@cdc.gov
OI Suchdev, Parmi/0000-0002-0350-3469
FU USAID through Centers for Disease Control and Prevention [OG11-12021];
USAID through the Nutrition Branch at the Centers for Disease Control
and Prevention
FX Funding for this study was obtained from USAID (No. OG11-12021) through
an inter-agency agreement with the Centers for Disease Control and
Prevention and through the Nutrition Branch at the Centers for Disease
Control and Prevention.
NR 52
TC 4
Z9 4
U1 0
U2 5
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2014
VL 91
IS 5
BP 1002
EP 1010
DI 10.4269/ajtmh.14-0060
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AS7PO
UT WOS:000344447800025
PM 25157123
ER
PT J
AU Stoddard, RA
Bui, D
Haberling, DL
Wuthiekanun, V
Thaipadungpanit, J
Hoffmaster, AR
AF Stoddard, Robyn A.
Bui, Duy
Haberling, Dana L.
Wuthiekanun, Vanaporn
Thaipadungpanit, Janjira
Hoffmaster, Alex R.
TI Viability of Leptospira Isolates from a Human Outbreak in Thailand in
Various Water Types, pH, and Temperature Conditions
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID PATHOGENIC LEPTOSPIRA; SURVIVAL; GROWTH
AB Leptospira spp. isolated from patients during a multiyear outbreak in Thailand were genotyped using multilocus sequence typing and a majority were identified as ST34, especially in earlier years. We tested whether ST34 isolates were better adapted to survive in various pH levels, temperatures, and water sources. Motility and growth were monitored over a 12-week period. Early year ST34 isolates did not appear to have a significant fitness advantage over non-ST34, however, this may have been because a majority of the isolates survived to the termination of the study, with the exception being at high temperature (37 degrees C) and/or basic pH (8.65). Failure to detect a significant fitness advantage of ST34 may be a result of the length of the study or the small sample size. Lengthening the study and looking at virulence and maintenance in the host could yield additional information about this outbreak.
C1 [Stoddard, Robyn A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Bui, Duy] CDC, Zoonot & Select Agent Lab, Atlanta, GA 30333 USA.
[Haberling, Dana L.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
[Wuthiekanun, Vanaporn] Mahidol Univ, Fac Trop Med, Wellcome Unit, Bangkok 10700, Thailand.
[Thaipadungpanit, Janjira] Mahidol Univ, Mahidol Oxford Trop Med Res Unit, Bangkok 10700, Thailand.
[Hoffmaster, Alex R.] Ctr Dis Control & Prevent, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA.
RP Stoddard, RA (reprint author), Ctr Dis Control & Prevent, Mailstop G-34, Atlanta, GA 30333 USA.
EM RAStoddard@cdc.gov; dbui85@gmail.com; fnj2@cdc.gov; lek@tropmedres.ac;
janjira@tropmedres.ac; ahoffmaster@cdc.gov
NR 19
TC 0
Z9 0
U1 1
U2 6
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2014
VL 91
IS 5
BP 1020
EP 1022
DI 10.4269/ajtmh.13-0748
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AS7PO
UT WOS:000344447800028
PM 25200260
ER
PT J
AU Nygren, BL
Blackstock, AJ
Mintz, ED
AF Nygren, Benjamin L.
Blackstock, Anna J.
Mintz, Eric D.
TI Cholera at the Crossroads: The Association Between Endemic Cholera and
National Access to Improved Water Sources and Sanitation
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID BURDEN
AB We evaluated World Health Organization (WHO) national water and sanitation coverage levels and the infant mortality rate as predictors of endemic cholera in the 5-year period following water and sanitation coverage estimates using logistic regression, receiver operator characteristic curves, and different definitions of endemicity. Each was a significant predictors of endemic cholera at P < 0.001. Using a value of 250 for annual cases reported in 3 of 5 years, a national water access level of 71% has 65% sensitivity and 65% specificity in predicting endemic cholera, a sanitation access level of 39% has 63% sensitivity and 62% specificity, and an infant mortality rate of 65/1,000 has 67% sensitivity and 69% specificity. Our findings reveal the tradeoff between sensitivity and specificity for these predictors of endemic cholera and highlight the substantial uncertainty in the data. More accurate global surveillance data will enable more precise characterization of the benefits of improved water and sanitation.
C1 [Nygren, Benjamin L.; Blackstock, Anna J.; Mintz, Eric D.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA.
RP Nygren, BL (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C09, Atlanta, GA 30329 USA.
EM bnygren@cdc.gov; hyp9@cdc.gov; emintz@cdc.gov
FU United States Agency for International Development
FX This work was supported in part by the United States Agency for
International Development.
NR 19
TC 1
Z9 1
U1 0
U2 4
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2014
VL 91
IS 5
BP 1023
EP 1028
DI 10.4269/ajtmh.14-0331
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AS7PO
UT WOS:000344447800029
PM 25200265
ER
PT J
AU Maharaj, PD
Bolling, BG
Anishchenko, M
Reisen, WK
Brault, AC
AF Maharaj, Payal D.
Bolling, Bethany G.
Anishchenko, Michael
Reisen, William K.
Brault, Aaron C.
TI Genetic Determinants of Differential Oral Infection Phenotypes of West
Nile and St. Louis Encephalitis Viruses in Culex spp. Mosquitoes
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID CULICIDAE VECTOR COMPETENCE; SAY DIPTERA-CULICIDAE;
PIPIENS-QUINQUEFASCIATUS; AEDES-AEGYPTI; NEW-YORK; VIRAL DISSEMINATION;
ENVELOPE PROTEIN; DISEASE VECTOR; TRANSMISSION; CALIFORNIA
AB St. Louis encephalitis virus (SLEV) has shown greater susceptibility to oral infectivity than West Nile virus (WNV) in Culex mosquitoes. To identify the viral genetic elements that modulate these disparate phenotypes, structural chimeras (WNV-pre-membrane [prM] and envelope [E] proteins [prME]/SLEV.IC (infectious clone) and SLEV-prME/WNV.IC) were constructed in which two of the structural proteins, the prM and E, were interchanged between viruses. Oral dose-response assessment with the chimeric/parental WNV and SLEV was performed to characterize the infection phenotypes in Culex mosquitoes by artificial blood meals. The median infectious dose required to infect 50% of Cx. quinquefasciatus with WNV was indistinguishable from that of the SLEV-prME/WNV.IC chimeric virus. Similarly, SLEV and WNV-prME/SLEV.IC virus exhibited an indistinguishable oral dose-response relationship in Cx. quinquefasciatus. Infection rates for WNV.IC and SLEV-prME/WNV.IC were significantly lower than SLEV.IC and WNV-prME/SLEV.IC infection rates. These results indicated that WNV and SLEV oral infectivities are not mediated by genetic differences within the prM and E proteins.
C1 [Bolling, Bethany G.; Anishchenko, Michael; Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
[Maharaj, Payal D.; Reisen, William K.] Univ Calif Davis, Ctr Vectorborne Dis, Davis, CA 95616 USA.
[Maharaj, Payal D.; Reisen, William K.] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA.
[Bolling, Bethany G.] Univ Texas Med Branch, Galveston, TX 77555 USA.
RP Brault, AC (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA.
EM pamahara@utmb.edu; bethanybolling@gmail.com; iot5@cdc.gov;
wkreisen@ucdavis.edu; abrault@cdc.gov
OI Maharaj, Payal/0000-0002-4157-4479
FU Biomedical Advanced Research Development Authority (BARDA); Pacific
Southwest Regional Center for Excellence Grant [AI065359]; National
Institutes of Health [AI061822, AI55607]; Centers for Disease Control
and Prevention Grant [CI000235]; University of California Mosquito
Research Program
FX Funding for these studies was provided by the Biomedical Advanced
Research Development Authority (BARDA), Pacific Southwest Regional
Center for Excellence Grant AI065359, National Institutes of Health
Grants AI061822 and AI55607, Centers for Disease Control and Prevention
Grant CI000235, and the University of California Mosquito Research
Program.
NR 51
TC 1
Z9 1
U1 1
U2 8
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2014
VL 91
IS 5
BP 1066
EP 1072
DI 10.4269/ajtmh.14-0289
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AS7PO
UT WOS:000344447800035
PM 25157120
ER
PT J
AU Bjornstad, K
Aberg, AT
Kalb, SR
Wang, DX
Barr, JR
Bondesson, U
Hedeland, M
AF Bjornstad, Kristian
Aberg, Annica Tevell
Kalb, Suzanne R.
Wang, Dongxia
Barr, John R.
Bondesson, Ulf
Hedeland, Mikael
TI Validation of the Endopep-MS method for qualitative detection of active
botulinum neurotoxins in human and chicken serum
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE Botulinum neurotoxin; Endopep-MS; Method validation; Botulism;
MALDI-Q-TOF
ID REAL-TIME PCR; CLOSTRIDIUM-BOTULINUM; MASS-SPECTROMETRY; TOXIN
PROTEOMICS; SUBTYPE; IDENTIFICATION; ORGANISMS; PATHOGEN; GENES; MOUSE
AB Botulinum neurotoxins (BoNTs) are highly toxic proteases produced by anaerobic bacteria. Traditionally, a mouse bioassay (MBA) has been used for detection of BoNTs, but for a long time, laboratories have worked with alternative methods for their detection. One of the most promising in vitro methods is a combination of an enzymatic and mass spectrometric assay called Endopep-MS. However, no comprehensive validation of the method has been presented. The main purpose of this work was to perform a validation for the qualitative analysis of BoNT-A, B, C, C/D, D, D/C, and F in serum. The limit of detection (LOD), selectivity, precision, stability in matrix and solution, and correlation with the MBA were evaluated. The LOD was equal to or even better than that of the MBA for BoNT-A, B, D/C, E, and F. Furthermore, Endopep-MS was for the first time successfully used to differentiate between BoNT-C and D and their mosaics C/D and D/C by different combinations of antibodies and target peptides. In addition, sequential antibody capture was presented as a new way to multiplex the method when only a small sample volume is available. In the comparison with the MBA, all the samples analyzed were positive for BoNT-C/D with both methods. These results indicate that the Endopep-MS method is a valid alternative to the MBA as the gold standard for BoNT detection based on its sensitivity, selectivity, and speed and that it does not require experimental animals.
C1 [Bjornstad, Kristian; Aberg, Annica Tevell; Bondesson, Ulf; Hedeland, Mikael] Natl Vet Inst SVA, Dept Chem Environm & Feed Hyg, S-75189 Uppsala, Sweden.
[Aberg, Annica Tevell; Bondesson, Ulf; Hedeland, Mikael] Uppsala Univ, Div Analyt Pharmaceut Chem, S-75123 Uppsala, Sweden.
[Kalb, Suzanne R.; Wang, Dongxia; Barr, John R.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
RP Hedeland, M (reprint author), Natl Vet Inst SVA, Dept Chem Environm & Feed Hyg, S-75189 Uppsala, Sweden.
EM mikael.hedeland@sva.se
OI Kalb, Suzanne/0000-0002-8067-136X; Hedeland, Mikael/0000-0001-8962-2815
FU EU-project AniBioThreat [Home/2009/ISECAG/191]; Prevention of and Fight
against Crime Programme of the European Union; European
Commission-Directorate General Home Affairs; Swedish Civil Contingencies
Agency (MSB)
FX The authors would like to thank Dr. James Marks and Dr. Jianlong Lou at
the University of California San Francisco for the help in selecting
antibodies suitable for this study. We would also like to thank Hanna
Skarin at SVA for providing PCR data and C. botulinum cultivation
broths. The financial support from the framework of the EU-project
AniBioThreat (Grant Agreement: Home/2009/ISECAG/191), the Prevention of
and Fight against Crime Programme of the European Union, European
Commission-Directorate General Home Affairs, and the Swedish Civil
Contingencies Agency (MSB) are greatly acknowledged. This publication
reflects the views only of the authors, and the European Commission
cannot be held responsible for any use which may be made of the
information contained therein. The findings and conclusions in this
report are those of the authors and do not necessarily represent the
official position of the Centers for Disease Control and Prevention.
NR 47
TC 7
Z9 7
U1 2
U2 10
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
EI 1618-2650
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD NOV
PY 2014
VL 406
IS 28
BP 7149
EP 7161
DI 10.1007/s00216-014-8170-4
PG 13
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA AS5OQ
UT WOS:000344320300009
PM 25228079
ER
PT J
AU Parson, TL
Marzinke, MA
Hoang, T
Bliven-Sizemore, E
Weiner, M
Mac Kenzie, WR
Dorman, SE
Dooley, KE
AF Parson, Teresa L.
Marzinke, Mark A.
Hoang, Thuy
Bliven-Sizemore, Erin
Weiner, Marc
Mac Kenzie, William R.
Dorman, Susan E.
Dooley, Kelly E.
TI Quantification of Rifapentine, a Potent Antituberculosis Drug, from
Dried Blood Spot Samples Using Liquid Chromatographic-Tandem Mass
Spectrometric Analysis
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID SOLID-PHASE EXTRACTION; RIFAMPIN CONCENTRATIONS; CLINICAL-CHEMISTRY;
CAPILLARY BLOOD; HUMAN PLASMA; LC-MS/MS; TUBERCULOSIS; PHARMACOKINETICS;
MOXIFLOXACIN; HEMATOCRIT
AB The quantification of antituberculosis drug concentrations in multinational trials currently requires the collection of modest blood volumes, centrifugation, aliquoting of plasma, freezing, and keeping samples frozen during shipping. We prospectively enrolled healthy individuals into the Tuberculosis Trials Consortium Study 29B, a phase I dose escalation study of rifapentine, a rifamycin under evaluation in tuberculosis treatment trials. We developed a liquid chromatography- tandem mass spectrometry (LC-MS/MS) method for quantifying rifapentine in whole blood on dried blood spots (DBS) to facilitate pharmacokinetic/pharmacodynamic analyses in clinical trials. Paired plasma and whole-blood samples were collected by venipuncture, and whole blood was spotted on Whatman protein saver 903 cards. The methods were optimized for plasma and then validated for DBS. The analytical measuring range for quantification of rifapentine and its metabolite was 50 to 80,000 ng/ml in whole-blood DBS. The analyte was stable on the cards for 11 weeks with a desiccant at room temperature and protected from light. The method concordance for paired plasma and whole-blood DBS samples was determined after correcting for participant hematocrit or population-based estimates of bias from Bland-Altman plots. The application of either correction factor resulted in acceptable correlation between plasma and whole-blood DBS (Passing-Bablok regression corrected for hematocrit; y = 0.98x + 356). Concentrations of rifapentine may be determined from whole-blood DBS collected via venipuncture after normalization in order to account for the dilutional effects of red blood cells. Additional studies are focused on the application of this methodology to capillary blood collected by finger stick. The simplicity of processing, storage, shipping, and low blood volume makes whole-blood DBS attractive for rifapentine pharmacokinetic evaluations, especially in international and pediatric trials.
C1 [Parson, Teresa L.; Marzinke, Mark A.; Hoang, Thuy; Dorman, Susan E.; Dooley, Kelly E.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
[Bliven-Sizemore, Erin; Mac Kenzie, William R.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Weiner, Marc] VA Med Ctr, San Antonio, TX USA.
RP Dooley, KE (reprint author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
EM kdooley1@jhmi.edu
FU Centers for Disease Control and Prevention; CDC Foundation; Pendleton
Enterprises; [K23AI080842]; [1S10 RR 27733]
FX This study was sponsored by the Centers for Disease Control and
Prevention and the CDC Foundation. Other support was provided by grant
K23AI080842 (to K.E.D.). The ABI-Sciex API5500 quadrupole linear
ion-trap console used for the quantification of RPT was purchased with
the proceeds of grant 1S10 RR 27733 awarded to Walter C. Hubbard. The
Waters Acquity ultraperformance liquid chromatograph (UPLC) interfaced
with the API-5500 was purchased with funds from Pendleton Enterprises
awarded to Craig W. Hendrix. RPT and desRPT were provided by Sanofi.
NR 36
TC 8
Z9 8
U1 4
U2 23
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD NOV
PY 2014
VL 58
IS 11
BP 6747
EP 6757
DI 10.1128/AAC.03607-14
PG 11
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA AS3EF
UT WOS:000344158600050
PM 25182637
ER
PT J
AU Johnson, SR
Grad, Y
Ganakammal, SR
Burroughs, M
Frace, M
Lipsitch, M
Weil, R
Trees, D
AF Johnson, Steven R.
Grad, Yonatan
Ganakammal, Satishkumar Ranganathan
Burroughs, Mark
Frace, Mike
Lipsitch, Marc
Weil, Ryan
Trees, David
TI In Vitro Selection of Neisseria gonorrhoeae Mutants with Elevated MIC
Values and Increased Resistance to Cephalosporins
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID PENICILLIN-BINDING PROTEIN-2; HIGH-LEVEL RESISTANCE; MOSAIC-LIKE
STRUCTURE; REDUCED SUSCEPTIBILITY; SEQUENCE ALIGNMENT; TREATMENT
FAILURE; AMINO-ACID; CEFTRIAXONE; MUTATIONS; GENE
AB Strains of Neisseria gonorrhoeae with mosaic penA genes bearing novel point mutations in penA have been isolated from ceftriaxone treatment failures. Such isolates exhibit significantly higher MIC values to third-generation cephalosporins. Here we report the in vitro isolation of two mutants with elevated MICs to cephalosporins. The first possesses a point mutation in the transpeptidase region of the mosaic penA gene, and the second contains an insertion mutation in pilQ.
C1 [Johnson, Steven R.; Burroughs, Mark; Trees, David] Ctr Dis Control & Prevent, Div STD Prevent, NCHHSTP, Atlanta, GA 30333 USA.
[Ganakammal, Satishkumar Ranganathan; Burroughs, Mark; Frace, Mike; Weil, Ryan] Ctr Dis Control & Prevent, Div Sci Resources, NCEZID, Atlanta, GA USA.
[Grad, Yonatan; Lipsitch, Marc] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Ctr Communicable Dis Dynam, Boston, MA 02115 USA.
[Grad, Yonatan] Harvard Univ, Brigham & Womens Hosp, Div Infect Dis, Sch Med, Boston, MA 02115 USA.
[Lipsitch, Marc] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
RP Johnson, SR (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, NCHHSTP, Atlanta, GA 30333 USA.
EM SBJ1@cdc.gov
FU NIAID [1-K08-AL104767]; NIGMS [U54GM088558]
FX Y.H.G was supported by grant 1-K08-AL104767 from NIAID, and M. L. was
supported by grant U54GM088558 from NIGMS.
NR 35
TC 3
Z9 3
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD NOV
PY 2014
VL 58
IS 11
BP 6986
EP 6989
DI 10.1128/AAC.03082-14
PG 4
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA AS3EF
UT WOS:000344158600083
PM 25199775
ER
PT J
AU Afanou, KA
Straumfors, A
Skogstad, A
Nilsen, T
Synnes, O
Skaar, I
Hjeljord, L
Tronsmo, A
Green, BJ
Eduard, W
AF Afanou, Komlavi Anani
Straumfors, Anne
Skogstad, Asbjorn
Nilsen, Terje
Synnes, Ole
Skaar, Ida
Hjeljord, Linda
Tronsmo, Arne
Green, Brett James
Eduard, Wijnand
TI Submicronic Fungal Bioaerosols: High-Resolution Microscopic
Characterization and Quantification
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID SCANNING-ELECTRON-MICROSCOPY; BETA-D-GLUCAN; BUILDING-MATERIALS;
AIR-FLOW; ASPERGILLUS-FUMIGATUS; INDOOR AIR; FRAGMENTS; AIRBORNE; SPORE;
AEROSOLIZATION
AB Submicronic particles released from fungal cultures have been suggested to be additional sources of personal exposure in mold-contaminated buildings. In vitro generation of these particles has been studied with particle counters, eventually supplemented by autofluorescence, that recognize fragments by size and discriminate biotic from abiotic particles. However, the fungal origin of submicronic particles remains unclear. In this study, submicronic fungal particles derived from Aspergillus fumigatus, A. versicolor, and Penicillium chrysogenum cultures grown on agar and gypsum board were aerosolized and enumerated using field emission scanning electron microscopy (FESEM). A novel bioaerosol generator and a fungal spores source strength tester were compared at 12 and 20 liters min(-1) airflow. The overall median numbers of aerosolized submicronic particles were 2 x 10(5) cm(-2), 2.6 x 10(3) cm(-2), and 0.9 x 10(3) cm(-2) for A. fumigatus, A. versicolor, and P. chrysogenum, respectively. A. fumigatus released significantly (P < 0.001) more particles than A. versicolor and P. chrysogenum. The ratios of submicronic fragments to larger particles, regardless of media type, were 1:3, 5:1, and 1:2 for A. fumigatus, A. versicolor, and P. chrysogenum, respectively. Spore fragments identified by the presence of rodlets amounted to 13%, 2%, and 0% of the submicronic particles released from A. fumigatus, A. versicolor, and P. chrysogenum, respectively. Submicronic particles with and without rodlets were also aerosolized from cultures grown on cellophane-covered media, indirectly confirming their fungal origin. Both hyphae and conidia could fragment into submicronic particles and aerosolize in vitro. These findings further highlight the potential contribution of fungal fragments to personal fungal exposure.
C1 [Afanou, Komlavi Anani; Straumfors, Anne; Skogstad, Asbjorn; Nilsen, Terje; Synnes, Ole; Eduard, Wijnand] Natl Inst Occupat Hlth, Oslo, Norway.
[Skaar, Ida] Norwegian Vet Inst, Oslo, Norway.
[Hjeljord, Linda; Tronsmo, Arne] Norwegian Univ Life Sci, Dept Chem Biotechnol & Food Sci, As, Norway.
[Green, Brett James] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA.
RP Eduard, W (reprint author), Natl Inst Occupat Hlth, Oslo, Norway.
EM wijnand.eduard@stami.no
FU Norwegian Research Council [NFR196130/H10]
FX This work was financially supported by the Norwegian Research Council
(grant NFR196130/H10).
NR 59
TC 3
Z9 3
U1 2
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0099-2240
EI 1098-5336
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD NOV
PY 2014
VL 80
IS 22
BP 7122
EP 7130
DI 10.1128/AEM.01740-14
PG 9
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA AS3FH
UT WOS:000344161700029
PM 25217010
ER
PT J
AU Law, RK
Sheikh, S
Bronstein, A
Thomas, R
Spiller, HA
Schier, JG
AF Law, R. K.
Sheikh, S.
Bronstein, A.
Thomas, R.
Spiller, H. A.
Schier, J. G.
TI Incidents of potential public health significance identified using
national surveillance of US poison center data (2008-2012)
SO CLINICAL TOXICOLOGY
LA English
DT Article
DE Public Health; Poisonings; Surveillance
ID CARBON-MONOXIDE EXPOSURES; UNITED-STATES; NPDS; ILLNESS; STORM
AB Background. The Centers for Disease Control and Prevention (CDC) and the American Association of Poison Control Centers conduct national surveillance on data collected by US poison centers to identify incidents of potential public health significance (IPHS). The overarching goals of this collaboration are to improve CDC's national surveillance capacity for public health threats, identify early markers of public health incidents and enhance situational awareness. The National Poison Data System (NPDS) is used as a surveillance system to automatically identify data anomalies. Purpose. To characterize data anomalies and IPHS captured by national surveillance of poison center data over 5 years. Methods. Data anomalies are identified through three surveillance methodologies: call-volume, clinical effect, and case-based. Anomalies are reviewed by a team of epidemiologists and clinical toxicologists to determine IPHS using standardized criteria. The authors reviewed IPHS identified by these surveillance activities from 2008 through 2012. Results. Call-volume surveillance identified 384 IPHS; most were related to gas and fume exposures (n = 229; 59.6%) with the most commonly implicated substance being carbon monoxide (CO) (n = 92; 22.8%). Clinical-effect surveillance identified 138 IPHS; the majority were related to gas and fume exposures (n = 58; 42.0%) and gastrointestinal complaints (n = 84; 16.2%), and the most commonly implicated substance was CO (n = 20; 14.4%). Among the 11 case-based surveillance definitions, the botulism case definition yielded the highest percentage of identified agent-specific illness. Conclusions. A small proportion of data anomalies were designated as IPHS. Of these, CO releases were the most frequently reported IPHS and gastrointestinal syndromes were the most commonly reported illness manifestations. poison center data surveillance may be used as an approach to identify exposures, illnesses, and incidents of importance at the national and state level.
C1 [Law, R. K.; Sheikh, S.; Schier, J. G.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Hlth Studies Branch, Atlanta, GA 30341 USA.
[Bronstein, A.; Thomas, R.; Spiller, H. A.] Amer Assoc Poison Control Ctr, Alexandria, VA USA.
RP Law, RK (reprint author), Ctr Dis Control & Prevent, CDC NCEH EHHE HSB, 4770 Buford Highway,Mail Stop F60, Atlanta, GA 30341 USA.
EM RLaw@cdc.gov
RI Sheikh, Sophia/F-9746-2015
FU Intramural CDC HHS [CC999999]
NR 16
TC 1
Z9 1
U1 2
U2 12
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 1556-3650
EI 1556-9519
J9 CLIN TOXICOL
JI Clin. Toxicol.
PD NOV
PY 2014
VL 52
IS 9
BP 958
EP 963
DI 10.3109/15563650.2014.953171
PG 6
WC Toxicology
SC Toxicology
GA AS6FH
UT WOS:000344359400007
PM 25175899
ER
PT J
AU Thomas, BS
Bailey, TC
Bhatnagar, J
Ritter, JM
Emery, BD
Jassim, OW
Hornstra, IK
George, SL
AF Thomas, Benjamin Stuart
Bailey, Thomas C.
Bhatnagar, Julu
Ritter, Jana M.
Emery, Brian D.
Jassim, Omar W.
Hornstra, Ian Kerst
George, Sarah L.
TI Mycobacterium ulcerans Infection Imported from Australia to Missouri,
USA, 2012
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID BURULI ULCER; DIAGNOSIS; SENSITIVITY; TRAVELER; DISEASE; VISITOR
AB Buruli ulcer, the third most common mycobacterial disease worldwide, rarely affects travelers and is uncommon in the United States. We report a travel-associated case imported from Australia and review 3 previous cases diagnosed and treated in the United States. The differential diagnoses for unusual chronic cutaneous ulcers and those nonresponsive to conventional therapy should include Mycobacterium ulcerans infection.
C1 [Thomas, Benjamin Stuart; Bailey, Thomas C.; Hornstra, Ian Kerst] Washington Univ, Sch Med, St Louis, MO 63110 USA.
[Bhatnagar, Julu; Ritter, Jana M.; Emery, Brian D.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Jassim, Omar W.; Hornstra, Ian Kerst; George, Sarah L.] John Cochran Vet Affairs Med Ctr, St Louis, MO USA.
[George, Sarah L.] St Louis Univ, St Louis, MO 63103 USA.
RP Thomas, BS (reprint author), Washington Univ, Sch Med, Div Infect Dis, 660 S Euclid Ave,Campus Box 8051, St Louis, MO 63110 USA.
EM bthomas@dom.wustl.edu
FU National Center for Advancing Translational Sciences [UL1 TR000448]
FX This work was supported by a grant (UL1 TR000448) from the National
Center for Advancing Translational Sciences to the Washington University
Institute of Clinical and Translational Sciences.
NR 15
TC 3
Z9 3
U1 0
U2 0
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD NOV
PY 2014
VL 20
IS 11
BP 1876
EP 1879
DI 10.3201/eid2011.131534
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AS0KO
UT WOS:000343966300013
PM 25341024
ER
PT J
AU Fan, M
Huang, B
Wang, A
Deng, LQ
Wu, DL
Lu, XR
Zhao, QL
Xu, S
Havers, F
Wang, YH
Wu, J
Yin, Y
Sun, BX
Yao, JY
Xiang, NJ
AF Fan, Ming
Huang, Biao
Wang, Ao
Deng, Liquan
Wu, Donglin
Lu, Xinrong
Zhao, Qinglong
Xu, Shuang
Havers, Fiona
Wang, Yanhui
Wu, Jing
Yin, Yuan
Sun, Bingxin
Yao, Jianyi
Xiang, Nijuan
TI Human Influenza A(H7N9) Virus Infection Associated with Poultry Farm,
Northeastern China
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID A H7N9 VIRUS; WET MARKETS; TRANSMISSION; EXPOSURE; CLOSURE; ORIGIN;
GENOME; RISK
AB We report on a case of human infection with influenza A(H7N9) virus in Jilin Province in northeastern China. This case was associated with a poultry farm rather than a live bird market, which may point to a new focus for public health surveillance and interventions in this evolving outbreak.
C1 [Fan, Ming; Huang, Biao; Wang, Ao; Deng, Liquan; Wu, Donglin; Lu, Xinrong; Zhao, Qinglong; Xu, Shuang] Jilin Prov Ctr Dis Control & Prevent, Changchun, Jilin, Peoples R China.
[Wang, Yanhui; Wu, Jing; Yin, Yuan; Sun, Bingxin] Changchun Prefectural Ctr Dis Control & Prevent, Changchun, Jilin, Peoples R China.
[Yao, Jianyi; Xiang, Nijuan] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China.
[Havers, Fiona] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Xiang, NJ (reprint author), Chinese Ctr Dis Control & Prevent, 155 Changbai Rd, Beijing, Peoples R China.
EM xiangnj@chinacdc.cn
FU China-US Collaborative Program on Emerging and Re-emerging Infectious
Diseases; National Ministry of Science and Technology Emergency Research
Project on human infection with avian influenza H7N9 virus (Epidemiology
Research Project) [KJYJ-2013-01-02]
FX This work was supported by the China-US Collaborative Program on
Emerging and Re-emerging Infectious Diseases and a grant from National
Ministry of Science and Technology Emergency Research Project on human
infection with avian influenza H7N9 virus (Epidemiology Research
Project) (KJYJ-2013-01-02).
NR 13
TC 7
Z9 8
U1 1
U2 6
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD NOV
PY 2014
VL 20
IS 11
BP 1902
EP 1905
DI 10.3201/eid2011.140608
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AS0KO
UT WOS:000343966300020
PM 25340624
ER
PT J
AU Folster, JP
Katz, L
McCullough, A
Parsons, MB
Knipe, K
Sammons, SA
Boncy, J
Tarr, CL
Whichard, JM
AF Folster, Jason P.
Katz, Lee
McCullough, Andre
Parsons, Michele B.
Knipe, Kristen
Sammons, Scott A.
Boncy, Jacques
Tarr, Cheryl Lea
Whichard, Jean M.
TI Multidrug-Resistant IncA/C Plasmid in Vibrio cholerae from Haiti
SO EMERGING INFECTIOUS DISEASES
LA English
DT Letter
ID IDENTIFICATION
C1 [Folster, Jason P.; Katz, Lee; Parsons, Michele B.; Knipe, Kristen; Sammons, Scott A.; Tarr, Cheryl Lea; Whichard, Jean M.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
[McCullough, Andre] Int Hlth Resources Consulting, Atlanta, GA USA.
[Boncy, Jacques] Lab Natl Sante Publ, Port Au Prince, Haiti.
RP Folster, JP (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30329 USA.
EM gux8@cdc.gov
NR 10
TC 7
Z9 7
U1 0
U2 3
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD NOV
PY 2014
VL 20
IS 11
BP 1951
EP 1953
DI 10.3201/eid2011.140889
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AS0KO
UT WOS:000343966300038
PM 25340576
ER
PT J
AU Ward, JW
AF Ward, John W.
TI Hepatitis C Virus: The 25-Year Journey From Discovery to Cure
SO HEPATOLOGY
LA English
DT Editorial Material
ID UNITED-STATES; VIRAL-HEPATITIS; PREVENTION; INFECTION; ADULTS
C1 Ctr Dis Control & Prevent CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
RP Ward, JW (reprint author), Ctr Dis Control & Prevent CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,Mailstop G-37, Atlanta, GA 30333 USA.
EM jww4@cdc.gov
NR 19
TC 8
Z9 8
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD NOV
PY 2014
VL 60
IS 5
BP 1479
EP 1482
DI 10.1002/hep.27377
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AS6CM
UT WOS:000344352400008
PM 25131647
ER
PT J
AU Ramsey, T
Davis, KG
Kotowski, SE
Anderson, VP
Waters, T
AF Ramsey, Todd
Davis, Kermit G.
Kotowski, Susan E.
Anderson, Vern P.
Waters, Thomas
TI Reduction of Spinal Loads Through Adjustable Interventions at the Origin
and Destination of Palletizing Tasks
SO HUMAN FACTORS
LA English
DT Article
DE intervention; manual material handling; item selectors; low back
injuries; compression spine load
ID BACK DISORDER RISK; 3-DIMENSIONAL MOTION MODEL; TRUNK-MOTION; LUMBAR
SPINE; LIFTING TASKS; VALIDATION; INDUSTRY; WORKERS
AB Objective: This article evaluates the effectiveness of two interventions: a self-leveling pallet carousel designed to position the loads vertically and horizontally at origin, and an adjustable cart designed to raise loads vertically at destination to reduce spine loads.
Background: Low back disorders among workers in manual material handling industries are very prevalent and have been linked to manual palletizing operations. Evidence into the effectiveness of ergonomic interventions is limited, with no research that investigates interventions with adjustable load location.
Method: Thirteen males experienced in manual material handling participated in simulated order selecting tasks where spine loads were quantified for each intervention condition: carousel to traditional cart, pallet to traditional cart, pallet to adjustable cart, and carousel to adjustable cart.
Results: The results showed that combining both devices results in reduction in spine compression (61%), anterior-posterior shear (72%), and lateral shear (63%) compared to traditional palletizing conditions. Individually, the carousel was responsible for the greatest reductions, but the lowest values were typically achieved by combining the adjustable cart and carousel.
Conclusion: The combination of the interventions (self-leveling carousel and adjustable cart) was most effective in reducing the spine loads when compared to the traditional pallet-cart condition. The individual interventions also reduced the loads compared to the traditional condition.
Application: With de-palletizing/palletizing tasks being a major source of low back injuries, the combination of self-leveling carousel and adjustable cart has been found to be effective in reducing the peak spine loading as compared to traditional pallet on floor and nonadjustable flat cart conditions.
C1 [Ramsey, Todd] Univ Cincinnati, Cincinnati, OH 45267 USA.
[Davis, Kermit G.] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA.
[Davis, Kermit G.] Univ Cincinnati, Low Back Biomech & Workplace Stress Lab, Cincinnati, OH 45267 USA.
[Kotowski, Susan E.] Univ Cincinnati, Coll Allied Hlth Sci, Cincinnati, OH 45267 USA.
[Anderson, Vern P.; Waters, Thomas] NIOSH, Cincinnati, OH 45226 USA.
RP Davis, KG (reprint author), Univ Cincinnati, Low Back Biomech & Workplace Stress Lab, 3223 Eden Ave,330 Kettering Lab, Cincinnati, OH 45267 USA.
EM Kermit.davis@uc.edu
FU NIOSH
FX The authors would like to thank James Galante and Southworth Ergonomic
Equipment for lending a carousel and adjustable cart as well as the
NIOSH for providing funding for participant incentives and the flat
cart. The authors would also like to thank Dr. William Marras, who
provided the EMG-assisted model that allowed the quantification of the
three-dimensional spine loads.
NR 36
TC 0
Z9 0
U1 2
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0018-7208
EI 1547-8181
J9 HUM FACTORS
JI Hum. Factors
PD NOV
PY 2014
VL 56
IS 7
BP 1222
EP 1234
DI 10.1177/0018720814528356
PG 13
WC Behavioral Sciences; Engineering, Industrial; Ergonomics; Psychology,
Applied; Psychology
SC Behavioral Sciences; Engineering; Psychology
GA AS6TH
UT WOS:000344394600002
PM 25490803
ER
PT J
AU Karim, MR
Zhang, SM
Jian, FC
Li, JC
Zhou, CX
Zhang, LX
Sun, MF
Yang, GY
Zou, FC
Dong, HJ
Li, J
Rume, FI
Qi, M
Wang, RJ
Ning, CS
Xiao, LH
AF Karim, Md Robiul
Zhang, Sumei
Jian, Fuchun
Li, Jiacheng
Zhou, Chunxiang
Zhang, Longxian
Sun, Mingfei
Yang, Guangyou
Zou, Fengcai
Dong, Haiju
Li, Jian
Rume, Farzana Islam
Qi, Meng
Wang, Rongjun
Ning, Changshen
Xiao, Lihua
TI Multilocus typing of Cryptosporidium spp. and Giardia duodenalis from
non-human primates in China
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Article
DE Cryptosporidium; Giardia; Multilocus typing; Non-human primates; China
ID PATHOGENIC ENTEROCYTOZOON-BIENEUSI; MOLECULAR EPIDEMIOLOGY; WESTERN
UGANDA; WASTE-WATER; ZOONOTIC TRANSMISSION; ENTERIC PARASITES;
SEQUENCE-ANALYSIS; PUBLIC-HEALTH; SP INFECTIONS; WILD ANIMALS
AB Non-human primates (NHPs) are commonly infected with Cryptosporidium spp. and Giardia duodenalis. However, molecular characterisation of these pathogens from NHPs remains scarce. In this study, 2,660 specimens from 26 NHP species in China were examined and characterised by PCR amplification of 18S rRNA, 70 kDa heat shock protein (hsp70) and 60 kDa glycoprotein (gp60) gene loci for Cryptosporidium; and 1,386 of the specimens by ssrRNA, triosephosphate isomerase (tpi) and glutamate dehydrogenase (gdh) gene loci for Giardia. Cryptosporidium was detected in 0.7% (19/2660) specimens of four NHP species including rhesus macaques (0.7%), cynomolgus monkeys (1.0%), slow lorises (10.0%) and Francois' leaf monkeys (6.7%), belonging to Cryptosporidium hominis (14/19) and Cryptosporidium muris (5/19). Two C hominis gp60 subtypes, IbA12G3 and IiA17 were observed. Based on the tpi locus, G. duodenalis was identified in 2.2% (30/1,386) of specimens including 2.1% in rhesus macaques, 33.3% in Japanese macaques, 16.7% in Assam macaques, 0.7% in white-headed langurs, 1.6% in cynomolgus monkeys and 16.7% in olive baboons. Sequence analysis of the three targets indicated that all of the Giardia-positive specimens belonged to the zoonotic assemblage B. Highest sequence polymorphism was observed at the tpi locus, including 11 subtypes: three known and eight new ones. Phylogenetic analysis of the subtypes showed that most of them were close to the so-called subtype BIV. Intragenotypic variations at the gdh locus revealed six types of sequences (three known and three new), all of which belonged to so-called subtype BIV. Three specimens had co-infection with C hominis (IbA12G3) and G. duodenalis (BIV). The presence of zoonotic genotypes and subtypes of Cryptosporidium spp. and G. duodenalis in NHPs suggests that these animals can potentially contribute to the transmission of human cryptosporidiosis and giardiasis. (C) 2014 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Karim, Md Robiul; Zhang, Sumei; Jian, Fuchun; Li, Jiacheng; Zhou, Chunxiang; Zhang, Longxian; Dong, Haiju; Qi, Meng; Wang, Rongjun; Ning, Changshen] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China.
[Sun, Mingfei] Guangdong Acad Agr Sci, Inst Vet Med, Guangzhou 510640, Guangdong, Peoples R China.
[Yang, Guangyou] Sichuan Agr Univ, Coll Vet Med, Yaan 625014, Peoples R China.
[Zou, Fengcai] Yunnan Agr Univ, Coll Anim Sci & Technol, Kunming 650201, Peoples R China.
[Li, Jian] Guangxi Univ, Coll Anim Sci & Technol, Nanning 530004, Peoples R China.
[Rume, Farzana Islam] Patuakhali Sci & Technol Univ, Dept Microbiol, Patuakhali 8602, Bangladesh.
[Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Zhang, LX (reprint author), Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China.
EM zhanglx8999@gmail.com; lxiao@cdc.gov
RI Xiao, Lihua/B-1704-2013;
OI Xiao, Lihua/0000-0001-8532-2727; zhang, longxian/0000-0002-5706-131X
FU International Cooperation and Exchange Projects of the National Natural
Science Foundation of China [31110103901]; State Key Program of National
Natural Science Foundation of China [31330079]; Key National Science and
Technology Specific Projects, China [2012ZX10004220-001]; Program for
Science and Technology Innovative Research Team in University of Henan
Province, China [012IRTSTHN005]
FX This study was supported in part by the International Cooperation and
Exchange Projects of the National Natural Science Foundation of China
(No. 31110103901), the State Key Program of National Natural Science
Foundation of China (31330079), the Key National Science and Technology
Specific Projects, China (No. 2012ZX10004220-001), the Program for
Science and Technology Innovative Research Team in University of Henan
Province, China (012IRTSTHN005).
NR 60
TC 9
Z9 11
U1 2
U2 19
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-7519
EI 1879-0135
J9 INT J PARASITOL
JI Int. J. Parasit.
PD NOV
PY 2014
VL 44
IS 13
BP 1039
EP 1047
DI 10.1016/j.ijpara.2014.07.006
PG 9
WC Parasitology
SC Parasitology
GA AS7GS
UT WOS:000344425700008
PM 25148945
ER
PT J
AU Morof, DF
Sami, S
Mangeni, M
Blanton, C
Cardozo, BL
Tomczyk, B
AF Morof, Diane F.
Sami, Samira
Mangeni, Maria
Blanton, Curtis
Cardozo, Barbara Lopes
Tomczyk, Barbara
TI A cross-sectional survey on gender-based violence and mental health
among female urban refugees and asylum seekers in Kampala, Uganda
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE Asylum seekers; Depression; Mental health; Post-traumatic stress
disorder; Refugees; Uganda; Urban refugees; Violence
ID REPRODUCTIVE HEALTH; ASSOCIATION; WOMEN
AB Objective: To assess gender-based violence and mental health outcomes among a population of female urban refugees and asylum seekers. Methods: In a questionnaire-based, cross-sectional study conducted in 2010 in Kampala, Uganda, a study team interviewed a stratified random sample of female refugees and asylum seekers aged 15-59 years from the Democratic Republic of Congo and Somalia. Questionnaires were used to collect information about recent and lifetime exposure to sexual and physical violence, and symptoms of depression and post-traumatic stress disorder (PTSD). Results: Among the 500 women selected, 117 (23.4%) completed interviews. The weighted lifetime prevalences of experiencing any (physical and/or sexual) violence, physical violence, and sexual violence were 77.5% (95% CI 66.6-88.4), 76.2% (95% CI 65.2-87.2), and 63.3% (95% CI 51.2-75.4), respectively. Lifetime history of physical violence was associated with PTSD symptoms (P < 0.001), as was lifetime history of sexual violence (P = 0.014). Overall, 112 women had symptoms of depression (weighted prevalence 92.0; 95% CI 83.9-100) and 83 had PTSD symptoms (weighted prevalence 71.1; 95% CI 59.9-82.4). Conclusion: Prevalences of violence, depression, and PTSD symptoms among female urban refugees in Kampala are high. Additional services and increased availability of psychosocial programs for refugees are needed. Published by Elsevier Ireland Ltd. on behalf of International Federation of Gynecology and Obstetrics.
C1 [Morof, Diane F.] Ctr Dis Control & Prevent, Div Reprod Hlth, Field Support Branch, Atlanta, GA 30341 USA.
[Sami, Samira; Blanton, Curtis; Cardozo, Barbara Lopes; Tomczyk, Barbara] Ctr Dis Control & Prevent, Div Global Hlth Protect, Emergency Response & Recovery Branch, Atlanta, GA 30341 USA.
[Mangeni, Maria] United Nat High Commissioner Refugees Uganda, Community Serv, Gender Based Violence Project, Kampala, Uganda.
RP Morof, DF (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Field Support Branch, 4770 Buford Hwy MS-F-74, Atlanta, GA 30341 USA.
EM dmorof@cdc.gov
NR 25
TC 2
Z9 2
U1 2
U2 21
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD NOV
PY 2014
VL 127
IS 2
BP 138
EP 143
DI 10.1016/j.ijgo.2014.05.014
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AS3WO
UT WOS:000344206200006
PM 25042145
ER
PT J
AU Lathrop, E
Jamieson, DJ
Danel, I
AF Lathrop, Eva
Jamieson, Denise J.
Danel, Isabella
TI HIV and maternal mortality
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE HIV; Maternal mortality; Pregnancy; Sub-Saharan Africa
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; PREGNANCY-RELATED
MORTALITY; INFECTED WOMEN; SOUTH-AFRICA; TUBERCULOSIS; MALARIA;
COINFECTION; HIV/AIDS; IMPACT
AB The majority of the 17 million women globally that are estimated to be infected with HIV live in Sub-Saharan Africa. Worldwide, HIV-related causes contributed to 19 000-56 000 maternal deaths in 2011 (6%-20% of maternal deaths). HIV-infected pregnant women have two to 10 times the risk of dying during pregnancy and the postpartum period compared with uninfected pregnant women. Many of these deaths can be prevented with the implementation of high-quality obstetric care, prevention and treatment of common co-infections, and treatment of HIV with ART. The paper summarizes what is known about HIV disease progression in pregnancy, specific causes of HIV-related maternal deaths, and the potential impact of treatment with antiretroviral therapy on maternal mortality. Recommendations are proposed for improving maternal health and decreasing maternal mortality among HIV-infected women based on existing evidence. (C) 2014 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Lathrop, Eva] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Jamieson, Denise J.; Danel, Isabella] Ctr Dis Control & Prevent, Natl Ctr Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA.
RP Lathrop, E (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA.
EM elathro@emory.edu
FU Intramural CDC HHS [CC999999]
NR 28
TC 4
Z9 4
U1 2
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD NOV
PY 2014
VL 127
IS 2
BP 213
EP 215
DI 10.1016/j.ijgo.2014.05.024
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AS3WO
UT WOS:000344206200023
PM 25097142
ER
PT J
AU Woodring, JV
Kruszon-Moran, D
Oster, AM
McQuillan, GM
AF Woodring, Joseph V.
Kruszon-Moran, Deanna
Oster, Alexandra M.
McQuillan, Geraldine M.
TI Did CDC's 2006 Revised HIV Testing Recommendations Make a Difference?
Evaluation of HIV Testing in the US Household Population, 2003-2010
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; population surveillance; HIV testing; health care disparities; risk
factors; Centers for Disease Control and Prevention
ID HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; COST-EFFECTIVENESS;
SEXUAL-BEHAVIOR; PERSONS AWARE; TRANSMISSION; CARE; PREVENTION;
INFECTION; UNAWARE
AB Objective:To examine changes in the prevalence of HIV testing among adults following the Centers for Disease Control and Prevention's 2006 revised HIV testing recommendations.Design:The 2003-2010 National Health and Nutrition Examination Survey, a nationally representative cross-sectional survey of the noninstitutionalized US population.Methods:Weighted estimates and multivariable modeling to assess the prevalence of lifetime HIV testing, outside of blood donations, based on 13,975 respondents aged 18-59 years, comparing the 2003-2006 and 2007-2010 National Health and Nutrition Examination Survey.Results:Overall, HIV testing was 42.1% during 2003-2006 and 44.5% during 2007-2010 (P > 0.05). After adjusting for significant predictors in a multivariate model, HIV testing increased from 2003-2006 to 2007-2010 (adjusted odds ratio [aOR] 1.14, P < 0.05), mostly among males (aOR 1.33, P < 0.001) as compared with females (aOR 1.02, P > 0.05). HIV testing also increased significantly among non-Hispanic blacks, heterosexuals, those aged 50-59 years, those without a sexually transmitted infection history, those without health insurance, and those who did not access health care in the past year. HIV testing did not change significantly among high-risk groups, including men who have sex with men, those with a history of injection or illicit drug use, and those with a sexually transmitted infection history.Conclusions:In multivariate modeling, we found a modest but significant increase in HIV testing overall and among males after publication of the revised recommendations for HIV testing. The significant increase in non-high-risk groups suggests an expansion in generalized HIV testing, as recommended. However, even in 2007-2010, 56% of the US population has never been tested for HIV.
C1 [Woodring, Joseph V.; Kruszon-Moran, Deanna; McQuillan, Geraldine M.] Ctr Dis Control & Prevent, Div Natl Hlth & Nutr Surveys, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
[Oster, Alexandra M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
RP Woodring, JV (reprint author), Ctr Dis Control & Prevent, Div Natl Hlth & Nutr Surveys, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4323, Hyattsville, MD 20782 USA.
EM jwoodring@cdc.gov
NR 30
TC 8
Z9 8
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD NOV 1
PY 2014
VL 67
IS 3
BP 331
EP 340
DI 10.1097/QAI.0000000000000303
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AS6GC
UT WOS:000344361400018
PM 25153918
ER
PT J
AU Dooling, KL
Shapiro, DJ
Van Beneden, C
Hersh, AL
Hicks, LA
AF Dooling, Kathleen L.
Shapiro, Daniel J.
Van Beneden, Chris
Hersh, Adam L.
Hicks, Lauri A.
TI Overprescribing and Inappropriate Antibiotic Selection for Children With
Pharyngitis in the United States, 1997-2010
SO JAMA PEDIATRICS
LA English
DT Letter
ID STREPTOCOCCAL PHARYNGITIS; SORE THROAT
C1 [Dooling, Kathleen L.; Van Beneden, Chris; Hicks, Lauri A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Shapiro, Daniel J.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Hersh, Adam L.] Univ Utah, Salt Lake City, UT USA.
RP Dooling, KL (reprint author), Peel Reg Publ Hlth, POB 667, Mississauga, ON L5M 2C2, Canada.
EM kathleen.dooling@peelregion.ca
NR 6
TC 2
Z9 2
U1 2
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6203
EI 2168-6211
J9 JAMA PEDIATR
JI JAMA Pediatr.
PD NOV
PY 2014
VL 168
IS 11
BP 1073
EP 1074
DI 10.1001/jamapediatrics.2014.1582
PG 2
WC Pediatrics
SC Pediatrics
GA AT1NS
UT WOS:000344701500023
PM 25264869
ER
PT J
AU El Bcheraoui, C
Dominguez, KL
Kilmarx, PH
AF El Bcheraoui, Charbel
Dominguez, Kenneth L.
Kilmarx, Peter H.
TI Undertreated and Untreated Pain Should Be Considered an Adverse Event of
Neonatal Circumcision Reply
SO JAMA PEDIATRICS
LA English
DT Letter
C1 [El Bcheraoui, Charbel] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Profess Dev Program,Off Surveillance E, Atlanta, GA USA.
[El Bcheraoui, Charbel; Dominguez, Kenneth L.; Kilmarx, Peter H.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
[El Bcheraoui, Charbel] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA.
RP El Bcheraoui, C (reprint author), Univ Washington, Inst Hlth Metr & Evaluat, 2301 Fifth Ave,Ste 600, Seattle, WA 98121 USA.
EM charbel@uw.edu
FU Intramural CDC HHS [CC999999]
NR 3
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6203
EI 2168-6211
J9 JAMA PEDIATR
JI JAMA Pediatr.
PD NOV
PY 2014
VL 168
IS 11
BP 1077
EP 1077
PG 1
WC Pediatrics
SC Pediatrics
GA AT1NS
UT WOS:000344701500026
PM 25365389
ER
PT J
AU Zuber, A
McCarthy, CF
Verani, AR
Msidi, E
Johnson, C
AF Zuber, Alexandra
McCarthy, Carey F.
Verani, Andre R.
Msidi, Eleanor
Johnson, Carla
TI A Survey of Nurse-Initiated and -Managed Antiretroviral Therapy (NIMART)
in Practice, Education, Policy, and Regulation in East, Central, and
Southern Africa
SO JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE
LA English
DT Article
DE Africa; midwifery; nurse initiated and managed of antiretroviral therapy
(NIMART); nursing; task shifting
ID RAPID EXPANSION; HIV; SHORTAGE; CARE; SYSTEMS; IMPACT
AB In sub-Saharan Africa, nurses and midwives perform many HIV service delivery tasks, such as diagnosis of HIV and prescription of antiretroviral therapy (ART), which used to be the responsibility of physicians. While this task shifting is critical to scaling-up HIV services in Africa, the extent of HIV task shifting is not well understood. A survey of senior nursing leadership teams from 15 African countries was carried out to describe the extent of nurse-initiated and -managed antiretroviral therapy (NI-MART) in practice, education, policy, and regulation. The survey took place at the African Health Professions Regulatory Collaborative meeting in Pretoria, South Africa, in June 2012. The findings indicated that NIMART is widely practiced and authorized in policy, but is not reinforced by regulation nor incorporated into preservice education. Further investment in policy, regulation, and pre-service education is needed to ensure sustainable, high quality ART service expansion through the region. Published by Elsevier Inc. on behalf of Association of Nurses in AIDS Care
C1 [Zuber, Alexandra; McCarthy, Carey F.; Verani, Andre R.] US Ctr Dis Control & Prevent, Hlth Syst & Human Resources Hlth Team, Div Global HIV AIDS, Atlanta, GA 30333 USA.
[Msidi, Eleanor] Columbia Univ Coordinating Ctr, ICAP, Global Nurse Capac Bldg Program, Lusaka, Zambia.
[Johnson, Carla] US Ctr Dis Control & Prevent, HIV Care & Treatment Branch, Div Global HIV AIDS, Atlanta, GA USA.
RP Zuber, A (reprint author), US Ctr Dis Control & Prevent, Hlth Syst & Human Resources Hlth Team, Div Global HIV AIDS, Atlanta, GA 30333 USA.
FU United States President's Emergency Plan for AIDS Relief (PEPFAR)
FX This work was supported by the United States President's Emergency Plan
for AIDS Relief (PEPFAR). The authors would like to acknowledge the
special assistance of Dr. Erdenekhuu Nansalmaa, a Centers for Disease
Control and Prevention research fellow, who validated data entry and
analysis.
NR 34
TC 8
Z9 9
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1055-3290
EI 1552-6917
J9 J ASSOC NURSE AIDS C
JI J. Assoc. Nurses Aids Care
PD NOV-DEC
PY 2014
VL 25
IS 6
BP 520
EP 531
DI 10.1016/j.jana.2014.02.003
PG 12
WC Nursing
SC Nursing
GA AS7EM
UT WOS:000344420100008
PM 24739661
ER
PT J
AU Brown, EJ
Thomas, P
Willis, LA
Sutton, MY
AF Brown, Emma J.
Thomas, Peter
Willis, Leigh A.
Sutton, Madeline Y.
TI Recruitment Strategies to Engage African American Men in HIV Testing
Randomized Controlled Trials in the Rural Southern United States
SO JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE
LA English
DT Article
ID INFECTION; ATTITUDES
C1 [Brown, Emma J.] Coalit Hlth & Advocacy Rural Minor CHARM Inc, Lake City, FL 32055 USA.
[Thomas, Peter; Willis, Leigh A.; Sutton, Madeline Y.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
RP Brown, EJ (reprint author), Coalit Hlth & Advocacy Rural Minor CHARM Inc, Lake City, FL 32055 USA.
FU Centers for Disease Control and Prevention's Minority HIV/AIDS Research
Initiative award [U01PS000677]
FX This study was supported with Centers for Disease Control and
Prevention's Minority HIV/AIDS Research Initiative award #U01PS000677.
We thank the men who participated in the HiTFARM study and the study
team members who helped with data collection. The findings and
conclusions in this report are those of the authors and do not
necessarily represent the official views of the Centers for Disease
Control and Prevention.
NR 15
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1055-3290
EI 1552-6917
J9 J ASSOC NURSE AIDS C
JI J. Assoc. Nurses Aids Care
PD NOV-DEC
PY 2014
VL 25
IS 6
BP 670
EP 674
DI 10.1016/j.jana.2014.06.006
PG 5
WC Nursing
SC Nursing
GA AS7EM
UT WOS:000344420100023
PM 25305031
ER
PT J
AU Haderxhanaj, LT
Dittus, PJ
Loosier, PS
Rhodes, SD
Bloom, FR
Leichliter, JS
AF Haderxhanaj, Laura T.
Dittus, Patricia J.
Loosier, Penny S.
Rhodes, Scott D.
Bloom, Fred R.
Leichliter, Jami S.
TI Acculturation, Sexual Behaviors, and Health Care Access Among Hispanic
and Non-Hispanic White Adolescents and Young Adults in the United
States, 2006-2010
SO JOURNAL OF ADOLESCENT HEALTH
LA English
DT Article
DE Adolescents; Sexual behavior; Sexually transmitted diseases; Access to
health care
ID REPRODUCTIVE HEALTH; LATINO ADOLESCENTS; GENDER; YOUTH
AB Purpose: To examine national estimates of sexual behaviors and health care access by acculturation among adolescents.
Methods: Using the 2006-2010 National Survey of Family Growth, four acculturation groups of Hispanic and non-Hispanic whites aged 15-24 years were analyzed by sexual behaviors and health care access.
Results: In analyses adjusted for demographics, English-speaking immigrants, Hispanic natives, and non-Hispanic white youth were less likely to have a partner age difference of >= 6 years (adjusted odds ratio [AOR], .28; 95% confidence interval [CI],.13-.60; AOR, .13; 95% CI, .07-.26; AOR, .16; 95% CI,.08-.32, respectively) and more likely to use a condom at the first vaginal sex (AOR, 1.99; 95% CI, 1.10-3.61; AOR, 2.10; 95% CI, 1.33-3.31; AOR, 2.39; 95% CI, 1.53-3.74, respectively) than Spanish-speaking immigrants. Non-Hispanic white youth and Hispanic natives were more likely to have a regular place for medical care (AOR, 2.07; 95% CI, 1.36-3.16; AOR, 3.66; 95% CI, 2.36-5.68, respectively) and a chlamydia test in the past 12 months (AOR, 3.62; 95% CI, 1.52-8.60; AOR, 2.94; 95% CI, 1.32-6.54) than Spanish-speaking immigrants.
Conclusions: Interventions to reduce risk and increase health care access are needed for immigrant Hispanic youth, particularly Spanish-speaking immigrants. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine.
C1 [Haderxhanaj, Laura T.; Dittus, Patricia J.; Loosier, Penny S.; Bloom, Fred R.; Leichliter, Jami S.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
[Rhodes, Scott D.] Wake Forest Univ, Sch Med, Div Publ Hlth Serv, Winston Salem, NC 27109 USA.
RP Haderxhanaj, LT (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,Mailstop E-02, Atlanta, GA 30333 USA.
EM LHaderxhanaj@cdc.gov
FU Centers for Disease Control and Prevention (CDC)
FX This research was supported in part by an appointment to the Research
Participation Program at the Centers for Disease Control and Prevention
(CDC) administered by the Oak Ridge Institute for Science and Education
through an interagency agreement between the U.S. Department of Energy
and CDC.
NR 10
TC 2
Z9 2
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1054-139X
EI 1879-1972
J9 J ADOLESCENT HEALTH
JI J. Adolesc. Health
PD NOV
PY 2014
VL 55
IS 5
BP 716
EP 719
DI 10.1016/j.jadohealth.2014.06.018
PG 4
WC Psychology, Developmental; Public, Environmental & Occupational Health;
Pediatrics
SC Psychology; Public, Environmental & Occupational Health; Pediatrics
GA AS4IA
UT WOS:000344236300021
PM 25156896
ER
PT J
AU Mirabelli, MC
Beavers, SF
Flanders, WD
Chatterjee, AB
AF Mirabelli, Maria C.
Beavers, Suzanne F.
Flanders, W. Dana
Chatterjee, Arjun B.
TI Reliability in reporting asthma history and age at asthma onset
SO JOURNAL OF ASTHMA
LA English
DT Article
DE Questionnaire methodology; reliability; repeatability; survey methods;
validity
ID YOUNG-ADULTS CARDIA; RISK DEVELOPMENT; RECRUITMENT; POPULATION;
AGREEMENT; KAPPA
AB Background: Evaluation of the prevalence and incidence of asthma and research into its etiology often rely on self-reported information. We conducted this analysis to investigate reliability in reporting asthma history across categories of demographic and socio-economic characteristics. Methods: We analyzed data from 3109 participants in the Coronary Artery Risk Development in Young Adults study, a longitudinal study of African-American and white adults. Responses to self-administered questionnaires completed at 15- and 20-year follow-up exams were used to evaluate agreement in reporting asthma history and age at diagnosis and assess variation in agreement across categories of demographic and health-related characteristics. Results: A history of asthma was reported by 12% of participants at the 15-year exam and 11% of participants at the 20-year exam, with 97% agreement and an overall Kappa coefficient of 0.845 (95% confidence interval: 0.815-0.874). Kappa coefficients were higher among women than men and increased monotonically across categories of educational attainment. One-hundred eight participants (35%) reported exactly the same age at diagnosis at the two time points; for another 120 (39%), the difference in reported ages was <= 2 years. Age at asthma diagnosis reported at the 20-year exam was, on an average, 1 year (SD: 5.2) older than that reported at the 15-year exam. Conclusions: Five-year reliability in self-reported asthma history is high, and variation in reporting age at diagnosis is low across categories of participant characteristics. Nevertheless, agreement in responses at two times does not guarantee that self-administered questionnaires are sensitive tools for detecting a true asthma history.
C1 [Mirabelli, Maria C.; Beavers, Suzanne F.] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA.
[Flanders, W. Dana] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.
[Chatterjee, Arjun B.] Wake Forest Sch Med, Dept Internal Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC USA.
RP Mirabelli, MC (reprint author), 4770 Buford Highway NE,Mailstop F-60, Atlanta, GA 30341 USA.
EM zif7@cdc.gov
OI Mirabelli, Maria/0000-0002-3540-0085
FU Intramural CDC HHS [CC999999]
NR 17
TC 5
Z9 5
U1 0
U2 3
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0277-0903
EI 1532-4303
J9 J ASTHMA
JI J. Asthma
PD NOV
PY 2014
VL 51
IS 9
BP 956
EP 963
DI 10.3109/02770903.2014.930480
PG 8
WC Allergy; Respiratory System
SC Allergy; Respiratory System
GA AS2AA
UT WOS:000344080200010
PM 24894742
ER
PT J
AU Wright, NC
Looker, AC
Saag, KG
Curtis, JR
Delzell, ES
Randall, S
Dawson-Hughes, B
AF Wright, Nicole C.
Looker, Anne C.
Saag, Kenneth G.
Curtis, Jeffrey R.
Delzell, Elizabeth S.
Randall, Susan
Dawson-Hughes, Bess
TI The Recent Prevalence of Osteoporosis and Low Bone Mass in the United
States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; LOW BONE MASS; PREVALENCE; NHANES
ID INCIDENT VERTEBRAL FRACTURES; NURSING-HOME RESIDENTS; OLDER US ADULTS;
HIP FRACTURE; NHANES-III; INCREASED MORTALITY; NATIONAL-HEALTH; RISK;
WOMEN; DEFORMITIES
AB The goal of our study was to estimate the prevalence of osteoporosis and low bone mass based on bone mineral density (BMD) at the femoral neck and the lumbar spine in adults 50 years and older in the United States (US). We applied prevalence estimates of osteoporosis or low bone mass at the femoral neck or lumbar spine (adjusted by age, sex, and race/ethnicity to the 2010 Census) for the noninstitutionalized population aged 50 years and older from the National Health and Nutrition Examination Survey 2005-2010 to 2010 US Census population counts to determine the total number of older US residents with osteoporosis and low bone mass. There were more than 99 million adults aged 50 years and older in the US in 2010. Based on an overall 10.3% prevalence of osteoporosis, we estimated that in 2010, 10.2 million older adults had osteoporosis. The overall low bone mass prevalence was 43.9%, from which we estimated that 43.4 million older adults had low bone mass. We estimated that 7.7 million non-Hispanic white, 0.5 million non-Hispanic black, and 0.6 million Mexican American adults had osteoporosis, and another 33.8, 2.9, and 2.0 million had low bone mass, respectively. When combined, osteoporosis and low bone mass at the femoral neck or lumbar spine affected an estimated 53.6 million older US adults in 2010. Although most of the individuals with osteoporosis or low bone mass were non-Hispanic white women, a substantial number of men and women from other racial/ethnic groups also had osteoporotic BMD or low bone mass. (c) 2014 American Society for Bone and Mineral Research.
C1 [Wright, Nicole C.; Delzell, Elizabeth S.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA.
[Looker, Anne C.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
[Saag, Kenneth G.; Curtis, Jeffrey R.] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Randall, Susan] Natl Osteoporosis Fdn, Washington, DC USA.
[Dawson-Hughes, Bess] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
RP Wright, NC (reprint author), 1665 Univ Blvd,RPHB 230N, Birmingham, AL 35294 USA.
EM ncwright@uab.edu
FU University of Alabama at Birmingham; National Osteoporosis Foundation
FX This work was funded by a contract between University of Alabama at
Birmingham and The National Osteoporosis Foundation. The findings and
conclusions in this study are those of the authors and do not
necessarily represent the views of the Centers for Disease Control and
Prevention.
NR 43
TC 103
Z9 103
U1 7
U2 28
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2014
VL 29
IS 11
BP 2520
EP 2526
DI 10.1002/jbmr.2269
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AS4DF
UT WOS:000344222800022
PM 24771492
ER
PT J
AU Sawadogo, S
Shiningavamwe, A
Chang, J
Maher, AD
Zhang, GQ
Yang, CF
Gaeb, E
Kaura, H
Ellenberger, D
Lowrance, DW
AF Sawadogo, Souleymane
Shiningavamwe, Andreas
Chang, Joy
Maher, Andrew D.
Zhang, Guoqing
Yang, Chunfu
Gaeb, Esegiel
Kaura, Harold
Ellenberger, Dennis
Lowrance, David W.
TI Limited Utility of Dried-Blood- and Plasma Spot-Based Screening for
Antiretroviral Treatment Failure with Cobas Ampliprep/TaqMan HIV-1
Version 2.0
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID VIRAL LOAD; WHOLE-BLOOD; FILTER-PAPER; TYPE-1 RNA; QUANTIFICATION;
SPECIMENS; ASSAY
AB The 2013 WHO antiretroviral therapy (ART) guidelines recommend dried blood spots (DBS) as an alternative specimen type for viral load (VL) monitoring. We assessed the programmatic utility of screening for antiretroviral (ARV) treatment failure (TF) at 5,000 and 1,000 copies/ml using DBS and dried plasma spots (DPS) with a commonly used VL assay, the Roche Cobas Ampliprep/ Cobas TaqMan V.2.0 (CAP/CTM). Plasma, DBS, and DPS were prepared from 839 whole-blood specimens collected from patients on ART for >= 6 months at three public facilities in Namibia. Using the CAP/CTM test, VL were measured in plasma, DBS, and DPS, and the results were compared using the plasma VL as the reference standard. The clinical sensitivities, specificities, and positive (PPV) and negative predictive values (NPV) of DBS at ARV TF diagnostic thresholds of 5,000 copies/ml and 1,000 copies/ml were 0.99, 0.55, 0.33, and 0.99 and 0.99, 0.26, 0.29, and 0.99, respectively, and for DPS at TF diagnostic thresholds of 5,000 copies/ml and 1,000 copies/ml, they were 0.88, 0.98, 0.92, and 0.97 and 0.91, 0.96, 0.89, and 0.97, respectively. The prevalences of TF were overestimated in DBS by 33% and 57% at these two thresholds, respectively. A high rate of false-positive results would occur if the CAP/CTM with DBS were to be used to screen for ARV TF. WHO recommendations for DBS-based VL monitoring should be specific to the VL assay version and type. Despite the better performance of DPS, the programmatic utility for TF screening may be limited by requirements for processing the whole blood at the collection site.
C1 [Sawadogo, Souleymane; Maher, Andrew D.; Lowrance, David W.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Windhoek, Namibia.
[Shiningavamwe, Andreas; Gaeb, Esegiel; Kaura, Harold] Namibia Inst Pathol, Windhoek, Namibia.
[Chang, Joy; Zhang, Guoqing; Yang, Chunfu; Ellenberger, Dennis] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA.
RP Sawadogo, S (reprint author), US Ctr Dis Control & Prevent, Div Global HIV AIDS, Windhoek, Namibia.
EM ssawadogo@cdc.gov
RI Yang, Chunfu/G-6890-2013
FU President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers
for Disease Control and Prevention; Namibia Institute of Pathology (NIP)
FX This research was partially supported by the President's Emergency Plan
for AIDS Relief (PEPFAR) through the Centers for Disease Control and
Prevention and the Namibia Institute of Pathology (NIP).
NR 27
TC 5
Z9 5
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD NOV
PY 2014
VL 52
IS 11
BP 3878
EP 3883
DI 10.1128/JCM.02063-14
PG 6
WC Microbiology
SC Microbiology
GA AS3EO
UT WOS:000344159500009
PM 25143579
ER
PT J
AU Vaughn, MF
Delisle, J
Johnson, J
Daves, G
Williams, C
Reber, J
Mendell, NL
Bouyer, DH
Nicholson, WL
Moncayo, AC
Meshnick, SR
AF Vaughn, Meagan F.
Delisle, Josie
Johnson, Joey
Daves, Gaylen
Williams, Carl
Reber, Jodi
Mendell, Nicole L.
Bouyer, Donald H.
Nicholson, William L.
Moncayo, Abelardo C.
Meshnick, Steven R.
TI Seroepidemiologic Study of Human Infections with Spotted Fever Group
Rickettsiae in North Carolina
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID AMBLYOMMA-AMERICANUM ACARI; NEWLY RECOGNIZED CAUSE; TICK BITE;
UNITED-STATES; PARKERI INFECTION; DISEASES; PREVALENCE; ANTIBODIES;
MACULATUM; DIAGNOSIS
AB Increasing entomologic and epidemiologic evidence suggests that spotted fever group rickettsiae (SFGR) other than Rickettsia rickettsii are responsible for spotted fever rickettsioses in the United States. A retrospective seroepidemiologic study was conducted on stored acute- and convalescent-phase sera that had been submitted for Rocky Mountain spotted fever testing to the North Carolina State Laboratory of Public Health. We evaluated the serologic reactivity of the paired sera to R. rickettsii, Rickettsia parkeri, and Rickettsia amblyommii antigens. Of the 106 eligible pairs tested, 21 patients seroconverted to one or more antigens. Cross-reactivity to multiple antigens was observed in 10 patients, and seroconversions to single antigens occurred in 11 patients, including 1 against R. rickettsii, 4 against R. parkeri, and 6 against R. amblyommii. Cross-absorption of cross-reactive sera and/or Western blots identified two presumptive cases of infection with R. parkeri, two presumptive cases of infection with R. rickettsii, and one presumptive case of infection with R. amblyommii. These findings suggest that species of SFGR other than R. rickettsii are associated with illness among North Carolina residents and that serologic testing using R. rickettsii antigen may miss cases of spotted fever rickettsioses caused by other species of SFGR.
C1 [Vaughn, Meagan F.; Meshnick, Steven R.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
[Delisle, Josie; Moncayo, Abelardo C.] Tennessee Dept Hlth, Nashville, TN USA.
[Johnson, Joey; Daves, Gaylen] North Carolina State Lab Publ Hlth, Raleigh, NC USA.
[Williams, Carl; Reber, Jodi] North Carolina Div Publ Hlth, Raleigh, NC USA.
[Mendell, Nicole L.; Bouyer, Donald H.] Univ Texas Med Branch Galveston, Ctr Trop Dis, Ctr Biodef & Emerging Infect Dis, Dept Pathol, Galveston, TX USA.
[Nicholson, William L.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA USA.
RP Vaughn, MF (reprint author), Rho Inc, Chapel Hill, NC 27514 USA.
EM meagan_vaughn@rhoworld.com
FU Centers for Disease Control and Prevention; National Institute for
Occupational Safety and Health [5R01-OH009874]
FX This work was supported by a grant from the Centers for Disease Control
and Prevention and the National Institute for Occupational Safety and
Health (grant no. 5R01-OH009874).
NR 29
TC 10
Z9 10
U1 4
U2 14
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD NOV
PY 2014
VL 52
IS 11
BP 3960
EP 3966
DI 10.1128/JCM.01733-14
PG 7
WC Microbiology
SC Microbiology
GA AS3EO
UT WOS:000344159500020
PM 25187639
ER
PT J
AU Gladney, LM
Tarr, CL
AF Gladney, Lori M.
Tarr, Cheryl L.
TI Molecular and Phenotypic Characterization of Vibrio navarrensis Isolates
Associated with Human Illness
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID IDENTIFICATION; SEQUENCES; GENETICS
AB We characterized 18 Vibrio isolates, including 15 recovered from human clinical specimens, and found that they clustered with two previously characterized Vibrio navarrensis isolates in a phylogenetic analysis. Four of the 18 strains may represent a new Vibrio species, distinct from V. navarrensis. The potential role of V. navarrensis in human disease needs further investigation.
C1 [Gladney, Lori M.; Tarr, Cheryl L.] Ctr Dis Control & Prevent, Natl Ctr Emerging Zoonot & Infect Dis, Div Foodborne Waterborne & Environm Dis, Enter Dis Lab Branch, Atlanta, GA 30333 USA.
[Gladney, Lori M.] IHRC Inc, Atlanta, GA USA.
RP Tarr, CL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging Zoonot & Infect Dis, Div Foodborne Waterborne & Environm Dis, Enter Dis Lab Branch, Atlanta, GA 30333 USA.
EM ctarr@cdc.gov
NR 13
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD NOV
PY 2014
VL 52
IS 11
BP 4070
EP 4074
DI 10.1128/JCM.01544-14
PG 5
WC Microbiology
SC Microbiology
GA AS3EO
UT WOS:000344159500045
PM 25187632
ER
PT J
AU Allen, MB
Pritt, BS
Sloan, LM
Paddock, CD
Musham, CK
Ramos, JM
Cetin, N
Rosenbaum, ER
AF Allen, M. Brandon
Pritt, Bobbi S.
Sloan, Lynne M.
Paddock, Christopher D.
Musham, Chaitanya K.
Ramos, Jeanette M.
Cetin, Neslihan
Rosenbaum, Eric R.
TI First Reported Case of Ehrlichia ewingii Involving Human Bone Marrow
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID HUMAN GRANULOCYTIC EHRLICHIOSIS; HUMAN MONOCYTIC EHRLICHIOSIS;
POLYMERASE-CHAIN-REACTION; ANAPLASMA-PHAGOCYTOPHILUM; FATAL
EHRLICHIOSIS; HGE AGENT; CHAFFEENSIS; INFECTION; DIAGNOSIS; STRAINS
AB A 65-year-old female with a history of multiple tick bites presented with fever and pancytopenia. Intracytoplasmic rickettsial morulae were detected on peripheral smear and bone marrow biopsy specimens, and PCR amplified Ehrlichia ewingii DNA from both specimens. To our knowledge, this is the first report of E. ewingii infection of human bone marrow.
C1 [Allen, M. Brandon; Ramos, Jeanette M.; Cetin, Neslihan; Rosenbaum, Eric R.] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA.
[Pritt, Bobbi S.; Sloan, Lynne M.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Paddock, Christopher D.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA.
[Musham, Chaitanya K.] Univ Arkansas Med Sci, Dept Internal Med, Little Rock, AR 72205 USA.
RP Rosenbaum, ER (reprint author), Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA.
EM errosenbaum@uams.edu
OI Pritt, Bobbi/0000-0003-0261-1326
NR 25
TC 4
Z9 4
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD NOV
PY 2014
VL 52
IS 11
BP 4102
EP 4104
DI 10.1128/JCM.01670-14
PG 3
WC Microbiology
SC Microbiology
GA AS3EO
UT WOS:000344159500053
PM 25187638
ER
PT J
AU Ford, ES
Cunningham, TJ
Mercado, CI
AF Ford, Earl S.
Cunningham, Timothy J.
Mercado, Carla I.
TI Lung function and metabolic syndrome: Findings of National Health and
Nutrition Examination Survey 2007-2010
SO JOURNAL OF DIABETES
LA English
DT Article
DE chronic obstructive pulmonary disease; cross-sectional studies;
metabolic syndrome; spirometry
ID PULMONARY-FUNCTION; RISK-FACTORS; ADULTS; ASSOCIATION; OBESITY; MALES;
US
AB Background: Considerable uncertainty remains about obstructive lung function (OLF) in adults with metabolic syndrome (MetS). The aim of the present study was to examine pulmonary function status in adults with and without MetS.
Methods: We used data from 3109 participants aged >= 20 years of the National Health and Nutrition Examination Survey 2007-2010. Subjects' MetS status was established on the basis of the 2009 harmonizing definition. Participants received spirometry.
Results: After age adjustment, 79.3% (SE 1.1) of participants with MetS had normal lung function, 8.7% (0.9) had restrictive lung function (RLF), 7.1% (0.8) had mild OLF, and 4.8% (0.6) had moderate OLF or worse. Among participants without MetS, these estimates were 78.7% (1.2), 3.9% (0.6), 10.9% (1.1), and 6.4% (0.8), respectively. After multiple adjustment, participants with MetS were more likely to have RLF (adjusted prevalence ratio [ aPR] 2.20; 95% confidence interval [ CI] 1.67, 2.90) and less likely to have any OLF (aPR 0.73; 95% CI 0.62, 0.86) than those without MetS. Furthermore, participants with MetS had lower mean levels of forced expiratory volume in one second (FEV1), FEV1 % predicted, forced vital capacity (FVC), and FVC % predicted, but a higher FEV1/FVC ratio than participants without MetS. Mean levels of FEV1, FEV1 % predicted, FVC, and FVC % predicted declined significantly, but not the FEV1 /FVC ratio, as the number of components increased.
Conclusions: Compared with adults without MetS, spirometry is more likely to show a restrictive pattern and less likely to show an obstructive pattern among adults with MetS.
C1 [Ford, Earl S.; Cunningham, Timothy J.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
[Mercado, Carla I.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
RP Ford, ES (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,MS F78, Atlanta, GA 30341 USA.
EM eford@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 19
TC 2
Z9 2
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1753-0393
EI 1753-0407
J9 J DIABETES
JI J. Diabetes
PD NOV
PY 2014
VL 6
IS 6
BP 603
EP 613
DI 10.1111/1753-0407.12136
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AS6BS
UT WOS:000344350500017
PM 26677470
ER
PT J
AU Zonfrillo, MR
Sauber-Schatz, EK
Hoffman, BD
Durbin, DR
AF Zonfrillo, Mark R.
Sauber-Schatz, Erin K.
Hoffman, Benjamin D.
Durbin, Dennis R.
TI Pediatricians' Self-Reported Knowledge, Attitudes, and Practices about
Child Passenger Safety
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID INJURY PREVENTION; RESTRAINT USE; RECOMMENDATIONS; PHYSICIANS; PARENTS
AB Objective To evaluate pediatricians' self-reported knowledge, attitudes, and dissemination practices regarding the new American Academy of Pediatrics' (AAP) child passenger safety (CPS) policy recommendations.
Study design A cross-sectional survey was distributed to pediatric primary care physicians via AAP e-mail distribution lists. Knowledge, attitudes, and practices related to current AAP CPS recommendations and the revised policy statement were ascertained.
Results There were 718 respondents from 3497 physicians with active e-mail addresses, resulting in a 20.5% response rate, of which 533 were eligible based on the initial survey question. All 6 CPS knowledge and scenario-based items were answered correctly by 52.9% of the sample; these respondents were identified as the "high knowledge" group. Pediatricians with high knowledge were more likely to be female (P < .001), to have completed a pediatrics residency (vs medicine-pediatrics) (P = .03), and have a child between 4 and 7 years of age (P = .001). CPS information was distributed more frequently at routine health visits for patients 0-2 years of age vs those 4-12 years of age. Those with high knowledge were less likely to report several specific barriers to dissemination of CPS information, more likely to allot adequate time and discuss CPS with parents, and had greater confidence for topics related to all CPS topics.
Conclusions Although CPS knowledge is generally high among respondents, gaps in knowledge still exist. Knowledge is associated with attitudes, practices, barriers, and facilitators of CPS guideline dissemination. These results identify opportunities to increase knowledge and implement strategies to routinely disseminate CPS information in the primary care setting.
C1 [Zonfrillo, Mark R.; Durbin, Dennis R.] Childrens Hosp Philadelphia, Div Emergency Med, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA.
[Zonfrillo, Mark R.; Durbin, Dennis R.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Sauber-Schatz, Erin K.] Ctr Dis Control & Prevent, Home Recreat & Transportat Branch, Natl Ctr Injury Prevent & Control, Atlanta, GA USA.
[Hoffman, Benjamin D.] Oregon Hlth & Sci Univ, Dept Pediat, Doernbecher Childrens Hosp, Portland, OR 97201 USA.
RP Zonfrillo, MR (reprint author), Childrens Hosp Philadelphia, Div Emergency Med, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM zonfrillo@email.chop.edu
OI Zonfrillo, Mark/0000-0002-0610-9563
FU National Institutes of Health, Eunice Kennedy Shriver National Institute
of Child Health and Human Development [1K08HD073241-01]
FX Supported by the National Institutes of Health, Eunice Kennedy Shriver
National Institute of Child Health and Human Development
(1K08HD073241-01). The views presented are those of the authors and not
necessarily the views or official position of the National Institutes of
Health or the Centers for Disease Control and Prevention. The authors
declare no conflicts of interest.
NR 26
TC 3
Z9 3
U1 1
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD NOV
PY 2014
VL 165
IS 5
BP 1040
EP U231
DI 10.1016/j.jpeds.2014.07.041
PG 8
WC Pediatrics
SC Pediatrics
GA AS4HP
UT WOS:000344235000035
PM 25195160
ER
PT J
AU Tsai, RJ
Luckhaupt, SE
Schumacher, P
Cress, RD
Deapen, DM
Calvert, GM
AF Tsai, Rebecca J.
Luckhaupt, Sara E.
Schumacher, Pam
Cress, Rosemary D.
Deapen, Dennis M.
Calvert, Geoffrey M.
TI Acute myeloid leukemia risk by industry and occupation
SO LEUKEMIA & LYMPHOMA
LA English
DT Article
DE Acute myeloid leukemia; industry; occupation; risk factors
ID ZEALAND CASE-CONTROL; CANCER-MORTALITY; PROSTATE-CANCER; AGRICULTURAL
HEALTH; PESTICIDE EXPOSURE; CLEANING WORKERS; FARMERS; STATES; MEN;
MINNESOTA
AB Acute myeloid leukemia (AML) is the most common type of leukemia found in adults. Identifying jobs that pose a risk for AML may be useful for identifying new risk factors. A matched case-control analysis was conducted using California Cancer Registry data from 1988 to 2007. This study included 8999 cases of AML and 24 822 controls. Industries with a statistically significant increased AML risk were construction (matched odds ratio [mOR] = 1.13); crop production (mOR = 1.41); support activities for agriculture and forestry (mOR = 2.05); and animal slaughtering and processing (mOR = 2.09). Among occupations with a statistically significant increased AML risk were miscellaneous agricultural workers (mOR = 1.76); fishers and related fishing workers (mOR = 2.02); nursing, psychiatric and home health aides (mOR = 1.65); and janitors and building cleaners (mOR = 1.54). Further investigation is needed to confirm study findings and to identify specific exposures responsible for the increased risks.
C1 [Tsai, Rebecca J.; Luckhaupt, Sara E.; Schumacher, Pam; Calvert, Geoffrey M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA.
[Cress, Rosemary D.] Canc Registry Greater Calif, Inst Publ Hlth, Sacramento, CA USA.
[Cress, Rosemary D.] UC Davis Sch Med, Dept Publ Hlth Sci, Davis, CA USA.
[Deapen, Dennis M.] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles Canc Surveillance Program, Los Angeles, CA USA.
RP Tsai, RJ (reprint author), NIOSH, 4676 Columbia Pkwy,R-17, Cincinnati, OH 45226 USA.
EM rtsai@cdc.gov
OI Tsai, Rebecca/0000-0001-8656-9836
FU California Department of Health Services, California Health and Safety
[103885]; National Cancer Institute, National Institutes of Health,
Department of Health and Human Services [N01-PC-2010-00035]; Centers for
Disease Control and Prevention [1U58DP000807-3]
FX The authors thank the following individuals for their review of earlier
versions of this manuscript: Dr. Aaron Blair and Dr. David McLean. The
collection of data used in this publication was supported by the
California Department of Health Services as part of the statewide cancer
reporting program mandated by California Health and Safety Code Section
103885; by the National Cancer Institute, National Institutes of Health,
Department of Health and Human Services under Contract No.
N01-PC-2010-00035; and grant number 1U58DP000807-3 from the Centers for
Disease Control and Prevention.
NR 51
TC 1
Z9 1
U1 2
U2 4
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1042-8194
EI 1029-2403
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PD NOV
PY 2014
VL 55
IS 11
BP 2584
EP 2591
DI 10.3109/10428194.2014.894189
PG 8
WC Oncology; Hematology
SC Oncology; Hematology
GA AS5XD
UT WOS:000344339000027
PM 24547710
ER
PT J
AU Malek, AM
Stickler, DE
Antao, VC
Horton, DK
AF Malek, Angela M.
Stickler, David E.
Antao, Vinicius C.
Horton, D. Kevin
TI THE NATIONAL ALS REGISTRY: A RECRUITMENT TOOL FOR RESEARCH
SO MUSCLE & NERVE
LA English
DT Article
DE ALS; amyotrophic lateral sclerosis; National ALS Registry; recruitment;
research
ID AMYOTROPHIC-LATERAL-SCLEROSIS; DOUBLE-BLIND; PLACEBO; TRIAL
AB Introduction: Subject recruitment is critical for understanding fatal diseases like ALS, however linking patients with researchers can be challenging. The U.S. population-based National ALS Registry allows recruitment of persons with ALS (PALS) for research opportunities. Methods: The Registry's Research Notification Mechanism was used to recruit PALS aged 21 years; participants completed a Web-based epidemiologic survey. PALS (n=2,232) were sent an email describing the study, and 268 surveys were completed. Results: The mean age (+/- SD) of eligible participants was 57.7 +/- 9.3 years for men and 61.5 +/- 8.9 for women. Most were men (63%) and Caucasian (92%). Of 256 potentially eligible participants, 37.5% (n=96) returned an authorization to disclose protected health information. ALS was confirmed for 94% (83/88) from physician responses. Conclusions: This analysis demonstrates the National ALS Registry's usefulness in recruiting PALS for research. This recruitment source can potentially foster the discovery of better treatment options and therapies, and of prevention strategies. Muscle Nerve50: 830-834, 2014
C1 [Malek, Angela M.; Stickler, David E.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Antao, Vinicius C.; Horton, D. Kevin] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA USA.
RP Malek, AM (reprint author), Med Univ S Carolina, Dept Neurosci, 135 Cannon St,Room 305L, Charleston, SC 29425 USA.
EM malek@musc.edu
FU Intramural CDC HHS [CC999999]; NCATS NIH HHS [UL1 TR000062]
NR 10
TC 4
Z9 4
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD NOV
PY 2014
VL 50
IS 5
BP 830
EP 834
DI 10.1002/mus.24421
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AS6KY
UT WOS:000344373700015
PM 25111654
ER
PT J
AU Jamieson, DJ
Uyeki, TM
Callaghan, WM
Meaney-Delman, D
Rasmussen, SA
AF Jamieson, Denise J.
Uyeki, Timothy M.
Callaghan, William M.
Meaney-Delman, Dana
Rasmussen, Sonja A.
TI What Obstetrician-Gynecologists Should Know About Ebola A Perspective
From the Centers for Disease Control and Prevention
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article
ID HEMORRHAGIC-FEVER; OUTBREAK
AB West Africa is currently in the midst of the largest Ebola outbreak in history. Although there have been no Ebola virus disease cases identified in the United States, two U.S. health care workers with Ebola virus disease were medically evacuated from Liberia to the United States in early August 2014. The Centers for Disease Control and Prevention has been working closely with other U.S. government agencies and international and nongovernmental partners for several months to respond to this global crisis. Limited evidence suggests that pregnant women are at increased risk for severe illness and death when infected with Ebola virus, but there is no evidence to suggest that pregnant women are more susceptible to Ebola virus disease. In addition, pregnant women with Ebola virus disease appear to be at an increased risk for spontaneous abortion and pregnancy-associated hemorrhage. Neonates born to mothers with Ebola virus disease have not survived. Although it is very unlikely that obstetrician-gynecologists (ob-gyns) in the United States will diagnose or treat a patient with Ebola virus disease, it is important that all health care providers are prepared to evaluate and care for these patients. Specifically, U.S. health care providers, including ob-gyns, should ask patients about recent travel and should know the signs and symptoms of Ebola virus disease and what to do if assessing a patient with compatible illness. This article provides general background information on Ebola and specifically addresses what is known about Ebola virus disease in pregnancy and the implications for practicing ob-gyns in the United States.
C1 Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30341 USA.
Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30341 USA.
Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA 30341 USA.
RP Jamieson, DJ (reprint author), Ctr Dis Control & Prevent, Womens Hlth & Fertil Branch, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS F74, Atlanta, GA 30341 USA.
EM djj0@cdc.gov
NR 24
TC 24
Z9 24
U1 0
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7844
EI 1873-233X
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD NOV
PY 2014
VL 124
IS 5
BP 1005
EP 1010
DI 10.1097/AOG.0000000000000533
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AS3ES
UT WOS:000344159900021
PM 25203368
ER
PT J
AU Lopez, AS
Ortega-Sanchez, IR
Bialek, SR
AF Lopez, Adriana S.
Ortega-Sanchez, Ismael R.
Bialek, Stephanie R.
TI Congenital Cytomegalovirus-related Hospitalizations in Infants < 1 Year
of Age, United States, 1997-2009
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE hospitalization rates; medical costs; congenital CMV
ID INCLUSION DISEASE; FOLLOW-UP; INFECTION; MORTALITY
AB Background: An estimated 3600 infants born with congenital cytomegalovirus (cCMV) infection annually in the United States are symptomatic at birth. The proportion of infants with symptomatic cCMV infection who require hospitalization is unknown yet important for understanding the full disease and economic burdens of cCMV.
Methods: Data from the Healthcare Cost and Utilization Project Kids' Inpatient Databases were analyzed to determine numbers and rates of cCMV-related hospitalizations among infants for 1997, 2000, 2003, 2006 and 2009, the years the survey was conducted. A cCMV-related hospitalization was defined as a hospitalization with an International Classification of Diseases, 9th revision, Clinical Modification code of 771.1 in an infant without HIV or transplant-related codes. After applying hospital type-specific cost-to-charge ratios and adjusting to 2012 US dollars, total medical costs associated with cCMV-related hospitalizations were assessed. Results were extrapolated to represent national estimates.
Results: Among infants <1 year of age in the United States, an estimated annual average of 747 cCMV-related hospitalizations (18.6/100,000 per year) were coded during the 5 study years; 408 (55%) were among infants <1 month of age (122.0/100,000 per year). Approximately 4% of hospitalizations among infants <1 year resulted in death. Total estimated annual cost associated with cCMV-related hospitalizations among the US infants <1 year was at least $14.3 million.
Conclusions: cCMV infection is associated with substantial numbers of hospitalizations, medical costs and mortality among the US infants. The true burden and costs of cCMV disease are likely much higher than our estimates when underascertainment of cCMV and total costs related to services and hospitalizations beyond the first year of life are considered.
C1 [Lopez, Adriana S.; Ortega-Sanchez, Ismael R.; Bialek, Stephanie R.] Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
RP Lopez, AS (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30333 USA.
EM alopez@cdc.gov
NR 19
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 2014
VL 33
IS 11
BP 1119
EP 1123
DI 10.1097/INF.0000000000000421
PG 5
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA AS6DH
UT WOS:000344354400011
PM 24871641
ER
PT J
AU Auld, AF
Tuho, MZ
Ekra, KA
Shiraishi, RW
Mohamed, F
Kouakou, JS
Ettiegne-Traore, V
Sabatier, J
Essombo, J
Rivadeneira, ED
Adjorlolo-Johnson, G
Marlink, R
Ellerbrock, TV
AF Auld, Andrew F.
Tuho, Moise Z.
Ekra, Kunomboa A.
Shiraishi, Ray W.
Mohamed, Fayama
Kouakou, Joseph S.
Ettiegne-Traore, Virginie
Sabatier, Jennifer
Essombo, Joseph
Rivadeneira, Emilia D.
Adjorlolo-Johnson, Georgette
Marlink, Richard
Ellerbrock, Tedd V.
TI Temporal Trends in Mortality and Loss to Follow-up Among Children
Enrolled in Cote d'Ivoire's National Antiretroviral Therapy Program
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE pediatric antiretroviral therapy; outcomes; Cote d'Ivoire
ID PHYSICIAN-PATIENT RELATIONSHIPS; HIV-INFECTED CHILDREN; HIV-1-INFECTED
CHILDREN; MEDICATION ADHERENCE; MULTIPLE IMPUTATION; MISSING VALUES;
SOUTH-AFRICA; SCALING-UP; OUTCOMES; SURVIVAL
AB Background: During 2004-2008, >2000 children (<15 years old) initiated antiretroviral therapy (ART) in Cote d'Ivoire. Nationally representative outcomes, temporal trends in outcomes during 2004-2008 and site-level outcome determinants have not been investigated.
Methods: Incidence rates of death, loss to follow-up (LTFU) and attrition (death or LTFU) were evaluated in a nationally representative, retrospective cohort study among 2,110 children, who initiated ART at 29 facilities in Cote d'Ivoire during 2004-2008.
Results: At ART initiation, 54% were male, 1% was HIV-2-infected and median age was 5.1 years. Median CD4% was 11%, and 61% had weight-for-age Z-score (WAZ) <=-2. Vaccination completion was documented for 9% of children. Eleven of 29 facilities had an integrated nutrition program. Over 4585 person-years of ART, 237 children died and 427 became LTFU. Twelve-month attrition was 22% overall, but increased from 4% to 34% during 2004-2008, due to increases in 12-month mortality (from 3-11%) and 12-month LTFU (from 2% to 23%). In adjusted analysis, compared with enrollees in 2004, enrollees in 2008 had nearly 4-fold higher mortality and 8-fold higher LTFU. World Health Organization stage III/IV, CD4% <10%, WAZ <= 2 and hemoglobin <8 g/dL, were predictive of mortality. Incomplete vaccination was predictive of mortality and LTFU. Facilities with nutrition programs had lower LTFU and mortality rates. Clinics reporting nurse dissatisfaction with working conditions had higher LTFU rates.
Conclusion: Investigation of causes of increasing mortality and LTFU is needed. Ensuring earlier ART initiation, vaccination completion, scale-up of site-level nutrition programs and nurse work-environment satisfaction, could improve pediatric ART program outcomes.
C1 [Auld, Andrew F.; Shiraishi, Ray W.; Sabatier, Jennifer; Rivadeneira, Emilia D.; Ellerbrock, Tedd V.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA.
[Tuho, Moise Z.; Ettiegne-Traore, Virginie] Ctr Dis Control & Prevent, Minist Hlth, Natl Program Med Care Persons Living HIV AIDS, Atlanta, GA USA.
[Ekra, Kunomboa A.; Kouakou, Joseph S.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA.
[Mohamed, Fayama; Kouakou, Joseph S.; Essombo, Joseph; Adjorlolo-Johnson, Georgette; Marlink, Richard] Elizabeth Glazer Pediat AIDS Fdn, Los Angeles, CA USA.
[Mohamed, Fayama] Dept Econ & Finance, Directorate Gen Budget & Finance, Abidjan, Cote Ivoire.
RP Auld, AF (reprint author), US Ctr Dis Control & Prevent CDC, 1600 Clifton Rd,Mailstop E04, Atlanta, GA 30333 USA.
EM aauld@cdc.gov
OI Auld, Andrew/0000-0001-5089-9163
FU President's Emergency Plan for AIDS Relief (PEPFAR) through the US
Centers for Disease Control and Prevention
FX This research has been supported by the President's Emergency Plan for
AIDS Relief (PEPFAR) through the US Centers for Disease Control and
Prevention.
NR 56
TC 8
Z9 8
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 2014
VL 33
IS 11
BP 1134
EP 1140
DI 10.1097/INF.0000000000000457
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA AS6DH
UT WOS:000344354400014
PM 25093975
ER
PT J
AU Becker-Dreps, S
Bucardo, F
Vilchez, S
Zambrana, LE
Liu, L
Weber, DJ
Pena, R
Barclay, L
Vinje, J
Hudgens, MG
Nordgren, J
Svensson, L
Morgan, DR
Espinoza, F
Paniagua, M
AF Becker-Dreps, Sylvia
Bucardo, Filemon
Vilchez, Samuel
Enrique Zambrana, Luis
Liu, Lan
Weber, David J.
Pena, Rodolfo
Barclay, Leslie
Vinje, Jan
Hudgens, Michael G.
Nordgren, Johan
Svensson, Lennart
Morgan, Douglas R.
Espinoza, Felix
Paniagua, Margarita
TI Etiology of Childhood Diarrhea After Rotavirus Vaccine Introduction A
Prospective, Population-based Study in Nicaragua
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE childhood; community; diarrhea; Nicaragua; Rotavirus vaccine
ID ENTEROTOXIGENIC ESCHERICHIA-COLI; POLYMERASE CHAIN-REACTION;
DEVELOPING-COUNTRIES; WESTERN KENYA; UNITED-STATES; CHILDREN; DISEASE;
GASTROENTERITIS; SURVEILLANCE; PREVALENCE
AB Background: Nicaragua was the first developing nation to implement routine immunization with the pentavalent rotavirus vaccine (RV5). In this RV5-immunized population, understanding infectious etiologies of childhood diarrhea is necessary to direct diarrhea treatment and prevention efforts.
Methods: We followed a population-based sample of children <5 years in Leon, Nicaragua for diarrhea episodes through household visits. Information was obtained on RV5 history and sociodemographics. Stool samples collected during diarrhea episodes and among healthy children underwent laboratory analysis for viral, bacterial and parasitic enteropathogens. Detection frequency and incidence of each enteropathogen was calculated.
Results: The 826 children in the cohort experienced 677 diarrhea episodes during 607.5 child-years of exposure time (1.1 episodes per child-year). At least 1 enteropathogen was detected among 61.1% of the 337 diarrheal stools collected. The most common enteropathogens among diarrheal stools were: norovirus (20.4%), sapovirus (16.6%), enteropathogenic Escherichia coli (11.3%), Entamoeba histolytica/dispar (8.3%), Giardia lamblia (8.0%) and enterotoxigenic E. coli (7.7%), with rotavirus detected among 5.3% of diarrheal stools. Enteropathogenic Escherichia coli and enterotoxigenic E. coli were frequently detected among stools from healthy children. Among children with diarrhea, norovirus was more commonly detected among younger children (<2 years) and G. lamblia was more commonly detected among older children (2-4 years). The mean age of rotavirus detection was 34.6 months.
Conclusions: In this Central American community after RV5 introduction, rotavirus was not commonly detected among children with diarrhea. Prevention and appropriate management of norovirus and sapovirus should be considered to further reduce the burden of diarrheal disease.
C1 [Becker-Dreps, Sylvia; Weber, David J.; Morgan, Douglas R.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA.
[Bucardo, Filemon; Vilchez, Samuel; Espinoza, Felix; Paniagua, Margarita] Natl Autonomous Univ Nicaragua, Dept Microbiol & Parasitol, Fac Med Sci, Leon UNAN Leon, Leon, Nicaragua.
[Enrique Zambrana, Luis] Ctr Epidemiol & Hlth CIDS, Leon, Nicaragua.
[Liu, Lan; Hudgens, Michael G.] Univ N Carolina, Dept Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
[Pena, Rodolfo] Ctr Hlth Res CIS, Leon, Nicaragua.
[Barclay, Leslie; Vinje, Jan] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Nordgren, Johan; Svensson, Lennart] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden.
[Morgan, Douglas R.] Vanderbilt Univ, Div Gastroenterol, Nashville, TN 37235 USA.
RP Becker-Dreps, S (reprint author), Univ N Carolina, Dept Family Med, Sch Med, Chapel Hill, NC 27599 USA.
EM sbd@unc.edu
FU Merck Investigator-Initiated Studies Program; Thrasher Research Fund;
Fogarty International Center at the National Institutes of Health
[5K01TW008401-04]; NETROPICA [05-N-2010]
FX This study received funding from the Merck Investigator-Initiated
Studies Program (laboratory analysis) and the Thrasher Research Fund
(field work). S. B. D. was supported by 5K01TW008401-04 from the Fogarty
International Center at the National Institutes of Health. F. B.
received support for calicivirus research in Nicaragua from NETROPICA
(05-N-2010).
NR 51
TC 18
Z9 18
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 2014
VL 33
IS 11
BP 1156
EP 1163
DI 10.1097/INF.0000000000000427
PG 8
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA AS6DH
UT WOS:000344354400017
PM 24879131
ER
PT J
AU Thomas, CA
Shwe, T
Bixler, D
del Rosario, M
Grytdal, S
Wang, CB
Haddy, LE
Bialek, SR
AF Thomas, Carrie A.
Shwe, Thein
Bixler, Dee
del Rosario, Maria
Grytdal, Scott
Wang, Chengbin
Haddy, Loretta E.
Bialek, Stephanie R.
TI Two-dose Varicella Vaccine Effectiveness and Rash Severity in Outbreaks
of Varicella Among Public School Students
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE varicella; varicella vaccine; vaccine effectiveness; breakthrough
varicella
ID UNITED-STATES; HEALTHY-CHILDREN; EPIDEMIOLOGY; SURVEILLANCE; COVERAGE;
PROGRAM; TIME; KINDERGARTEN; IMPACT; SITES
AB Background: Universal 2-dose varicella vaccination was recommended in 2006 to further reduce varicella disease burden. This study examined 2-dose varicella vaccine effectiveness (VE) and rash severity in the setting of school-associated varicella outbreaks.
Methods: A case control study was conducted from January 2010 to May 2011 in all West Virginia public schools. Clinically diagnosed cases from varicella outbreaks were matched with classmate controls. Vaccination information was collected from school, health department and healthcare provider immunization information systems.
Results: Among the 133 cases and 365 controls enrolled, VE against all varicella was 83.2% [95% confidence interval (CI): 69.2%-90.8%] for 1-dose of varicella vaccine and 93.9% (95% CI: 86.9%-97.1%) for 2-dose; the incremental VE (2-dose vs. 1-dose) was 63.6% (95% CI: 32.6%-80.3%). In preventing moderate/severe varicella, 1-dose varicella vaccine was 88.2% (95% CI: 72.7%-94.9%) effective, and 2-dose vaccination was 97.5% (95% CI: 91.6%-99.2%) effective, with the incremental VE of 78.6% (95% CI: 40.9%-92.3%). One-dose VE declined along with time since vaccination (VE = 93.0%, 88.0% and 81.8% in <5, 5-9 and = 10 years after vaccination, P = 0.001 for trend). Both 1-and 2-dose breakthrough cases had milder rash than unvaccinated cases (<50 lesion: 24.6%, 49.1% and 70.0% in unvaccinated, 1-dose and 2-dose cases, P < 0.001), and no severe disease was found in 2-dose cases.
Conclusions: Two-dose varicella vaccination is highly effective and confers higher protection than a 1-dose regimen. High 2-dose varicella vaccination coverage should maximize the benefits of the varicella vaccination program and further reduce varicella disease burden in the United States.
C1 [Thomas, Carrie A.; Shwe, Thein; Bixler, Dee; del Rosario, Maria; Haddy, Loretta E.] West Virginia Dept Hlth & Human Resources, Charleston, WV 25301 USA.
[Grytdal, Scott; Wang, Chengbin; Bialek, Stephanie R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Thomas, CA (reprint author), West Virginia Dept Hlth & Human Resources, 350 Capitol St Room 125, Charleston, WV 25301 USA.
EM Carrie.A.Thomas@wv.gov; cwang1@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 35
TC 7
Z9 7
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 2014
VL 33
IS 11
BP 1164
EP 1168
DI 10.1097/INF.0000000000000444
PG 5
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA AS6DH
UT WOS:000344354400019
PM 24911894
ER
PT J
AU Heiman, KE
Grass, JE
Sjolund-Karlsson, M
Bowen, A
AF Heiman, Katherine E.
Grass, Julian E.
Sjoelund-Karlsson, Maria
Bowen, Anna
TI Shigellosis With Decreased Susceptibility to Azithromycin
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
C1 [Heiman, Katherine E.; Grass, Julian E.; Sjoelund-Karlsson, Maria; Bowen, Anna] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Heiman, KE (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
FU Intramural CDC HHS [CC999999]
NR 4
TC 1
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 2014
VL 33
IS 11
BP 1204
EP 1205
DI 10.1097/INF.0000000000000397
PG 3
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA AS6DH
UT WOS:000344354400035
PM 25361413
ER
PT J
AU Person, MK
Esposito, DH
Holman, RC
Mehal, JM
Stoll, BJ
AF Person, Marissa K.
Esposito, Douglas H.
Holman, Robert C.
Mehal, Jason M.
Stoll, Barbara J.
TI Risk Factors for Infectious Disease Death Among Infants in the United
States
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE infant; infectious disease; mortality; birth weight
ID B STREPTOCOCCAL DISEASE; INTRAPARTUM ANTIBIOTIC-PROPHYLAXIS; ONSET
NEONATAL SEPSIS; MORTALITY; PREVENTION; GUIDELINES; OUTCOMES; BURDEN
AB Background: Infectious diseases (IDs) are an important cause of infant mortality in the United States. This study describes maternal and infant characteristics associated with infant ID deaths in the United States.
Methods: Infant deaths with an ID underlying cause of death occurring in the United States were examined using the 2008-2009 Period Linked Birth/Infant Death public use data files. Average annual ID infant mortality rates for singleton infants were calculated. A retrospective case-control study was conducted to determine infant and maternal risk factors for infant ID death among low (LBW) and normal (NBW) birth weight groups. Controls were defined as infants surviving to the end of their birth year. Risk factors for infant ID deaths were determined through multivariable logistic regression.
Results: An estimated 3843 infant ID deaths occurred in the United States during 2008-2009, an overall ID infant mortality rate of 47.5 deaths per 100,000 live births. The mortality rate for LBW and NBW infants were 514.8 and 15.5, respectively. Male sex, younger maternal age (<25 years), a live birth order of fourth or more and low 5-minute Apgar score were associated with increased ID death among LBW and NBW infants. Additionally, black maternal race was associated with increased ID death among LBW infants, and having an unmarried mother was associated with increased ID death among NBW infants.
Conclusions: Awareness of associations with infant ID death should help in development of further strategic measures to reduce infant ID morbidity and mortality.
C1 [Person, Marissa K.; Holman, Robert C.; Mehal, Jason M.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, US Dept HHS, Atlanta, GA USA.
[Esposito, Douglas H.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, US Dept HHS, Atlanta, GA USA.
[Stoll, Barbara J.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA.
[Stoll, Barbara J.] Childrens Healthcare Atlanta, Atlanta, GA USA.
RP Person, MK (reprint author), CDC, 1600 Clifton Rd,MS A-30, Atlanta, GA 30333 USA.
EM WNU6@cdc.gov
FU Centers for Disease Control and Prevention
FX Funded through the Centers for Disease Control and Prevention. The
authors have no other funding or conflicts of interest to disclose.
NR 33
TC 5
Z9 5
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 2014
VL 33
IS 11
BP E280
EP E285
DI 10.1097/INF.0000000000000414
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA AS6DH
UT WOS:000344354400002
PM 24853540
ER
PT J
AU Hart-Cooper, GD
Tao, GY
Stock, JA
Hoover, KW
AF Hart-Cooper, Geoffrey D.
Tao, Guoyu
Stock, Jeffrey A.
Hoover, Karen W.
TI Circumcision of Privately Insured Males Aged 0 to 18 Years in the United
States
SO PEDIATRICS
LA English
DT Article
DE circumcision; neonatal; postneonatal
ID POSTNEONATAL CIRCUMCISION; NEONATAL CIRCUMCISION; POLICY STATEMENT;
CULTURAL-BIAS; INFECTION; NEWBORN; HEALTH; RISK; MEN; PREVALENCE
AB BACKGROUND: Male circumcision confers protection against HIV, sexually transmitted infections, and urinary tract infections. Compared with circumcision of postneonates (>28 days), circumcision of neonates is associated with fewer complications and usually performed with local rather than general anesthesia. We assessed circumcision of commercially insured males during the neonatal or postneonatal period.
METHODS: We analyzed 2010 MarketScan claims data from commercial health plans, using procedural codes to identify circumcisions performed on males aged 0 to 18 years, and diagnostic codes to assess clinical indications for the procedure. Among circumcisions performed in the first year of life, we estimated rates for neonates and postneonates. We estimated the percentage of circumcisions by age among males who had circumcisions in 2010, and the mean payment for neonatal and postneonatal procedures.
RESULTS: We found that 156 247 circumcisions were performed, with 146 213 (93.6%) in neonates and 10 034 (6.4%) in postneonates. The neonatal circumcision rate was 65.7%, and 6.1% of uncircumcised neonates were circumcised by their first birthday. Among postneonatal circumcisions, 46.6% were performed in males younger than 1 year and 25.1% were for nonmedical indications. The mean payment was $285 for a neonatal and $1885 for a postneonatal circumcision.
CONCLUSIONS: The large number of nonmedical postneonatal circumcisions suggests that neonatal circumcision might be a missed opportunity for these boys. Delay of nonmedical circumcision results in greater risk for the child, and a more costly procedure. Discussions with parents early in pregnancy might help them make an informed decision about circumcision of their child.
C1 [Hart-Cooper, Geoffrey D.; Tao, Guoyu; Hoover, Karen W.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA.
[Hart-Cooper, Geoffrey D.] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA 30329 USA.
[Stock, Jeffrey A.] Mt Sinai Hosp, Dept Pediat, New York, NY 10029 USA.
[Stock, Jeffrey A.] Mt Sinai Hosp, Dept Urol, New York, NY 10029 USA.
RP Hoover, KW (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE MS E45, Atlanta, GA 30329 USA.
EM khoover@cdc.gov
FU Centers for Disease Control and Prevention
FX This study was supported by the Centers for Disease Control and
Prevention.
NR 32
TC 2
Z9 2
U1 0
U2 6
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD NOV
PY 2014
VL 134
IS 5
BP 950
EP 956
DI 10.1542/peds.2014-1007
PG 7
WC Pediatrics
SC Pediatrics
GA AS6PU
UT WOS:000344385900044
PM 25332502
ER
PT J
AU Gray, TM
Steup, D
Roberts, LG
O'Callaghan, JP
Hoffman, G
Schreiner, CA
Clark, CR
AF Gray, Thomas M.
Steup, David
Roberts, Linda G.
O'Callaghan, James P.
Hoffman, Gary
Schreiner, Ceinwen A.
Clark, Charles R.
TI Health assessment of gasoline and fuel oxygenate vapors: Reproductive
toxicity assessment
SO REGULATORY TOXICOLOGY AND PHARMACOLOGY
LA English
DT Article
DE Reproductive toxicity; Gasoline vapor condensates; Methyl tert-butyl
ether (MTBE); Ethyl tert butyl ether (ETBE); t-Amyl methyl ether (TAME);
Diisopropyl ether (DIPE); t-Butyl alcohol (TBA); Ethanol (EtOH); Glial
fibrillary acid protein; Fuel oxygenates
ID FORTRAN-IV FUNCTIONS; ETHER; RATS
AB Vapor condensates of baseline gasoline (BGVC), or gasoline-blended with methyl tertiary butyl ether (G/ MTBE), ethyl t-butyl ether (G/ETBE), t-amyl methyl ether (G/TAME), diisopropyl ether (G/DIPE), ethanol (G/EtOH), or t-butyl alcohol (G/TBA) were evaluated for reproductive toxicity in rats at target concentrations of 2000, 10,000, or 20,000 mg/m(3), 6 h/day, 7 days/week. BGVC and G/MTBE were assessed over two generations, the others for one generation. BGVC and G/MTBE F1 offspring were evaluated for neuropathology and changes in regional brain glial fibrillary acidic protein content. No neurotoxicity was observed. Male kidney weight was increased consistent with light hydrocarbon nephropathy. In adult rats, decreased body weight gain and increased liver weight were seen. Spleen weight decreased in adults and pups exposed to G/TBA. No pathological changes to reproductive organs occurred in any study. Decreased food consumption was seen in G/TAME lactating females. Transient decreases in G/TAME offspring weights were observed during lactation. Except for a minor increase in time to mating in G/TBA which did not affect other reproductive parameters, there were no adverse reproductive findings. The NOAEL for reproductive and offspring parameters was 20,000 mg/m(3) for all vapor condensates except for lower offspring NOAELs of 10,000 mg/m(3) for G/TBA and 2000 mg/m(3) for G/TAME. (C) 2014 Elsevier Inc.
C1 [Gray, Thomas M.] Amer Petr Inst, Potomac Falls, VA 20165 USA.
[Steup, David] Shell Oil Co, Houston, TX 77002 USA.
[Roberts, Linda G.] Chevron Energy Technol Co, San Ramon, CA 94583 USA.
[O'Callaghan, James P.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA.
[Hoffman, Gary] Huntingdon We Sci, Princeton Res Ctr, E Millstone, NJ 08873 USA.
[Schreiner, Ceinwen A.] C&C Consulting Toxicol, Meadowbrook, PA 19046 USA.
[Clark, Charles R.] Phillips 66, Bartlesville, OK 74006 USA.
RP Schreiner, CA (reprint author), C&C Consulting Toxicol, 1950 Briarcliff Ave, Meadowbrook, PA 19046 USA.
EM tmgray@reagan.com; david.steup@shell.com; LRoberts@chevron.com;
jdo5@cdc.gov; hoffmang@princeton.huntingdon.com; castox@comcast.net;
okietox@gmail.com
FU Intramural CDC HHS [CC999999]
NR 26
TC 8
Z9 8
U1 3
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0273-2300
EI 1096-0295
J9 REGUL TOXICOL PHARM
JI Regul. Toxicol. Pharmacol.
PD NOV 1
PY 2014
VL 70
IS 2
SU 1
BP S48
EP S57
DI 10.1016/j.yrtph.2014.04.014
PG 10
WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology
SC Legal Medicine; Pharmacology & Pharmacy; Toxicology
GA AS0FQ
UT WOS:000343954000008
PM 24813181
ER
PT J
AU O'Callaghan, JP
Daughtrey, WC
Clark, CR
Schreiner, CA
White, R
AF O'Callaghan, James P.
Daughtrey, Wayne C.
Clark, Charles R.
Schreiner, Ceinwen A.
White, Russell
TI Health assessment of gasoline and fuel oxygenate vapors: Neurotoxicity
evaluation
SO REGULATORY TOXICOLOGY AND PHARMACOLOGY
LA English
DT Article
DE Neurotoxicity; Glial fibrillary acidic protein (GFAP); Astrogliosis;
Gasoline vapor condensates; Methyl tertiary butyl ether; Ethyl t-butyl
ether; t-Amyl methyl ether; Diisopropyl ether; Ethanol; t-Butyl alcohol
ID FIBRILLARY ACIDIC PROTEIN; GLIOTYPIC PROTEINS; RATS
AB Sprague-Dawley rats were exposed via inhalation to vapor condensates of either gasoline or gasoline combined with various fuel oxygenates to assess potential neurotoxicity of evaporative emissions. Test articles included vapor condensates prepared from "baseline gasoline" (BGVC), or gasoline combined with methyl tertiary butyl ether (G/MTBE), ethyl t-butyl ether (G/ETBE), t-amyl methyl ether (G/TAME), diisopropyl ether (G/DIPE), ethanol (G/EtOH), or t-butyl alcohol (G/TBA). Target concentrations were 0, 2000, 10,000 or 20,000 mg/mg(3) and exposures were for 6 h/day, 5 days/week for 13 weeks. The functional observation battery (FOB) with the addition of motor activity (MA) testing, hematoxylin and eosin staining of brain tissue sections, and brain regional analysis of glial fibrillary acidic protein (GFAP) were used to assess behavioral changes, traditional neuropathology and astrogliosis, respectively. FOB and MA data for all agents, except G/TBA, were negative. G/TBA behavioral effects resolved during recovery. Neuropathology was negative for all groups. Analyses of GFAP revealed increases in multiplebrain regions largely limited to males of the G/EtOH group, findings indicative of minor gliosis, most significantly in the cerebellum. Small changes (both increases and decreases) in GFAP were observed for other test agents but effects were not consistent across sex, brain region or exposure concentration. (C) 2014 Elsevier Inc.
C1 [O'Callaghan, James P.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA.
[Daughtrey, Wayne C.] ExxonMobil Biomed Sci Inc, East Annandale, NJ 08801 USA.
[Clark, Charles R.] Phillips 66 Co, Bartlesville, OK USA.
[Schreiner, Ceinwen A.] C&C Consulting Toxicol, Meadowbrook, PA 19046 USA.
[White, Russell] Amer Petr Inst, Washington, DC 20005 USA.
RP Clark, CR (reprint author), 5901 Woodland Rd, Bartlesville, OK 74006 USA.
EM jdo5@cdc.gov; wayne.c.daughtrey@exxonmobil.com; okietox@gmail.com;
castox@comcast.net; whiter@api.org
FU Intramural CDC HHS [CC999999]
NR 25
TC 9
Z9 9
U1 3
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0273-2300
EI 1096-0295
J9 REGUL TOXICOL PHARM
JI Regul. Toxicol. Pharmacol.
PD NOV 1
PY 2014
VL 70
IS 2
SU 1
BP S35
EP S42
DI 10.1016/j.yrtph.2014.05.002
PG 8
WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology
SC Legal Medicine; Pharmacology & Pharmacy; Toxicology
GA AS0FQ
UT WOS:000343954000006
PM 24879970
ER
PT J
AU Kapellusch, JM
Gerr, FE
Malloy, EJ
Garg, A
Harris-Adamson, C
Bao, SS
Burt, SE
Dale, AM
Eisen, EA
Evanoff, BA
Hegmann, KT
Silverstein, BA
Theise, MS
Rempel, DM
AF Kapellusch, Jay M.
Gerr, Frederic E.
Malloy, Elizabeth J.
Garg, Arun
Harris-Adamson, Carisa
Bao, Stephen S.
Burt, Susan E.
Dale, Ann Marie
Eisen, Ellen A.
Evanoff, Bradley A.
Hegmann, Kurt T.
Silverstein, Barbara A.
Theise, Matthew S.
Rempel, David M.
TI Exposure-response relationships for the ACGIH threshold limit value for
hand-activity level: results from a pooled data study of carpal tunnel
syndrome
SO SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH
LA English
DT Article
DE American Conference of Governmental Industrial Hygienists; biomechanical
overload; CTS; epidemiology; HAL; hand force; MSD; musculoskeletal
disorder; peak force; physical exposure; repetition; threshold limit
value; upper extremity
ID INDIVIDUAL RISK-FACTORS; MARTINGALE-BASED RESIDUALS; MUSCULOSKELETAL
DISORDERS; OCCUPATIONAL COHORT; STRAIN INDEX; PREVALENCE; WORKERS;
WORKPLACE; TLV; MODELS
AB Objective This paper aimed to quantify exposure response relationships between the American Conference of Governmental Industrial Hygienists' (ACGIH) threshold limit value (TLV) for hand-activity level (HAL) and incidence of carpal tunnel syndrome (CTS).
Methods Manufacturing and service workers previously studied by six research institutions had their data combined and re-analyzed. CTS cases were defined by symptoms and abnormal nerve conduction. Hazard ratios (HR) were calculated using proportional hazards regression after adjusting for age, gender, body mass index, and CTS predisposing conditions.
Results The longitudinal study comprised 2751 incident-eligible workers, followed prospectively for up to 6.4 years and contributing 6243 person-years of data. Associations were found between CTS and TLV for HAL both as a continuous variable [HR 1.32 per unit, 95% confidence interval (95% CI) 1.11-1.57] and when categorized using the ACGIH action limit (AL) and TLV. Those between the AL and TLV and above the TLV had HR of 1.7 (95% CI 1.2-2.5) and 1.5 (95% CI 1.0-2.1), respectively. As independent variables (in the same adjusted model) the HR for peak force (PF) and HAL were 1.14 per unit (95% CI 1.05-1.25), and 1.04 per unit (95% CI 0.93-1.15), respectively.
Conclusion Those with exposures above the AL were at increased risk of CTS, but there was no further increase in risk for workers above the TLV. This suggests that the current AL may not be sufficiently protective of workers. Combinations of PF and HAL are useful for predicting risk of CTS.
C1 [Kapellusch, Jay M.; Garg, Arun] Univ Wisconsin, Dept Occupat Sci & Technol, Milwaukee, WI 53201 USA.
[Gerr, Frederic E.] Univ Iowa, Coll Publ Hlth, Dept Occupat & Environm Hlth, Iowa City, IA USA.
[Malloy, Elizabeth J.] Amer Univ, Dept Math & Stat, Washington, DC 20016 USA.
[Harris-Adamson, Carisa] Samual Merritt Univ, Dept Phys Therapy, Oakland, CA USA.
[Harris-Adamson, Carisa; Eisen, Ellen A.] Univ Calif Berkeley, Dept Environm Hlth Sci, Berkeley, CA 94720 USA.
[Bao, Stephen S.; Silverstein, Barbara A.] Washington State Dept Labor & Ind, SHARP Program, Olympia, WA 98504 USA.
[Burt, Susan E.] NIOSH, Cincinnati, OH USA.
[Dale, Ann Marie; Evanoff, Bradley A.] Washington Univ, Sch Med, St Louis, MO USA.
[Hegmann, Kurt T.; Theise, Matthew S.] Univ Utah, RMCOEH, Salt Lake City, UT USA.
[Rempel, David M.] Univ Calif San Francisco, Div Occupat & Environm Med, San Francisco, CA 94143 USA.
RP Kapellusch, JM (reprint author), Univ Wisconsin, Dept Occupat Sci & Technol, POB 413 Milwaukee, Milwaukee, WI 53201 USA.
EM kap@uwm.edu
RI Dale, Ann Marie/P-1382-2014;
OI Dale, Ann Marie/0000-0002-5624-8967; Evanoff, Bradley
A./0000-0003-0085-333X
FU Center for Disease Control / NIOSH [R01OH009712]; Washington University
Institute of Clinical and Translational Sciences Award (CTSA) from the
National Center for Advancing Translational Sciences (NCATS) of the
National Institutes of Health (NIH) [UL1 TR000448]
FX This study was supported by research funding from the Center for Disease
Control / NIOSH (R01OH009712). The findings and conclusions in this
report are those of the authors and do not necessarily represent the
views of the NIOSH. The authors would like to acknowledge the efforts of
the research assistants from each of the research study groups that made
the collection of the data possible and the study participants and
employers for their time and willingness to participate in this study.
This study was supported by the Washington University Institute of
Clinical and Translational Sciences Award (CTSA) (grant # UL1 TR000448)
from the National Center for Advancing Translational Sciences (NCATS) of
the National Institutes of Health (NIH). Its contents are solely the
responsibility of the authors and do not necessarily represent the
official view of NIOSH, NCATS, or NIH.
NR 48
TC 9
Z9 9
U1 1
U2 9
PU SCANDINAVIAN JOURNAL WORK ENVIRONMENT & HEALTH
PI HELSINKI
PA TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND
SN 0355-3140
EI 1795-990X
J9 SCAND J WORK ENV HEA
JI Scand. J. Work Environ. Health
PD NOV
PY 2014
VL 40
IS 6
BP 610
EP 620
DI 10.5271/sjweh.3456
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AS3YG
UT WOS:000344210400007
PM 25266844
ER
PT J
AU Stenger, MR
Samuel, MC
Anschuetz, GL
Pugsley, R
Eaglin, M
Klingler, E
Reed, M
Schumacher, CM
Simon, J
Weinstock, H
AF Stenger, Mark R.
Samuel, Michael C.
Anschuetz, Greta L.
Pugsley, River
Eaglin, Margaret
Klingler, Ellen
Reed, Mary
Schumacher, Christina M.
Simon, Julie
Weinstock, Hillard
TI Neighborhoods at Risk: Estimating Risk of Higher Neisseria gonorrhoeae
Incidence Among Women at the Census Tract Level
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID SEXUALLY-TRANSMITTED INFECTIONS; GEOGRAPHIC INFORMATION-SYSTEM; STD
SURVEILLANCE NETWORK; SOCIAL DETERMINANTS; DISPARITIES; RATES; DISEASE;
HEALTH; ASSOCIATIONS; EPIDEMICS
AB Background: The association between area-based social factors and sexually transmitted diseases has been demonstrated in numerous studies. Such associations have not previously been explored for their potential to quantify likelihood of higher transmission of gonorrhea in small geographic areas.
Methods: Aggregate census tract-level sociodemographic factors in 4 domains (demographics, educational attainment, household income, and housing characteristics) were merged with female gonorrhea incidence data from 113 counties in 10 US states. Multivariate models were constructed, and a tract-level composite gonorrhea risk index was calculated. This composite risk index was validated against gonorrhea incidence among women from 2 independent states.
Results: Seven tract-level factors were found to be most strongly correlated with female gonorrhea incidence: educational attainment, proportion of female headed households, annual household income below US $20,000, proportion of population non-Hispanic black, proportion of housing units currently vacant, proportion of population reporting moving in last year, and proportion of households that are nonfamily units. Composite index was highly correlated with female gonorrhea in the study area and validated with independent data.
Conclusions: Social factors predict gonorrhea incidence at the census tract level and identify small areas at risk for higher morbidity. These data may be used by health departments and health care practices to develop geographically based disease prevention and control efforts. This is especially useful because gonorrhea incidence data are not routinely available below the county level in many states.
C1 [Stenger, Mark R.; Weinstock, Hillard] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
[Samuel, Michael C.] Calif Dept Publ Hlth, Sacramento, CA USA.
[Anschuetz, Greta L.] Philadelphia Dept Publ Hlth, Philadelphia, PA USA.
[Pugsley, River] Virginia Dept Hlth, Richmond, VA USA.
[Eaglin, Margaret] Chicago Dept Publ Hlth, Chicago, IL USA.
[Klingler, Ellen] New York City Dept Hlth & Mental Hyg, New York, NY USA.
[Reed, Mary] Colorado Dept Publ Hlth & Environm, Denver, CO USA.
[Schumacher, Christina M.] Johns Hopkins Univ, Sch Med, Baltimore City Hlth Dept, Baltimore, MD USA.
[Simon, Julie] Washington State Dept Hlth, Tumwater, WA USA.
RP Stenger, MR (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,Mail Stop E-63, Atlanta, GA 30333 USA.
EM MStenger@cdc.gov
NR 29
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD NOV
PY 2014
VL 41
IS 11
BP 649
EP 655
DI 10.1097/OLQ.0000000000000195
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA AS3GJ
UT WOS:000344165300002
PM 25299410
ER
PT J
AU Chesson, HW
Ekwueme, DU
Saraiya, M
Dunne, EF
Markowitz, LE
AF Chesson, Harrell W.
Ekwueme, Donatus U.
Saraiya, Mona
Dunne, Eileen F.
Markowitz, Lauri E.
TI The Estimated Impact of Human Papillomavirus Vaccine Coverage on the
Lifetime Cervical Cancer Burden Among Girls Currently Aged 12 Years and
Younger in the United States
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID MODEL-BASED ANALYSIS; COST-EFFECTIVENESS; HPV VACCINATION; ADOLESCENTS;
EFFICACY; RESOURCE; BIVALENT; PROGRAM; HEALTH; BOYS
AB Using a previously published dynamic model, we illustrate the potential benefits of human papillomavirus vaccination among girls currently 12 years or younger in the United States. Increasing vaccine coverage of young girls to 80% would avert 53,300 lifetime cervical cancer cases versus 30% coverage and 28,800 cases versus 50% coverage.
C1 [Chesson, Harrell W.; Dunne, Eileen F.; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
[Ekwueme, Donatus U.; Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
RP Chesson, HW (reprint author), Ctr Dis Control & Prevent, Mail Stop E-80,1600 Clifton Rd, Atlanta, GA 30333 USA.
EM HChesson@cdc.gov
NR 20
TC 5
Z9 5
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD NOV
PY 2014
VL 41
IS 11
BP 656
EP 659
DI 10.1097/OLQ.0000000000000199
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA AS3GJ
UT WOS:000344165300003
PM 25299411
ER
PT J
AU Chesson, HW
Dunne, EF
Hariri, S
Markowitz, LE
AF Chesson, Harrell W.
Dunne, Eileen F.
Hariri, Susan
Markowitz, Lauri E.
TI The Estimated Lifetime Probability of Acquiring Human Papillomavirus in
the United States
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID GENITAL HUMAN-PAPILLOMAVIRUS; SEXUALLY-TRANSMITTED-DISEASES; NUTRITION
EXAMINATION SURVEY; NATURAL-HISTORY; YOUNG-WOMEN; NATIONAL-HEALTH;
INFECTION; PREVALENCE; VACCINE; SEX
AB Background: Estimates of the lifetime probability of acquiring human papillomavirus (HPV) can help to quantify HPV incidence, illustrate how common HPV infection is, and highlight the importance of HPV vaccination.
Methods: We developed a simple model, based primarily on the distribution of lifetime numbers of sex partners across the population and the per-partnership probability of acquiring HPV, to estimate the lifetime probability of acquiring HPV in the United States in the time frame before HPV vaccine availability.
Results: We estimated the average lifetime probability of acquiring HPV among those with at least 1 opposite sex partner to be 84.6% (range, 53.6%-95.0%) for women and 91.3% (range, 69.5%-97.7%) for men. Under base case assumptions, more than 80% of women and men acquire HPV by age 45 years.
Conclusions: Our results are consistent with estimates in the existing literature suggesting a high lifetime probability of HPV acquisition and are supported by cohort studies showing high cumulative HPV incidence over a relatively short period, such as 3 to 5 years.
C1 [Chesson, Harrell W.; Dunne, Eileen F.; Hariri, Susan; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
RP Chesson, HW (reprint author), Ctr Dis Control & Prevent, Mail Stop E-80,1600 Clifton Rd, Atlanta, GA 30333 USA.
EM HChesson@cdc.gov
NR 33
TC 23
Z9 23
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD NOV
PY 2014
VL 41
IS 11
BP 660
EP 664
DI 10.1097/OLQ.0000000000000193
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA AS3GJ
UT WOS:000344165300004
PM 25299412
ER
PT J
AU Vaidya, S
Johnson, K
Rogers, M
Nash, D
Schillinger, JA
AF Vaidya, Sheila
Johnson, Kimberly
Rogers, Meighan
Nash, Denis
Schillinger, Julia A.
TI Predictors of Index Patient Acceptance of Expedited Partner Therapy for
Chlamydia trachomatis Infection and Reasons for Refusal, Sexually
Transmitted Disease Clinics, New York City, 2011 to 2012
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID GONORRHEA; RECURRENT; PROGRAM
AB Background: Expedited partner therapy (EPT) for Chlamydia trachomatis (Ct) reduces repeat Ct infection and was legalized in New York State in 2009. It is a practice in which a Ct-infected index patient delivers medication or a prescription directly to sex partner(s), without those partners receiving medical evaluation. There have been few evaluations of EPT implementation assessing acceptance and uptake among index patients. We measured EPT acceptance among index patients, identified predictors of accepting EPT, and described reasons for declining EPT.
Methods: We conducted a retrospective analysis using electronic medical records from patients attending New York City Department of Health and Mental Hygiene STD clinics from July 2011 to October 2012. A multivariable model examined the associations between accepting EPT and patient and clinic-level characteristics.
Results: Overall, 54.8% (1076/1964) of index patients accepted EPT when offered (55.9% of males and 54.4% of females [P = 0.55]). Predictors of EPT acceptance included having a male provider offer EPT (adjusted odds ratio, 1.43; 95% confidence interval, 1.12-1.83). Index patients who had a partner present at the clinic during the treatment visit were less likely to accept EPT (adjusted odds ratio, 0.28; 95% confidence interval, 0.20-0.40). Among 888 patients who refused EPT, common reasons were as follows: "partner in clinic today for treatment" (26.3% [234/888]), "no longer with partner" (25.0% [222/888]), "partner already treated" (20.3% [180/888]), and "prefer medication be delivered by clinician" (19.6% [174/888]). Expedited partner therapy acceptance did not differ by patient age, sex, or race. Excluding persons whose partners were already treated and persons whose partners were in the clinic for treatment, EPT acceptance rates were 69.4%.
Conclusions: Expedited partner therapy acceptance rates were high among index patients whose partners were not otherwise treated.
C1 [Vaidya, Sheila] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
[Johnson, Kimberly; Rogers, Meighan; Schillinger, Julia A.] New York City Dept Hlth & Mental Hyg, New York, NY USA.
[Nash, Denis] CUNY, Sch Publ Hlth, New York, NY 10021 USA.
[Nash, Denis] CUNY Hunter Coll, New York, NY 10021 USA.
[Schillinger, Julia A.] US Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
RP Schillinger, JA (reprint author), 42-09 28th St,CN 73, New York, NY 11101 USA.
EM jschilli@health.nyc.gov
NR 14
TC 3
Z9 3
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD NOV
PY 2014
VL 41
IS 11
BP 690
EP 694
DI 10.1097/OLQ.0000000000000197
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA AS3GJ
UT WOS:000344165300010
PM 25299418
ER
PT J
AU Wulsin, L
Alterman, T
Bushnell, PT
Li, J
Shen, R
AF Wulsin, Lawson
Alterman, Toni
Bushnell, P. Timothy
Li, Jia
Shen, Rui
TI Prevalence rates for depression by industry: a claims database analysis
SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
LA English
DT Article
DE Depression; Occupation; Industry; Group medical insurance claims; Work
stress; Prevalence rates
ID EFFORT-REWARD IMBALANCE; SOCIAL SURVEY GSS; O-ASTERISK-NET;
MENTAL-HEALTH; RISK-FACTORS; PSYCHOSOCIAL FACTORS; COST-EFFECTIVENESS;
MAJOR DEPRESSION; WORK-ENVIRONMENT; JOB STRAIN
AB Purpose To estimate and interpret differences in depression prevalence rates among industries, using a large, group medical claims database.
Methods Depression cases were identified by ICD-9 diagnosis code in a population of 214,413 individuals employed during 2002-2005 by employers based in western Pennsylvania. Data were provided by Highmark, Inc. (Pittsburgh and Camp Hill, PA). Rates were adjusted for age, gender, and employee share of health care costs. National industry measures of psychological distress, work stress, and physical activity at work were also compiled from other data sources.
Results Rates for clinical depression in 55 industries ranged from 6.9 to 16.2 %, (population rate = 10.45 %). Industries with the highest rates tended to be those which, on the national level, require frequent or difficult interactions with the public or clients, and have high levels of stress and low levels of physical activity.
Conclusions Additional research is needed to help identify industries with relatively high rates of depression in other regions and on the national level, and to determine whether these differences are due in part to specific work stress exposures and physical inactivity at work.
Clinical significance Claims database analyses may provide a cost-effective way to identify priorities for depression treatment and prevention in the workplace.
C1 [Wulsin, Lawson] Univ Cincinnati, Med Ctr, Dept Psychiat, Cincinnati Vet Adm, Cincinnati, OH 45267 USA.
[Wulsin, Lawson] Univ Cincinnati, Dept Family Med, Cincinnati, OH 45267 USA.
[Alterman, Toni; Bushnell, P. Timothy; Li, Jia] NIOSH, Div Surveillance, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA.
[Shen, Rui] Emergint Technol, Cincinnati, OH USA.
RP Wulsin, L (reprint author), Univ Cincinnati, Med Ctr, Dept Psychiat, Cincinnati Vet Adm, POB 670559, Cincinnati, OH 45267 USA.
EM lawson.wulsin@uc.edu
OI Alterman, Toni/0000-0003-1512-4367
FU National Institute for Occupational Safety and Health, Centers for
Disease Control and Prevention
FX We wish to gratefully acknowledge the collaboration and support of
Highmark Inc., headquartered in Pittsburgh and Camp Hill, Pennsylvania,
whose data is analyzed in this paper. We thank Brian Day, Andrea
DeVries, and Cara Hirsch at Highmark for their assistance in
establishing and guiding the project, and Jerry O'Donnell, also at
Highmark, for his assistance with the data.; Funding was provided by the
National Institute for Occupational Safety and Health, Centers for
Disease Control and Prevention.
NR 52
TC 2
Z9 3
U1 3
U2 14
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0933-7954
EI 1433-9285
J9 SOC PSYCH PSYCH EPID
JI Soc. Psychiatry Psychiatr. Epidemiol.
PD NOV
PY 2014
VL 49
IS 11
BP 1805
EP 1821
DI 10.1007/s00127-014-0891-3
PG 17
WC Psychiatry
SC Psychiatry
GA AS1UM
UT WOS:000344067300012
PM 24907896
ER
PT J
AU Othumpangat, S
Noti, JD
Beezhold, DH
AF Othumpangat, Sreekumar
Noti, John D.
Beezhold, Donald H.
TI Lung epithelial cells resist influenza A infection by inducing the
expression of cytochrome c oxidase VIc which is modulated by miRNA 4276
SO VIROLOGY
LA English
DT Article
DE miRNA; COX6C; Influenza virus; Lung epithelial cells
ID VIRAL PATHOGENESIS; VIRUS PROPAGATION; APOPTOSIS; MICRORNAS; INDUCTION;
DEATH; HEMAGGLUTININ; REPLICATION; MECHANISM; IMMUNITY
AB Influenza virus infection induces several changes in host miRNA profile, host cell death and tissue damage. Cytochrome c is a regulator of the intrinsic apoptotic pathway and is altered during viral infections. Within the first 3 h of infection with influenza virus, significant down-regulation of hsa-miRNA-4276 (miRNA-4276) is followed by a 2-fold increase in cytochrome c oxidase VIC (COX6C) mRNA was found to occur in human alveolar and bronchial epithelial cells. Expression of caspase-9 also increased within the first 3 h of infection, but subsequently decreased. Modulation of miR-4276 using mimic and inhibitor oligonucleotides showed significant down-regulation or up-regulation, respectively, of COX6C expression. Our data suggests that on initial exposure to influenza virus, host cells upregulate COX6C mRNA expression through silencing miR-4276 and repressed viral replication by inducing the apoptotic protein caspase-9. Taken together, these data suggest that miR-4276 may be an important regulator of the early stages of infection by influenza. Published by Elsevier Inc.
C1 [Othumpangat, Sreekumar; Noti, John D.; Beezhold, Donald H.] Ctr Dis Control & Prevent, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, NIOSH, Morgantown, WV USA.
RP Othumpangat, S (reprint author), NIOSH, Allergy & Clin Immunol Branch, 1095 Willowdale Rd,MS 4020, Morgantown, WV 26505 USA.
EM seo8@cdc.gov
OI Othumpangat, Sreekumar/0000-0002-6563-611X
FU Intramural CDC HHS [CC999999]
NR 34
TC 6
Z9 7
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD NOV
PY 2014
VL 468
BP 256
EP 264
DI 10.1016/j.virol.2014.08.007
PG 9
WC Virology
SC Virology
GA AS7KF
UT WOS:000344434400030
PM 25203353
ER
PT J
AU O'Leary, A
Jemmott, JB
Stevens, R
Rutledge, SE
Icard, LD
AF O'Leary, Ann
Jemmott, John B., III
Stevens, Robin
Rutledge, Scott Edward
Icard, Larry D.
TI Optimism and Education Buffer the Effects of Syndemic Conditions on HIV
Status Among African American Men Who Have Sex with Men
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Syndemics; African American men who have sex with men; HIV; Resilience;
Buffering
ID PSYCHOSOCIAL HEALTH-PROBLEMS; UNITED-STATES; SUBSTANCE USE; BLACK-MEN;
RISK; GAY; MARGINALIZATION; RESILIENCE; INFECTION; AIDS
AB The present study sought to replicate effects of the number of syndemic psychosocial health conditions on sexual risk behavior and HIV infection among a sample of high-risk African American men who have sex with men (MSM) and to identify resilience factors that may buffer these effects. We used baseline data from an HIV risk-reduction trial to examine whether a higher number of syndemic conditions was associated with higher rates of self-reported sexual risk behavior and HIV infection. Using logistic regression models, we tested for interactions between number of syndemic conditions and several potential resilience factors to identify buffering effects. Replicating previous studies, we found significant associations between numbers of syndemic conditions and higher rates of sexual risk behavior and HIV infection. Surprisingly, we also replicated a previous finding (Stall et al., Am J Public Health, 93(6):939-942, 2003) that the effects of syndemic burden on HIV status fell off at the highest levels of syndemic conditions. Among a variety of potential resilience factors, two-optimism and education-buffered the syndemic effect on HIV prevalence. This is, to our knowledge, the first paper to identify resilience factors buffering against syndemic effects among MSM. It also constitutes a significant contribution to the literature regarding prevention among black MSM. These results point to the need to identify HIV-positive black MSM and provide effective treatment for them and to develop interventions addressing both syndemic and resilience factors.
C1 [O'Leary, Ann] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
[Jemmott, John B., III] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Jemmott, John B., III] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA.
[Stevens, Robin] Rutgers State Univ, Dept Childhood Studies, Camden, NJ 08102 USA.
[Rutledge, Scott Edward; Icard, Larry D.] Temple Univ, Sch Social Work, Philadelphia, PA 19122 USA.
RP O'Leary, A (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E-37, Atlanta, GA 30333 USA.
EM aoleary@cdc.gov
FU NIAID NIH HHS [P30 AI045008]; NIMH NIH HHS [1R01 MH079736., R01
MH065867, R01 MH079736]
NR 36
TC 13
Z9 13
U1 3
U2 9
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD NOV
PY 2014
VL 18
IS 11
BP 2080
EP 2088
DI 10.1007/s10461-014-0708-0
PG 9
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA AR8BY
UT WOS:000343801700004
PM 24705710
ER
PT J
AU Cummings, B
Gutin, SA
Jaiantilal, P
Correia, D
Malimane, I
Rose, CD
AF Cummings, Beverley
Gutin, Sarah A.
Jaiantilal, Prafulta
Correia, Della
Malimane, Inacio
Rose, Carol Dawson
TI The Role of Social Support Among People Living with HIV in Rural
Mozambique
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID CLUSTER-RANDOMIZED TRIAL; SOUTH-AFRICAN ADULTS; PEER HEALTH-WORKERS;
ANTIRETROVIRAL THERAPY; AIDS CARE; ADHERENCE; UGANDA; HIV/AIDS;
ENVIRONMENT; BEHAVIORS
AB A Positive Health, Dignity, and Prevention framework is being implemented in Mozambique to maintain the health of persons living with HIV (PLHIV) and prevent onward HIV transmission. An important intervention component is psycho-social support. However, coordinating support services has been challenging. Seventy in-depth individual interviews were conducted with PLHIV between January and June 2010 in three rural provinces to clarify the receipt and provision of support by PLHIV. Thematic coding and analysis were conducted to identify salient responses. PLHIV reported that the majority of social support received was instrumental, followed by emotional and informational support. Instrumental support included material, medical, and financial assistance. Emotional support was mentioned less frequently and was supplied most by family and friends. PLHIV also received informational support from a variety of sources, the most common being family members. Informational support from health providers was rarely mentioned, but this advice was valued and used to educate others. Although most participants described receiving social support from many sources, there were consistently identified needs. This study revealed that social support is central in the lives of PLHIV and identified areas where social support can be improved to better respond to the needs of PLHIV in the Mozambican context.
C1 [Cummings, Beverley; Jaiantilal, Prafulta; Correia, Della; Malimane, Inacio] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Maputo, Mozambique.
[Gutin, Sarah A.; Rose, Carol Dawson] Univ Calif San Francisco, Sch Nursing, Dept Community Hlth Syst, San Francisco, CA 94143 USA.
RP Cummings, B (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, 2330 Maputo Pl, Dulles, VA 20189 USA.
EM BCummings@cdc.gov
OI Gutin, Sarah/0000-0002-7634-1296
FU President's Emergency Plan for AIDS Relief (PEPFAR) through the United
States Department of Health and Human Services; Centers for Disease
Control and Prevention (CDC) [H-F3-MOZ-07-PTR-PWPs]
FX This research has been supported by the President's Emergency Plan for
AIDS Relief (PEPFAR) through the United States Department of Health and
Human Services and the Centers for Disease Control and Prevention (CDC)
under the terms of Cooperative Agreement Number H-F3-MOZ-07-PTR-PWPs.
The findings and conclusions presented in this article are those of the
authors and do not necessarily represent the official position of the
CDC.
NR 36
TC 4
Z9 4
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD NOV 1
PY 2014
VL 28
IS 11
BP 602
EP 612
DI 10.1089/apc.2014.0193
PG 11
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AS0QM
UT WOS:000343982600007
PM 25290317
ER
PT J
AU Thomas, TN
Kolasa, MS
Zhang, F
Shefer, AM
AF Thomas, Tracy N.
Kolasa, Maureen S.
Zhang, Fan
Shefer, Abigail M.
TI Assessing Immunization Interventions in the Women, Infants, and Children
(WIC) Program
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID AGED 19-35 MONTHS; VACCINATION COVERAGE; UNITED-STATES; IMPACT; HEALTH;
RATES
AB Background: Vaccination promotion strategies are recommended in Women, Infants, and Children (WIC) settings for eligible children at risk for under-immunization due to their low-income status.
Purpose: To determine coverage levels of WIC and non-WIC participants and assess effectiveness of immunization intervention strategies.
Methods: The 2007-2011 National Immunization Surveys were used to analyze vaccination histories and WIC participation among children aged 24-35 months. Grantee data on immunization activities in WIC settings were collected from the 2010 WIC Linkage Annual Report Survey. Coverage by WIC eligibility and participation status and grantee-specific coverage by intervention strategy were determined at 24 months for select antigens. Data were collected 2007-2011 and analyzed in 2013.
Results: Of 13,183 age-eligible children, 5,699 (61%, weighted) had participated in WIC, of which 3,404 (62%, weighted) were current participants. In 2011, differences in four or more doses of the diphtheria, tetanus toxoid, and acellular pertussis (DTaP) vaccine by WIC participation status were observed: 86% (ineligible); 84% (current); 77% (previous); and 69% (never-eligible). Children in WIC exposed to an immunization intervention strategy had higher coverage levels than WIC-eligible children who never participated, with differences as great as 15% (DTaP).
Conclusions: Children who never participated in WIC, but were eligible, had the lowest vaccination coverage. Current WIC participants had vaccination coverage comparable to more affluent children, and higher coverage than previous WIC participants. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine
C1 [Thomas, Tracy N.; Kolasa, Maureen S.; Zhang, Fan; Shefer, Abigail M.] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Thomas, TN (reprint author), CDC, 1600 Clifton Rd,Mailstop A-19, Atlanta, GA 30333 USA.
EM tct5@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 24
TC 2
Z9 2
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD NOV
PY 2014
VL 47
IS 5
BP 624
EP 628
DI 10.1016/j.amepre.2014.06.017
PG 5
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AR6DP
UT WOS:000343673800011
PM 25217817
ER
PT J
AU Kepka, D
Breen, N
King, JB
Meissner, HI
Roland, KB
Benard, VB
Saraiya, M
AF Kepka, Deanna
Breen, Nancy
King, Jessica B.
Meissner, Helen I.
Roland, Katherine B.
Benard, Vicki B.
Saraiya, Mona
TI Demographic Factors Associated with Overuse of Pap Testing
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID CERVICAL-CANCER; UNITED-STATES; OLDER WOMEN; PREVENTION; GUIDELINES
AB Background: Since 2003, U.S. Preventive Services Task Force guidelines recommend against Pap testing for women without a cervix following a hysterectomy and those aged >65 years. Few population-based studies have investigated factors associated with overuse of Pap testing in the U.S.
Purpose: To evaluate patient characteristics associated with overuse of Pap testing.
Methods: A cross-sectional study was conducted using data from the 2010 National Health Interview Survey (NHIS) for women aged >= 30 years. NHIS is a nationally representative survey that employs a random, stratified, multi-stage cluster sampling design. In 2010, the NHIS administered a Cancer Control Supplement with questions on cervical cancer screening and hysterectomy status. Conducted in 2011-2013, all analyses account for the stratification and clustering of data within the complex NHIS survey design. Multivariate logistic regression models were used in all analyses.
Results: Among women who have undergone a hysterectomy, younger age, Hispanic and black race/ethnicity, exceeding 400% of poverty level, and private health insurance coverage were significantly associated with receipt of a recent Pap test since hysterectomy. Among women aged >65 years, non-Hispanic white ethnicity, higher education level, exceeding 400% of poverty level, and no hysterectomy were significantly associated with receipt of a recent Pap test.
Conclusions: Targeted efforts to reduce unnecessary testing among older women and women with a hysterectomy in compliance with clinical recommendations for cervical cancer prevention are needed. Specific attention should be paid to privately insured women with incomes above 400% of the federal poverty level. (C) 2014 American Journal of Preventive Medicine. All rights reserved.
C1 [Kepka, Deanna] Univ Utah, Coll Nursing, Salt Lake City, UT 84112 USA.
[Kepka, Deanna; Breen, Nancy] NIH, NCI, Hlth Serv & Econ Branch, Rockville, MD USA.
[Meissner, Helen I.] NIH, Tobacco Regulatory Sci Program, Off Dis Prevent, Bethesda, MD 20892 USA.
[King, Jessica B.] CDC, Canc Surveillance Branch, Atlanta, GA 30333 USA.
[Roland, Katherine B.; Benard, Vicki B.; Saraiya, Mona] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA 30333 USA.
RP Kepka, D (reprint author), Univ Utah, Coll Nursing, Huntsman Canc Inst, 2000 Circle Hope,Room 4144, Salt Lake City, UT 84112 USA.
EM deanna.kepka@hci.utah.edu
FU University of Utah College of Nursing; Huntsman Cancer Institute
Foundation; National Center for Advancing Translational Sciences of the
National Institutes of Health [1ULTR001067]
FX This research was supported by the University of Utah College of
Nursing, Huntsman Cancer Institute Foundation, and National Center for
Advancing Translational Sciences of the National Institutes of Health
(Award No. 1ULTR001067).
NR 17
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD NOV
PY 2014
VL 47
IS 5
BP 629
EP 633
DI 10.1016/j.amepre.2014.07.034
PG 5
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AR6DP
UT WOS:000343673800012
PM 25175763
ER
PT J
AU Richardson, LC
Parker, CS
Tsai, J
AF Richardson, Lisa C.
Parker, Christopher S.
Tsai, James
TI Blood Disorders and Public Health
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Editorial Material
ID SICKLE-CELL-ANEMIA; HYDROXYUREA; PROPHYLAXIS
C1 [Richardson, Lisa C.; Parker, Christopher S.; Tsai, James] CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
RP Richardson, LC (reprint author), CDC, 1600 Clifton Rd NE,Mail Stop E-64, Atlanta, GA 30333 USA.
EM lrichardson@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 10
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD NOV
PY 2014
VL 47
IS 5
BP 656
EP 657
DI 10.1016/j.amepre.2014.07.006
PG 2
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AR6DP
UT WOS:000343673800016
PM 25245798
ER
PT J
AU Parker, CS
Tsai, J
Siddiqi, AE
Atrash, HK
Richardson, LC
AF Parker, Christopher S.
Tsai, James
Siddiqi, Azfar-e-Alam
Atrash, Hani K.
Richardson, Lisa C.
TI Meeting the Emerging Public Health Needs of Persons With Blood Disorders
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID RISK-FACTORS; UNITED-STATES; HEMOPHILIA; MALES; DISEASE; RACE/ETHNICITY;
SURVEILLANCE; PREVALENCE; HISTORY; CARE
AB In its decades-long history, the Division of Blood Disorders (DBD) at CDC has evolved from a patient-focused, services-supporting entity at inception, to one of the world leaders in the practice of public health to improve the lives of people at risk for or affected by nonmalignant blood disorders. The DBD's earliest public health activities consisted of working with care providers in a network of hemophilia treatment centers to provide AIDS risk reduction services to people with hemophilia. Because this infectious disease threat has been reduced over time as a result of the development of safer treatment products, the DBD under the auspices of congressional appropriations guidance has expanded its core activities to encompass blood disorders other than hemophilia, including hemoglobinopathies such as thalassemia and sickle cell disease, and Diamond Blackfan anemia. Simultaneously, in ransitioning to a greater public health role, the DBD has expanded its network of partners to new consumer and professional organizations, as well as state and other federal health agencies. The DBD has also developed and maintains many surveillance and registry activities beyond the Universal Data Collection system aimed at providing a better understanding of the health status, health needs, and health-related quality of life of people with nonmalignant blood disorders. The DBD has integrated applicable components of the Essential Services of Public Health successfully to promote and advance the agenda of blood disorders in public health. Published by Elsevier Inc.
C1 [Parker, Christopher S.; Tsai, James; Siddiqi, Azfar-e-Alam; Richardson, Lisa C.] CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
[Atrash, Hani K.] Hlth Resources & Serv Adm, Maternal & Child Hlth Bur, Div Healthy Start & Perinatal Serv, Rockville, MD USA.
RP Parker, CS (reprint author), CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mail Stop E-64, Atlanta, GA 30333 USA.
EM csp2@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 27
TC 2
Z9 2
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD NOV
PY 2014
VL 47
IS 5
BP 658
EP 663
DI 10.1016/j.amepre.2014.07.008
PG 6
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AR6DP
UT WOS:000343673800017
PM 25245797
ER
PT J
AU Beckman, MG
Hulihan, MM
Byams, VR
Oakley, MA
Reyes, N
Trimble, S
Grant, AM
AF Beckman, Michele G.
Hulihan, Mary M.
Byams, Vanessa R.
Oakley, Meredith A.
Reyes, Nimia
Trimble, Sean
Grant, Althea M.
TI Public Health Surveillance of Nonmalignant Blood Disorders
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID SICKLE-CELL-DISEASE; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;
PULMONARY-EMBOLISM; UNITED-STATES; HEMOPHILIA; TRENDS; MALES; US;
HOSPITALIZATION
AB Nonmalignant blood disorders currently affect millions of Americans, and their prevalence is expected to grow over the next several decades. This is owing to improvements in treatment leading to increased life expectancy of people with hereditary conditions, like sickle cell disease and hemophilia, but also the rising occurrence of risk factors for venous thromboembolism. The lack of adequate surveillance systems to monitor these conditions and their associated health indicators is a significant barrier to successfully assess, inform, and measure prevention efforts and progress toward national health goals. CDC is strengthening surveillance activities for blood disorders by improving and developing new methods that are tailored to best capture and monitor the epidemiologic characteristics unique to each disorder. These activities will provide a robust evidence base for public health action to improve the health of patients affected by or at risk for these disorders. Published by Elsevier Inc.
C1 [Beckman, Michele G.; Hulihan, Mary M.; Byams, Vanessa R.; Oakley, Meredith A.; Reyes, Nimia; Trimble, Sean; Grant, Althea M.] CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
RP Beckman, MG (reprint author), CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-64, Atlanta, GA 30333 USA.
EM mbeckman@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 32
TC 2
Z9 2
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD NOV
PY 2014
VL 47
IS 5
BP 664
EP 668
DI 10.1016/j.amepre.2014.07.025
PG 5
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AR6DP
UT WOS:000343673800018
PM 25245796
ER
PT J
AU Soucie, JM
Miller, CH
Kelly, FM
Oakley, M
Brown, DL
Kucab, P
AF Soucie, J. Michael
Miller, Connie H.
Kelly, Fiona M.
Oakley, Meredith
Brown, Deborah L.
Kucab, Phillip
TI A Public Health Approach to the Prevention of Inhibitors in Hemophilia
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID FACTOR-VIII INHIBITORS; UNITED-STATES; NIJMEGEN MODIFICATION; CARE
EXPENDITURES; BETHESDA ASSAY; C INHIBITORS; A PATIENTS; MALES;
SURVEILLANCE; COAGULATION
AB The development of an antibody in people with hemophilia to products used in the treatment and prevention of bleeding, also referred to as an inhibitor, is the most serious complication of hemophilia care today. CDC, together with healthcare providers, consumer organizations, hemophilia organizations, and federal partners, has developed a public health agenda to prevent the development of inhibitors. This paper describes a public health approach that combines a national surveillance program with epidemiologic, laboratory, and prevention research to address knowledge gaps in rates and risk factors for inhibitor development, and in knowledge and behaviors of patients and providers, in addition to screening and treatment practices. Published by Elsevier Inc.
C1 [Soucie, J. Michael; Miller, Connie H.; Kelly, Fiona M.; Oakley, Meredith] CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
[Brown, Deborah L.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
[Brown, Deborah L.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Brown, Deborah L.] Gulf States Hemophilia & Thrombophilia Treatment, Houston, TX USA.
[Kucab, Phillip] Wayne State Univ, Sch Med, Detroit, MI USA.
RP Soucie, JM (reprint author), CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E64, Atlanta, GA 30333 USA.
EM msoucie@cdc.gov
OI Miller, Connie H/0000-0002-3989-7973
FU Intramural CDC HHS [CC999999]
NR 29
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD NOV
PY 2014
VL 47
IS 5
BP 669
EP 673
DI 10.1016/j.amepre.2014.07.007
PG 5
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AR6DP
UT WOS:000343673800019
PM 25245801
ER
PT J
AU Rhynders, PA
Sayers, CA
Presley, RJ
Thierry, JM
AF Rhynders, Patricia A.
Sayers, Cynthia A.
Presley, Rodney J.
Thierry, JoAnn M.
TI Providing Young Women with Credible Health Information about Bleeding
Disorders
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID VON-WILLEBRAND-DISEASE; QUALITY-OF-LIFE; FRAMED MESSAGES; EXPERT PANEL;
MENORRHAGIA; BEHAVIOR; MANAGEMENT; ADULTS; CARE
AB Background: Approximately 1% of U.S. women may have an undiagnosed bleeding disorder, which can diminish quality of life and lead to life-threatening complications during menstruation, childbirth, and surgery.
Purpose: To understand young women's knowledge, attitudes, and perceptions about bleeding disorders and determine the preferred messaging strategy (e.g., gain- versus loss-framed messages) for presenting information.
Methods: In September 2010, a web-assisted personal interview of women aged 18-25 years was conducted. Preliminary analyses were conducted in 2011 with final analyses in 2013. In total, 1,243 women participated. Knowledge of blood disorders was tabulated for these respondents. Menstrual experiences of women at risk for a bleeding disorder were compared with those not at risk using chi-square analyses. Perceived influence of gain- versus loss-framed messages also was compared.
Results: Participants knew that a bleeding disorder is a condition in which bleeding takes a long time to stop (77%) or blood does not clot (66%). Of the women, 57% incorrectly thought that a bleeding disorder is characterized by thin blood; many were unsure if bleeding disorders involve blood types, not getting a period, or mother and fetus having a different blood type. Women at risk for a bleeding disorder were significantly more likely to report that menstruation interfered with daily activities (36% vs 9%); physical or sports activities (46% vs 21%); social activities (29% vs 7%); and school or work activities (20% vs 9%) than women not at risk. Gain-framed messages were significantly more likely to influence women's decisions to seek medical care than parallel loss-framed messages. Findings suggest that the most influential messages focus on knowing effective treatment is available (86% gain-framed vs 77% loss-framed); preventing pregnancy complications (79% gain- vs 71% loss-framed); and maintaining typical daily activities during menstrual periods.
Conclusions: Lack of information about bleeding disorders is a serious public health concern. Health communications focused on gain-framed statements might encourage symptomatic young women to seek diagnosis and treatment. These findings and corresponding recommendations align with Healthy People 2020 and with CDC's goal of working to promote the health, safety, and quality of life of women at every life stage. (C) 2014 Published by Elsevier Inc.
C1 [Rhynders, Patricia A.] Natl Hemophilia Fdn, New York, NY USA.
[Sayers, Cynthia A.; Presley, Rodney J.; Thierry, JoAnn M.] CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
RP Thierry, JM (reprint author), CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS-E64, Atlanta, GA 30333 USA.
EM jxt4@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 29
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD NOV
PY 2014
VL 47
IS 5
BP 674
EP 680
DI 10.1016/j.amepre.2014.07.040
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AR6DP
UT WOS:000343673800020
PM 25245800
ER
PT J
AU Ortiz, JR
Neuzil, KM
Shay, DK
Rue, TC
Neradilek, MB
Zhou, H
Seymour, CW
Hooper, LG
Cheng, PY
Goss, CH
Cooke, CR
AF Ortiz, Justin R.
Neuzil, Kathleen M.
Shay, David K.
Rue, Tessa C.
Neradilek, Moni B.
Zhou, Hong
Seymour, Christopher W.
Hooper, Laura G.
Cheng, Po-Yung
Goss, Christopher H.
Cooke, Colin R.
TI The Burden of Influenza-Associated Critical Illness Hospitalizations
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE critical care; epidemiology; influenza; statistical modeling
ID RESPIRATORY SYNCYTIAL VIRUS; UNITED-STATES; EMERGENCY CARE; SEVERE
SEPSIS; MORTALITY; CHILDREN; FAILURE; ADULTS; INFECTION; MORBIDITY
AB Objective: Influenza is the most common vaccine-preventable disease in the United States; however, little is known about the burden of critical illness due to influenza virus infection. Our primary objective was to estimate the proportion of all critical illness hospitalizations that are attributable to seasonal influenza.
Design: Retrospective cohort study.
Setting: Arizona, California, and Washington from January 2003 to March 2009.
Patients: All adults hospitalized with critical illness, defined by International Classification of Diseases, 9th Edition, Clinical Modification diagnosis and procedure codes for acute respiratory failure, severe sepsis, or in-hospital death.
Measurements and Main Results: We combined the complete hospitalization discharge databases for three U.S. states, regional influenza virus surveillance, and state census data. Using negative binomial regression models, we estimated the incidence rates of adult influenza-associated critical illness hospitalizations and compared them with all-cause event rates. We also compared modeled outcomes to International Classification of Diseases, 9th Edition, Clinical Modification-coded influenza hospitalizations to assess potential underrecognition of severe influenza disease. During the study period, we estimated that 26,760 influenza-associated critical illness hospitalizations (95% CI, 14,541, 47,464) occurred. The population-based incidence estimate for influenza-associated critical illness was 12.0 per 100,000 person-years (95% CI, 6.6, 21.6) or 1.3% of all critical illness hospitalizations (95% CI, 0.7%, 2.3%). During the influenza season, 3.4% of all critical illness hospitalizations (95% CI, 1.9%, 5.8%) were attributable to influenza. There were only 2,612 critical illness hospitalizations with International Classification of Diseases, 9th Edition, Clinical Modification-coded influenza diagnoses, suggesting influenza is either undiagnosed or undercoded in a substantial proportion of critical illness.
Conclusions: Extrapolating our data to the 2010 U.S. population, we estimate that about 28,000 adults are hospitalized for influenza-associated critical illness annually. Influenza in many of these critically ill patients may be undiagnosed. Critical care physicians should have a high index of suspicion for influenza in the ICU, particularly when influenza is known to be circulating in their communities.
C1 [Ortiz, Justin R.; Neuzil, Kathleen M.; Hooper, Laura G.; Goss, Christopher H.] Univ Washington, Dept Med, Seattle, WA 98119 USA.
[Ortiz, Justin R.; Neuzil, Kathleen M.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
[Ortiz, Justin R.; Neuzil, Kathleen M.] PATH, Vaccine Access & Delivery Global Program, Seattle, WA USA.
[Shay, David K.; Cheng, Po-Yung] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
[Rue, Tessa C.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Neradilek, Moni B.] Mt Whisper Light Stat, Seattle, WA USA.
[Zhou, Hong] Ctr Dis Control & Prevent, Div Hlth Informat & Surveillance Proposed, Atlanta, GA USA.
[Seymour, Christopher W.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA.
[Seymour, Christopher W.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA.
[Cooke, Colin R.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA.
RP Ortiz, JR (reprint author), Univ Washington, Dept Med, Seattle, WA 98119 USA.
EM jrortiz@uw.edu
OI Cooke, Colin/0000-0001-9713-5371; Shay, David/0000-0001-9619-4820
FU Robert Wood Johnson Harold Amos Medical Faculty Development Program;
Robert Wood Johnson; National Institutes of Health (NIH); NIH
[R01HL103965, R01HL113382, R01AI101307, UM1HL119073, P30DK089507];
Cystic Fibrosis Foundation (CFF); Food and Drug Administration
[R01FD003704]; Transave; Vertex Pharmaceuticals; CFF; NIH; Food and Drug
Administration; Agency for Healthcare Research and Quality (AHRQ)
[K08HS020672]; AHRQ
FX Dr. Ortiz receives funding from the Robert Wood Johnson Harold Amos
Medical Faculty Development Program. His institution received grant
support from Robert Wood Johnson. Dr. Shay has disclosed government
work. Ms. Rue's institution received grant support from Robert Wood
Johnson. Mr. Neradilek has disclosed work for hire. Her institution
received support for participation in review activities and support for
manuscript writing/review. Dr. Seymour received support for article
research from the National Institutes of Health (NIH). His institution
received grant support from the NIH. Dr. Goss receives funding from the
Cystic Fibrosis Foundation (CFF), the NIH (R01HL103965, R01HL113382,
R01AI101307, UM1HL119073, and P30DK089507), and the Food and Drug
Administration (R01FD003704). He served as a board member for Transave
(no fee paid) and KaloBios Pharmaceuticals (fee donated to cystic
fibrosis [CF] clinical research), received grant support from Transave
(grant to analyze symptom score data in a clinical trial) and Vertex
Pharmaceuticals (grant to perform analysis using multiple existing
datasets), lectured for F. Hoffmann-La Roche (honoraria for preparing
and giving symposium talk), and received support for manuscript
preparation from Johns Hopkins University (honoraria for preparing and
giving Continuing Medical Education talks). His institution received
grant support from the CFF (grants to conduct clinical trials in
methicillin-resistant Staphylococcus aureus eradication, home
monitoring, and use of IV Gallium all in CF; grant to Chair CFF Patient
Registry Committee), the NIH (grants to conduct clinical trials in home
monitoring in CF and the use of IV gallium in CF), and the Food and Drug
Administration (grants to conduct a clinical trial in the use of IV
gallium in CF). Dr. Cooke is supported by a Mentored Clinical Scientist
Research Career Development Award from the Agency for Healthcare
Research and Quality (AHRQ) (K08HS020672). He received support for
article research from the AHRQ. His institution received grant support
from the AHRQ. The remaining authors have disclosed that they do not
have any potential conflicts of interest.
NR 43
TC 15
Z9 15
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD NOV
PY 2014
VL 42
IS 11
BP 2325
EP 2332
DI 10.1097/CCM.0000000000000545
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA AR9JC
UT WOS:000343889000013
PM 25148596
ER
PT J
AU Lawrence, JM
Imperatore, G
Dabelea, D
Mayer-Davis, EJ
Linder, B
Saydah, S
Klingensmith, GJ
Dolan, L
Standiford, DA
Pihoker, C
Pettitt, DJ
Talton, JW
Thomas, J
Bell, RA
D'Agostino, RB
AF Lawrence, Jean M.
Imperatore, Giuseppina
Dabelea, Dana
Mayer-Davis, Elizabeth J.
Linder, Barbara
Saydah, Sharon
Klingensmith, Georgeanna J.
Dolan, Lawrence
Standiford, Debra A.
Pihoker, Catherine
Pettitt, David J.
Talton, Jennifer W.
Thomas, Joan
Bell, Ronny A.
D'Agostino, Ralph B., Jr.
CA SEARCH Diabet Youth Study Grp
TI Trends in Incidence of Type 1 Diabetes Among Non-Hispanic White Youth in
the U.S., 2002-2009
SO DIABETES
LA English
DT Article
ID CHILDHOOD TYPE-1; TIME TRENDS; PROSPECTIVE REGISTRATION; INCREASING
INCIDENCE; CHILDREN; SWEDEN; WORLDWIDE; MELLITUS; MULTICENTER;
PREVALENCE
AB The SEARCH for Diabetes in Youth Study prospectively identified youth aged <20 years with physician-diagnosed diabetes. Annual type 1 diabetes (T1D) incidence per 100,000 person-years (95% Cl) overall, by age-group, and by sex were calculated for at-risk non-Hispanic white (NHVV) youth from 2002 through 2009. Joinpoint and Poisson regression models were used to test for temporal trends. The age- and sex-adjusted incidence of T1D increased from 24.4/100,000 (95% CI 23.9-24.8) in 2002 to 27.4/100,000 (26.9-27.9) in 2009 (P for trend = 0.0008). The relative annual increase in T1D incidence was 2.72% (1.18-4.28) per year; 2.84% (1.12-4.58) per year for males and 2.57% (0.68-4.51) per year for females. After adjustment for sex, significant increases were found for youth aged 5-9 years (P = 0.0023), 10-14 years (P = 0.0008), and 15-19 years (P = 0.004) but not among 0-4-year-olds (P = 0.1862). Mean age at diagnosis did not change. The SEARCH study demonstrated a significant increase in the incidence of T1D among NHW youth from 2002 through 2009 overall and in all but the youngest agegroup. Continued surveillance of T1D in U.S. youth to identify future trends in T1D incidence and to plan for health care delivery is warranted.
C1 [Lawrence, Jean M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA.
[Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA.
[Dabelea, Dana] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA.
[Mayer-Davis, Elizabeth J.; Thomas, Joan] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC USA.
[Mayer-Davis, Elizabeth J.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
[Linder, Barbara] NIDDK, NIH, Bethesda, MD USA.
[Saydah, Sharon] Ctr Dis Control & Prevent, Div Diabet Translat, Hyattsville, MD USA.
[Klingensmith, Georgeanna J.] Univ Colorado Denver, Sch Med, Barbara Davis Ctr, Aurora, CO USA.
[Dolan, Lawrence; Standiford, Debra A.] Cincinnati Childrens Hosp Med Ctr, Div Endocrinol, Cincinnati, OH 45229 USA.
[Dolan, Lawrence] Univ Cincinnati, Dept Pediat, Cincinnati, OH USA.
[Pihoker, Catherine] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
[Pettitt, David J.] Sansum Diabet Res Inst, Santa Barbara, CA USA.
[Talton, Jennifer W.; D'Agostino, Ralph B., Jr.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA.
[Bell, Ronny A.] Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA.
RP Lawrence, JM (reprint author), Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA.
EM jean.m.lawrence@kp.org
RI Dagostino Jr, Ralph/C-4060-2017
OI Dagostino Jr, Ralph/0000-0002-3550-8395
FU Centers for Disease Control and Prevention [00097, DP-05-069,
DP-10-001]; National Institute of Diabetes and Digestive and Kidney
Diseases; Kaiser Permanente Southern California [U48/CCU919219,
U01-DP-000246, U18-DP-002714]; University of Colorado Denver
[U48/CCU819241-3, U01-DP-000247, U18-DP-000247-06A1]; Children's
Hospital Medical Center (Cincinnati) [U48/CCU519239, U01-DP-000248,
1U18-DP002709]; University of North Carolina at Chapel Hill
[U48/CCU419249, U01-DP000254, U18-DP-002708-01]; University of
Washington School of Medicine [U58/CCU019235-4, U01-DP-000244,
U18-DP-002710-01]; Wake Forest School of Medicine [U48/CCU919219,
U01-DP-000250, 200-2010-35171]; General Clinical Research Centers at the
South Carolina Clinical and Translational Research Institute at the
Medical University of South Carolina (National Institutes of
Health/National Center for Research Resources) [UURR029882]; Seattle
Children's Hospital (National Institutes of Health Clinical and
Translational Science Awards of the University of Washington) [UL1
TR00423]; University of Colorado Pediatric Clinical and Translational
Research Center [UL1 TR000154]; Barbara Davis Center at the University
of Colorado Denver (DERC NIH) [P30 DK57516]; National Center for
Research Resources; National Center for Advancing Translational
Sciences, National Institutes of Health [8 UL1 TR000077]; Children with
Medical Handicaps program
FX SEARCH for Diabetes in Youth Study is funded by the Centers for Disease
Control and Prevention (PA numbers 00097, DP-05-069, and DP-10-001) and
supported by the National Institute of Diabetes and Digestive and Kidney
Diseases. Contract numbers: Kaiser Permanente Southern California
(U48/CCU919219, U01-DP-000246, and U18-DP-002714), University of
Colorado Denver (U48/CCU819241-3, U01-DP-000247, and
U18-DP-000247-06A1), Children's Hospital Medical Center (Cincinnati)
(U48/CCU519239, U01-DP-000248, and 1U18-DP002709), University of North
Carolina at Chapel Hill (U48/CCU419249, U01-DP000254, and
U18-DP-002708-01), University of Washington School of Medicine
(U58/CCU019235-4, U01-DP-000244, and U18-DP-002710-01), and Wake Forest
School of Medicine (U48/CCU919219, U01-DP-000250, and 200-2010-35171).
The authors wish to acknowledge the involvement of General Clinical
Research Centers at the South Carolina Clinical and Translational
Research Institute at the Medical University of South Carolina (National
Institutes of Health/National Center for Research Resources grant number
UURR029882); Seattle Children's Hospital (National Institutes of Health
Clinical and Translational Science Awards grant UL1 TR00423 of the
University of Washington); University of Colorado Pediatric Clinical and
Translational Research Center (grant number UL1 TR000154); the Barbara
Davis Center at the University of Colorado Denver (DERC NIH P30
DK57516); the National Center for Research Resources and the National
Center for Advancing Translational Sciences, National Institutes of
Health, through grant 8 UL1 TR000077; and the Children with Medical
Handicaps program managed by the Ohio Department of Health.
NR 26
TC 25
Z9 26
U1 1
U2 5
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD NOV
PY 2014
VL 63
IS 11
BP 3938
EP 3945
DI 10.2337/db13-1891
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AS0KM
UT WOS:000343966100041
PM 24898146
ER
PT J
AU Rha, B
Tate, JE
Weintraub, E
Haber, P
Yen, C
Patel, M
Cortese, MM
DeStefano, F
Parashar, UD
AF Rha, Brian
Tate, Jacqueline E.
Weintraub, Eric
Haber, Penina
Yen, Catherine
Patel, Manish
Cortese, Margaret M.
DeStefano, Frank
Parashar, Umesh D.
TI Intussusception following rotavirus vaccination: an updated review of
the available evidence
SO EXPERT REVIEW OF VACCINES
LA English
DT Review
DE intussusception; rotavirus; rotavirus disease; rotavirus vaccine;
safety; vaccines
ID UNITED-STATES; US INFANTS; DOUBLE-BLIND; VACCINES; RISK; PENTAVALENT;
EFFICACY; HOSPITALIZATIONS; MONOVALENT; PROGRAM
AB In 1999, the first rotavirus vaccine licensed in the USA was withdrawn 9 months after introduction due to an association with intussusception that was detected in post-licensure surveillance. This association prompted large clinical trials designed to ensure the safety of two current live oral rotavirus vaccines, RotaTeq and Rotarix, which have since been recommended for use worldwide. Following their introduction, post-licensure studies have focused not only on the effectiveness and impact of these vaccines, but also on continued surveillance for intussusception. Most recent evidence from several countries shows a small increased risk of intussusception following vaccination with Rotarix and RotaTeq within the context of their demonstrated benefits. This review summarizes the available data on the safety of rotavirus vaccines with regards to intussusception.
C1 [Rha, Brian; Tate, Jacqueline E.; Yen, Catherine; Patel, Manish; Cortese, Margaret M.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Rha, Brian] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Weintraub, Eric; Haber, Penina; DeStefano, Frank] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Rha, B (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,MS A-34, Atlanta, GA 30333 USA.
EM wif8@cdc.gov
NR 54
TC 12
Z9 13
U1 0
U2 7
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1476-0584
EI 1744-8395
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD NOV
PY 2014
VL 13
IS 11
BP 1339
EP 1348
DI 10.1586/14760584.2014.942223
PG 10
WC Immunology
SC Immunology
GA AR8DC
UT WOS:000343804700009
PM 25066368
ER
PT J
AU Warner, M
Mocarelli, P
Brambilla, P
Wesselink, A
Patterson, DG
Turner, WE
Eskenazi, B
AF Warner, Marcella
Mocarelli, Paolo
Brambilla, Paolo
Wesselink, Amelia
Patterson, Don G., Jr.
Turner, Wayman E.
Eskenazi, Brenda
TI Serum TCDD and TEQ concentrations among Seveso women, 20 years after the
explosion
SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY
LA English
DT Article
DE dioxin; half-life; TCDD; TEQ; PCDD; PCDF
ID DIOXIN-LIKE COMPOUNDS; US POPULATION;
2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; EXPOSURE; ELIMINATION; HEALTH; AGE;
RESIDENTS; TOXICITY; ADULTS
AB The Seveso Women's Health Study (SWHS) is a historical cohort study of the female population residing near Seveso, Italy, on 10 July 1976, when a chemical explosion resulted in the highest known residential exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Individual TCDD concentration was measured in serum collected near the time of the explosion, and in 1996, we collected adequate blood for TCDD and total dioxin toxic equivalent (TEQ) measurement. Polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls were measured in 1996 serum for a sample (n = 225, 23%) of the SWHS cohort and WHO 2005 TEQs were calculated. We examined characteristics that predict 1996 TCDD concentrations and estimated TCDD elimination half-life over the 20-year period since the explosion. Median lipid-adjusted TCDD and total TEQ concentrations in 1996 serum were 7.3 and 26.2 p.p.t., respectively. Initial 1976 TCDD and age at explosion were the strongest predictors of 1996 TCDD. The TCDD elimination half-life was 7.1 years for women older than 10 years in 1976, but was shorter in those who were younger. Twenty years after the explosion, TCDD concentrations in this SWHS sample, the majority of who were children in 1976, remain elevated relative to background. These data add to the limited data available on TCDD elimination half-life in children.
C1 [Warner, Marcella; Wesselink, Amelia; Eskenazi, Brenda] Univ Calif Berkeley, Sch Publ Hlth, Ctr Environm Res & Childrens Hlth, Berkeley, CA 94720 USA.
[Mocarelli, Paolo; Brambilla, Paolo] Univ Milano Bicocca, Sch Med, Hosp Desio, Dept Lab Med, Desio, Italy.
[Patterson, Don G., Jr.; Turner, Wayman E.] Ctr Dis Control & Prevent, Div Environm Hlth Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA USA.
RP Warner, M (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Ctr Environm Res & Childrens Hlth, 1995 Univ Ave,Suite 265, Berkeley, CA 94720 USA.
EM mwarner@berkeley.edu
FU National Institutes of Health [R01 ES07171, F06 TW02075-01]; US
Environmental Protection Agency [R82471]; National Institute of
Environmental Health Sciences [2P30-ESO01896-17]; Regione Lombardia and
Fondazione Lombardia Ambiente, Milan, Italy [2896]
FX We gratefully acknowledge Aliza Parigi for coordinating data collection
at Hospital of Desio and Larry L. Needham for the significant
contributions he made to the Seveso Women's Health Study. This study was
supported by grant numbers R01 ES07171 and F06 TW02075-01 from the
National Institutes of Health, R82471 from the US Environmental
Protection Agency, 2P30-ESO01896-17 from the National Institute of
Environmental Health Sciences, and #2896 from Regione Lombardia and
Fondazione Lombardia Ambiente, Milan, Italy.
NR 33
TC 6
Z9 7
U1 5
U2 20
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1559-0631
EI 1559-064X
J9 J EXPO SCI ENV EPID
JI J. Expo. Sci. Environ. Epidemiol.
PD NOV-DEC
PY 2014
VL 24
IS 6
BP 588
EP 594
DI 10.1038/jes.2013.70
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA AS0IJ
UT WOS:000343960800006
PM 24149975
ER
PT J
AU Uddin, MS
Blount, BC
Lewin, MD
Potula, V
Ragin, AD
Dearwent, SM
AF Uddin, Mohammed S.
Blount, Benjamin C.
Lewin, Michael D.
Potula, Vijayalakshnni
Ragin, Angela D.
Dearwent, Steve M.
TI Comparison of blood volatile organic compound levels in residents of
Calcasieu and Lafayette Parishes, LA, with US reference ranges
SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY
LA English
DT Article
DE 1,4-dichlorobenzene; benzene; ethylbenzene; m-/p-xylene; styrene;
volatile organic compounds
ID EXPOSURE; POPULATION; INDOOR; SAMPLE; AIR
AB Agency for Toxic Substances and Disease Registry conducted a study to evaluate body burden levels of volatile organic compounds (VOCs) among residents of highly industrialized Calcasieu Parish, LA, USA, in 2002. Blood VOC levels in a representative sample of participants in Calcasieu Parish were compared with a similar group of participants in the less-industrialized Lafayette Parish. Participants' ages ranged from 15 to 91 years, 46% were men, and 89% were Caucasian. VOC levels in these two populations were also compared at the national levels. Solid-phase microextraction coupled with gas chromatography mass spectrometry was used to measure levels of 30 VOCs in blood samples collected from 283 self-described non-smoking study participants. Of the 30 VOCs, 6 had quantifiable levels in at least 25% of the blood samples analyzed. The frequency of detection was >95% for benzene and m-/p-xylene, >60% for 1,4-dichlorbenzene and toluene, 27% for ethylbenzene, and 39% for styrene. Calcasieu and Lafayette Parish participants had similar distributions for six VOCs in key percentiles and geometric means. When compared with a representative sampling of the 1999-2000 US general population, no significant differences were found between the parish data and the US general population.
C1 [Uddin, Mohammed S.; Lewin, Michael D.; Ragin, Angela D.; Dearwent, Steve M.] Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA 30333 USA.
[Blount, Benjamin C.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA.
[Potula, Vijayalakshnni] NIOSH, Off Director, Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Uddin, MS (reprint author), Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, 4770 Buford Highway,Mail Stop F-58, Atlanta, GA 30333 USA.
EM mbu1@cdc.gov
NR 22
TC 0
Z9 0
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1559-0631
EI 1559-064X
J9 J EXPO SCI ENV EPID
JI J. Expo. Sci. Environ. Epidemiol.
PD NOV-DEC
PY 2014
VL 24
IS 6
BP 602
EP 607
DI 10.1038/jes.2013.94
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA AS0IJ
UT WOS:000343960800008
PM 24472757
ER
PT J
AU Mirkovic, KR
Perrine, CG
Scanlon, KS
Grummer-Strawn, LM
AF Mirkovic, Kelsey R.
Perrine, Cria G.
Scanlon, Kelley S.
Grummer-Strawn, Laurence M.
TI Maternity Leave Duration and Full-time/Part-time Work Status Are
Associated with US Mothers' Ability to Meet Breastfeeding Intentions
SO JOURNAL OF HUMAN LACTATION
LA English
DT Article
DE breastfeeding; breastfeeding intentions; employment; maternity leave;
work status
ID UNITED-STATES; 1ST YEAR; INITIATION; SAMPLE; WOMEN; LIFE
AB Background: Breastfeeding provides numerous health benefits for infants and mothers; however, many infants are not breastfed as long as recommended or desired by mothers. Maternal employment is frequently cited as a barrier to breastfeeding.
Objective: This study aimed to assess whether maternity leave duration and return status (full-time [FT], part-time [PT]) were associated with not meeting a mother's intention to breastfeed at least 3 months.
Methods: We used data from the Infant Feeding Practices Study II, a cohort study. Analyses were limited to women employed prenatally who intended to breastfeed 3 months or longer (n = 1172). Multivariable logistic regression was used to assess the relationship between maternity leave duration and return-to-work status (< 6 weeks/FT, < 6 weeks/PT, 6 weeks-3 months/FT, 6 weeks-3 months/PT, not working by 3 months) and meeting a mother's intention to breastfeed at least 3 months.
Results: Overall, 28.8% of mothers did not meet their intention to breastfeed at least 3 months. Odds of not meeting intention to breastfeed at least 3 months were higher among mothers who returned to work FT before 3 months (< 6 weeks/FT: adjusted odds ratio = 2.25, 95% confidence interval, 1.23-4.12; 6 weeks-3 months/FT: adjusted odds ratio = 1.82, 95% confidence interval, 1.30-2.56), compared with mothers not working at 3 months.
Conclusion: Returning to work full-time before 3 months may reduce a mother's ability to meet her intention to breastfeed at least 3 months. Employer support for flexible work scheduling may help more women achieve their breastfeeding goals.
C1 [Mirkovic, Kelsey R.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Publ Hlth Sci Serv, Atlanta, GA USA.
[Perrine, Cria G.; Scanlon, Kelley S.; Grummer-Strawn, Laurence M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA.
RP Mirkovic, KR (reprint author), Off Publ Hlth Sci Serv, Epidem Intelligence Serv, 4770 Buford Highway NE,Mailstop F-77, Atlanta, GA 30341 USA.
EM xdj1@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 21
TC 11
Z9 11
U1 1
U2 15
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0890-3344
EI 1552-5732
J9 J HUM LACT
JI J. Hum. Lact.
PD NOV
PY 2014
VL 30
IS 4
BP 416
EP 419
DI 10.1177/0890334414543522
PG 4
WC Nursing; Obstetrics & Gynecology; Pediatrics
SC Nursing; Obstetrics & Gynecology; Pediatrics
GA AS0MZ
UT WOS:000343972700009
PM 25034868
ER
PT J
AU Pratt, VM
Aggarwal, P
Beyer, BN
Broeckel, U
Epstein-Baak, R
Everts, RE
Hujsak, P
Kornreich, R
Liao, J
Lorier, R
Scott, SA
Smith, CH
Toji, LH
Turner, A
Kalman, LV
AF Pratt, V. M.
Aggarwal, P.
Beyer, B. N.
Broeckel, U.
Epstein-Baak, R.
Everts, R. E.
Hujsak, P.
Kornreich, R.
Liao, J.
Lorier, R.
Scott, S. A.
Smith, C. Huang
Toji, L. H.
Turner, A.
Kalman, L. V.
TI Characterization of 137 Genomic DNA Reference Materials for 27
Pharmacogenetic Genes: A GeT-RM Collaborative Project
SO JOURNAL OF MOLECULAR DIAGNOSTICS
LA English
DT Meeting Abstract
CT Annual Meeting of the Association-for-Molecular-Pathology (AMP)
CY NOV 12-15, 2014
CL National Harbor, MD
SP Assoc Mol Pathol
C1 [Pratt, V. M.; Beyer, B. N.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
[Aggarwal, P.; Broeckel, U.; Lorier, R.; Turner, A.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Epstein-Baak, R.; Hujsak, P.; Smith, C. Huang] Autogenomics Inc, Vista, CA USA.
[Everts, R. E.] Seguenom Inc, San Diego, CA USA.
[Kornreich, R.; Liao, J.; Scott, S. A.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Toji, L. H.] Coriell Cell Repository, Camden, NJ USA.
[Kalman, L. V.] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-1578
EI 1943-7811
J9 J MOL DIAGN
JI J. Mol. Diagn.
PD NOV
PY 2014
VL 16
IS 6
MA G01
BP 699
EP 699
PG 1
WC Pathology
SC Pathology
GA AR7YZ
UT WOS:000343794200015
ER
PT J
AU Brunson, T
Gjeltema, LA
Zhong, J
Chen, B
AF Brunson, T.
Gjeltema, L. A.
Zhong, J.
Chen, B.
TI Knowledge Improvement and Learners' Feedback from an Online Education
Module on Quality Practices for Molecular Genetic Testing
SO JOURNAL OF MOLECULAR DIAGNOSTICS
LA English
DT Meeting Abstract
CT Annual Meeting of the Association-for-Molecular-Pathology (AMP)
CY NOV 12-15, 2014
CL National Harbor, MD
SP Assoc Mol Pathol
C1 [Brunson, T.; Gjeltema, L. A.; Zhong, J.; Chen, B.] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-1578
EI 1943-7811
J9 J MOL DIAGN
JI J. Mol. Diagn.
PD NOV
PY 2014
VL 16
IS 6
MA OTH05
BP 745
EP 745
PG 1
WC Pathology
SC Pathology
GA AR7YZ
UT WOS:000343794200216
ER
PT J
AU Qari, SH
Abramson, DM
Kushma, JA
Halverson, PK
AF Qari, Shoukat H.
Abramson, David M.
Kushma, Jane A.
Halverson, Paul K.
TI Preparedness and Emergency Response Research Centers: Early Returns on
Investment in Evidence-Based Public Health Systems Research
SO PUBLIC HEALTH REPORTS
LA English
DT Editorial Material
C1 [Qari, Shoukat H.] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.
[Abramson, David M.] Columbia Univ, Earth Inst, Natl Ctr Disaster Preparedness, New York, NY USA.
[Kushma, Jane A.] Jacksonville State Univ, Jacksonville, AL 36265 USA.
[Halverson, Paul K.] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN 46202 USA.
RP Halverson, PK (reprint author), Indiana Univ, Richard M Fairbanks Sch Publ Hlth, 714 N Senate Ave,EF 250, Indianapolis, IN 46202 USA.
EM pkhalver@iupui.edu
NR 21
TC 1
Z9 1
U1 1
U2 9
PU ASSOC SCHOOLS PUBLIC HEALTH
PI WASHINGTON
PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA
SN 0033-3549
J9 PUBLIC HEALTH REP
JI Public Health Rep.
PD NOV-DEC
PY 2014
VL 129
SU 4
BP 1
EP 4
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AS3XD
UT WOS:000344207600001
PM 25355968
ER
PT J
AU Leinhos, M
Qari, SH
Williams-Johnson, M
AF Leinhos, Mary
Qari, Shoukat H.
Williams-Johnson, Mildred
TI Preparedness and Emergency Response Research Centers: Using a Public
Health Systems Approach to Improve All-Hazards Preparedness and Response
SO PUBLIC HEALTH REPORTS
LA English
DT Article
ID NORTH-CAROLINA; STATE; COMMUNITY; IMPACT; ORGANIZATIONS; INSTITUTIONS;
WILLINGNESS; DEPARTMENTS; INFORMATION; MANAGEMENT
AB In 2008, at the request of the Centers for Disease Control and Prevention (CDC), the Institute of Medicine (IOM) prepared a report identifying knowledge gaps in public health systems preparedness and emergency response and recommending near-term priority research areas. In accordance with the Pandemic and All-Hazards Preparedness Act mandating new public health systems research for preparedness and emergency response, CDC provided competitive awards establishing nine Preparedness and Emergency Response Research Centers (PERRCs) in accredited U.S. schools of public health. The PERRCs conducted research in four IOM-recommended priority areas: (1) enhancing the usefulness of public health preparedness and response (PHPR) training, (2) creating and maintaining sustainable preparedness and response systems, (3) improving PHPR communications, and (4) identifying evaluation criteria and metrics to improve PHPR for all hazards. The PERRCs worked closely with state and local public health, community partners, and advisory committees to produce practice-relevant research findings. PERRC research has generated more than 130 peer-reviewed publications and nearly 80 practice and policy tools and recommendations with the potential to significantly enhance our nation's PHPR to all hazards and that highlight the need for further improvements in public health systems.
C1 [Leinhos, Mary; Qari, Shoukat H.; Williams-Johnson, Mildred] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.
RP Qari, SH (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.
EM sqari@cdc.gov
NR 61
TC 1
Z9 1
U1 3
U2 12
PU ASSOC SCHOOLS PUBLIC HEALTH
PI WASHINGTON
PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA
SN 0033-3549
J9 PUBLIC HEALTH REP
JI Public Health Rep.
PD NOV-DEC
PY 2014
VL 129
SU 4
BP 8
EP 18
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AS3XD
UT WOS:000344207600003
PM 25355970
ER
PT J
AU Richards, CL
Iademarco, MF
Anderson, TC
AF Richards, Chesley L.
Iademarco, Michael F.
Anderson, Tara C.
TI A NEW STRATEGY FOR PUBLIC HEALTH SURVEILLANCE AT CDC: IMPROVING NATIONAL
SURVEILLANCE ACTIVITIES AND OUTCOMES
SO PUBLIC HEALTH REPORTS
LA English
DT Editorial Material
C1 [Richards, Chesley L.] CDC, Off Publ Hlth Sci Serv, Atlanta, GA 30333 USA.
[Iademarco, Michael F.; Anderson, Tara C.] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA.
[Iademarco, Michael F.; Anderson, Tara C.] US PHS, Atlanta, GA USA.
RP Richards, CL (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Sci Serv, 1600 Clifton Rd NE,MS E-33, Atlanta, GA 30333 USA.
EM cir6@cdc.gov
NR 12
TC 5
Z9 5
U1 0
U2 2
PU ASSOC SCHOOLS PUBLIC HEALTH
PI WASHINGTON
PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA
SN 0033-3549
J9 PUBLIC HEALTH REP
JI Public Health Rep.
PD NOV-DEC
PY 2014
VL 129
IS 6
BP 472
EP 476
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AS3WS
UT WOS:000344206600003
PM 25364046
ER
PT J
AU Shrestha, RK
Sansom, SL
Laffoon, BT
Farnham, PG
Shouse, RL
Macmaster, K
Hall, HI
AF Shrestha, Ram K.
Sansom, Stephanie L.
Laffoon, Benjamin T.
Farnham, Paul G.
Shouse, R. Luke
Macmaster, Karen
Hall, H. Irene
TI Estimating the Cost to US Health Departments to Conduct HIV Surveillance
SO PUBLIC HEALTH REPORTS
LA English
DT Article
ID UNITED-STATES; INFECTION; HEPATITIS; SYSTEM; AIDS
AB Objectives. HIV case surveillance is a primary source of information for monitoring HIV burden in the United States and guiding the allocation of prevention and treatment funds. While the number of people living with HIV and the need for surveillance data have increased, little is known about the cost of surveillance. We estimated the economic cost to health departments of conducting high-quality HIV case surveillance.
Methods. We collected primary data on the unit cost and quantity of resources used to operate the HIV case surveillance program in Michigan, where HIV burden (i.e., the number of HIV cases) is moderate to high (n=14,864 cases). Based on Michigan's data, we projected the expected annual HIV surveillance cost for U.S., state, local, and territorial health departments. We based our cost projection on the variation in the number of new and established cases, area-specific wages, and potential economies of scale.
Results. We estimated the annual total HIV surveillance cost to the Michigan health department to be $1,286,524 ($87/case), the annual total cost of new cases to be $108,657 ($133/case), and the annual total cost of established cases to be $1,177,867 ($84/case). Our projected median annual HIV surveillance cost per health department ranged from $210,600 in low-HIV burden sites to $1,835,000 in high-HIV burden sites.
Conclusions. Our analysis shows that a systematic approach to costing HIV surveillance at the health department level is feasible. For HIV surveillance, a substantial portion of total surveillance costs is attributable to maintaining established cases.
C1 [Shrestha, Ram K.; Sansom, Stephanie L.; Laffoon, Benjamin T.; Farnham, Paul G.; Shouse, R. Luke; Hall, H. Irene] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
[Macmaster, Karen] Michigan Dept Community Hlth, Lansing, MI USA.
RP Shrestha, RK (reprint author), Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E48, Atlanta, GA 30333 USA.
EM rshrestha@cdc.gov
NR 33
TC 0
Z9 0
U1 3
U2 4
PU ASSOC SCHOOLS PUBLIC HEALTH
PI WASHINGTON
PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA
SN 0033-3549
J9 PUBLIC HEALTH REP
JI Public Health Rep.
PD NOV-DEC
PY 2014
VL 129
IS 6
BP 496
EP 504
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AS3WS
UT WOS:000344206600008
PM 25364051
ER
PT J
AU Ross, TM
Pereira, LE
Luckay, A
McNicholl, JM
Garcia-Lerma, JG
Heneine, W
Eugene, HS
Pierce-Paul, BR
Zhang, JN
Hendry, RM
Smith, JM
AF Ross, Ted M.
Pereira, Lara E.
Luckay, Amara
McNicholl, Janet M.
Garcia-Lerma, J. Gerardo
Heneine, Walid
Eugene, Hermancia S.
Pierce-Paul, Brooke R.
Zhang, Jining
Hendry, R. Michael
Smith, James M.
TI A Polyvalent Clade B Virus-Like Particle HIV Vaccine Combined with
Partially Protective Oral Preexposure Prophylaxis Prevents Simian-Human
Immunodeficiency Virus Infection in Macaques and Primes for
Virus-Amplified Immunity
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID ANTIRETROVIRAL PROPHYLAXIS; ANAL INTERCOURSE; EFFICACY TRIALS; AIDS
VACCINES; ANIMAL-MODELS; TRANSMISSION; MICROBICIDE; TENOFOVIR; THAILAND;
RISK
AB Vaccination and preexposure prophylaxis (PrEP) with antiretrovirals have shown only partial protection from HIV-1 infection in human trials. Oral Truvada (emtricitabine/tenofovir disoproxil fumarate) is FDA approved as PrEP but partial adherence reduces efficacy. If combined as biomedical preventions (CBP), an HIV vaccine could protect when PrEP adherence is low and PrEP could prevent vaccine breakthroughs. The efficacy of combining oral PrEP with an HIV vaccine has not been evaluated in humans. We determined the efficacy of combining a DNA/virus-like particle (VLP) vaccine with partially effective intermittent PrEP in Indian rhesus macaques (RM). Eight RM received intramuscular inoculations of five DNA plasmids encoding four HIV-1 Clade B primary isolate Envs and SIVmac239 Gag (at weeks 0 and 4), followed by intramuscular and intranasal inoculations of homologous Gag VLPs and four Env VLPs (at weeks 12, 16, and 53). At week 61, we initiated weekly rectal exposures with heterologous SHIV162p3 (10 TCID50) along with oral Truvada (TDF, 22 mg/kg; FTC 20 mg/kg) dosing 2 h before and 22 h after each exposure. This PrEP regimen previously demonstrated 50% efficacy. Five controls (no vaccine, no PrEP) received weekly SHIV162p3. All controls were infected after a median of four exposures; the mean peak plasma viral load (VL) was 3.9x10(7) vRNA copies/ml. CBP protected seven of eight (87.5%) RM. The one infected CBP RM had a reduced peak VL of 8.8x10(5) copies/ml. SHIV exposures during PrEP amplified Gag and Env antibody titers in protected RM. These results suggest that combining oral PrEP with HIV vaccines could enhance protection against HIV-1 infection.
C1 [Ross, Ted M.] Univ Pittsburgh, Pittsburgh, PA USA.
[Pereira, Lara E.] LifeSource Biomed LLC, Moffett Field, CA USA.
[Luckay, Amara; McNicholl, Janet M.; Garcia-Lerma, J. Gerardo; Heneine, Walid; Eugene, Hermancia S.; Pierce-Paul, Brooke R.; Zhang, Jining; Hendry, R. Michael; Smith, James M.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
RP Smith, JM (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Bldg 17,Mailstop A25,1600 Clifton Rd, Atlanta, GA 30333 USA.
EM ajo9@cdc.gov
FU CDC; NIAID [R01AI068507]
FX The authors thank members of CDC's DHAP-Laboratory Branch Kelly Curtis
and Susan Kennedy for performing the antibody avidity assays and for
helpful discussions, and Mian-er Cong for her assistance in the drug
dosage calculations and preparation. This study was supported by funding
from CDC and from NIAID R01AI068507 to Ted M. Ross. We thank Debra
Hanson for guidance on statistical analysis. We acknowledge the
following members of CDC's DHAP-Laboratory Branch/Pre-clinical
Evaluation Team for their contributions to our nonhuman primate
research: David Garber, James Mitchell, Leecresia Jenkins, Shanon Ellis,
and Frank Deyounks for animal technical assistance as well as Chou-Pong
Pao, Chuong Dinh, Amy Martin, and Angela Holder for their assistance
with analytical chemistry. The views expressed by the authors do not
necessarily reflect those of the Centers for Disease Control and
Prevention.
NR 35
TC 1
Z9 1
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV 1
PY 2014
VL 30
IS 11
BP 1072
EP 1081
DI 10.1089/aid.2014.0030
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AR7OY
UT WOS:000343770300009
PM 24914761
ER
PT J
AU Curtis, KA
Kennedy, MS
Owen, SM
AF Curtis, Kelly A.
Kennedy, M. Susan
Owen, S. Michele
TI Longitudinal Analysis of HIV-1-Specific Antibody Responses
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IGG SUBCLASS RESPONSE; EARLY HIV-1
INFECTION; ENZYME-IMMUNOASSAY; HOMOSEXUAL MEN; LYMPHADENOPATHY SYNDROME;
VACCINE PREPAREDNESS; TYPE-1 INFECTION; CONTINUING RISK; FOLLOW-UP
AB Laboratory assays for determining recent HIV-1 infection are of great public health importance for aiding in the estimation of HIV incidence. Concerns have been raised about the potential for misclassification with serology-based assays due to fluctuations in the antibody response, particularly following progression to AIDS. We characterized longitudinal antibody responses to HIV using a cohort of men who have sex with men (MSM) sampled for up to 17 years, in which 57% of the 65 study subjects included in the current analyses progressed to AIDS during the study period. Envelope-specific total IgG antibody levels, avidity, and p24-specific IgG3 levels were evaluated using a multiplexed Bio-Plex assay. For the majority of the analytes, no significant difference in IgG reactivity was observed between AIDS and non-AIDS specimens. Although a slight decline in gp120 reactivity was noted with decreasing CD4(+) T cell count, the drop in assay values was relatively minimal and would likely not lead to an increase in the misclassification rate of the assay. A peak in HIV-1 p24 IgG3 levels was observed during early infection, as confirmed by testing 1,216 specimens from 342 recent seroconverters with the Bio-Plex assay. As expected, IgG3 reactivity declined with disease progression and decreasing CD4(+) T cell count in the MSM cohort; however, 37% of the study subjects exhibited relatively high IgG3 levels late in the course of infection.
C1 [Curtis, Kelly A.; Kennedy, M. Susan; Owen, S. Michele] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA.
RP Curtis, KA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE MS-A25, Atlanta, GA 30333 USA.
EM czv2@cdc.gov
NR 39
TC 1
Z9 1
U1 1
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV 1
PY 2014
VL 30
IS 11
BP 1099
EP 1105
DI 10.1089/aid.2014.0105
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AR7OY
UT WOS:000343770300012
PM 25314631
ER
PT J
AU Henning, TR
Hanson, D
Vishwanathan, SA
Butler, K
Dobard, C
Garcia-Lerma, G
Radzio, J
Smith, J
McNicholl, JM
Kersh, EN
AF Henning, Tara R.
Hanson, Debra
Vishwanathan, Sundaram A.
Butler, Katherine
Dobard, Charles
Garcia-Lerma, Gerardo
Radzio, Jessica
Smith, James
McNicholl, Janet M.
Kersh, Ellen N.
TI Short Communication: Viremic Control Is Independent of Repeated Low-Dose
SHIVSF162p3 Exposures
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID SIMIAN IMMUNODEFICIENCY VIRUS; RHESUS MACAQUES; SHIV INFECTION;
PERSISTENT VIREMIA; NONHUMAN-PRIMATES; NO EVIDENCE; RESPONSES;
CHALLENGES; TRANSMISSION; TRANSIENT
AB The repeat low-dose virus challenge model is commonly used in nonhuman primate studies of HIV transmission and biomedical preventions. For some viruses or challenge routes, it is uncertain whether the repeated exposure design might induce virus-directed innate or adaptive immunity that could affect infection or viremic outcomes. Retrospective cohorts of male Indian rhesus (n=40) and female pigtail (n=46) macaques enrolled in repeat low-dose rectal or vaginal SHIVSF162p3 challenge studies, respectively, were studied to compare the relationship between the number of previous exposures and peak plasma SHIV RNA levels or viral load area under the curve (AUC), surrogate markers of viral control. Repeated mucosal exposures of 10 or 50 TCID50 of virus for rectal and vaginal exposures, respectively, were performed. Virus levels were measured by quantitative reverse-transcriptase real-time PCR. The cumulative number of SHIVSF162p3 exposures did not correlate with observed peak virus levels or with AUC in rectally challenged rhesus macaques [peak: rho (rho)=0.04, p=0.8; AUC: rho=0.33, p=0.06] or vaginally challenged pigtail macaques (peak: rho=-0.09, p=0.7; AUC: rho=0.11, p=0.6). Infections in these models occur independently of exposure history and provide assurance that neither inoculation route nor number of exposures required for infection correlates with postinfection viremia. These data also indicate that both the vaginal and rectal repeated low-dose virus exposure models using SHIVSF162p3 provide a reliable system for nonhuman primate studies.
C1 [Henning, Tara R.; Hanson, Debra; Vishwanathan, Sundaram A.; Butler, Katherine; Dobard, Charles; Garcia-Lerma, Gerardo; Radzio, Jessica; Smith, James; McNicholl, Janet M.; Kersh, Ellen N.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
RP Kersh, EN (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE MS A-25, Atlanta, GA 30333 USA.
EM ekersh@cdc.gov
FU CDC [Y1-A1-0681-02]; NIH [Y1-A1-0681-02]
FX The authors gratefully acknowledge the intellectual contributions of Dr.
Sal Butera, as well as the previously published macaque infection work
and contributions of the Preclinical Evaluation Team's animal procedure
staff, James Mitchell, Elizabeth Sweeney, Shanon Ellis, Frank Deyounks,
Lecreesia Jenkins, Kristen Kelley, David Garber, and others, without
whom these studies would not have been possible. The authors also
acknowledge the excellent laboratory support work of Debra Adams,
Patricia Guenthner, Priya Srinivasan, Sunita Sharma, Mian-er Cong, and
Rolieria West. A portion of the animal studies was funded by an
intraagency agreement (Y1-A1-0681-02) between CDC and NIH.
SHIVSF162P3 was obtained through the NIH AIDS Reagent
Program, NIAID, NIH from Drs. Janet Harouse, Cecilia Cheng-Mayer,
Ranajit Pal, and DAIDS/NIAID. The findings and conclusions in this
article are those of the authors and do not necessarily represent the
views of the CDC.
NR 23
TC 2
Z9 2
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV 1
PY 2014
VL 30
IS 11
BP 1125
EP 1129
DI 10.1089/aid.2014.0238
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AR7OY
UT WOS:000343770300015
PM 25313448
ER
PT J
AU Lakoff, A
Fazili, Z
Aufreiter, S
Pfeiffer, CM
Connolly, B
Gregory, JF
Pencharz, PB
O'Connor, DL
AF Lakoff, Alanna
Fazili, Zia
Aufreiter, Susanne
Pfeiffer, Christine M.
Connolly, Bairbie
Gregory, Jesse F., III
Pencharz, Paul B.
O'Connor, Deborah L.
TI Folate is absorbed across the human colon: evidence by using
enteric-coated caplets containing C-13-labeled
[6S]-5-formyltetrahydrofolate
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID BACTERIALLY SYNTHESIZED FOLATE; FOLIC-ACID; LARGE-INTESTINE; SERUM
FOLATE; TRANSIT-TIME; PLASMA; TRANSPORTER; POPULATIONS; METABOLISM;
KINETICS
AB Background: Folate intakes that do not meet or greatly exceed requirements may be associated with negative health outcomes. A better understanding of contributors that influence the input side will help establish dietary guidance that ensures health benefits without associated risks. Colonic microbiota produce large quantities of folate, and [C-13(5)]5-formyltetrahydrofolate infused during colonoscopy is absorbed. However, it is unclear if significant quantities of folate are absorbed in an intact microbiome.
Objective: We determined whether and how much of a physiologic dose of [C-13(5)]5-formyltetrahydrofolate delivered in a pH-sensitive enteric caplet to an intact colonic microbiome is absorbed.
Design: Healthy adults ingested a specially designed pH-sensitive acrylic copolymer coated barium sulfate caplet that contained 855 nmol (400 mu g) [C-13(5)]5-formyltetrahydrofolate. After a washout period >= 4 wk, subjects received an intravenous injection of the same compound (214 nmol). Serially collected blood samples before and after each test dose were analyzed by using a microbiological assay and liquid chromatography tandem mass spectrometry.
Results: Caplet disintegration in the colon was observed by fluoroscopic imaging for 6 subjects with a mean (+/- SD) complete disintegration time of 284 +/- 155 min. The mean (+/- SEM) rate of appearance of [C-13(5)]5-methyltetrahydrofolate in plasma was 0.33 +/- 0.09 (caplet) and 5.8 +/- 1.2 (intravenous) nmol/h. Likely because of the significant time in the colon, the mean apparent absorption across the colon was 46%.
Conclusions: Folate is absorbed across the colon in humans with an undisturbed microbiome. This finding and previous observations of the size of the colonic depot of folate and its potential for manipulation by diet (eg, dietary fiber, oligosaccharides, and probiotics) suggest that an individual's dietary folate requirement may differ depending on the consumption of dietary constituents that affect the size and composition of their gastrointestinal microbiota. In addition, a systematic investigation of the role of colonic folate on gastrointestinal development and the prevention of colorectal cancer is warranted.
C1 [Lakoff, Alanna; Pencharz, Paul B.; O'Connor, Deborah L.] Univ Toronto, Dept Nutr Sci, Toronto, ON, Canada.
[Connolly, Bairbie] Univ Toronto, Dept Radiol, Toronto, ON M5S 1A1, Canada.
[Pencharz, Paul B.] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada.
[Lakoff, Alanna; Aufreiter, Susanne; Connolly, Bairbie; Pencharz, Paul B.; O'Connor, Deborah L.] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada.
[Fazili, Zia; Pfeiffer, Christine M.] CDC, Atlanta, GA 30333 USA.
[Gregory, Jesse F., III] Univ Florida, Food Sci & Human Nutr Dept, Gainesville, FL USA.
RP O'Connor, DL (reprint author), Univ Toronto, Hosp Sick Children, Dept Nutr Sci, Room 327,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.
EM deborah.oconnor@utoronto.ca
FU National Sciences & Engineering Research Council of Canada [453108];
Canadian Institutes of Health Training Program in Clinical Research [STP
53889]
FX Supported by the National Sciences & Engineering Research Council of
Canada (453108) and a trainee award through the Canadian Institutes of
Health Training Program in Clinical Research (STP 53889; to AL).
NR 40
TC 6
Z9 6
U1 2
U2 9
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD NOV
PY 2014
VL 100
IS 5
BP 1278
EP 1286
DI 10.3945/ajcn.114.091785
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AR3ZT
UT WOS:000343528500009
PM 25332326
ER
PT J
AU Taylor, J
Thompson, P
Hickner, J
AF Taylor, Julie
Thompson, Pamela
Hickner, John
TI Physicians' Challenges and Potential Solutions in Clinical Laboratory
Test Ordering and Result Interpretation
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Meeting Abstract
CT 49th Annual Meeting of
Academy-of-Clinical-Laboratory-Physicians-and-Scientists (ACLPS) /
Conference on Lab Medicine
CY MAY 29-31, 2014
CL San Francisco, CA
SP Acad Clin Lab Phys & Scientists
C1 [Taylor, Julie; Thompson, Pamela] CDC, Div Lab Programs Stand & Serv, Atlanta, GA 30333 USA.
[Hickner, John] Univ Illinois, Dept Family Med, Chicago, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL PATHOLOGY
PI CHICAGO
PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA
SN 0002-9173
EI 1943-7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD NOV
PY 2014
VL 142
IS 5
MA 37
BP 708
EP 708
PG 1
WC Pathology
SC Pathology
GA AR6IJ
UT WOS:000343687100043
ER
PT J
AU Beck, AJ
Boulton, ML
Coronado, F
AF Beck, Angela J.
Boulton, Matthew L.
Coronado, Fatima
TI Enumeration of the Governmental Public Health Workforce, 2014
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID UNITED-STATES
AB Background: Regular assessment of the size and composition of the U.S. public health workforce has been a challenge for decades. Previous enumeration efforts estimated 450,000 public health workers in governmental and voluntary agencies in 2000, and 326,602 governmental public health workers in 2012, although differences in enumeration methodology and the definitions of public health worker between the two make comparisons problematic.
Purpose: To estimate the size of the governmental public health workforce in 14 occupational classifications recommended for categorizing public health workers.
Methods: Six data sources were used to develop enumeration estimates: five for state and local public health workers and one for the federal public health workforce. Statistical adjustments were made to address missing data, overcounting, and duplicate counting of workers across surveys. Data were collected for 2010-2013; analyses were conducted in 2014.
Results: The multiple data sources yielded an estimate of 290,988 (range=231,464-341,053) public health workers in governmental agencies, 50%, 30%, and 20% of whom provide services in local, state, and federal public health settings, respectively. Administrative or clerical personnel (19%) represent the largest group of workers, followed by public health nurses (16%); environmental health workers (8%); public health managers (6%); and laboratory workers (5%).
Conclusions: Using multiple data sources for public health workforce enumeration potentially improves accuracy of estimates but also adds methodologic complexity. Improvement of data sources and development of a standardized study methodology is needed for continuous monitoring of public health workforce size and composition. (C) 2014 American Journal of Preventive Medicine.
C1 [Beck, Angela J.] Univ Michigan, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA.
[Beck, Angela J.; Boulton, Matthew L.] Univ Michigan, Ctr Excellence Publ Hlth Workforce Studies, Ann Arbor, MI 48109 USA.
Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Coronado, Fatima] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA.
RP Beck, AJ (reprint author), Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, 1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM ajbeck@umich.edu
FU U.S. Centers for Disease Control and Prevention (CDC), Agency of the
Department of Health and Human Services under Public Health Foundation;
University of Michigan Center of Excellence in Public Health Workforce
Studies [CDC RFA-OT13-1302]; Public Health Foundation
FX Publication of this article was supported by the U.S. Centers for
Disease Control and Prevention (CDC), an Agency of the Department of
Health and Human Services, under the Cooperative Agreement with the
Public Health Foundation and University of Michigan Center of Excellence
in Public Health Workforce Studies (CDC RFA-OT13-1302). The ideas
expressed in the articles are those of the authors and do not
necessarily reflect the official position of CDC.; The authors
acknowledge the National Association of County and City Health Officials
and Association of State and Territorial Health Officials for their data
contributions to this project and the Health Resources and Services
Administration for previous partnership on this study. This study was
funded under a contract with the Public Health Foundation and a
cooperative agreement with CDC.
NR 21
TC 15
Z9 15
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD NOV
PY 2014
VL 47
IS 5
SU 3
BP S306
EP S313
DI 10.1016/j.amepre.2014.07.018
PG 8
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AR5OP
UT WOS:000343634000008
PM 25439250
ER
PT J
AU Boulton, ML
Beck, AJ
Coronado, F
Merrill, JA
Friedman, CP
Stamas, GD
Tyus, N
Sellers, K
Moore, J
Tilson, HH
Leep, CJ
AF Boulton, Matthew L.
Beck, Angela J.
Coronado, Fatima
Merrill, Jacqueline A.
Friedman, Charles P.
Stamas, George D.
Tyus, Nadra
Sellers, Katie
Moore, Jean
Tilson, Hugh H.
Leep, Carolyn J.
TI Public Health Workforce Taxonomy
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID ENUMERATION
AB Thoroughly characterizing and continuously monitoring the public health workforce is necessary for ensuring capacity to deliver public health services. A prerequisite for this is to develop a standardized methodology for classifying public health workers, permitting valid comparisons across agencies and over time, which does not exist for the public health workforce. An expert working group, all of whom are authors on this paper, was convened during 2012-2014 to develop a public health workforce taxonomy. The purpose of the taxonomy is to facilitate the systematic characterization of all public health workers while delineating a set of minimum data elements to be used in workforce surveys. The taxonomy will improve the comparability across surveys, assist with estimating duplicate counting of workers, provide a framework for describing the size and composition of the workforce, and address other challenges to workforce enumeration. The taxonomy consists of 12 axes, with each axis describing a key characteristic of public health workers. Within each axis are multiple categories, and sometimes subcategories, that further define that worker characteristic. The workforce taxonomy axes are occupation, workplace setting, employer, education, licensure, certification, job tasks, program area, public health specialization area, funding source, condition of employment, and demographics. The taxonomy is not intended to serve as a replacement for occupational classifications but rather is a tool for systematically categorizing worker characteristics. The taxonomy will continue to evolve as organizations implement it and recommend ways to improve this tool for more accurate workforce data collection. (C) 2014 American Journal of Preventive Medicine.
C1 [Boulton, Matthew L.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Boulton, Matthew L.; Beck, Angela J.] Univ Michigan, Ctr Excellence Publ Hlth Workforce Studies, Ann Arbor, MI 48109 USA.
[Boulton, Matthew L.; Beck, Angela J.; Friedman, Charles P.] Univ Michigan, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA.
[Coronado, Fatima] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA.
[Merrill, Jacqueline A.] Columbia Univ, Sch Nursing, Ctr Hlth Policy, Lab Informat Complex & Org Study, New York, NY USA.
[Stamas, George D.] US Bur Labor Stat Formerly, Washington, DC USA.
[Leep, Carolyn J.] Natl Assoc Cty & City Hlth Officials, Washington, DC USA.
[Tyus, Nadra] Hlth Resources & Serv Adm, Natl Ctr Hlth Workforce Anal, Rockville, MD USA.
[Sellers, Katie] Assoc State & Territorial Hlth Officials, Arlington, VA USA.
[Moore, Jean] SUNY Albany, Ctr Hlth Workforce Studies, Albany, NY USA.
[Tilson, Hugh H.] Univ N Carolina, Gillings Sch Global Publ Hlth, Publ Hlth Leadership Program, Chapel Hill, NC USA.
RP Boulton, ML (reprint author), Univ Michigan, Sch Publ Hlth, Ctr Excellence Publ Hlth Workforce Studies, 1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM mboulton@umich.edu
FU U.S. Centers for Disease Control and Prevention (CDC), Agency of the
Department of Health and Human Services under Public Health Foundation;
University of Michigan Center of Excellence in Public Health Workforce
Studies [CDC RFA-OT13-1302]; CDC; Health Resources and Services
Administration (HRSA)
FX Publication of this article was supported by the U.S. Centers for
Disease Control and Prevention (CDC), an Agency of the Department of
Health and Human Services, under the Cooperative Agreement with the
Public Health Foundation and University of Michigan Center of Excellence
in Public Health Workforce Studies (CDC RFA-OT13-1302).; This project
was supported by CDC and Health Resources and Services Administration
(HRSA). Dr. Tilson served as a senior advisor for public health
workforce to HRSA and a consultant to the National Association for
County and City Health Officials during the development of this project.
The findings and conclusions in this report are those of the authors and
do not necessarily represent the official position of CDC, HRSA, or the
Bureau of Labor Statistics.
NR 33
TC 12
Z9 13
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD NOV
PY 2014
VL 47
IS 5
SU 3
BP S314
EP S323
DI 10.1016/j.amepre.2014.07.015
PG 10
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AR5OP
UT WOS:000343634000009
PM 25439251
ER
PT J
AU Coronado, F
Koo, D
Gebbie, K
AF Coronado, Fatima
Koo, Denise
Gebbie, Kristine
TI The Public Health Workforce Moving Forward in the 21st Century
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Editorial Material
C1 [Coronado, Fatima] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30329 USA.
[Koo, Denise] CDC, Off Publ Hlth Sci Serv, Atlanta, GA 30329 USA.
[Gebbie, Kristine] Flinders Univ S Australia, Fac Hlth Sci, Adelaide, SA 5001, Australia.
RP Coronado, F (reprint author), CDC, 1600 Clifton Rd NE,MS E-96, Atlanta, GA 30329 USA.
EM fec2@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 33
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD NOV
PY 2014
VL 47
IS 5
SU 3
BP S275
EP S277
DI 10.1016/j.amepre.2014.07.045
PG 3
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AR5OP
UT WOS:000343634000001
PM 25439243
ER
PT J
AU Dean, HD
Myles, RL
Spears-Jones, C
Bishop-Cline, A
Fenton, KA
AF Dean, Hazel D.
Myles, Ranell L.
Spears-Jones, Crystal
Bishop-Cline, Audriene
Fenton, Kevin A.
TI A Strategic Approach to Public Health Workforce Development and Capacity
Building
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
AB In February 2010, CDC's National Center for HIV/AIDS, Viral Hepatitis, Sexually Transmitted Disease (STD), and Tuberculosis (TB) Prevention (NCHHSTP) formally institutionalized workforce development and capacity building (WDCB) as one of six overarching goals in its 2010-2015 Strategic Plan. Annually, workforce team members finalize an action plan that lays the foundation for programs to be implemented for NCHHSTP's workforce that year. This paper describes selected WDCB programs implemented by NCHHSTP during the last 4 years in the three strategic goal areas: (1) attracting, recruiting, and retaining a diverse and sustainable workforce; (2) providing staff with development opportunities to ensure the effective and innovative delivery of NCHHSTP programs; and (3) continuously recognizing performance and achievements of staff and creating an atmosphere that promotes a healthy work-life balance. Programs have included but are not limited to an Ambassador Program for new hires, career development training for all staff, leadership and coaching for mid-level managers, and a Laboratory Workforce Development Initiative for laboratory scientists. Additionally, the paper discusses three overarching areas employee communication, evaluation and continuous review to guide program development, and the implementation of key organizational and leadership structures to ensure accountability and continuity of programs. Since 2010, many lessons have been learned regarding strategic approaches to scaling up organization-wide public health workforce development and capacity building. Perhaps the most important is the value of ensuring the high-level strategic prioritization of this issue, demonstrating to staff and partners the importance of this imperative in achieving NCHHSTP's mission. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine.
C1 [Dean, Hazel D.; Myles, Ranell L.; Spears-Jones, Crystal; Bishop-Cline, Audriene] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Director, Atlanta, GA 30333 USA.
[Fenton, Kevin A.] Publ Hlth England, Hlth & Wellbeing, London, England.
RP Dean, HD (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Director, 1600 Clifton Rd,NE Mailstop E-07, Atlanta, GA 30333 USA.
EM hdean@cdc.gov
FU U.S. Centers for Disease Control and Prevention (CDC) an Agency of the
Department of Health and Human Services under Public Health Foundation;
University of Michigan Center of Excellence in Public Health Workforce
Studies [CDC RFA-OT13-1302]
FX Publication of this article was supported by the U.S. Centers for
Disease Control and Prevention (CDC), an Agency of the Department of
Health and Human Services, under the Cooperative Agreement with the
Public Health Foundation and University of Michigan Center of Excellence
in Public Health Workforce Studies (CDC RFA-OT13-1302). The ideas
expressed in the articles are those of the authors and do not
necessarily reflect the official position of CDC.
NR 22
TC 3
Z9 3
U1 2
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD NOV
PY 2014
VL 47
IS 5
SU 3
BP S288
EP S296
DI 10.1016/j.amepre.2014.07.016
PG 9
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AR5OP
UT WOS:000343634000005
PM 25439247
ER
PT J
AU Drehobl, P
Stover, BH
Koo, D
AF Drehobl, Patricia
Stover, Beth H.
Koo, Denise
TI On the Road to a Stronger Public Health Workforce Visual Tools to
Address Complex Challenges
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
AB The public health workforce is vital to protecting the health and safety of the public, yet for years, state and local governmental public health agencies have reported substantial workforce losses and other challenges to the workforce that threaten the public's health. These challenges are complex, often involve multiple influencing or related causal factors, and demand comprehensive solutions. However, proposed solutions often focus on selected factors and might be fragmented rather than comprehensive. This paper describes approaches to characterizing the situation more comprehensively and includes two visual tools: (1) a fishbone, or Ishikawa, diagram that depicts multiple factors affecting the public health workforce; and (2) a roadmap that displays key elements goals and strategies to strengthen the public health workforce, thus moving from the problems depicted in the fishbone toward solutions. The visual tools aid thinking about ways to strengthen the public health workforce through collective solutions and to help leverage resources and build on each other's work. The strategic roadmap is intended to serve as a dynamic tool for partnership, prioritization, and gap assessment. These tools reflect and support CDC's commitment to working with partners on the highest priorities for strengthening the workforce to improve the public's health. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine.
C1 [Drehobl, Patricia; Stover, Beth H.] CDC, Ctr Surveillance Epidemiol & Lab Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.
[Koo, Denise] CDC, Off Publ Hlth Sci Serv, Atlanta, GA 30333 USA.
RP Drehobl, P (reprint author), CDC, Ctr Surveillance Epidemiol & Lab Serv, Div Sci Educ & Profess Dev, Off Publ Hlth Sci Serv, 1600 Clifton Rd,NE,MS E-92, Atlanta, GA 30333 USA.
EM pdrehobl@cdc.gov
FU U.S. Centers for Disease Control and Prevention (CDC), Agency of the
Department of Health and Human Services under Public Health Foundation;
University of Michigan Center of Excellence in Public Health Workforce
Studies [CDC RFA-OT13-1302]
FX Publication of this article was supported by the U.S. Centers for
Disease Control and Prevention (CDC), an Agency of the Department of
Health and Human Services, under the Cooperative Agreement with the
Public Health Foundation and University of Michigan Center of Excellence
in Public Health Workforce Studies (CDC RFA-OT13-1302). The ideas
expressed in the articles are those of the authors and do not
necessarily reflect the official position of CDC.
NR 17
TC 6
Z9 7
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD NOV
PY 2014
VL 47
IS 5
SU 3
BP S280
EP S285
DI 10.1016/j.amepre.2014.07.013
PG 6
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AR5OP
UT WOS:000343634000003
PM 25439245
ER
PT J
AU Duffus, WA
Trawick, C
Moonesinghe, R
Tola, J
Truman, BI
Dean, HD
AF Duffus, Wayne A.
Trawick, Cynthia
Moonesinghe, Rama
Tola, Jigsa
Truman, Benedict I.
Dean, Hazel D.
TI Training Racial and Ethnic Minority Students for Careers in Public
Health Sciences
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID ACADEMIC MEDICINE; DIVERSITY; PROFESSIONS; DISPARITIES; WORKFORCE; RACE;
PHYSICIANS; PROGRAMS; SCHOOLS; BLACK
AB Background: A workforce that resembles the society it serves is likely to be more effective in improving health equity for racial and ethnic minorities in the U.S. Racial and ethnic minorities are underrepresented in the U.S. public health professions. Project Imhotep is operated by Morehouse College with funding and technical assistance from CDC. Imhotep trains racial and ethnic minority students for entry into graduate and professional training programs for careers in the public health sciences. The curriculum focuses on biostatistics, epidemiology, and occupational safety and health with practical training in statistical data analysis, scientific writing, and oral presentation skills.
Purpose: To describe the Imhotep program and highlight some of its outcomes.
Methods: Data were collected every year by self-administered questionnaire or follow-up telephone and e-mail interviews of students who participated in Imhotep during 1982-2010 and were followed through December 2013.
Results: Findings demonstrated that 100% of the 481 trained students earned bachelor's degrees; 73.2% earned graduate degrees (53% earned master's degrees, 11.1% earned medical degrees, and 7.3% earned other doctoral degrees); and 60% entered public health careers.
Conclusions: The Imhotep program has improved the representation of racial and ethnic minorities among public health professionals in the U.S. A diverse workforce involving Imhotep graduates could augment the pool of pubic health professionals who make strategic and tactical decisions around program design and resource allocation that impact health in the Most affected communities. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine.
C1 [Duffus, Wayne A.; Truman, Benedict I.; Dean, Hazel D.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
[Moonesinghe, Rama] CDC, Off Minor Hlth & Hlth Equity, Atlanta, GA 30333 USA.
[Trawick, Cynthia; Tola, Jigsa] Morehouse Coll, Publ Hlth Sci Inst, Atlanta, GA USA.
RP Duffus, WA (reprint author), CDC, Off Director, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,NE Mailstop E-07, Atlanta, GA 30333 USA.
EM wed4@cdc.gov
FU U.S. Centers for Disease Control and Prevention (CDC), Agency of the
Department of Health and Human Services under Public Health Foundation;
University of Michigan Center of Excellence in Public Health Workforce
Studies [CDC RFA-OT13-1302]
FX Publication of this article was supported by the U.S. Centers for
Disease Control and Prevention (CDC), an Agency of the Department of
Health and Human Services, under the Cooperative Agreement with the
Public Health Foundation and University of Michigan Center of Excellence
in Public Health Workforce Studies (CDC RFA-OT13-1302). The ideas
expressed in the articles are those of the authors and do not
necessarily reflect the official position of CDC.
NR 32
TC 4
Z9 4
U1 2
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD NOV
PY 2014
VL 47
IS 5
SU 3
BP S368
EP S375
DI 10.1016/j.amepre.2014.07.028
PG 8
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AR5OP
UT WOS:000343634000017
PM 25439259
ER
PT J
AU Kattan, JA
Apostolou, A
Al-Samarrai, T
El Bcheraoui, C
Kay, MK
Khaokham, CB
Pillai, P
Sapkota, S
Jani, AA
Koo, D
Taylor, WC
AF Kattan, Jessica A.
Apostolou, Andria
Al-Samarrai, Teeb
El Bcheraoui, Charbel
Kay, Meagan K.
Khaokham, Christina B.
Pillai, Parvathy
Sapkota, Sanjeeb
Jani, Asim A.
Koo, Denise
Taylor, William C.
TI Beyond Content Leadership Development Through a Journal Club
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
AB CDC designed its Health Systems Integration Program to prepare leaders to function-at the interface of public health and health care. Specific Health Systems Integration Program competencies in the areas of communication, analysis and assessment, and health systems were developed to nurture evidence-based decision-making and leadership skills crucial for future public health leaders. The program therefore designed an innovative journal club as part of its competency-based curriculum not only to meet the standard goals for a journal club critical reading, interpretation, and acquiring content knowledge but also to foster leadership development. This report describes the Health Systems Integration Program journal club format, its implementation, challenges, and key elements of success. Other programs using a journal club model as a learning format might consider using the Health Systems Integration Program's innovative approach that focuses on leadership development. (C) 2014 Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine.
C1 [Kattan, Jessica A.; Apostolou, Andria; Al-Samarrai, Teeb; El Bcheraoui, Charbel; Kay, Meagan K.; Khaokham, Christina B.; Pillai, Parvathy; Sapkota, Sanjeeb] SciMetr LLC, Atlanta, GA USA.
[Jani, Asim A.; Koo, Denise] CDC, Atlanta, GA USA.
[Taylor, William C.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA.
[Taylor, William C.] Harvard Pilgrim Hlth Care, Boston, MA USA.
[Taylor, William C.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Taylor, William C.] Harvard Univ, Sch Med, Boston, MA USA.
[Taylor, William C.] Harvard Vanguard Med Assoc, Boston, MA USA.
RP Jani, AA (reprint author), Ctr Surveillance Epidemiol & Lab Serv, Div Sci Educ & Profess Dev, Mailstop E92,1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM ajani@cdc.gov
FU U.S. Centers for Disease Control and Prevention (CDC), Agency of the
Department of Health and Human Services under Public Health Foundation;
University of Michigan Center of Excellence in Public Health Workforce
Studies [CDC RFA-OT13-1302]; SciMetrika LLC
FX Publication of this article was supported by the U.S. Centers for
Disease Control and Prevention (CDC), an Agency of the Department of
Health and Human Services, under the Cooperative Agreement with the
Public Health Foundation and University of Michigan Center of Excellence
in Public Health Workforce Studies (CDC RFA-OT13-1302). The ideas
expressed in the articles are those of the authors and do not
necessarily reflect the official position of CDC.; Dr. Taylor was paid a
consulting fee by SciMetrika LLC for his role as a coach for the Health
Systems Integration Program journal club. No financial disclosures were
reported by the other authors of this paper.
NR 5
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD NOV
PY 2014
VL 47
IS 5
SU 3
BP S301
EP S305
DI 10.1016/j.amepre.2014.06.023
PG 5
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AR5OP
UT WOS:000343634000007
PM 25439249
ER
PT J
AU Click, ES
Chirenda, J
Kibias, S
Menzies, HJ
Oeltmann, JE
Sentle, C
Muribe, T
Lere, TD
Makombe, R
Bamrah, S
Moore, BK
Cain, KP
AF Click, E. S.
Chirenda, J.
Kibias, S.
Menzies, H. J.
Oeltmann, J. E.
Sentle, C.
Muribe, T.
Lere, T. D.
Makombe, R.
Bamrah, S.
Moore, B. K.
Cain, K. P.
TI The disconnect between a national tuberculosis drug resistance survey
and treatment outcomes: a lost opportunity
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE drug; resistance; survey; treatment; outcome
AB We linked results from the Fourth Botswana National Drug Resistance Survey (DRS), 2007-2008, to patient records from the national Electronic Tuberculosis Registry to determine treatment outcomes. Of 915 new patients, 651 (71%) had treatment data available. Completion or cure was achieved for 10/15 (67%, 95% CI 42-85) with isoniazid monoresistance, (6/16, 38%, 95%CI 18-61) with multidrug resistance, while 73% (391/537,95% CI 69-76) were susceptible to first-line drugs. The analysis was limited because of unavailable treatment records and undocumented outcomes. Prospective analyses following DRSs should be considered to ensure adequate outcome data.
C1 [Click, E. S.; Menzies, H. J.; Oeltmann, J. E.; Bamrah, S.; Moore, B. K.; Cain, K. P.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA.
[Chirenda, J.; Kibias, S.; Sentle, C.; Lere, T. D.] Botswana Natl TB Program, Gaborone, Botswana.
[Muribe, T.] Natl TB Reference Lab, Gaborone, Botswana.
[Makombe, R.] US Ctr Dis Control & Prevent Botswana, Gaborone, Botswana.
RP Click, ES (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd,MS E-10, Atlanta, GA 30333 USA.
EM eoc9@cdc.gov
NR 11
TC 0
Z9 0
U1 0
U2 2
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
EI 1815-7920
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD NOV
PY 2014
VL 18
IS 11
BP 1319
EP 1322
DI 10.5588/ijtld.13.0710
PG 4
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA AR4AK
UT WOS:000343530200011
PM 25299864
ER
PT J
AU Jackson, D
Rosales-Guevara, L
Blake, R
AF Jackson, Diane
Rosales-Guevara, Lourdes (Luly)
Blake, Robert
TI Environmental Odors Web Site: Providing Communities and Health Officials
With the Tools to Address Odor Issues
SO JOURNAL OF ENVIRONMENTAL HEALTH
LA English
DT Editorial Material
C1 [Jackson, Diane] ATSDR, Div Community Hlth Invest, Off Associate Director Sci, Atlanta, GA 30341 USA.
[Rosales-Guevara, Lourdes (Luly)] ATSDR, Exposure Invest Team, Atlanta, GA 30341 USA.
RP Jackson, D (reprint author), ATSDR, 4770 Buford Highway NE,Mailstop F-59, Atlanta, GA 30341 USA.
EM dxj0@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 0
TC 0
Z9 0
U1 1
U2 2
PU NATL ENVIRON HEALTH ASSOC
PI DENVER
PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA
SN 0022-0892
J9 J ENVIRON HEALTH
JI J. Environ. Health
PD NOV
PY 2014
VL 77
IS 4
BP 38
EP 39
PG 2
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AR6EA
UT WOS:000343675000007
PM 25603622
ER
PT J
AU Kochtitzky, CS
AF Kochtitzky, Chris S.
TI Applying a General Best Practices Identification Framework to
Environmental Health
SO JOURNAL OF ENVIRONMENTAL HEALTH
LA English
DT Editorial Material
ID INTERVENTIONS
C1 [Kochtitzky, Chris S.] CDC, Div Emergency & Environm Hlth Serv, Atlanta, GA 30341 USA.
RP Kochtitzky, CS (reprint author), CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, 4770 Buford Highway NE,Mailstop F-58, Atlanta, GA 30341 USA.
EM csk3@cdc.gov
NR 15
TC 0
Z9 0
U1 2
U2 4
PU NATL ENVIRON HEALTH ASSOC
PI DENVER
PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA
SN 0022-0892
J9 J ENVIRON HEALTH
JI J. Environ. Health
PD NOV
PY 2014
VL 77
IS 4
BP 40
EP 43
PG 4
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AR6EA
UT WOS:000343675000008
PM 25603623
ER
PT J
AU Fazili, Z
Sternberg, MR
Paladugula, N
Whitehead, RD
Chen, HP
Pfeiffer, CM
AF Fazili, Zia
Sternberg, Maya R.
Paladugula, Neelima
Whitehead, Ralph D., Jr.
Chen, Huiping
Pfeiffer, Christine M.
TI The Loss of 5-Methyltetrahydrofolate in Human Serum under Suboptimal
Preanalytical Conditions Can Only Partially Be Recovered by an Oxidation
Product
SO JOURNAL OF NUTRITION
LA English
DT Article
ID TANDEM MASS-SPECTROMETRY; DEGRADATION-PRODUCTS; MICROBIOLOGIC ASSAY;
FOLATE VITAMERS; STABILITY; VITAMIN-B-12; RADIOASSAY; PLASMA
AB Background: Maintaining folate stability during sample handling is important, yet challenging.
Objective: We investigated the effects of suboptimal preanalytical conditions on serum folate stability.
Methods: By using an HPLC-tandem MS method we measured folates [5-methyltetrahydrofolate (5-methylTHF), folic acid, MeFox (5-methylTHF oxidation product, pyrazino-s-triazine derivative of 4 alpha-hydroxy-5-methyITHF), and other minor folate forms at or below the limit of detection] in human serum exposed to suboptimal conditions.
Results: Whole blood samples (n = 21) stored at 32 degrees C for <= 3 d (Expt. 1: delayed processing) showed significant decreases in serum total folate (tFOL; sum of folate forms: 11-32%, 5.5-15.9 nmol/L) and 5-methylTHF (36-62%, 14.5-25.1 nmol/L) and a significant increase in MeFox (346-415%, 7.17-8.63 nmol/L). Serum samples (n = 21) stored at 11 degrees C for 7-14 d (Expt. 2: delayed freezing) also showed significant decreases in tFOL (4.6-10.4%, 2.3-5.1 nmol/L) and 5-methylTHF (8.4-29%, 3.4-11.6 nmol/L) and significant increases in MeFox (88-320%, 1.82-6.62 nmol/L). The molar loss in 5-methylTHF exceeded the gain in MeFox in these 2 experiments. When we exposed 3 serum pools (tFOL: 16.7-58.3 nmol/L) for 24 h to an elevated temperature of 37 degrees C (Expt. 31, the significant decrease in 5-methylTHF 133% on average) was compensated for by an equimolar gain in MeFox. Repeated freeze/thaw cycles (53 cycles) of serum [closed (Expt. 4) and open (Expt. 5) vials] showed generally stable folates with small (<1 nmol/L) changes. Long-term (<= 12 mo) exposure of 3 serum pools (tFOL: 17.5-63.7 nmol/L) to a suboptimal (-20 degrees C) freezing temperature (Expt. 61 showed significant decreases in tFOL (5% on average) already after 3 mo. The molar loss in 5-methylTHF exceeded the gain in MeFox. Folic acid generally showed good stability.
Conclusions: To avoid folate losses, unprocessed whole blood should be protected from elevated temperatures and serum should not be refrigerated for -2 d or for a long term stored at -20 degrees C.
C1 [Fazili, Zia; Sternberg, Maya R.; Paladugula, Neelima; Whitehead, Ralph D., Jr.; Chen, Huiping; Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.
RP Pfeiffer, CM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.
EM cpfeiffer@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 18
TC 0
Z9 0
U1 0
U2 5
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD NOV
PY 2014
VL 144
IS 11
BP 1873
EP 1879
DI 10.3945/jn.114.198358
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AR6GN
UT WOS:000343681400028
PM 25332487
ER
PT J
AU Goodman, CH
Russell, BJ
Velez, JO
Laven, JJ
Nicholson, WL
Bagarozzi, DA
Moon, JL
Bedi, K
Johnson, BW
AF Goodman, C. H.
Russell, B. J.
Velez, J. O.
Laven, J. J.
Nicholson, W. L.
Bagarozzi, D. A., Jr.
Moon, J. L.
Bedi, K.
Johnson, B. W.
TI Development of an algorithm for production of inactivated arbovirus
antigens in cell culture
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Arbovirus; Antigen; Immunoglobulin M antibody-capture enzyme-linked
immunosorbent assay (MAC-ELISA); Beta-propiolactone; Gamma-irradiation
ID WEST-NILE-VIRUS; SODIUM LAURYL SULFATE; BETA-PROPIOLACTONE;
IMMUNOGLOBULIN-M; ENCEPHALITIS; IMMUNOASSAY; CHIKUNGUNYA; ANTIBODIES;
DISEASE; INFECTIONS
AB Arboviruses are medically important pathogens that cause human disease ranging from a mild fever to encephalitis. Laboratory diagnosis is essential to differentiate arbovirus infections from other pathogens with similar clinical manifestations. The Arboviral Diseases Branch (ADB) reference laboratory at the CDC Division of Vector-Borne Diseases (DVBD) produces reference antigens used in serological assays such as the virus-specific immunoglobulin M antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA). Antigen production in cell culture has largely replaced the use of suckling mice; however, the methods are not directly transferable. The development of a cell culture antigen production algorithm for nine arboviruses from the three main arbovirus families, Flaviviridae, Togaviridae, and Bunyaviridae, is described here. Virus cell culture growth and harvest conditions were optimized, inactivation methods were evaluated, and concentration procedures were compared for each virus. Antigen performance was evaluated by the MAC-ELISA at each step of the procedure. The antigen production algorithm is a framework for standardization of methodology and quality control; however, a single antigen production protocol was not applicable to all arboviruses and needed to be optimized for each virus. Published by Elsevier B.V.
C1 [Goodman, C. H.; Russell, B. J.; Velez, J. O.; Laven, J. J.; Johnson, B. W.] Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
[Nicholson, W. L.] CDC, Rickettsial Zoonosis Branch, Div Vector Borne Dis, Atlanta, GA 30333 USA.
[Bagarozzi, D. A., Jr.; Moon, J. L.; Bedi, K.] CDC, Div Sci Resources, Atlanta, GA 30333 USA.
RP Goodman, CH (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA.
EM bvv0@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 39
TC 4
Z9 4
U1 3
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD NOV
PY 2014
VL 208
BP 66
EP 78
DI 10.1016/j.jviromet.2014.07.030
PG 13
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Virology
GA AR1KN
UT WOS:000343344200012
PM 25102428
ER
PT J
AU Olowokure, B
Francis, L
Polson-Edwards, K
Nasci, R
Quenel, P
Aldighieri, S
Rousset, D
Gutierrez, C
Ramon-Pardo, P
dos Santos, T
Hospedales, CJ
AF Olowokure, Babatunde
Francis, Lorraine
Polson-Edwards, Karen
Nasci, Roger
Quenel, Philippe
Aldighieri, Sylvain
Rousset, Dominique
Gutierrez, Cristina
Ramon-Pardo, Pilar
dos Santos, Thais
Hospedales, C. James
TI The Caribbean response to chikungunya
SO LANCET INFECTIOUS DISEASES
LA English
DT Editorial Material
C1 [Olowokure, Babatunde; Francis, Lorraine; Polson-Edwards, Karen; Gutierrez, Cristina; Hospedales, C. James] Caribbean Publ Hlth Agcy CARPHA, Port Of Spain, Trinid & Tobago.
[Nasci, Roger] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA.
[Quenel, Philippe; Rousset, Dominique] Inst Pasteur, Cayenne, French Guiana.
[Aldighieri, Sylvain; Ramon-Pardo, Pilar] WHO, Pan Amer Hlth Org, Washington, DC USA.
[dos Santos, Thais] WHO, Pan Amer Hlth Org, Off Barbados & Eastern Caribbean Countries, Bridgetown, Barbados.
RP Olowokure, B (reprint author), Caribbean Publ Hlth Agcy CARPHA, Port Of Spain, Trinid & Tobago.
EM olowokba@carpha.org
RI QUENEL, PHILIPPE/J-4351-2015
OI QUENEL, PHILIPPE/0000-0003-3361-3623
FU World Health Organization [001]
NR 6
TC 4
Z9 4
U1 1
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD NOV
PY 2014
VL 14
IS 11
BP 1039
EP 1040
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA AR7EZ
UT WOS:000343743700012
PM 25444399
ER
PT J
AU Baeten, JM
Donnell, D
Mugo, NR
Ndase, P
Thomas, KK
Campbell, JD
Wangisi, J
Tappero, JW
Bukusi, EA
Cohen, CR
Katabira, E
Ronald, A
Tumwesigye, E
Were, E
Fife, KH
Kiarie, J
Farquhar, C
John-Stewart, G
Kidoguchi, L
Coombs, RW
Hendrix, C
Marzinke, MA
Frenkel, L
Haberer, JE
Bangsberg, D
Celum, C
AF Baeten, Jared M.
Donnell, Deborah
Mugo, Nelly R.
Ndase, Patrick
Thomas, Katherine K.
Campbell, James D.
Wangisi, Jonathan
Tappero, Jordan W.
Bukusi, Elizabeth A.
Cohen, Craig R.
Katabira, Elly
Ronald, Allan
Tumwesigye, Elioda
Were, Edwin
Fife, Kenneth H.
Kiarie, James
Farquhar, Carey
John-Stewart, Grace
Kidoguchi, Lara
Coombs, Robert W.
Hendrix, Craig
Marzinke, Mark A.
Frenkel, Lisa
Haberer, Jessica E.
Bangsberg, David
Celum, Connie
CA Partners PrEP Study Team
TI Single-agent tenofovir versus combination emtricitabine plus tenofovir
for pre-exposure prophylaxis for HIV-1 acquisition: an update of data
from a randomised, double-blind, phase 3 trial
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; PREVENTION; INFECTION; TRANSMISSION; INITIATION;
MACAQUES; WOMEN; MEN
AB Background Antiretroviral pre-exposure prophylaxis (PrEP), with daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in combination with emtricitabine, has been shown to be efficacious for HIV-1 prevention. Although the use of more than one antiretroviral agent is essential for effective HIV-1 treatment, more than one agent might not be required for effective prophylaxis. We assessed the efficacy of single-agent tenofovir disoproxil fumarate relative to combination emtricitabine plus tenofovir disoproxil fumarate as PrEP.
Methods We did a randomised, double-blind, placebo-controlled three-group phase 3 trial of daily oral tenofovir disoproxil fumarate and emtricitabine plus tenofovir disoproxil fumarate PrEP in HIV-1 uninfected individuals in heterosexual HIV-1 serodiscordant couples from Kenya and Uganda. After an interim review, the trial's placebo group was discontinued and thereafter the active groups were continued, and participants initially randomly assigned to placebo were offered rerandomisation in a 1:1 ratio to tenofovir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate as PrEP. The primary endpoints were HIV-1 seroconversion and safety. This trial is registered with ClinicalTrials.gov, number NCT00557245.
Findings 4410 (99.6%) of 4427 couples received tenofovir disoproxil fumarate or emtridtabine plus tenofovir disoproxil fumarate and were followed up for HIV-1 acquisition. Of 52 incident HIV-1 infections, 31 occurred in individuals assigned tenofovir disoproxil fumarate (incidence 0.71 cases per 100 person-years) and 21 were in those assigned emtridtabine plus tenofovir disoproxil fumarate (0.48 cases per 100 person-years); HIV-1 incidence in the placebo group until discontinuation was two cases per 100 person-years. HIV-1 prevention efficacy with emtridtabine plus tenofovir disoproxil fumarate was not significantly different from that of tenofovir disoproxil fumarate alone (hazard ratio [HR] 0.67, 95% CI 0.39-1.17; p=0.16). Detection of tenofovir in plasma samples, compared with no detection and as measured in seroconverters and a subset of non-seroconverters, was associated with an 85% relative risk reduction in HIV-1 acquisition for the tenofovir disoproxil fumarate group (HR 0-15, 95% CI 0.06-0.37; p<0.0001) and 93% for the emtridtabine plus tenofovir disoproxil fumarate group (0.07, 0.02-0.23; p<0.0001). No significant differences were noted in the frequency of deaths, serious adverse events, or serum creatinine and phosphorus abnormalities between the two groups.
Interpretation These results do not rule out the potential for a slight difference in HIV-1 protection with tenofovir disoproxil fumarate compared with emtricitabine plus tenofovir disoproxil fumarate, but show that once-daily oral tenofovir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate regimens both provide high protection against HIV-1 acquisition in heterosexual men and women.
C1 [Baeten, Jared M.; Donnell, Deborah; Mugo, Nelly R.; Ndase, Patrick; Thomas, Katherine K.; Bukusi, Elizabeth A.; Kiarie, James; Farquhar, Carey; John-Stewart, Grace; Kidoguchi, Lara; Celum, Connie] Univ Washington, Dept Global Hlth, Seattle, WA 98104 USA.
[Baeten, Jared M.; Farquhar, Carey; John-Stewart, Grace; Coombs, Robert W.; Celum, Connie] Univ Washington, Dept Med, Seattle, WA 98104 USA.
[Baeten, Jared M.; Farquhar, Carey; John-Stewart, Grace; Celum, Connie] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA.
[Coombs, Robert W.; Frenkel, Lisa] Univ Washington, Dept Lab Med, Seattle, WA 98104 USA.
[John-Stewart, Grace; Frenkel, Lisa] Univ Washington, Dept Pediat, Seattle, WA 98104 USA.
[Donnell, Deborah] Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, Seattle, WA 98104 USA.
[Mugo, Nelly R.] Kenya Govt Med Res Ctr, Clin Res Ctr, Nairobi, Kenya.
[Bukusi, Elizabeth A.] Kenya Govt Med Res Ctr, Ctr Microbiol Res, Nairobi, Kenya.
[Campbell, James D.] Ctr Dis Control & Prevent, Entebbe, Uganda.
[Wangisi, Jonathan] AIDS Support Org, Kampala, Uganda.
[Tappero, Jordan W.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Bukusi, Elizabeth A.; Kiarie, James] Univ Nairobi, Dept Obstet & Gynecol, Nairobi, Kenya.
[Bukusi, Elizabeth A.; Kiarie, James] Kenyatta Natl Hosp, Nairobi, Kenya.
[Bukusi, Elizabeth A.; Cohen, Craig R.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
[Katabira, Elly; Ronald, Allan] Makerere Univ, Infect Dis Inst, Kampala, Uganda.
[Ronald, Allan] Univ Manitoba, Dept Med, Winnipeg, MB, Canada.
[Tumwesigye, Elioda] Kabwohe Clin Res Ctr, Kabwohe, Uganda.
[Were, Edwin] Moi Univ, Dept Reprod Hlth, Eldoret, Kenya.
[Fife, Kenneth H.] Indiana Univ, Dept Med, Indianapolis, IN USA.
[Hendrix, Craig; Marzinke, Mark A.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
[Frenkel, Lisa] Seattle Childrens Hosp, Res Inst, Seattle, WA USA.
[Haberer, Jessica E.; Bangsberg, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Haberer, Jessica E.; Bangsberg, David] Harvard Univ, Sch Med, Boston, MA USA.
RP Baeten, JM (reprint author), Univ Washington, Int Clin Res Ctr, Dept Global Hlth, Box 359927,325 Ninth Ave, Seattle, WA 98104 USA.
EM jbaeten@uw.edu
OI Ronald, Allan/0000-0002-5746-3490; Donnell, Deborah/0000-0002-0587-7480
FU Bill & Melinda Gates Foundation; US National Institutes of Health
FX Bill & Melinda Gates Foundation and US National Institutes of Health.
NR 29
TC 27
Z9 29
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD NOV
PY 2014
VL 14
IS 11
BP 1055
EP 1064
DI 10.1016/S1473-3099(14)70937-5
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA AR7EZ
UT WOS:000343743700030
PM 25300863
ER
PT J
AU de Noordhout, CM
Devleesschauwer, B
Angulo, FJ
Verbeke, G
Haagsma, J
Kirk, M
Havelaar, A
Speybroeck, N
AF de Noordhout, Charline Maertens
Devleesschauwer, Brecht
Angulo, Frederick J.
Verbeke, Geert
Haagsma, Juanita
Kirk, Martyn
Havelaar, Arie
Speybroeck, Niko
TI The global burden of listeriosis: a systematic review and meta-analysis
SO LANCET INFECTIOUS DISEASES
LA English
DT Review
ID ADJUSTED LIFE YEARS; EPIDEMIC LISTERIOSIS; FOODBORNE DISEASES;
UNITED-STATES; MONOCYTOGENES; HEALTH; STILLBIRTHS; INFECTION; PATHOGENS;
ILLNESS
AB Background Listeriosis, caused by Listeria monocytogenes, is an important foodborne disease that can be difficult to control and commonly results in severe clinical outcomes. We aimed to provide the first estimates of global numbers of illnesses, deaths, and disability-adjusted life-years (DALYs) due to listeriosis, by synthesising information and knowledge through a systematic review.
Methods We retrieved data on listeriosis through a systematic review of peer-reviewed and grey literature (published in 1990-2012). We excluded incidence data from before 1990 from the analysis. We reviewed national surveillance data where available. We did a multilevel meta-analysis to impute missing country-specific listeriosis incidence rates. We used a meta-regression to calculate the proportions of health states, and a Monte Carlo simulation to generate DALYs by WHO subregion.
Findings We screened 11 722 references and identified 87 eligible studies containing listeriosis data for inclusion in the meta-analyses. We estimated that, in 2010, listeriosis resulted in 23 150 illnesses (95% credible interval 6061-91247), 5463 deaths (1401-21497), and 172 823 DALYs (44079-676 465). The proportion of perinatal cases was 20.7% (SD 1.7).
Interpretation Our quantification of the global burden of listeriosis will enable international prioritisation exercises. The number of DALYs due to listeriosis was lower than those due to congenital toxoplasmosis but accords with those due to echinococcosis. Urgent efforts are needed to fill the missing data in developing countries. We were unable to identify incidence data for the AFRO, EMRO, and SEARO WHO regions.
C1 [de Noordhout, Charline Maertens; Devleesschauwer, Brecht; Speybroeck, Niko] Catholic Univ Louvain, Inst Hlth & Soc IRSS, B-1200 Brussels, Belgium.
[Devleesschauwer, Brecht] Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, B-9000 Ghent, Belgium.
[Angulo, Frederick J.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA USA.
[Verbeke, Geert] Katholieke Univ Leuven, Interuniv Inst Biostat & Stat Bioinformat, Leuven, Belgium.
[Haagsma, Juanita] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands.
[Kirk, Martyn] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia.
[Havelaar, Arie] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands.
[Havelaar, Arie] Univ Utrecht, Inst Risk Assessment Sci, Fac Vet Med, Utrecht, Netherlands.
RP de Noordhout, CM (reprint author), Catholic Univ Louvain, Inst Hlth & Soc IRSS, B-1200 Brussels, Belgium.
EM charline.maertens@uclouvain.be
RI Verbeke, Geert/I-5587-2015
FU WHO Foodborne Diseases Epidemiology Reference Group; Universite
catholique de Louvain
FX WHO Foodborne Diseases Epidemiology Reference Group and the Universite
catholique de Louvain.
NR 54
TC 23
Z9 23
U1 4
U2 31
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD NOV
PY 2014
VL 14
IS 11
BP 1073
EP 1082
DI 10.1016/S1473-3099(14)70870-9
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA AR7EZ
UT WOS:000343743700032
ER
PT J
AU Groome, MJ
Page, N
Cortese, MM
Moyes, J
Zar, HJ
Kapongo, CN
Mulligan, C
Diedericks, R
Cohen, C
Fleming, JA
Seheri, M
Mphahlele, J
Walaza, S
Kahn, K
Chhagan, M
Steele, AD
Parashar, UD
Zell, ER
Madhi, SA
AF Groome, Michelle J.
Page, Nicola
Cortese, Margaret M.
Moyes, Jocelyn
Zar, Heather J.
Kapongo, Constant N.
Mulligan, Christine
Diedericks, Ralph
Cohen, Cheryl
Fleming, Jessica A.
Seheri, Mapaseka
Mphahlele, Jeffrey
Walaza, Sibongile
Kahn, Kathleen
Chhagan, Meera
Steele, A. Duncan
Parashar, Umesh D.
Zell, Elizabeth R.
Madhi, Shabir A.
TI Effectiveness of monovalent human rotavirus vaccine against admission to
hospital for acute rotavirus diarrhoea in South African children: a
case-control study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; PUBLIC IMMUNIZATION PROGRAM; 1ST 2
YEARS; DOUBLE-BLIND; INFANTS; EFFICACY; GASTROENTERITIS; SAFETY; LIFE;
EPIDEMIOLOGY
AB Background The effectiveness of the rotavirus vaccine under conditions of routine use in an African setting with a high prevalence of HIV infection needs to be established. We assessed the vaccine effectiveness of monovalent human rotavirus vaccine in preventing admission to hospital for acute rotavirus diarrhoea, after its introduction at age 6 and 14 weeks into South Africa's national immunisation programme.
Methods This case-control study was done at seven hospitals in South Africa between April 19,2010, and Oct 31,2012. The hospitals were located in a range of urban, pen-urban, and rural settings, with varying rates of population HIV infection. Cases were children aged from 18 weeks to 23 months who were age-eligible to have received at least one dose of the human rotavirus vaccine (ie, those born after June 14,2009) admitted to hospital with laboratory-confirmed acute rotavirus diarrhoea, and the primary control group was children admitted to hospital with diarrhoea testing negative for rotavirus. A second control group comprised children admitted to a subset of three of the seven hospitals with respiratory illness. The primary endpoint was adjusted vaccine effectiveness (1 adjusted odds ratio x100%) in children aged from 18 weeks to 23 months and was calculated by unconditional logistic regression. This study is registered on the South African National Clinical Trial Register, number DOH-27-0512-3247.
Findings Of 540 rotavirus-positive cases, 278 children (52%) received two doses, 126 (23%) one dose, and 136 (25%) no doses of human rotavirus vaccine, compared with 1434 rotavirus-negative controls of whom 856 (60%) received two doses, 334 (23%) one dose, and 244 (17%) no doses. Adjusted vaccine effectiveness using rotavirus-negative controls was 57% (95% CI 40-68) for two doses and 40% (16-57) for one dose; estimates were similar when respiratory controls were used as the control group. Adjusted vaccine effectiveness for two doses was similar between age groups 18 weeks-11 months (54%, 95% CI 32-68) and 12-23 months (61%, 35-77), and was similar in HIV-exposed-uninfected (64%, 95% CI 34-80) and HIV-unexposed-uninfected children (54%, 31-69).
Interpretation Human rotavirus vaccine provided sustained protection against admission to hospital for acute rotavirus diarrhoea during the first and second years of life. This finding is encouraging and establishes the public health value of rotavirus vaccine in an African setting, especially as rotavirus vaccines are introduced into an increasing number of African countries.
C1 [Groome, Michelle J.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa.
[Groome, Michelle J.; Madhi, Shabir A.] Univ Witwatersrand, Resp & Meningeal Pathogens Res Unit, MRC, Johannesburg, South Africa.
[Moyes, Jocelyn; Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Johannesburg, South Africa.
[Kahn, Kathleen] Univ Witwatersrand, MRC, Wits Rural Publ Hlth & Hlth Transit Res Unit Agin, Sch Publ Hlth,Fac Hlth Sci, Johannesburg, South Africa.
[Page, Nicola; Moyes, Jocelyn; Cohen, Cheryl; Walaza, Sibongile; Madhi, Shabir A.] Natl Inst Communicable Dis, Johannesburg, South Africa.
[Cortese, Margaret M.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
[Zar, Heather J.; Mulligan, Christine; Diedericks, Ralph] Univ Cape Town, Dept Paediat & Child Hlth, Red Cross War Mem Childrens Hosp, ZA-7925 Cape Town, South Africa.
[Kapongo, Constant N.] Ngwelezane Hosp, Dept Paediat, Empangeni, South Africa.
[Fleming, Jessica A.; Steele, A. Duncan] PATH, Seattle, WA USA.
[Seheri, Mapaseka; Mphahlele, Jeffrey; Steele, A. Duncan] Univ Limpopo, Dept Virol, Diarrhoeal Pathogens Res Unit, Natl Hlth Lab Serv,MRC, Pretoria, South Africa.
[Kahn, Kathleen] Umea Univ, Ctr Global Hlth Res, Umea, Sweden.
[Kahn, Kathleen] INDEPTH Network, Accra, Ghana.
[Chhagan, Meera] Univ KwaZulu Natal, Dept Paediat & Child Hlth, Johannesburg, South Africa.
[Steele, A. Duncan] Bill & Melinda Gates Fdn, Seattle, WA USA.
[Zell, Elizabeth R.] Stat Epi Associates Inc, Palm Beach, FL USA.
RP Groome, MJ (reprint author), Chris Hani Baragwanath Acad Hosp, 11th Floor West Wing,Chris Hani Rd, ZA-2013 Soweto, South Africa.
EM groomem@rmpru.co.za
OI Page, Nicola/0000-0001-5845-4417
FU GAVI Alliance; PATH
FX GAVI Alliance (with support from PATH).
NR 33
TC 31
Z9 32
U1 1
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD NOV
PY 2014
VL 14
IS 11
BP 1096
EP 1104
DI 10.1016/S1473-3099(14)70940-5
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA AR7EZ
UT WOS:000343743700035
PM 25303843
ER
PT J
AU Pan, Y
Caudill, SP
Li, RS
Caldwell, KL
AF Pan, Yi
Caudill, Samuel P.
Li, Ruosha
Caldwell, Kathleen L.
TI Median and quantile tests under complex survey design using SAS and R
SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
LA English
DT Article
DE Median; Quantile; Complex survey; SAS; R
AB Techniques for conducting hypothesis testing on the median and other quantiles of two or more subgroups under complex survey design are limited. In this paper, we introduce programs in both SAS and R to perform such a test. A detailed illustration of the computations, macro variable definitions, input and output for the SAS and R programs are also included in the text. Urinary iodine data from National Health and Nutrition Examination Survey (NHANES) are used as examples for comparing medians between females and males as well as comparing the 75th percentiles among three salt consumption groups. Published by Elsevier Ireland Ltd.
C1 [Pan, Yi; Caudill, Samuel P.; Caldwell, Kathleen L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA.
[Li, Ruosha] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
RP Pan, Y (reprint author), 4770 Buford Hwy,NE,MS F18, Atlanta, GA 30341 USA.
EM jnu5@cdc.gov
NR 20
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0169-2607
EI 1872-7565
J9 COMPUT METH PROG BIO
JI Comput. Meth. Programs Biomed.
PD NOV
PY 2014
VL 117
IS 2
BP 292
EP 297
DI 10.1016/j.cmpb.2014.07.007
PG 6
WC Computer Science, Interdisciplinary Applications; Computer Science,
Theory & Methods; Engineering, Biomedical; Medical Informatics
SC Computer Science; Engineering; Medical Informatics
GA AQ8PV
UT WOS:000343091400023
PM 25123100
ER
PT J
AU Edwards, JK
McGrath, LJ
Buckley, JP
Schubauer-Berigan, MK
Cole, SR
Richardson, DB
AF Edwards, Jessie K.
McGrath, Leah J.
Buckley, Jessie P.
Schubauer-Berigan, Mary K.
Cole, Stephen R.
Richardson, David B.
TI Occupational Radon Exposure and Lung Cancer Mortality Estimating
Intervention Effects Using the Parametric g-Formula
SO EPIDEMIOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; URANIUM MINERS; RISK; COHORT; DAUGHTERS;
MIDLIFE; UPDATE; WHITE; WOMEN
AB Background: Traditional regression analysis techniques used to estimate associations between occupational radon exposure and lung cancer focus on estimating the effect of cumulative radon exposure on lung cancer. In contrast, public health interventions are typically based on regulating radon concentration rather than workers' cumulative exposure. Estimating the effect of cumulative occupational exposure on lung cancer may be difficult in situations vulnerable to the healthy worker survivor bias.
Methods: Workers in the Colorado Plateau Uranium Miners cohort (n = 4,134) entered the study between 1950 and 1964 and were followed for lung cancer mortality through 2005. We use the parametric g-formula to compare the observed lung cancer mortality to the potential lung cancer mortality had each of 3 policies to limit monthly radon exposure been in place throughout follow-up.
Results: There were 617 lung cancer deaths over 135,275 person-years of follow-up. With no intervention on radon exposure, estimated lung cancer mortality by age 90 was 16%. Lung cancer mortality was reduced for all interventions considered, and larger reductions in lung cancer mortality were seen for interventions with lower monthly radon exposure limits. The most stringent guideline, the Mine Safety and Health Administration standard of 0.33 working-level months, reduced lung cancer mortality from 16% to 10% (risk ratio = 0.67 [95% confidence interval = 0.61 to 0.73]).
Conclusions: This work illustrates the utility of the parametric g-formula for estimating the effects of policies regarding occupational exposures, particularly in situations vulnerable to the healthy worker survivor bias.
C1 [Edwards, Jessie K.; McGrath, Leah J.; Buckley, Jessie P.; Cole, Stephen R.; Richardson, David B.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA.
[Schubauer-Berigan, Mary K.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA.
RP Edwards, JK (reprint author), Univ N Carolina, McGavran Greenberg Hall,CB 7435, Chapel Hill, NC 27599 USA.
EM jessedwards@unc.edu
FU NIH [R01CA117841]
FX This article was funded by NIH R01CA117841.
NR 30
TC 6
Z9 6
U1 1
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1044-3983
EI 1531-5487
J9 EPIDEMIOLOGY
JI Epidemiology
PD NOV
PY 2014
VL 25
IS 6
BP 829
EP 834
DI 10.1097/EDE.0000000000000164
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ8XJ
UT WOS:000343122000007
PM 25192403
ER
PT J
AU Johnson, CY
Flanders, WD
Strickland, MJ
Honein, MA
Howards, PP
AF Johnson, Candice Y.
Flanders, W. Dana
Strickland, Matthew J.
Honein, Margaret A.
Howards, Penelope P.
TI Potential Sensitivity of Bias Analysis Results to Incorrect Assumptions
of Nondifferential or Differential Binary Exposure Misclassification
SO EPIDEMIOLOGY
LA English
DT Article
ID OBSERVATIONAL DATA; SYSTEMATIC-ERRORS; UNCERTAINTY; OBESITY; WEIGHT;
HEIGHT; RISK; BMI
AB Background: Results of bias analyses for exposure misclassification are dependent on assumptions made during analysis. We describe how adjustment for misclassification is affected by incorrect assumptions about whether sensitivity and specificity are the same (nondifferential) or different (differential) for cases and noncases.
Methods: We adjusted for exposure misclassification using probabilistic bias analysis, under correct and incorrect assumptions about whether exposure misclassification was differential or not. First, we used simulated data sets in which nondifferential and differential misclassification were introduced. Then, we used data on obesity and diabetes from the National Health and Nutrition Examination Survey (NHANES) in which both self-reported (misclassified) and measured (true) obesity were available, using literature estimates of sensitivity and specificity to adjust for bias. The ratio of odds ratio (ROR; observed odds ratio divided by true odds ratio) was used to quantify magnitude of bias, with ROR = 1 signifying no bias.
Results: In the simulated data sets, under incorrect assumptions (eg, assuming nondifferential misclassification when it was truly differential), results were biased, with RORs ranging from 0.18 to 2.46. In NHANES, results adjusted based on incorrect assumptions also produced biased results, with RORs ranging from 1.26 to 1.55; results were more biased when making these adjustments than when using the misclassified exposure values (ROR = 0.91).
Conclusions: Making an incorrect assumption about nondifferential or differential exposure misclassification in bias analyses can lead to more biased results than if no adjustment is performed. In our analyses, incorporating uncertainty using probabilistic bias analysis was not sufficient to overcome this problem.
C1 [Johnson, Candice Y.; Flanders, W. Dana; Strickland, Matthew J.; Howards, Penelope P.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
[Johnson, Candice Y.; Flanders, W. Dana; Strickland, Matthew J.; Howards, Penelope P.] Emory Univ, Laney Grad Sch, Atlanta, GA 30322 USA.
[Johnson, Candice Y.; Honein, Margaret A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
RP Johnson, CY (reprint author), NIOSH, Ctr Dis Control & Prevent, 1090 Tusculum Ave,MS R-15, Cincinnati, OH 45226 USA.
EM cyjohnson@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 27
TC 4
Z9 4
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1044-3983
EI 1531-5487
J9 EPIDEMIOLOGY
JI Epidemiology
PD NOV
PY 2014
VL 25
IS 6
BP 902
EP 909
DI 10.1097/EDE.0000000000000166
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ8XJ
UT WOS:000343122000018
PM 25120106
ER
PT J
AU Flegal, KM
AF Flegal, Katherine M.
TI Bias in Calculation of Attributable Fractions Using Relative Risks from
Nonsmokers Only
SO EPIDEMIOLOGY
LA English
DT Article
ID UNITED-STATES; OBESITY; DEATHS; DISEASE; WOMEN
AB Studies of weight and mortality sometimes state that the mortality relative risks for obesity from nonsmokers are valid estimates of the relative risks for obesity in both smokers and nonsmokers. Extending this idea, several influential articles have used relative risks for obesity from nonsmokers and attributable fraction methods for unadjusted risks to estimate attributable fractions of deaths in the entire population (smokers and nonsmokers combined). However, stratification by smoking is a form of adjustment for confounding. Simplified examples show that the use of relative risks from only 1 stratum to estimate attributable fractions, without incorporating data on the stratification variable, gives incorrect results for the entire population. Even if the mortality relative risks for obesity from nonsmokers are indeed valid in both smokers and nonsmokers, these relative risks nonetheless need to be treated as adjusted relative risks for the purpose of calculating attributable fractions for the whole sample.
C1 Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
RP Flegal, KM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4336, Hyattsville, MD 20782 USA.
EM kmf2@cdc.gov
OI Flegal, Katherine/0000-0002-0838-469X
FU Intramural CDC HHS [CC999999]
NR 18
TC 2
Z9 2
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1044-3983
EI 1531-5487
J9 EPIDEMIOLOGY
JI Epidemiology
PD NOV
PY 2014
VL 25
IS 6
BP 913
EP 916
DI 10.1097/EDE.0000000000000181
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ8XJ
UT WOS:000343122000020
PM 25210928
ER
PT J
AU Karch, DL
Chen, M
Tang, T
AF Karch, Debra L.
Chen, Mi
Tang, Tian
TI Evaluation of the National Human Immunodeficiency Virus Surveillance
System for the 2011 Diagnosis Year
SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE
LA English
DT Article
DE acquired immunodeficiency syndrome; AIDS; evaluation; HIV; surveillance
ID CAPTURE-RECAPTURE METHODS
AB Context: In 2009, the Centers for Disease Control and Prevention completed migration of all 59 surveillance project areas (PAs) from the case-based HIV/AIDS Reporting System to the document-based Enhanced HIV/AIDS Reporting System. Objectives: We conducted a PA-level assessment of Enhanced HIV/AIDS Reporting System process and outcome standards for HIV infection cases. Design: Process standards were reported by PAs and outcome standards were calculated using standardized Centers for Disease Control and Prevention SAS code. Setting: A total of 59 PAs including 50 US states, the District of Columbia, 6 separately funded cities (Chicago, Houston, Los Angeles County, New York City, Philadelphia, and San Francisco), and 2 territories (Puerto Rico and the Virgin Islands). Participants: Cases diagnosed or reported to the PA surveillance system between January 1, 2011, and December 31, 2011, using data collected through December 2012. Main Outcome Measures: Process standards for death ascertainment and intra-and interstate case de-duplication; outcome standards for completeness and timeliness of case reporting, data quality, intrastate duplication rate, risk factor ascertainment, and completeness of initial CD4 and viral load reporting. Results: Fifty-five of 59 PAs (93%) reported linking cases to state vital records death certificates during 2012, 76% to the Social Security Death Master File, and 59% to the National Death Index. Seventy percent completed monthly intrastate, and 63% completed semiannual interstate de-duplication. Eighty-three percent met the 85% or more case ascertainment standard, and 92% met the 66% or more timeliness standard; 75% met the 97% or more data quality standard; all PAs met the 5% or less intrastate duplication rate; 41% met the 85% or more risk factor ascertainment standard; 90% met the 50% or more standard for initial CD4; and 93% met the same standard for viral load reporting. Overall, 7% of PAs met all 11 process and outcome standards. Conclusions: Findings support the need for continued improvement in HIV surveillance activities and monitoring of system outcomes.
C1 [Karch, Debra L.; Chen, Mi] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
[Tang, Tian] ICF Int Inc, Atlanta, GA USA.
RP Karch, DL (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV Prevent, HIV Incidence & Case Surveillance Branch, 1600 Clifton Rd NE,MS E-47, Atlanta, GA 30333 USA.
EM DKarch@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 15
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1078-4659
EI 1550-5022
J9 J PUBLIC HEALTH MAN
JI J. Public Health Manag. Pract.
PD NOV-DEC
PY 2014
VL 20
IS 6
BP 598
EP 607
DI 10.1097/PHH.0000000000000033
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ8YT
UT WOS:000343127500010
PM 24253405
ER
PT J
AU Behbod, B
Parker, EM
Jones, EA
Bayleyegn, T
Guarisco, J
Morrison, M
McIntyre, MG
Knight, M
Eichold, B
Yip, F
AF Behbod, Behrooz
Parker, Erin M.
Jones, Erin A.
Bayleyegn, Tesfaye
Guarisco, John
Morrison, Melissa
McIntyre, Mary G.
Knight, Monica
Eichold, Bert
Yip, Fuyuen
TI Community Health Assessment Following Mercaptan Spill: Eight Mile,
Mobile County, Alabama, September 2012
SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE
LA English
DT Article
DE health effects; mercaptan; natural gas; odor; spill
ID ODOR; IRRITATION; PERCEPTION; CHEMICALS; ANNOYANCE; EXPOSURE; FIELD;
RISK
AB Context: In 2008, a lightning strike caused a leak of tert-butyl mercaptan from its storage tank at the Gulf South Natural Gas Pumping Station in Prichard, Alabama. On July 27, 2012, the Alabama Department of Public Health requested Centers for Disease Control and Prevention epidemiologic assistance investigating possible health effects resulting from airborne exposure to mercaptan from a contaminated groundwater spring, identified in January 2012. Objective: To assess the self-reported health effects in the community, to determine the scope of the reported medical services received, and to develop recommendations for prevention and response to future incidents. Design: In September 2012, we performed a representative random sampling design survey of households, comparing reported exposures and health effects among residents living in 2 circular zones located within 1 and 2 miles from the contaminated source. Setting: Eight Mile community, Prichard, Alabama. Participants: We selected 204 adult residents of each household (>= 18 years) to speak for all household members. Main Outcome Measures: Self-reported mercaptan odor exposure, physical and mental health outcomes, and medical-seeking practices, comparing residents in the 1 and 2-mile zones. Results: In the past 6 months, 97.9% of respondents in the 1-mile zone and 77.6% in the 2-mile zone reported mercaptan odors. Odor severity was greater in the 1-mile zone, in which significantly more subjects reported exposures aggravating their physical and mental health including shortness of breath, eye irritations, and agitated behavior. Overall, 36.5% sought medical care for odor-related symptoms. Conclusions: Long-term odorous mercaptan exposures were reportedly associated with physical and psychological health complaints. Communication messages should include strategies to minimize exposures and advise those with cardiorespiratory conditions to have medications readily available. Health care practitioners should be provided information on mercaptan health effects and approaches to prevent exacerbating existing chronic diseases.
C1 [Behbod, Behrooz; Parker, Erin M.] US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA.
[Behbod, Behrooz; Bayleyegn, Tesfaye; Yip, Fuyuen] US Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA USA.
[Parker, Erin M.] US Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA USA.
[Morrison, Melissa] US Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Off Sci & Publ Hlth Practice, Career Epidemiol Field Officer Program, Atlanta, GA USA.
[Jones, Erin A.] Boston Univ Med Sch, Boston, MA USA.
[Guarisco, John; Morrison, Melissa; McIntyre, Mary G.] Alabama Dept Publ Hlth, Montgomery, AL 36102 USA.
[Knight, Monica; Eichold, Bert] Mobile Cty Hlth Dept, Mobile, AL USA.
RP Behbod, B (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd,Mailstop E-92, Atlanta, GA 30333 USA.
EM bbehbod@post.harvard.edu
NR 18
TC 4
Z9 4
U1 4
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1078-4659
EI 1550-5022
J9 J PUBLIC HEALTH MAN
JI J. Public Health Manag. Pract.
PD NOV-DEC
PY 2014
VL 20
IS 6
BP 632
EP 639
DI 10.1097/PHH.0000000000000024
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ8YT
UT WOS:000343127500014
PM 24253404
ER
PT J
AU Mainor, A
Leeman, J
Sommers, J
Heiser, C
Gonzales, C
Farris, RP
Ammerman, A
AF Mainor, Avia
Leeman, Jennifer
Sommers, Janice
Heiser, Claire
Gonzales, Cecilia
Farris, Rosanne P.
Ammerman, Alice
TI A Systematic Approach to Evaluating Public Health Training: The Obesity
Prevention in Public Health Course
SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE
LA English
DT Article
DE competency-based; evaluation; public health practice; training
ID ENVIRONMENTS; STRATEGIES; WORKFORCE
AB Objective: Public health practitioners require new knowledge and skills to address the multilevel factors contributing to obesity. This article presents the systematic approach the Center of Excellence for Training and Research Translation (Center TRT) used both to assess practitioners' competencies to lead public health obesity prevention initiatives and to evaluate its annual, competency-based obesity prevention course. Design: In 2006, Center TRT identified priority public health competencies for obesity prevention and then planned 7 annual courses to address the priority competencies progressively over time. Each year, a longitudinal evaluation based on Kirkpatrick's training evaluation framework was administered to course participants (n = 243) to assess perceptions of the course (daily), changes in self-reported competency (immediately pre- and postcourse), and course impact on practice over time (at 6 months). Results: Participants rated the course highly for quality and relevance. Although many participants reported low levels of confidence prior to the course, following the course, at least 70% reported feeling confident to perform almost all competencies. At 6-month follow-up, the majority of participants reported completing at least 1 activity identified during course action planning. Conclusions: We identified practitioners' high-priority competency needs and then designed 7 annual courses to progressively address those needs and new needs as they arose. This approach resulted in trainings valued by practitioners and effective in increasing their sense of competence to lead public health obesity prevention initiatives. The course's continuing impact was evidenced by participants' high level of completion of their action plans at 6-month follow-up. Competency-based training is important to develop a skilled public health workforce.
C1 [Mainor, Avia; Leeman, Jennifer; Sommers, Janice; Gonzales, Cecilia; Ammerman, Alice] Univ N Carolina, Ctr Hlth Promot & Dis Prevent, Chapel Hill, NC 27599 USA.
[Leeman, Jennifer] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27599 USA.
[Heiser, Claire; Farris, Rosanne P.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA.
RP Mainor, A (reprint author), Univ N Carolina, Ctr Hlth Promot & Dis Prevent, 1700 Martin Luther King Blvd,CB 7426, Chapel Hill, NC 27599 USA.
EM avia_mainor@unc.edu
FU Centers for Disease Control and Prevention; Nutrition and Physical
Activity Program to Prevent Obesity and Other Chronic Diseases, Center
of Excellence for Training and Research Translation [U48/DP001944]
FX This project has been funded in whole or in part with federal funds from
the Centers for Disease Control and Prevention, Nutrition and Physical
Activity Program to Prevent Obesity and Other Chronic Diseases, Center
of Excellence for Training and Research Translation (grant
U48/DP001944).
NR 21
TC 0
Z9 0
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1078-4659
EI 1550-5022
J9 J PUBLIC HEALTH MAN
JI J. Public Health Manag. Pract.
PD NOV-DEC
PY 2014
VL 20
IS 6
BP 647
EP 653
DI 10.1097/PHH.0000000000000046
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ8YT
UT WOS:000343127500016
PM 24402433
ER
PT J
AU Yang, J
Hall, K
Nuriddin, A
Woolard, D
AF Yang, Jun
Hall, Keri
Nuriddin, Azizeh
Woolard, Diane
TI Risk for Hepatitis B and C Virus Transmission in Nail Salons and
Barbershops and State Regulatory Requirements to Prevent Such
Transmission in the United States
SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE
LA English
DT Article
DE barbers; government regulation; hepatitis virus; nails; prevention
ID PARENTERALLY TRANSMITTED HEPATITIS; BLOOD-DONORS; HCV INFECTION;
PREVALENCE; PAKISTAN; COMMUNITY; KARACHI; SEROPREVALENCE; EPIDEMIOLOGY;
SURVEILLANCE
AB Context: The potential for hepatitis B and C virus (HBV/HCV) transmission in nail salons and barbershops has been reported, but a systematic review has not been conducted. These businesses are regulated by state cosmetology or barbering boards, but adequacy of sanitary requirements has not been evaluated. Objectives: To conduct literature review to assess risk for HBV/HCV transmission in nail salons and barbershops and to evaluate sanitary requirements in HBV/HCV prevention in these businesses in 50 states and District of Columbia. Design: Several search engines were used for literature search. Studies that quantified risks associated with manicuring, pedicuring, or barbering were included. State requirements for disinfection and sterilization were reviewed and evaluated. Main Outcome Measure: For literature review, odds ratios, 95% confidence intervals, and confounding adjustment were extracted and evaluated. For regulation review, requirements for disinfection or sterilization for multiuse items in nail salons and barbershops were assessed according to the US federal guidelines. Results: Forty-six studies were identified and 36 were included in this study. Overall, the results were not consistent on risk for HBV/HCV transmission in nail salons and barbershops. For sanitary requirements, disinfection with an Environmental Protection Agency-registered disinfectant is required in 39 states for nail salons and in 26 states for barbershops. Sterilization was described in 15 states for nail salons and in 11 states for barbershops, but the majority of these states listed it as an optional approach. Sanitary requirements are consistent in states where 1 board regulates both businesses but are substantially discrepant in states with separate boards. Conclusions: Current literature cannot confirm or exclude the risk for HBV/HCV transmission in nail salons and barbershops. Existing sanitary requirements are adequate in the majority of states, but compliance is needed to prevent HBV/HCV transmission in these businesses.
C1 [Yang, Jun; Woolard, Diane] Virginia Dept Hlth, Off Epidemiol, Div Surveillance & Invest, Richmond, VA 23219 USA.
[Hall, Keri] Sentara Hlth Syst, Martha Jefferson Hosp, Charlottesville, VA USA.
[Nuriddin, Azizeh] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Yang, J (reprint author), Virginia Dept Hlth, Off Epidemiol, Div Surveillance & Invest, 109 Governor St, Richmond, VA 23219 USA.
EM Jun.Yang@vdh.virginia.gov
NR 45
TC 0
Z9 0
U1 1
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1078-4659
EI 1550-5022
J9 J PUBLIC HEALTH MAN
JI J. Public Health Manag. Pract.
PD NOV-DEC
PY 2014
VL 20
IS 6
BP E20
EP E30
DI 10.1097/PHH.0000000000000042
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ8YT
UT WOS:000343127500003
PM 25250760
ER
PT J
AU Brener, ND
Wechsler, H
Kann, L
AF Brener, Nancy D.
Wechsler, Howell
Kann, Laura
TI Challenges in and Strategies for the Surveillance of School Health
Policies and Practices: A Commentary
SO JOURNAL OF SCHOOL HEALTH
LA English
DT Editorial Material
C1 [Brener, Nancy D.; Wechsler, Howell] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA 30329 USA.
[Wechsler, Howell] Alliance Healthier Generat, Atlanta, GA 30329 USA.
[Kann, Laura] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Sch Based Surveillance Branch, Atlanta, GA 30329 USA.
RP Brener, ND (reprint author), Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Mailstop E-75,1600 Clifton Road NE, Atlanta, GA 30329 USA.
EM nbrener@cdc.gov; howell.wechsler@healthiergeneration.org; lkk1@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 6
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4391
EI 1746-1561
J9 J SCHOOL HEALTH
JI J. Sch. Health
PD NOV
PY 2014
VL 84
IS 11
BP 687
EP 689
DI 10.1111/josh.12204
PG 3
WC Education & Educational Research; Education, Scientific Disciplines;
Health Care Sciences & Services; Public, Environmental & Occupational
Health
SC Education & Educational Research; Health Care Sciences & Services;
Public, Environmental & Occupational Health
GA AQ6BS
UT WOS:000342893100001
PM 25274167
ER
PT J
AU Ryan, U
Fayer, R
Xiao, LH
AF Ryan, Una
Fayer, Ronald
Xiao, Lihua
TI Cryptosporidium species in humans and animals: current understanding and
research needs
SO PARASITOLOGY
LA English
DT Review
DE Cryptosporidium; taxonomy; epidemiology; species; genotype; subtype
ID N. SP APICOMPLEXA; PIG GENOTYPE II; PRINCE-EDWARD-ISLAND; HUMAN FECAL
SAMPLES; DEER-LIKE GENOTYPE; PRE-WEANED CALVES; CATTLE BOS-TAURUS; BOARS
SUS-SCROFA; MOLECULAR CHARACTERIZATION; GENETIC-CHARACTERIZATION
AB Cryptosporidium is increasingly recognized as one of the major causes of moderate to severe diarrhoea in developing countries. With treatment options limited, control relies on knowledge of the biology and transmission of the members of the genus responsible for disease. Currently, 26 species are recognized as valid on the basis of morphological, biological and molecular data. Of the nearly 20 Cryptosporidium species and genotypes that have been reported in humans, Cryptosporidium hominis and Cryptosporidium parvum are responsible for the majority of infections. Livestock, particularly cattle, are one of the most important reservoirs of zoonotic infections. Domesticated and wild animals can each be infected with several Cryptosporidium species or genotypes that have only a narrow host range and therefore have no major public health significance. Recent advances in next-generation sequencing techniques will significantly improve our understanding of the taxonomy and transmission of Cryptosporidium species, and the investigation of outbreaks and monitoring of emerging and virulent subtypes. Important research gaps remain including a lack of subtyping tools for many Cryptosporidium species of public and veterinary health importance, and poor understanding of the genetic determinants of host specificity of Cryptosporidium species and impact of climate change on the transmission of Cryptosporidium.
C1 [Ryan, Una] Murdoch Univ, Sch Vet & Life Sci, Murdoch, WA 6150, Australia.
[Fayer, Ronald] USDA ARS, Beltsville, MD 20705 USA.
[Xiao, Lihua] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Ryan, U (reprint author), Murdoch Univ, Sch Vet & Life Sci, Murdoch, WA 6150, Australia.
EM Una.Ryan@murdoch.edu.au
RI Xiao, Lihua/B-1704-2013
OI Xiao, Lihua/0000-0001-8532-2727
NR 234
TC 76
Z9 83
U1 8
U2 83
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0031-1820
EI 1469-8161
J9 PARASITOLOGY
JI Parasitology
PD NOV
PY 2014
VL 141
IS 13
BP 1667
EP 1685
DI 10.1017/S0031182014001085
PG 19
WC Parasitology
SC Parasitology
GA AQ6KE
UT WOS:000342919500001
PM 25111501
ER
PT J
AU Luna-Gierke, RE
Wymore, K
Sadlowski, J
Clogher, P
Gierke, RW
Tobin-D'Angelo, M
Palmer, A
Medus, C
Nicholson, C
McGuire, S
Martin, H
Garman, K
Griffin, PM
Mody, RK
AF Luna-Gierke, R. E.
Wymore, K.
Sadlowski, J.
Clogher, P.
Gierke, R. W.
Tobin-D'Angelo, M.
Palmer, A.
Medus, C.
Nicholson, C.
McGuire, S.
Martin, H.
Garman, K.
Griffin, P. M.
Mody, R. K.
TI Multiple-Aetiology Enteric Infections Involving Non-O157 Shiga
Toxin-Producing Escherichia coli - FoodNet, 2001-2010
SO ZOONOSES AND PUBLIC HEALTH
LA English
DT Article
DE Shiga toxin-producing Escherichia coli; multiple-aetiology infections;
diarrhoea
ID SURVEILLANCE NETWORK FOODNET; HEMOLYTIC-UREMIC SYNDROME; RISK-FACTORS;
UNITED-STATES; EMERGENCY-DEPARTMENT; CAMPYLOBACTER-JEJUNI; WATERBORNE
OUTBREAK; DIARRHEA ETIOLOGY; O157 INFECTIONS; DAIRY-CATTLE
AB We describe multiple-aetiology infections involving non-O157 Shiga toxin-producing Escherichia coli (STEC) identified through laboratory-based surveillance in nine FoodNet sites from 2001 to 2010. A multiple-aetiology infection (MEI) was defined as isolation of non-O157 STEC and laboratory evidence of any of the other nine pathogens under surveillance or isolation of >1 non-O157 STEC serogroup from the same person within a 7-day period. We compared exposures of patients with MEI during 2001-2010 with those of patients with single-aetiology non-O157 STEC infections (SEI) during 2008-2009 and with those of the FoodNet population from a survey conducted during 2006-2007. In total, 1870 non-O157 STEC infections were reported; 68 (3.6%) were MEI; 60 included pathogens other than non-O157 STEC; and eight involved >1 serogroup of non-O157 STEC. Of the 68 MEI, 21 (31%) were part of six outbreaks. STEC O111 was isolated in 44% of all MEI. Of patients with MEI, 50% had contact with farm animals compared with 29% (P<0.01) of persons with SEI; this difference was driven by infections involving STEC O111. More patients with non-outbreak-associated MEI reported drinking well water (62%) than respondents in a population survey (19%) (P<0.01). Drinking well water and having contact with animals may be important exposures for MEI, especially those involving STEC O111.
C1 [Luna-Gierke, R. E.; Martin, H.; Griffin, P. M.; Mody, R. K.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Wymore, K.] Calif Emerging Infect Program, Oakland, CA USA.
[Sadlowski, J.] Colorado Dept Publ Hlth & Environm, Denver, CO USA.
[Clogher, P.] Connecticut Emerging Infect Program, New Haven, CT USA.
[Gierke, R. W.] Georgia Emerging Infect Program, Atlanta, GA USA.
[Gierke, R. W.] Vet Affairs Med Ctr, Atlanta, GA 30033 USA.
[Tobin-D'Angelo, M.] Georgia Dept Publ Hlth, Atlanta, GA USA.
[Palmer, A.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA.
[Medus, C.] Minnesota Dept Hlth, St Paul, MN USA.
[Nicholson, C.] New Mexico Emerging Infect Program, Albuquerque, NM USA.
[McGuire, S.] New York Emerging Infect Program, Albany, NY USA.
[Garman, K.] Tennessee Dept Hlth, Nashville, TN USA.
RP Luna-Gierke, RE (reprint author), Ctr Dis Control & Prevent, Mailstop C-09,1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM ihg3@cdc.gov
NR 39
TC 5
Z9 5
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1863-1959
EI 1863-2378
J9 ZOONOSES PUBLIC HLTH
JI Zoonoses Public Health
PD NOV
PY 2014
VL 61
IS 7
BP 492
EP 498
DI 10.1111/zph.12098
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases;
Veterinary Sciences
SC Public, Environmental & Occupational Health; Infectious Diseases;
Veterinary Sciences
GA AQ4TS
UT WOS:000342793200004
PM 24484079
ER
PT J
AU Phillips, AN
Cambiano, V
Miners, A
Revill, P
Pillay, D
Lundgren, JD
Bennett, D
Raizes, E
Nakagawa, F
De Luca, A
Vitoria, M
Barcarolo, J
Perriens, J
Jordan, MR
Bertagnolio, S
AF Phillips, Andrew N.
Cambiano, Valentina
Miners, Alec
Revill, Paul
Pillay, Deenan
Lundgren, Jens D.
Bennett, Diane
Raizes, Elliott
Nakagawa, Fumiyo
De Luca, Andrea
Vitoria, Marco
Barcarolo, Jhoney
Perriens, Joseph
Jordan, Michael R.
Bertagnolio, Silvia
TI Effectiveness and cost-effectiveness of potential responses to future
high levels of transmitted HIV drug resistance in antiretroviral
drug-naive populations beginning treatment: modelling study and economic
analysis
SO LANCET HIV
LA English
DT Article
ID RESOURCE-LIMITED SETTINGS; VIROLOGICAL FAILURE; THERAPY; HEALTH; IMPACT;
SURVEILLANCE; TRANSMISSION; INDIVIDUALS; MORTALITY; ROLLOUT
AB Background With continued roll-out of antiretroviral therapy (ART) in resource-limited settings, evidence is emerging of increasing levels of transmitted drug-resistant HIV. We aimed to compare the effectiveness and cost-effectiveness of different potential public health responses to substantial levels of transmitted drug resistance.
Methods We created a model of HIV transmission, progression, and the effects of ART, which accounted for resistance generation, transmission, and disappearance of resistance from majority virus in the absence of drug pressure. We simulated 5000 ART programmatic scenarios with different prevalence levels of detectable resistance in people starting ART in 2017 (t0) who had not previously been exposed to antiretroviral drugs. We used the model to predict cost-effectiveness of various potential changes in policy triggered by different prevalence levels of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) measured in the population starting ART.
Findings Individual-level resistance testing before ART initiation was not generally a cost-effective option, irrespective of the cost-effectiveness threshold. At a cost-effectiveness threshold of US$500 per quality-adjusted life-year (QALY), no change in policy was cost effective (ie, no change in policy would involve paying less than $500 per QALY gained), irrespective of the prevalence of pretreatment NNRTI resistance, because of the increased cost of the policy alternatives. At thresholds of $1000 or higher, and with the prevalence of pretreatment NNRTI resistance greater than 10%, a policy to measure viral load 6 months after ART initiation became cost effective. The policy option to change the standard first-line treatment to a boosted protease inhibitor regimen became cost effective at a prevalence of NNRTI resistance higher than 15%, for cost-eff ectiveness thresholds greater than $2000.
Interpretation Cost-effectiveness of potential policies to adopt in response to different levels of pretreatment HIV drug resistance depends on competing budgetary claims, reflected in the cost-eff ectiveness threshold. Results from our model will help inform WHO recommendations on monitoring of HIV drug resistance in people starting ART.
C1 [Phillips, Andrew N.; Cambiano, Valentina; Nakagawa, Fumiyo] UCL, Res Dept Infect & Populat Hlth, London NW3 2PF, England.
[Miners, Alec] London Sch Hyg & Trop Med, London WC1, England.
[Revill, Paul] Univ York, York YO10 5DD, N Yorkshire, England.
[Pillay, Deenan] Africa Ctr, Kwa Zulu, South Africa.
[Lundgren, Jens D.] Univ Copenhagen, Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark.
[Bennett, Diane; Raizes, Elliott] Ctr Dis Control & Prevent, Atlanta, GA USA.
[De Luca, Andrea] Siena Univ Hosp, Univ Div Infect Dis, Siena, Italy.
[Vitoria, Marco; Barcarolo, Jhoney; Perriens, Joseph; Bertagnolio, Silvia] WHO, CH-1211 Geneva 27, Switzerland.
[Jordan, Michael R.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Jordan, Michael R.] Tufts Med Ctr, Boston, MA USA.
RP Bertagnolio, S (reprint author), WHO, Dept HIV AIDS, CH-1211 Geneva 27, Switzerland.
EM andrew.phillips@ucl.ac.uk; bertagnolios@who.int
RI Phillips, Andrew/B-4427-2008;
OI Phillips, Andrew/0000-0003-2384-4807; Nakagawa,
Fumiyo/0000-0002-6646-8744; Pillay, Dorsamy/0000-0003-3640-2573;
Lundgren, Jens/0000-0001-8901-7850
FU WHO; Bill & Melinda Gates Foundation [38180]; CHAIN (Co-ordination and
Harmonisation of Advanced e-Infrastructures for Research and Education
Data Sharing); European Commission; CFAR [1P30A142853]; Department for
International Development (DFID)
FX This study was supported by WHO (with funds provided by the Bill &
Melinda Gates Foundation, grant number 38180) and CHAIN (Co-ordination
and Harmonisation of Advanced e-Infrastructures for Research and
Education Data Sharing; with funds provided by the European Commission).
We acknowledge use of the UCL Legion High Performance Computing Facility
(Legion@UCL) and associated support services in completion of this work.
MRJ is supported by CFAR (grant number 1P30A142853). PR is supported by
funding from the Department for International Development (DFID) for the
Lablite project; Lablite is funded by DFID for the benefit of developing
countries. The views expressed here are not necessarily those of DFID.
NR 38
TC 9
Z9 9
U1 0
U2 0
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD NOV
PY 2014
VL 1
IS 2
BP E85
EP E93
DI 10.1016/S2352-3018(14)70021-9
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CU8JY
UT WOS:000363789800010
PM 26423990
ER
PT J
AU Musolin, K
Ramsey, JG
Wassell, JT
Hard, DL
AF Musolin, Kristin
Ramsey, Jessica G.
Wassell, James T.
Hard, David L.
TI Prevalence of carpal tunnel syndrome among employees at a poultry
processing plant
SO APPLIED ERGONOMICS
LA English
DT Article
DE Ergonomics; Poultry processing; Occupation
ID EXTREMITY MUSCULOSKELETAL SYMPTOMS; RISK-FACTORS; DIABETES-MELLITUS; JOB
ROTATION; WORKERS; DISORDERS; OBESITY; DISEASE; COHORT
AB Objective: To determine prevalence of carpal tunnel syndrome (CTS) among poultry processing employees while taking into account non-occupational factors and assess any association between CTS prevalence and exposure groups.
Methods: Performed a cross-sectional survey to assess CTS (n = 318). A CTS case was defined as an employee with self-reported CTS symptoms, an abnormal hand symptom diagram, and an abnormal nerve conduction study (NCS). Log-binomial regression was used to estimate prevalence ratios.
Results: Three hundred and one participants had sufficient symptom information or NCS data to be classified. 126 (42%) of 301 participants had evidence of CTS. In the adjusted analysis, the highest exposure group had CTS prevalence that was significantly higher than that for the lower exposure group [PR: 1.61; 95% CI = (1.20, 2.17)].
Conclusions: Increasing levels of hand activity and force were associated with increased CTS prevalence among participants. Recommendations were provided to reduce exposure to these risk factors. Published by Elsevier Ltd.
C1 [Musolin, Kristin; Ramsey, Jessica G.] NIOSH, Hlth Hazard Evaluat Tech Assistance Branch, Cincinnati, OH 45226 USA.
[Wassell, James T.; Hard, David L.] NIOSH, Div Safety Res, Morgantown, WV 26501 USA.
RP Musolin, K (reprint author), NIOSH, Hlth Hazard Evaluat Tech Assistance Branch, 4676 Columbia Pkwy,MS R10, Cincinnati, OH 45226 USA.
EM jwy1@cdc.gov; ddq2@cdc.gov; jtw2@cdc.gov; d1h6@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 36
TC 3
Z9 3
U1 0
U2 59
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0003-6870
EI 1872-9126
J9 APPL ERGON
JI Appl. Ergon.
PD NOV
PY 2014
VL 45
IS 6
BP 1377
EP 1383
DI 10.1016/j.apergo.2014.03.005
PG 7
WC Engineering, Industrial; Ergonomics; Psychology, Applied
SC Engineering; Psychology
GA AN6IB
UT WOS:000340697100001
PM 24820549
ER
PT J
AU Nolen, L
Haberling, D
Scollard, D
Truman, R
Rodriguez-Lainz, A
Blum, L
Blaney, D
AF Nolen, Leisha
Haberling, Dana
Scollard, David
Truman, Richard
Rodriguez-Lainz, Alfonso
Blum, Laura
Blaney, David
TI Incidence of Hansen's Disease - United States, 1994-2011
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID LEPROSY
C1 [Nolen, Leisha; Haberling, Dana; Blaney, David] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Scollard, David; Truman, Richard] US Hlth Resources & Serv Adm, Natl Hansens Dis Programs, Rockville, MD 20857 USA.
[Rodriguez-Lainz, Alfonso] CDC, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.
[Blum, Laura] Univ Calif Berkeley, Berkeley, CA 94720 USA.
RP Nolen, L (reprint author), CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM lnolen@cdc.gov
NR 6
TC 9
Z9 9
U1 0
U2 9
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 31
PY 2014
VL 63
IS 43
BP 969
EP 972
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AS9PW
UT WOS:000344575200001
PM 25356604
ER
PT J
AU Farag, NH
Alexander, J
Hadler, S
Quddus, A
Durry, E
Wadood, MZ
Tangermann, RH
Ehrhardt, D
AF Farag, Noha H.
Alexander, James
Hadler, Stephen
Quddus, Arshad
Durry, Elias
Wadood, Mufty Zubair
Tangermann, Rudolph H.
Ehrhardt, Derek
TI Progress Toward Poliomyelitis Eradication - Afghanistan and Pakistan,
January 2013-August 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Farag, Noha H.; Alexander, James; Durry, Elias; Ehrhardt, Derek] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Hadler, Stephen] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Quddus, Arshad] World Hlth Org WHO Country Off, Kabul, Afghanistan.
[Wadood, Mufty Zubair] WHO Country Off, Islamabad, Pakistan.
[Wadood, Mufty Zubair] WHO Headquarters, Geneva, Switzerland.
RP Farag, NH (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
EM nfarag@cdc.gov
NR 6
TC 8
Z9 8
U1 0
U2 7
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 31
PY 2014
VL 63
IS 43
BP 973
EP 977
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AS9PW
UT WOS:000344575200002
PM 25356605
ER
PT J
AU Forrester, JD
Meiman, J
Mullins, J
Nelson, R
Ertel, SH
Cartter, M
Brown, CM
Lijewski, V
Schiffman, E
Neitzel, D
Daly, ER
Mathewson, AA
Howe, W
Lowe, LA
Kratz, NR
Semple, S
Backenson, PB
White, JL
Kurpiel, PM
Rockwell, R
Waller, K
Johnson, DH
Steward, C
Batten, B
Blau, D
DeLeon-Carnes, M
Drew, C
Muehlenbachs, A
Ritter, J
Sanders, J
Zaki, SR
Molins, C
Schriefer, M
Perea, A
Kugeler, K
Nelson, C
Hinckley, A
Mead, P
AF Forrester, Joseph D.
Meiman, Jonathan
Mullins, Jocelyn
Nelson, Randall
Ertel, Starr-Hope
Cartter, Matt
Brown, Catherine M.
Lijewski, Virginia
Schiffman, Elizabeth
Neitzel, David
Daly, Elizabeth R.
Mathewson, Abigail A.
Howe, Whitney
Lowe, Lindsay A.
Kratz, Natalie R.
Semple, Shereen
Backenson, P. Bryon
White, Jennifer L.
Kurpiel, Phillip M.
Rockwell, Russell
Waller, Kirsten
Johnson, Diep Hoang
Steward, Christopher
Batten, Brigid
Blau, Dianna
DeLeon-Carnes, Marlene
Drew, Clifton
Muehlenbachs, Atis
Ritter, Jana
Sanders, Jeanine
Zaki, Sherif R.
Molins, Claudia
Schriefer, Martin
Perea, Anna
Kugeler, Kiersten
Nelson, Christina
Hinckley, Alison
Mead, Paul
TI Update on Lyme Carditis, Groups at High Risk, and Frequency of
Associated Sudden Cardiac Death - United States
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Forrester, Joseph D.; Meiman, Jonathan; Mullins, Jocelyn] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Forrester, Joseph D.; Molins, Claudia; Schriefer, Martin; Perea, Anna; Kugeler, Kiersten; Nelson, Christina; Hinckley, Alison; Mead, Paul] CDC, Div Vector Borne Infect Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Meiman, Jonathan; Johnson, Diep Hoang; Steward, Christopher] Wisconsin Dept Hlth & Social Serv, Madison, WI USA.
[Mullins, Jocelyn; Nelson, Randall; Ertel, Starr-Hope; Cartter, Matt] Connecticut Dept Publ Hlth & Addict Serv, Hartford, CT 06106 USA.
[Brown, Catherine M.; Lijewski, Virginia] Massachusetts Dept Publ Hlth, Boston, MA 02111 USA.
[Schiffman, Elizabeth; Neitzel, David] Minnesota Dept Hlth, Minneapolis, MN 55414 USA.
[Daly, Elizabeth R.; Mathewson, Abigail A.; Howe, Whitney] New Hampshire Dept Hlth & Human Serv, Concord, NH 03301 USA.
[Lowe, Lindsay A.; Kratz, Natalie R.; Semple, Shereen] New Jersey State Dept Hlth, Trenton, NJ 08625 USA.
[Backenson, P. Bryon; White, Jennifer L.; Kurpiel, Phillip M.; Rockwell, Russell] New York State Dept Hlth, Albany, NY 12237 USA.
[Batten, Brigid; Blau, Dianna; DeLeon-Carnes, Marlene; Drew, Clifton; Muehlenbachs, Atis; Ritter, Jana; Sanders, Jeanine; Zaki, Sherif R.] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Forrester, JD (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
EM jforrester@cdc.gov
NR 3
TC 10
Z9 10
U1 0
U2 3
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 31
PY 2014
VL 63
IS 43
BP 982
EP 983
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AS9PW
UT WOS:000344575200004
PM 25356607
ER
PT J
AU Kohler, PK
Okanda, J
Kinuthia, J
Mills, LA
Olilo, G
Odhiambo, F
Laserson, KF
Zierler, B
Voss, J
John-Stewart, G
AF Kohler, Pamela K.
Okanda, John
Kinuthia, John
Mills, Lisa A.
Olilo, George
Odhiambo, Frank
Laserson, Kayla F.
Zierler, Brenda
Voss, Joachim
John-Stewart, Grace
TI Community-Based Evaluation of PMTCT Uptake in Nyanza Province, Kenya
SO PLOS ONE
LA English
DT Article
ID TO-CHILD TRANSMISSION; SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; HIV
TRANSMISSION; ANTENATAL CARE; PREVENTION; PREGNANCY; COUNTRIES;
PROGRAMS; TANZANIA
AB Introduction: Facility-based assessments of prevention of mother-to-child HIV transmission (PMTCT) programs may overestimate population coverage. There are few community-based studies that evaluate PMTCT coverage and uptake.
Methods: During 2011, a cross-sectional community survey among women who gave birth in the prior year was performed using the KEMRI-CDC Health and Demographic Surveillance System in Western Kenya. A random sample (n = 405) and a sample of women known to be HIV-positive through previous home-based testing (n = 247) were enrolled. Rates and correlates of uptake of antenatal care (ANC), HIV-testing, and antiretrovirals (ARVs) were determined.
Results: Among 405 women in the random sample, 379 (94%) reported accessing ANC, most of whom (87%) were HIV tested. Uptake of HIV testing was associated with employment, higher socioeconomic status, and partner HIV testing. Among 247 known HIV-positive women, 173 (70%) self-disclosed their HIV status. Among 216 self-reported HIV-positive women (including 43 from the random sample), 82% took PMTCT ARVs, with 54% completing the full antenatal, peripartum, and postpartum course. Maternal ARV use was associated with more ANC visits and having an HIV tested partner. ARV use during delivery was lowest (62%) and associated with facility delivery. Eighty percent of HIV infected women reported having their infant HIV tested, 11% of whom reported their child was HIV infected, 76% uninfected, 6% declined to say, 7% did not recall; 79% of infected children were reportedly receiving HIV care and treatment.
Conclusions: Community-based assessments provide data that complements clinic-based PMTCT evaluations. In this survey, antenatal HIV test uptake was high; most HIV infected women received ARVs, though many women did not self-disclose HIV status to field team. Community-driven strategies that encourage early ANC, partner involvement, and skilled delivery, and provide PMTCT education, may facilitate further reductions in vertical transmission.
C1 [Kohler, Pamela K.] Univ Washington, Seattle, WA 98195 USA.
[Okanda, John; Olilo, George; Odhiambo, Frank] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya.
[Kinuthia, John] Univ Nairobi, Kenyatta Natl Hosp, Nairobi, Kenya.
[Mills, Lisa A.; Laserson, Kayla F.] KEMRI, CDC Res & Publ Hlth Collaborat, Ctr Dis Control & Prevent, Kisumu, Kenya.
[Mills, Lisa A.; Laserson, Kayla F.] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
[Zierler, Brenda; Voss, Joachim] Univ Washington, Seattle, WA 98195 USA.
[John-Stewart, Grace] Univ Washington, Seattle, WA 98195 USA.
RP Kohler, PK (reprint author), Univ Washington, Seattle, WA 98195 USA.
EM pkohler2@uw.edu
FU National Institutes of Health: A Kenya Free of AIDS [R24 HD056799]
FX This study was funded by the National Institutes of Health
(www.nih.gov): A Kenya Free of AIDS (R24 HD056799); and received
assistance from the University of Washington Center for AIDS Research
(P30 AI027757 and K24 HD054314). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 38
TC 5
Z9 5
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 31
PY 2014
VL 9
IS 10
AR e110110
DI 10.1371/journal.pone.0110110
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS0BN
UT WOS:000343943700025
PM 25360758
ER
PT J
AU Caierao, J
Hawkins, P
Sant'anna, FH
da Cunha, GR
d'Azevedo, PA
McGee, L
Dias, C
AF Caierao, Juliana
Hawkins, Paulina
Sant'anna, Fernando Hayashi
da Cunha, Gabriela Rosa
d'Azevedo, Pedro Alves
McGee, Lesley
Dias, Cicero
TI Serotypes and Genotypes of Invasive Streptococcus pneumoniae Before and
After PCV10 Implementation in Southern Brazil
SO PLOS ONE
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; MOLECULAR EPIDEMIOLOGY; UNITED-STATES;
CLONE ST320; DISEASE; CHILDREN; 19A; CARRIAGE; POPULATION; MENINGITIS
AB To reduce the burden of pneumococcal diseases, different formulations of pneumococcal conjugate vaccines (PCV) have been introduced in many countries. In Brazil, PCV10 has been available since 2010. We aimed to analyze the serotype and genetic composition of invasive pneumococci from Brazil in pre- and post-vaccination periods (2007-2012). Antibiotic susceptibility was determined and genotypes of macrolide and fluoroquinolone resistance were characterized. The genotypes of isolates of the most frequent serotypes were determined by multilocus sequence typing. The study included 325 isolates, which were primarily recovered from blood. The most common serotypes recovered were 14, 3, 4, 23F, 7F, 9V, 12F, 20, 19F, 8, 19A, and 5. Thirty-eight pneumococci (11.7%) were from children <= 5 years old. Considering the overall population, PCV10 and PCV13 serotype coverage was 50.1% and 64.9%, respectively. During the pre-vaccine period, isolates with serotypes belonging to the PVC10 represented 51.5% (100/194), whereas in the post vaccine they represented 48.0% (63/131). PCV13 serotypes represented 67.5% (131/194) and 59.2% (77/131) of total for pre- and post-vaccination periods, respectively. Seventy different sequence types [STs] were found, accounting for 9 clonal complexes [CCs] and 45 singletons. Eight STs (156, 180, 218, 8889, 53, 191, 770, and 4967) represented the majority (51.5%) of isolates. Fifty STs were associated with the pre-vaccination period (27 exclusive) and 43 (20 exclusive) with the post-vaccination period; 23 STs were identified in both periods. Some serotypes were particularly clonal (7F, 8, 12F, 20). Non-susceptibility to penicillin was associated with serotype 19A, CC320. Erythromycin resistance was heterogeneous when considering serotype and ST. A single serotype 23F (ST4967) isolate was resistant to levofloxacin. Continued surveillance is required to determine vaccine impact and to monitor changes in pneumococcal population biology post-PCV10 introduction in Brazil.
C1 [Caierao, Juliana; Sant'anna, Fernando Hayashi; da Cunha, Gabriela Rosa; d'Azevedo, Pedro Alves; Dias, Cicero] Fed Univ Hlth Sci, Porto Alegre, RS, Brazil.
[Hawkins, Paulina] Emory Univ, Atlanta, GA 30322 USA.
[McGee, Lesley] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Dias, C (reprint author), Fed Univ Hlth Sci, Porto Alegre, RS, Brazil.
EM cicero@ufcspa.edu.br
RI Hayashi Sant'Anna, Fernando/I-9129-2016
OI Hayashi Sant'Anna, Fernando/0000-0001-7767-8168
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
[CNPq: Edital MCT/CNPq14/2008, 473607/2008-5]
FX Funding from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
(CAPES) CNPq: Edital MCT/CNPq14/2008, 473607/2008-5. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 55
TC 13
Z9 13
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 30
PY 2014
VL 9
IS 10
AR e111129
DI 10.1371/journal.pone.0111129
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX2HU
UT WOS:000346765000042
PM 25356595
ER
PT J
AU Vagi, SJ
Azziz-Baumgartner, E
Sjodin, A
Calafat, AM
Dumesic, D
Gonzalez, L
Kato, K
Silva, MJ
Ye, XY
Azziz, R
AF Vagi, Sara J.
Azziz-Baumgartner, Eduardo
Sjoedin, Andreas
Calafat, Antonia M.
Dumesic, Daniel
Gonzalez, Leonardo
Kato, Kayoko
Silva, Manori J.
Ye, Xiaoyun
Azziz, Ricardo
TI Exploring the potential association between brominated diphenyl ethers,
polychlorinated biphenyls, organochlorine pesticides, perfluorinated
compounds, phthalates, and bisphenol a in polycystic ovary syndrome: a
case-control study
SO BMC ENDOCRINE DISORDERS
LA English
DT Article
ID HUMAN SERUM; WOMEN; PREVALENCE; ENDOCRINE; SUBFECUNDITY; EXTRACTION;
CHEMICALS; ANDROGEN; URINE; RISK
AB Background: Polycystic Ovary Syndrome (PCOS) is an endocrine-metabolic disorder that affects approximately 6-10% of women of child-bearing age. Although preliminary studies suggest that certain pollutants may act as endocrine disruptors in animals, little is known about their potential association with PCOS. The objective of this case-control pilot study is to determine whether women with PCOS have higher concentrations of specific environmental contaminants compared to women who have not developed PCOS.
Methods: Fifty-two PCOS case-patients (diagnosed using the National Institutes of Health 1990 definition) and 50 controls were recruited in 2007-2008, from an urban academic medical center in Los Angeles, CA. Brominated diphenyl ethers, polychlorinated biphenyls (PCBs), organochlorine pesticides, and perfluorinated compounds (PFCs) were measured in serum, and phthalates metabolites and bisphenol A (BPA) in urine.
Results: PCOS case-patients had significantly higher geometric mean (GM) serum concentrations of two PFCs: perfluorooctanoate (PFOA) (GMcases = 4.1 mu g/L, GMcontrols = 2.3 mu g/L; p = 0.001) and perfluorooctane sulfonate (PFOS) (GMcases = 8.2 mu g/L, GMcontrols = 4.9 mu g/L; p = 0.01), and lower urinary concentrations of monobenzyl phthalate (mBzP) (GMcases = 7.5 mu g/g creatinine, GMcontrols = 11.7 mu g/g creatinine; p = 0.02). Logistic regression, controlling for body mass index, age and race, identified an increased likelihood of PCOS in subjects with higher serum concentrations of PFOA and PFOS (adjusted-ORs = 5.8-6.9, p < 0.05), and with lower urine concentrations of mBzP and mono-n-butyl phthalate (mBP) (aORs = 0.14-0.25, p < 0.05).
Conclusions: Our data suggest that PCOS case-patients may differ from controls in their environmental contaminant profile. PCOS subjects had higher serum concentrations of two PFCs, PFOA and PFOS, and lower urine concentrations of mBP and mBzP. Future studies are needed to confirm these preliminary findings and determine if these chemicals or their precursors may have a role in the pathogenesis of PCOS.
C1 [Vagi, Sara J.; Azziz-Baumgartner, Eduardo; Sjoedin, Andreas; Calafat, Antonia M.; Kato, Kayoko; Silva, Manori J.; Ye, Xiaoyun] US Ctr Dis Control & Prevent, Atlanta, GA USA.
[Dumesic, Daniel; Azziz, Ricardo] Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
[Gonzalez, Leonardo; Azziz, Ricardo] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Azziz, Ricardo] Georgia Regents Univ, Augusta, GA 30904 USA.
RP Azziz, R (reprint author), Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
EM razziz@gru.edu
RI Azziz, Ricardo/N-7229-2014
OI Azziz, Ricardo/0000-0002-3917-0483
FU Health Studies Branch at the Centers for Disease Control and Prevention
(CDC)
FX We would like to acknowledge the contribution of Martin Belson, Dana
Flanders, Carol Rubin, John Osterloh, Michael A. McGeehin in the
development of the study protocol and the leadership of the Health
Studies Branch at the Centers for Disease Control and Prevention (CDC)
for their support. We also would like to thank Marita Pall for her help
in collecting the samples. We also thank CDC's Division of Environmental
Hazards and Health Effects and Division of Laboratory Sciences, and an
endowment from the Helping Hand of Los Angeles for funding this
investigation.
NR 36
TC 11
Z9 11
U1 3
U2 20
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6823
J9 BMC ENDOCR DISORD
JI BMC Endocr. Disord.
PD OCT 28
PY 2014
VL 14
AR 86
DI 10.1186/1472-6823-14-86
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AZ3TH
UT WOS:000348149000001
PM 25348326
ER
PT J
AU Arnett, DK
Goodman, RA
Halperin, JL
Anderson, JL
Parekh, AK
Zoghbi, WA
AF Arnett, Donna K.
Goodman, Richard A.
Halperin, Jonathan L.
Anderson, Jeffrey L.
Parekh, Anand K.
Zoghbi, William A.
TI AHA/ACC/HHS Strategies to Enhance Application of Clinical Practice
Guidelines in Patients With Cardiovascular Disease and Comorbid
Conditions From the American Heart Association, American College of
Cardiology, and US Department of Health and Human Services
SO CIRCULATION
LA English
DT Editorial Material
DE AHA Scientific Statements; epidemiology; health care; methodology;
comorbidity; multiple chronic conditions
ID MULTIPLE CHRONIC CONDITIONS; CARE
C1 [Arnett, Donna K.] Univ Alabama Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
[Goodman, Richard A.] US Dept HHS, Off Assistant Secretary Hlth, Washington, DC USA.
[Goodman, Richard A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
[Halperin, Jonathan L.] Mt Sinai Med Ctr, Cardiovasc Inst, Div Cardiol, New York, NY USA.
[Anderson, Jeffrey L.] Intermt Healthcare, Intermt Heart Inst, Salt Lake City, UT USA.
[Parekh, Anand K.] US Dept HHS, Washington, DC USA.
[Zoghbi, William A.] Houston Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA.
[Zoghbi, William A.] Houston Methodist Hosp, Houston, TX USA.
RP Arnett, DK (reprint author), Univ Alabama Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
NR 22
TC 36
Z9 37
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD OCT 28
PY 2014
VL 130
IS 18
BP 1662
EP +
DI 10.1161/CIR.0000000000000128
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AS1TY
UT WOS:000344065700020
PM 25212466
ER
PT J
AU Yu, GQ
Dye, BA
Gail, MH
Shi, J
Klepac-Ceraj, V
Paster, BJ
Wang, GQ
Wei, WQ
Fan, JH
Qiao, YL
Dawsey, SM
Freedman, ND
Abnet, CC
AF Yu, Guoqin
Dye, Bruce A.
Gail, Mitchell H.
Shi, Jianxin
Klepac-Ceraj, Vanja
Paster, Bruce J.
Wang, Guo-Qing
Wei, Wen-Qiang
Fan, Jin-Hu
Qiao, You-Lin
Dawsey, Sanford M.
Freedman, Neal D.
Abnet, Christian C.
TI The association between the upper digestive tract microbiota by HOMIM
and oral health in a population-based study in Linxian, China
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Microbiota; Oral health; Dental caries; Periodontitis; Bleeding on
probe; Attachment loss
ID HUMAN SUBGINGIVAL PLAQUE; BACTERIAL DIVERSITY; PERIODONTAL-DISEASE;
MOLECULAR ANALYSIS; CHILDHOOD CARIES; RISK INDICATORS; PERMANENT TEETH;
ATTACHMENT LOSS; DENTAL-CARIES; COMMUNITY
AB Background: Bacteria affect oral health, but few studies have systematically examined the role of bacterial communities in oral diseases. We examined this relationship in a large population-based Chinese cancer screening cohort.
Methods: Human Oral Microbe Identification Microarrays were used to test for the presence of 272 human oral bacterial species (97 genera) in upper digestive tract (UDT) samples collected from 659 participants. Oral health was assessed using US NHANES (National Health and Nutrition Examination Survey) protocols. We assessed both dental health (total teeth missing; tooth decay; and the decayed, missing, and filled teeth (DMFT) score) and periodontal health (bleeding on probing (BoP) extent score, loss of attachment extent score, and a periodontitis summary estimate).
Results: Microbial richness, estimated by number of genera per sample, was positively correlated with BoP score (P = 0.015), but negatively correlated with tooth decay and DMFT score (P = 0.008 and 0.022 respectively). Regarding beta-diversity, as estimated by the UniFrac distance matrix for pairwise differences among samples, at least one of the first three principal components of the UniFrac distance matrix was correlated with the number of missing teeth, tooth decay, DMFT, BoP, or periodontitis. Of the examined genera, Parvimonas was positively associated with BoP and periodontitis. Veillonellacease [G-1] was associated with a high DMFT score, and Filifactor and Peptostreptococcus were associated with a low DMFT score.
Conclusions: Our results suggest distinct relationships between UDT microbiota and dental and periodontal health. Poor dental health was associated with a less microbial diversity, whereas poor periodontal health was associated with more diversity and the presence of potentially pathogenic species.
C1 [Yu, Guoqin; Gail, Mitchell H.; Shi, Jianxin; Dawsey, Sanford M.; Freedman, Neal D.; Abnet, Christian C.] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD 20852 USA.
[Dye, Bruce A.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
[Klepac-Ceraj, Vanja; Paster, Bruce J.] Forsyth Inst, Cambridge, MA USA.
[Klepac-Ceraj, Vanja] Wellesley Coll, Wellesley, MA 02181 USA.
[Paster, Bruce J.] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA.
[Wang, Guo-Qing; Wei, Wen-Qiang; Fan, Jin-Hu; Qiao, You-Lin] Chinese Acad Med Sci, Inst Canc, Beijing 100021, Peoples R China.
[Yu, Guoqin] NCI, Div Canc Epidemiol & Genet, Genet Epidemiol Branch, Bethesda, MD 20892 USA.
RP Yu, GQ (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD 20852 USA.
EM yug3@mail.nih.gov
RI Freedman, Neal/B-9741-2015; Abnet, Christian/C-4111-2015; Qiao,
You-Lin/B-4139-2012
OI Freedman, Neal/0000-0003-0074-1098; Abnet,
Christian/0000-0002-3008-7843; Qiao, You-Lin/0000-0001-6380-0871
FU Intramural Research Program of the NIH, National Cancer Institute
FX This study was supported by the Intramural Research Program of the NIH,
National Cancer Institute.
NR 43
TC 0
Z9 0
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD OCT 27
PY 2014
VL 14
AR 1110
DI 10.1186/1471-2458-14-1110
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AU1AN
UT WOS:000345353500001
PM 25348940
ER
PT J
AU McIntyre, PB
Clark, TA
AF McIntyre, Peter B.
Clark, Thomas A.
TI Pertussis vaccine in pregnancy-first dose for every infant?
SO LANCET
LA English
DT Editorial Material
ID IMMUNIZATION; DIPHTHERIA; TDAP
C1 [McIntyre, Peter B.] Sydney Childrens Hosp Network, Kids Res Inst, Natl Ctr Immunisat Res & Surveillance Vaccine Pre, Sydney, NSW 2145, Australia.
[McIntyre, Peter B.] Univ Sydney, Sydney, NSW 2145, Australia.
[Clark, Thomas A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
RP McIntyre, PB (reprint author), Sydney Childrens Hosp Network, Kids Res Inst, Natl Ctr Immunisat Res & Surveillance Vaccine Pre, Sydney, NSW 2145, Australia.
EM peter.mcintyre@health.nsw.gov.au
NR 12
TC 1
Z9 1
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD OCT 25
PY 2014
VL 384
IS 9953
BP 1484
EP 1486
DI 10.1016/S0140-6736(14)60977-6
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AR9MO
UT WOS:000343899600007
PM 25037989
ER
PT J
AU Xu, F
Mawokomatanda, T
Flegel, D
Pierannunzi, C
Garvin, W
Chowdhury, P
Salandy, S
Crawford, C
Town, M
AF Xu, Fang
Mawokomatanda, Tebitha
Flegel, David
Pierannunzi, Carol
Garvin, William
Chowdhury, Pranesh
Salandy, Simone
Crawford, Carol
Town, Machell
TI Surveillance for Certain Health Behaviors Among States and Selected
Local Areas - Behavioral Risk Factor Surveillance System, United States,
2011
SO MMWR SURVEILLANCE SUMMARIES
LA English
DT Article
ID INTERVIEW SURVEY; NATIONAL-HEALTH; US ADULTS; PREVALENCE; COMMUNITY;
DISEASE; RELIABILITY; MORTALITY; INFLUENZA; SERVICES
AB Problem: Chronic conditions (e.g., heart diseases, cerebrovascular diseases, malignant neoplasms, and diabetes), infectious diseases (e.g., influenza and pneumonia), and unintentional injuries are the leading causes of morbidity and mortality in the United States. Adopting positive health behaviors (e.g., staying physically active, quitting tobacco use, always wearing seatbelts in automobiles) and accessing preventive health-care services (e.g., getting routine physical checkups, receiving recommended vaccinations on appropriate schedules, checking blood pressure and cholesterol and maintaining them at healthy levels) can reduce morbidity and mortality from chronic and infectious diseases. Monitoring the health-risk behaviors of a community's residents as well as their participation in and access to health-care services provides information critical to the development and maintenance of intervention programs as well as the implementation of strategies and health policies that address public health problems at the levels of state and territory, metropolitan and micropolitan statistical area (MMSA), and county.
Reporting Period: January-December 2011.
Description of the System: The Behavioral Risk Factor Surveillance System (BRFSS) is an ongoing, state-based, random-digit-dialed telephone survey of noninstitutionalized adults aged >= 18 years residing in the United States. BRFSS collects data on health-risk behaviors, chronic diseases and conditions, access to health care, and use of preventive health services and practices related to the leading causes of death and disabilities in the United States. In 2011, BRFSS adopted a new weighting methodology (iterative proportional fitting, or raking) and for the first time included data from respondents who solely use cellular telephones (i.e., do not use landlines). This report presents results for the year 2011 for all 50 states, the District of Columbia, and participating U.S. territories including the Commonwealth of Puerto Rico and Guam, 198 MMSAs, and 224 counties.
Results: In 2011, the estimated prevalence of health-risk behaviors, chronic conditions, access to health care, and use of preventive health services substantially varied by state and territory, MMSA, and county. The following portion of this abstract summarizes selected results by some BRFSS measures. Each set of proportions refers to the range of estimated prevalence of the behaviors, diseases, or use of preventive health-care services as reported by survey respondents. Adults with good or better health: 65.5%-88.0% for states and territories, 72.0%-92.4% for MMSAs, and 74.3%-94.2% for counties. Adults aged <65 years with health-care coverage: 65.4%-92.3% for states and territories, 66.8%-94.7% for MMSAs, and 61.3%-95.6% for counties. Influenza vaccination received during the preceding 12 months among adults aged >= 65 years: 28.6%-70.2% for states and territories, 42.0%-80.0% for MMSAs, and 41.1%-78.2% for counties. Adults meeting the federal physical activity recommendations for both aerobic physical activity and muscle-strengthening activity: 8.5%-27.3% for states and territories, 7.3%-32.0% for MMSAs, and 11.0%-32.0% for counties. Current cigarette smokers: 11.8%-30.5% for states and territories, 8.4%-30.6% for MMSAs, and 8.1%-35.2% for counties. Binge drinking during the last month: 10.0%-25.0% for states and territories, 7.0%-32.5% for MMSAs, and 7.0%-32.5% for counties. Adults always wearing seatbelts while driving or riding in a car: 63.9%-94.1% for states and territories, 51.8%-96.9% for MMSAs, and 51.8%-97.0% for counties.Adults aged >= 18 who were obese: 20.7%-34.9% for states and territories, 15.1%-37.2% for MMSAs, and 15.1%-41.0% for counties. Adults with diagnosed diabetes: 6.7%-13.5% for states and territories, 3.9%-15.9% for MMSAs, and 3.5%-18.3% for counties. Adults with current asthma: 4.3%-12.1% for states and territories, 2.9%-14.1% for MMSAs, and 2.9%-15.6% for counties. Adults aged >= 45 years who have had coronary heart disease: 7.1%-16.2% for states and territories, 5.0%-19.4% for MMSAs, and 3.9%-18.5% for counties. Adults using special equipment because of any health problem: 5.1%-11.3% for states and territories, 3.9%-13.2% for MMSAs, and 2.4%-14.7% for counties.
Interpretation: Because of the recent change in the BRFSS methodology, the results should not be compared with those from previous years. The findings in this report indicate that substantial variations exist in the reported health-risk behaviors, chronic diseases, disabilities, access to health-care services, and the use of preventive health services among U. S. adults at state and territory, MMSA, and county levels. The findings underscore the continued need for surveillance of health-risk behaviors, chronic conditions, and use of preventive health-care services as well as surveillance-informed programs designed to help improve health-related risk behaviors, levels of chronic disease and disability, and the access to and use of preventive services and health-care resources.
Public Health Action: State and local health departments and agencies can continue to use BRFSS data to identify populations at high risk for certain unhealthy behaviors and chronic conditions. Additionally, they can use the data to inform the design, implementation, direction, monitoring, and evaluation of public health programs, policies, and use of preventive services that can lead to a reduction in morbidity and mortality among U.S. residents.
C1 [Xu, Fang; Mawokomatanda, Tebitha; Flegel, David; Salandy, Simone] Northrop Grumman Corp, Atlanta, GA USA.
[Pierannunzi, Carol; Garvin, William; Chowdhury, Pranesh; Crawford, Carol; Town, Machell] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
RP Town, M (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM mpt2@cdc.gov
NR 65
TC 7
Z9 7
U1 0
U2 8
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 1545-8636
J9 MMWR SURVEILL SUMM
JI MMWR Surv. Summ.
PD OCT 24
PY 2014
VL 63
IS 9
BP 1
EP 150
PG 150
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AY5RT
UT WOS:000347630100001
PM 25340985
ER
PT J
AU Rainey, JJ
Cheriyadat, A
Radke, RJ
Crumly, JS
Koch, DB
AF Rainey, Jeanette J.
Cheriyadat, Anil
Radke, Richard J.
Crumly, Julie Suzuki
Koch, Daniel B.
TI Estimating contact rates at a mass gathering by using video analysis: a
proof-of-concept project
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Mass gathering; Video analysis; Contact rates; Social mixing; Simulation
ID PANDEMIC INFLUENZA; INFECTIOUS-DISEASE; SURVEILLANCE; H1N1
AB Background: Current approaches for estimating social mixing patterns and infectious disease transmission at mass gatherings have been limited by various constraints, including low participation rates for volunteer-based research projects and challenges in quantifying spatially and temporally accurate person-to-person interactions. We developed a proof-of-concept project to assess the use of automated video analysis for estimating contact rates of attendees of the GameFest 2013 event at Rensselaer Polytechnic Institute (RPI) in Troy, New York.
Methods: Video tracking and analysis algorithms were used to estimate the number and duration of contacts for 5 attendees during a 3-minute clip from the RPI video. Attendees were considered to have a contact event if the distance between them and another person was <= 1 meter. Contact duration was estimated in seconds. We also simulated 50 attendees assuming random mixing using a geo-spatially accurate representation of the same GameFest location.
Results: The 5 attendees had an overall median of 2 contact events during the 3-minute video clip (range: 0-6). Contact events varied from less than 5 seconds to the full duration of the 3-minute clip. The random mixing simulation was visualized and presented as a contrasting example.
Conclusion: We were able to estimate the number and duration of contacts for 5 GameFest attendees from a 3-minute video clip that can be compared to a random mixing simulation model at the same location. The next phase will involve scaling the system for simultaneous analysis of mixing patterns from hours-long videos and comparing our results with other approaches for collecting contact data from mass gathering attendees.
C1 [Rainey, Jeanette J.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.
[Cheriyadat, Anil; Koch, Daniel B.] Oak Ridge Natl Lab, Oak Ridge, TN USA.
[Radke, Richard J.] Rensselaer Polytech Inst, Dept Elect Comp & Syst Engn, Troy, NY USA.
[Crumly, Julie Suzuki] Oak Ridge Associated Univ, Oak Ridge, TN USA.
RP Rainey, JJ (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.
EM jkr7@cdc.gov
NR 27
TC 3
Z9 3
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD OCT 24
PY 2014
VL 14
AR 1101
DI 10.1186/1471-2458-14-1101
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AT7TI
UT WOS:000345139700001
PM 25341363
ER
PT J
AU Aquino, TL
Brice, GT
Hayes, S
Myers, CA
McDowell, J
White, B
Garten, R
Johnston, D
AF Aquino, Theodore L.
Brice, Gary T.
Hayes, Sherry
Myers, Christopher A.
McDowell, Jaqueline
White, Brenda
Garten, Rebecca
Johnston, Daniel
TI Influenza Outbreak in a Vaccinated Population - USS Ardent, February
2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID NAVY SHIP; TRANSMISSION; VIRUS
C1 [Aquino, Theodore L.] US Navy, Mine Counter Measures Squadron 3, Arlington, VA 22201 USA.
[Brice, Gary T.; Myers, Christopher A.; White, Brenda] US Navy, Naval Hlth Res Ctr, Arlington, VA USA.
[Hayes, Sherry; McDowell, Jaqueline] US Navy, Navy Environm & Prevent Med Unit 5, Arlington, VA USA.
[Garten, Rebecca] CDC, World Hlth Org Collaborating Ctr Influenza, Atlanta, GA 30333 USA.
[Johnston, Daniel] USS Ardent, Independent Duty Corpsman, San Diego, CA USA.
RP Aquino, TL (reprint author), US Navy, Mine Counter Measures Squadron 3, Arlington, VA 22201 USA.
EM taquino@health.usf.edu
NR 11
TC 9
Z9 9
U1 0
U2 1
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 24
PY 2014
VL 63
IS 42
BP 947
EP 949
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AR7ZL
UT WOS:000343795400003
PM 25340911
ER
PT J
AU Smith, JC
Hinman, AR
Pickering, LK
AF Smith, Jean Clare
Hinman, Alan R.
Pickering, Larry K.
TI History and Evolution of the Advisory Committee on Immunization
Practices - United States, 1964-2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Smith, Jean Clare; Pickering, Larry K.] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Hinman, Alan R.] Task Force Global Hlth, Ctr Vaccine Equ, Decatur, GA USA.
RP Smith, JC (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM jis6@cdc.gov
NR 10
TC 7
Z9 7
U1 0
U2 2
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 24
PY 2014
VL 63
IS 42
BP 955
EP 958
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AR7ZL
UT WOS:000343795400005
PM 25340913
ER
PT J
AU Reaves, EJ
Mabande, LG
Thoroughman, DA
Arwady, MA
Montgomery, JM
AF Reaves, Erik J.
Mabande, Lyndon G.
Thoroughman, Douglas A.
Arwady, M. Allison
Montgomery, Joel M.
TI Control of Ebola Virus Disease - Firestone District, Liberia 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Reaves, Erik J.; Arwady, M. Allison] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Mabande, Lyndon G.] Firestone Liberia Inc, Firestone Hlth Serv, Nashville, TN USA.
[Thoroughman, Douglas A.] CDC, Atlanta, GA 30333 USA.
[Montgomery, Joel M.] CDC, Div Global Hlth Protect Kenya, Atlanta, GA 30333 USA.
RP Reaves, EJ (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
EM ereaves@cdc.gov
NR 3
TC 15
Z9 15
U1 0
U2 33
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 24
PY 2014
VL 63
IS 42
BP 959
EP 965
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AR7ZL
UT WOS:000343795400006
PM 25340914
ER
PT J
AU Bahl, S
Kumar, R
Menabde, N
Thapa, A
McFarland, J
Swezy, V
Tangermann, RH
Jafari, HS
Elsner, L
Wassilak, SGF
Kew, OM
Cochi, SL
AF Bahl, Sunil
Kumar, Rakesh
Menabde, Nata
Thapa, Arun
McFarland, Jeffrey
Swezy, Virginia
Tangermann, Rudolph H.
Jafari, Hamid S.
Elsner, Linda
Wassilak, Steven G. F.
Kew, Olen M.
Cochi, Stephen L.
TI Polio-Free Certification and Lessons Learned - South-East Asia Region,
March 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID ERADICATION; PROGRESS; INDIA
C1 [Bahl, Sunil] WHO, Natl Polio Surveillance Project, Geneva, Switzerland.
[Kumar, Rakesh] Govt India, Minist Hlth & Family Welf, New Delhi, India.
[Menabde, Nata] World Hlth Org Country Off, Geneva, Switzerland.
[Thapa, Arun; McFarland, Jeffrey; Swezy, Virginia] South East Asia Reg Off, Immunizat & Vaccine Dev Dept, New Delhi, India.
[Tangermann, Rudolph H.; Jafari, Hamid S.] WHO, Polio Eradicat Dept, CH-1211 Geneva, Switzerland.
[Elsner, Linda; Wassilak, Steven G. F.; Cochi, Stephen L.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Kew, Olen M.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Wassilak, SGF (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
EM swassilak@cdc.gov
NR 10
TC 0
Z9 0
U1 1
U2 4
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 24
PY 2014
VL 63
IS 42
BP COVER1
EP 946
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AR7ZL
UT WOS:000343795400002
ER
PT J
AU Buskirk, AD
Green, BJ
Lemons, AR
Nayak, AP
Goldsmith, WT
Kashon, ML
Anderson, SE
Hettick, JM
Templeton, SP
Germolec, DR
Beezhold, DH
AF Buskirk, Amanda D.
Green, Brett J.
Lemons, Angela R.
Nayak, Ajay P.
Goldsmith, W. Travis
Kashon, Michael L.
Anderson, Stacey E.
Hettick, Justin M.
Templeton, Steven P.
Germolec, Dori R.
Beezhold, Donald H.
TI A Murine Inhalation Model to Characterize Pulmonary Exposure to Dry
Aspergillus fumigatus Conidia
SO PLOS ONE
LA English
DT Article
ID FUNGAL SPORES; C57BL/6 MICE; RESPONSES; ASTHMA; CELLS; MICROORGANISMS;
SENSITIZATION; GERMINATION; INFECTION; ALLERGENS
AB Most murine models of fungal exposure are based on the delivery of uncharacterized extracts or liquid conidia suspensions using aspiration or intranasal approaches. Studies that model exposure to dry fungal aerosols using whole body inhalation have only recently been described. In this study, we aimed to characterize pulmonary immune responses following repeated inhalation of conidia utilizing an acoustical generator to deliver dry fungal aerosols to mice housed in a nose only exposure chamber. Immunocompetent female BALB/cJ mice were exposed to conidia derived from Aspergillus fumigatus wild-type (WT) or a melanin-deficient (Delta alb1) strain. Conidia were aerosolized and delivered to mice at an estimated deposition dose of 1 x 10(5) twice a week for 4 weeks (8 total). Histopathological and immunological endpoints were assessed 4, 24, 48, and 72 hours after the final exposure. Histopathological analysis showed that conidia derived from both strains induced lung inflammation, especially at 24 and 48 hour time points. Immunological endpoints evaluated in bronchoalveolar lavage fluid (BALF) and the mediastinal lymph nodes showed that exposure to WT conidia led to elevated numbers of macrophages, granulocytes, and lymphocytes. Importantly, CD8(+) IL17(+) (Tc17) cells were significantly higher in BALF and positively correlated with germination of A. fumigatus WT spores. Germination was associated with specific IgG to intracellular proteins while Delta alb1 spores elicited antibodies to cell wall hydrophobin. These data suggest that inhalation exposures may provide a more representative analysis of immune responses following exposures to environmentally and occupationally prevalent fungal contaminants.
C1 [Buskirk, Amanda D.; Green, Brett J.; Lemons, Angela R.; Nayak, Ajay P.; Anderson, Stacey E.; Hettick, Justin M.; Templeton, Steven P.; Beezhold, Donald H.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA.
[Goldsmith, W. Travis] NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA.
[Kashon, Michael L.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA.
[Germolec, Dori R.] Natl Inst Environm Hlth Sci, Natl Toxicol Program Div, Toxicol Branch, Res Triangle Pk, NC USA.
RP Beezhold, DH (reprint author), NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA.
EM zec1@cdc.gov
OI Lemons, Angela/0000-0003-3057-9888
FU intramural National Institute for Occupational Safety and Health
(NIOSH); NIEHS IAA [AES 12007-00100000]
FX This study was supported by intramural National Institute for
Occupational Safety and Health (NIOSH) funding and by an interagency
agreement with NIEHS IAA# AES 12007-00100000. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 41
TC 4
Z9 4
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 23
PY 2014
VL 9
IS 10
AR e109855
DI 10.1371/journal.pone.0109855
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AR5ZY
UT WOS:000343662800019
PM 25340353
ER
PT J
AU Horm, SV
Mardy, S
Rith, S
Ly, S
Heng, S
Vong, S
Kitsutani, P
Ieng, V
Tarantola, A
Ly, S
Sar, B
Chea, N
Sokhal, B
Barr, I
Kelso, A
Horwood, PF
Timmermans, A
Hurt, A
Lon, C
Saunders, D
Ung, SA
Asgari, N
Roces, MC
Touch, S
Komadina, N
Buchy, P
AF Horm, Srey Viseth
Mardy, Sek
Rith, Sareth
Ly, Sovann
Heng, Seng
Vong, Sirenda
Kitsutani, Paul
Ieng, Vannra
Tarantola, Arnaud
Ly, Sowath
Sar, Borann
Chea, Nora
Sokhal, Buth
Barr, Ian
Kelso, Anne
Horwood, Paul F.
Timmermans, Ans
Hurt, Aeron
Lon, Chanthap
Saunders, David
Ung, Sam An
Asgari, Nima
Roces, Maria Concepcion
Touch, Sok
Komadina, Naomi
Buchy, Philippe
TI Epidemiological and Virological Characteristics of Influenza Viruses
Circulating in Cambodia from 2009 to 2011
SO PLOS ONE
LA English
DT Article
ID ADAMANTANE RESISTANCE; SEASONAL INFLUENZA; A VIRUSES; ANTIVIRAL
RESISTANCE; UNITED-STATES; SURVEILLANCE; REASSORTMENT; MORTALITY;
EVOLUTION; TAIWAN
AB Background: The Cambodian National Influenza Center (NIC) monitored and characterized circulating influenza strains from 2009 to 2011.
Methodology/Principal Findings: Sentinel and study sites collected nasopharyngeal specimens for diagnostic detection, virus isolation, antigenic characterization, sequencing and antiviral susceptibility analysis from patients who fulfilled case definitions for influenza-like illness, acute lower respiratory infections and event-based surveillance. Each year in Cambodia, influenza viruses were detected mainly from June to November, during the rainy season. Antigenic analysis show that A/H1N1pdm09 isolates belonged to the A/California/7/2009-like group. Circulating A/H3N2 strains were A/Brisbane/10/2007-like in 2009 before drifting to A/Perth/16/2009-like in 2010 and 2011. The Cambodian influenza B isolates from 2009 to 2011 all belonged to the B/Victoria lineage represented by the vaccine strains B/Brisbane/60/2008 and B/Malaysia/2506/2004. Sequences of the M2 gene obtained from representative 2009-2011 A/H3N2 and A/H1N1pdm09 strains all contained the S31N mutation associated with adamantanes resistance except for one A/H1N1pdm09 strain isolated in 2011 that lacked this mutation. No reduction in the susceptibility to neuraminidase inhibitors was observed among the influenza viruses circulating from 2009 to 2011. Phylogenetic analysis revealed that A/H3N2 strains clustered each year to a distinct group while most A/H1N1pdm09 isolates belonged to the S203T clade.
Conclusions/Significance: In Cambodia, from 2009 to 2011, influenza activity occurred throughout the year with peak seasonality during the rainy season from June to November. Seasonal influenza epidemics were due to multiple genetically distinct viruses, even though all of the isolates were antigenically similar to the reference vaccine strains. The drug susceptibility profile of Cambodian influenza strains revealed that neuraminidase inhibitors would be the drug of choice for influenza treatment and chemoprophylaxis in Cambodia, as adamantanes are no longer expected to be effective.
C1 [Horm, Srey Viseth; Mardy, Sek; Rith, Sareth; Vong, Sirenda; Tarantola, Arnaud; Ly, Sowath; Horwood, Paul F.; Buchy, Philippe] Reseau Int Inst Pasteur, Inst Pasteur Cambodge, Phnom Penh, Cambodia.
[Mardy, Sek; Ieng, Vannra; Asgari, Nima; Roces, Maria Concepcion] WHO, Phnom Penh, Cambodia.
[Ly, Sovann; Heng, Seng; Touch, Sok] Minist Hlth, Dept Communicable Dis Control, Phnom Penh, Cambodia.
[Kitsutani, Paul] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA.
[Sar, Borann; Chea, Nora] Ctr Dis Control & Prevent, Cambodia Off, Phnom Penh, Cambodia.
[Sokhal, Buth; Ung, Sam An] Natl Inst Publ Hlth, Phnom Penh, Cambodia.
[Barr, Ian; Kelso, Anne; Hurt, Aeron; Komadina, Naomi] WHO Collaborating Ctr Reference & Res Influenza, Melbourne, Vic, Australia.
[Timmermans, Ans; Lon, Chanthap; Saunders, David] Armed Forces Res Inst Med Sci, Bangkok 10400, Thailand.
RP Buchy, P (reprint author), Reseau Int Inst Pasteur, Inst Pasteur Cambodge, Phnom Penh, Cambodia.
EM buchyphilippe@hotmail.com
OI Barr, Ian/0000-0002-7351-418X; Hurt, Aeron/0000-0003-1826-4314;
Tarantola, Arnaud/0000-0002-6946-7958
FU World Health Organization office in Cambodia; French Agency for
Development (SISEA project); Office of the Assistant Secretary for
Preparedness and Response within the U.S. Department of Health and Human
Services
FX The study was funded by the World Health Organization office in
Cambodia, the French Agency for Development (SISEA project) and by the
Office of the Assistant Secretary for Preparedness and Response within
the U.S. Department of Health and Human Services. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 58
TC 3
Z9 3
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 23
PY 2014
VL 9
IS 10
AR e110713
DI 10.1371/journal.pone.0110713
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AR5ZY
UT WOS:000343662800050
PM 25340711
ER
PT J
AU Turner, N
Pierse, N
Huang, QS
Radke, S
Bissielo, A
Thompson, MG
Kelly, H
AF Turner, N.
Pierse, N.
Huang, Q. S.
Radke, S.
Bissielo, A.
Thompson, M. G.
Kelly, H.
CA SHIVERS Invest Team
TI Interim estimates of the effectiveness of seasonal trivalent inactivated
influenza vaccine in preventing influenza hospitalisations and primary
care visits in Auckland, New Zealand, in 2014
SO EUROSURVEILLANCE
LA English
DT Article
AB We present preliminary results of influenza vaccine effectiveness (VE) in New Zealand using a case test-negative design for 28 April to 31 August 2014. VE adjusted for age and time of admission among all ages against severe acute respiratory illness hospital presentation due to laboratory-confirmed influenza was 54% (95% CI: 19 to 74) and specifically against A(H1N1) pdm09 was 65% (95% CI: 33 to 81). For influenza-confirmed primary care visits, VE was 67% (95% CI: 48 to 79) overall and 73% (95% CI: 50 to 85) against A(H1N1) pdm09.
C1 [Turner, N.; Radke, S.] Univ Auckland, Auckland 1, New Zealand.
[Pierse, N.] Univ Otago, Wellington, New Zealand.
[Huang, Q. S.; Radke, S.; Bissielo, A.] Inst Environm Sci & Res, Wellington, New Zealand.
[Thompson, M. G.] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
[Kelly, H.] Australian Natl Univ, Canberra, ACT, Australia.
[Kelly, H.] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia.
RP Turner, N (reprint author), Univ Auckland, Auckland 1, New Zealand.
EM n.turner@auckland.ac.nz
FU United States Department of Health and Human Services, Centers for
Disease Control and Prevention (CDC) [1U01IP000480]
FX The SHIVERS (Southern Hemisphere Influenza and Vaccine Effectiveness
Research and Surveillance) project is funded by the United States
Department of Health and Human Services, Centers for Disease Control and
Prevention (CDC) (1U01IP000480). The findings and conclusions in this
report are those of the authors and do not necessarily represent the
view of the United States CDC.
NR 14
TC 8
Z9 8
U1 0
U2 4
PU EUR CENTRE DIS PREVENTION & CONTROL
PI STOCKHOLM
PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN
SN 1560-7917
J9 EUROSURVEILLANCE
JI Eurosurveillance
PD OCT 23
PY 2014
VL 19
IS 42
BP 19
EP 24
AR 20934
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA AR7MX
UT WOS:000343764900004
ER
PT J
AU Alavanja, MCR
Hofmann, JN
Lynch, CF
Hines, CJ
Barry, KH
Barker, J
Buckman, DW
Thomas, K
Sandler, DP
Hoppin, JA
Koutros, S
Andreotti, G
Lubin, JH
Blair, A
Freeman, LEB
AF Alavanja, Michael C. R.
Hofmann, Jonathan N.
Lynch, Charles F.
Hines, Cynthia J.
Barry, Kathryn H.
Barker, Joseph
Buckman, Dennis W.
Thomas, Kent
Sandler, Dale P.
Hoppin, Jane A.
Koutros, Stella
Andreotti, Gabriella
Lubin, Jay H.
Blair, Aaron
Freeman, Laura E. Beane
TI Non-Hodgkin Lymphoma Risk and Insecticide, Fungicide and Fumigant se in
the Agricultural Health Study
SO PLOS ONE
LA English
DT Article
ID PESTICIDE EXPOSURE; OCCUPATIONAL-EXPOSURE; CANCER-RISK; ADIPOSE-TISSUE;
UNITED-STATES; FARMERS; ORGANOCHLORINES; APPLICATORS; LINDANE; COHORT
AB Farming and pesticide use have previously been linked to non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). We evaluated agricultural use of specific insecticides, fungicides, and fumigants and risk of NHL and NHL-subtypes (including CLL and MM) in a U.S.-based prospective cohort of farmers and commercial pesticide applicators. A total of 523 cases occurred among 54,306 pesticide applicators from enrollment (1993-97) through December 31, 2011 in Iowa, and December 31, 2010 in North Carolina. Information on pesticide use, other agricultural exposures and other factors was obtained from questionnaires at enrollment and at follow-up approximately five years later (1999-2005). Information from questionnaires, monitoring, and the literature were used to create lifetime-days and intensity-weighted lifetime days of pesticide use, taking into account exposure-modifying factors. Poisson and polytomous models were used to calculate relative risks (RR) and 95% confidence intervals (CI) to evaluate associations between 26 pesticides and NHL and five NHL-subtypes, while adjusting for potential confounding factors. For total NHL, statistically significant positive exposure-response trends were seen with lindane and DDT. Terbufos was associated with total NHL in ever/never comparisons only. In subtype analyses, terbufos and DDT were associated with small cell lymphoma/chronic lymphocytic leukemia/marginal cell lymphoma, lindane and diazinon with follicular lymphoma, and permethrin with MM. However, tests of homogeneity did not show significant differences in exposure-response among NHL-subtypes for any pesticide. Because 26 pesticides were evaluated for their association with NHL and its subtypes, some chance finding could have occurred. Our results showed pesticides from different chemical and functional classes were associated with an excess risk of NHL and NHL subtypes, but not all members of any single class of pesticides were associated with an elevated risk of NHL or NHL subtypes. These findings are among the first to suggest links between DDT, lindane, permethrin, diazinon and terbufos with NHL subtypes.
C1 [Alavanja, Michael C. R.; Hofmann, Jonathan N.; Barry, Kathryn H.; Koutros, Stella; Andreotti, Gabriella; Lubin, Jay H.; Blair, Aaron; Freeman, Laura E. Beane] NCI, Div Canc Epidemiol & Genet, Rockville, MD 20850 USA.
[Lynch, Charles F.] Univ Iowa, Coll Publ Hlth, Iowa City, IA USA.
[Hines, Cynthia J.] NIOSH, Cincinnati, OH 45226 USA.
[Barker, Joseph; Buckman, Dennis W.] IMS Inc, Calverton, MD USA.
[Thomas, Kent] US EPA, Natl Exposure Res Lab, Res Triangle Pk, NC 27711 USA.
[Sandler, Dale P.; Hoppin, Jane A.] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA.
RP Alavanja, MCR (reprint author), NCI, Div Canc Epidemiol & Genet, Rockville, MD 20850 USA.
EM alavanjm@mail.nih.gov
RI Beane Freeman, Laura/C-4468-2015
OI Beane Freeman, Laura/0000-0003-1294-4124
FU Intramural Research Program of the NIH, National Cancer Institute,
Division of Cancer Epidemiology and Genetics [Z01CP010119]; National
Institutes of Environmental Health Sciences [Z01ES049030]; IMS, Inc
FX This work was supported by the Intramural Research Program of the NIH,
National Cancer Institute, Division of Cancer Epidemiology and Genetics
(Z01CP010119) and The National Institutes of Environmental Health
Sciences (Z01ES049030). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript. IMS, Inc, provided support in the form of salaries for
authors Joseph Barker and Denis W Buckman, but did not have any
additional role in the study design, data collection and analysis,
decision to publish, or preparation of the manuscript. The specific
roles of these authors are articulated in the 'author contributions'
section.
NR 49
TC 12
Z9 12
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 22
PY 2014
VL 9
IS 10
AR e109332
DI 10.1371/journal.pone.0109332
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AR6DY
UT WOS:000343674800010
PM 25337994
ER
PT J
AU Mackenzie, JS
Drury, P
Arthur, RR
Ryan, MJ
Grein, T
Slattery, R
Suri, S
Domingo, CT
Bejtullahu, A
AF Mackenzie, John S.
Drury, Patrick
Arthur, Ray R.
Ryan, Michael J.
Grein, Thomas
Slattery, Raphael
Suri, Sameera
Domingo, Christine Tiffany
Bejtullahu, Armand
TI The Global Outbreak Alert and Response Network
SO GLOBAL PUBLIC HEALTH
LA English
DT Article
DE International Health Regulations; World Health Organization; outbreak
response; Global Outbreak Alert and Response Network; public health
emergencies
ID HEMORRHAGIC-FEVER; EBOLA; UGANDA
AB The Global Outbreak Alert and Response Network (GOARN) was established in 2000 as a network of technical institutions, research institutes, universities, international health organisations and technical networks willing to contribute and participate in internationally coordinated responses to infectious disease outbreaks. It reflected a recognition of the need to strengthen and coordinate rapid mobilisation of experts in responding to international outbreaks and to overcome the sometimes chaotic and fragmented operations characterising previous responses. The network partners agreed that the World Health Organization would coordinate the network and provide a secretariat, which would also function as the operational support team. The network has evolved to comprise 153 institutions/technical partners and 37 additional networks, the latter encompassing a further 355 members and has been directly involved in 137 missions to 79 countries, territories or areas. Future challenges will include supporting countries to achieve the capacity to detect and respond to outbreaks of international concern, as required by the International Health Regulations (2005). GOARN's increasing regional focus and expanding geographic composition will be central to meeting these challenges. The paper summarises some of network's achievements over the past 13 years and presents some of the future challenges.
C1 [Mackenzie, John S.] Curtin Univ, Fac Hlth Sci, Perth, WA 6845, Australia.
[Mackenzie, John S.] Burnet Inst, Melbourne, Vic, Australia.
[Drury, Patrick; Ryan, Michael J.; Grein, Thomas; Slattery, Raphael; Suri, Sameera; Domingo, Christine Tiffany; Bejtullahu, Armand] WHO, CH-1211 Geneva, Switzerland.
[Arthur, Ray R.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Mackenzie, JS (reprint author), Curtin Univ, Fac Hlth Sci, Perth, WA 6845, Australia.
EM j.mackenzie@curtin.edu.au
NR 21
TC 7
Z9 7
U1 2
U2 31
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1744-1692
EI 1744-1706
J9 GLOB PUBLIC HEALTH
JI Glob. Public Health
PD OCT 21
PY 2014
VL 9
IS 9
BP 1023
EP 1039
DI 10.1080/17441692.2014.951870
PG 17
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AS8AL
UT WOS:000344472800003
PM 25186571
ER
PT J
AU Zaman, K
Nasera, A
Power, M
Yaich, M
Zhang, L
Ginsburg, AS
Luby, SP
Rahman, M
Hills, S
Bhardwaj, M
Flores, J
AF Zaman, K.
Nasera, Abu Mohd
Power, Maureen
Yaich, Mansour
Zhang, Lei
Ginsburg, Amy Sarah
Luby, Stephen P.
Rahman, Mahmudur
Hills, Susan
Bhardwaj, Mukesh
Flores, Jorge
TI Lot-to-lot consistency of live attenuated SA 14-14-2 Japanese
encephalitis vaccine manufactured in a good manufacturing practice
facility and non-inferiority with respect to an earlier product
SO VACCINE
LA English
DT Article
DE Japanese encephalitis vaccine; Immunogenicity; Children; Bangladesh
ID SA-14-14-2 VACCINE; NEPALESE CHILDREN; 3-DOSE SCHEDULE; 2-DOSE SCHEDULE;
INFANTS; IMMUNOGENICITY; IMMUNIZATION; SA14-14-2; SAFETY
AB We conducted a four-arm, double-blind, randomized controlled trial among 818 Bangladeshi infants between 10 and 12 months of age to establish equivalence among three lots of live attenuated SA 14-14-2 JE vaccine manufactured by the China National Biotec Group's Chengdu Institute of Biological Products (CDIBP) in a new Good Manufacturing Practice (GMP) facility and to evaluate non-inferiority of the product with a lot of the same vaccine manufactured in CDIBP's original facility.
The study took place in two sites in Bangladesh, rural Matlab and Mirpur in urban Dhaka. We collected pre-vaccination (Day 0) and post-vaccination Day 28 (-4 to +14 days) blood samples to assess neutralizing anti-JE virus antibody titers in serum by plaque reduction neutralization tests (PRNT).
Seroprotection following vaccination was defined as a PRNT titer >= 1:10 at Day 28 in participants non-immune at baseline. Follow-up for reactogenicity and safety was conducted through home visits at Day 7 and monitoring for serious adverse events through Day 28. Seroprotection rates ranged from 80.2% to 86.3% for all four lots of vaccine. Equivalence of the seroprotection rates between pairs of vaccine lots produced in the new GMP facility was satisfied at the pre-specified 10% margin of the 95% confidence interval (CI) for two of the three pairwise comparisons, but not for the third (-4.3% observed difference with 95% CI of 11.9 to 3.3%). Nevertheless, the aggregate seroprotection rate for all three vaccine lots manufactured in the GMP facility was calculated and found to be within the non-inferiority margin (within 10%) to the vaccine lot produced in the original facility. All four lots of vaccine were safe and well tolerated.
dThese study results should facilitate the use of SA 14-14-2 JE vaccine as a routine component of immunization programs in Asian countries. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Zaman, K.; Nasera, Abu Mohd; Luby, Stephen P.] Int Ctr Diarrhoea Dis Res Bangladesh, Dhaka, Bangladesh.
[Power, Maureen; Yaich, Mansour; Ginsburg, Amy Sarah; Flores, Jorge] PATH, Washington, DC USA.
[Zhang, Lei] Chengdu Inst Biol Prod Co Ltd, Chengdu, Peoples R China.
[Luby, Stephen P.] Stanford Univ, Palo Alto, CA 94304 USA.
[Rahman, Mahmudur] Inst Epidemiol Dis Control & Res, Dhaka, Bangladesh.
[Hills, Susan] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Bhardwaj, Mukesh] GVK Biosci Private Ltd, Hyderabad, Andhra Pradesh, India.
RP Zaman, K (reprint author), Int Ctr Diarrhoea Dis Res Bangladesh, Dhaka, Bangladesh.
EM kzaman@icddrb.org
OI Luby, Stephen/0000-0001-5385-899X
FU PATH, USA [00945]
FX Funding and technical support for this research study was provided by
PATH, USA, grant number 00945. icddr,b acknowledges with gratitude the
commitment of PATH to its research efforts. We are grateful to the study
participants and caregivers for their valuable time and information. The
authors wish to thank Maher Issa and Iksung Cho for his assistance in
data analysis.
NR 22
TC 1
Z9 2
U1 0
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 21
PY 2014
VL 32
IS 46
BP 6061
EP 6066
DI 10.1016/j.vaccine.2014.09.012
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AR8SS
UT WOS:000343845300007
PM 25239483
ER
PT J
AU Crow, BS
Pantazides, BG
Quinones-Gonzalez, J
Garton, JW
Carter, MD
Perez, JW
Watson, CM
Tomcik, DJ
Crenshaw, MD
Brewer, BN
Riches, JR
Stubbs, SJ
Read, RW
Evans, RA
Thomas, JD
Blake, TA
Johnson, RC
AF Crow, Brian S.
Pantazides, Brooke G.
Quinones-Gonzalez, Jennifer
Garton, Joshua W.
Carter, Melissa D.
Perez, Jonas W.
Watson, Caroline M.
Tomcik, Dennis J.
Crenshaw, Michael D.
Brewer, Bobby N.
Riches, James R.
Stubbs, Sarah J.
Read, Robert W.
Evans, Ronald A.
Thomas, Jerry D.
Blake, Thomas A.
Johnson, Rudolph C.
TI Simultaneous Measurement of Tabun, Sarin, Soman, Cyclosarin, VR, VX, and
VM Adducts to Tyrosine in Blood Products by Isotope Dilution UHPLC-MS/MS
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID TANDEM MASS-SPECTROMETRY; ORGANOPHOSPHORUS NERVE AGENTS; INTERACTION
LIQUID-CHROMATOGRAPHY; HUMAN SERUM; ACETYLCHOLINESTERASE ACTIVITY; HUMAN
BUTYRYLCHOLINESTERASE; BIOLOGICAL MARKERS; KINETIC-ANALYSIS; SULFUR
MUSTARD; HUMAN ALBUMIN
AB This work describes a new specific, sensitive, and rapid stable isotope dilution method for the simultaneous detection of the organophosphorus nerve agents (OPNAs) tabun (GA), sarin (GB), soman (GD), cyclosarin (GF), VR, VX, and VM adducts to tyrosine (Tyr). Serum, plasma, and lysed whole blood samples (50 mu L) were prepared by protein precipitation followed by digestion with Pronase. Specific Tyr adducts were isolated from the digest by a single solid phase extraction (SPE) step, and the analytes were separated by reversed-phase ultra high performance liquid chromatography (UHPLC) gradient elution in less than 2 min. Detection was performed on a triple quadrupole tandem mass spectrometer using time-triggered selected reaction monitoring (SRM) in positive electrospray ionization (ESI) mode. The calibration range was characterized from 0.100-50.0 ng/mL for GB- and VR-Tyr and 0.250-50.0 ng/mL for GA-, GD-, GF-, and VX/VM-Tyr (R-2 >= 0.995). Inter- and intra-assay precision had coefficients of variation of <= 17 and <= 10%, respectively, and the measured concentration accuracies of spiked samples were within 15% of the targeted value for multiple spiking levels. The limit of detection was calculated to be 0.097, 0.027, 0.018, 0.074, 0.023, and 0.083 ng/mL for GA-, GB-, GD-, GF-, VR-, and VX/VM-Tyr, respectively. A convenience set of 96 serum samples with no known nerve agent exposure was screened and revealed no baseline values or potential interferences. This method provides a simple and highly specific diagnostic tool that may extend the time postevent that a confirmation of nerve agent exposure can be made with confidence.
C1 [Crow, Brian S.; Pantazides, Brooke G.; Carter, Melissa D.; Thomas, Jerry D.; Blake, Thomas A.; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
[Quinones-Gonzalez, Jennifer; Garton, Joshua W.; Watson, Caroline M.] Ctr Dis Control & Prevent, Oak Ridge Inst Sci & Educ, Atlanta, GA 30341 USA.
[Perez, Jonas W.] Battelle Mem Inst, Atlanta, GA 30329 USA.
[Tomcik, Dennis J.; Crenshaw, Michael D.; Brewer, Bobby N.] Battelle Mem Inst, Columbus, OH 43201 USA.
[Riches, James R.; Stubbs, Sarah J.; Read, Robert W.] Def Sci & Technol Lab, Salisbury SP4 0JQ, Wilts, England.
[Evans, Ronald A.] US Army Edgewood Chem Biol Ctr, Analyt Toxicol Branch, R&T Directorate, Aberdeen Proving Ground, MD 21010 USA.
RP Crow, BS (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
EM jgz8@cdc.gov
OI Garton, Joshua/0000-0002-4549-1224; Blake, Thomas/0000-0001-8536-9998
FU Centers for Disease Control and Prevention; Defense Threat and Reduction
Agency [11-005-12430]; Oak Ridge Institute for Science and Education
FX This work was supported by the Centers for Disease Control and
Prevention, the Defense Threat and Reduction Agency (11-005-12430), and
the Oak Ridge Institute for Science and Education. The authors would
like to thank Ms. Chariety Sapp of CDC's Incident Response Laboratory
(IRL) for dispensing convenience set samples prior to analysis. The
findings and conclusions in this article are those of the authors and do
not necessarily represent the views of the Centers for Disease Control
and Prevention. Use of trade names is for identification only and does
not imply endorsement by the Centers for Disease Control and Prevention,
the Public Health Service, or the U.S. Department of Health and Human
Services.
NR 41
TC 8
Z9 8
U1 8
U2 39
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD OCT 21
PY 2014
VL 86
IS 20
BP 10397
EP 10405
DI 10.1021/ac502886c
PG 9
WC Chemistry, Analytical
SC Chemistry
GA AR5QY
UT WOS:000343639800056
PM 25286390
ER
PT J
AU Zhao, S
Zhao, H
Wang, HY
Wang, YB
Shi, GQ
Li, ZX
Yang, L
Zhang, J
Lei, PP
Qu, YQ
Ma, L
Li, JG
Bao, JZ
Li, HC
Ke, CR
Fontaine, RE
Yang, YJ
Zeng, G
Huang, WL
AF Zhao Su
Zhao Hong
Wang Hongyue
Wang Yuebing
Shi Guoqing
Li Zhaoxiang
Yang Lin
Zhang Jian
Lei Pu-Ping
Qu Yongqiang
Ma Lin
Li Jiaguo
Bao Jianzhong
Li Huachang
Ke Chunrong
Fontaine, Robert E.
Yang Yuejin
Zeng Guang
Huang Wenli
TI Epidemiological, clinical and pathological features of the unexplained
sudden death clustered in the mountain area of Yunnan province in China:
a retrospective study of 44 cases from 1975 to 2013
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 25th Great Wall International Congress of Cardiology (GW-ICC) / Asia
Pacific Heart Congress (APHC) / International Congress of Cardiovascular
Prevention and Rehabilitation (ICCPR)
CY OCT 16-19, 2014
CL Beijing, PEOPLES R CHINA
C1 [Zhao Su; Wang Yuebing; Li Zhaoxiang; Yang Lin; Ma Lin; Li Jiaguo; Huang Wenli] Yunnan Inst Endem Dis Control & Prevent, Kunming, Yunnan, Peoples R China.
[Zhao Hong; Wang Hongyue; Wang Yuebing; Shi Guoqing; Zhang Jian; Yang Yuejin] Fuwai Hosp, Beijing, Peoples R China.
[Zhao Hong; Wang Hongyue; Wang Yuebing; Shi Guoqing; Zhang Jian; Yang Yuejin] Chinese Acad Med Sci, Cardiovasc Inst, Beijing, Peoples R China.
[Zhao Hong; Wang Hongyue; Wang Yuebing; Shi Guoqing; Zhang Jian; Yang Yuejin] Peking Union Med Coll, Beijing, Peoples R China.
[Shi Guoqing; Lei Pu-Ping; Qu Yongqiang; Zeng Guang] Chinese Ctr Dis Control & Prevent, Chinese Field Epidemiol Training Program, Nanning, Peoples R China.
[Lei Pu-Ping; Qu Yongqiang] Kunming Med Univ, Forens Med Coll, Kunming, Yunnan, Peoples R China.
[Bao Jianzhong] Ctr Dis Control & Prevent Chuxiong Prefecture, Kunming, Yunnan, Peoples R China.
[Li Huachang] Ctr Dis Control & Prevent Linchang City, Linchang, Peoples R China.
[Ke Chunrong] Ctr Dis Control & Prevent Dali Prefecture, Dalian, Peoples R China.
[Fontaine, Robert E.] US Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 21
PY 2014
VL 64
IS 16
SU S
MA GW25-e3400
BP C101
EP C101
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CP1UO
UT WOS:000359662000451
ER
PT J
AU Golokhvast, KS
Shvedova, AA
AF Golokhvast, Kirill S.
Shvedova, Anna A.
TI Galvanic Manufacturing in the Cities of Russia: Potential Source of
Ambient Nanoparticles
SO PLOS ONE
LA English
DT Article
ID IRON-OXIDE NANOPARTICLES; AMERICAN-HEART-ASSOCIATION; AIR-POLLUTION;
PARTICULATE MATTER; HEAVY-METALS; CARDIOVASCULAR-DISEASE;
RISK-ASSESSMENT; IN-VITRO; HEALTH; SLUDGE
AB Galvanic manufacturing is widely employed and can be found in nearly every average city in Russia. The release and accumulation of different metals (Me), depending on the technology used can be found in the vicinities of galvanic plants. Under the environmental protection act in Russia, the regulations for galvanic manufacturing do not include the regulations and safety standards for ambient ultrafine and nanosized particulate matter (PM). To assess whether Me nanoparticles (NP) are among environmental pollutants caused by galvanic manufacturing, the level of Me NP were tested in urban snow samples collected around galvanic enterprises in two cities. Employing transmission electronic microscopy, energy-dispersive X-ray spectroscopy, and a laser diffraction particle size analyzer, we found that the size distribution of tested Me NP was within 10-120 nm range. This is the first study to report that Me NP of Fe, Cr, Pb, Al, Ni, Cu, and Zn were detected around galvanic shop settings.
C1 [Golokhvast, Kirill S.] Far Eastern Fed Univ, Sci Educ Ctr Nanotechnol, Vladivostok, Russia.
[Shvedova, Anna A.] CDC, NIOSH, Pathol & Physiol Res Branch, Morgantown, WV USA.
[Shvedova, Anna A.] W Virginia Univ, Sch Med, Dept Physiol & Pharmacol, Morgantown, VA USA.
RP Golokhvast, KS (reprint author), Far Eastern Fed Univ, Sci Educ Ctr Nanotechnol, Vladivostok, Russia.
EM droopy@mail.ru
RI Golokhvast, Kirill/E-5051-2014
OI Golokhvast, Kirill/0000-0002-4873-2281
FU Far Eastern Federal University [13-06-0318-m_a]; Presidential Grant for
supporting young scientists [MK-1547.2013.5]; Ministry of Education and
Science of the Russian Federation [14.594.21.0006]
FX The work is financially supported by the Scientific Fund of the Far
Eastern Federal University (No. 13-06-0318-m_a), the Presidential Grant
for supporting young scientists (MK-1547.2013.5) and the Grant of the
Ministry of Education and Science of the Russian Federation (No.
14.594.21.0006). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 34
TC 0
Z9 0
U1 3
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 20
PY 2014
VL 9
IS 10
AR e110573
DI 10.1371/journal.pone.0110573
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS0AY
UT WOS:000343942100075
PM 25329582
ER
PT J
AU Seither, R
Masalovich, S
Knighton, CL
Mellerson, J
Singleton, JA
Greby, SM
AF Seither, Ranee
Masalovich, Svetlana
Knighton, Cynthia L.
Mellerson, Jenelle
Singleton, James A.
Greby, Stacie M.
TI Vaccination Coverage Among Children in Kindergarten - United States,
2013-14 School Year
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID NONMEDICAL EXEMPTIONS; IMMUNIZATION LAWS
C1 [Seither, Ranee; Knighton, Cynthia L.; Singleton, James A.; Greby, Stacie M.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Masalovich, Svetlana; Mellerson, Jenelle] Carter Consulting Inc, Atlanta, GA 30345 USA.
RP Seither, R (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM rseither@cdc.gov
NR 9
TC 27
Z9 27
U1 3
U2 12
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 17
PY 2014
VL 63
IS 41
BP 913
EP 920
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ9SR
UT WOS:000343197100001
PM 25321068
ER
PT J
AU Silfen, SL
Farley, SM
Shih, SC
Duquaine, DC
Ricci, JM
Kansagra, SM
Edwards, SM
Babb, S
McAfee, T
AF Silfen, Sheryl L.
Farley, Shannon M.
Shih, Sarah C.
Duquaine, Damon C.
Ricci, Jenna Mandel
Kansagra, Susan M.
Edwards, Sarah Matthes
Babb, Stephen
McAfee, Tim
TI Increases in Smoking Cessation Interventions After a Feedback and
Improvement Initiative Using Electronic Health Records-19 Community
Health Centers, New York City, October 2010-March 2012
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID TOBACCO CESSATION; CARE
C1 [Silfen, Sheryl L.; Farley, Shannon M.; Shih, Sarah C.; Duquaine, Damon C.; Ricci, Jenna Mandel; Kansagra, Susan M.] New York City Dept Hlth & Mental Hyg, New York, NY USA.
[Edwards, Sarah Matthes; Babb, Stephen; McAfee, Tim] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
RP Babb, S (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM sbabb@cdc.gov
NR 10
TC 3
Z9 3
U1 3
U2 5
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 17
PY 2014
VL 63
IS 41
BP 921
EP 924
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ9SR
UT WOS:000343197100002
PM 25321069
ER
PT J
AU Forrester, JD
Hunter, JC
Pillai, SK
Arwady, MA
Ayscue, P
Matanock, A
Monroe, B
Schafer, IJ
Nyenswah, TG
De Cock, KM
AF Forrester, Joseph D.
Hunter, Jennifer C.
Pillai, Satish K.
Arwady, M. Allison
Ayscue, Patrick
Matanock, Almea
Monroe, Ben
Schafer, Ilana J.
Nyenswah, Tolbert G.
De Cock, Kevin M.
TI Cluster of Ebola Cases Among Liberian and US Health Care Workers in an
Ebola Treatment Unit and Adjacent Hospital - Liberia, 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Forrester, Joseph D.; Hunter, Jennifer C.; Arwady, M. Allison; Ayscue, Patrick; Matanock, Almea] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Pillai, Satish K.] CDC, Div Preparedness & Emerging Infect, Atlanta, GA 30333 USA.
[Monroe, Ben] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Schafer, Ilana J.] CDC, Div Epidemiol Anal & Lib Serv, Ctr Surveillance Epidemiol & Lib Serv, Atlanta, GA 30333 USA.
[Nyenswah, Tolbert G.] Liberian Minist Hlth & Social Welf, Monrovia, Liberia.
[De Cock, Kevin M.] CDC Kenya, Kisumu, Kenya.
[De Cock, Kevin M.] CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Forrester, JD (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
EM jforrester@cdc.gov
NR 2
TC 21
Z9 21
U1 0
U2 21
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 17
PY 2014
VL 63
IS 41
BP 925
EP 929
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ9SR
UT WOS:000343197100003
PM 25321070
ER
PT J
AU Pillai, SK
Nyenswah, T
Rouse, E
Arwady, MA
Forrester, JD
Hunter, JC
Matanock, A
Ayscue, P
Monroe, B
Schafer, IJ
Poblano, L
Neatherlin, J
Montgomery, JM
De Cock, KM
AF Pillai, Satish K.
Nyenswah, Tolbert
Rouse, Edward
Arwady, M. Allison
Forrester, Joseph D.
Hunter, Jennifer C.
Matanock, Almea
Ayscue, Patrick
Monroe, Benjamin
Schafer, Ilana J.
Poblano, Luis
Neatherlin, John
Montgomery, Joel M.
De Cock, Kevin M.
TI Developing an Incident Management System to Support Ebola Response -
Liberia, July-August 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Pillai, Satish K.] CDC, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Nyenswah, Tolbert] Minist Hlth & Social Welf, Monrovia, Liberia.
[Rouse, Edward; Poblano, Luis] CDC, Div Emergency Operat, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.
[Arwady, M. Allison; Forrester, Joseph D.; Hunter, Jennifer C.; Matanock, Almea; Ayscue, Patrick] CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA.
[Hunter, Jennifer C.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Monroe, Benjamin] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Schafer, Ilana J.] CDC, Div Epidemiol Anal & Lib Serv, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA.
[Neatherlin, John; Montgomery, Joel M.; De Cock, Kevin M.] CDC, CDC Kenya, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Neatherlin, John; Montgomery, Joel M.] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA.
[De Cock, Kevin M.] CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Pillai, SK (reprint author), CDC, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM vig8@cdc.gov
NR 4
TC 12
Z9 12
U1 0
U2 14
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 17
PY 2014
VL 63
IS 41
BP 930
EP 933
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ9SR
UT WOS:000343197100004
PM 25321071
ER
PT J
AU Benowitz, I
Ackelsberg, J
Baker, SE
Baumgartner, JC
Dentinger, C
Fine, AD
Harper, SA
Jones, LE
Laraque, F
Lee, EH
Merizalde, G
Quinn, C
Slavinski, S
Winters, AI
Weiss, D
Yacisin, KA
Varma, JK
Layton, MC
AF Benowitz, Isaac
Ackelsberg, Joel
Baker, Sharon E.
Baumgartner, Jennifer C.
Dentinger, Catherine
Fine, Anne D.
Harper, Scott A.
Jones, Lucretia E.
Laraque, Fabienne
Lee, Ellen H.
Merizalde, Giselle
Quinn, Celia
Slavinski, Sally
Winters, Ann I.
Weiss, Don
Yacisin, Kari A.
Varma, Jay K.
Layton, Marcelle C.
TI Surveillance and Preparedness for Ebola Virus Disease - New York City,
2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Benowitz, Isaac; Yacisin, Kari A.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Benowitz, Isaac; Ackelsberg, Joel; Baker, Sharon E.; Baumgartner, Jennifer C.; Dentinger, Catherine; Fine, Anne D.; Harper, Scott A.; Jones, Lucretia E.; Laraque, Fabienne; Lee, Ellen H.; Merizalde, Giselle; Slavinski, Sally; Winters, Ann I.; Weiss, Don; Varma, Jay K.; Layton, Marcelle C.] Dept Hlth & Mental Hyg, Bur Communicable Dis, New York, NY USA.
[Dentinger, Catherine; Harper, Scott A.] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.
[Quinn, Celia] Dept Hlth & Mental Hyg, Off Emergency Planning & Response, New York, NY USA.
[Yacisin, Kari A.] Dept Hlth & Mental Hyg, Div Epidemiol, New York, NY USA.
RP Benowitz, I (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
EM ibenowitz@cdc.gov
NR 7
TC 5
Z9 7
U1 2
U2 18
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 17
PY 2014
VL 63
IS 41
BP 934
EP 936
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ9SR
UT WOS:000343197100005
PM 25321072
ER
PT J
AU Nett, RJ
Choi, P
Murolo, C
Murphy, JS
AF Nett, Randall J.
Choi, Peter
Murolo, Cara
Murphy, James S.
TI Increase in Gonorrhea Cases in Counties Associated with American Indian
Reservations - Montana, January 2012-August 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID HOME
C1 [Nett, Randall J.] CDC, Div State & Local Readiness, Atlanta, GA 30333 USA.
[Nett, Randall J.; Choi, Peter; Murolo, Cara; Murphy, James S.] Montana Dept Publ Hlth & Human Serv, Helena, MT 59604 USA.
RP Nett, RJ (reprint author), CDC, Div State & Local Readiness, Atlanta, GA 30333 USA.
EM rnett@cdc.gov
NR 7
TC 0
Z9 0
U1 0
U2 0
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 17
PY 2014
VL 63
IS 41
BP 937
EP 937
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ9SR
UT WOS:000343197100006
PM 25321073
ER
PT J
AU Johnson, T
Tyagi, R
Lee, PR
Lee, MH
Johnson, KR
Kowalak, J
Medynets, M
Hategan, A
Nutman, TB
Sejvar, J
Makumbi, I
Aceng, JR
Dowell, SF
Nath, A
AF Johnson, Tory
Tyagi, Richa
Lee, Paul R.
Lee, Myoung-hwa
Johnson, Kory R.
Kowalak, Jeffery
Medynets, Marie
Hategan, Alina
Nutman, Thomas B.
Sejvar, James
Makumbi, Issa
Aceng, Jane R.
Dowell, Scott F.
Nath, Avindra
TI Detection of auto-antibodies to leiomodin-1 in patients with nodding
syndrome
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Meeting Abstract
CT 12th International Congress of Neuroimmunology (ISNI)
CY NOV 09-13, 2014
CL Mainz, GERMANY
C1 [Johnson, Tory; Tyagi, Richa; Lee, Paul R.; Lee, Myoung-hwa; Johnson, Kory R.; Kowalak, Jeffery; Medynets, Marie; Hategan, Alina; Nutman, Thomas B.; Nath, Avindra] NINDS, NIH, Bethesda, MD 20892 USA.
[Sejvar, James] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
[Makumbi, Issa; Aceng, Jane R.] Minist Hlth, Kampala, Uganda.
[Dowell, Scott F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA.
NR 0
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
EI 1872-8421
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD OCT 15
PY 2014
VL 275
IS 1-2
SI SI
MA 444
BP 103
EP 103
DI 10.1016/j.jneuroim.2014.08.275
PG 1
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA AT8OK
UT WOS:000345192100267
ER
PT J
AU Patel, JC
Lucchi, NW
Srivastava, P
Lin, JT
Sug-aram, R
Aruncharus, S
Bharti, PK
Shukla, MM
Congpuong, K
Satimai, W
Singh, N
Udhayakumar, V
Meshnick, SR
AF Patel, Jaymin C.
Lucchi, Naomi W.
Srivastava, Priyanka
Lin, Jessica T.
Sug-aram, Rungniran
Aruncharus, Supannee
Bharti, Praveen K.
Shukla, Man M.
Congpuong, Kanungnit
Satimai, Wichai
Singh, Neeru
Udhayakumar, Venkatachalam
Meshnick, Steven R.
TI Field Evaluation of a Real-Time Fluorescence Loop-Mediated Isothermal
Amplification Assay, RealAmp, for the Diagnosis of Malaria in Thailand
and India
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE malaria; Plasmodium falciparum; Plasmodium vivax; diagnosis;
loop-mediated isothermal amplification; LAMP; RealAmp; sensitivity;
specificity; positive predictive value; low-transmission; surveillance;
elimination
ID POLYMERASE CHAIN-REACTION; ELIMINATION; EPIDEMIOLOGY; PARASITEMIA;
MICROSCOPY; STRATEGIES; TESTS; KIT; DNA
AB Background. To eliminate malaria, surveillance for submicroscopic infections is needed. Molecular methods can detect submicroscopic infections but have not hitherto been amenable to implementation in surveillance programs. A portable loop-mediated isothermal amplification assay called RealAmp was assessed in 2 areas of low malaria transmission.
Methods. RealAmp was evaluated in 141 patients from health clinics in India (passive surveillance) and in 127 asymptomatic persons in Thailand (active surveillance). The diagnostic validity, precision, and predictive value of RealAmp were determined using polymerase chain reaction (PCR) as the reference method. A pilot study of RealAmp was also performed on samples from patients presenting at a Thai health center.
Results. A total of 96 and 7 positive cases were detected in India and Thailand, respectively, via PCR. In comparison with nested PCR, the sensitivity and specificity of RealAmp in India were 94.8% (95% confidence interval [CI], 88.3%-98.3%) and 100% (95% CI, 92.1%-100%), respectively, with correct identification of all 5 Plasmodium vivax cases. In Thailand, compared with pooled real-time PCR, RealAmp demonstrated 100% sensitivity (95% CI, 59.0%-100%) and 96.7% specificity (95% CI, 91.7%-99.1%). Testing at the health center demonstrated RealAmp's potential to serve as a point-of-care test with results available in 30-75 minutes.
Conclusion. RealAmp was comparable to PCR in detecting malaria parasites and shows promise as a tool to detect submicroscopic infections in malaria control and elimination programs worldwide.
C1 [Patel, Jaymin C.; Meshnick, Steven R.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA.
[Lin, Jessica T.] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC 27599 USA.
[Lucchi, Naomi W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA USA.
[Srivastava, Priyanka; Bharti, Praveen K.; Shukla, Man M.; Singh, Neeru] Reg Med Res Ctr Tribals, Jabalpur, India.
[Sug-aram, Rungniran; Aruncharus, Supannee; Congpuong, Kanungnit; Satimai, Wichai] Minist Publ Hlth, Bur Vector Borne Dis, Nonthaburi, Thailand.
RP Patel, JC (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Michael Hooker Res Ctr, 135 Dauer Dr, Chapel Hill, NC 27599 USA.
EM jaymin86@email.unc.edu
FU Global Fund to Fight HIV/AIDS, Tuberculosis, and Malaria in Thailand;
Indian Council of Medical Research
FX This work was supported by the Global Fund to Fight HIV/AIDS,
Tuberculosis, and Malaria in Thailand, and by the Indian Council of
Medical Research.
NR 40
TC 24
Z9 25
U1 4
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 15
PY 2014
VL 210
IS 8
BP 1180
EP 1187
DI 10.1093/infdis/jiu252
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0EI
UT WOS:000344609600003
PM 24795480
ER
PT J
AU Henning, TR
Butler, K
Hanson, D
Sturdevant, G
Ellis, S
Sweeney, EM
Mitchell, J
Deyounks, F
Phillips, C
Farshy, C
Fakile, Y
Papp, J
Secor, WE
Caldwell, H
Patton, D
McNicholl, JM
Kersh, EN
AF Henning, Tara R.
Butler, Katherine
Hanson, Debra
Sturdevant, Gail
Ellis, Shanon
Sweeney, Elizabeth M.
Mitchell, James
Deyounks, Frank
Phillips, Christi
Farshy, Carol
Fakile, Yetunde
Papp, John
Secor, W. Evan
Caldwell, Harlan
Patton, Dorothy
McNicholl, Janet M.
Kersh, Ellen N.
TI Increased Susceptibility to Vaginal Simian/Human Immunodeficiency Virus
Transmission in Pig-tailed Macaques Coinfected With Chlamydia
trachomatis and Trichomonas vaginalis
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV risk; STI or STD; Chlamydia; Trichomonas; menstrual cycle; macaque;
HIV susceptibility model
ID SEXUALLY-TRANSMITTED-DISEASES; TENOFOVIR DISOPROXIL FUMARATE;
GENITAL-TRACT; PREEXPOSURE PROPHYLAXIS; HIV-1 TRANSMISSION;
MENSTRUAL-CYCLE; T-CELLS; INFECTION; MODEL; PROTECTION
AB Background. Sexually transmitted infections (STIs) are associated with an increased risk of human immunodeficiency virus (HIV) infection, but their biological effect on HIV susceptibility is not fully understood.
Methods. Female pig-tailed macaques inoculated with Chlamydia trachomatis and Trichomonas vaginalis (n = 9) or medium (controls; n = 7) were repeatedly challenged intravaginally with SHIVSF162p3. Virus levels were evaluated by real-time polymerase chain reaction, plasma and genital cytokine levels by Luminex assays, and STI clinical signs by colposcopy.
Results. Simian/HIV (SHIV) susceptibility was enhanced in STI-positive macaques (P = .04, by the log-rank test; relative risk, 2.5 [95% confidence interval, 1.1-5.6]). All STI-positive macaques were SHIV infected, whereas 3 controls (43%) remained uninfected. Moreover, relative to STI-negative animals, SHIV infections occurred earlier in the menstrual cycle in STI-positive macaques (P = .01, by the Wilcoxon test). Levels of inflammatory cytokines (interferon gamma, interleukin 6, and granulocyte colony-stimulating factor [G-CSF]) were higher in STI-positive macaques during STI inoculation and SHIV exposure periods (P <= .05, by the Wilcoxon test).
Conclusions. C. trachomatis and T. vaginalis infection increase the susceptibility to SHIV, likely because of prolonged genital tract inflammation. These novel data demonstrate a biological link between these nonulcerative STIs and the risk of SHIV infection, supporting epidemiological assocations of HIV and STIs. This study establishes a macaque model for studies of high-risk HIV transmission and prevention.
C1 [Henning, Tara R.; Butler, Katherine; Hanson, Debra; Sweeney, Elizabeth M.; Mitchell, James; Deyounks, Frank; McNicholl, Janet M.; Kersh, Ellen N.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
[Phillips, Christi; Farshy, Carol; Fakile, Yetunde; Papp, John] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA.
[Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA.
[Ellis, Shanon] Total Solut, Atlanta, GA USA.
[Sturdevant, Gail; Caldwell, Harlan] NIAID, Lab Intracellular Parasites, Rocky Mt Labs, NIH, Hamilton, MT USA.
[Patton, Dorothy] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA.
RP Kersh, EN (reprint author), 1600 Clifton Rd NE,MS A-25, Atlanta, GA 30333 USA.
EM ekersh@cdc.gov
FU Centers for Disease Control and Prevention (CDC); National Institutes of
Health; CDC [Y1-AI-0681-02]
FX This work was supported by the Centers for Disease Control and
Prevention (CDC) and by the National Institutes of Health and CDC
(interagency agreement Y1-AI-0681-02).
NR 44
TC 16
Z9 17
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 15
PY 2014
VL 210
IS 8
BP 1239
EP 1247
DI 10.1093/infdis/jiu240
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0EI
UT WOS:000344609600009
PM 24755433
ER
PT J
AU Sanderson-Smith, M
De Oliveira, DMP
Guglielmini, J
McMillan, DJ
Vu, T
Holien, JK
Henningham, A
Steer, AC
Bessen, DE
Dale, JB
Curtis, N
Beall, BW
Walker, MJ
Parker, MW
Carapetis, JR
Van Melderen, L
Sriprakash, KS
Smeesters, PR
AF Sanderson-Smith, Martina
De Oliveira, David M. P.
Guglielmini, Julien
McMillan, David J.
Vu, Therese
Holien, Jessica K.
Henningham, Anna
Steer, Andrew C.
Bessen, Debra E.
Dale, James B.
Curtis, Nigel
Beall, Bernard W.
Walker, Mark J.
Parker, Michael W.
Carapetis, Jonathan R.
Van Melderen, Laurence
Sriprakash, Kadaba S.
Smeesters, Pierre R.
CA M Prot Study Grp
TI A Systematic and Functional Classification of Streptococcus pyogenes
That Serves as a New Tool for Molecular Typing and Vaccine Development
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Streptococcus pyogenes; vaccine; M protein; fibrinogen; plasminogen;
IgA; IgG; molecular typing; epidemiology
ID GROUP-A STREPTOCOCCI; M-PROTEIN; PLASMINOGEN-BINDING; SURFACE PROTEIN;
HISTIDINE-RESIDUES; SEQUENCE ALIGNMENT; GENETIC DIVERSITY; ANTIBODIES;
VIRULENCE; PEPTIDE
AB Streptococcus pyogenes ranks among the main causes of mortality from bacterial infections worldwide. Currently there is no vaccine to prevent diseases such as rheumatic heart disease and invasive streptococcal infection. The streptococcal M protein that is used as the substrate for epidemiological typing is both a virulence factor and a vaccine antigen. Over 220 variants of this protein have been described, making comparisons between proteins difficult, and hindering M protein-based vaccine development. A functional classification based on 48 emm-clusters containing closely related M proteins that share binding and structural properties is proposed. The need for a paradigm shift from type-specific immunity against S. pyogenes to emm-cluster based immunity for this bacterium should be further investigated. Implementation of this emm-cluster-based system as a standard typing scheme for S. pyogenes will facilitate the design of future studies of M protein function, streptococcal virulence, epidemiological surveillance, and vaccine development.
C1 [Sanderson-Smith, Martina; De Oliveira, David M. P.] Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW 2522, Australia.
[Sanderson-Smith, Martina; De Oliveira, David M. P.] Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia.
[Guglielmini, Julien] Inst Pasteur, Dept Genomes & Genet, Paris, France.
[Guglielmini, Julien] CNRS, UMR3525, Paris, France.
[McMillan, David J.; Vu, Therese; Sriprakash, Kadaba S.] QIMR Berghofer Med Res Inst, Bacterial Pathogenesis Lab, Brisbane, Qld, Australia.
[McMillan, David J.; Vu, Therese] Univ Sunshine Coast, Sch Hlth & Sports Sci, Inflammat & Healing Res Cluster, Sippy Downs, Qld 4556, Australia.
[Van Melderen, Laurence; Smeesters, Pierre R.] Univ Libre Bruxelles, IBMM, Lab Genet & Physiol Bacterienne, Fac Sci, B-6041 Gosselies, Belgium.
[Holien, Jessica K.; Parker, Michael W.] St Vincents Inst Med Res, ACRF Rat Drug Discovery Ctr, Biota Struct Biol Lab, Melbourne, Vic, Australia.
[Henningham, Anna; Walker, Mark J.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia.
[Henningham, Anna; Walker, Mark J.] Univ Queensland, Australian Infect Dis Res Ctr, Brisbane, Qld, Australia.
[Steer, Andrew C.; Curtis, Nigel; Smeesters, Pierre R.] Univ Melbourne, Murdoch Children Res Inst, Melbourne, Vic 3010, Australia.
[Steer, Andrew C.] Univ Melbourne, Ctr Int Child Hlth, Melbourne, Vic 3010, Australia.
[Steer, Andrew C.] Royal Childrens Hosp Melbourne, Dept Gen Med, Melbourne, Vic, Australia.
[Bessen, Debra E.] New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA.
[Dale, James B.] Univ Tennessee Hlth Sci Ctr, Dept Med, Memphis, TN USA.
[Dale, James B.] Dept Vet Affairs Med Ctr, Memphis, TN USA.
[Dale, James B.] Univ Tennessee Hlth Sci Ctr, Dept Microbiol Immunol & Biochem, Memphis, TN USA.
[Curtis, Nigel] Royal Childrens Hosp Melbourne, Infect Dis Unit, Melbourne, Vic, Australia.
[Curtis, Nigel] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia.
[Beall, Bernard W.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA.
[Parker, Michael W.] Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst Bio21, Melbourne, Vic 3010, Australia.
[Carapetis, Jonathan R.] Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia.
RP Smeesters, PR (reprint author), Univ Libre Bruxelles, IBMM, Lab Genet & Physiol Bacterienne, 12 Rue Prof Jeener & Brachet, B-6041 Gosselies, Belgium.
EM psmeeste@ulb.ac.be
RI Parker, Michael/F-9069-2013; van der Linden, Mark/B-9305-2009; Wu,
Jiunn-Jong/E-6075-2011; Ramirez, Mario/B-4993-2008; Guglielmini,
Julien/E-8029-2011; Krizova, Pavla/M-6120-2015; McMillan,
David/P-5582-2016; Melo-Cristino, Jose/H-3726-2013; Henningham,
Anna/C-7355-2017;
OI Curtis, Nigel/0000-0003-3446-4594; McGeer, Allison/0000-0001-5647-6137;
Parker, Michael/0000-0002-3101-1138; van der Linden,
Mark/0000-0002-6574-4313; Sriprakash, Kadaba/0000-0001-7844-323X;
Ramirez, Mario/0000-0002-4084-6233; Guglielmini,
Julien/0000-0002-8566-1726; McMillan, David/0000-0002-9339-0639;
Melo-Cristino, Jose/0000-0001-8643-1722; Henningham,
Anna/0000-0002-0554-6593; Sanderson-Smith, Martina/0000-0002-6366-4993
FU European Society for Clinical Microbiology and Infectious Diseases;
European Society for Paediatric Infectious Diseases; Fonds National de
la Recherche Scientifique (Belgium); Fonds Brachet and Fondation Van
Buuren (Belgium); Australian National Health and Medical Research
Council (Australia); National Institutes of Health (USA); Victorian
Government Operational Infrastructure Support Scheme; Murdoch Childrens
Research Institute
FX This project has been funded by the European Society for Clinical
Microbiology and Infectious Diseases, European Society for Paediatric
Infectious Diseases, Fonds National de la Recherche Scientifique
(Belgium), Fonds Brachet and Fondation Van Buuren (Belgium), Australian
National Health and Medical Research Council (Australia) and the
National Institutes of Health (USA). Funding was also obtained from the
Victorian Government Operational Infrastructure Support Scheme to St
Vincent's Institute and Murdoch Childrens Research Institute. M. S.-S.
is an NHMRC Career Development Fellow. M. W. P. is an NHMRC Senior
Principal Research Fellow. J. K. H. is a joint Cure Cancer/Leukaemia
Foundation Postdoctoral Fellow. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 51
TC 52
Z9 52
U1 1
U2 20
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 15
PY 2014
VL 210
IS 8
BP 1325
EP 1338
DI 10.1093/infdis/jiu260
PG 14
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0EI
UT WOS:000344609600019
PM 24799598
ER
PT J
AU Qi, M
Huang, L
Wang, RJ
Xiao, LH
Xu, LN
Li, JQ
Zhang, LX
AF Qi, Meng
Huang, Lei
Wang, Rongjun
Xiao, Lihua
Xu, Lina
Li, Junqiang
Zhang, Longxian
TI Natural infection of Cryptosporidium muris in ostriches (Struthio
camelus)
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Cryptosporidium muris; Ostrich; Cross-transmission; SSU rRNA; Actin;
HSP70
ID MOLECULAR CHARACTERIZATION; PHYLOGENETIC ANALYSIS; GENETIC DIVERSITY;
PUBLIC-HEALTH; PREVALENCE; PARASITES; GENOTYPES; CHINA; BIRDS;
IDENTIFICATION
AB A total of 303 fecal samples were collected from ostriches (Struthio camelus) and 31 samples (10.2%) were Oyptosporidium-positive upon microscopic analysis. The infection rate was 27.6% in ostriches aged 16-60 days, 1.2% in those aged 61-180 days, and 20.4% in those aged >10 years. The Cryptosporidium-positive isolates were genotyped with a restriction fragment length polymorphism analysis and DNA sequence analysis of the small subunit (SSU) rRNA gene. The 22 isolates from ostriches aged >10 years were identified as Gyptosporidium muris, whereas the nine isolates from ostriches <180 days were Cryptosporidium baileyi. Ten of the 22 C. muris isolates were analyzed based on the actin and HSP70 genes, and the results were identical to those observed for the SSU rRNA gene. Cross-transmission studies demonstrated that the C muris isolate infected BALB/c mice and Mongolian gerbils, but did not infect chickens. C muris isolated in this study appears to be host-adapted, consistent with a previous multilocus sequence typing analysis. Further studies are required to understand the prevalence and transmission of Cryptosporidium spp. in ostriches in different geographic areas. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Qi, Meng; Huang, Lei; Wang, Rongjun; Xu, Lina; Li, Junqiang; Zhang, Longxian] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Henan, Peoples R China.
[Qi, Meng; Huang, Lei; Wang, Rongjun; Xu, Lina; Li, Junqiang; Zhang, Longxian] Int Joint Res Lab Zoonot Dis Henan, Zhengzhou 450002, Peoples R China.
[Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Zhang, LX (reprint author), Henan Agr Univ, Coll Anim Sci & Vet Med, 95 Wenhua Rd, Zhengzhou 450002, Henan, Peoples R China.
EM zhanglx8999@gmail.com
RI Xiao, Lihua/B-1704-2013
OI Xiao, Lihua/0000-0001-8532-2727
FU State Key Program of National Natural Science Foundation of China
[31330079]; Specialized Research Fund for the Doctoral Program of Higher
Education [20124105120003]; National Natural Science Foundation of China
[U1204328, 31302079]
FX This study was supported in part by the State Key Program of National
Natural Science Foundation of China (31330079), Specialized Research
Fund for the Doctoral Program of Higher Education (no. 20124105120003),
the National Natural Science Foundation of China (U1204328, 31302079).
NR 32
TC 4
Z9 5
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD OCT 15
PY 2014
VL 205
IS 3-4
BP 518
EP 522
DI 10.1016/j.vetpar.2014.06.035
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA AS7GN
UT WOS:000344425200014
PM 25178556
ER
PT J
AU Cegielski, JP
Dalton, T
Yagui, M
Wattanaamornkiet, W
Volchenkov, GV
Via, LE
Van der Walt, M
Tupasi, T
Smith, SE
Odendaal, R
Leimane, V
Kvasnovsky, C
Kuznetsova, T
Kurbatova, E
Kummik, T
Kuksa, L
Kliiman, K
Kiryanova, EV
Kim, H
Kim, CK
Kazennyy, BY
Jou, RW
Huang, WL
Ershova, J
Erokhin, VV
Diem, L
Contreras, C
Cho, SN
Chernousova, LN
Chen, MP
Caoili, JC
Bayona, J
Akksilp, S
AF Cegielski, J. Peter
Dalton, Tracy
Yagui, Martin
Wattanaamornkiet, Wanpen
Volchenkov, Grigory V.
Via, Laura E.
Van der Walt, Martie
Tupasi, Thelma
Smith, Sarah E.
Odendaal, Ronel
Leimane, Vaira
Kvasnovsky, Charlotte
Kuznetsova, Tatiana
Kurbatova, Ekaterina
Kummik, Tiina
Kuksa, Liga
Kliiman, Kai
Kiryanova, Elena V.
Kim, HeeJin
Kim, Chang-ki
Kazennyy, Boris Y.
Jou, Ruwen
Huang, Wei-Lun
Ershova, Julia
Erokhin, Vladislav V.
Diem, Lois
Contreras, Carmen
Cho, Sang Nae
Chernousova, Larisa N.
Chen, Michael P.
Campos Caoili, Janice
Bayona, Jaime
Akksilp, Somsak
CA Global Preserving Effective TB Tre
TI Extensive Drug Resistance Acquired During Treatment of
Multidrug-Resistant Tuberculosis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE tuberculosis; multidrug-resistant tuberculosis; extensively
drug-resistant tuberculosis; Green Light Committee
ID PROPENSITY SCORE; HEALTH
AB Background. Increasing access to drugs for the treatment of multidrug-resistant (MDR) tuberculosis is crucial but could lead to increasing resistance to these same drugs. In 2000, the international Green Light Committee (GLC) initiative began to increase access while attempting to prevent acquired resistance.
Methods. To assess the GLC's impact, we followed adults with pulmonary MDR tuberculosis from the start to the end of treatment with monthly sputum cultures, drug susceptibility testing, and genotyping. We compared the frequency and predictors of acquired resistance to second-line drugs (SLDs) in 9 countries that volunteered to participate, 5 countries that met GLC criteria, and 4 countries that did not apply to the GLC.
Results. In total, 832 subjects were enrolled. Of those without baseline resistance to specific SLDs, 68 (8.9%) acquired extensively drug-resistant (XDR) tuberculosis, 79 (11.2%) acquired fluoroquinolone (FQ) resistance, and 56 (7.8%) acquired resistance to second-line injectable drugs (SLIs). The relative risk (95% confidence interval [CI]) of acquired resistance was lower at GLC-approved sites: 0.27 (.16-.47) for XDR tuberculosis, 0.28 (.17-.45) for FQ, and 0.15 (.06-.39) to 0.60 (.34-1.05) for 3 different SLIs. The risk increased as the number of potentially effective drugs decreased. Controlling for baseline drug resistance and differences between sites, the odds ratios (95% CIs) were 0.21 (.07-.62) for acquired XDR tuberculosis and 0.23 (.09-.59) for acquired FQ resistance.
Conclusions. Treatment of MDR tuberculosis involves substantial risk of acquired resistance to SLDs, increasing as baseline drug resistance increases. The risk was significantly lower in programs documented by the GLC to meet specific standards.
C1 [Cegielski, J. Peter; Dalton, Tracy; Smith, Sarah E.; Kvasnovsky, Charlotte; Kurbatova, Ekaterina; Ershova, Julia; Diem, Lois; Chen, Michael P.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Yagui, Martin] Natl Inst Hlth, Lima, Peru.
[Wattanaamornkiet, Wanpen; Akksilp, Somsak] Minist Publ Hlth, Dept Dis Control, Bangkok, Thailand.
[Volchenkov, Grigory V.; Kuznetsova, Tatiana] Vladimir Oblast TB Dispensary, Vladimir, Russia.
[Via, Laura E.] NIAID, NIH, Bethesda, MD 20892 USA.
[Van der Walt, Martie; Odendaal, Ronel] MRC, Pretoria, South Africa.
[Tupasi, Thelma; Campos Caoili, Janice] Trop Dis Fdn, Manila, Philippines.
[Leimane, Vaira; Kuksa, Liga] Riga East Univ Hosp Ctr TB & Lung Dis, Riga, Latvia.
[Kummik, Tiina; Kliiman, Kai] Tartu Univ Hosp, Tartu, Estonia.
[Kiryanova, Elena V.; Kazennyy, Boris Y.] Orel Oblast TB Dispensary, Oryol, Russia.
[Kim, HeeJin; Kim, Chang-ki] Korean Inst TB, Seoul, South Korea.
[Jou, Ruwen; Huang, Wei-Lun] Taiwan Ctr Dis Control, Taipei, Taiwan.
[Erokhin, Vladislav V.; Chernousova, Larisa N.] Russian Acad Med Sci, Cent TB Res Inst, Moscow 109801, Russia.
[Contreras, Carmen; Bayona, Jaime] Socios Salud Sucursal, Lima, Peru.
[Cho, Sang Nae] Int TB Res Ctr, Chang Won, South Korea.
[Cho, Sang Nae] Yonsei Univ, Coll Med, Seoul, South Korea.
RP Cegielski, JP (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-10, Atlanta, GA 30333 USA.
EM pcegielski@cdc.gov
FU US Agency for International Development [IAA: OGH09-011:CGH10-1010196];
US CDC, Division of Tuberculosis Elimination [CDC-OGH11-12021]
FX This work was supported by the US Agency for International Development
(IAA: OGH09-011:CGH10-1010196) and the US CDC, Division of Tuberculosis
Elimination (CDC-OGH11-12021).
NR 23
TC 43
Z9 43
U1 1
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 15
PY 2014
VL 59
IS 8
BP 1049
EP 1063
DI 10.1093/cid/ciu572
PG 15
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AR2KG
UT WOS:000343413200002
PM 25057101
ER
PT J
AU Kirkcaldy, RD
Weinstock, HS
Moore, PC
Philip, SS
Wiesenfeld, HC
Papp, JR
Kerndt, PR
Johnson, S
Ghanem, KG
Hook, EW
AF Kirkcaldy, Robert D.
Weinstock, Hillard S.
Moore, Page C.
Philip, Susan S.
Wiesenfeld, Harold C.
Papp, John R.
Kerndt, Peter R.
Johnson, Shacondra
Ghanem, Khalil G.
Hook, Edward W., III
TI The Efficacy and Safety of Gentamicin Plus Azithromycin and Gemifloxacin
Plus Azithromycin as Treatment of Uncomplicated Gonorrhea
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Neisseria gonorrhoeae; gonorrhea treatment; azithromycin; gentamicin;
gemifloxacin
ID SEXUALLY-TRANSMITTED INFECTIONS; RESISTANT NEISSERIA-GONORRHOEAE;
IN-VITRO ACTIVITY; TREATMENT FAILURE; GONOCOCCAL URETHRITIS;
CEFTRIAXONE; CEFIXIME; FLUOROQUINOLONE; SUSCEPTIBILITY
AB Background. Ceftriaxone is the foundation of currently recommended gonorrhea treatment. There is an urgent need for backup treatment options for patients with cephalosporin allergy or infections due to suspected cephalosporin-resistant Neisseria gonorrhoeae. We evaluated the efficacy and tolerability of 2 combinations of existing non-cephalosporin antimicrobials for treatment of patients with urogenital gonorrhea.
Methods. We conducted a randomized, multisite, open-label, noncomparative trial in 5 outpatient sexually transmitted disease clinic sites in Alabama, California, Maryland, and Pennsylvania. Patients aged 15-60 years diagnosed with uncomplicated urogenital gonorrhea were randomly assigned to either gentamicin 240 mg intramuscularly plus azithromycin 2 g orally, or gemifloxacin 320 mg orally plus azithromycin 2 g orally. The primary outcome was microbiological cure of urogenital infections (negative follow-up culture) at 10-17 days after treatment among 401 participants in the per protocol population.
Results. Microbiological cure was achieved by 100% (lower 1-sided exact 95% confidence interval [CI] bound, 98.5%) of 202 evaluable participants receiving gentamicin/azithromycin, and 99.5% (lower 1-sided exact 95% CI bound, 97.6%) of 199 evaluable participants receiving gemifloxacin/azithromycin. Gentamicin/azithromycin cured 10 of 10 pharyngeal infections and 1 of 1 rectal infection; gemifloxacin/azithromycin cured 15 of 15 pharyngeal and 5 of 5 rectal infections. Gastrointestinal adverse events were common in both arms.
Conclusions. Gentamicin/azithromycin and gemifloxacin/azithromycin were highly effective for treatment of urogenital gonorrhea. Gastrointestinal adverse events may limit routine use. These non-cephalosporin-based regimens may be useful alternative options for patients who cannot be treated with cephalosporin antimicrobials. Additional treatment options for gonorrhea are needed.
C1 [Kirkcaldy, Robert D.; Weinstock, Hillard S.; Papp, John R.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
[Moore, Page C.] Univ Arkansas Med Sci, Dept Biostat, Little Rock, AR 72205 USA.
[Philip, Susan S.] San Francisco Dept Publ Hlth, San Francisco, CA USA.
[Wiesenfeld, Harold C.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Wiesenfeld, Harold C.] Allegheny Cty Hlth Dept, Pittsburgh, PA USA.
[Kerndt, Peter R.] Cty Los Angeles Dept Publ Hlth, Pittsburgh, PA 15207 USA.
[Johnson, Shacondra] FHI360, Durham, NC USA.
[Ghanem, Khalil G.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Hook, Edward W., III] Univ Alabama Birmingham, Birmingham, AL USA.
[Hook, Edward W., III] Jefferson Cty Dept Hlth, Birmingham, AL USA.
RP Kirkcaldy, RD (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-02, Atlanta, GA 30333 USA.
EM rkirkcaldy@cdc.gov
FU National Institute of Allergy and Infectious Diseases of the National
Institutes of Health [HHSN 26620040073C]
FX This work was supported by the National Institute of Allergy and
Infectious Diseases of the National Institutes of Health (grant number
HHSN 26620040073C).
NR 38
TC 31
Z9 32
U1 3
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 15
PY 2014
VL 59
IS 8
BP 1083
EP 1091
DI 10.1093/cid/ciu521
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AR2KG
UT WOS:000343413200006
PM 25031289
ER
PT J
AU File, TM
Srinivasan, A
Bartlett, JG
AF File, Thomas M., Jr.
Srinivasan, Arjun
Bartlett, John G.
TI Antimicrobial Stewardship: Importance for Patient and Public Health
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE antimicrobial stewardship programs; public health
ID INFECTIOUS-DISEASES SOCIETY; CARE EPIDEMIOLOGY; PROGRAM; RESISTANCE;
ANTIBIOTICS; AMERICA; COMMUNITY; HOSPITALS; IMPACT
C1 [File, Thomas M., Jr.] Summa Hlth Syst, Akron, OH 44304 USA.
[Srinivasan, Arjun] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA.
[Bartlett, John G.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
RP File, TM (reprint author), Summa Hlth Syst, Div Infect Dis, 75 Arch St,Ste 506, Akron, OH 44304 USA.
EM filet@summahealth.org
FU Cubist Pharmaceuticals
FX This article appears as part of a supplement titled "Antimicrobial
Stewardship: Patients Over Process," sponsored by Cubist
Pharmaceuticals.
NR 27
TC 14
Z9 15
U1 0
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 15
PY 2014
VL 59
SU 3
BP S93
EP S96
DI 10.1093/cid/ciu543
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AR2KZ
UT WOS:000343415900001
PM 25261547
ER
PT J
AU Pollack, LA
Srinivasan, A
AF Pollack, Loria A.
Srinivasan, Arjun
TI Core Elements of Hospital Antibiotic Stewardship Programs From the
Centers for Disease Control and Prevention
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE antibacterial agents/therapeutic use; drug utilization; hospitals;
practice guidelines as topic; program development
ID ANTIMICROBIAL STEWARDSHIP; CLOSTRIDIUM-DIFFICILE; COMMUNITY HOSPITALS;
ECONOMIC OUTCOMES; COST-ANALYSIS; GUIDELINES; INFECTION; IMPACT
AB The proven benefits of antibiotic stewardship programs (ASPs) for optimizing antibiotic use and minimizing adverse events, such as Clostridium difficile and antibiotic resistance, have prompted the Centers for Disease Control and Prevention (CDC) to recommend that all hospitals have an ASP. This article summarizes Core Elements of Hospital Antibiotic Stewardship Programs, a recently released CDC document focused on defining the infrastructure and practices of coordinated multidisciplinary programs to improve antibiotic use and patient care in US hospitals.
C1 [Pollack, Loria A.; Srinivasan, Arjun] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
RP Pollack, LA (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,MS A-31, Atlanta, GA 30333 USA.
EM lop5@cdc.gov
FU Cubist Pharmaceuticals
FX This article appears as part of a supplement titled "Antimicrobial
Stewardship: Patients Over Process," sponsored by Cubist
Pharmaceuticals.
NR 28
TC 24
Z9 24
U1 0
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 15
PY 2014
VL 59
SU 3
BP S97
EP S100
DI 10.1093/cid/ciu542
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AR2KZ
UT WOS:000343415900002
PM 25261548
ER
PT J
AU Trivedi, KK
Pollack, LA
AF Trivedi, Kavita K.
Pollack, Loria A.
TI The Role of Public Health in Antimicrobial Stewardship in Healthcare
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE antimicrobial resistance; antimicrobial stewardship; public health;
surveillance
AB Education, surveillance, and promotion of antimicrobial stewardship align with the goals of public health to prevent disease, promote health, and prolong life. Many US federal and state public health organizations are already engaged in antimicrobial stewardship activities. Healthcare providers are encouraged to work with public health officials on appropriate local antimicrobial stewardship strategies to attain the common goal of reducing antimicrobial resistance and preserving antimicrobials for future generations.
C1 [Trivedi, Kavita K.] Trivedi Consults LLC, Albany, CA 94706 USA.
[Pollack, Loria A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA.
RP Trivedi, KK (reprint author), Trivedi Consults LLC, 1020 Curtis St, Albany, CA 94706 USA.
EM kavita@trivediconsults.com
FU Cubist Pharmaceuticals
FX This article appears as part of a supplement titled "Antimicrobial
Stewardship: Patients Over Process," sponsored by Cubist
Pharmaceuticals.
NR 17
TC 2
Z9 2
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 15
PY 2014
VL 59
SU 3
BP S101
EP S103
DI 10.1093/cid/ciu544
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AR2KZ
UT WOS:000343415900003
PM 25261535
ER
PT J
AU Boyle, CA
Perrin, JM
Moyer, VA
AF Boyle, Coleen A.
Perrin, James M.
Moyer, Virginia A.
TI Use of Clinical Preventive Services in Infants, Children, and
Adolescents
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
C1 [Boyle, Coleen A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
[Perrin, James M.] MassGen Hosp Children, Div Gen Pediat, Ctr Child & Adolescent Hlth Res & Policy, Boston, MA USA.
[Perrin, James M.] Harvard Univ, Sch Med, Boston, MA USA.
[Moyer, Virginia A.] Amer Board Pediat Inc, Chapel Hill, NC USA.
RP Boyle, CA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd, Atlanta, GA 30333 USA.
FU Intramural CDC HHS [CC999999]
NR 7
TC 3
Z9 3
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 15
PY 2014
VL 312
IS 15
BP 1509
EP 1510
DI 10.1001/jama.2014.12890
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AQ7HL
UT WOS:000342983200010
PM 25208100
ER
PT J
AU Pavuk, M
Olson, JR
Wattigney, WA
Dutton, ND
Sjodin, A
Shelton, C
Turner, WE
Bartell, SM
AF Pavuk, M.
Olson, J. R.
Wattigney, W. A.
Dutton, N. D.
Sjoedin, A.
Shelton, C.
Turner, W. E.
Bartell, S. M.
CA Anniston Environm Hlth Res
TI Predictors of serum polychlorinated biphenyl concentrations in Anniston
residents
SO SCIENCE OF THE TOTAL ENVIRONMENT
LA English
DT Article
DE Polychlorinated biphenyls; Linear regression; Anniston
ID PERSISTENT ORGANIC POLLUTANTS; MULTIVARIATE STATISTICAL-ANALYSIS;
COMMUNITY-HEALTH SURVEY; PCB EXPOSURE; ENVIRONMENTAL CONTAMINANTS;
ADIPOSE-TISSUE; BODY BURDEN; CONSUMPTION; POPULATION; WOMEN
AB The Anniston Community Health Survey was a community-based cross-sectional study of Anniston, Alabama, residents who live in close proximity to a former PCB production facility to identify factors associated with serum PCB levels. The survey comprises 765 Anniston residents who completed a questionnaire interview and provided a blood sample for analysis in 2005-2007. Several reports based on data from the Anniston survey have been previously published, including associations between PCB exposure and diabetes and blood pressure. In this study we examine demographic, behavioral, dietary, and occupational characteristics of Anniston survey participants as predictors of serum PCB concentrations. Of the 765 participants, 54% were White and 45% were African-American; the sample was predominantly female (70%), with a mean age of 55 years. Serum PCB concentrations varied widely between participants (range for sum of 35 PCBs: 0.11-170.4 ng/g wet weight). Linear regression models with stepwise selection were employed to examine factors associated with serum PCBs. Statistically significant positive associations were observed between serum PCB concentrations and age, race, residential variables, current smoking, and local fish consumption, as was a negative association with education level. Age and race were the most influential predictors of serum PCB levels. A small age by sex interaction was noted, indicating that the increase in PCB levels with age was steeper for women than for men. Significant interaction terms indicated that the associations between PCB levels and having ever eaten locally raised livestock and local clay were much stronger among African-Americans than among White participants. In summary, demographic variables and past consumption of locally produced foods were found to be the most important predictors of PCB concentrations in residents living in the vicinity of a former PCB manufacturing facility. Published by Elsevier B.V.
C1 [Pavuk, M.; Wattigney, W. A.] Agcy Tox Subst & Dis Registry, Atlanta, GA USA.
[Olson, J. R.] SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14260 USA.
[Dutton, N. D.] Agcy Tox Subst & Dis Registry, Oak Ridge Inst Sci & Educ ORISE Res Participant, Atlanta, GA USA.
[Sjoedin, A.; Turner, W. E.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
[Shelton, C.] Jacksonville State Univ, Coll Nursing, Jacksonville, AL 36265 USA.
[Bartell, S. M.] Univ Calif Irvine, Program Publ Hlth, Irvine, CA USA.
[Bartell, S. M.] Univ Calif Irvine, Dept Stat, Irvine, CA USA.
RP Pavuk, M (reprint author), Ctr Dis Control & Prevent, Div Toxicol & Human Hlth Sci, Agcy Tox Subst & Dis Registry, 4770 Buford Highway,Mail Stop F-57, Atlanta, GA 30341 USA.
EM MPavuk@cdc.gov
RI Sjodin, Andreas/F-2464-2010
FU Agency for Toxic Substances and Disease Registry [5U50TS473215]
FX The data used for the present study were collected using a grant from
the Agency for Toxic Substances and Disease Registry to Jacksonville
State University, #5U50TS473215. The contents of this publication are
solely the responsibility of the authors and do not necessarily
represent ATSDR's or CDC's official views.
NR 70
TC 5
Z9 5
U1 1
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0048-9697
EI 1879-1026
J9 SCI TOTAL ENVIRON
JI Sci. Total Environ.
PD OCT 15
PY 2014
VL 496
BP 624
EP 634
DI 10.1016/j.scitotenv.2014.06.113
PG 11
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA AP7GK
UT WOS:000342245600066
PM 25115605
ER
PT J
AU Costa, C
Garcia-Leston, J
Costa, S
Coelho, P
Silva, S
Pingarilho, M
Valdiglesias, V
Mattei, F
Dall'Armi, V
Bonassi, S
Laffon, B
Snawder, J
Teixeira, JP
AF Costa, Carla
Garcia-Leston, Julia
Costa, Solange
Coelho, Patricia
Silva, Susana
Pingarilho, Marta
Valdiglesias, Vanessa
Mattei, Francesca
Dall'Armi, Valentina
Bonassi, Stefano
Laffon, Blanca
Snawder, John
Teixeira, Joao Paulo
TI Is organic farming safer to farmers' health? A comparison between
organic and traditional farming
SO TOXICOLOGY LETTERS
LA English
DT Article
DE Biomarkers; Pesticides; Organic farming; Genotoxicity; Immunotoxicity
ID PERIPHERAL-BLOOD LYMPHOCYTES; EXPOSED FRUIT GROWERS; LASER FLOW
CYTOMETER; COMET ASSAY; DNA-DAMAGE; OCCUPATIONAL-EXPOSURE; PESTICIDE
EXPOSURE; MICRONUCLEUS FREQUENCY; GENETIC POLYMORPHISMS;
AGRICULTURAL-WORKERS
AB Exposure to pesticides is a major public health concern, because of the widespread distribution of these compounds and their possible long term effects. Recently, organic farming has been introduced as a consumer and environmental friendly agricultural system, although little is known about the effects on workers' health. The aim of this work was to evaluate genetic damage and immunological alterations in workers of both traditional and organic farming. Eighty-five farmers exposed to several pesticides, thirty-six organic farmers and sixty-one controls took part in the study. Biomarkers of exposure (pyrethroids, organophosphates, carbamates, and thioethers in urine and butyrylcholinesterase activity in plasma), early effect (micronuclei in lymphocytes and reticulocytes, T-cell receptor mutation assay, chromosomal aberrations, comet assay and lymphocytes subpopulations) and susceptibility (genetic polymorphisms related to metabolism - EPHX1, GSTM1, GSTT1 and GSTP1 - and DNA repair-XRCC1 and XRCC2) were evaluated. When compared to controls and organic farmers, pesticide farmers presented a significant increase of micronuclei in lymphocytes (frequency ratio, FR = 2.80) and reticulocytes (FR = 1.89), chromosomal aberrations (FR = 2.19), DNA damage assessed by comet assay (mean ratio, MR = 1.71), and a significant decrease in the proportion of B lymphocytes (MR = 0.88). Results were not consistent for organic farmers when compared to controls, with a 48% increase of micronuclei in lumphocytes frequency (p = 0.016) contrasted by the significant decreases of TCR-Mf (p = 0.001) and %T (p = 0.001). Our data confirm the increased presence of DNA damage in farmers exposed to pesticides, and show as exposure conditions may influence observed effects. These results must be interpreted with caution due to the small size of the sample and the unbalanced distribution of individuals in the three study groups. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Costa, Carla; Costa, Solange; Coelho, Patricia; Silva, Susana; Teixeira, Joao Paulo] Portuguese Natl Inst Hlth, Dept Environm Hlth, P-4000055 Oporto, Portugal.
[Garcia-Leston, Julia; Valdiglesias, Vanessa; Laffon, Blanca] Univ A Coruna, Dept Psychobiol, Toxicol Unit, La Coruna 15071, Spain.
[Pingarilho, Marta] Fac Med Sci UNL, Dept Genet, P-1349008 Lisbon, Portugal.
[Valdiglesias, Vanessa; Mattei, Francesca; Dall'Armi, Valentina; Bonassi, Stefano] IRCCS San Raffaele Pisana, Unit Clin & Mol Epidemiol, I-00166 Rome, Italy.
[Snawder, John] NIOSH, Biomonitoring & Hlth Assessment Branch, Div Appl Res & Technol, Cincinnati, OH 45226 USA.
RP Costa, C (reprint author), Portuguese Natl Inst Hlth, Dept Environm Hlth, Rua Alexandre Herculano 321, P-4000055 Oporto, Portugal.
EM cstcosta@gmail.com
RI Coelho, Patricia/N-7996-2014; Laffon, Blanca/K-4608-2014; Costa,
Carla/K-4048-2014; Faculdade de Ciencias Medicas, Nova Medical
School/K-6209-2013;
OI Coelho, Patricia/0000-0002-6069-0942; Laffon,
Blanca/0000-0001-7649-2599; Costa, Carla/0000-0002-0027-8462; bonassi,
stefano/0000-0003-3833-6717; Valdiglesias, Vanessa/0000-0002-5572-1089
FU Portuguese Foundation for Science and Technology [SFRH/BD/37190/2007];
Associazione Itaiana per la Ricerca sul Cancro (AIRC)
FX This work was supported by the Portuguese Foundation for Science and
Technology under the grant SFRH/BD/37190/2007. The work of F.M., V.D.,
and S.B. was supported by grants funded by the Associazione Itaiana per
la Ricerca sul Cancro (AIRC).
NR 98
TC 7
Z9 7
U1 9
U2 63
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0378-4274
EI 1879-3169
J9 TOXICOL LETT
JI Toxicol. Lett.
PD OCT 15
PY 2014
VL 230
IS 2
BP 166
EP 176
DI 10.1016/j.toxlet.2014.02.011
PG 11
WC Toxicology
SC Toxicology
GA AP2CV
UT WOS:000341881000009
PM 24576785
ER
PT J
AU Lohiniva, AL
Barakat, A
Dueger, E
Restrepo, S
El Aouad, R
AF Lohiniva, Anna-Leena
Barakat, Amal
Dueger, Erica
Restrepo, Suzanne
El Aouad, Rajae
TI A Qualitative Study of Vaccine Acceptability and Decision Making among
Pregnant Women in Morocco during the A (H1N1) pdm09 Pandemic
SO PLOS ONE
LA English
DT Article
ID INFLUENZA VACCINE; PERCEPTIONS; ACCEPTANCE; KNOWLEDGE
AB Vaccination uptake of pregnant women in Morocco during the A (H1N1) pdm09 pandemic was lower than expected. A qualitative study using open-ended questions was developed to explore the main determinants of acceptance and nonacceptance of the monovalent A (H1N1) pdm09 vaccine among pregnant women in Morocco and to identify information sources that influenced their decision-making process. The study sample included 123 vaccinated and unvaccinated pregnant women who were in their second or third trimester between December 2009 and March 2010. They took part in 14 focus group discussions and eight in-depth interviews in the districts of Casablanca and Kenitra. Thematic qualitative analysis identified reasons for vaccine non-acceptance: (1) fear of the monovalent A (H1N1) pdm09 vaccine, (2) belief in an A (H1N1) pdm09 pandemic conspiracy, (3) belief in the inapplicability of the monovalent A (H1N1) pdm09 vaccine to Moroccans, (4) lack of knowledge of the monovalent A (H1N1) pdm09 vaccine, and (5) challenges of vaccination services/logistics. Reasons for vaccine acceptance included: (1) perceived benefits and (2) modeling. Decision-making was strongly influenced by family, community, mass media, religious leaders and health providers suggesting that broad communication efforts should also be used to advocate for vaccination. Meaningful communication for future vaccine campaigns must consider these context-specific findings. As cultural and religious values are shared across many Arab countries, these findings may also provide valuable insights for seasonal influenza vaccine planning in the Middle East and North Africa region at large.
C1 [Lohiniva, Anna-Leena; Dueger, Erica; Restrepo, Suzanne] US Naval Med Res Unit 3, Global Dis Detect Ctr Egypt, Cairo, Egypt.
[Barakat, Amal; El Aouad, Rajae] Minist Hlth, Natl Inst Hyg, Ctr Natl Reference Grippe, Rabat, Morocco.
[Dueger, Erica] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Lohiniva, AL (reprint author), US Naval Med Res Unit 3, Global Dis Detect Ctr Egypt, Cairo, Egypt.
EM anna.leena.lohiniva@hotmail.com
FU Centers for Disease Control and Prevention Influenza Division
FX This study was funded by the Centers for Disease Control and Prevention
Influenza Division. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 35
TC 2
Z9 2
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 14
PY 2014
VL 9
IS 10
AR e96244
DI 10.1371/journal.pone.0096244
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AR5ZW
UT WOS:000343662500001
PM 25313555
ER
PT J
AU Lindley, MC
Dube, D
Kalayil, EJ
Kim, H
Paiva, K
Raymond, P
AF Lindley, Megan C.
Dube, Donna
Kalayil, Elizabeth J.
Kim, Hanna
Paiva, Kristi
Raymond, Patricia
TI Qualitative evaluation of Rhode Island's healthcare worker influenza
vaccination regulations
SO VACCINE
LA English
DT Article
DE Healthcare personnel; Influenza; Vaccination; Occupational health;
Qualitative research
ID RANDOMIZED-TRIAL; HOME STAFF; ATTITUDES; PERSONNEL; RESIDENTS;
MORTALITY; MORBIDITY; RATES
AB Objective: To evaluate Rhode Island's revised vaccination regulations requiring healthcare workers (HCWs) to receive annual influenza vaccination or wear a mask during patient care when influenza is widespread.
Design: Semi-structured telephone interviews conducted in a random sample of healthcare facilities.
Setting: Rhode Island healthcare facilities covered by the HCW regulations, including hospitals, nursing homes, community health centers, nursing service agencies, and home nursing care providers.
Participants Staff responsible for collecting and/or reporting facility-level HCW influenza vaccination data to comply with Rhode Island HCW regulations.
Methods: Interviews were transcribed and individually coded by interviewers to identify themes; consensus on coding differences was reached through discussion. Common themes and illustrative quotes are presented.
Results: Many facilities perceived the revised regulations as extending their existing influenza vaccination policies and practices. Despite variations in implementation, nearly all facilities implemented policies that complied with the minimum requirements of the regulations. The primary barrier to implementing the HCW regulations was enforcement of masking among unvaccinated HCWs, which required timely tracking of vaccination status and additional time and effort by supervisors. Factors facilitating implementation included early and regular communication from the state health department and facilities' ability to adapt existing influenza vaccination programs to incorporate provisions of the revised regulations.
Conclusions: Overall, facilities successfully implemented the revised HCW regulations during the 2012-2013 influenza season. Continued maintenance of the regulations is likely to reduce transmission of influenza and resulting morbidity and mortality in Rhode Island's healthcare facilities. Published by Elsevier Ltd.
C1 [Lindley, Megan C.] Ctrs Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Dube, Donna] Independent Healthcare Consultant, Providence, RI USA.
[Kalayil, Elizabeth J.] Carter Consult Inc, Atlanta, GA 30345 USA.
[Kim, Hanna; Paiva, Kristi; Raymond, Patricia] Rhode Isl Dept Hlth, Div Community Family Hlth & Equ, Providence, RI 02908 USA.
RP Lindley, MC (reprint author), Ctrs Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM MLindley@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 22
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 14
PY 2014
VL 32
IS 45
BP 5962
EP 5966
DI 10.1016/j.vaccine.2014.08.052
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AR5MZ
UT WOS:000343629900012
PM 25192807
ER
PT J
AU Azonobi, IC
Anderson, BL
Byams, VR
Grant, AM
Schulkin, J
AF Azonobi, Ijeoma C.
Anderson, Britta L.
Byams, Vanessa R.
Grant, Althea M.
Schulkin, Jay
TI Obstetrician-Gynecologists' knowledge of sickle cell disease screening
and management
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Article
DE Sickle cell disease; Physician practice patterns; Obstetrics
ID CARE; STRATEGIES; PHYSICIANS; CHILDREN; US
AB Background: Although obstetrician/gynecologists (OB/GYNs) play an important role in sickle cell disease (SCD) screening and patient care, there is little information on knowledge of SCD or sickle cell trait (SCT) or related practices in this provider group. Our objective was to assess SCD screening and prenatal management practices among OB/GYNs.
Methods: Twelve hundred Fellows and Junior Fellows of the American College of Obstetricians and Gynecologists (the College)(a) were invited to complete a mailed survey, of which half (n = 600) belonged to the Collaborative Ambulatory Research Network.(b) Participants answered questions regarding appropriate target patient groups for prenatal SCD screening, folic acid requirements, practice behaviors and adequacy of their medical school and residency training.
Results: A total of 338 CARN members (56.3%) and 165 non-CARN members (27.5%) returned a survey. Of the 503 responders, 382 provided obstetric services and were included in the analyses. Forty percent of these respondents (n = 153) reported seeing at least 1 patient with SCD in the last year. Of these, 97.4% reported regularly screening people of African descent for SCD or SCT, whereas 52.9% reported regularly screening people of Mediterranean descent and 30.1% reported regularly screening people of Asian descent. Only 56.2% knew the correct recommended daily dose of folic acid for pregnant women with SCD. The proportion of respondents that rated training on SCD screening, assessment and treatment as barely adequate or inadequate ranged from 19.7% to 39.3%.
Conclusions: The practice of many OB/GYNs who care for patients with SCD are not consistent with the College Practice Guidelines on the screening of certain target groups and on folic acid supplementation. There may be an opportunity to improve this knowledge gap through enhanced medical education.
C1 [Azonobi, Ijeoma C.] Morehouse Sch Med, Dept Community Hlth & Prevent Med, Atlanta, GA 30310 USA.
[Anderson, Britta L.; Schulkin, Jay] Amer Coll Obstetricians & Gynecologists, Washington, DC 20024 USA.
[Byams, Vanessa R.; Grant, Althea M.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
RP Schulkin, J (reprint author), Amer Coll Obstetricians & Gynecologists, 409 12th St SW, Washington, DC 20024 USA.
EM JSchulkin@acog.org
FU U.S. Department of Health and Human Services, Health Resources and
Services Administration, Maternal and Child Health Research Program
[UA6MC19010]
FX This study is funded in part by grant, UA6MC19010, through the U.S.
Department of Health and Human Services, Health Resources and Services
Administration, Maternal and Child Health Research Program. The findings
and conclusions in this report are those of the authors and do not
necessarily represent the official position of the Centers for Disease
Control and Prevention.
NR 22
TC 3
Z9 3
U1 1
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD OCT 14
PY 2014
VL 14
AR 356
DI 10.1186/1471-2393-14-356
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AQ9LS
UT WOS:000343176100001
PM 25311876
ER
PT J
AU Rist, CL
Arriola, CS
Rubin, C
AF Rist, Cassidy Logan
Arriola, Carmen Sofia
Rubin, Carol
TI Prioritizing Zoonoses: A Proposed One Health Tool for Collaborative
Decision-Making
SO PLOS ONE
LA English
DT Article
ID INFECTIOUS-DISEASES; PUBLIC-HEALTH; SURVEILLANCE; METHODOLOGY; PATHOGENS
AB Emerging and re-emerging zoonotic diseases pose a threat to both humans and animals. This common threat is an opportunity for human and animal health agencies to coordinate across sectors in a more effective response to zoonotic diseases. An initial step in the collaborative process is identification of diseases or pathogens of greatest concern so that limited financial and personnel resources can be effectively focused. Unfortunately, in many countries where zoonotic diseases pose the greatest risk, surveillance information that clearly defines burden of disease is not available. We have created a semi-quantitative tool for prioritizing zoonoses in the absence of comprehensive prevalence data. Our tool requires that human and animal health agency representatives jointly identify criteria (e.g., pandemic potential, human morbidity or mortality, economic impact) that are locally appropriate for defining a disease as being of concern. The outcome of this process is a ranked disease list that both human and animal sectors can support for collaborative surveillance, laboratory capacity enhancement, or other identified activities. The tool is described in a five-step process and its utility is demonstrated for the reader.
C1 [Rist, Cassidy Logan; Arriola, Carmen Sofia; Rubin, Carol] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Rubin, C (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
EM chr1@cdc.gov
NR 32
TC 3
Z9 3
U1 5
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 10
PY 2014
VL 9
IS 10
AR e109986
DI 10.1371/journal.pone.0109986
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AR6ZS
UT WOS:000343730400101
PM 25302612
ER
PT J
AU Rottinghaus, EK
Beard, RS
Bile, E
Modukanele, M
Maruping, M
Mine, M
Nkengasong, J
Yang, CF
AF Rottinghaus, Erin K.
Beard, R. Suzanne
Bile, Ebi
Modukanele, Mosetsanagape
Maruping, Maruping
Mine, Madisa
Nkengasong, John
Yang, Chunfu
TI Evaluation of Dried Blood Spots Collected on Filter Papers from Three
Manufacturers Stored at Ambient Temperature for Application in HIV-1
Drug Resistance Monitoring
SO PLOS ONE
LA English
DT Article
ID VIRAL LOAD; ANTIRETROVIRAL THERAPY; GENOTYPING ASSAY; SURVEILLANCE;
PLASMA; SPECIMENS
AB As more HIV-infected people gain access to antiretroviral therapy (ART), monitoring HIV drug resistance (HIVDR) becomes essential to combat both acquired and transmitted HIVDR. Studies have demonstrated dried blood spots (DBS) are a suitable alternative in HIVDR monitoring using DBS collected on Whatman 903 (W-903). In this study, we sought to evaluate two other commercially available filter papers, Ahlstrom 226 (A-226) and Munktell TFN (M-TFN), for HIVDR genotyping following ambient temperature storage. DBS were prepared from remnant blood specimens collected from 334 ART patients and stored at ambient temperature for a median time of 30 days. HIV-1 viral load was determined using NucliSENS EasyQ (R) HIV-1 v2.0 RUO test kits prior to genotyping of the protease and reverse transcriptase regions of the HIV-1 pol gene using an in-house assay. Among the DBS tested, 26 specimens had a viral load >= 1000 copies/mL in all three types of filter paper and were included in the genotyping analysis. Genotyping efficiencies were similar between DBS collected on W-903 (92.3%), A-226 (88.5%), and M-TFN (92.3%) filter papers (P = 1.00). We identified 50 DR-associated mutations in DBS collected on W-903, 33 in DBS collected on A-226, and 48 in DBS collected on M-TFN, resulting in mutation detection sensitivities of 66.0% for A-226 and 88.0% for M-TFN when compared to W-903. Our data indicate that differences among filter papers may exist at this storage condition and warrant further studies evaluating filter paper type for HIVDR monitoring.
C1 [Rottinghaus, Erin K.; Beard, R. Suzanne; Nkengasong, John; Yang, Chunfu] Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30329 USA.
[Bile, Ebi; Modukanele, Mosetsanagape; Maruping, Maruping] CDC Botswana, Gaborone, Botswana.
[Mine, Madisa] Botswana Minist Hlth, Gaborone, Botswana.
RP Yang, CF (reprint author), Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30329 USA.
EM CYang1@cdc.gov
RI Yang, Chunfu/G-6890-2013
FU American Public Health Laboratory (APHL); U.S. Centers for Disease
Control and Prevention (CDC); President's Emergency Plan for AIDS Relief
(PEPFAR) through The Centers for Disease Control and Prevention
FX ER and RSB were the recipients of the 2009-2011 and 2012-2014,
respectively, Emerging Infectious Disease (EID) Fellowship sponsored by
American Public Health Laboratory (APHL) and the U.S. Centers for
Disease Control and Prevention (CDC). This research has been supported
by the President's Emergency Plan for AIDS Relief (PEPFAR) through The
Centers for Disease Control and Prevention. The sponsors and funding
agency had no role in the study design, in the collection, analysis and
interpretation of data or in the writing of the report.
NR 20
TC 1
Z9 1
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 10
PY 2014
VL 9
IS 10
AR e109060
DI 10.1371/journal.pone.0109060
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AR6ZS
UT WOS:000343730400044
PM 25303690
ER
PT J
AU Jones, CM
Paulozzi, LJ
Mack, KA
AF Jones, Christopher M.
Paulozzi, Leonard J.
Mack, Karin A.
TI Alcohol Involvement in Opioid Pain Reliever and Benzodiazepine Drug
Abuse-Related Emergency Department Visits and Drug-Related Deaths -
United States, 2010
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Jones, Christopher M.] US FDA, Off Publ Hlth Strategy & Anal, Off Commissioner, Rockville, MD 20857 USA.
[Paulozzi, Leonard J.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
[Mack, Karin A.] CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
RP Jones, CM (reprint author), US FDA, Off Publ Hlth Strategy & Anal, Off Commissioner, Rockville, MD 20857 USA.
EM christopher.m.jones@fda.hhs.gov
NR 9
TC 23
Z9 23
U1 0
U2 5
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 10
PY 2014
VL 63
IS 40
BP 881
EP 885
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ6WX
UT WOS:000342955700001
PM 25299603
ER
PT J
AU Gant, Z
Bradley, H
Hu, XH
Skarbinski, J
Hall, HI
Lansky, A
AF Gant, Zanerta
Bradley, Heather
Hu, Xiaohong
Skarbinski, Jacek
Hall, H. Irene
Lansky, Amy
TI Hispanics or Latinos Living with Diagnosed HIV: Progress Along the
Continuum of HIV Care - United States, 2010
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID INFECTION
C1 [Gant, Zanerta; Bradley, Heather; Hu, Xiaohong; Skarbinski, Jacek; Hall, H. Irene; Lansky, Amy] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
RP Gant, Z (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
EM zgant@cdc.gov
NR 10
TC 17
Z9 17
U1 0
U2 5
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 10
PY 2014
VL 63
IS 40
BP 886
EP 890
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ6WX
UT WOS:000342955700002
PM 25299604
ER
PT J
AU Forrester, JD
Pillai, SK
Beer, KD
Bjork, A
Neatherlin, J
Massaquoi, M
Nyenswah, TG
Montgomery, JM
De Cock, K
AF Forrester, Joseph D.
Pillai, Satish K.
Beer, Katlyn D.
Bjork, Adam
Neatherlin, John
Massaquoi, Moses
Nyenswah, Tolbert G.
Montgomery, Joel M.
De Cock, Kevin
TI Assessment of Ebola Virus Disease, Health Care Infrastructure, and
Preparedness - Four Counties, Southeastern Liberia, August 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Forrester, Joseph D.; Beer, Katlyn D.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Pillai, Satish K.] CDC, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Bjork, Adam; De Cock, Kevin] CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Neatherlin, John; Montgomery, Joel M.] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Neatherlin, John; Montgomery, Joel M.; De Cock, Kevin] CDC, CDC Kenya, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Massaquoi, Moses] Clinton Hlth Access Initiat, New York, NY USA.
[Nyenswah, Tolbert G.] Liberian Minist Hlth & Social Welfare, New York, NY USA.
RP Forrester, JD (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
EM jforrester@cdc.gov
NR 3
TC 14
Z9 14
U1 1
U2 31
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 10
PY 2014
VL 63
IS 40
BP 891
EP 893
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ6WX
UT WOS:000342955700003
PM 25299605
ER
PT J
AU Bergen, G
Peterson, C
Ederer, D
Florence, C
Haileyesus, T
Kresnow, MJ
Xu, LK
AF Bergen, Gwen
Peterson, Cora
Ederer, David
Florence, Curtis
Haileyesus, Tadesse
Kresnow, Marcie-jo
Xu, Likang
TI Vital Signs: Health Burden and Medical Costs of Nonfatal Injuries to
Motor Vehicle Occupants - United States, 2012
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID INTERVENTIONS; INCREASE; REVIEWS; SEATS
AB Background: Motor vehicle crashes are a leading cause of death and injury in the United States. The purpose of this study was to describe the current health burden and medical and work loss costs of nonfatal crash injuries among vehicle occupants in the United States.
Methods: CDC analyzed data on emergency department (ED) visits resulting from nonfatal crash injuries among vehicle occupants in 2012 using the National Electronic Injury Surveillance System - All Injury Program (NEISS-AIP) and the Healthcare Cost and Utilization Project National Inpatient Sample (HCUP-NIS). The number and rate of all ED visits for the treatment of crash injuries that resulted in the patient being released and the number and rate of hospitalizations for the treatment of crash injuries were estimated, as were the associated number of hospital days and lifetime medical and work loss costs.
Results: In 2012, an estimated 2,519,471 ED visits resulted from nonfatal crash injuries, with an estimated lifetime medical cost of $18.4 billion (2012 U.S. dollars). Approximately 7.5% of these visits resulted in hospitalizations that required an estimated 1,057,465 hospital days in 2012.
Conclusions: Nonfatal crash injuries occur frequently and result in substantial costs to individuals, employers, and society. For each motor vehicle crash death in 2012, eight persons were hospitalized, and 100 were treated and released from the ED. Implications for Public Health: Public health practices and laws, such as primary seat belt laws, child passenger restraint laws, ignition interlocks to prevent alcohol impaired driving, sobriety checkpoints, and graduated driver licensing systems have demonstrated effectiveness for reducing motor vehicle crashes and injuries. They might also substantially reduce associated ED visits, hospitalizations, and medical costs.
C1 [Bergen, Gwen; Ederer, David] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
[Peterson, Cora; Florence, Curtis; Haileyesus, Tadesse; Kresnow, Marcie-jo; Xu, Likang] CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
[Ederer, David] McNeal Profess Serv, Kennesaw, GA USA.
RP Bergen, G (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
EM gbergen@cdc.gov
OI Peterson, Cora/0000-0001-7955-0977
NR 20
TC 4
Z9 4
U1 0
U2 5
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 10
PY 2014
VL 63
IS 40
BP 894
EP 900
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ6WX
UT WOS:000342955700004
PM 25299606
ER
PT J
AU Pastula, DM
Aliabadi, N
Haynes, AK
Messacar, K
Schreiner, T
Maloney, J
Dominguez, SR
Davizon, ES
Leshem, E
Fischer, M
Nix, WA
Oberste, MS
Seward, J
Feikin, D
Miller, L
AF Pastula, Daniel M.
Aliabadi, Negar
Haynes, Amber K.
Messacar, Kevin
Schreiner, Teri
Maloney, John
Dominguez, Samuel R.
Davizon, Emily Spence
Leshem, Eyal
Fischer, Marc
Nix, W. Allan
Oberste, M. Steven
Seward, Jane
Feikin, Daniel
Miller, Lisa
TI Acute Neurologic Illness of Unknown Etiology in Children - Colorado,
August-September 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Pastula, Daniel M.; Aliabadi, Negar] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Haynes, Amber K.; Leshem, Eyal; Nix, W. Allan; Oberste, M. Steven; Seward, Jane; Feikin, Daniel] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Messacar, Kevin; Schreiner, Teri; Maloney, John; Dominguez, Samuel R.] Childrens Hosp Colorado, Denver, CO USA.
[Messacar, Kevin; Schreiner, Teri; Maloney, John; Dominguez, Samuel R.] Univ Colorado, Sch Med, Boulder, CO 80309 USA.
[Davizon, Emily Spence; Miller, Lisa] Colorado Dept Publ Hlth & Environm, Denver, CO USA.
[Fischer, Marc] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Pastula, DM (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
EM dpastula@cdc.gov
NR 4
TC 38
Z9 38
U1 0
U2 2
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 10
PY 2014
VL 63
IS 40
BP 901
EP 902
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ6WX
UT WOS:000342955700005
PM 25299607
ER
PT J
AU Ayscue, P
Van Haren, K
Sheriff, H
Waubant, E
Waldron, P
Yagi, S
Yen, C
Clayton, A
Padilla, T
Pan, C
Reichel, J
Harriman, K
Watt, J
Sejvar, J
Nix, WA
Feikin, D
Glaser, C
AF Ayscue, Patrick
Van Haren, Keith
Sheriff, Heather
Waubant, Emmanuelle
Waldron, Paul
Yagi, Shigeo
Yen, Cynthia
Clayton, Anna
Padilla, Tasha
Pan, Chao
Reichel, John
Harriman, Kathleen
Watt, James
Sejvar, James
Nix, William Allan
Feikin, Daniel
Glaser, Carol
TI Acute Flaccid Paralysis with Anterior Myelitis - California, June
2012-June 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID ENTEROVIRUS
C1 [Ayscue, Patrick] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Ayscue, Patrick; Sheriff, Heather; Yagi, Shigeo; Yen, Cynthia; Clayton, Anna; Padilla, Tasha; Pan, Chao; Reichel, John; Harriman, Kathleen; Watt, James; Glaser, Carol] Calif Dept Publ Hlth, Stanford, CA USA.
[Van Haren, Keith; Waldron, Paul] Stanford Univ, Stanford, CA 94305 USA.
[Van Haren, Keith] Lucile Packard Childrens Hosp, Palo Alto, CA USA.
[Waubant, Emmanuelle] Univ Calif San Francisco, Multiple Sclerosis Ctr, San Francisco, CA 94143 USA.
[Sejvar, James] CDC, Natl Ctr Zoonot Vectorborne & Enter Dis, Atlanta, GA 30333 USA.
[Nix, William Allan; Feikin, Daniel] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Ayscue, P (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
EM payscue@cdc.gov
NR 10
TC 28
Z9 28
U1 0
U2 2
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 10
PY 2014
VL 63
IS 40
BP 903
EP 906
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ6WX
UT WOS:000342955700006
PM 25299608
ER
PT J
AU Baker, BJ
Poonja, S
Mesrobian, M
Lai, AN
Hwang, S
AF Baker, Brian J.
Poonja, Shameer
Mesrobian, Myrna
Lai, Anna
Hwang, Steven
TI Use of Genotyping to Disprove a Presumed Outbreak of Mycobacterium
tuberculosis - Los Angeles County, 2013-2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID UNITED-STATES
C1 [Baker, Brian J.; Poonja, Shameer] CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
[Mesrobian, Myrna; Lai, Anna; Hwang, Steven] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA.
RP Baker, BJ (reprint author), CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
EM bjbaker@cdc.gov
NR 6
TC 0
Z9 0
U1 0
U2 1
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 10
PY 2014
VL 63
IS 40
BP 907
EP 908
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ6WX
UT WOS:000342955700007
PM 25299609
ER
PT J
AU Rasmussen, SA
Jamieson, DJ
AF Rasmussen, Sonja A.
Jamieson, Denise J.
TI 2009 H1N1 Influenza and Pregnancy-5 Years Later
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Rasmussen, Sonja A.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Rasmussen, SA (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
OI Rasmussen, Sonja/0000-0002-0574-4928
NR 5
TC 10
Z9 10
U1 0
U2 9
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 9
PY 2014
VL 371
IS 15
BP 1373
EP 1375
DI 10.1056/NEJMp1403496
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AQ3FJ
UT WOS:000342674800004
PM 25295498
ER
PT J
AU Wallace, RM
Gilbert, A
Slate, D
Chipman, R
Singh, A
Wedd, C
Blanton, JD
AF Wallace, Ryan M.
Gilbert, Amy
Slate, Dennis
Chipman, Richard
Singh, Amber
Wedd, Cassie
Blanton, Jesse D.
TI Right Place, Wrong Species: A 20-Year Review of Rabies Virus Cross
Species Transmission among Terrestrial Mammals in the United States
SO PLOS ONE
LA English
DT Article
ID RACCOONS PROCYON-LOTOR; SKUNKS MEPHITIS-MEPHITIS; DENSITY; HOST;
EPIDEMIOLOGY; SURVEILLANCE; INJURIES; DYNAMICS; COYOTES; DISEASE
AB Introduction: In the continental US, four terrestrial mammalian species are reservoirs for seven antigenic rabies virus variants. Cross species transmission (CST) occurs when a rabies virus variant causes disease in non-reservoir species.
Methods: This study analyzed national surveillance data for rabies in terrestrial mammals. The CST rate was defined as: number of rabid non-reservoir animals/number of rabid reservoir animals. CST rates were analyzed for trend. Clusters of high CST rate counties were evaluated using space-time scanning statistics.
Results: The number of counties reporting a raccoon variant CST rate >1.0 increased from 75 in 1992 to 187 in 2011; counties with skunk variant CST rates >1.0 remained unchanged during the same period. As of 2011, for every rabid raccoon reported within the raccoon variant region, there were 0.73 cases of this variant reported in non-reservoir animals. Skunks were the most common non-reservoir animal reported with the raccoon rabies variant. Domestic animals were the most common non-reservoir animal diagnosed with a skunk rabies virus variant (n = 1,601). Cross species transmission rates increased fastest among domestic animals.
Conclusions: Cross species transmission of rabies virus variants into non-reservoir animals increases the risk of human exposures and threatens current advances toward rabies control. Cross species transmission in raccoon rabies enzootic regions increased dramatically during the study period. Pet owners should vaccinate their dogs and cats to ensure against CST, particularly in regions with active foci of rabies circulation. Clusters of high CST activity represent areas for further study to better understand interspecies disease transmission dynamics. Each CST event has the potential to result in a rabies virus adapted for sustained transmission in a new species; therefore further understanding of the dynamics of CST may help in early detection or prevention of the emergence of new terrestrial rabies virus variants.
C1 [Wallace, Ryan M.; Singh, Amber; Wedd, Cassie; Blanton, Jesse D.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
[Gilbert, Amy] USDA, Natl Wildlife Res Ctr, Ft Collins, CO USA.
[Slate, Dennis; Chipman, Richard] USDA, Wildlife Serv, Concord, NH USA.
RP Wallace, RM (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
EM euk5@cdc.gov
NR 49
TC 5
Z9 5
U1 2
U2 45
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 8
PY 2014
VL 9
IS 10
AR e107539
DI 10.1371/journal.pone.0107539
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AT8TE
UT WOS:000345204000007
PM 25295750
ER
PT J
AU Frieden, TR
Brudney, KF
Harries, AD
AF Frieden, Thomas R.
Brudney, Karen F.
Harries, Anthony D.
TI Global Tuberculosis Perspectives, Prospects, and Priorities
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID PRIMARY-CARE
C1 [Frieden, Thomas R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Brudney, Karen F.] Columbia Univ, New York, NY USA.
[Harries, Anthony D.] Int Union TB & Lung Dis, Paris, France.
[Harries, Anthony D.] London Sch Hyg & Trop Med, London WC1, England.
RP Frieden, TR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS D-14, Atlanta, GA 30333 USA.
EM tfrieden@cdc.gov
NR 8
TC 9
Z9 10
U1 2
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 8
PY 2014
VL 312
IS 14
BP 1393
EP 1394
DI 10.1001/jama.2014.11450
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AQ2PQ
UT WOS:000342630200009
PM 25188638
ER
PT J
AU Magill, SS
Edwards, JR
Beldavs, ZG
Dumyati, G
Janelle, SJ
Kainer, MA
Lynfield, R
Nadle, J
Neuhauser, MM
Ray, SM
Richards, K
Rodriguez, R
Thompson, DL
Fridkin, SK
AF Magill, Shelley S.
Edwards, Jonathan R.
Beldavs, Zintars G.
Dumyati, Ghinwa
Janelle, Sarah J.
Kainer, Marion A.
Lynfield, Ruth
Nadle, Joelle
Neuhauser, Melinda M.
Ray, Susan M.
Richards, Katherine
Rodriguez, Richard
Thompson, Deborah L.
Fridkin, Scott K.
CA Emerging Infect Program Healthcare
Associated Infect Antimicrobial Us
TI Prevalence of Antimicrobial Use in US Acute Care Hospitals,
May-September 2011
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; COMMUNITY-ACQUIRED PNEUMONIA;
ANTIBIOTIC USE; UNITED-STATES; GENERAL HOSPITALS; TRACT-INFECTIONS;
RISK-FACTORS; THERAPY; ENTEROBACTERIACEAE; STEWARDSHIP
AB IMPORTANCE Inappropriate antimicrobial drug use is associated with adverse events in hospitalized patients and contributes to the emergence and spread of resistant pathogens. Targeting effective interventions to improve antimicrobial use in the acute care setting requires understanding hospital prescribing practices.
OBJECTIVE To determine the prevalence of and describe the rationale for antimicrobial use in participating hospitals.
DESIGN, SETTING, AND PARTICIPANTS One-day prevalence surveys were conducted in acute care hospitals in 10 states between May and September 2011. Patients were randomly selected from each hospital's morning census on the survey date. Data collectors reviewed medical records retrospectively to gather data on antimicrobial drugs administered to patients on the survey date and the day prior to the survey date, including reasons for administration, infection sites treated, and whether treated infections began in community or health care settings.
MAIN OUTCOMES AND MEASURES Antimicrobial use prevalence, defined as the number of patients receiving antimicrobial drugs at the time of the survey divided by the total number of surveyed patients.
RESULTS Of 11 282 patients in 183 hospitals, 5635 (49.9%; 95% CI, 49.0%-50.9%) were administered at least 1 antimicrobial drug; 77.5%(95% CI, 76.6%-78.3%) of antimicrobial drugs were used to treat infections, most commonly involving the lower respiratory tract, urinary tract, or skin and soft tissues, whereas 12.2%(95% CI, 11.5%-12.8%) were given for surgical and 5.9% (95% CI, 5.5%-6.4%) for medical prophylaxis. Of 7641 drugs to treat infections, the most common were parenteral vancomycin (1103, 14.4%; 95% CI, 13.7%-15.2%), ceftriaxone (825, 10.8%; 95% CI, 10.1%-11.5%), piperacillin-tazobactam (788, 10.3%; 95% CI, 9.6%-11.0%), and levofloxacin (694, 9.1%; 95% CI, 8.5%-9.7%). Most drugs administered to treat infections were given for community-onset infections (69.0%; 95% CI, 68.0%-70.1%) and to patients outside critical care units (81.6%; 95% CI, 80.4%-82.7%). The 4 most common treatment antimicrobial drugs overall were also the most common drugs used for both community-onset and health care facility-onset infections and for infections in patients in critical care and noncritical care locations.
CONCLUSIONS AND RELEVANCE In this cross-sectional evaluation of antimicrobial use in US hospitals, use of broad-spectrum antimicrobial drugs such as piperacillin-tazobactam and drugs such as vancomycin for resistant pathogens was common, including for treatment of community-onset infections and among patients outside critical care units. Further work is needed to understand the settings and indications for which reducing antimicrobial use can be most effectively and safely accomplished.
C1 [Magill, Shelley S.; Edwards, Jonathan R.; Neuhauser, Melinda M.; Fridkin, Scott K.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Beldavs, Zintars G.] Oregon Hlth Author, Oregon Publ Hlth Div, Portland, Dorset, England.
[Dumyati, Ghinwa] New York Rochester Emerging Infect Program, Rochester, NY USA.
[Dumyati, Ghinwa] Univ Rochester, Med Ctr, Rochester, NY 14627 USA.
[Janelle, Sarah J.] Colorado Dept Publ Hlth & Environm, Denver, CO USA.
[Kainer, Marion A.] Tennessee Dept Hlth, Nashville, TN USA.
[Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA.
[Nadle, Joelle] Calif Emerging Infect Program, Oakland, CA USA.
[Neuhauser, Melinda M.] Pharm Benefits Management Serv, Dept Vet Affairs, Hines, IL USA.
[Ray, Susan M.] Atlanta Vet Affairs Med Ctr, Georgia Emerging Infect Program, Decatur, GA USA.
[Ray, Susan M.] Emory Univ, Sch Med, Georgia Emerging Infect Program, Atlanta, GA USA.
[Richards, Katherine] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA.
[Rodriguez, Richard] Connecticut Dept Publ Hlth, Hartford, CT USA.
[Thompson, Deborah L.] New Mexico Dept Hlth, Santa Fe, NM USA.
RP Magill, SS (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-24, Atlanta, GA 30333 USA.
EM smagill@cdc.gov
FU Emerging Infections Program; CDC's Division of Healthcare Quality
Promotion, Division of Preparedness and Emerging Infections; CDC's
Office of Antimicrobial Resistance
FX The survey was supported through a cooperative agreement with the
Emerging Infections Program. Funds to conduct the survey came from the
CDC's Division of Healthcare Quality Promotion, Division of Preparedness
and Emerging Infections, and Office of Antimicrobial Resistance.
NR 38
TC 31
Z9 31
U1 0
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 8
PY 2014
VL 312
IS 14
BP 1438
EP 1446
DI 10.1001/jama.2014.12923
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA AQ2PQ
UT WOS:000342630200020
PM 25291579
ER
PT J
AU Epstein, L
Hunter, JC
Arwady, MA
Tsai, V
Stein, L
Gribogiannis, M
Frias, M
Guh, AY
Laufer, AS
Black, S
Pacilli, M
Moulton-Meissner, H
Rasheed, JK
Avillan, JJ
Kitchel, B
Limbago, BM
MacCannell, D
Lonsway, D
Noble-Wang, J
Conway, J
Conover, C
Vernon, M
Kallen, AJ
AF Epstein, Lauren
Hunter, Jennifer C.
Arwady, M. Allison
Tsai, Victoria
Stein, Linda
Gribogiannis, Marguerite
Frias, Mabel
Guh, Alice Y.
Laufer, Alison S.
Black, Stephanie
Pacilli, Massimo
Moulton-Meissner, Heather
Rasheed, J. Kamile
Avillan, Johannetsy J.
Kitchel, Brandon
Limbago, Brandi M.
MacCannell, Duncan
Lonsway, David
Noble-Wang, Judith
Conway, Judith
Conover, Craig
Vernon, Michael
Kallen, Alexander J.
TI New Delhi Metallo-beta-Lactamase-Producing Carbapenem-Resistant
Escherichia coli Associated With Exposure to Duodenoscopes
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FIELD
GEL-ELECTROPHORESIS; PSEUDOMONAS-AERUGINOSA; ENTEROBACTERIACEAE;
OUTBREAK; EPIDEMIOLOGY; ACQUISITION; PREVENTION; GUIDELINE
AB IMPORTANCE Carbapenem-resistant Enterobacteriaceae (CRE) producing the New Delhi metallo-beta-lactamase (NDM) are rare in the United States, but have the potential to add to the increasing CRE burden. Previous NDM-producing CRE clusters have been attributed to person-to-person transmission in health care facilities.
OBJECTIVE To identify a source for, and interrupt transmission of, NDM-producing CRE in a northeastern Illinois hospital.
DESIGN, SETTING, AND PARTICIPANTS Outbreak investigation among 39 case patients at a tertiary care hospital in northeastern Illinois, including a case-control study, infection control assessment, and collection of environmental and device cultures; patient and environmental isolate relatedness was evaluated with pulsed-field gel electrophoresis (PFGE). Following identification of a likely source, targeted patient notification and CRE screening cultures were performed.
MAIN OUTCOMES AND MEASURES Association between exposure and acquisition of NDM-producing CRE; results of environmental cultures and organism typing.
RESULTS In total, 39 case patients were identified from January 2013 through December 2013, 35 with duodenoscope exposure in 1 hospital. No lapses in duodenoscope reprocessing were identified; however, NDM-producing Escherichia coli was recovered from a reprocessed duodenoscope and shared more than 92% similarity to all case patient isolates by PFGE. Based on the case-control study, case patients had significantly higher odds of being exposed to a duodenoscope (odds ratio [OR], 78 [95% CI, 6.0-1008], P < .001). After the hospital changed its reprocessing procedure from automated high-level disinfection with ortho-phthalaldehyde to gas sterilization with ethylene oxide, no additional case patients were identified.
CONCLUSIONS AND RELEVANCE In this investigation, exposure to duodenoscopes with bacterial contamination was associated with apparent transmission of NDM-producing E coli among patients at 1 hospital. Bacterial contamination of duodenoscopes appeared to persist despite the absence of recognized reprocessing lapses. Facilities should be aware of the potential for transmission of bacteria including antimicrobial-resistant organisms via this route and should conduct regular reviews of their duodenoscope reprocessing procedures to ensure optimal manual cleaning and disinfection.
C1 [Epstein, Lauren; Hunter, Jennifer C.; Guh, Alice Y.; Laufer, Alison S.; Moulton-Meissner, Heather; Rasheed, J. Kamile; Avillan, Johannetsy J.; Kitchel, Brandon; Limbago, Brandi M.; MacCannell, Duncan; Lonsway, David; Noble-Wang, Judith; Kallen, Alexander J.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
[Epstein, Lauren; Hunter, Jennifer C.; Arwady, M. Allison] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.
[Arwady, M. Allison; Tsai, Victoria; Conway, Judith; Conover, Craig] Illinois Dept Publ Hlth, Chicago, IL USA.
[Stein, Linda; Gribogiannis, Marguerite] Advocate Lutheran Gen Hosp, Park Ridge, IL USA.
[Frias, Mabel; Vernon, Michael] Cook Cty Dept Publ Hlth, Oak Forest, IL USA.
[Black, Stephanie; Pacilli, Massimo] Chicago Dept Publ Hlth, Chicago, IL USA.
RP Epstein, L (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,Mailstop A-24, Atlanta, GA 30333 USA.
EM xdd0@cdc.gov
NR 36
TC 83
Z9 84
U1 3
U2 19
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 8
PY 2014
VL 312
IS 14
BP 1447
EP 1455
DI 10.1001/jama.2014.12720
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA AQ2PQ
UT WOS:000342630200021
PM 25291580
ER
PT J
AU Iavicoli, I
Leso, V
Ricciardi, W
Hodson, LL
Hoover, MD
AF Iavicoli, Ivo
Leso, Veruscka
Ricciardi, Walter
Hodson, Laura L.
Hoover, Mark D.
TI Opportunities and challenges of nanotechnology in the green economy
SO ENVIRONMENTAL HEALTH
LA English
DT Review
DE Green economy; Nanotechnology; Sustainable development; Occupational
health; Safety; Environmental risk; Ecology; Engineered nanomaterials;
Material science
ID LITHIUM-ION BATTERIES; SENSITIZED SOLAR-CELLS; CARBON NANOTUBES;
HYDROGEN STORAGE; ENGINEERED NANOPARTICLES; MEDICAL-SURVEILLANCE;
RISK-ASSESSMENT; WASTE-WATER; EPIDEMIOLOGIC-RESEARCH;
ENVIRONMENTAL-HEALTH
AB In a world of finite resources and ecosystem capacity, the prevailing model of economic growth, founded on ever-increasing consumption of resources and emission pollutants, cannot be sustained any longer. In this context, the "green economy" concept has offered the opportunity to change the way that society manages the interaction of the environmental and economic domains. To enable society to build and sustain a green economy, the associated concept of "green nanotechnology" aims to exploit nano-innovations in materials science and engineering to generate products and processes that are energy efficient as well as economically and environmentally sustainable. These applications are expected to impact a large range of economic sectors, such as energy production and storage, clean up-technologies, as well as construction and related infrastructure industries. These solutions may offer the opportunities to reduce pressure on raw materials trading on renewable energy, to improve power delivery systems to be more reliable, efficient and safe as well as to use unconventional water sources or nano-enabled construction products therefore providing better ecosystem and livelihood conditions.
However, the benefits of incorporating nanomaterials in green products and processes may bring challenges with them for environmental, health and safety risks, ethical and social issues, as well as uncertainty concerning market and consumer acceptance. Therefore, our aim is to examine the relationships among guiding principles for a green economy and opportunities for introducing nano-applications in this field as well as to critically analyze their practical challenges, especially related to the impact that they may have on the health and safety of workers involved in this innovative sector. These are principally due to the not fully known nanomaterial hazardous properties, as well as to the difficulties in characterizing exposure and defining emerging risks for the workforce. Interestingly, this review proposes action strategies for the assessment, management and communication of risks aimed to precautionary adopt preventive measures including formation and training of employees, collective and personal protective equipment, health surveillance programs to protect the health and safety of nano-workers. It finally underlines the importance that occupational health considerations will have on achieving an effectively sustainable development of nanotechnology.
C1 [Iavicoli, Ivo; Leso, Veruscka; Ricciardi, Walter] Univ Cattolica Sacro Cuore, Inst Publ Hlth, I-00168 Rome, Italy.
[Hodson, Laura L.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA.
[Hoover, Mark D.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA.
RP Iavicoli, I (reprint author), Univ Cattolica Sacro Cuore, Inst Publ Hlth, Largo Francesco Vito 1, I-00168 Rome, Italy.
EM iavicoli.ivo@rm.unicatt.it
RI Iavicoli, Ivo/K-9062-2016
OI Iavicoli, Ivo/0000-0003-0444-3792
NR 124
TC 6
Z9 7
U1 16
U2 199
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-069X
J9 ENVIRON HEALTH-GLOB
JI Environ. Health
PD OCT 7
PY 2014
VL 13
AR 78
DI 10.1186/1476-069X-13-78
PG 11
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AS9JR
UT WOS:000344559600001
PM 25294341
ER
PT J
AU Rudd, RA
Paulozzi, LJ
Bauer, MJ
Burleson, RW
Carlson, RE
Dao, D
Davis, JW
Dudek, J
Eichler, BA
Fernandes, JC
Fondario, A
Gabella, B
Hume, B
Huntamer, T
Kariisa, M
Largo, TW
Miles, J
Newmyer, A
Nitcheva, D
Perez, BE
Proescholdbell, SK
Sabel, JC
Skiba, J
Slavova, S
Stone, K
Tharp, JM
Wendling, T
Wright, D
Zehner, AM
AF Rudd, Rose A.
Paulozzi, Len J.
Bauer, Michael J.
Burleson, Richard W.
Carlson, Rick E.
Dao, Dan
Davis, James W.
Dudek, Jennifer
Eichler, Beth Ann
Fernandes, Jessie C.
Fondario, Anna
Gabella, Barbara
Hume, Beth
Huntamer, Theron
Kariisa, Mbabazi
Largo, Thomas W.
Miles, JoAnne
Newmyer, Ashley
Nitcheva, Daniela
Perez, Beatriz E.
Proescholdbell, Scott K.
Sabel, Jennifer C.
Skiba, Jessica
Slavova, Svetla
Stone, Kathy
Tharp, John M.
Wendling, Tracy
Wright, Dagan
Zehner, Anne M.
TI Increases in Heroin Overdose Deaths-28 States, 2010 to 2012
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID UNITED-STATES
C1 [Rudd, Rose A.; Paulozzi, Len J.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
[Bauer, Michael J.] New York State Dept Hlth, Albany, NY 12237 USA.
[Burleson, Richard W.] Alabama Dept Publ Hlth, Montgomery, AL USA.
[Carlson, Rick E.] Minnesota Dept Hlth, Minneapolis, MN 55414 USA.
[Dao, Dan] Kansas Dept Hlth & Environm, Wichita, KS USA.
[Davis, James W.] New Mexico Dept Hlth, Santa Fe, NM USA.
[Dudek, Jennifer] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA.
[Eichler, Beth Ann] Florida Dept Hlth, Tallahassee, FL USA.
[Fernandes, Jessie C.] Montana Dept Publ Hlth & Hlth Serv, Hamilton, MT USA.
[Fondario, Anna] Utah Dept Hlth, Salt Lake City, UT 84116 USA.
[Gabella, Barbara] Colorado Dept Publ Hlth & Environm, Denver, CO USA.
[Hume, Beth] Massachusetts Dept Publ Hlth, Boston, MA 02111 USA.
[Huntamer, Theron] Nevada Div Publ & Behav Hlth, Carson City, NV USA.
[Kariisa, Mbabazi] Ohio Dept Hlth, Columbus, OH 43266 USA.
[Largo, Thomas W.] Michigan Dept Community Hlth, Providence, RI USA.
[Miles, JoAnne] New Hampshire Dept Hlth & Human Serv, Concord, NH 03301 USA.
[Newmyer, Ashley] Nebraska Dept Hlth & Human Serv, Ogallala, NE USA.
[Nitcheva, Daniela] S Carolina Dept Hlth & Environm Control, Columbia, SC 29201 USA.
[Perez, Beatriz E.] Rhode Isl Dept Hlth, Providence, RI 02908 USA.
[Proescholdbell, Scott K.] North Carolina Dept Hlth & Human Serv, Res Triangle Pk, NC USA.
[Sabel, Jennifer C.] Washington State Dept Hlth, Washington, DC USA.
[Skiba, Jessica] Indiana State Dept Hlth, Indianapolis, IN 46202 USA.
[Slavova, Svetla] Univ Kentucky, Kentucky Injury Prevent & Res Ctr, Lexington, KY 40506 USA.
[Stone, Kathy] Iowa Dept Publ Hlth, Des Moines, IA 50319 USA.
[Tharp, John M.] Illinois Dept Publ Hlth, Springfield, IL 62761 USA.
[Wendling, Tracy] Oklahoma Dept Hlth, Oklahoma City, OK 73117 USA.
[Wright, Dagan] Oregon Hlth Author, Portland, OR USA.
[Zehner, Anne M.] Virginia Dept Hlth, Henrico, VA USA.
RP Paulozzi, LJ (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
EM lpaulozzi@cdc.gov
NR 10
TC 52
Z9 53
U1 3
U2 10
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 3
PY 2014
VL 63
IS 39
BP 849
EP 854
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ1WG
UT WOS:000342573900001
PM 25275328
ER
PT J
AU Date, KA
Bentsi-Enchill, AD
Fox, KK
Abeysinghe, N
Mintz, ED
Khan, MI
Sahastrabuddhe, S
Hyde, TB
AF Date, Kashmira A.
Bentsi-Enchill, Adwoa D.
Fox, Kimberley K.
Abeysinghe, Nihal
Mintz, Eric D.
Khan, M. Imran
Sahastrabuddhe, Sushant
Hyde, Terri B.
TI Typhoid Fever Surveillance and Vaccine Use - South-East Asia and Western
Pacific Regions, 2009-2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID BURDEN; IMPACT
C1 [Date, Kashmira A.; Hyde, Terri B.] CDC, Global Immunizat Div, Ctr Global Hlth, Washington, DC 20201 USA.
[Bentsi-Enchill, Adwoa D.] WHO, Immunizat Vaccines & Biol, Washington, DC USA.
[Fox, Kimberley K.] WHO, Reg Off Western Pacific, Washington, DC USA.
[Abeysinghe, Nihal] WHO, Reg Off South East Asia, Washington, DC USA.
[Mintz, Eric D.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Washington, DC USA.
[Khan, M. Imran] Sabin Vaccine Inst, Coalit Typhoid Secretariat, Washington, DC USA.
[Sahastrabuddhe, Sushant] Int Vaccine Inst, Seoul, South Korea.
RP Date, KA (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Washington, DC 20201 USA.
EM kdate@cdc.gov; bentsienchilla@who.int
NR 10
TC 7
Z9 8
U1 1
U2 5
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 3
PY 2014
VL 63
IS 39
BP 855
EP 860
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ1WG
UT WOS:000342573900002
PM 25275329
ER
PT J
AU Blanton, L
Brammer, L
Smith, S
Mustaquim, D
Steffens, C
Abd Elal, AI
Gubareva, L
Hall, H
Wallis, T
Villanueva, J
Xu, XY
Bresee, J
Cox, N
Finelli, L
AF Blanton, Lenee
Brammer, Lynnette
Smith, Sophie
Mustaquim, Desiree
Steffens, Craig
Abd Elal, Anwar Isa
Gubareva, Larisa
Hall, Henrietta
Wallis, Teresa
Villanueva, Julie
Xu, Xiyan
Bresee, Joseph
Cox, Nancy
Finelli, Lyn
TI Update: Influenza Activity - United States and Worldwide, May
18-September 20, 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Blanton, Lenee; Brammer, Lynnette; Smith, Sophie; Mustaquim, Desiree; Steffens, Craig; Abd Elal, Anwar Isa; Gubareva, Larisa; Hall, Henrietta; Wallis, Teresa; Villanueva, Julie; Xu, Xiyan; Bresee, Joseph; Cox, Nancy; Finelli, Lyn] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Blanton, L (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM lblanton@cdc.gov
NR 7
TC 8
Z9 8
U1 0
U2 1
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 3
PY 2014
VL 63
IS 39
BP 861
EP 864
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ1WG
UT WOS:000342573900003
PM 25275330
ER
PT J
AU Shuaib, F
Gunnala, R
Musa, EO
Mahoney, FJ
Oguntimehin, O
Nguku, PM
Nyanti, SB
Knight, N
Gwarzo, NS
Idigbe, O
Nasidi, A
Vertefeuille, JF
AF Shuaib, Faisal
Gunnala, Rajni
Musa, Emmanuel O.
Mahoney, Frank J.
Oguntimehin, Olukayode
Nguku, Patrick M.
Nyanti, Sara Beysolow
Knight, Nancy
Gwarzo, Nasir Sani
Idigbe, Oni
Nasidi, Abdulsalam
Vertefeuille, John F.
TI Ebola Virus Disease Outbreak - Nigeria, July-September 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Shuaib, Faisal; Gwarzo, Nasir Sani; Nasidi, Abdulsalam] Fed Minist Hlth, Abuja, Nigeria.
[Gunnala, Rajni; Mahoney, Frank J.; Vertefeuille, John F.] CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA.
[Musa, Emmanuel O.] WHO, Nigeria Off, Damaturu, Yobe, Niger.
[Oguntimehin, Olukayode] Lagos State Primary Hlth Care Board, Yaba, Lagos, Niger.
[Nguku, Patrick M.] Nigeria Field Epidemiol & Lab Training Program, Abuja, Niger.
[Nyanti, Sara Beysolow] UNICEF, Lagos Off, New York, NY USA.
[Knight, Nancy] CDC, Ctr Global Hlth, Div Global HIV AIDS, South Africa Off, Atlanta, GA 30333 USA.
[Idigbe, Oni] Nigerian Inst Med Res, Yaba, Lagos, Niger.
RP Vertefeuille, JF (reprint author), CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA.
EM jvertefeuille@cdc.gov
NR 8
TC 65
Z9 66
U1 0
U2 67
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD OCT 3
PY 2014
VL 63
IS 39
BP 867
EP 872
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ1WG
UT WOS:000342573900005
PM 25275332
ER
EF